Kentucky Cancer Registry 2020 Abstractor's Manual For use with CPDMS.net

1. KCR Abstractors Manual	
1.1 Introduction	
1.1.1 Computerized Record Structure	11
1.1.2 Case Reporting Requirements	12
1.1.3 Reporting of Tumor Molecular Test Data	15
1.1.4 Ambiguous Terminology at Diagnosis	16
1.1.5 Casefinding	18
1.1.6 Staging Systems	25
1.1.7 First Course Therapy	
1.1.8 Follow Up Policies And Procedures	
1.1.9 Changes To The Manual	
1.1.9 Changes to the Manual	31
1.1.10 General Rules Multiple Primaries	35
1.1.11 Hematopoietic And Lymphoid Malignancy Coding Rules	36
1.1.12 Lymphatic And Hematopoietic Multiple Primary Rules	37
1.1.13 Solid Tumors Rules for Coding Multiple Primaries	
1.2 Patient Data	
1.2.1 Page 1	46
1.2.1.1 Soc Sec Number	47
1.2.1.2 Last Name	48
1.2.1.3 First Name	
1.2.1.4 Middle Name	
1.2.1.5 Maiden Name	
1.2.1.6 Street Address 1	
1.2.1.7 Street Address 2	
1.2.1.8 City	
1.2.1.9 State	
1.2.1.10 Zip Code	
1.2.1.11 Country	
1.2.1.12 Home Phone	
1.2.1.13 Date of Birth	
1.2.1.14 State of Birth	
1.2.1.15 Country of Birth	
1.2.1.16 Sex	62
1.2.2 Page 2	63
1.2.2.1 Race 1	
1.2.2.2 Race 2	66
1.2.2.3 Race 3	
1.2.2.4 Race 4	
1.2.2.5 Race 5	
1.2.2.6 Computed Ethnicity	
1.2.2.7 Spanish Origin	
1.2.2.8 Tobacco Use	
1.2.2.9 Cigarette Pack Years	73
1.2.2.10 Number of Live Births	
1.2.2.11 Occupation	
1.2.2.12 Industry	
1.2.2.13 Cause of Death(ICD)	77
1.2.2.14 Place of Death	
1.2.2.15 State of Death	
1.2.2.16 Country of Death	80
1.2.2.17 Contact Patient	
1.2.2.18 Contact Patient Comments	82
1.2.2.19 Number of Primaries	
1.2.2.20 Vital Status	84
1.2.2.21 Occupation Code	
1.2.2.22 Industry Code	
1.2.2.23 Patient DLC	
1.2.3 Page 3	
1.2.3.1 Clinical Trial Type 1	
1.2.3.2 Clinical Trial Accrual Date 1	
1.2.3.3 Clinical Trial Site Code 1	
1.2.3.4 Clinical Trial Text 1	
1.2.3.5 Clinical Trial Type 2	
1.2.3.6 Clinical Trial Accrual Date 2	
1.2.3.7 Clinical Trial Site Code 2	
1.2.3.8 Clinical Trial Text 2	
1.2.3.9 Clinical Trial Type 3	
1.2.3.10 Clinical Trial Accrual Date 3	98
1.2.3.11 Clinical Trial Site Code 3	99
1.2.3.12 Clinical Trial Text 3	100
1.2.3.13 Clinical Trial Type 4	
1.2.3.14 Clinical Trial Accrual Date 4	
1.2.3.15 Clinical Trial Site Code 4	
1.2.3.16 Clinical Trial Text 4	
1.2.4 Patient Misc	
1.2.4 Patient Misc	
1.2.4.1 SEER Patient to	
1.2.4.2 IPS LINK	
1.2.4.4 Time Modified (Patient)	109

10 -	I.2.4.6 Patient Incomplete Flag
1.2.5	L2.5.1 CPDMS Create Patient from a Pathology Report Workflow
ase	
.3.1	Diagnosis
	I.3.1.1 Case Sequence Num
	I.3.1.2 Case Site Code
	I.3.1.3 Case Type
	I.3.1.4 ICDO Version
	I.3.1.5 ICD-O-3 Conversion Flag
	I.3.1.6 Topography Code (ICD-O)
	I.3.1.7 Histology
	I.3.1.8 Behavior Code
	I.3.1.9 Histology (ICD-O-2)
	I.3.1.10 Behavior Code (ICD-O-2)
	.3.1.11 Tumor Grade
	3.1.12 Lymphovascular Invasion
	I.3.1.13 Class of Case
	I.3.1.14 Place of Diagnosis
	1.3.1.15 Date of First Contact
	1.3.1.16 Date of Diagnosis
	I.3.1.17 Age at Diagnosis
	I.3.1.18 Laterality
	Personal
	I.3.2.1 Hospital Chart No
	I.3.2.2 Family History
	I.3.2.3 Marital Status at Diag
	1.3.2.4 Menopausal Status
	1.3.2.5 Primary Payer
	1.3.2.6 ACOS Sequence Num
	1.3.2.7 SEER Sequence Num
	I.3.2.8 Address at Diag 1
	1.3.2.9 Address at Diag 2
	I.3.2.10 City at Diag
	1.3.2.11 State at Diag
	1.3.2.12 Zip Code at Diag
	I.3.2.13 Country at Diag
	I.3.2.14 County at Diag
	I.3.2.15 Registry Accession Year
	I.3.2.16 Diag Confirmation Code
	I.3.2.17 Path Report No
	Collab Stg
	I.3.3.1 Collaborative Staging
	1.3.3.2 Regional Lymph Nodes Examined
	1.3.3.3 Regional Lymph Nodes Positive
	I.3.3.4 Mets at DX - Bone
	I.3.3.5 Mets at DX - Bone
	I.3.3.6 Mets at DX - Liver
	I.3.3.7 Mets at DX - Distant LN
	1.3.3.8 Mets at DX - Lung
	1.3.3.9 Mets at DX - Other
	I.3.3.10 Summary Stage 1977
	I.3.3.11 SummStg1977Disp
	I.3.3.12 Summary Stage 2000
	I.3.3.13 SummStg2000Disp
	I.3.3.14 CS Version Input Current
	1.3.3.15 CS Version Derived
	3.3.16 CS Version Input Original
	EOD
	I.3.4.1 EOD Primary Tumor
	I.3.4.2 Prostate Pathological Extension
	I.3.4.3 EOD Regional Nodes
	1.3.4.4 Date of Sentinel Lymph Node Biopsy
	1.3.4.5 Sentinel Lymph Nodes Examined
	I.3.4.6 Sentinel Lymph Nodes Positive
	I.3.4.7 Date Regional Lymph Node Dissection
	1.3.4.8 EOD Metastases
	I.3.4.9 Derived Summary Stage 2018
	SSDI/Grade
	.3.5.1 Grade Clinical
	I.3.5.2 Grade Pathological
	I.3.5.3 Grade Post Therapy
	I.3.5.3 Grade Post Therapy
	1.3.5.5 SEER SSF 1 (HPV Status)
	AJCC Docs
1.3.6	1.0.0.1 Directly October Oter 0000
1.3.6	I.3.6.1 Directly Coded Summ Stg 2000

1.3.6.4 Tumor Size Path	nologic
	ical
1.3.6.6 Tumor Size Sum	mary
1.3.6.7 AJCC Staging E	dition
	· · · · · · · · · · · · · · · · · · ·
	1
	nn
	roup
	or
1.3.6.13 Staged By - Cli	nical
1.3.6.14 pT Classification	n
	nn
	on
	roup
	or
1.3.6.19 Alt (Ped) Stage	9 Sys
1.3.6.20 Alt (Ped) Stage	•
1.3.6.21 Managing Phys	sician
	n
	ngist
	ologist
1.3.6.25 Staged By - Pa	thologic
	nical Ť
	nical T Suffix
	nical N
	nical N Suffix
	nical M
	nical Stage Group
	thological T Suffix
	thological N
1.3.6.35 AJCC TNM Pa	thological N Suffix
1.3.6.36 AJCC TNM Pa	thological M
	thological Stage Group
	st Therapy T
	st Therapy T Suffix
	st Therapy N
	st Therapy N Suffix
	st Therapy М
1.3.6.43 AJCC TNM Po	st Therapy Stage Group
3.7 Admin NoTx	
	riginal
	ng Src
	y 010
1.3.7.5 Reason No The	apy (Non-def Surg)
1.3.7.6 Reason No The	apy (Surg)
	apy (Chemo)
1.3.7.8 Reason No The	apy (Rad)
	apy (Horm)
	erapy (Immuno)
	erapy (Trans)
	erapy (Other)
	Needed
	apy/Surg Seq
1.3.7.15 Radiation/Surg	ery Sequence
	us
	herapy
	ACOS)
	(First)
	(All)
	v Status
1.3.7.23 Date Case Cor	npleted CoC
	nosis
	condary Diagnosis
	om
	Jure
1.3.8.5 Inst Referred To	
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Proced	nure - Lois Facility
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Procee 1.3.8.7 Palliative Procee	Jure - This Facility
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Proced 1.3.8.7 Palliative Proced 1.3.8.8 Date Surgical Di	scharge
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Procec 1.3.8.7 Palliative Procec 1.3.8.8 Date Surgical Di 1.3.8.9 Date Surgical Di	scharge
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Procec 1.3.8.7 Palliative Procec 1.3.8.8 Date Surgical Di 1.3.8.9 Date Surgical Di 1.3.8.10 Readmit within	scharge scharge Flag
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Procec 1.3.8.7 Palliative Procec 1.3.8.8 Date Surgical Di 1.3.8.9 Date Surgical Di 1.3.8.10 Readmit within .3.9 Overrides	scharge
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Procec 1.3.8.7 Palliative Procec 1.3.8.8 Date Surgical Di 1.3.8.9 Date Surgical Di 1.3.8.10 Readmit within .3.9 Overrides	scharge scharge Flag
1.3.8.5 Inst Referred To 1.3.8.6 Palliative Procec 1.3.8.7 Palliative Procec 1.3.8.8 Date Surgical Di 1.3.8.9 Date Surgical Di 1.3.8.10 Readmit within 3.9 Overrides 1.3.9.1 Summary Stage	scharge

1.3.9.4 COC-Site/Type Override	342
1.3.9.5 HospSeq/Site Override	343
1.3.9.6 Site/TNM-StgGrp Override	344
1.3.9.7 Age/Site/Morph Override (IF15)	345
1.3.9.8 SeqNo/DxConf Override (IF23)	
1.3.9.9 Site/Lat/SeqNo Override (IR09)	347
1.3.9.10 Surg/DxConf Override (IF46)	
1.3.9.11 Site/Type Override (IF25)	
1.3.9.12 Histology Override (MORPH)	350
1.3.9.13 Report Source Override (IF04)	351
1.3.9.14 III-Define Site Override (IF22)	352
1.3.9.15 Leuk, Lymphoma Override (IF48)	353
1.3.9.16 Site/Behavior Override (IF39)	354
1.3.9.17 Site/Eod/Dx Dt Override (IF40)	355
1.3.9.18 Site/Lat/Eod Override (IF41)	356
1.3.9.19 Site/Lat/Morph Override (IF42)	
1.3.9.20 CS Override	
1.3.9.21 Override TNM Tis	
1.3.9.22 Override TNM Stage	
1.3.9.23 Override TNM 3	
1.3.10 Historical	
1.3.10.1 Grade Path Value	363
1.3.10.2 Grade Path System	364
1.3.10.3 Tumor Marker 1	
1.3.10.4 Tumor Marker 2	
1.3.10.5 Tumor Marker 3	
1.3.10.6 Biopsy Procedure	
1.3.10.7 Multiplicity Counter	
1.3.10.9 Date Multiple Tumors Flag	
1.3.10.10 Type of Multiple Tumors	375
1.3.10.11 Ambiguous Terminology	
1.3.10.12 Date of Conclusive Terminology	378
1.3.10.13 Date of Conclusive Terminology Flag	379
1.3.10.14 SEER Extent	380
1.3.10.15 SEER PEP	
1.3.10.16 Tumor Size (largest)	
1.3.10.17 SEER Lymph Node	
1.3.10.18 Site of Mets	
1.3.11 Text	
1.3.11.2 Case Text	
1.3.11.3 Modified By (Case Text)	392
1.3.11.4 Time Modified (Case Text)	393
1.3.11.5 COVID-19DX PROCLAB TESTS	394
1.3.11.6 COVID-19 Impact - SURGERY	396
1.3.11.7 COVID-19 Impact - RADIATION (BEAM)	397
1.3.11.8 COVID-19 Impact - RADIATION OTHER	
1.3.11.9 COVID-19 Impact - CHEMO	
1.3.11.10 COVID-19 Impact- HORMONE	
1.3.11.11 COVID-19 Impact - BRM	
1.3.11.12 COVID-19 TEXT	402
1.3.11.13 COVID-19 Impact - BMT	404
1.3.11.14 COVID-19 Impact - RADIATION (ICB)	405
1.3.12 Case Misc	
1.3.12.2 Case Other Stee Code	
1.3.12.3 Year of Diagnosis	
1.3.12.4 Case Other Comment	
1.3.12.5 Modified By (Case Other)	
1.3.12.6 Time Modified (Case Other)	412
1.3.12.7 EOD Coding System	
1.3.12.8 Vendor	414
1.3.12.9 Census Tract 2000	
1.3.12.10 Census Tract Certainty 2000	
1.3.12.11 Census Tract 2010	
1.3.12.12 Census Block Group 2010	
1.3.12.13 Census Tract Certainty 2010	
1.3.12.14 Latitude	
1.3.12.16 GIS Coordinate Quality	
1.3.12.17 Date Case Completed	
1.3.12.18 Date Case Last Updated	
1.3.12.19 Import Reporting Facility	
1.3.12.20 Area Development District	
1.3.12.21 Appalachia	
1.3.12.22 Beale Code 2003	
1.3.12.23 Beale Code 2013	
1.3.12.24 Best Stage Group	433

1.3.12.25 SEER Site	
1.3.12.26 ICCC Site	
1.3.12.27 ICCC Extended Site	439
1.3.12.28 Source Status	440
1.3.12.29 Class Hospital Id	
1.3.12.30 Original Case Type	
1.3.12.31 Patient Acc No	
1.3.12.32 ArchiveFIN	444
1.3.12.33 Modified By (Case)	445
1.3.12.34 Time Modified (Case)	446
1.3.12.35 Date of First Recurrence Flag	117
1.3.12.36 Case User Defined Data a	
1.3.12.37 2018 Best Stage Group	
1.3.13 Census Tract	452
1.3.14 Census Tract Coding System	453
1.3.15 Seer Extent Of Disease	454
1.3.16 CPDMS Create Case From Pathology Report Application	455
1.4 Follow Up	/01
4.4 Drivery Follow Us Division	400
1.4.1 Primary Follow-Up Physician	482
1.4.2 Follow-Up Physician 2	483
1.4.3 Follow-Up Physician 3	
1.4.4 Follow-Up Physician 4	485
1.4.5 Follow-Up Physician 5	
1.4.6 Date of Last Contact or Death	487
1.4.7 Survival Status	189
	400
1.4.8 Cancer Status	
1.4.9 Date of First Recurrence	490
1.4.10 Survival Interval	
1.4.11 Type of First Recurrence	492
1.4.12 First Disease Free Start Date	494
1.4.13 Site of First Recurrence 1	
1.4.14 Dz Free Interval	406
1.4.15 Following Registry	
1.4.16 Follow-Up Last Name	498
1.4.17 Follow-Up First Name	499
1.4.18 Follow-Up Source Central	500
1.4.19 Follow-Up Source COC	
1.4.20 Next Follow-Up Method	503
1.4.21 Alternate Follow-Up Method	504
1.4.22 Follow-Up Address 1	505
1.4.23 Follow-Up City	506
1.4.24 Follow-Up State	
1.4.25 Follow-Up Zip Code	
1.4.26 Follow-Up Phone	
1.4.27 Follow-Up Relationship	505
1.4.27 Follow Up Relationship	510
1.4.28 Follow-Up Text	
1.4.29 Last Follow-up Hosp Id	512
1.4.30 Modified By (FU)	
1.4.31 Time Follow-up Modified	514
1.4.32 Date of Last Cancer (Tumor) Status	
1.5 Therapy Data	516
1.5.1 Common	517
1.5.1.1 Tx Type	518
1.5.1.2 Tx Course	
1.5.1.3 Date Tx Started	
1.5.1.4 Therapy Facility	
1.5.1.5 Therapy Local Hospital Id	
1.5.1.6 Treatment Notes	
1.5.1.7 Therapy Clinical Trial Number	
1.5.1.8 Modified By (Therapy)	
1.5.1.9 Time Modified (Therapy)	
	527
1.5.1.10 Therapy Information	
1.5.1.10 Therapy Information	529
1.5.1.10 Therapy Information	
1.5.1.10 Therapy Information	
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE)	
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE)	531
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE)	531 532
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010	531 532 533
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS)	531 532 533 534
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS)	531 532 533 534 535
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.8 Scope Reg LN (ROADS)	531 532 533 534 535 536
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.8 Scope Reg LN (ROADS) 1.5.2.9 Num LN Removed (ROADS)	531 532 533 534 535 536 536 537
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.10 Surg Other Site (ROADS)	531 532 533 534 535 536 537 538
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.10 Surg Other Site (ROADS) 1.5.2.11 Reconstruction (ROADS)	531 532 533 534 535 536 536 537 538 539
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.10 Surg Other Site (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.3 Non-Definitive Surgery	531 532 533 534 535 536 537 538 539 540
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach 2010 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.8 Scope Reg LN (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.10 Surg Other Site (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.3.1 Non-Definitive Surgery	531 532 533 534 535 536 537 538 539 540 541
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.10 Surg Other Site (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.3 Non-Definitive Surgery	531 532 533 534 535 536 537 538 539 540 541
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach 2010 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.8 Scope Reg LN (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.10 Surg Other Site (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.3.1 Non-Definitive Surgery	531 532 533 534 535 536 537 538 539 540 541 542
1.5.1.10 Therapy Information 1.5.2 Surgery 1.5.2.1 Surgery Primary Site (STORE) 1.5.2.2 Scope Regional LN (STORE) 1.5.2.3 Surgery Other Site (STORE) 1.5.2.4 Surgical Margins (STORE) 1.5.2.5 Surgical Approach 2010 1.5.2.6 Surgical Approach (ROADS) 1.5.2.7 Surg Prim Site (ROADS) 1.5.2.8 Scope Reg LN (ROADS) 1.5.2.9 Num LN Removed (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.2.11 Reconstruction (ROADS) 1.5.3.1 Non-Definitive Surgery 1.5.4 Chemotherapy	531 532 533 534 535 536 537 538 539 540 541 542 543

1.5.5.1 Radiation Therapy Code	
1.5.5.2 Radiation Site 1	
1.5.5.3 Total Rads	
1.5.5.4 Location of Radiation	
1.5.5.5 Rad Treatment Volume	549
1.5.5.6 Regional Tx Modality	552
1.5.5.7 Regional Dose	
1.5.5.8 Boost Tx Modality	
1.5.5.9 Boost Dose	
1.5.5.10 Num Treatments This Volume	
1.5.5.11 Date Radiation Ended	
1.5.5.12 Date Radiation Ended Flag	
1.5.5.13 Phase I Radiation Primary Treatment Volume	561
1.5.5.14 Phase I Radiation to Draining Lymph Nodes	564
1.5.5.15 Phase I Radiation Treatment Modality	
1.5.5.16 Phase I Radiation External Beam Planning Technique	566
1.5.5.17 Phase I Dose per Fraction	
1.5.5.18 Phase I Number of Fractions	568
1.5.5.19 Phase I Total Dose	
1.5.5.20 Phase I Therapy Local Hospital ID	570
1.5.5.21 Phase II Radiation Primary Treatment Volume	571
1.5.5.22 Phase II Radiation to Draining Lymph Nodes	574
1.5.5.23 Phase II Radiation Treatment Modality	
1.5.5.24 Phase II Radiation External Beam Planning Technique	
1.5.5.25 Phase II Dose per Fraction	577
1.5.5.25 Phase II Dose per Plaction	579
1.5.5.27 Phase II Total Dose	
1.5.5.27 Phase II Total Dose	
1.5.5.20 Phase III Radiation Primary Treatment Volume	500
1.5.5.30 Phase III Radiation Primary Treatment Volume	501
1.5.5.31 Phase III Radiation Treatment Modality	
1.5.5.32 Phase III Radiation Treatment Modality	202
1.5.5.33 Phase III Dose per Fraction	587
1.5.5.34 Phase III Number of Fractions	
1.5.5.35 Phase III Total Dose	
1.5.5.36 Phase III Therapy Local Hospital ID	
1.5.5.37 Radiation Treatment Discontinued Early	591
1.5.5.38 Number of Phases of Radiation Treatment to this Volume	
1.5.5.39 Total Dose	
1.5.6 Hormone	
1.5.6.1 Hormone Therapy Code	
1.5.7 Immunotherapy	
1.5.7.1 Immunotherapy Code	
1.5.8 Trans Endo	598
1.5.8.1 Transplant/Endocrine Code	599
1.5.9 Other	600
1.5.9.1 Other Therapy Code	
1.6 Naaccr Tx	
1.6.1 RX Date Systemic [3230]	605
1.6.2 RX Date Systemic Flag [3231]	
1.6.3 RX HospPalliative Proc [3280]	
1.6.4 Date Initial RX SEER [1260]	
1.6.5 Date Initial RX SEER Flag [1261]	
1.6.6 Date 1st Crs RX CoC [1270]	610
1.6.7 Date 1st Crs RX CoC Flag [1271]	
1.6.8 RX SummTreatment Status [1285]	
1.6.9 RX SummReg LN Examined [1296]	
1.6.10 Reason for No Surgery [1340]	
1.6.11 RX SummPalliative Proc [3270]	
1.6.12 RX SummSurg/Rad Seq [1380]	
1.6.13 Reason for No Radiation [1430]	
1.6.14 RX SummSystemic/Sur Seq [1639]	
1.6.15 Readm Same Hosp 30 Days [3190]	
1.6.16 Naaccr Chemotherapy	
1.6.16.1 RX HospChemo [700]	
1.6.16.2 RX Date Chemo [1220]	
1.6.16.3 RX Date Chemo Flag [1221]	
1.6.16.4 RX SummChemo [1390]	
1.6.17 Naaccr Hormone	
1.6.17.1 RX HospHormone [710]	
1.6.17.2 RX Date Hormone [1230]	
1.6.17.3 RX Date Hormone Flag [1231]	
1.6.17.4 RX SummHormone [1400]	
1.6.18 Naaccr Immunotherapy	
1.6.18.1 RX HospBRM [720]	
1.6.18.2 RX Date BRM [1240]	
1.6.18.3 RX Date BRM Flag [1241]	
1.6.18.4 RX SummBRM [1410] 1.6.19 Naaccr Non-Definitive Surgery	
1.0.19 Haddon Holf-Definitive Outgery	000

1 1	
1	.6.19.1 RX HospDX/Stg Proc [740]
1	.6.19.2 RX Date DX/Stg Proc [1280]
	.6.19.3 RX Date DX/Stg Proc Flag [1281]
1	.6.19.4 RX SummDX/Stg Proc [1350]
1620	Naaccr Other
	.6.20.1 RX HospOther [730]
1	.6.20.2 RX Date Other [1250]
1	.6.20.3 RX Date Other Flag [1251]
	.6.20.4 RX SummOther [1420]
	Naaccr Radiation
1	.6.21.1 RX Date Radiation [1210]
	.6.21.2 RX HospRadiation [690]
1	.6.21.3 RX Date Radiation Flag [1211]
	.6.21.4 RX Date Rad Ended [3220]
	.6.21.5 RX Date Rad Ended Flag [3221]
1	.6.21.6 RX SummRadiation [1360]
1	.6.21.7 RX SummRad to CNS [1370]
I	.6.21.8 RadRegional Dose: cGy [1510]
1	.6.21.9 RadNo of Treatment Vol [1520]
	.6.21.10 RadTreatment Volume [1540]
	.6.21.11 RadLocation of RX [1550]
1	.6.21.12 RadRegional RX Modality [1570]
	.6.21.13 RadBoost RX Modality [3200]
	.6.21.14 RadBoost Dose cGy [3210]
1.6.22	Paaccr Surgery
1	.6.22.1 RX Date Surgery [1200]
	6.22.2 RX Date Surgery Flag [1201]
1	.6.22.3 RX HospSurg App 2010 [668]
1	.6.22.4 RX HospSurg Prim Site [670]
	.6.22.5 RX Date Mst Defn Srg [3170]
1	.6.22.6 RX HospScope Reg LN Sur [672]
1	.6.22.7 RX Date Mst Defn Srg Flag [3171]
	.6.22.8 RX HospSurg Oth Reg/Dis [674]
1	
	.6.22.9 RX Date Surg Disch [3180]
1	.6.22.10 RX HospReg LN Removed [676]
1	.6.22.11 RX Date Surg Disch Flag [3181]
	.6.22.12 RX HospSurg Site 98-02 [746]
	.6.22.13 RX HospScope Reg 98-02 [747]
	.6.22.14 RX HospSurg Oth 98-02 [748]
	.6.22.15 RX SummSurg Prim Site [1290]
	.6.22.16 RX SummScope Reg LN Sur [1292]
	.6.22.17 RX SummSurg Oth Reg/Dis [1294]
	.6.22.18 RX SummSurgical Approch [1310]
	.6.22.19 RX SummSurgical Margins [1320]
1	.6.22.20 RX SummReconstruct 1st [1330]
1	.6.22.21 RX SummSurgery Type [1640]
1	.6.22.22 RX SummSurg Site 98-02 [1646]
1	.6.22.23 RX SummScope Reg 98-02 [1647]
1	.6.22.24 RX SummSurg Oth 98-02 [1648]
160	B Naaccr Trans Endo
	.6.23.1 RX SummTransplnt/Endocr [3250]
.7 Class	Data
	Hospital Chart No (Class)
	Class Local Hosp Id
1.7.3	Registry Accession Year (Class)
	Class of Case (Class)
	Date of First Contact (Class)
1.7.6	Inst Referred From (Class)
	Inst Referred To (Class)
177	
	Date Class Hx Completed CoC
1.7.8	Date Class Hx Completed
1.7.8) Palliative Procedure - This Facility (Class)
1.7.8 1.7.9	
1.7.8 1.7.9 1.7.10	
1.7.8 1.7.9 1.7.1(1.7.1	Abstracted By (Class)
1.7.8 1.7.9 1.7.1(1.7.1	
1.7.8 1.7.9 1.7.1(1.7.1 1.7.12	Abstracted By (Class)
1.7.8 1.7.9 1.7.10 1.7.12 1.7.12 1.7.12	Abstracted By (Class)
1.7.8 1.7.9 1.7.10 1.7.12 1.7.12 1.7.12 1.7.12	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated
1.7.8 1.7.9 1.7.10 1.7.12 1.7.12 1.7.12 1.7.12	Abstracted By (Class)
1.7.8 1.7.9 1.7.1(1.7.12 1.7.12 1.7.12 1.7.14 1.7.15	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Import Reporting Facility (Class)
1.7.8 1.7.9 1.7.10 1.7.11 1.7.12 1.7.13 1.7.14 1.7.15 1.7.15 1.7.16	Abstracted By (Class) 2 Patient Acc No (Class) 3 ArchiveFIN (Class) 4 Date Class Hx Last Updated 5 Import Reporting Facility (Class) 3 CS Override 1 (Class)
1.7.8 1.7.9 1.7.1 1.7.1 1.7.1 1.7.1 1.7.1 1.7.1 1.7.1 1.7.1 1.7.1	Abstracted By (Class) 2 Patient Acc No (Class) 3 ArchiveFIN (Class) 4 Date Class Hx Last Updated 5 Import Reporting Facility (Class) 3 CS Override 1 (Class) 7 Modified By (Class)
1.7.8 1.7.9 1.7.10 1.7.12 1.7.12 1.7.12 1.7.14 1.7.15 1.7.16 1.7.17 1.7.18	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Import Reporting Facility (Class) CS Override 1 (Class) Modified By (Class) Time Modified (Class)
1.7.8 1.7.9 1.7.10 1.7.12 1.7.12 1.7.12 1.7.14 1.7.15 1.7.16 1.7.17 1.7.18	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Import Reporting Facility (Class) CS Override 1 (Class) Modified By (Class) Time Modified (Class)
1.7.8 1.7.9 1.7.10 1.7.12 1.7.12 1.7.12 1.7.14 1.7.15 1.7.16 1.7.15 1.7.18 1.7.18 1.7.18	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Date Class Hx Last Updated Constraints of the second
1.7.8 1.7.9 1.7.10 1.7.11 1.7.12 1.7.12 1.7.12 1.7.14 1.7.15 1.7.15 1.7.15 1.7.15 8.8 Appen 1.8.1	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Date Class Hx Last Updated Construction of the second
1.7.8 1.7.9 1.7.10 1.7.11 1.7.12 1.7.12 1.7.12 1.7.14 1.7.15 1.7.15 1.7.15 1.7.15 8.8 Appen 1.8.1	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Date Class Hx Last Updated Construction of the second
1.7.8 1.7.9 1.7.10 1.7.11 1.7.12 1.7.13 1.7.14 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.15 1.7.10	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Date Class Hx Last Updated Class) CS Override 1 (Class) Modified By (Class) Time Modified (Class) Time Modified (Class) Appendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases Appendix B - SEER Geocodes
1.7.8 1.7.9 1.7.11 1.7.12 1.7.12 1.7.12 1.7.14 1.7.15 1.7.16 1.7.11 1.7.18 1.8 Appen 1.8.1 1.8.2 1.8.3	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Import Reporting Facility (Class) S CS Override 1 (Class) Modified By (Class) 3 Time Modified (Class) 3 Time Modified (Class) Appendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases Appendix B - SEER Geocodes Appendix C - Site Groups
1.7.8 1.7.9 1.7.11 1.7.12 1.7.12 1.7.13 1.7.14 1.7.15 1.7.14 1.7.15 1.7.14 1.7.15 1.8.Appen 1.8.1 1.8.2 1.8.3 1.8.4	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) I Date Class Hx Last Updated 5 Import Reporting Facility (Class) 3 CS Override 1 (Class) 3 CS Override 1 (Class) 4 Modified By (Class) 3 Time Modified (Class) 4 Time Modified (Class) 4 Opendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases Appendix B - SEER Geocodes Appendix C - Site Groups Appendix D - County Codes for Kentucky and its Contiguous States
1.7.8 1.7.9 1.7.11 1.7.12 1.7.12 1.7.13 1.7.14 1.7.15 1.7.14 1.7.15 1.7.14 1.7.15 1.8.Appen 1.8.1 1.8.2 1.8.3 1.8.4	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) Date Class Hx Last Updated Import Reporting Facility (Class) S CS Override 1 (Class) Modified By (Class) 3 Time Modified (Class) 3 Time Modified (Class) Appendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases Appendix B - SEER Geocodes Appendix C - Site Groups
1.7.8 1.7.9 1.7.11 1.7.12 1.7.12 1.7.12 1.7.13 1.7.14 1.7.15 1.7.14 1.8 Appen 1.8.1 1.8.2 1.8.3 1.8.4 1.8.5	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) I Date Class Hx Last Updated 5 Import Reporting Facility (Class) 5 CS Override 1 (Class) 7 Modified By (Class) 8 Trime Modified (Class) 9 Time Modified (Class) 9 Time Modified (Class) 9 Appendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases Appendix B - SEER Geocodes Appendix C - Site Groups Appendix D - County Codes for Kentucky and its Contiguous States Appendix E - General Site Codes
1.7.8 1.7.9 1.7.10 1.7.11 1.7.12 1.7.12 1.7.14 1.7.15 1.7.16 1.7.16 1.7.11 1.7.16 1.8.4 1.8.1 1.8.2 1.8.3 1.8.4 1.8.5 1.8.6	Abstracted By (Class) Patient Acc No (Class) ArchiveFIN (Class) I Date Class Hx Last Updated 5 Import Reporting Facility (Class) 3 CS Override 1 (Class) 3 CS Override 1 (Class) 4 Modified By (Class) 3 Time Modified (Class) 4 Time Modified (Class) 4 Opendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases Appendix B - SEER Geocodes Appendix C - Site Groups Appendix D - County Codes for Kentucky and its Contiguous States

	1.8.9 Appendix I - Common Abbreviations	794
	1.8.10 Appendix J - ICD-O-3 Errata and Clarifications	802
	1.8.11 Appendix K - Race Coding Rules and Tables	803
	1.8.12 Appendix L - Frequent Surnames	806
	1.8.13 Appendix M - Supplemental ICD-10-CM Codes	807
	1.8.14 Appendix N - Pre-2014 Grade Coding Instructions	856
	1.8.15 Appendix O - Area Development District Map	860
1	.9 Instructional Videos	861

KCR Abstractors Manual

The Cancer Patient Data Management System (CPDMS.net) is a comprehensive, web-based application for collecting, managing and analyzing information related to the diagnosis and treatment of cancer patients in Kentucky. CPDMS.net was developed by the Kentucky Cancer Registry (KCR) to provide individual hospitals with the ability to monitor the type of cancer patients seen in the hospital, the extent of disease at diagnosis, the type of diagnostic procedures used and the type of therapy provided. CPDMS.net enables hospital registries to follow cancer patients over time. Data on all known medical intervention and the health status of each patient can be periodically recorded using CPDMS.net. These data allow individual hospitals to examine both the use of various diagnostic and therapeutic resources as well as the potential effect of these resources on patient survival.

CPDMS.net is designed for independent and autonomous use by individual health care facilities. However, a central repository of data on all cancer patients diagnosed and treated in Kentucky has been established in the Kentucky Cancer Registry. This central data base allows for the calculation and publication of cancer incidence rates for the entire state of Kentucky, as well as for smaller geographic regions within the state.

CPDMS.net includes complete documentation. This abstractor's manual describes each data item which will be collected and precise instruction regarding how the information is to be coded. Mandatory data items are identified by using all UPPER CASE letters in the variable name. Optional items are shown in upper and lower case letters in the item's name. A list of all of the data items in CPDMS.net may be obtained here. The KCR website also contains a printable copy of the abstract form (CPDMS.net Abstract Form 2018). On the form, mandatory items are in bold faced type. In addition, a CPDMS.net operator's manual has been developed. The operator's manual contains step-by-step instructions for performing each function of this registry software.

CPDMS.net is a valuable tool for any hospital wishing to develop and maintain a high quality cancer care program. The application meets all of the requirements for an American College of Surgeons approved cancer program and all of the requirements for the National Cancer Institute's SEER Program. Regional coordinators are available through the KCR to assist hospitals using CPDMS.net in setting up their registry, training personnel, abstracting data and analyzing the information.

- Introduction
- Patient Data
- Case Data
- Follow Up
- Therapy Data
- Naaccr Tx
- Class Data
- Appendices
- Instructional Videos

Introduction

- Computerized Record Structure
- Case Reporting Requirements
 Reporting of Tumor Molecular Test Data
 Ambiguous Terminology at Diagnosis

- Ambiguous Terminology at Diagnosis
 Casefinding
 Staging Systems
 First Course Therapy
 Follow Up Policies And Procedures
 Changes To The Manual
 General Rules Multiple Primaries
 Hematopoietic And Lymphoid Malignancy Coding Rules
 Lymphatic And Hematopoietic Multiple Primary Rules
 Solid Tumors Rules for Coding Multiple Primaries

Computerized Record Structure

CPDMS.net is a fully relational database designed in a modular fashion. Each patient record has a unique identification number internally generated by the computer which links all information stored about that patient. Patient identification information occurs only once in the patient record.

Attached to the patient record is a file containing ten optional, user-defined fields for patient level data.

Each patient may have more than one primary malignancy, or case. These are identified by the primary sequence number and site group code. Those cases which are reportable by your hospital will also have segments of the record containing diagnosis and staging information, as well as follow up data. These data items will occur only once in a case record.

Attached to the case record are segments containing therapy and open text data. The therapy segments may be repeated as often as necessary to record all the appropriate information about a case. Additionally, there are record segments which contain hospital-specific identifiers for each case. Twenty optional, user-defined fields are available for each case record.

For further information regarding CPDMS.net, please refer to the Operator's Manual.

Case Reporting Requirements

CASES TO BE REPORTED:

All cases of primary malignant disease diagnosed or treated at a Kentucky health care facility on or after January 1, 1991, should be reported to the Kentucky Cancer Registry (KCR). These are usually described by the terms: carcinoma, sarcoma, melanoma, leukemia, or lymphoma. Reportable cases may be identified by specified ICD-10-CM codes. Refer to Casefinding for a list of these codes. They may also be classified by ICD-0 topography, morphology, and behavior codes. Effective with diagnoses in 2010, all hematopoietic and lymphoid neoplasms classified with a behavior code 3 in the "WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues" are reportable. These fall into the histology code range of 9590/3 - 9992 /3. Only in-situ and malignant neoplasms are reportable (behavior codes 2 and 3); benign, borderline, and metastatic tumors are not reportable to the KCR, except as noted below. However, if a term is used which usually has a behavior code of '0' or '1', but is verified by a pathologist as in-situ or malignant (behavior code 2 or 3), these cases are reportable.

THE ONLY EXCEPTIONS to this are:

- Neoplasms of the skin (ICD-O Topography codes C44.0 to C44.9) with the following ICD-O Morphology codes are NOT reportable:
- M 8000-8005 Neoplasms, NOS
- M 8010-8046 Epithelial neoplasms
- M 8050-8084 Squamous cell neoplasms of the skin
- M 8090-8110 Basal cell neoplasms of the skin

NOTE: Localized basal and squamous cell skin cancers greater than 5 cm at diagnosis, as well as those diagnosed at a regional or distant stage, were previously required by ACoS for approved hospitals prior to 2003. They are not required to be reported to KCR or to ACoS after January 1, 2003.

- Cases of intraepithelial neoplasia, Grade III, of the cervix or prostate (M-8077/2). These are often designated by terms such as CIN III or PIN III. These cases are not required to be abstracted or reported. However, the following cases of Laryngeal intraepithelial neoplasia III (LIN III) (C320-C329), Lobular neoplasia grade III (LN III)/Iobular intraepithelial neoplasia grade III (LIN III), Penile intraepithelial neoplasia, grade III (PelN III) (C600-C609), Squamous intraepithelial neoplasia III (SIN III) excluding cervix, Vaginal intraepithelial neoplasia III (VAIN III) (C529), Vulvar intraepithelial neoplasia III (VIN III) (C510-C519), Anal intraepithelial neoplasia III (AIN III) of the anus or anal canal (C210-C211) are reportable.
- Any carcinoma in-situ of the cervix is not to be reported to KCR, as of January 1, 1998. This includes any type of malignancy with a topography code of C53 and a behavior code of 2.
- Pilocytic astrocytoma (C71.__, M-9421/1) is required to be reported as a malignant brain tumor with 9421/3.
- As of January 1, 2004, the following non-malignant primary intracranial and central nervous system tumors with a behavior code of /0 or /1 (benign and borderline, or "non-malignant") are required to be reported, regardless of histologic type, for these ICD-O-3 topography codes.

Table 1. Topography Codes for Benign Brain Tumors

Code	Description
Meninges	
C70.0	Cerebral meninges
C70.1	Spinal meninges
C70.9	Meninges, NOS
Brain	
C71.0	Cerebrum
C71.1	Frontal lobe
C71.2	Temporal lobe
C71.3	Parietal lobe
C71.4	Occipital lobe
C71.5	Ventricle, NOS
C71.6	Cerebellum, NOS
C71.7	Brain stem
C71.8	Overlapping lesion of brain
C71.9	Brain, NOS
Spinal Cord, Cranial Nerves, and Other Parts of the Central Nervous System	
C72.0	Spinal cord

C72.1	Cauda equina
C72.2	Olfactory nerve
C72.3	Optic nerve
C72.4	Acoustic nerve
C72.5	Cranial nerve, NOS
C72.8	Overlapping lesion of brain and central nervous system
C72.9	Nervous system, NOS
Other endocrine glands and related structures	
C75.1	Pituitary gland
C75.2	Craniopharyngeal duct
C75.3	Pineal gland

NOTE: Benign and borderline tumors of cranial bones (C41.0) are not reportable.

NOTE: For non-malignant primary intracranial and central nervous system tumors (C70.0 - C72.9, C75.1 - C75.3), the terms "tumor" and "neoplasm" are considered diagnostic for the purpose of case reporting, in addition to the terms generally applicable to malignant tumors.

PATIENTS TO BE REPORTED:

All patients first seen and/or treated at each Kentucky hospital after January 1, 1991 for a diagnosis of cancer should be reported to the Kentucky Cancer Registry. This includes inpatient admissions and patients seen in ambulatory care settings that are hospital affiliated. It includes all clinical diagnoses of cancer, whether histologically confirmed or not. It also includes patients diagnosed as autopsy.

As of January 1, 1995, all patients seen or treated in any licensed health facility in the state, which provides diagnostic or treatment services to cancer patients, shall report cases to the Kentucky Cancer Registry. Physicians in private practice should report any cases of cancer diagnosed or treated in their offices which are not otherwise reported to KCR by another health care facility.

PATIENTS NOT REQUIRED TO BE REPORTED BY HOSPITALS:

1. Patients who are seen only in consultation to confirm a cancer diagnosis or treatment plan, and no treatment was provided by your facility.

EXAMPLE: Patient comes to your institution for a second opinion. Staff physicians order diagnostic tests. The physicians support the original treatment plan. Patient returns to the other institution for treatment.

2. Patients who receive transient care to avoid interrupting a course of therapy initiated elsewhere, for example, while vacationing, or because of equipment failure at the original hospital.

- 3. Patients whose medical chart indicates a history of cancer only, and who were diagnosed prior to 1991.
- 4. Patients with in-situ or localized neoplasms of the skin (as listed above).
- 5. Patients with preinvasive neoplasia of the cervix (as listed above).

TIME FRAME FOR REPORTING:

Cases must be reported to the KCR within 6 months from the date of initial diagnosis or date first seen at the reporting facility if not diagnosed there. For those patients seen on an outpatient basis only, the outpatient visit date is considered the date of discharge.

CLASSES OF CASE:

The class of case codes as defined by the American College of Surgeons in their Facility Oncology Registry Data Standards (FORDS) manual, describe categories (or classes) of cases based on the facility's role in managing the cancer, whether the cancer is required to be reported, and whether the case was diagnosed after the program's reference date. The reporting requirements of the Kentucky Cancer Registry may differ from those of the American College of Surgeons. For a discussion of ACoS requirements, refer to the FORDS manual.

Class of Case divides cases into two groups. Analytic cases (codes 00–22) are those that are required by CoC to be abstracted because of the program's primary responsibility in managing the cancer. Nonanalytic cases (codes 30–49 and 99) may be abstracted by the facility to meet central registry requirements or in response to a request by the facility's cancer program.

KCR requires all analytic cases (class 00-22) as well as autopsy only cases (class 38) to be fully abstracted and reported to KCR. In addition, cases of VIN III, VAIN III, AIN III (8077/2), PeIN III, LIN III, AIN SIN III, though not required by COC, are required to be reported to SEER and KCR. Therefore, these cases should be coded in the analytic classes (00-22) rather than 34 or 36. They will automatically be excluded from transmission to NCDB by CPDMS.net. KCR also requires information about non-analytic cases (class 32 and 40-43) to be reported to KCR. See Section below: INFORMATION TO BE REPORTED TO KCR.

In the 2010 class of case conversion, skin cancers which were reportable prior to 2003 and CIN/CIS of the cervix diagnosed prior to 1998 are converted to class 34 or 36, as applicable. See Class of Case for a comprehensive list of all classes of cases.

INFORMATION TO BE REPORTED TO KCR:

Cases in classes 00-22 and 38 must be fully abstracted in CPDMS.net. All mandatory data elements must be filled in. Detailed instructions for completing the Abstract Form can be found in this manual.

These cases must also be followed annually throughout the life of the patient. A comprehensive method to identify and track patients must be implemented by the reporting hospital. The follow up information that is required to be reported is detailed in items Follow Up. The only exceptions to the follow up requirements are patients residing in foreign countries and patients with carcinoma in situ of the cervix. These two categories of patients are not required to be followed, regardless of class of case. The ACoS does not require CoC approved hospitals to follow patients over 100 years of age. However, KCR requires Kentucky hospitals to follow all patients in classes 00-22, regardless of age.

Cases diagnosed prior to January 1, 2000, which are class 32 (formerly class 3 before 2010) must be reported to KCR. Effective with year 2000 diagnoses, registries have a choice in reporting class 32 cases to KCR. Facilities may choose to continue abstracting these cases, or instead they may send the case information to KCR to be abstracted. If your registry chooses to forward the case to KCR, you are still required to send all applicable case information to KCR in a timely manner!

Cases in class 37 (formerly class 4 prior to 2010) are not required to be reported to the Kentucky Cancer Registry. Abstracting the case and lifetime follow up are entirely optional.

Cases in class 49 (formerly class 8 prior to 2010) are those discovered through death certificate files only. KCR staff will abstract these cases. Class 49 is only for use by the central registry.

Cases in class 99 (formerly class 9 prior to 2010) are nonhospital facility cases. Class 99 is only for use by the central registry. NOTE: If your hospital has read an outside pathology report diagnosing cancer, this is not reportable by your facility. However, information regarding the diagnosis MUST be sent to KCR so that the case may be abstracted by nonhospital facility staff.

THERAPY - FIRST AND SUBSEQUENT COURSE

First course of therapy includes any and all procedures or treatments planned by the managing physician(s), and administered during or after the first clinical diagnosis of cancer. Treatment usually modifies, controls, removes, or destroys proliferating cancer tissue, whether primary or metastatic, regardless of the patient's response. First course may include multiple modes of therapy, and may encompass intervals of a year or more.

No therapy is a treatment option that occurs if the patient or family refuses treatment, or the patient dies before treatment starts, or the physician recommends "watchful waiting" or no treatment be given.

When a treatment plan is not available, evaluate the therapy and the time it started. If the therapy is a part of an established protocol or within accepted management guidelines for the disease, it is first course of therapy. Consult the attending physician or registry's physician advisor if protocols or management guidelines are not available.

If there is no treatment plan, established protocol, or management guidelines, and you cannot consult with a physician, use the principle: "initial treatment must begin within four months of the date of initial diagnosis." All other cancer-directed therapy that begins within four months of the date of the initial treatment would be first course of therapy.

TIME FRAME FOR REPORTING FOLLOW-UP INFORMATION:

Current follow-up information must be reported to KCR for every case diagnosed since 1995 that is class 00-22. Follow-up information is considered current if the date of last contact with the patient is within 15 months of the current date. CPDMS.net can generate reports which identify patients who require updated follow-up information.

Reporting of Tumor Molecular Test Data

All next generation sequencing (NGS)-derived molecular test results of cancer specimens used in the diagnosis, clinical evaluation or treatment of cancer patients must be reported to the Kentucky Cancer Registry (KCR) and in a format prescribed by KCR in accordance with KRS 214.556. Tests include, but are not limited to, targeted panels, RNAseq, whole genome sequencing (WGS), whole exome sequencing (WES), and DNA Methylation. Reportable data currently include, but are not limited to FASTQ, binary sequence alignment maps (BAM), structured RNAseq and the accompanying clinical mutation results (MAF, VCF and/or clinical mutation reports). Mutation results should include all variants of both known and unknown significance. PDF clinical reports alone are not sufficient.

Identifiers needed for record linkage

Associated patient identifiers such as name, birth date, social security numbers, medical record numbers, pathology specimen number and other identifiers must accompany test result files. Identifiers must be sufficient to identify the patient, cancer case and pathology specimen used for sequencing.

Reporting methods and formats

In accordance with KRS 214.556, all healthcare providers are required to report these data to the KCR. However, it is preferable for molecular testing laboratories report the results directly to the Kentucky Cancer Registry electronically on behalf of the providers.

National standard formats for reporting these data to cancer registries have not yet been established. KCR is working with NGS labs and national and federal agencies to facilitate the development of such standards. For new providers, KCR will facilitate the establishment of a secure and mutually agreeable transmission mechanism and file format. Please contact KCR for more information.

Supported vendors

KCR has an established reporting protocol in place with the following providers:

- · Foundation Medicine, Inc., Cambridge, MA.
- HudsonAlpha Institute for Biotechnology, Huntsville, AL.
- The Translational Genomics Research Institute (TGen), Phoenix, AZ.

This information is current as of 09/27/2019.

Ambiguous Terminology at Diagnosis

According to the Reporting Requirements, all cases of primary malignant disease diagnosed or treated at a Kentucky hospital on or after January 1, 1991 are required to be included. These are usually described by the terms: carcinomas, sarcomas, melanomas, leukemias, and lymphomas. The primary reference book which lists all malignant diseases is the International Classification of Diseases for Oncology (ICD-O), third edition. In addition to providing a list of all morphologies considered to be malignant (or cancerous), the ICD-O book also contains cell behavior codes: 0=benign, 1=borderline malignancy, 2=in-situ, 3=malignant primary, 6=malignant metastasis, and 9=malignant, unknown if primary or metastatic. All malignancies with a behavior code of 2 or 3 in ICD-O, 3rd edition, should be included in the registry, except specified neoplasms of the skin and preinvasive cervical neoplasia, as described in Case Reporting Requirements. Benign and borderline CNS tumors diagnosed on or after January 1, 2004 are required to be reported.

Other benign tumors and borderline malignancies (behavior codes 0 and 1) may be listed in the registry in a separate accession register. They should not be entered into CPDMS.net. These diagnoses are referred to as "reportable-by-agreement" cases.

Metastatic tumors and tumors that are unknown if primary or metastatic (behavior codes 6 and 9) are indicative of a primary malignancy of an unknown site. These cases should be reported with the primary site coded as "unknown primary" (topography code of C80.9) and the appropriate morphology code with a behavior code of /3.

1. Inconclusive diagnostic terms

Occasionally the diagnosis contains vague or inconclusive terms, such as probable carcinoma of the lung. The following terms are considered to be diagnostic of cancer if they modify a term such as malignancy or carcinoma:

- apparent(ly)
- appears
- compatible with
- comparable with
- consistent with
- favor(s)
- most likely
- malignant appearing
- most likely
- presumed
- probable
- suspect(ed)
- suspicious (for)
- typical of

EXCEPTION: If a cytology report says "suspicious," do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology. The diagnosis date is date of supporting documentation - either physician statement or positive biopsy.

If a term does not appear on the above list, or is not a form of a word on this list, the term is not diagnostic of cancer. Do not accession the case. Examples of forms of a word are "favored" rather than "favor(s)" and "appeared to be" rather "appears." Do **not** substitute synonyms such as "supposed" for "presumed" or "equal" for "comparable."

Any other ambiguous terminology regarding the diagnosis of a malignancy is not to be interpreted as diagnostic of cancer. Some examples are:

cannot be ruled out
equivocal
likely
lump
lytic lesion (on x-ray)
mass
neoplasm*
nodule
possible
potentially malignant

questionable

rule out

suggests

tumor*

worrisome

For example, a diagnosis of probable carcinoma of the left lung would be abstracted as a lung primary. A possible carcinoma is not reportable.

*EXCEPTION: For benign and borderline brain and CNS tumors, the terms "tumor" and "neoplasm" will be considered diagnostic of a reportable disease.

2. Changing the diagnosis

Over time, information may be added to the patient's medical chart that was missing or ambiguous in the original record. It is the practice to accept the thinking and information about the case based on the latest or most complete information. Thus, it is acceptable to change the primary site and histology as information becomes more complete. However, information about the Collaborative Stage and extent of disease at diagnosis may only be changed as long as the new information reflects the time period within four months of the date of diagnosis in the absence of disease progression or through first course surgeries, whichever is longer.

There may be cases reported originally as cancer with the ambiguous terms listed previously, which later information indicates never were malignancies. These cases must be deleted from the file, and the sequence number of any remaining cases for the same person adjusted accordingly.

Casefinding

All participating institutions should establish procedures for complete casefinding within their institution. In many hospitals, records are housed in one location (i.e., the medical records department). In others, procedures for identifying patients from multiple independent ancillary service areas may be necessary (i.e., outpatient clinics, radiation therapy, etc). It is important that the following multiple sources in the hospital be searched to keep missed reportable cases to a minimum. The procedures outlined below should be adapted to each individual hospital.

1. Medical record disease discharge diagnostic index:

Any patient record coded with the diagnoses listed below should be reviewed to determine if the case is one which meets KCR reportability criteria. Note that a diagnosis is not necessarily reportable simply because it falls within the codes below; refer to the Case Reportability Requirements to make sure the case is truly reportable to KCR.

ICD-10-CM Codes (Effective 10-01-2018 through 09-30-2019)

ICD-10 Code	Explanation of Code
C00 C43, C4A, C45 C48, C49 -C96	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies
C44.00, C44. 09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44. 19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018
C44.20-, C44. 29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44. 39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44. Unspecified/other malignant neoplasm of skin of scalp & neck 49	
C44.50-, C44. 59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44. 69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44. 79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44. Unspecified/other malignant neoplasm of skin of overlapping sites of skin 89	
C44.90, C44. 99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A-	Gastrointestinal Stromal Tumors Note: GIST is only reportable when it is malignant (/3). GIST, NOS (not stated whether malignant or benign) is a /1 and is not reportable.
D00 D09	In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable
D18.02	Hemangioma of intracranial structures and any site
D32	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33	Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42, D43	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland

D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)
D46	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)
D47.02	Systemic mastocytosis
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82)
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia
D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3)
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

ICD-10-CM Codes (Effective 10-01-2017 through 09-30-2018)

REPORTABLE NEOPLASMS

ICD- 10 CODE	EXPLANATION OF CODE
C00 C43, C4A, C45 C48, C49 C96	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies NEW for FY2018: C96.20 Malignant mast cell neoplasm, unspecified C96.21 Aggressive systemic mastocytosis C96.22 Mast cell sarcoma C96.29 Other malignant cell neoplasm
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip

C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin	
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin	
C49.A-	Gastrointestinal Stromal Tumors Note: GIST is only reportable when it is malignant (/3). GIST, NOS (not stated whether malignant or benign) is a /1 and is not reportable.	
D00 D09	In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable	
D18.02	Hemangioma of intracranial structures and any site	
D32	Benign neoplasm of meninges (cerebral, spinal and unspecified)	
D33	Benign neoplasm of brain and other parts of central nervous system	
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland	
D42, D43	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS	
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland	
D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)	
D46	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)	
D47.02	Systemic mastocytosis Note: Effective 10/1/2017	
D47.1	Chronic myeloproliferative disease (9963/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_), Chronic myeloid leukemia BCR/ABL-positive (C92.1_), Myelofibrosis & Secondary myelofibrosis (D75.81), Myelophthisic anemia & Myelophthisis (D61.82)	
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia	
D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis, Myelofibrosis (idiopathic) (with myeloid metaplasia), Myelosclerosis (megakaryocytic) with myeloid metaplasia), Secondary myelofibrosis in myeloproliferative disease	
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3)	
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)	
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS	
R85.614	Cytologic evidence of malignancy on smear of anus	
R87.614	Cytologic evidence of malignancy on smear of cervix	
R87.624	Cytologic evidence of malignancy on smear of vagina	

¹ Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).

ICD-10-CM Codes (Effective 10-01-2016 through 09-30-2017)

ICD-10-CM Code	Explanation of ICD-10-CM Code
C00 C43, C4A, C45 C96	Malignant neoplasms (excluding category C44), stated or presumed to be primary (of specified site) and certain specified histologies. <i>NEW for FY2017: C49.A-, Gastrointestinal Stromal Tumors, Effective 10/1 /2016</i>
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid

C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
D00 D09	In-situ neoplasms
	Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable
D18.02	Hemangioma of intracranial structures and any site
D18.1	Lymphangioma, any site
	Note: Includes Lymphangiomas of Brain, Other parts of nervous system and endocrine glands, which are r eportable
D32	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33	Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42, D43	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D45	Polycythemia vera (9950/3)
	ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D7 5.1)
D46	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3)
	ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C9 2.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelo phthisis (D61.82)
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3)
	Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia
D47.4	Osteomyelofibrosis (9961/3)
	Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with m yeloid metaplasia)
	Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3)

D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, uns pecified (9970/1, 9931/3)
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3(malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will C ONTINUE to report these cases and code behavior as /3 (malignant).

ICD-9-CM Code	Explanation of Code
140.0 - 172.9	Malignant neoplasms
173.00	Unspecified malignant neoplasm of skin of lip
173.09	Other specified malignant neoplasm of skin of lip
173.19	Other specified malignant neoplasm of skin of eyelid
173.29	Other specified malignant neoplasm of skin of ear
173.39	Other specified malignant neoplasm of skin of face
173.49	Other specified malignant neoplasm of skin of scalp
173.59	Other specified malignant neoplasm of skin of trunk
173.69	Other specified malignant neoplasm of skin of arm
173.79	Other specified malignant neoplasm of skin of leg
173.89	Other specified malignant neoplasm of skin of other
173.99	Other specified malignant neoplasm of skin NOS
174.0 - 209.36	Malignant neoplasms
209.70 - 209.79	Secondary neuroendocrine tumors
225.0 - 225.9	Benign neoplasm of brain and spinal cord neoplasm
227.3 - 227.4	Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland
227.9	Benign neoplasm; endocrine gland, site unspecified
228.02	Hemangioma; of intracranial structures
228.1	Lymphangioma, any site

230.0 - 234.9	Carcinoma in situ
236.0	Endometrial stroma, low grade
237.0 - 237.9	Neoplasm of uncertain behavior (borderline) of endocrine glands an d nervous system
238.4	Polycythemia vera
238.6 - 238.79	Other lymphatic and hematopoietic diseases
239.6 - 239.89	Neoplasms of unspecified nature
273.2	Other paraproteinemias
273.3	Macroglobulinemia
288.3	Eosinophilia
288.4	Hemophagocytic syndromes
795.06	Pap smear of cervix with cytologic evidence of malignancy
795.16	Pap smear of vagina with cytologic evidence of malignancy
796.76	Pap smear of anus with cytologic evidence of malignancy
V10.0 - V10.91	Personal history of malignancy
V12.41	Personal history of benign neoplasm of the brain

This procedure is imperative to assure that no cases have been missed, including those originally diagnosed by clinical methods only. A list of detailed and supplemental ICD-10-CM codes effective 10/01/2016 thru 09/30/2017 which may also be used for casefinding is available in APPENDIX M.

-ollow this link for a casefinding list of reportable ICD-10 codes effective 10/01/2015, which includes a comprehensive list plus a supplemental list. http://see r.cancer.gov/tools/casefinding/case2016-icd10cm.html

2. Pathology reports:

All pathology reports on both inpatients and outpatients should be reviewed for case reportability. Since most cancer patients have a biopsy or operative resection performed, nearly all of the reportable cases can be identified through pathology reports alone. Histologic diagnoses are based upon microscopic examination of tissue taken from such procedures as biopsy, frozen section, surgery, or D & C. Expand path report screening to include benign CNS tumors, beginning with 1-1-04 diagnoses. Check for cases of anal intraepithelial neoplasia, grade III (AIN III), ductal intraepithelial neoplasia (DIN 3), vaginal intraepithelial neoplasia, grade III (VIN III), Laryngeal intraepithelial neoplasia III (LIN III), bultar intraepithelial neoplasia grade III (VIN III), and Squamous intraepithelial neoplasia III (SIN III) excluding cervix.

NOTE: Path reports may be the best source for finding cases of VIN, VAIN, and AIN (8077/2) and DIN (8500/2).

3. Cytology reports:

All cytology reports for both inpatients and outpatients should be reviewed for case reportability. Cytologic diagnoses are based upon microscopic examination of cells as contrasted with tissues. Included are smears from sputum, bronchial bushings, bronchial washings, tracheal washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, and urinary sediment. Cervical and vaginal smears are common examples.

- 4. Autopsy reports.
- 5. Radiation Therapy Department logs.
- 3. Medical Oncology Department logs.
- 7. Outpatient Department:

New patient registration rosters, clinic appointment books, surgery schedules, diagnostic imaging, and billing departments are additional casefinding sources.

3. Alpha listing of previously included cases:

Casefinding cannot be considered complete until the CPDMS.net accession list and any previous registry accession lists have been checked to be sure that this is a new patient or a new primary.

Creating and Maintaining a Nonreportable List

n the course of routine casefinding activities, cases which are found to be nonreportable by your hospital should be added to a nonreportable list. The list should consist of each patient's name, DOB, SSN, medical record number, the type/site of cancer, and a brief explanation of why the case is not reportable to the hospital registry (i.e., "patient was seen for consult only, no dx or tx," or "patient originally diagnosed prior to reference date"). A well-maintained nonreportable list will save registrars time by preventing them from reviewing a chart multiple times to check on a particular primary that does not not be abstracted. The list can be invaluable during casefinding audits by allowing quick resolution of possible missed cases. It is also helpful during the death clearance process.

Bear in mind that cases which are not reportable by your hospital, but which **ARE** reportable to KCR (see Case Reporting Requirements) should be sent to the central registry to be abstracted there. These may include:

- A specimen from an outside doctor's office which was sent to your hospital's path lab
- Any case that was diagnosed and/or treated only in a nonhospital facility
- A Kentucky resident who was initially diagnosed or treated out of state

Staging Systems

AJCC Staging

The American College of Surgeons (ACoS) Commission on Cancer has required that all approved programs must TNM stage all sites contained in the AJCC *Manual for Staging of Cancer* since January 1, 1991. Effective with 1995 cases, all cancers must be coded for the AJCC staging elements both clinically and pathologically.

Clinical extent of disease is based on information and evidence accumulated before cancer-directed treatment. It is based on the physical examination, imaging, endoscopy, biopsy, surgical exploration, and other relevant findings. Clinical classification is appropriate for sites accessible for clinical examination. Use clinical classification when an organ does not have a pathologic evaluation.

Pathologic extent of disease is based on information gathered before cancer-directed treatment, as well as evidence gathered from surgery and pathological examination of the resected specimen. Pathologic extent of disease is a combination of all findings through first course of surgery, or 4 months, whichever is longer, in the absence of disease progression.

In 2016, other national standard setters began to require AJCC staging as well. These include the CDC's National Program of Cancer Registries and the NCI's Surveillance, Epidemiology, and End Results (SEER) Program.

EOD 2018

Beginning in January 1, 2018, Extent of Disease (EOD) and Summary Stage data items are being incorporated into cancer staging. Extent of Disease should include all information available through completion of surgery(ies) in first course treatment or within four months of diagnosis in the absence of disease progression, whichever is longer.

SEER Summary Stage 2018

The Commission on Cancer also requires Summary Staging for any and all sites not included or not appropriate for AJCC TNM staging. The Kentucky Cancer Registry required Summary Staging 1977 on all cases diagnosed prior to January 1, 2001. On January 1, 2001, the SEER Summary Stage 2000 coding scheme was implemented. This field will be calculated from the data values entered in the SEER Extent of Disease and Collaborative Stage fields, so it does not have to be manually coded. Summary Stage 2018 is new for 2018 and stores the directly assigned Summary Stage 2018. This data item is effective for cases diagnosed January 1, 2018 and later.

Extent of disease is limited to all information available through completion of first course surgery(ies) or within four months of diagnosis in the absence of disease progression, whichever is longer.

Summary Stage for all sites is based on pathological, operative, and clinical assessments. The priority for using these reports is:

-Pathologic

-Operative (Particularly important when the surgical procedure does not remove all malignant tissue)

-Clinical

Directly Coded Summary Stage 2018

This field is required in 2018, in addition to the derived Summary Stage 2018 field mentioned above.

SEER Extent of Disease (EOD)

For cases diagnosed from January 1, 2000 to December 31, 2003, the Kentucky Cancer Registry requires SEER Extent of Disease coding. Extent of Disease should include all information available through completion of surgery(ies) in first course treatment or within four months of diagnosis in the absence of disease progression, whichever is longer.

For all sites, extent of disease is based on a combined clinical and operative/pathological assessment. Use the SEER Extent of Disease Coding Manual, Third Edition (1998) to determine the code values for these fields.

Collaborative Staging

Collaborative Staging (CS) is to be used for cases diagnosed on or after January 1, 2004 through December 31, 2017. It is not to be used for cases diagnosed prior to that date. Its introduction does not affect CoC requirements for physicians to assign AJCC staging or the requirement that the physician-assigned staging values be recorded in the registry.

With Collaborative Staging, registrars code discrete pieces of information once and the CS computer algorithm derives the values for AJCC T, N, M and Stage Group, Summary Stage 1977, and Summary Stage 2000. The derived stage codes are ideally suited for data analysis because of the consistency that can be obtained with objectively-recorded, identically-processed data items.

The timing rule for CS coding was designed to make use of the most complete information possible to yield the "best stage" information for the tumor at the time of diagnosis- "use all information gathered through completion of surgery(ies) in first course of treatment or all information available within four months of the date of diagnosis in the absence of disease progression, whichever is *longer*." Disease progression is defined as further direct extension or distant metastasis known to have developed after the diagnosis was established. Information about tumor extension, lymph node involvement, or distant metastasis obtained after disease progression is documented, should be excluded from the CS coding.

CS data items are coded by the registrar. The CS algorithm produces the output items listed as derived fields. The derived AJCC items are separate from the physician-coded items; and the derived Summary Stage items are separate from the manually-coded items collected by the CoC in the past. The derived items cannot be manually altered.

Like the AJCC and Summary Stage codes that are derived from it, CS is a site-specific staging system. The CS algorithm uses tumor site and histology to determine which CS schema to apply. Depending on the schema, the coding instructions and code definitions will vary. Collaborative Staging codes are defined for every site and histology combination. The AJCC *Cancer Staging Manual* does not cover all sites, and some histologies are excluded from sites with an AJCC coding scheme. When the CS algorithm processes a site-histology combination that does not have an applicable AJCC code, it assigns the display string "NA" for "Not applicable." A blank display string for a derived item means the CS algorithm was not run for the case.

The complete instructions and site-histology defined codes are available in the *Collaborative Staging Manual and Coding Instructions*. Part I provides general instructions and the instructions and codes for generic (non site-specific) items. Part II contains the site-specific instructions and codes. The *CS Manual* and related information is available electronically on the AJCC Web site at https://cancerstaging.org/cstage/Pages/default.aspx.

In 2016, The Commission on Cancer (CoC) and the National Program of Cancer Registries (NPCR) both discontinued the collection of collaborative stage and implemented AJCC staging. However, at the request of The SEER Program, KCR will continue to collect CS data elements as well as AJCC Staging.

First Course Therapy

Treatment Plan

A treatment plan describes the type(s) of treatment(s) intended to modify or control the malignancy. The documentation confirming a treatment plan may be fragmented. It is frequently found in several different sources, i.e., medical record, clinic record, consultation reports, and outpatient records. All cancerdirected treatments specified in the physician(s) treatment plan are a part of the first course of therapy.

A treatment plan may specify only one method of treatment (i.e., surgery) or any combination of therapies (i.e., surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy, or other therapy). A single regimen includes the combination of concurrent or adjuvant treatments. All treatments specified in the treatment plan and delivered to the patient are first course of therapy.

Time Period

All Malignancies Except Leukemia

First course of therapy includes all cancer-directed treatment planned by the physician(s) during or after the first diagnosis of cancer. Planned treatment may include multiple modes of therapy, and may encompass intervals of a year or more. No treatment may be a planned treatment option; therefore, first course of therapy may be No treatment.

When a treatment plan is not available, evaluate the therapy and the time it started. If the therapy is a part of an established protocol or within accepted management guidelines for the disease, it is first course of therapy.

Consult the attending physician or registry's physician advisor if protocols or management guidelines are not available. If there is no treatment plan, established protocol, or management guidelines, and you cannot consult with a physician, use the principle: "first course treatment must begin within four months of the date of initial diagnosis." Any treatment given after four months is subsequent treatment.

Treatment failure or disease progression may prompt the physician to stop therapy before the full course has been completed. Record any treatments administered after the discontinuation of first course as secondary or subsequent therapy <u>only</u>. If there is no documentation of a treatment plan, a progression, recurrence, or treatment failure, first course ends four months after diagnosis date. Any treatment given after four months is second course treatment in the absence of a documented treatment plan or therapy standard.

<u>Leukemia</u>

Treatment for leukemia is divided into three phases: remission induction, consolidation, and maintenance. Remission induction is initial intensive chemotherapy and/or biological response modifiers. Consolidation is repetitive cycles of chemotherapy and/or irradiation to the brain, given immediately after remission. Maintenance is chemotherapy given for a period of months or even years to maintain remission. Code all therapy that is remission induction, consolidation or maintenance as first course. Do not record treatment that is given after a patient relapses. Some patients do not have a remission, if a patient does not have a remission, record the treatment given in the first attempt to induce a remission. Do not record treatment administered as a change in the original treatment plan.

Definitive Treatment

Definitive treatment usually modifies, controls, removes, or destroys proliferating cancer tissue. Treatment may be directed toward either the primary or metastatic sites. Physicians administer the treatment(s) to minimize the size of tumor, or to delay the spread of disease.

NOTE: Only definitive therapy should be included in statistical analyses of treatment. Surgical codes 00-07, and Other treatment code 0 must be excluded. These codes are not considered definitive therapy.

Palliative treatment is treatment that improves the patient's quality of life by preventing or relieving suffering. Palliative therapy may include definitive treatment procedures as well as non-definitive patient care procedures. **For example:** The patient was diagnosed with stage IV cancer of the prostate with painful bony metastases. The patient starts radiation treatment intended to shrink the tumor in the bone and relieve the intense pain. The radiation treatments are palliative because they relieve the bone pain; the radiation is also first course of therapy because it destroys proliferating cancer tissue. Record any palliative treatment that modifies or destroys cancer tissue as first course therapy.

Non-Definitive Treatment (Non-treatment patient care procedures)

Non-definitive treatments prolong the patient's life, make the patient comfortable, or prepare the patient for definitive therapy. These treatments are <u>not</u> tumor directed. They are not meant to reduce the size of the tumor or delay the spread of disease. Non-definitive procedures include diagnostic procedures and supportive care (treatments designed to relieve symptoms and minimize the effects of the cancer). Non-definitive therapies are generally not used in statistical analysis of treatment.

EXAMPLES:

Surgical procedures:

Incisional biopsies

Exploratory procedures with or without biopsies

Supportive care/relieving symptoms:

Palliative care, including surgery, radiation, and chemotherapy for symptom relief only

Pain medication

Oxygen

Antibiotics administered for an associated infection

Transfusions*

Intravenous therapy to maintain fluid or nutritional balance

Laser therapy directed at relieving symptoms

*NOTE: Coding Treatment for Hematopoietic Diseases: For many of the newly reportable hematopoietic diseases, the principal treatment is another type of treatment that does not meet the usual definition that treatment "modifies, controls, removes or destroys proliferating cancer tissue." Such treatments include phlebotomy, transfusions, and aspirin. In order to document that patients with hematopoietic diseases did have some medical treatment, SEER and the Commission on Cancer have agreed to record these treatments as First Course "Other Treatment" (code 1) for the hematopoietic diseases ONLY. A complete description of the treatment plan should be recorded in the text field for "Other Treatment" on the abstract. For more details, consult the Hematopoietic Database.

Follow Up Policies And Procedures

I. Definition

A. Follow-up of cancer patients is the systematic process of obtaining accurate information at least annually, on the patient's health, vital status, and progression of disease.

Follow-up information is extremely important for the following reasons:

- 1. To assist in the early identification of the recurrence of a cancer.
- 2. To assist the physician in getting former cancer patients to return for scheduled treatments and/or checkups.
- 3. To insure periodic examinations of former cancer patients since they are prone to develop other cancers.
- 4. To gather information so physicians can review various types of treatment in terms of survival.
- B. Follow-up information must be sought on analytic cases only (classes 0, 1, and 2), with the following exceptions:
 - 1. Patients who are currently residing in foreign countries (New in NAACCR)
 - 2. Patients whose only malignancy is carcinoma in situ of the cervix

These are not required to be followed, regardless of the class of the case.

- C. Follow-up is considered delinquent by the American College of Surgeons (ACoS) if the information is not successfully obtained and documented within 15 months of the patient's previous date of last contact. A successful follow-up rate of 90% of a hospital's analytic cases is considered in compliance with ACoS standards for an approved Cancer Program. It is best to maintain the highest follow-up rate possible; survival rates and other valuable statistical analyses are heavily dependent on accurate and timely follow-up information.
- II. Follow-up information to be collected includes:
 - A. The date of last contact. This is either the date of death or the most current date the patient was known to be alive.
 - B. Survival status. This indicates whether the patient is alive (with or without disease) or dead (from causes related or unrelated to cancer).
 - C. Present address of patient, if different from that originally recorded.
 - D. Disease Status. This is information about whether the patient was ever disease free, and if so, the start date of the disease free interval.
 - E. Date Last Cancer Status. This is the last time a physician reported on the status of the cancer in the patient.
 - F. Recurrence information. This includes the date of first recurrence, the type of first recurrence, and the site(s) of first recurrence.
 - G. Additional treatment received. This includes the type(s) and date(s) of therapy given after the last date of last contact.
 - H. If dead, cause of death. This includes any autopsy information available on this patient.
 - I. Method of obtaining follow-up information. This includes any change in the name or address of the primary or alternate contact persons or in the method for pursuing follow-up on the next attempt.

III. Procedures

- A. A list of all patients in the tumor registry for whom no contact has been recorded in the last 12 months can be generated using CPDMS.net.
- B. All cancer registries, even the smallest, need form letters, particularly to make physician contact. All form letters should be printed on hospital letterhead and should have the correct phone number, including extension, for the staff contact person. Be sure there is ample space to insert names, addresses, and any additional information about the patient on the form. The information request form for physicians requires a great deal of care in design. You must provide adequate information: the full name of the patient, the diagnosis clearly stated, and the date of your latest information. The data items you request must be arranged in a logical sequence and must be easily recorded. If you must secure physician permission to contact a patient, include that request on the form.
- C. It is customary in most registries to obtain physician permission to contact patients directly when contact through that physician is not possible. This permission may be obtained in several ways:
 - 1. Blanket permission may be granted by action of the medical staff.
 - 2. In some hospitals, blanket permission to contact patients is not granted for any number of reasons. It then becomes necessary to obtain permission on a case by case basis.

D. Follow-up information on all patients named on the follow-up control list should be pursued in an orderly and stepwise fashion:

- 1. Pull and review charts or any internal lists which would indicate these patients' vital status and/or disease status.
- 2. Identify any patients who have returned to this hospital and record the most current date of last contact. Review these charts for any
- other follow-up information related to the patient's cancer progression or treatment and update the patient's record in CPDMS.net. 3. Send letters to the primary following physician designated for the patients remaining on the list. Labels can be generated by CPDMS.net
- to the appropriate contact person for each patient needing follow- up.
- 4. When letters are returned with current information about your cancer patients, update the patient's record in CPDMS.net.
- 5. If no new information is available, or no response at all is returned, pursue alternate contacts for information about these patients. These may be other physicians, relatives or friends of the patients, or the patients themselves.
- 6. If there are any patients remaining on the control list for whom no current information has been located, you may be able to confirm the patient's vital status through various public agencies: The Department of Motor Vehicles, The Department of Vital Statistics, Voters' Registration, Social Security Administration, U.S. Office of Veterans Affairs, U.S. Postal Service, newspapers, etc.

- If all leads fail to return any current information, re-contact the patient's original or last known physician before you consider them "lost" to follow-up.
 Record all follow-up efforts and the resulting information in the text of the patient's record.

Changes To The Manual

A. CHANGES RESULTING FROM IMPLEMENTATION OF THE COC'S FORDS MANUAL IN 2003:

Several data items previously required by CoC were deleted in their FORDS Manual, and many new data items were added. CPDMS.net has not deleted any data items with its 2003 release. However, the required new elements have been added. One of these is an ACoS approval flag, which a hospital user may set in order to invoke data entry processes that provide access to and edit checking on all CoC required fields. Otherwise, only KCR data collection requirements will be enforced by the software routines.

The greatest impact of the FORDS Manual is in the collection of therapy information. The site specific surgery codes have been revised significantly since the CoC's 1998 surgery code revisions. Due to ACoS and SEER reporting requirements, KCR will maintain the old data values in the ROADS surgery fields. These will be identified by the acronym 'ROADS' beside the field name and they <u>must</u> be coded for diagnoses prior to 1/1/2003. Three of the new CoC data items - Surgery at Primary Site, Scope of Regional Lymph Node Surgery, and Surgery at Distant Sites - will have the acronym 'FORDS' beside the new field name and they must be coded for diagnoses on or after 1/1/2003. The other ROADS surgery data items will either be discontinued (Surgical Approach, Number of Regional Lymph Nodes Removed, Reconstruction) or converted to generic codes in FORDS, applicable to all sites (Surgical Margins).

There are eight new Radiation Therapy data items required in FORDS. These will be available only to hospitals that set their ACoS flag to 'approved.' These are <u>NOT</u> required by KCR. Finally, there will be new and separate therapy records specifically for non-definitive surgeries, Hormone Therapy, Immunotherapy, and Transplants/Endocrine procedures. The 'Other' therapy codes and definitions will be converted and revised accordingly.

B. CHANGES FOR 2004:

The two most significant changes for 2004 are the implementation of the collaborative staging system and the inclusion of benign and bordering intracranial and CNS tumors in the list of reportable conditions.

C. CHANGES FOR 2005:

The SEER Rx program is now used to categorize systemic treatments as chemotherapy, hormone therapy or immunotherapy. The most significant change is the classification of drugs according to their mechanism of action. These drugs are now coded as chemotherapy:

- cytostatic agents, including monoclonal antibodies (such as Rituxan and Herceptin), growth factor inhibitors (such as Iressa), anti-angiogenesis agents (such as thalidomide, Avastin, and Neovastat)

-anti-metabolites (such as Vidaza and Alimta)

The SEER Rx program used to classify drugs may be found at www.seer.cancer.gov/tools/seerrx.

D. CHANGES FOR 2006

The CoC no longer requires class of case 0 cases to be followed by the registry or AJCC staged by the physician. However, KCR continues to require registries to follow these cases. Four additional comorbidity fields were added and the data item "Systemic Therapy/Surgery Sequence" was added.

E. CHANGES FOR 2007

The SEER 2007 Multiple Primary and Histology Coding rules were implemented effective with cases diagnosed in 2007. These site-specific rules for determining the number of primary malignancies in solid tumors supersede all previous multiple primary rules. (Existing rules for determining the number of primary malignancies for lymphatic and hematopoietic diseases, and for benign and borderline intracranial and CNS tumors, remain in effect.) Along with the new Multiple Primary rules, six additional data items were introduced in 2007: Ambiguous Terminology, Date of Conclusive Diagnosis, Multiplicity Counter, Date of Multiple Tumors, Type of Multiple Tumors, and Managing Physician. Per ACoS requirements, the National Provider Identification (NPI) numbers were initiated in 2007. These are unique 10-digit identifiers for health care providers who bill Medicare (CMS) for services. The NPI data values are stored in the two support files: physician list and institution list. A lookup for NPI numbers is available at https://npiregistry.cms.hhs.gov/.

F. CHANGES FOR 2008

For cases diagnosed in 2008, the CoC considers pathologic staging information to be adequately collected by the CS items, and thus physician-assigned pathologic AJCC staging is no longer required to be collected. Clinical AJCC staging continues to be required for ACoS approved facilities. Collaborative Stage version 01.04.00 was released and is available at http://cancerstaging.org/cstage/Pages/default.aspx. Clarifications regarding the coding of embolization were issued by the CoC, NPCR, and SEER. Chemoembolization, in which tumor blood-flow is blocked by other means and a chemotherapy drug is injected into the tumor, is coded as chemotherapy. Radioembolization, in which tumor blood-flow is blocked and tiny radioactive beads or coils are injected into the tumor, is coded as radiation therapy. When blood flow to the tumor is blocked using other chemicals or materials (such as alcohol or acrylic), without the use of chemotherapy or radiotherapy, code this treatment in the 'Other' therapy field. Pre-surgical embolization of hypervascular tumors using particles, coils, or alcohol is NOT coded as therapy. This type of embolization is performed to make subsequent surgical resection easier, not as cancer-directed therapy.

G. CHANGES FOR 2009

Beginning with 2009 diagnoses, maiden name should be collected, when known. HER2 test results will be recorded for breast cases. Cases which are diagnosed *in utero* will use the actual date of diagnosis, rather than the date of birth (note: this situation requires an IF15 override). Two additional optional following physician fields were added. The codes 209.0-209.3 and 511.81 were added to the ICD-9-CM casefinding list, and a supplemental list of codes to aid in casefinding was made available as Appendix M - Supplemental ICD-10-CM Codes.

H. CHANGES FOR 2010

Collaborative Stage version 2.0 was implemented, which entailed a great number of changes and the conversion of CS data elements for all diagnoses from 2004-2009. SSF 7-25 were added at this time. The *AJCC Cancer Staging Manual*, 7th Edition was adopted for coding the T, N, M, and Stage Group fields. The Hematopoietic Database (which includes the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual) was released and replaced all previous coding rules for these malignancies. New histology codes which are not in ICD-O-3 were added to the Histology Support File and the following diseases were changed from borderline to malignant: Langerhans cell histiocytosis (9751/3), T cell large granular lymphocytic leukemia (9831/3), and myeloproliferative neoplasm, unclassifiable (9975/3).

Several new fields were added, including Radiation/Systemic Tx Sequence, Grade Path System, Grade Path Value, Lymph-Vascular Invasion, Treatment Status, Date Case Completed-COC, Surgical Approach 2010, Place of Diagnosis, and Reason No Non-definitive Surgery. Modifications were made to the existing items Race 1-5, Class of Case, Laterality, Diagnostic Confirmation, AJCC Staging, and Radiation Number of Treatments to This Volume.

I. CHANGES FOR 2011

Collaborative Stage version 02.03 was implemented. Cases diagnosed from January 1, 2011 forward were coded using the new version. Version 02.03 introduced one new schema (for myeloma/plasma cell malignancies), added and revised codes, incorporated new algorithms, and revised some coding instructions. It also added the following new SSF's to existing schema: SSF15 for breast, SSF10 for bile duct intrahepatic, and SSF13-16 for testis.

FORDS 2011 requires that comorbidities be coded using ICD-10, upon a facility's transition from ICD-9. Minor revisions were made to the surgery codes for liver, breast, and prostate.

A "Do Not Contact" flag was added as a patient level field so that registries may mark patients who should never be directly contacted.

J. CHANGES FOR 2013

Country codes were added to address current, address at diagnosis, place of birth and place of death. (See new APPENDIX B). Secondary diagnosis 1-10 were added to capture co-morbidities when they are recorded in the medical record using ICD-10 codes. These data items are no longer required: Ambiguous Terminology, Date of Conclusive Diagnosis, Multiplicity Counter, Date of Multiple Tumors, and Type of Multiple Tumors Reported as One Primary.

Four Clinical Trial data items were added (type, date, site, and text) and these items are repeated to capture up to four different clinical trials per patient.

Also in 2013, these drugs, which were coded as chemotherapy, are now considered immunotherapy:

- Alemtuzumab/Campath
- Bevacizumab/Avastin
- Rituximab
- Trastuzumab/Herceptin
- Pertuzumab Perjeta
- Cetuximab/Erbitux
- K. CHANGES FOR 2014

Collaborative Stage Version 02.05 was implemented. Cases diagnosed from January 1, 2014 forward must be entered using CS V02.05. This version contained a few corrections to the mapping algorithm, and several clarifications to the coding instructions with this version, Grade Path System and Grade Path Value were discontinued, as well as all Site Specific Factors that had been defined by never required by any standard setter.

The Tumor Grade field was changed slightly in 2014, with all standard setters (COC, SEER, and NPCR) in agreement with the new coding instructions.

New preferred terms and synonyms were added to the ICD-0-3 histology table.

A revised version of the Hematopoietic and Lymphoid Neoplasm Database was released in 2014.

L. CHANGES FOR 2015

Two new code values were added to the SEX field: 5 - Transsexual, natal male and 6 - Transsexual, natal female.

Pathological stage data elements T, N, M, and stage group are now required to be coded.

Carcinoids of the appendix are now considered reportable (8240/3). Nature teratomas of the testes in adults is malignant and reportable (9080/3). It is not reportable for pre-public entrance males.

New terms for pancreatic cancers are now reportable:

- Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia is reportable. This term replaces mucinous cystadenocarcinoma, non-invasive (8470/2).
- Cystic pancreatic endocrine neoplasm (CPEN) is reportable. Assign code 8150/3, unless specified as NET grade 1 (8240/3) or NET grade 2 (8249 /3).
- Solid pseudopapillary neoplasm of the pancreas is reprotable as 8452/3.

Directly coded Summary Stage 2000, Treatment Follow-back Text, and Treatment Plan were added as new data items.

M. CHANGES FOR 2016

Code 3 for the data field SEX is now defined as 'Other, (intersex, disorders of sexual development/DSD).'

New data items in 2016 include

- Mets at diagnosis Distant Lymph Node
- Mets at diagnosis Other (Other than Bone, Brain, Liver, Lung, Distant Lymph Nodes)
- Tumor size Clinical
- Tumor size Pathological
- Tumor size Summary

Staged by - Clinical and Staged-by Pathological have been expanded to 2-digit codes to include more physician specialties. Data entered before 2016 was converted to the new 2-digit codes.

The valid codes for the AJCC T, N, and M categories now contain the prefix 'c' for clinical or 'p' for pathologic. Data entered before 2016 was converted to include these prefixes.

Although CoC and NPCR have discontinued the collection of collaborative stage data, KCR will continue to abstract these fields in 2016. However, CS derived values will no longer be displayed for cases diagnosed on or after 01-01-2016.

N. CHANGES FOR 2018

*Note all changes are in effect for cases diagnosed 01/01/2018 and later only.

Added Schema ID and Schema Discriminators 1, 2, and 3 at the case level for cases diagnosed 01/01/2018 and later. Schema discriminator 3 will not be used for 2018 cases, but we did add the place holder for future years.

Collaborative Stage tab was removed for 2018+ cases and replace with EOD staging tab.

New fields include:

- EOD--Primary Tumor
- EOD--Regional Nodes
- EOD-Mets
- Date Regional Lymph Node Dissection (for breast and melanoma cases only)
- Sentinel Lymph Nodes Positive (for breast and melanoma cases only)
- Sentinel Lymph Nodes Examined (for breast and melanoma cases only)
- Date of Sentinel Lymph Node Biopsy (for breast and melanoma cases only)
- Prostate Pathological Extension (For prostate cases only)

Added code a code to Mets at Diagnosis - Other

· Code 2 for generalized metastases such as carcinomatosis

Tumor grade was removed and replaced on the new SSDI/Grade tab with 3 new grade fields:

- Clinical Tumor Grade
- Pathological Tumor Grade
- Post Therapy Tumor Grade

Site Specific Factors were removed and replaced with site/histology specific SSDIs that were put on the SSDI/Grade tab.

Added SEERSSF1 (HPV Status) for applicable site/histologies

The AJCC staging tab was updated to now include these new fields:

- AJCC TNM Clin T
- AJCC TNM Clin T Suffix
- AJCC TNM Clin N
- AJCC TNM Clin N Suffix
- AJCC TNM Clin M
- AJCC TNM Clin Stage Group
- AJCC TNM Path T
- AJCC TNM Path T Suffix

- AJCC TNM Path N
- AJCC TNM Path N Suffix
- AJCC TNM Path M
- AJCC TNM Path Stage Group
- AJCC TNM Post Therapy T
- AJCC TNM Post Therapy T Suffix
 AJCC TNM Post Therapy N
- AJCC TNM Post Therapy N Suffix
- AJCC TNM Post Therapy M
- AJCC TNM Post Therapy Stage Group

Removed staged by on the AJCC tab for 2018 forward cases.

Radiation Treatment Changes:

Added new tabs to radiation and these new fields

- Phase I Radiation Primary Treatment Volume
- Phase I Radiation to Draining Lymph Nodes
- Phase I Radiation Treatment Modality
- Phase I Radiation External Beam Planning Tech
- Phase I Dose per Fraction
- Phase I Number of Fractions
- Phase I Total Dose
- Phase I Therapy Local Hospital ID
- Phase II Radiation Primary Treatment Volume
- Phase II Radiation to Draining Lymph Nodes
- Phase II Radiation Treatment Modality
 Phase II Radiation External Beam Planning Tech
- Phase II Dose per Fraction
- Phase II Number of Fractions
- Phase II Total Dose
- Phase II Therapy Local Hospital ID
- Phase III Radiation Primary Treatment Volume
- Phase III Radiation to Draining Lymph Nodes
- Phase III Radiation Treatment Modality
- Phase III Radiation External Beam Planning Tech
- Phase III Dose per Fraction
- Phase III Number of Fractions
- Phase III Total Dose
- Phase III Therapy Local Hospital ID
- Number of Phases of Rad Treatment to this Volume
- Total Dose
- Radiation Treatment Discontinued Early

Moved Total Rads and Rad Sites to the Historical Tab.

Date of last cancer (tumor) status was added to the follow up tab.

O. CHANGES FOR 2020

Added new tab for COVID-19 and these new fields

- COVID-19 DX PROC LAB TEST
- COVID-19 Impact BMT
- COVID-19 Impact BRM
- COVID-19 Impact CHEMO
- COVID-19 Impact HORMONE
- COVID-19 Impact RADIATION OTHER
- COVID-19 Impact RADIATION (BEAM)
- COVID-19 Impact RADIATION (ICB)
- COVID-19 Impact SURGERY
- COVID-19 TEXT

General Rules Multiple Primaries

Use the following references to determine the number of cases to be abstracted:

Solid Tumors -- Use the SEER 2018 Solid Tumor Rules for solid tumors diagnosed on or after January 1, 2018. Use SEER 2007 MP/H Rules for cases diagnosed January 1, 2007 through December 31, 2017.

Hematopoietic Malignancies -- Use the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database for cases of this type diagnosed on or after January 1, 2010. Use Appendix A, 'Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases,' for cases diagnosed prior to that date.

Hematopoietic And Lymphoid Malignancy Coding Rules

New reportability instructions and data collection rules for hematopoietic and lymphoid neoplasms go into effect for cases diagnosed beginning January 1, 2010. The Hematopoietic Database is an electronic tool developed to assist in screening for reportable cases and determining reportability requirements, as well as determination of multiple primaries. The database contains abstracting and coding information for all hematopoietic and lymphoid neoplasms (9590/3-9992/3).

Two tools have been developed for use beginning in 2010:

- The Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual
- The Hematopoietic Database

The Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual is embedded in the Hematopoietic Database (Hematopoietic DB). This manual contains reportability instructions and rules for determining the number of primaries, the primary site and histology, and the cell lineage or phenotype. The manual also includes several appendices. Use the instructions and rules within the manual first. The Hematopoietic DB is used when the rules specifically instruct the abstractor to refer to the DB or when the registrar has used all of the rules in the manual. The Hematopoietic and Lymphoid Database was updated in 2014, but all coding changes are effective with 2010 cases forward.

The manual and database are available online and for download from the SEER web site: http://seer.cancer.gov/tools/heme/index.html.

Lymphatic And Hematopoietic Multiple Primary Rules

If the physician clearly states that a hematopoietic diagnosis is a new primary, use that information. Otherwise, the determination of multiple primaries should be done using the guidelines in Appendix A.

Rules:

- 1. Topography is NOT considered in determining multiple primaries of lymphatic and hematopoietic diseases.
- 2. The time interval between diagnoses does NOT enter into the decision.

Appendix A was completely revised with the implementation of ICD-O-3 and the newer table for determining multiple hematopoietic malignancies is effective with cancers diagnosed between 2001-2010. Appendix A contains links to both the revised table and the previous table, which is to be used for pre-2001 diagnoses.

One of the major changes that took place with the implementation of ICD-O-3 was the inclusion of newly reportable hematopoietic diseases (myeloproliferative and myelodysplastic syndromes). These cases are not accessioned or sequenced <u>unless they were diagnosed on or after January 1, 2001</u>, even if the patient received treatment for this disease after that date.

NOTE: If a reportable hematopoietic malignancy is diagnosed after January 1, 2001 in the same person who has another hematopoietic disease diagnosed prior to 2001, use Appendix A to determine if the second condition must be abstracted. If the cross check is D, it should be abstracted. If the cross check is S, it should not be abstracted if the first condition was abstracted; it should be abstracted if the first condition was not.

Solid Tumors Rules for Coding Multiple Primaries

The SEER 2018 Solid Tumor Rules are effective with cases diagnosed on or after January 1, 2018. They contain site-specific rules for lung, breast, colon, melanoma of the skin, head and neck, kidney, renal pelvis/ureter/bladder, and malignant and benign brain tumors. An additional set of rules addresses the specific and general rules for all other sites. The multiple primary rules guide and standardize the process of determining the number of primaries to be abstracted. The histology rules contain detailed histology coding instruction. The complete Multiple Primary and Histology Coding rules may be downloaded from the SEER web site at: https://seer.cancer.gov/tools/solidtumor/

The SEER 2018 Solid Tumor Rules do not apply to hematopoietic primaries (lymphoma and leukemia M9590-9989).

Use the Site-specific rules for the following primary site groups:

Brain, malignant
Brian, benign
Breast
Colon
Head and Neck
Kidney
Lung
Malignant Melanoma of the skin
Renal pelvis, ureter, bladder, and other urinary
e Other Sites Rules for solid malignant tumors that occur in primary sites not covered by site-specific rules.

For solid tumors diagnosed January 1, 2007 through December 31, 2017 use the 2007 SEER MP/H Rules Manual.

For solid malignant tumors and benign/borderline brain tumors diagnosed before 2007, use the SEER Multiple Primary Rules below, which are based on the *International Classification of Diseases for Oncology* (ICD-O-3), to determine if a diagnosis is a single or multiple primary.

1. Use the definitions below under the heading "Primary Site" to decide whether the tumor(s) involve one site or multiple sites.

2. Follow the instructions under the heading "Rules for Coding Histology of Solid Tumors Diagnosed Prior to 2007" in item #30090 (Histology) to decide whether the tumor(s) are a single histology or mixed/multiple histologies.

3. Use the "Rules for Determining Multiple Primary Cancers" to decide whether the case should be abstracted as one primary or multiple primaries.

1. Definitions for determining a single site and a single histology.

Primary Site

Use the

A single site is defined as the same first three characters in the topography code for the sites listed below:

Code	D
C03	Gum
C04	Floor of emouth
C11	Nasopharynx
C14	Oral, other and ill-defined
C15	Esophagus
C16	Stomach
C17	Small intestine
C19	Rectosigmoid junction
C20	Rectum
C22	Liver and bile ducts

C25	Pancreas
C26	Digestive, other and ill-defined
C32	Larynx
	-
C39	Respiratory, other and ill-defined
C42	Hematopoietic and reticuloendothelial
C44	Skin, other than melanoma
C48	Retroperitoneum and peritoneum
C50	Breast
C53	Cervix uteri
C54	Corpus uteri
C55	Uterus NOS
C58	Placenta
C61	Prostate
C62	Testis
C67	Bladder
C69	Eye and adnexa
C70	Meninges
C71	Brain
C72	CNS
C73	Thyroid
C76	III-defined sites
C77	Lymph nodes
C80	Unknown primary

EXAMPLE: The trigone of bladder (C67.0) and lateral wall of bladder (C67.2) are considered subsites of the bladder, and would be treated as one site. A tumor or lesion involving both subsites would be coded either to overlapping sites of bladder (C67.8), or bladder, NOS (C67.9).

A single site is defined as the same fourth character in the topography code for the anatomic sites listed below:

Code	Description
C18	Colon
C21	Anus
C38.4	Pleura
C40	Bones of limbs
C41	Bones of other sites
C44	Melanoma of skin
C47	Peripheral and autonomic nervous system
C49	Connective tissue

EXAMPLE: The transverse colon (C18.4), and the descending colon (C18.6), are considered separate sites. The only EXCEPTION to this is familial polyposis or polyposis coli involving more than one segment of the colon. This is abstracted as only one primary, coded to colon, NOS (C18.9). If the familial polyposis involves both the colon and the rectum, abstract as one primary with site code C19.9.

A single site involves more than one three character category in the topography coding scheme for the anatomic sites listed below:

С	Code	Description	Code To:
---	------	-------------	----------

C01 and C02	Tongue	C02.9
C05 and C06	Palate and other unspecified parts of mouth	C06.9
C07 and C08	Parotid and other major salivary glands	C08.9
C09 and C10	Tonsil and oropharynx	C10.9
C12 and C13	Pyriform sinus and hypopharynx	C13.9
C23 and C24	Gallbladder and other parts of biliary tract	C24.9
C30 and C31	Nasal cavity, middle ear, and accessory sinuses	C31.9
C33 and C34	Trachea and bronchus and lung	C34.9
C37 and C38 (except 38.4)	Thymus, heart, mediastinum, and overlapping lesions	C38.3
C51, C52, and C57.7- C57.9	Vulva, vagina, and other and unspecified parts of female genital organs	C57.9
C56 and C57.0-C57.4	Ovary, fallopian tube, broad ligament, round ligament, parametrium, and uterine adnexa	C56.9 if ovary; C57.9 if other
C60 and C63	Penis and other and unspecified male genital organs	C63.9
C64, C65, C66, and C68	Kidney, renal pelvis, ureter, and other and unspecified urinary organs	C64.9 if kidney; C68.9 if other
C74 and C75	Adrenal gland and other endocrine glands and related structures	C75.9

EXAMPLE: Base of tongue (C01.9), and border of tongue (C02.1), are considered subsites of the tongue, and would be treated as one site - either overlapping lesion of tongue (C02.8) or tongue, NOS (C02.9).

Each side of a paired organ is considered a separate site. Tumors arising on different sides of a paired organ are considered separate primaries, unless the tumor on one side is stated to be metastatic. Exceptions are bilateral involvement of the ovaries in which a single histology is reported, bilateral retinoblastomas, and bilateral Wilms' tumors, which are all considered single primaries.

Histologic Type

When the **FIRST THREE DIGITS** of the ICD-O-3 morphology codes are **IDENTICAL**, the lesions are the **SAME HISTOLOGY**, except for lymphatic and hematopoietic diseases and benign and borderline CNS tumors.

Exception: Code the following as single primaries with a single histology, even though the first three digits of the ICD-O-3 morphology codes differ:

Bladder lesions (8120-8130)

Breast lesions (ductal carcinoma - 8500/3) and (lobular carcinoma - 8520/3) Code to 8522/3

Exception: Non-small cell carcinoma (8046/3) is not considered the same as 8041/3-8045/3, even though the first three digits are the same.

Exception: Lymphatic and hematopoietic diseases (see "Pre-2010 Lymphatic and Hematopoietic Multiple Primary Rules" and use Appendix A to determine multiple primaries).

Exception: Benign and borderline CNS tumors (see the section "Rules for Determining Multiple Primaries for Benign and Borderline Intracranial and CNS Tumors" below for multiple primary rules).

Simultaneous/synchronous diagnosis

Diagnoses that occur within two months of each other are considered simultaneous.

2. Rules for Determining Multiple Primary Cancers (except for lymphatic and hematopoietic diseases and benign and borderline CNS tumors).

Single Primary

1. A single lesion of one histologic type is considered a single primary even if the lesion crosses site boundaries.

2. A single lesion with multiple histologic types is to be considered as a single primary. The most frequent combinations are listed in ICD-O-3. For example, combination terms such as "adenosquamous carcinoma (8560/3)" or "combined small cell-large cell carcinoma (8045/3)" are included. Any of these mixed histologies are to be considered one primary.

3. A single lesion with an in-situ component and an invasive component is considered a single primary.

4. a) If a new cancer of the same histology as an earlier one is diagnosed in the same site within two months, consider this to be the same primary cancer.

b) If a new cancer of the same histology is diagnosed in the same site after two months, consider this new cancer a separate primary unless stated to be recurrent or metastatic.

Exception to 4b: If there is an in-situ cancer followed by an invasive cancer in the same site with the same histology more than two months apart, report as two primaries even if stated to be a recurrence.

NOTE: Bladder cancers, site codes C67.0 - C67.9, with histology codes 8120-8130 may be abstracted at most twice; one abstract for the first in-situ lesion if it precedes the first invasive lesion, and one for the first invasive lesion (if diagnosed at least 2 months later than the in-situ lesion). This also applies to adenocarcinoma of the prostate. These are reported at most only twice; once for the first in-situ lesion if it precedes the first invasive lesion (these are very rare) and once for the first invasive lesion.

NOTE: Kaposi's sarcoma (9140/3) is reported only once. Kaposi's sarcoma is coded to the site in which it arises. If Kaposi's sarcoma arises in skin and another site simultaneously, code to skin (C44._). If no primary site is stated, code to skin (C44._).

5. Multiple lesions of the same histologic type:

a. Simultaneous multiple lesions of the same histologic type within the same site will be considered a single primary. Further, if one lesion has a behavior code of in-situ and another has a behavior code of malignant (invasive), still consider this to be a single primary whose behavior is malignant.

b. Multiple lesions of the same histologic type occurring in different sites are considered to be separate primaries unless stated to be metastatic.

Exception: Adenocarcinoma in multiple adenomatous polyps of the colon.

NOTE: For paired organs, each side is considered a separate site.

c. If only one histologic type is reported and if both sides of a paired site are involved within two months of diagnosis, a determination must be made as to whether the patient has one or two independent primaries. If it is determined that there are two independent primaries, two records are to be submitted, each with the appropriate laterality and extent of disease information.

There are THREE EXCEPTIONS to this rule. Simultaneous bilateral involvement of the ovaries in which there is only a single histology is to be considered one primary and laterality is to be coded '4'. Bilateral retinoblastomas and bilateral Wilms' tumor are always considered single primaries (whether simultaneous or not), and laterality is coded as '4'.

d. If one histologic type is reported in one side of a paired organ and a different histologic type is reported in the other paired organ, consider these two primaries unless there is a statement to the contrary.

EXAMPLE: If a ductal lesion occurs in one breast and a lobular

lesion occurs in the opposite breast, these are considered to be two primaries.

6. Multiple lesions of different histologic types:

a. Multiple lesions of mixed histologies in the same site are a single primary.

EXAMPLE: Tumors with predominant features or combination codes such as combined small cell-large cell carcinoma 8045/3.

b. Multiple lesions of different histologic types within a single site are to be considered separate primaries whether occurring simultaneously or at different times.

Exception: For multiple lesions within a single site occurring within two months, if one lesion is stated to be carcinoma, NOS, adenocarcinoma, NOS, Melanoma, NOS, or sarcoma, NOS and the second lesion is a more specific term, such as large cell carcinoma, mucinous adenocarcinoma, or spindle cell sarcoma, consider this to be a single primary and code to the more specific term.

Exception: Within each breast, combinations of ductal and lobular carcinoma occurring within two months of each other are to be considered a single primary and the histology coded according to ICD-O-3. (8522/3)

Exception: Thyroid carcinomas, reported with two separate carcinomas - one papillary and the other follicular - should be reported as one primary with the mixed histology code 8340/3.

c. Multiple lesions of different histologic types occurring in different sites are considered separate primaries whether occurring simultaneously or at different times.

LESIONS	SITE(S)	HISTOLOGY	VARIABLES	PRIMARY
Single	Single	Single		Single
	Single	Mixed/multiple		Single
Single or multiple*	Single	Single	Different behavior codes, in-situ (2) and invasive (3)	Single
	Same as previous site	Same as previous histology	Within two months of diagnosis	Recurrence of the original primary

	Same as previous site	Same as previous histology	More than two months after diagnosis	New primary unless physician states it is metastatic. Exceptions: bladder, Kaposi's sarcoma, adenocarcinoma of prostate.
Same as previous site Invasive after in-situ			More than two months after diagnosis	New primary even if stated as recurrence.
Multiple*	Single	Single	Simultaneous	Single
	Multiple	Single	Simultaneous	Multiple UNLESS physician states metastatic.
	Paired site	Single	Simultaneous	Physician determines
	Paired site	Multiple	Simultaneous	Exceptions: Ovaries (simultaneous bilateral), retinoblastoma, and Wilms' tumor are single primaries.
				Multiple
	Single	Mixed	Simultaneous	Single
	Single	Multiple (Each tumor has a different histology.)	Simultaneous or different	Multiple Exceptions: Breast (lobular and ductal); bladder (transitional and papillary,) and thyroid (papillary and follicular).
	Multiple	Multiple	Simultaneous or different	Multiple

*See the preceding site and histology rules for definition of "multiple".

Rules for determining multiple primaries for benign and borderline intracranial and CNS tumors (C70.0 - C72.9, C75.1 - C75.3):

For non-malignant CNS tumors, subsite, histology, and laterality must be considered.

A.. Primary Site -

A single site is defined as the same fourth character (subsite) in the topography code for the anatomic sites listed below:

C70	Meninges	C72 Spinal Cord and Cranial Nerves
C71	Brain	C75 Pituitary, Pineal, Craniopharyngeal

If different tumors arise in different subsites, then they are separate primaries.

Example: A benign tumor in the parietal lobe (C71.3) and a separate benign tumor in the frontal lobe (C71.1). Count and abstract as separate primaries.

Example: Meningioma of cervical spine dura (C70.1) and separate meningioma overlying occipital lobe (C70.0, cerebral meninges). Count and abstract as separate primaries.

Exception: If one subsite is non-specific (such as brain, NOS C71.9), and other is specific in same 3 character category (such as C71.__), count as one primary only. For example, biopsy of temporal lobe (C71.2) shows benign tumor and diagnosis from CT scan states "neoplasm of brain" (C71.9). Report one primary only (C71.2).

B. Histology -

If separate tumors have different histologies, then they are separate primaries. To determine whether tumors have different histologies, code the histology of each tumor and look them up in the table below.

Histologic Groupings To Determine Same Histology for Non-malignant Brain Tumors

Choroid plexus neoplasms	9390/0, 9390/1
Ependymomas	9393, 9394, 9444
Neuronal and neuronal-glial neoplasms	9384, 9412, 9413, 9505/1, 9506, 9442
Neurofibromas	9540/0, 9540/1, 9541, 9550, 9560/0
Neurinomatosis	9560/1
Neurothekeoma	9562
Neuroma	9570
Perineurioma, NOS	9571/0

1. If neither histology code is in the table above and codes are the same at the three-digit level, abstract as one primary.

Example: Patient has clear cell meningioma (9538/1) of the cerebral meninges and a separate transitional cell meningioma (9537/0) in another part of the same hemisphere. Count and abstract as one primary.

2. If the two histology codes are in the same category of the table, count as one primary.

Example: Patient has a ganglioglioma (9505/1) of the cerebellum (C71.6) and a neurocytoma (9506/1) of the cerebellopontine angle (C71. 6). Count and abstract as one primary.

3. If the histology codes are in different categories of the table, count and abstract as separate primaries.

Example: Patient has a choroid plexus papilloma (9390/0) of the third ventricle (C71.5) and a choroid glioma (9444/1) of the third ventricle (C71.5). Count and abstract as separate primaries.

4. If one histology is in the benign brain histology table and the other is not, compare codes at the three-digit level. If they are the same, count as one primary. If they are different, count as two primaries.

Example: Patient has a subependymal glioma (9383/1) diagnosed on needle biopsy in August, and at resection in September the diagnosis is subependymal giant cell astrocytoma (9384/1). Count and abstract as one primary.

Example: Patient has a Pacinian tumor (9507/0) diagnosed in March and a dysembryoplastic neuroepithelial tumor (9413/1) of the occipital lobe diagnosed in July. Count and abstract as separate primaries.

C. Laterality -

For each non-malignant (and malignant) primary brain and CNS tumor for the sites shown below and with a diagnostic date on or after January 1, 2004, code laterality using codes 1-4 or 9. Midline tumors are coded 9.

Prior to 1-1-04 diagnoses, primary brain and CNS tumors were coded '0' for laterality.

CNS Sites for which laterality is to be coded:

Code	Description
C71.0	Cerebrum
C71.1	Frontal lobe
C71.2	Temporal lobe
C71.3	Parietal lobe
C71.4	Occipital lobe
C72.2	Olfactory nerve
C72.3	Optic nerve
C72.4	Acoustic nerve
C72.5	Cranial nerve, NOS

1. If laterality is same side, one side unknown or not applicable, and same subsite and same histology, then abstract as one primary.

2. If laterality is both sides, abstract separate primaries.

Example: Benign tumors (same histology) in left and right temporal lobes. Count and abstract as separate primaries.

D. Timing -

If a new non-malignant tumor is diagnosed in the same subsite with the same histology as a previous one, then one primary is abstracted, regardless of time elapsed. (For tumors with an initial diagnosis prior to 1-1-04, do not abstract recurrent non-malignant CNS tumors.)

- E. Multiple lesions with different behavior codes -
 - 1. Non-malignant tumor followed by malignant tumor: abstract separate primaries regardless of timing.
 - 2. Malignant tumor followed by non-malignant tumor: abstract separate primaries regardless of timing.
 - 3. Benign tumor transforms to malignancy (rare occurrence): create second abstract for malignancy.

Example: Patient is diagnosed and treated for choroid plexus papilloma (9390/0) of right lateral ventricle in June 2004. Eighteen months later, patient is symptomatic again and re-biopsy of same area is reported as choroid plexus carcinoma (9390/3). Count and abstract as two primaries.

Patient Data

- Page 1
 - Soc Sec Number
 - Last Name
 - First Name
 - Middle Name
 - Maiden Name
 - Street Address 1 • Street Address 2
 - City
 - State
 - Zip Code
 - Country
 - Home Phone
 - Date of Birth
 - State of Birth
 - Country of Birth
 - Sex
- Page 2
 - Race 1
 - Race 2
 - Race 3
 - Race 4
 - Race 5
 - Computed Ethnicity
 - Spanish Origin Tobacco Use

 - Cigarette Pack Years • Number of Live Births
 - Occupation
 - Industry
 - Cause of Death(ICD)
 - Place of Death
 - State of Death
 - Country of Death
 - Contact Patient
 - Contact Patient Comments
 - Number of Primaries
 - Vital Status
 - Occupation Code
 Industry Code

 - Patient DLC
- Page 3
 - Clinical Trial Type 1
 - Clinical Trial Accrual Date 1
 - Clinical Trial Site Code 1
 - Clinical Trial Text 1
 - Clinical Trial Type 2
 - Clinical Trial Accrual Date 2
 - Clinical Trial Site Code 2
 - Clinical Trial Text 2
 - Clinical Trial Type 3
 Clinical Trial Accrual Date 3

 - Clinical Trial Site Code 3
 - Clinical Trial Text 3
 - Clinical Trial Type 4 Clinical Trial Accrual Date 4
 - Clinical Trial Site Code 4
 - Clinical Trial Text 4
- Patient Misc
 - SEER Patient Id
 - IHS Link
 - Modified By (Patient)
 - Time Modified (Patient)
 - Patient User Defined Data 01
 - Patient Incomplete Flag
- CPDMS Create Patient from a Pathology Report Workflow
 - CPDMS Create Patient From Pathology Report Application

Page 1

- Soc Sec NumberLast NameFirst Name

- First Name
 Middle Name
 Maiden Name
 Street Address 1
 Street Address 2
 City
 State
 Zip Code
 Country
 Home Phone
 Date of Birth
 State of Birth
 Country of Birth
 Sex

Soc Sec Number

Organization	Field Name	ID	Required
KCR	Soc Sec Number (SSN)	10020	yes
NAACCR	Social Security Number	2320	yes

Field Length: 9

Enter the patient's social security number in the field provided. If the patient does not have a social security number, use the formula below to assign a unique temporary number.

NOTE: The social security number is the main element used in identifying patients, matching information, etc., and must be recorded accurately for every patient entered in the system.

FORMULA: Temporary "social security" numbers are assigned only to patients not possessing a verifiable social security number. Use the initials of the patient's first, middle and last names, followed by digits representing the birth date. (Use zero when the patient's middle initial is unknown.)

Thus, John Brown, born January 21, 1946, would be issued the following number:

J0B - 01 - 2146

Where month, day or year of birth is not known, enter "99".

Temporary numbers should be checked for duplication within your hospital's cancer registry before the patient is accessioned. If the temporary number works out to be exactly the same as that of a different patient, the registrar should change the middle initial to the number "1". If there are more than two patients with the same temporary number, continue to substitute numbers in the middle initial in sequential order.

[FYI: If the Medicare billing number is a Social Security Number followed by a B or D, this indicates that the SSN belongs to the spouse of the patient.]

Last Name

Organization	Field Name	ID	Required
KCR	Last Name (LastName)	10030	yes
NAACCR	NameLast	2230	yes

Field Length: 20

Enter the patient's last name in the spaces provided. If the name exceeds the number of spaces provided, enter as much as possible. If during the course of follow-up, the patient's name changes, update the record with the current name.

Use the following rules when recording patient last names:

- 1. Name fields should contain alpha characters and blanks only -- no special characters such as apostrophes, commas, hyphens, etc.
- 2. Any name titles or suffixes, such as DR., M.D., MR., MS., JR., SR., III, IV, and so on, should be recorded in the middle name field after, or instead of, the middle name. These data are optional, and need not be recorded at all.
- 3. Blanks are allowed in the last name field, but they must be used consistently in order to match patients at the central data base. Therefore, the following rules are established:
 - a. When a patient has two last names, or a hyphenated last name, you may type both in the last name field separated by a blank space.
 - b. Patients with two-part last names, such as VAN HORN or ST JOHN, may have a space between the two parts, but no special punctuation marks.
 - c. Names like 'MCCOY' or 'O'BRYAN' should be typed 'MCCOY' or 'OBRYAN' with no spaces and no punctuation.

First Name

Organization	Field Name	ID	Required
KCR	First Name (FirstName)	10040	yes
NAACCR	NameFirst	2240	yes

Field Length: 15

Enter the patient's first name in the spaces provided. If the name exceeds the number of spaces provided, enter as much as possible.

Use the following rules when recording the patient's first name:

- 1. Name fields should contain alpha characters and blanks only -- no special characters such as apostrophes, commas, hyphens, etc.
- 2. Any name titles or suffixes, such as DR., M.D., MR., MS., JR., SR., III, IV, and so on, should be recorded in the middle name field after, or instead of, the middle name. These data are optional, and need not be recorded at all.
- 3. Blanks are allowed in the first name field, but they must be used consistently in order to match patients at the central data base. Therefore, the following rules are established:
 - a. Patients with two-part first names, or two first names, may have them both recorded in the first name field, separated by a blank space. For example: MARY JO MARY ANN JOHN ED etc.
 - b. Patients who go by their initials should have their first initial recorded in the first name field, and the second in the middle name field. For example: J.B. JONES would have 'J' in first name and 'B' in middle name.
 - c. Patients with a name and an initial should have them recorded in separate fields. For example: H. EDWARD SMITH should have 'H' in first name and 'EDWARD' in middle name.

Middle Name

Organization	Field Name	ID	Required
KCR	Middle Name (MidName)	10050	no
NAACCR	NameMiddle	2250	no

Field Length: 10

Enter the patient's middle name in the spaces provided. If the name exceeds the number of spaces, enter as much as possible. If only an initial is given, enter the initial.

You may also record the patient's title or name suffix in this field -- such as: DR, JR, SR, III, M.D., etc.

Maiden Name

Organization	Field Name	ID	Required
KCR	Maiden Name (MaidenName)	10055	no
NAACCR	NameMaiden	2390	no

Field Length: 15

This is a required field if the patient's maiden name is available. Leave blank for males or if it is unknown.

Street Address 1

Organization	Field Name	ID	Required
KCR	Street Address 1 (Address1)	10060	yes
NAACCR	Addr CurrentNo & Street	2350	yes

Field Length: 40

Record the currently known number and street address of the patient's usual residence. Leave a blank between numbers and words if space permits. Punctuation should be limited to slashes for fractional addresses (i.e., 103 1/2 MAIN ST) and hyphens (289-01 MONTGOMERY AVE). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 MAIN ST APT 408. **Do not use periods after abbreviations.** When entering addresses, use the U.S. Postal Service Guidelines found at: http://pe.usps.gov/cpim/ftp/pubs/pub28/pub28.pdf

This item is different from patient address at diagnosis in that it provides a current address for follow-up purposes. Address-Line 1 will be used for mailing labels, so it should contain the patient's mailing address. This item should be updated as newer information becomes available.

Normally a residence is the home named by the patient. Do not use a temporary address. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with rules used by the Census Bureau whenever possible.

Rules for persons without apparent residences:

Persons with More than One Residence (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.

Persons with No Usual Residence (transients, homeless, migrant workers): Use the address of the place they were staying when the cancer was diagnosed. This could be a shelter or the diagnosing institution.

Persons Away at School: College students are residents of the school area. Boarding school children below college level are residents of their parents' home.

Persons in Institutions: The Census Bureau states "Persons under formally authorized, supervised care or custody" are residents of the institution. This includes:

-Incarcerated persons

-Persons in homes, schools, hospitals, or wards for the physically disabled, mentally retarded, or mentally ill

-Long-term residents of other hospitals, such as Veterans Administration (VA) hospitals

Persons in the Armed Forces and on Maritime Ships: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their family. Military personnel may use the installation address or the surrounding community's address.

Street Address 2

Organization	Field Name	ID	Required
KCR	Street Address 2 (Address2)	10070	no
NAACCR	Addr CurrentSupplementl	2355	no

Field Length: 40

This field provides space to record additional address information, such as the name of a nursing home, apartment complex, etc. This line will <u>not</u> be displayed on mailing labels. If the patient has both a PO Box (for a mailing address), and a street name and number (for a living address), put the street name and number on address-line 2. Update this item if the patient's address changes. Leave this field blank if the additional address space is not needed.

City

Organization	Field Name	ID	Required
KCR	City (City)	10080	yes
NAACCR	Addr CurrentCity	1810	yes

Field Length: 20

Enter the city of current residence in the spaces provided. Abbreviate only if necessary. A list of Kentucky cities and towns is located in Appendix D. This item is different from city at diagnosis in that it provides the current city or town for follow up purposes. This item should be updated as newer information becomes available.

Additional rules for determining residency may be found under the data item "CURRENT STREET ADDRESS."

State

Organization	Field Name	ID	Required
KCR	State (State)	10090	yes
NAACCR	Addr CurrentState	1820	yes

Field Length: 2

Record the two character abbreviation for the state in which the patient currently resides. Refer to Appendix B also for a list of the state abbreviations. Appendix B contains abbreviations for U.S. territories and Canadian provinces, as well. Residents of the United States, or its territories, with the state unknown should be coded to 'US'. Residents of Canada and the province unknown should be coded to 'CD'. Residents of countries outside the United States s, its territories, or Canada, should be coded with the two-character code 'XX' or 'YY' if the state or country or current residence is unknown. Residence unknown should be coded 'ZZ'.

This item is different from state at diagnosis in that it provides the current state or country for follow up purposes. This item should be updated as newer information becomes available. Update this data item if patient's state of residence changes. Do not change this item when the patient dies.

Additional rules for determining residency may be found under the data item "CURRENT STREET ADDRESS."

Examples:

Code	Description
KY	If the state in which the patient resides at the time of diagnosis and treatment is Kentucky, then use the USPS code for the state of Kentucky
XX	Resident of a country of than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is known
ΥY	Resident of a country other than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is <i>unkno</i> wn
US	Resident of the U.S. (including it territories, commonwealths, or possessions) and the state is unknown
CD	Resident of Canada and the province is unknown
ZZ	Residence unknown

Zip Code

Organization	Field Name	ID	Required
KCR	Zip Code (ZipCode)	10100	yes
NAACCR	Addr CurrentPostal Code	1830	yes
KCR	Zip Ext (ZipExt)	10110	no
NAACCR	Addr CurrentPostal Code	1830	no

Field Length: 9

Enter the nine digit zip code for the patient's current address. If only five digits are given, record those and leave the rest of the field blank.

Refer to the U.S. Postal Service web site (see Appendix D) for the appropriate code if none is recorded in patient's record.

Code 888888888 if the patient's address is in a county other than Canada, the United States, or U.S. possessions. Code 999999999 if the patient's address is in Canada, the United States, or a U.S. possession, but the zip code is unknown.

This item is different from zip code at diagnosis in that it provides the current zip code for follow up purposes. This item should be updated as newer information becomes available.

Additional rules for determining residency may be found under the data item "CURRENT STREET ADDRESS."

Country

Organization	Field Name	ID	Required
KCR	Country (Country)	10111	yes
NAACCR	Addr CurrentCountry	1832	yes

Field Length: 3

Record the three character abbreviation for the country in which the patient currently resides. This item corresponds to Current Address – State. See APP ENDIX B.

Common Country Codes

Code	Description
USA	United States
CAN	Canada
ZZX	Not US or Canada, but no other information
ZZU	Unknown

Home Phone

Organization	Field Name	ID	Required
KCR	Home Phone (Phone)	10120	no
NAACCR	Telephone	2360	no

Field Length: 10

Enter the patient's area code in the first three spaces followed by the seven digit number.

Enter '0000000000' if the patient does not have a telephone.

Enter '9999999999' if the telephone number is unknown.

Date of Birth

Organization	Field Name	ID	Required
KCR	Date of Birth (BDate)	10130	yes
NAACCR	Date of Birth	240	yes

Field Length: 8

Enter the month, day, and year the patient was born. Precede all single digit dates with "0".

If the exact day is unknown, code the 15th of the month.

If the month is unknown, approximate or code as June. If the year is unknown, enter your best estimate. You must use a valid date. Do not leave blank.

State of Birth

Organization	Field Name	ID	Required
KCR	State of Birth (BirthState)	10141	yes
NAACCR	BirthplaceState	252	yes

Field Length: 2

Record the 2 character abbreviation for the patient's state of birth. See APPENDIX B for alphabetic listings of the appropriate codes and their definitions. Use the most specific code.

Code 'ZZ' when unknown.

Examples:

Code	Description
KY	If the state in which the patient was born is Kentucky, then use the USPS code for the state of Kentucky.
хх	State of birth other than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is known.
YY	State of birth other than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is unknown.
US	Born in the U.S. (including it territories, commonwealths, or possessions) and the state is unknown.
CD	Born in Canada and the province is <i>unknown</i> .
ZZ	State of birth and country are unknown.

Country of Birth

Organization	Field Name	ID	Required
KCR	Country of Birth (BirthCountry)	10142	yes
NAACCR	BirthplaceCountry	254	yes

Field Length: 3

Record the 3 character abbreviation for the patient's country of birth. See APPENDIX B.

Common Country Codes

Code	Description
USA	United States
CAN	Canada
ZZN	North America, NOS
ZZC	Central America, NOS
ZZS	South America, NOS
ZZP	Pacific, NOS
ZZE	Europe, NOS
ZZF	Africa, NOS
ZZA	Asia, NOS
ZZX	Not US or Canada, but no other information
ZZU	Unknown

Sex

Organization	Field Name	ID	Required
KCR	Sex (Sex)	10150	yes
NAACCR	Sex	220	yes

Field Length: 1

Enter the one character code which describes the patient's sex:

Code	Description
1	Male
2	Female
3	Other (intersex, disorders of sexual development/DSD)
4	Transsexual, NOS
5	Transsexual, natal male
6	Transsexual, natal female
9	Unknown

If the patient is transsexual, code to the gender at birth, if known.

Page 2

- Race 1Race 2
- Race 3Race 4

- Race 4
 Race 5
 Computed Ethnicity
 Spanish Origin
 Tobacco Use
 Cigarette Pack Years
 Number of Live Births
 Occupation

- Number of Live Births
 Occupation
 Industry
 Cause of Death(ICD)
 Place of Death
 State of Death
 Country of Death
 Contact Patient
 Contact Patient

- Contact Patient Comments
 Number of Primaries
 Vital Status

- Occupation Code
 Industry Code
 Patient DLC

Organization	Field Name	ID	Required
KCR	Race 1 (Race1)	10160	yes
NAACCR	Race 1	160	yes

Field Length: 2

Enter the two digit code which describes the patient's race group. If the patient is multiracial, code all races using data fields Race2-Race5. Effective with 2004 diagnoses, use the race coding rules and tables in APPENDIX K.

Code	Description
01	White
02	Black
03	American Indian, Aleutian, Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean (Cambodian)
14	Thai
15	Asian Indian or Pakistani, NOS (formerly 09)
16	Asian Indian
17	Pakistani
21	Chamorran
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
96	Other Asian including Asian, NOS and Oriental, NOS
98	Other
99	Unknown

-White includes Mexican, Puerto Rican, Cuban, and all other Caucasians.

-Black includes the designations Negro or Afro-American.

-Race is based on birth place information when place of birth is given as China, Japan, or the Philippines, and race is reported only as Asian, Oriental, or Mongolian.

Organization	Field Name	ID	Required
KCR	Race 2 (Race2)	10170	yes
NAACCR	Race 2	161	yes

Field Length: 2

Enter the two digit code which describes the patient's race group. If the patient is multiracial, code all races using data fields Race2-Race5.

Code	Description
01	White
02	Black
03	American Indian, Aleutian, Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean (Cambodian)
14	Thai
15	Asian Indian or Pakistani, NOS (formerly 09)
16	Asian Indian
17	Pakistani
21	Chamorran
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
96	Other Asian including Asian, NOS and Oriental, NOS
98	Other
99	Unknown

-White includes Mexican, Puerto Rican, Cuban, and all other Caucasians.

-Race is based on birth place information when place of birth is given as China, Japan, or the Philippines, and race is reported only as Asian, Oriental, or Mongolian.

-If Race1 is '99', then Race2 through Race5 must be '99'

Organization	Field Name	ID	Required
KCR	Race 3 (Race3)	10180	yes
NAACCR	Race 3	162	yes

Field Length: 2

Enter the two digit code which describes the patient's race group. If the patient is multiracial, code all races using data fields Race2-Race5.

Code	Description
01	White
02	Black
03	American Indian, Aleutian, Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean (Cambodian)
14	Thai
15	Asian Indian or Pakistani, NOS (formerly 09)
16	Asian Indian
17	Pakistani
21	Chamorran
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
96	Other Asian including Asian, NOS and Oriental, NOS
98	Other
99	Unknown

-White includes Mexican, Puerto Rican, Cuban, and all other Caucasians.

-Race is based on birth place information when place of birth is given as China, Japan, or the Philippines, and race is reported only as Asian, Oriental, or Mongolian.

- If Race1 is '99', then Race2 through Race5 must be '99'

Organization	Field Name	ID	Required
KCR	Race 4 (Race4)	10190	yes
NAACCR	Race 4	163	yes

Field Length: 2

Enter the two digit code which describes the patient's race group. If the patient is multiracial, code all races using data fields Race2-Race5.

Code	Description
01	White
02	Black
03	American Indian, Aleutian, Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean (Cambodian)
14	Thai
15	Asian Indian or Pakistani, NOS (formerly 09)
16	Asian Indian
17	Pakistani
21	Chamorran
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
96	Other Asian including Asian, NOS and Oriental, NOS
98	Other
99	Unknown

-White includes Mexican, Puerto Rican, Cuban, and all other Caucasians.

-Race is based on birth place information when place of birth is given as China, Japan, or the Philippines, and race is reported only as Asian, Oriental, or Mongolian.

- If Race1 is '99', then Race2 through Race5 must be '99'

Organization	Field Name	ID	Required
KCR	Race 5 (Race5)	10200	yes
NAACCR	Race 5	164	yes

Field Length: 2

Enter the two digit code which describes the patient's race group. If the patient is multiracial, code all races using data fields Race2-Race5.

Code	Description
01	White
02	Black
03	American Indian, Aleutian, Eskimo
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean
10	Vietnamese
11	Laotian
12	Hmong
13	Kampuchean (Cambodian)
14	Thai
15	Asian Indian or Pakistani, NOS (formerly 09)
16	Asian Indian
17	Pakistani
21	Chamorran
22	Guamanian, NOS
25	Polynesian, NOS
26	Tahitian
27	Samoan
28	Tongan
30	Melanesian, NOS
31	Fiji Islander
96	Other Asian including Asian, NOS and Oriental, NOS
98	Other
99	Unknown

-White includes Mexican, Puerto Rican, Cuban, and all other Caucasians.

-Race is based on birth place information when place of birth is given as China, Japan, or the Philippines, and race is reported only as Asian, Oriental, or Mongolian.

- If Race1 is '99', then Race2 through Race5 must be '99'

Computed Ethnicity

Organization	Field Name	ID	Required
KCR	Computed Ethnicity (CompEthnicity)	10210	No
NAACCR	Computed Ethnicity	200	No
KCR	Computed Ethnicity Source (CompEthnicSrc)	10220	No
NAACCR	Computed Ethnicity Source	210	No

This field contains codes identifying ethnicity as determined by a software algorithm or computer list-based method to identify cancer patients' ethnicity based on last name or maiden name. The effective date for implementation of this field is for cases diagnosed January 1, 1995, and after.

There are two parts to this field:

Computed Ethnicity

Computed Ethnicity Source

10210 - Computed Ethnicity:

Field Length: 1

Code	Description
0	No match was run for 1995 and later cases
1	Non-Hispanic last name and non-Hispanic maiden name
2	Non-Hispanic last name, didn't check maiden name (or male)
3	Non-Hispanic last name, missing maiden name
4	Hispanic last name, non-Hispanic maiden name
5	Hispanic last name, didn't check maiden name (or male)
6	Hispanic last name, missing maiden name
7	Hispanic maiden name (females only) (regardless of last name)
Blank	1994 and earlier cases

10220 - Computed Ethnicity Source:

Field Length: 1

Code	Description
0	No match was run for 1995 and later cases
1	Census Bureau list of Spanish surnames, NOS
2	1980 Census Bureau list of Spanish surnames
3	1990 Census Bureau list of Spanish surnames
4	GUESS program
5	Combination list including South Florida names
6	Combination of Census and other locally generated list
7	Combination of Census and GUESS, with or without other lists
8	Other type of match
9	Unknown type of match
Blank	1994 and earlier cases

Spanish Origin

Organization	Field Name	ID	Required
KCR	Spanish Origin (Ethnicity)	10230	yes
NAACCR	Spanish/Hispanic Origin	190	yes

Field Length: 1

Code the patient's Spanish/Hispanic ethnicity.

The codes are:

Code	Description
0	Non-Spanish
1	Mexican
2	Puerto Rican
3	Cuban
4	South or Central American (except Brazil)
5	Other Spanish (includes European)
6	Spanish, NOS (There is evidence other than the patient's surname that the patient is Hispanic, but he/she cannot be assigned to codes 1-5 above.)
7	Spanish surname only
8	Dominican Republic (effective with 1/1/2005 cases)
9	Unknown whether Spanish or not

Persons of Spanish surname or origin may be of any race.

Portuguese and Brazilians are not considered Spanish and should be coded 0.

See APPENDIX L for a list of commonly occurring Hispanic surnames.

Tobacco Use

Organization	Field Name	ID	Required
KCR	Tobacco Use (TobaccoUse)	10240	no

Field Length: 1

Enter the code which describes the patient's tobacco use. Record as a cigarette smoker if the chart says only "smoker" or "tobacco user".

Code	Description
0	Never used
1	Cigarette smoker
2	Cigar/pipe smoker
3	Snuff/chew/smokeless tobacco user
4	Mixed use of more than one type of tobacco product
9	Not recorded/unknown

Cigarette Pack Years

Organization	Field Name	ID	Required
KCR	Cigarette Pack Years (PackYears)	10250	no

Field Length: 3

Enter the total pack years for the span of cigarette use. Pack years equal the average number of packs smoked per day multiplied by the number of years of cigarette use. For example, if a person smokes two packs a day for 30 years, then the cigarette pack years equals 60.

- Enter "0" if patient never smoked cigarettes.
- Enter "999" if the pack years of cigarette use is unknown.

The computer will automatically right justify digits at data entry.

Number of Live Births

Organization	Field Name	ID	Required
KCR	Number of Live Births (LiveBirths)	10260	no

Field Length: 2

For female patients, record the number of live births the patient has delivered. If male, enter "99". The computer will automatically right justify single digit entries.

This is not the same as gravidity or parity. Gravidity refers to the number of pregnancies. Parity refers to the number deliveries of viable offspring (even if stillborn). Number of live births refers to the actual number of offspring born alive.

If unknown, enter "99".

Occupation

Organization	Field Name	ID	Required
KCR	Occupation (Occupation)	10270	no
NAACCR	TextUsual Occupation	310	no

Field Length: 20

Enter the patient's primary occupation throughout his/her lifetime. If retired, enter the primary occupation prior to retirement. This field is required only to the extent that the information is available from source documents. If the patient's occupation is unknown or not recorded, enter 'UNKNOWN' or 'NOT RECORDED'.

Industry

Organization	Field Name	ID	Required
KCR	Industry (Industry)	10280	no
NAACCR	TextUsual Industry	320	no

Field Length: 20

Enter the industry which describes the type of business activity in which the patient was employed. The U.S. Department of Commerce lists 14 major categories or industry groups, which are listed below for your information.

They are:

Agriculture, Forestry, Fisheries Mining

Construction

Manufacturing

Transportation, Communications, Public Utilities

Wholesale Trade

Retail Trade

Finance, Insurance, Real Estate

Business and Repair Services

Personal Services

Entertainment and Recreation Services

Professional Services (medical, legal, educational, etc.)

Public Administration

Active Military Duty

This field is required only to the extent that the information is available from the source documents. If the industry is unknown or not applicable, enter 'UNKNOWN' or 'NOT APPLICABLE'.

Cause of Death(ICD)

Organization	Field Name	ID	Required
KCR	Cause of Death(ICD) (DeathCause)	10290	no
NAACCR	Cause of Death	1910	no

Field Length: 6

As specified in the SEER Program Coding and Staging Manual, page 207, enter the underlying cause of death *as coded on the Death Certificate*. Even when the code is believed to be in error, the entry as coded on the Death Certificate is to be used.

Code: Underlying Cause of Death

0000 Patient alive at last contact

7777 State death certificate or listing not available

7797 State death certificate or listing available, but underlying death not coded.

All other cases: ICD-9 Underlying Cause of Death Code if date of death prior to January 1, 1999 or ICD-10 Underlying Cause of Death Code if date of death on or after January 1, 1999. **Do not code this field from the medical record.** A list of all ICD-10 codes is available online at http://www.who.int /classifications/apps/icd/icd10online/.

Underlying cause of death codes usually have four digits. Some codes may have an optional fifth digit. The decimal point will already appear on the form and on the data entry screen.

Left justify if less than ICD-10 code is less than 4 digits and leave the 4th character blank.

In Kentucky, the state central registry will match all death certificates with the central database. A file of matched patient records will be generated for each Kentucky hospital. This file will automatically be loaded into CPDMS.net and will be used by each hospital to update that hospital's patients with date of death and cause of death from the death certificate.

It is not necessary to have a copy of the death certificate as long as the official code for the underlying cause of death is available. You may use the Cause of Death code obtained from a linkage with the National Death Index, or from an out-of-state data exchange cancer report.

If the death certificate is not available, do not attempt to code it; use code '777.7'.

For example:

Underlying Cause of Death	ICD-10 Code	Enter:
Cancer of the thyroid	C73	C73
Acute appendicitis with peritonitis	K35.0	K350
Adenocarcinoma of stomach	C16.9	C169

Place of Death

Organization	Field Name	ID	Required
KCR	Place of Death (DeathPlace)	10300	no
NAACCR	Place of Death	1940	no

Field Length: 3

Record the 3 digit code for the patient's state or country of death. See Appendix B for numeric and alphabetic listings of the appropriate codes and their definitions.

Code '999' when unknown.

State of Death

Organization	Field Name	ID	Required
KCR	State of Death (DeathState)	10303	no
NAACCR	Place of DeathState	1942	no

Field Length: 2

Record the 2 character abbreviation for the patient's state of death. See APPENDIX B for alphabetic listings of the appropriate codes and their definitions. Use the most specific code.

Code	Definition
KY	If the state in which the patient died was Kentucky, then use the USPS code for the state of Kentucky
XX	Died in a country other than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is known
YY	Died in a country other than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is unknown
US	Died in the U.S. (including it territories, commonwealths, or possessions) and the state is unknown
CD	Died in Canada and the province is unknown
ZZ	State of death unknown

Country of Death

Organization	Field Name	ID	Required
KCR	Country of Death (DeathCountry)	10304	no
NAACCR	Place of DeathCountry	1944	no

Field Length: 3

Record the 3 character abbreviation for the patient's country of death. See APPENDIX B for alphabetic listings of the appropriate codes and their definitions. Use the most specific code.

Code 'ZZU' when unknown.

Contact Patient

Organization	Field Name	ID	Required
KCR	Contact Patient (ContactPatient)	10301	yes

Field Length: 1

This field allows the registry to identify patients who should not be directly contacted. The codes are:

Code	Description
0	No
1	Yes

Code 1 is the default value. The value in this field is displayed on the patient status screen when a record has been pulled up in CPDMS.net. When this field is coded '0', the patient will be excluded from Patient Label reports or Follow-Up mailing labels. In the Follow-Up Control List, an "X" will appear adjacent to the patient name in the "Contact Patient" column.

There is an edit check between this field and the fields Next Follow-Up Method (item 31910) and Alternate Follow-Up Method (item 31920). When Contact Patient is coded '0', those two follow-up fields cannot be coded '04' ("Patient by letter") or '05' ("Patient by phone call").

Contact Patient Comments

Organization	Field Name	ID	Required
KCR	Contact Patient Comments (ContactPatientTxt)	10302	no

Field Length: 40

This a text field in which a brief remark regarding patient contact may be recorded (i.e., "patient has requested no further contact from registry").

Number of Primaries

Organization	Field Name	ID	Required
KCR	Number of Primaries (CaseCount)	10310	No

Field Length: 2

This is a field calculated by the computer. It does not appear on the abstract form. However, it is a patient level field that is available for analysis and reporting purposes. It is calculated as the highest sequence number stored for a patient.

Vital Status

Organization	Field Name	ID	Required
KCR	Vital Status (VitalStat)	10320	No
NAACCR	Vital Status	1760	No

Field Length: 1

This is a field calculated by the computer. It does not appear on the abstract form. However, it is a patient level field that is available for analysis and reporting purposes.

It is calculated from the latest survival status entered for a patient. If Item 31760 (Survival Status) is 1, 2, or 3, then the value in this field is "1" (Alive); if Item 31760 is 4, 5, 6, or 9, then the value in this field is "0" (Dead).

At the central registry, this field may also be assigned through linkages with authoritative sources of vital status information such as Kentucky death certificates or the United States National Death Index.

Code	Description
1	Alive
0	Dead

Occupation Code

Organization	Field Name	ID	Required
KCR	Occupation Code (OccCode)	10330	No

Field Length: 3

 * This data item has been retired and is no longer in use *

This field is automatically generated by the computer based on the U.S. Census Bureau code for the patient's occupation.

Industry Code

Organization	Field Name	ID	Required
KCR	Industry Code (IndCode)	10340	No

Field Length: 3

 * This data item has been retired and is no longer in use *

This field is automatically generated by the computer based on the U.S. Census Bureau code for the patient's usual industry.

Patient DLC

Organization	Field Name	ID	Required
KCR	Patient DLC (DateLastContact)	10350	No
NAACCR	Date of Last Contact	1750	No

Field Length: 8

This field is automatically calculated from the most recent date of contact in all cases associated with a patient's record.

Page 3

- Clinical Trial Type 1
 Clinical Trial Accrual Date 1
 Clinical Trial Site Code 1
 Clinical Trial Text 1

- Clinical Trial Type 2
 Clinical Trial Accrual Date 2
 Clinical Trial Site Code 2

- Clinical Trial Site Code 2
 Clinical Trial Text 2
 Clinical Trial Type 3
 Clinical Trial Accrual Date 3
 Clinical Trial Site Code 3
 Clinical Trial Text 3
 Clinical Trial Type 4
 Clinical Trial Accrual Date 4
 Clinical Trial Site Code 4
 Clinical Trial Text 4

Clinical Trial Type 1

Organization	Field Name	ID	Required
KCR	Clinical Trial Type 1 (ClinTrialType1)	10580	yes

Code the type of clinical trial in which the patient is enrolled.

Code	Туре	Description
0	None	Not on any protocol or unknown whether or not on protocol.
1	Diagnostic	Protocol designed to evaluate one of more interventions aimed at identifying a disease or health condition.
2	Health Services Research	Protocol designed to evaluate the delivery, processes, management, organization, or financing of health care.
3	Prevention	Protocol designed to assess one or more interventions aimed at preventing the development of a specific disease or health condition.
4	Screening	Protocol designed to assess or examine methods of identifying a condition (or risk factor for a condition) in people who are not yet known to have the condition (or risk factor)
5	Supportive Care	Protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects, or mitigate against a decline in the participant's health or function. In general, supportive care interventions are not intended to cure a disease.
6	Basic Science	Protocol designed to examine the basic mechanisms of action (e.g., physiology, biomechanics) of an intervention.
7	Treatment	Protocol designed to evaluate one or more interventions for treating a disease, syndrome, or condition.
8	Other	Protocol other than those described in codes 1-7.
9	Unknown	Patient is enrolled in a clinical trial, but the type of trial is unknown.

Clinical Trial Accrual Date 1

Organization	Field Name	ID	Required
KCR	Clinical Trial Accrual Date 1 (ClinTrialDate1)	10590	no

Enter the month, day, and year the patient was enrolled in this clinical trial.

If the date is unknown, you may enter '99' for the month or day, but you must enter a valid year. If the year is unknown, enter your best estimate.

Clinical Trial Site Code 1

Organization	Field Name	ID	Required
KCR	Clinical Trial Site Code 1 (ClinTrialSite1)	10600	no

Choose the site code for the type of cancer involved in clinical trial 1. Use APPENDIX C for site codes.

If the site is unknown or not applicable, use code 55.

Clinical Trial Text 1

Organization	Field Name	ID	Required
KCR	Clinical Trial Text 1 (ClinTrialText1)	10610	no

Enter any information here about Clinical Trial 1, such as the trial number, sponsor, design, or purpose. You may also enter information about the patient's clinical trial experience, such as protocol arm, completion date, etc.

Clinical Trial Type 2

Organization	Field Name	ID	Required
KCR	Clinical Trial Type 2 (ClinTrialType2)	10620	yes

Code the type of clinical trial in which the patient is enrolled.

Code	Туре	Description
0	None	Not on any protocol or unknown whether or not on protocol.
1 Diagnostic Protocol designed to evaluate one of more interventions aimed at identifying a disease or health condition.		Protocol designed to evaluate one of more interventions aimed at identifying a disease or health condition.
2	Health Services Research	Protocol designed to evaluate the delivery, processes, management, organization, or financing of health care.
3 Prevention Protocol designed to assess one or more interventions aimed at preventing condition.		Protocol designed to assess one or more interventions aimed at preventing the development of a specific disease or health condition.
4	Screening	Protocol designed to assess or examine methods of identifying a condition (or risk factor for a condition) in people who are not yet known to have the condition (or risk factor)
5	Supportive Care	Protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects, or mitigate against a decline in the participant's health or function. In general, supportive care interventions are not intended to cure a disease.
6	Basic Science	Protocol designed to examine the basic mechanisms of action (e.g., physiology, biomechanics) of an intervention.
7	Treatment	Protocol designed to evaluate one or more interventions for treating a disease, syndrome, or condition.
8	Other	Protocol other than those described in codes 1-7.
9	Unknown	Patient is enrolled in a clinical trial, but the type of trial is unknown.

Clinical Trial Accrual Date 2

Organization	Field Name	ID	Required
KCR	Clinical Trial Accrual Date 2 (ClinTrialDate2)	10630	no

Enter the month, day, and year the patient was enrolled in this clinical trial.

If the date is unknown, you may enter '99' for the month or day, but you must enter a valid year. If the year is unknown, enter your best estimate.

Clinical Trial Site Code 2

Organization	Field Name	ID	Required
KCR	Clinical Trial Site Code 2 (ClinTrialSite2)	10640	no

Choose the site code for the type of cancer involved in clinical trial 2. Use APPENDIX C for site codes.

If the site is unknown or not applicable, use code 55.

Clinical Trial Text 2

Organization	Field Name	ID	Required
KCR	Clinical Trial Text 2 (ClinTrialText2)	10650	no

Enter any information here about Clinical Trial 1, such as the trial number, sponsor, design, or purpose. You may also enter information about the patient's clinical trial experience, such as protocol arm, completion date, etc.

Clinical Trial Type 3

Organization	Field Name	ID	Required
KCR	Clinical Trial Type 3 (ClinTrialType3)	10660	yes

Code the type of clinical trial in which the patient is enrolled.

Code	Туре	Description
0	None	Not on any protocol or unknown whether or not on protocol.
1 Diagnostic Protocol designed to evaluate one of more interventions aimed at identifying a disease or health condition.		Protocol designed to evaluate one of more interventions aimed at identifying a disease or health condition.
2	Health Services Research	Protocol designed to evaluate the delivery, processes, management, organization, or financing of health care.
3 Prevention Protocol designed to assess one or more interventions aimed at preventing condition.		Protocol designed to assess one or more interventions aimed at preventing the development of a specific disease or health condition.
4	Screening	Protocol designed to assess or examine methods of identifying a condition (or risk factor for a condition) in people who are not yet known to have the condition (or risk factor)
5	Supportive Care	Protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects, or mitigate against a decline in the participant's health or function. In general, supportive care interventions are not intended to cure a disease.
6	Basic Science	Protocol designed to examine the basic mechanisms of action (e.g., physiology, biomechanics) of an intervention.
7	Treatment	Protocol designed to evaluate one or more interventions for treating a disease, syndrome, or condition.
8	Other	Protocol other than those described in codes 1-7.
9	Unknown	Patient is enrolled in a clinical trial, but the type of trial is unknown.

Clinical Trial Accrual Date 3

Organization	Field Name	ID	Required
KCR	Clinical Trial Accrual Date 3 (ClinTrialDate3)	10670	no

Enter the month, day, and year the patient was enrolled in this clinical trial.

If the date is unknown, you may enter '99' for the month or day, but you must enter a valid year. If the year is unknown, enter your best estimate.

Clinical Trial Site Code 3

Organization	Field Name	ID	Required
KCR	Clinical Trial Site Code 3 (ClinTrialSite3)	10680	no

Choose the site code for the type of cancer involved in clinical trial 3. Use APPENDIX C for site codes.

If the site is unknown or not applicable, use code 55.

Clinical Trial Text 3

Organization	Field Name	ID	Required
KCR	Clinical Trial Text 3 (ClinTrialText3)	10690	no

Enter any information here about Clinical Trial 1, such as the trial number, sponsor, design, or purpose. You may also enter information about the patient's clinical trial experience, such as protocol arm, completion date, etc.

Clinical Trial Type 4

Organization	Field Name	ID	Required
KCR	Clinical Trial Type 4 (ClinTrialType4)	10700	yes

Code the type of clinical trial in which the patient is enrolled.

Code	Туре	Description
0	None	Not on any protocol or unknown whether or not on protocol.
1	Diagnostic	Protocol designed to evaluate one of more interventions aimed at identifying a disease or health condition.
2	Health Services Research	Protocol designed to evaluate the delivery, processes, management, organization, or financing of health care.
3	Prevention	Protocol designed to assess one or more interventions aimed at preventing the development of a specific disease or health condition.
4	Screening	Protocol designed to assess or examine methods of identifying a condition (or risk factor for a condition) in people who are not yet known to have the condition (or risk factor)
5	Supportive Care	Protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects, or mitigate against a decline in the participant's health or function. In general, supportive care interventions are not intended to cure a disease.
6	Basic Science	Protocol designed to examine the basic mechanisms of action (e.g., physiology, biomechanics) of an intervention.
7	Treatment	Protocol designed to evaluate one or more interventions for treating a disease, syndrome, or condition.
8	Other	Protocol other than those described in codes 1-7.
9	Unknown	Patient is enrolled in a clinical trial, but the type of trial is unknown.

Clinical Trial Accrual Date 4

Organization	Field Name	ID	Required
KCR	Clinical Trial Accrual Date 4 (ClinTrialDate4)	10710	no

Enter the month, day, and year the patient was enrolled in this clinical trial.

If the date is unknown, you may enter '99' for the month or day, but you must enter a valid year. If the year is unknown, enter your best estimate.

Clinical Trial Site Code 4

Organization	Field Name	ID	Required
KCR	Clinical Trial Site Code 4 (ClinTrialSite4)	10720	no

Choose the site code for the type of cancer involved in clinical trial 4. Use APPENDIX C for site codes.

If the site is unknown or not applicable, use code 55.

Clinical Trial Text 4

Organization	Field Name	ID	Required
KCR	Clinical Trial Text 4 (ClinTrialText4)	10730	no

Enter any information here about Clinical Trial 1, such as the trial number, sponsor, design, or purpose. You may also enter information about the patient's clinical trial experience, such as protocol arm, completion date, etc.

Patient Misc

- SEER Patient Id

- SEER Patient Id
 IHS Link
 Modified By (Patient)
 Time Modified (Patient)
 Patient User Defined Data 01
 Patient Incomplete Flag

SEER Patient Id

Organization	Field Name	ID	Required
KCR	SEER Patient Id (SEERPatId)	10390	No
NAACCR	Patient System ID-Hosp	21	No

Field Length: 8

This is a unique number assigned to an individual patient by the central registry. KCR will assign the same number to all the patient's subsequent tumor (records).

The SEER Patient ID does not appear on the patient abstract and is not available for analysis.

IHS Link

Organization	Field Name	ID	Required
KCR	IHS Link (IHSLink)	10410	No
NAACCR	IHS Link	192	No

Field Length: 1

The Indian Health Service (IHS) linkage reports the results of linking the central registry database with the Indian Health Service patient registration database.

The IHS linkage idenitifies American Indians who were misclassified as non-Indian in the registry. The computer linkage program will automatically assign the code for this data item.

Code	Description
0	Record sent for linkage, no IHS match
1	Record sent for linkage, IHS match
Blank	Record not sent for linkage or linkage results pending

Modified By (Patient)

Organization	Field Name	ID	Required
KCR	Modified By (Patient) (PModUser)	10420	no

Field Length: 8

This field is calculated by the computer. The user name of the last person to modify patient data is recorded and is updated each time the record is edited.

Time Modified (Patient)

Organization	Field Name	ID	Required
KCR	Time Modified (Patient) (PModTime)	10430	no

Field Length: 19

The date and time that patient data was last edited is automatically recorded by the computer.

Patient User Defined Data 01

Organization	Field Name	ID	Required
KCR	Patient User Defined Data 01 (PUData1)	10440	No
KCR	Patient User Defined Data 02 (PUData2)	10450	No
KCR	Patient User Defined Data 03 (PUData3)	10460	No
KCR	Patient User Defined Data 04 (PUData4)	10470	No
KCR	Patient User Defined Data 05 (PUData5)	10480	No
KCR	Patient User Defined Data 06 (PUData6)	10490	No
KCR	Patient User Defined Data 07 (PUData7)	10500	No
KCR	Patient User Defined Data 08 (PUData8)	10510	No
KCR	Patient User Defined Data 09 (PUData9)	10520	No
KCR	Patient User Defined Data 10 (PUData10)	10530	No

Field Length: 15 (x 10)

This element provides up to ten fields for coding additional information for each patient. These will be user defined fields based on the individual institution's need or desire to track patterns of diagnostic and treatment procedures, as well as survival, with particular types of cancer patients.

For example:

"a" could be used to code alcohol use.

"b" could be used to code religion

"c" could be used to code exposure to hazardous substances, etc.

Patient Incomplete Flag

Organization	Field Name	ID	Required
KCR	Patient Incomplete Flag (PIncomplete)	10540	No

Field Length: 1

This element is populated automatically by CPDMS on Patient Create/Edit.

The following are the possible values:

- 0 Patient is complete
- 1 Patient is incomplete due to an error with the Patient Data

2 - Patient is incomplete due to an error with data associated with Patient (e.g. Inter-Record error, no case data, etc.)

Data Analysis

This field was added to Data Analysis for users to query over entered 2018 cases before the 2018 Implementation was fully integrated with CPDMS.

By default, Data Analysis only returns complete patients, including this flag will prevent the exclusion of incomplete patients.

If you wish to see these 2018 patients in Data Analysis, add Patient Patient Incomplete Flag "IN" 0,1, and 2 (as shown below).

Patient V Patient Incomplete Flag V in V	All, None O Complete 1 Incomplete 2 Incomplete by Association
--	--

CPDMS Create Patient from a Pathology Report Workflow

Please visit Instructional Videos for a video walkthrough of these new features.

In order to streamline the process of data entry, the CPDMS Development team (Dev Team) has developed a method to populate patient level data fields in CPDMS Data Entry by pulling from the ever increasing pathology report library. The Dev team weaved this capability into the abstractor workflow increasing learning, familiarity, and time efficiency.

The following instructions follow the workflow a user will experience in order to launch the new feature. Simply, if you are entering a new patient into the facility database AND this patient has a pathology report, the user will be directed to the new feature.

Locating a Patient:

When it comes to data entry, the abstractor workflow begins at Patient List.

David Rust	CANCER PATIENT DATA MANAGEMENT SYSTEM .net UK HEALTHCARE	Locate Patient
	Enter Patient Information	
	Social Security Number	
	Last Name	
	First Name	
	Date of Birth	
	Class Accession Year/No.	
	Submit Cancel	

From this page, users can peruse their respective facility's database using a patient's Social Security Number, Last Name, First Name, Accession Year & Number, and a new optional field, Date of Birth.

CPDMS searches for a patient in the following way:

- 1. If a SSN has been entered, CPDMS looks for an identical SSN match in the hospital's database.
- 2. If no SSN has been entered or no identical match has been found, CPDMS will search using the other populated fields: last name, first name, and date of birth.
- 3. If SSN, Last Name, First Name, and Date of Birth have not been populated, Accession Year and Number can be searched over.

The workflow divides from here.

- 1. A Patient is Located in the Hospital's Database
- 2. A Patient is Not Found in the Hospital's Database

Patient is Located In the Hospital's Database:

In the image below you can see the SSN, First Name, Last Name, and Birth Date is searched over using "151-51-5151", "TESTFIRSTNAME", "TESTLAS TNAME", and "12/12/1980" respectively. For our test a PHI free example patient exists in our training database.

As you can see the SSN and Birth Date are different, for our test case we determine that the patient found in CPDMS is **not** the patient we entered. Thus, we must create this patient in our hospital's database.

The "Create" button will only appear if you have searched the following three fields: "SSN", "First Name", and "Last Name". This button will appear if you additionally search with Date of Birth.

Hitting create will direct the abstractor to one of two workflows:

- 1. Creating a patient using the SSN, Last Name, First Name, and Date of Birth.
- 2. Creating a patient that has a respective pathology report.

CANCER PATIENT DATA MANAGEMENT SYSTEM .net				
DAVID RUST	TRAININ	IG DATABASE	Patient List	
	Pat	ient List		
SSN : 151-51-5151		atients matching LastName : TESTLASTNAME	BirthDate : 04/04/1965	
123-45-6789	TESTLASTNAME TESTFI	RSTNAME	12-12-1980	
Highlight and c	click "Select" to edit an existing patie Prev Next Sel		ate a new patient record Create	

Patient is not found in the Hospital's Database:

Upon hitting submit the user will be directed to one of two workflows:

- 1. Creating a patient using the SSN, Last Name, First Name, and Date of Birth.
- 2. Creating a patient that has a respective pathology report.

Creating a Patient Using the SSN, Last Name, First Name, and Date Of Birth:

The user will be directed to a page similar to one of the two pages below:

Patient Information

Social Security Number	151515151
Last Name	TESTLASTNAME
First Name	TESTFIRSTNAME
Date of Birth	19650404
Create	Cancel

DAVID RUST	CANCER PATIENT DATA MANAGEMENT SYSTEM .net TRAINING DATABASE	Patient Data Edit
Page 1 Page 2 Page 3		
	Patient Data Edit Form 151-51-5151, TESTFIRSTNAME TESTLASTNAME	
Soc Sec Number	151515151	
<u>Last Name</u>	TESTLASTNAME	
<u>First Name</u>	TESTFIRSTNAME	
Middle Name		
<u>Maiden Name</u>		
Address 1		
Address 2		
<u>City</u>	<u>م</u>	
<u>State</u>	P	
Zip Code		
Country		
Home Phone		
Date of Birth	04 /04 /1965	
State of Birth		
Country of Birth		
Sex		~
		Dago 1 of 3
ESC - Cancel, ALT+(Highlighted K	Prev Next Save Cancel ey) - Page Tab, F2 - Search, ALT+Down - Activate Dropdown, F7 - P	Page 1 01 5

The Abstractor will follow their normal workflow from the above pages.

Creating a Patient with a Pathology Report:

An abstractor will be directed here if and only if the patient searched over has a pathology report that matches the search criteria they entered, and the user wants to create this patient.

The following data was searched over in this example:

AVID RUST	TRAINING DATABASI		Locate Patien
	Enter Patient Info	mation	
	Social Security Number 987	- 65 - 4321	
	Last Name PATL	IST	
	First Name PATE	RST	
	Date of Birth	04 / 1965	
	Class Accession Year/No.		
	Submit Car	cel	

Please disregard the mismatching data between the pathology text and discrete data. These are made up patients that were linked together. Much of the Pathology Report Text was removed.

^
~

Please follow this link for the explanation of this new feature.

CPDMS Create Patient From Pathology Report Application

Please visit Instructional Videos for a video walkthrough of these new features.

This page is to demonstrate the capabilities for populating patient data using a pathology report. Please refer to this page to see how we arrived at this workflow.

You may read through this guide or hop to a specific topic using the following table of contents:

- 1. Pathology Report Search
- 2. Copying Discrete Pathology Data to the Patient
- 3. Resetting Patient Data Panel
- 4. Validating an Address
- 5. Patient Data Panel Fields' Description
- 6. Creating the Patient
- 7. Sample Errors
- 8. Additional Features
 - a. CPDMS Field Definitions
 - b. Search Combo Boxes
 - c. Customizable Interface Options
 - i. Resize Interface Panels
 - ii. Pathology Details Grid Panel Features

Pathology Report Search:

After searching over the patient SSN (987-65-4321), Last Name (PATLAST), First Name (PATFIRST), and Date of Birth (04/04/1965), CPDMS is directed to a page similar to the image below.

CPDMS first searches for the pathology reports, and it will show the following load screen:

Back		TRAINING DA	ATAB	ASE (90201)	DAVID RUST
	Patient Data		Reset	Selected Patholgy Report Data	
	987-65-4321 PATLAST,	PATFIRST (04/04/1965)			
	Middle Name:			Middle Name:	
	Maiden Name:			Maiden Name:	
	Sex:	~		Sex:	
	Race:			Race:	
	Ethnicity:	Y		Ethnicity:	
	Address			Address	
	Address 1:			Address 1:	
	Address 2:			Address 2:	
	City, State, Country: Zip Code:	, , , Validate Address		City,State,Country: Zip Code:	
		Validate Address		Ζμ τουε.	
	Cre	eate		Copy Pathology Data	
		 Searchir 	ng for Pa	athology Reports	
				•	
Pathology Details		Selected Pat			
SSN Specimen	Date 🔻 Full Name	Date of Birth A Select a pa	athold	gy report to auto-populate patient information	
Page 0	of 0 🛛 😕 📃 👘 No d	ata to display			

In this example we are creating a patient with the SSN, Last Name, First Name, and Date of Birth of "987-65-4321", "PATLAST", "PATFIRST", "04/04 /1965" highlighted in the orange box.

The facility and username are also displayed in the blue boxes.

The SSN, Last Name, First Name, and Date of Birth cannot be changed from this point. This is similar to the original workflow. If you need to change any of these fields please hit the "Back" button located in the upper left corner of the page.

There are two pathology reports found in the registry, shown below highlighted by the **red** box. The **green** background shows which fields in the pathology report **match** with the ones searched by the registrar denoted in the **orange** box.

Back			TRAINING DATAB	ASE (90201)		DAVI	D RUST
	Patient Data		Reset	IM17-6332 - Selec	ted Pathology Report Data		
	987-65-4	321 PATLAS	, PATFIRST (04/04/1965)	987-65-43	321 PATLAST, PATFIRST (04/04	4/1965)	
		Middle Name:		Middle Na	ame: M.		
	<u>4</u>	laiden Name:		Maiden Na	ame:		
		<u>Sex</u> :	*		Sex: M		
		Race:		R	ace: WHITE		
		Ethnicity:	¥	Ethn	icity: 2186-5Not Hispanic or LatinoCl	DC .	
	Address	iress 1:		Address	ess 1: 1234 TEST STREET CT		
		tress 2:			ess 2:		
	<u>City, State, C</u>				untry: LEXINGTON, KY		
		Code:	- Validate Address		Code: 40503		
		C	reate		Copy Pathology Data		
Pathology De	etails		IM17-6332 - Selected Pathology Re	• port Text			
SSN	Full Name 🔺	Date of Birth ▲	PATHOLOGY TEST HOSPITAL				^
987-65-4321	PATLAST, PATFIRST M.	04/04/1965	TESTING CANCER CENTER LEXINGTON, KENTUCKY 40503				
987-65-4321	PATLAST, PATFIRST MIDDLE	04/04/1965	Collect D	ate: 8/10/2017 (
			Receipt D Page 1	ate: 8/10/2017 1	15:59		
			DEPARTMENT OF PATHOLOGY				
			AND LABORATORY MEDICINE IMMUNO-MOLECULAR PATHOLOGY				
				55-555-5555			
			Email: nopath@test.com		17-6332		
			ATTENDING MD: S. Strange, MD PTH Reported: 8/20/2017 02:				
			DIRECTOR/SUPERVISOR: JJ. Jam				
			Collected: 8/5/2017 01:01				
			Interpretation				
<		>	LA DNA typing with serologic	-	-		
	je 1 of 1 ≥ ≥	1 - 2 of 2	NAME A B Bw4/6 C DRB1 DRB5 D	RB3 DRB4 DQB1 DQ	QA1 DPB1 DPA1 C	Cola,	~

NOTE EXAMPLE: Sometimes what we search doesn't match <u>exactly</u> with what is in the pathology database. If the abstractor searched over SSN = "987114321" and DOB = 19651104 as denoted by green box. The mismatched fields will show up in red as denoted by the orange boxes.

Back			TRAINING DATABASE (90201)	DAVID RUST
	Patient Data		Reset IM17-6332 - Selected Pathology Report Data	
	987-11-4	321 PATLAS	, PATFIRST (11/04/1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965)	
		Middle Name:	Middle Name: M.	
	1	Maiden Name:	Maiden Name:	
		Sex:	✓ Sex: M	
		Race:	Race: WHITE	
		Ethnicity:	Ethnicity: 2186-5Not Hispanic or LatinoCDC	
	Address	dress 1:	Address Address 1: 1234 TEST STREET CT	
		dress 2:	Address 2:	
	<u>City, State, C</u>		, , City,State,Country: LEXINGTON, KY	
	Zi	p Code:	- Validate Address Zip Code: 40503	
			reate Copy Pathology Data	
Pathology De	etails		IM17-6332 - Selected Pathology Report Text	
SSN	Full Name 🔺	Date of Birth ▲	PATHOLOGY TEST HOSPITAL TESTING CANCER CENTER	^
987-65-4321 987-65-4321	PATLAST, PATFIRST M. PATLAST, PATFIRST MIDDLE	04/04/1965 04/04/1965	LEXINGTON, KENTUCKY 40503 Collect Date: 8/10/2017 01:01	
907-00-4021	PATLAST, PATFIRST MIDDLE	04/04/1965	Receipt Date: 8/10/2017 15:59 Page 1	
			DEPARIMENT OF PATHOLOGY	
			AND LABORATORY MEDICINE IMMUNO-MOLECULAR PATHOLOGY	
			Phone: 859-867-5309 Fax:555-5555	
			Email: nopath@test.com IM17-6332 ATTENDING MD: S. Strange, MD Service:	
			PTH Reported: 8/20/2017 02:02	
			DIRECTOR/SUPERVISOR: JJ. Jameson Collected: 8/5/2017 01:01	
			Interpretation	
<		>	LA DNA typing with serological equivalent interpretation:	
	ge 1 of 1 🔀 🕅	1 - 2 of 2	NAME A B Bw4/6 C DRB1 DRB5 DRB3 DRB4 DQB1 DQA1 DPB1 DPA1 Cola,	~

Selecting A Pathology Report:

Once the search has been loaded, the first report is automatically selected. When a report is selected, it populates the pathology's narrative text in the "Selected Pathology Report Text Area" panel denoted in green. The discrete data items available are populated in the CPDMS Data Entry fields denoted in **blue**. The Pathology Report Id is inserted into the header of both **blue** and green panels. In this example the Pathology Report Id is "IM17-6332".

An abstractor can click through the list of reports in order to find the one that matches the patient they wish to create.

The pathology reports are initially sorted from most recent til oldest according to the Specimen Date.

EDIT: There is now a new column for the match score of a pathology report. The reports are now sorted by the match score column.

Back				TRAINING DATAE	BASE (90201)	DAVID RUST
		Patient Data		Reset	IM17-6332 - Selected Pathology Report Data	
		987-65-4	321 PATLAS	r, Patfirst (04/04/1965)	987-65-4321 PATLAST, PATFIRST (04/04/1965	5)
		1	Middle Name:		Middle Name: M.	
		M	laiden Name:		Maiden Name:	
			Sex:	*	Sex: M	
			Race:		Race: WHITE	
			Ethnicity:	~	Ethnicity: 2186-5Not Hispanic or LatinoCDC	
		Address			Address	
			ress 1:		Address 1: 1234 TEST STREET CT Address 2:	
		<u>City,State,Co</u>			City,State,Country: LEXINGTON, KY	
			Code:	- Validate Address	Zip Code: 40503	
			(Create	Copy Pathology Data	
	1					
Pathology De	Full Name 4		Date of Birth 🔺	IM17-6332 - Selected Pathology Re PATHOLOGY TEST HOSPITAL	port lext	
987-65-4321		ATFIRST M.	04/04/1965	TESTING CANCER CENTER LEXINGTON, KENTUCKY 40503		
987-65-4321		ATFIRST MIDDLE	04/04/1965	Collect	Date: 8/10/2017 01:01	
				Receipt Page 1	Date: 8/10/2017 15:59	
				DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE		
				IMMUNO-MOLECULAR PATHOLOGY Phone: 859-867-5309 Fax:	555-555-5555	
				Email: nopath@test.com	IM17-6332	
				ATTENDING MD: S. Strange, MD PTH Reported: 8/20/2017 02		
				DIRECTOR/SUPERVISOR: JJ. Ja Collected: 8/5/2017 01:01	meson	
				Interpretation		
<			>	LA DNA typing with serologi	cal equivalent interpretation:	
Id d Pag	je 1 of	1 > >	1 - 2 of 2	NAME A B Bw4/6 C DRB1 DRB5	DRB3 DRB4 DQB1 DQA1 DPB1 DPA1 Cola,	~

Copying the Discrete Pathology Data to the Patient Data:

If we find that the first patient in our scenario is the right one, we can copy the information over to the "Patient Data" panel denoted below in red by clicking the "Copy Pathology Data" button denoted in blue.


When the patient data is copied over from the path report, a few conversions happen:

- 1. All data values are Upper Cased
- 2. The Sex value in the pathology report is converted to the respective KCR encoding if the encoding can be found/applied
- 3. The Race value in the pathology report is converted to the respective KCR encoding if the encoding can be found/applied
- 4. The Ethnicity value in the pathology report is converted to the respective KCR encoding if the encoding can be found/applied
- 5. The Country field in the "Patient Data Panel" denoted in red is calculated based on the pathology report's State value.
- 6. The Zip Extension is not provided in the pathology report, so this will not be populated.
- 7. The Zip Extension can be populated using the "Validate Address" function of this application which is discussed later.

These conversions **are not** perfect. The CPDMS development team will rely on abstractors to double check the conversions. The development teams asks uses to report incorrect conversions when discovered.

Social Security Number, Last Name, and First Name will remain the same even if the Pathology Report values differ. The Date of Birth will remain the same if and only if it was entered in the search as well. If it is not, a Date of Birth field will be displayed in the Patient Data and Pathology Data Panels. If you do not include the Date of Birth in the search, the interface will include the DOB field

We notice there is an error displayed in the Patient Data Panel. In this example this message appears due to the period, ".", character appearing in the middle name. The NAACCR standard does not accept special characters like ".", "-", etc. However, the standard states the abstractor may change the invalid character as they see fit. The development team wants users to change values according to their preference, so these special characters are copied over as well. The application will leave the abstractor to change them before creation. We will remove the "." for this workflow.




The Reset Button:

Every field shown can be reset at the same time by hitting the "Reset" button denoted in orange.


The SSN, Last Name, and First Name will remain unchanged. The Date of Birth will remain unchanged as well if it was used during the search process.

Back			TRAINING D	ATAB	ASE (90201)	DAVID RUST
	Patient Data			Reset	IM17-6332 - Selected Pathology Report Data	
	987-65-4	987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name:			987-65-4321 PATLAST, PATFIRST (04/04/1965)	
	1				Middle Name: M.	
	M	laiden Name:			Maiden Name:	
		Sex:	¥		Sex: M	
		Race:			Race: WHITE	
		Ethnicity:	*		Ethnicity: 2186-5Not Hispanic or LatinoCDC	
	Address				Address	
		lress 1:		-1	Address 1: 1234 TEST STREET CT Address 2:	
		Iress 2:		-1		
	<u>City, State, Ci</u>	Code:	- Validate Address	-11	City,State,Country: LEXINGTON, KY Zip Code: 40503	
		Code:	- Validate Address		Zip code: 40503	
		c	Create		Copy Pathology Data	
Pathology De	ataile		IM17-6332 - Selected Pathol		and Tout	_
SSN	Full Name A	Date of Birth 🔺	PATHOLOGY TEST HOSPITAL			^
987-65-4321	PATLAST, PATFIRST M.	04/04/1965	TESTING CANCER CENTER LEXINGTON, KENTUCKY 40	503		
987-65-4321	PATLAST, PATFIRST MIDDLE	04/04/1965	Coli	lect D	ate: 8/10/2017 01:01 ate: 8/10/2017 15:59	
AND LABORATORY MED: IMMUNO-MOLECULAR PA' Phone: 859-867-5309 Email: nopath@test.(ATTENDING MD: S. St PTH Reported: 8/2(DIRECTOR/SUPERVISO)			Pag DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICIN IMMUNO-MOLECULAR PATHOL/ Phone: 859-867-5309 Email: nopath@test.com ATTENDING MD: S. Strang PTH Reported: 8/20/200 DIRECTOR/SUPERVISOR: J. Collected: 8/5/2017 01 Interpretation	e 1 E OGY Fax:5 e, MD 17 02: J. Jam :01	55-555-5555 IM17-6332 Service: 02 eson	
				-	RB3 DRB4 DQB1 DQA1 DPB1 DPA1 Cola,	
<	ge 1 of 1 > >	> 1 - 2 of 2		ER	HIGH-RES 02:01,	~

The Validate Address Button: User's can check the address provided against the CPDMS geocoder by hitting the "Validate Address" button denoted below in green.



When this search button is click it will pop up the "Validate Address" window denoted below in **blue**. Initially, the user will see a loading message as shown in the image below.



Since this address does not exist, an error will show displaying the cause. The user is allowed to keep the original value by clicking the "Cancel" button denoted below in red

Va	lidate Address		×
	Entered Address		
	Address 1:	1234 TEST STREET CT	
	Address 2:		
	City, State, Country:	LEXINGTON , KY , USA	
	Zip Code:	40503 - Validate	
	Valid Addresses		
	Full Address		
	ERROR: Unknown Street		
	Cancel	Accept	

Or the user could enter another valid address, click "Validate" to search again, click the valid result and hit the "Accept" button denoted in green

Validate Address		×
Entered Address		1
Address 1:	2365 HARRODSBURG ROAD	
Address 2:	SUITE A230	
City, State, Country:	LEXINGTON , KY , USA	
Zip Code:	40504 - Validate	
Valid Addresses		
Full Address		
2365 Harrodsburg Rd, Lex	xington, Kentucky, 40504	
Consul		
Cancel	Accept	_

For the rest of this explanation we will continue to use the original fake address provided.

The Patient Data Panel Fields:

An abstractor can change the fields in the "Patient Data" panel if necessary, but these changes will be overwritten if the "Copy Pathology Data" button is clicked again.

Drop down fields are provided for:

For fields that do not have the toggle button, Users can trigger the drop down by pressing the "Down Arrow" on their keyboard if their cursor is in the respective field.

Sex:			
Patient Data		Reset	IM17-6332 - Selected Pathology Report Data
987-65-4321 PATLAS	ST, PATFIRST (04/04/1965)		987-65-4321 PATLAST, PATFIRST (04/04/1965)
Middle Name:	М		Middle Name: M.
Maiden Name:			Maiden Name:
Sex:	1 - MALE 👻		Sex: M
Race:	1 - Male		ace: WHITE
Ethnicity:	 Female Other (intersex, disorders of 	sexual	city: 2186-5Not Hispanic or LatinoCDC al development/DSD)
Address <u>Address 1</u> : 1234	4 - Transsexual, NOS 5 - Transsexual, natal male		ss 1: 1234 TEST STREET CT
Address 2:	6 - Transsexual, natal female		ss 2:
City, State, Country: LEXIN	9 - Unknown		ntry: LEXINGTON, KY
Zip Code: 4050	3 - Validate Address		Zip Code: 40503
	Create		Copy Pathology Data

2. Date of Birth: (This will only appear if you do not search over Date of Birth. Please notice the inclusion of the Date of Birth fields in the Patient Data Panel and the Selected Pathology Report Data Panel)

Back	TRAINING DATABASE (90201)				
	Patient Data		Reset	IM17-6332 - Selected Pathology Report Data	
	987-65-4321	PATLAST, PATFIRST	r	987-65-4321 PATLAST, PATFIRST	
	Middle Name:			Middle Name: M.	
	Maiden Name:			Maiden Name:	
	Sex:		v	Sex: M	
	Date of Birth:	mm/dd/YYYY		Date of Birth: 04/04/1965	
	Race:	November 2017	-	Race: WHITE	
	Ethnicity:	5 M T W T 29 30 31 1 2		Ethnicity: 2186-5Not Hispanic or LatinoCDC	
	Address <u>Address 1</u> :	5 6 7 8 9 12 13 14 15 16		Address Address 1: 1234 TEST STREET CT	
	Address 2:	19 20 21 22 23	24 25	Address 2:	
	City, State, Country:	26 27 28 29 30		City,State,Country: LEXINGTON, KY	
	Zip Code:	3 4 5 6 7	8 9 Address	Zip Code: 40503	
		Create		Copy Pathology Data	
Patholo	gy Details	IMI	17-6332 - Selecte	d Pathology Report Text	
SSN	Full Name 🔺		THOLOGY TEST HO STING CANCER CE		^
987-65-4	4321 PATLAST, PATFIRST M.		XINGTON, KENTU	CKY 40503	
987-65-4	4321 PATLAST, PATFIRST MIDDLE	04/04/1965		Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59	
			PTH Reported: 8	MEDICINE PATHOLOGY 309 Fax:555-555-5555 st.com IM17-6332 Strange, MD Service: 8/20/2017 02:02 ISOR: JJ. Jameson	
	Page 1 of 1	1 - 2 of 2 In	nterpretation		~

3. Each Race Field:

Patient Data	Reset IM17-6332 - Selected Pathology Report Data
987-65-4321 PATLAST, PATFIRST (04/04/	/1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965)
Middle Name: M	Middle Name: M.
Maiden Name:	Maiden Name:
Sex: 1 - MALE	▼ Sex: M
<u>Race</u> : 01 88 88 88 8	8 Race: WHITE
Ethnicity: 01 - White	 Ethnicity: 2186-5Not Hispanic or LatinoCDC
Address 02 - Black	Address
Address 1: 1234 03 - Amer. Indian Eskim	Address 1: 1234 TEST STREET CT
Address 2: 05 - Japanese	Address 2:
City, State, Country: LEXIN 06 - Filipino	City,State,Country: LEXINGTON, KY
Zip Code: 4050 07 - Hawaiian	Zip Code: 40503
08 - Korean	Copy Pathology Data
10 - Vietnamese	Copy Pathology Data
11 - Laotian	
12 - Hmong	
13 - Kampuchean (Cam	hodian) Report Toxt
13 - Kampuchean (Cam Date of Birth 14 - Thai	bodian) Report Text
Date of Birth 14 - Thai	
Date of Birth 14 - Thai	
Date of Birth 14 - Thai	istani KT 40503
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 152x51RG10N, RENTOC Ethnicity: Ethnicity:	Collect Date: 8/10/2017 01-01 Reset IM17-6332 - Selected Pathology Report Data
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 15 Extingion, weblock Ethnicity: Patient Data	Collect Date: 8/10/2017 01:01 Reset IM17-6332 - Selected Pathology Report Data
Date of Birth PATFIRST M. 04/04/1965 Ethnicity: Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/	Idani V KY 40503 Follect Date: 8/10/2017 01:01 Reset IM17-6332 - Selected Pathology Report Data /1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965)
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Ethnicity: Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: Maiden Name:	Internation Internation Reset IM17-6332 - Selected Pathology Report Data 1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: M.
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Ethnicity: Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: Sex: 1 - MALE	IM17-6332 - Selected Pathology Report Data Reset IM17-6332 - Selected Pathology Report Data /1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: Midden Name: Sex: M
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 1 Sexfile: Indiance: Patient Data Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Maiden Name: M Sex: 1 - MALE Race: 01 88 88 88	Image: Second
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 1 Sexfile: Indiance: Patient Data Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 88 88 88	Image: Ward of the second s
Date of Birth 14 - Thai PATEIRST M. 04/04/1965 1 Sexfile Today of Pake Ethnicity: Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 - 88 88 88 Ethnicity: 0 - NON-SPANISH 0 - NON-SPANISH	Reset IM17-6332 - Selected Pathology Report Data P1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: Middle Name: Sex: M Race: WHITE Ethnicity: 2186-5Not Hispanic or LatinoCDC
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 15 EXFIRST ON IP NOT DATE Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 88 88 88 Ethnicity: 0 - NON-SPANISH 0 - Non-Spanish Address 1 - Mexican 2 - Puerto Rican	Image: Second State 10/2017_01:01 Reset IM17-6332 - Selected Pathology Report Data 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: Middle Name: Sex: M Sex: M Race: WHITE Ethnicity: 2186-5Not Hispanic or LatinoCDC Address Address
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Patient Data 1 EXFIRST ON, PARKING Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 88 88 88 Ethnicity: 0 - NON-SPANISH Address 1: 1234 Address 2: 2 - Puerto Rican Address 2: 2 - Puerto Rican 3 - Cuban 3 - Cuban	istani 40503 Collect Date: 8/10/2017 01:01 Reset IM17-6332 - Selected Pathology Report Data /1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: M. Maiden Name: Sex: M 8 Race: WHITE Ethnicity: 2186-5Not Hispanic or LatinoCDC Address 1: 1234 TEST STREET CT Address 2: City.State.Country: LEXINGTON, KY
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Patient Data 1 EXFIRST ON PARAMENT OF PARAM	istani 40503 Collect Date: 8/10/2017 01:01 Reset IM17-6332 - Selected Pathology Report Data /1965) 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: Midde Name: Sex: M Sex: M 8 Race: WHITE Ethnicity: 2186-5Not Hispanic or LatinoCDC Address Address 1: 1234 TEST STREET CT Address 2: City.State.Country: LEXINGTON, KY
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Patient Data 1 EXFIRST ON (IN FIGURATION) Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 88 88 88 Ethnicity: 0 - NON-SPANISH Address 0 - Non-Spanish Address 2: 2 - Puerto Rican Address 2: 2 - Puerto Rican City, State, Country: LEXII Zip Code: 4050	Imitor Reset Imitor 1:012 Reset Imitor 987-65-4321 PATLAST, PATFIRST (04/04/1965) 91965) 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: Middle Name: Sex: M Race: WHITE Ethnicity: 2186-5Not Hispanic or LatinoCDC Address Address 1: Address 2: City,State,Country: LEXINGTON, KY Zip Code: 40503
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Patient Data 1 EXFIRST ON, PARKING Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 88 Address 0 - NON-SPANISH Address 0 - Non-Spanish Address 2: 2 - Puerto Rican 3 - Cuban 4 - South/Central Amer((not Brazil (not Brazil (not Brazil (not Brazil (not Brazil (not Brazil (not Brazil) (not Brazil (not Brazil (not Brazil) (not Brazil (not Brazil) (not Brazil (not Brazil) (not Brazil)
Date of Birth 14 - Thai PATFIRST M. 04/04/1965 Patient Data 1 EXFIRST ON, PARKING Patient Data 987-65-4321 PATLAST, PATFIRST (04/04/ Middle Name: M Sex: 1 - MALE Race: 01 88 Address 0 - NON-SPANISH Address 0 - Non-Spanish Address 2: 2 - Puerto Rican Address 2: 2 - Puerto Rican 3 - Cuban 4 - South/Central Amer(Zip Code: 4050 6 - Spanish NOS	(not Brazil (not Brazil (not Brazil (not Brazil (not Brazil (not Brazil (not Brazil) (not Brazil (not Brazil (not Brazil) (not Brazil (not Brazil) (not Brazil (not Brazil) (not Brazil)
Address 1: 1234 Address 1: 1234 Address 2: 2: 2: 0-NON-Spanish Address 2: 2: 0-NON-Spanish Address 2: 0-NON-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Non-Spanish 0-Spanish NOS 0-Spanish NOS	Image: Selected Pathology Report Data Reset IM17-6332 - Selected Pathology Report Data 987-65-4321 PATLAST, PATFIRST (04/04/1965) Middle Name: Middle Name: Sex: M Race: WHITE Ethnicity: 2186-5Not Hispanic or LatinoCDC Address Address 1: 1234 TEST STREET CT Address 2: City,State,Country: LEXINGTON, KY Zip Code: 40503

5. State:

Patient Data			Reset	IM17-6332 - Selected Pat	thology i	Report Data	
987-65-4	321 PATLAS	T, PATFIRST (04/04	4/1965)	987-65-4321 P	ATLAST,	, PATFIRST (04/04/1965)	
Middle Name: M				Middle Name: M.			
M	laiden Name:			Maiden Name:			
	Sex:	1 - MALE	¥	Sex: M			
	Race:	01 88 88 88	88	Race: WHITE			
	Ethnicity:	0 - NON-SPANISH	~	Ethnicity: 2	186-5Not	Hispanic or LatinoCDC	
Address				Address			
Add	lress 1: 1234 1	TEST STREET CT		Address 1: 1	234 TES	ST STREET CT	
Add	Iress 2:			Address 2:			
City, State, Co	ountry: LEXING	GTON ,	KY , USA				
Zip	Code: 40503	- Validate	CA - Cairornia CO - Colorado		^		
	0	Create	CT - Connecticut		r Pa	athology Data	
			DE - Delaware				
			DC - District of C	olumbia			
			FL - Florida				
			GA - Georgia				
*	Date of Birth ▲	PATHOLOGY TEST I TESTING CANCER (HI - Hawaii				
PATFIRST M.	04/04/1965	LEXINGTON, KENTU	ID - Idaho				
PATFIRST MIDDLE	04/04/1965		IL - Illinois				
			IN - Indiana				
		DEPARTMENT OF PA AND LABORATORY	IA - Iowa				
		IMMUNO-MOLECULAI	KS - Kansas				
		Phone: 859-867-! Email: nopath@te			~		

6. and Country:

Patient Data			Reset	IM17-6332 - Selected Pathology Report Data	
987-65-43	321 PATLAS	T, PATFIRST (04/04/196	55)	987-65-4321 PATLAST, PATFIRST	(04/04/1965)
Middle Name: M				Middle Name: M.	
Mi	aiden Name:			Maiden Name:	
	Sex:	1 - MALE 👻		Sex: M	
	Race:	01 88 88 88 88		Race: WHITE	
	Ethnicity:	0 - NON-SPANISH 👻		Ethnicity: 2186-5Not Hispanic or L	atinoCDC
Address				C Address	
Addr	r <u>ess 1</u> : 1234 1	TEST STREET CT		Address 1: 1234 TEST STREET CT	·
Addr	ress 2:			Address 2:	
City, State, Co	untry: LEXING	GTON , KY ,		City,State,Country: LEXINGTON, KY	
Zin	Code: 40503	- Validate Addres		idad and Topago	^
	. 10505		TUN - Tun	isia	
	(Create	TUR - Turk	cey .	
		a cate	TKM - Tur	rmenistan	
			TCA - Turk	is and Caicos	
				alu (Ellice Islands)	
		IM17-6332 - Selected Pa	UMI - U.S.	Minor Outlying Islands	
•	Date of Birth 🔺	PATHOLOGY TEST HOSPI TESTING CANCER CENTE		Virgin Islands	
PATFIRST M.			UGA - Uga	nda	
PATFIRST MIDDLE 04/04/1965			UKR - Ukra	ine	
			ARE - Unit	ed Arab Emirates	
		DEPARTMENT OF PATHOL AND LABORATORY MEDI			
		IMMUNO-MOLECULAR PAT	YUG - Yug	oslavia	
			USA - Unit	ed States (states and armed forces)	~

The Create Button:

Once the user reviews the data in the "Patient Data" panel, they can hit the "Create" button denoted in green

Back			TRAINING DAT	TAB/	ASE (90201)		DAVID RUST
	Patient Data		Re	Reset	IM17-6332 - Selected Pathology Report Data		
	987-65-4	321 PATLAST	, PATFIRST (04/04/1965)		987-65-4321 PATLAST, PATFIRST (04/04/	1965)	
		Middle Name: N	1		Middle Name: M.		
	1	Maiden Name:			Maiden Name:		
		<u>Sex</u> : 1	- MALE 🗡		Sex: M		
		Race: 0	1 88 88 88 88		Race: WHITE		
		Ethnicity: 0	- NON-SPANISH		Ethnicity: 2186-5Not Hispanic or LatinoCDC		
	Address				Address		
			EST STREET CT		Address 1: 1234 TEST STREET CT		
		dress 2:			Address 2:		
		ountry: LEXING	TON , KY , USA		City,State,Country: LEXINGTON, KY		
		<u>o Code</u> : 40503	- Validate Address		Zip Code: 40503		
	(C	reate		Copy Pathology Data		
					-		
Pathology De			IM17-6332 - Selected Pathology	jy Rep	ort Text		
SSN	Full Name A	Date of Birth ▲	PATHOLOGY TEST HOSPITAL TESTING CANCER CENTER				^
987-65-4321 987-65-4321	PATLAST, PATFIRST M. PATLAST, PATFIRST MIDDLE	04/04/1965 04/04/1965	LEXINGTON, KENTUCKY 40503 Collect		ate: 8/10/2017 01:01		
507 05 1521		0 1/0 1/ 1505	Receip Page 1		ate: 8/10/2017 15:59		
			DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE				
			IMMUNO-MOLECULAR PATHOLOGY				
			Email: nopath@test.com		55-555-5555 IM17-6332		
			ATTENDING MD: S. Strange, PTH Reported: 8/20/2017				
			DIRECTOR/SUPERVISOR: JJ. Collected: 8/5/2017 01:01		eson		
			Interpretation				
			-	logic	al equivalent interpretation:		
					RB3 DRB4 DQB1 DQA1 DPB1 DPA1 Col	a	
<		>	Gary DNA SER		HIGH-RES 02:01,	,	
Pag	je 1 of 1 ▷ ▷	1 - 2 of 2	02:01 41:02,				¥

This will direct the user to the "Patient Data Edit" screen below. The data entered in the "Patient Data" panel will then be populated for final review.

DAVID RUST	CANCER PATIENT DATA MANAGEMENT SYSTEM .net TRAINING DATABASE	Patient Data Edit
Page 1 Page 2 Page 3		
	Patient Data Edit Form 987-65-4321, PATFIRST PATLAST	
Soc Sec Number	987654321	
Last Name	PATLAST	
<u>First Name</u>	PATFIRST	
Middle Name	М	
Maiden Name		
Address 1	1234 TEST STREET CT	
Address 2		
<u>City</u>	LEXINGTON	
State	KY \wp	
Zip Code	40503 -	
Country	USA P	
Home Phone		
Date of Birth	04 / 04 / 1965	
State of Birth	KY P	
Country of Birth	USA P	
<u>Sex</u>	1 Male	~
ESC - Cancel, ALT+(Highlighted Ke	Prev Next Save Cancel Page (y) - Page Tab, F2 - Search, ALT+Down - Activate Dropdown, F7 - Prev, F8 - Next,	e 1 of 3 F10 - Save

DAVID RUST TRINING DATABASE Patient Data Edit Page 1 Page 2 Page 3 Page 2 Page 3 Page 3 Page 4 Page 5 Page 5 Page 6 Page 7 Page 7 <th>CANCER</th> <th>PATIENT DATA MANAGEMENT SYSTEM .net</th> <th></th>	CANCER	PATIENT DATA MANAGEMENT SYSTEM .net	
Patient Data Edit Form S87-65-4321, PATFIRST PATLAST Race 1 P A Race 2 BB A Race 3 BB A Race 4 BB A Race 5 BB A Race 5 BB A Spanish Origin O Non-Spanish V Tobacco Use V Gigarette Pack Years 999 Number of Live Births 99 Occupation Industry Cause of Death A Country of Death A Contact Patient 1 Yeav Contact Patient 1 Yeav Mumber of Primaries Number of Primaries	DAVID RUST	TRAINING DATABASE	Patient Data Edit
987-65-4321, PATFIRST PATLAST Race 1 P Race 2 88 P Race 3 88 P Race 4 88 P Race 5 88 P Spanish Origin O Non-Spanish V Tobacco Use V Cigarette Pack Years 999 Number of Live Births 99 Occupation Industry Cause of Death CD State of Death P Contact Patient 1 Yes V Contact Patient 1 Yes V Contact Patient 1 Yes V Contact Patient 1 Yes V Contact Patient Comments Vital Status 1 Patient Accession No -1 Last Modification By david V Vare Tore 1 Contact Patient 2 A Contact Patient Comments Vare Tore 1 Contact Patient Comments Vare Tore 1 Contact Patient Comments Vare Tore 1 Contact Patient Comments 0 Contact Patient 0	Page 1 Page 2 Page 3		
Race 2 88 P Race 3 88 P Race 4 88 P Race 5 88 P Spanish Origin 0 Non-Spanish \checkmark Tobacco Use \checkmark Cigarette Pack Years 999 Number of Live Births 99 Occupation Industry Cause of Death (ICD) 000.0 P State of Death P Country of Death P Contact Patient 1 Yes \checkmark Contact Patient 2 Yes \checkmark Number of Primaries Vital Status 1 Patient Accession No -1 Last Modification By david			^
Race 3 88 P Race 4 88 P Race 5 88 P Spanish Origin 0 Non-Spanish Tobacco Use	Race 1	ي 🔟 ۲	
Race 4 88 P Race 5 88 P Spanish Origin 0 Non-Spanish V Tobacco Use	Race	88 🔎	
Race 5 88 P Spanish Origin 0 Non-Spanish Tobacco Use - - Cigarette Pack Years 999 Number of Live Births 99 Occupation - - Industry - - State of Death(ICD) 000.0 P State of Death P - Country of Death P - Contact Patient 1 Yes ~ - Number of Primaries - - Vital Status 1 - Patient Accession No -1 -1 Last Modification By david -	Race 3	1 88 P	
Spanish Origin 0 Non-Spanish Tobacco Use Cigarette Pack Years 999 Number of Live Births 99 Occupation	Race	88 9	
Tobacco Use	Race	2 88 P	
Cigarette Pack Years 999 Number of Live Births 99 Occupation Industry Industry Industry Cause of Death(ICD) 000.0 State of Death P Country of Death P Contact Patient 1 Yes > Contact Patient Comments Vital Status Vital Status 1 Patient Accession No -1 Last Modification By Number Of 3	<u>Spanish Origi</u>	0 Non-Spanish V	
Number of Live Births 99 Occupation Industry Industry 000.0 State of Death(ICD) 000.0 State of Death P Country of Death P Contact Patient 1 Yes > Contact Patient Comments Vital Status Vital Status 1 Patient Accession No -1 Last Modification By david	Tobacco Use		
Occupation Industry Industry Cause of Death(ICD) 000.0 State of Death Country of Death Contact Patient 1 Yes Vital Status Patient Accession No -1 Last Modification By Number 0 2 of 3	Cigarette Pack Years	<u>999</u>	
Industry Cause of Death(ICD) State of Death State of Death Country of Death Contact Patient 1 Yes > Contact Patient Comments Vital Status 1 Patient Accession No -1 Last Modification By North North Same Cause of 3	Number of Live Birth	<u>5</u> 99	
Cause of Death(ICD) 000.0 State of Death P Country of Death P Contact Patient 1 Yes >	Occupation	2	
State of Death P Country of Death P Contact Patient 1 Yes > Contact Patient Comments P Number of Primaries Vital Status Vital Status 1 Patient Accession No -1 Last Modification By david Next Same Dave Next	Industry	۷	
Country of Death P Contact Patient 1 Yes > Contact Patient Comments Patient Accession No Vital Status 1 Patient Accession No -1 Last Modification By david Neutre Sause Cancel Page 2 of 3	Cause of Death(ICD)) 000.0 P	
Contact Patient 1 Yes v Contact Patient Comments	State of Deat		
Contact Patient Comments Number of Primaries Vital Status 1 Patient Accession No -1 Last Modification By Neutre Neutre Neutre Neutre Vital Status 1 Patient Accession No -1 Last Modification By Neutre Neure Neure <th>Country of Deat</th> <th></th> <th></th>	Country of Deat		
Number of Primaries Vital Status 1 Patient Accession No -1 Last Modification By david	Contact Patien	t 1 Yes V	
Vital Status 1 Patient Accession No -1 Last Modification By david	Contact Patient Comments	<u> </u>	
Patient Accession No -1 Last Modification By david Page 2 of 3	Number of Primaries	5	
Last Modification By david	Vital Statu:	- 5 1	
Prove Neutr Saus Cancel Dage 2 of 3	Patient Accession No	2 -1	
	Last Modification By		× ()
ESC - Cancel, ALT+(Highlighted Key) - Page Tab, F2 - Search, ALT+Down - Activate Dropdown, F7 - Prev, F8 - Next, F10 - Save			yez 015

Errors:

As with all software, errors can occur: some intended, some not. This new feature does its best to display the necessary information to the abstractor when an error occurs.

Here are some examples a user may encounter:

Errors that prevent the user from continuing their workflow:

In the example below the user's session has expired. This would only occur if the user sat at this page for over a half hour without progressing.

A small identifiable feature in the "Alert Window" is the font color of the "Error Title". If the title is **red**, this denotes an error which prevents any progress of the user workflow. If it is **black**, the user can proceed as normal as this case is more of a warning than an error. Upon hitting okay the "Create" button will be disabled, and the user should either close out of the browser or hit the "Back" button.

Back	TRAINING DATABASE (90201)			DAVID RUST	
	Patient Data		Reset	IM17-6332 - Selected Pathology Report Dat	а
	987-65-4321	PATLAST, PATFI	RST	987-65-4321 PATLAST, F	
		M			
		1 - MALE			
Patholo			bired CPDMS Hours: Monday - Frida Phone: (859)-218-22 Email: <u>cpdmsnetsupp</u> C		
SSN	Full Name A	Date of Birth 🔺	PATHOLOGY TEST H	OSPITAL	A
987-65-4 987-65-4		04/04/1965 04/04/1965		CKY 40503 Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59 Page 1 THOLOGY MEDICINE PATHOLOGY 309 Fax:555-555-5555 st.com IM17-6332 Strange, MD Service: 8/20/2017 02:02 ISOR: JJ. Jameson	
	Page 1 of 1 > >	1 - 2 of 2			

Invalid value in field:

This can show it a few ways:

1. The invalid message is shown below the field:

Patient Data	Reset
987-65-4321 PATLAST, PATFIRST (04/04/1965)	
Middle Name: 123	
Only alphabetic and space characters	
Maiden Name:	
Sex: 💌	
Race:	
Ethnicity:	
Address	
Address 1:	
Address 2:	
City, State, Country:	
Zip Code: - Validate Address	
Create	

2. The invalid message is denoted by the red line, and the messsage is shown when you use your cursor to hover over the field.

Patient Data	Reset
987-65-4321 PATLA	ST, PATFIRST (04/04/1965)
Middle Name:	
Maiden Name:	
<u>Sex</u> :	v
Race:	
Ethnicity:	v
Address	
Address 1:	
Address 2:	
City, State, Country:	, , , , , , , , , , , , , , , , , , , ,
Zip Code: asd	- Validate Address
	Cr I The minimum length for this field is 5 Numeric values only

3. In a new window if you hit the "Create" button:

The "Error Title" here is in **black**, this means the user may progress with their workflow. In this case they just need to correct the invalid values.

OPDMS Alert		×
Error: Invalid	f Form	
Middle Nam	e: Only alphabetic and space characters	
Zip Code:	The minimum length for this field is 5	
	Numeric values only	
	CPDMS Support	
H	Iours: Monday - Friday, 7AM to 5PM Eastern	
P	Phone: (859)-218-2222	
1	Email: cpdmsnetsupport@kcr.uky.edu	
	ОК	

Additonal Features:

CPDMS Field Definitions:

Each field has a link beside it which will direct the user via a new browser window to the Kentucky Cancer Registry's Registrar Manual to the respective field's page.

987-65-4321 PATLA	ST, PATFIRST (04/04/1965)
Middle Name:	
Maiden Name:	
Sex:	~
Race:	01 88 88 88 88
Ethnicity:	▼
Address	
Address 1:	
Address 2:	
City, State, Country:	, ,
Zip Code:	- Validate Address
	Create
(Inttps://confluence.kcr.uky.edu	ı/display/KAM/Middle+Name
≡ XConfluence Spaces -	

Pages /... / Page 1

ta •

Middle Name

Created by David Rust on Mar 14, 2017

Organization	Field Name	ID	Required
KCR	Middle Name (MidName)	10050	no
NAACCR	NameMiddle	2250	no

Field Length: 10

Enter the patient's middle name in the spaces provided. If the name exceeds the number of spaces, enter as much as possible. If only an initial is given, enter the initial. You may also record the patient's title or name suffix in this field -- such as: DR, JR, SR, III, M.D., etc.

Search Combo Boxes:


There are multiple combo boxes in the Patient Data panel that have type ahead assist. As the user enters in data in the field, the field will search the available values.

Below shows the user entering in "1" for the Male code. Only "1 - Male" is displayed. The second image shows the user entering in "MA", there are multiple values available for "MA". The user can use the Up and Down, Tab or Enter Key to pick and choose respectively what values they would like to fill.

Searching over the Text Value only works for the Sex and Ethnicity field. Searching over the Code will work in the Sex, Race 1-5, Ethnicity, State, and Country fields.

Pat	ient Data		Reset
	987-65-4321 PATLAS	ST, PATFIRST (04/04/1965)	
	Middle Name:		
	Maiden Name:		
	<u>Sex</u> :	1	
	Race:	1 - Male	
	Ethnicity:		
	- Address		
	Address 1:		
	Address 2:		Ī
	City, State, Country:	, ,	ī.
	Zip Code:	- Validate Address	ī.
l			
		Create	
Pat	tient Data		Reset
Pat		ST, PATFIRST (04/04/1965)	Reset
Pat		ST, PATFIRST (04/04/1965)	Reset
Pat	987-65-4321 PATLA	ST, PATFIRST (04/04/1965)	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> :		Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> :		Reset
Pat	987-65-4321 PATLA Middle Name: Maiden Name: Sex: Race:	MA ~	Reset
Pat	987-65-4321 PATLA Middle Name: Maiden Name: Sex: <u>Sex:</u> <u>Race</u> :	MA 1 - Male 2 - Female 5 - Transsexual, natal male	Reset
Pat	987-65-4321 PATLA Middle Name: Maiden Name: Sex: Race:	MA V 1 - Male 2 - Female	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> : <u>Race</u> : <u>Ethnicity</u> : Address	MA 1 - Male 2 - Female 5 - Transsexual, natal male	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> : <u>Sex</u> : <u>Race</u> : <u>Ethnicity</u> : Address <u>Address 1</u> : <u>Address 2</u> :	MA 1 - Male 2 - Female 5 - Transsexual, natal male	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> : <u>Race</u> : <u>Ethnicity</u> : Address <u>Address 1</u> :	MA V 1 - Male 2 - Female 5 - Transsexual, natal male 6 - Transsexual, natal female	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> : <u>Sex</u> : <u>Race</u> : <u>Ethnicity</u> : Address 1: <u>Address 2</u> : <u>City, State, Country</u> :	MA V 1 - Male 2 - Female 5 - Transsexual, natal male 6 - Transsexual, natal female , , ,	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> : <u>Sex</u> : <u>Race</u> : <u>Ethnicity</u> : Address 1: <u>Address 2</u> : <u>City, State, Country</u> :	MA V 1 - Male 2 - Female 5 - Transsexual, natal male 6 - Transsexual, natal female , , ,	Reset
Pat	987-65-4321 PATLA <u>Middle Name</u> : <u>Maiden Name</u> : <u>Sex</u> : <u>Sex</u> : <u>Race</u> : <u>Ethnicity</u> : Address 1: <u>Address 2</u> : <u>City, State, Country</u> :	MA V 1 - Male 2 - Female 5 - Transsexual, natal male 6 - Transsexual, natal female , , , - Validate Address	Reset

You can also hit the Down key to bring up the available values for these combo boxes as well.



Auto-fill Race Fields:

The Patient Data Panel will auto fill Race fields 2-5 when Race field 1 is populated with "01" (White), "02" (Black), and "99" (Unknown).

Pat	tient Data				Reset
	987-65-4321 PA	TLAS	ST, PATFIR	ST (04/04/	1965)
	Middle N	ame:			
	Maiden Ni				-
		Sex:			~
		<u>ace</u> :	01		
		icity:	01 - White		~
	- Address	icity:		3	×
	Address Address 1:				
	Address 2:				
	City, State, Country:				
	Zip Code:		-	Validate Ad	Idress
			Create		
Pa	tient Data				Reset
Pa	tient Data 987-65-4321 P/	ATLAS	ST, PATFIR	ST (04/04/	
Pa	987-65-4321 P/		ST, PATFIR	ST (04/04/	
Pa	987-65-4321 P/ <u>Middle N</u>	<u>ame</u> :	ST, PATFIR	ST (04/04/	
Pa	987-65-4321 P/	ame: ame:	ST, PATFIR	ST (04/04)	
Pa	987-65-4321 P/ <u>Middle N</u> <u>Maiden N</u>	ame: ame: <u>Sex</u> :			/1965) ~
Pat	987-65-4321 P/ <u>Middle N</u> <u>Maiden N</u>	ame: ame: <u>Sex</u> : Race:	01 88		/1965) ▼ 8
Pa	987-65-4321 P/ Middle N Maiden N <u>Haiden N</u>	ame: ame: <u>Sex</u> :	01 88		/1965) ~
Pa	987-65-4321 P/ <u>Middle N</u> <u>Maiden N</u>	ame: ame: <u>Sex</u> : Race:	01 88		/1965) ▼ 8
Pa	987-65-4321 P/ Middle N Maiden N Ethr	ame: ame: <u>Sex</u> : Race:	01 88		/1965) ▼ 8
Pa	987-65-4321 P/ Middle N Maiden N I Ethr Address Address 1: Address 2:	ame: ame: <u>Sex</u> : Race:	01 88		/1965) ▼ 8
Pa	987-65-4321 P/ Middle N Maiden N Ethr Address Address 1: Address 2: City,State,Country:	ame: ame: <u>Sex</u> : Race:	01 88		/1965)
Pa	987-65-4321 P/ Middle N Maiden N I Ethr Address Address 1: Address 2:	ame: ame: <u>Sex</u> : Race:	01 88	88 88 8	/1965)
Pa	987-65-4321 P/ Middle N Maiden N Ethr Address Address 1: Address 2: City,State,Country:	ame: ame: <u>Sex</u> : Race:	01 88	88 88 8	/1965)
Pa	987-65-4321 P/ Middle N Maiden N Ethr Address Address 1: Address 2: City,State,Country:	ame: ame: <u>Sex</u> : Race:	01 88	88 88 8	/1965)

Customizable Interface Options:

There are many ways to change the appearance of this application. The following are a list of items that can be modified. They will automatically be saved, so every adjustment made will be seen the next time the application is launched.

Resize Interface Panels:


There are two borders which split the application in a couple sections. The user can moves border by using the cursor to hover over the borders followed by clicking and dragging the border to their specified place.

1. The border between the "Pathology Details Grid Panel" and the "Selected Pathology Report Text Panel"

Pathology Details			IM17-6332 - Selected Pathology Report Text	
Pathology Details SSN Full Name A Date of Birth A 987-65-4321 PATLAST, PATFIRST M. 04/04/1965 987-65-4321 PATLAST, PATFIRST MIDDLE 04/04/1965		04/04/1965	PATHOLOGY TEST HOSPITAL TESTING CANCER CENTER LEXINGTON, KENTUCKY 40503 Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59 Page 1 DEPARTMENT OF PATHOLOGY AND LABORT RY MEDICINE Phone Email: nopace@test.com MI17-6332 ATTENDING MD: S. Strange, MD Service: PTH Reported: 8/20/2017 02:02 DIRECTOR/SUPERVISOR: JJ. Jameson Collected: 8/5/2017 01:01	
Pathology	e 1 of 1 > >	1 - 2 of 2 iology Report Te	Inscipic Subion	v
SSN 987-65-4321 987-65-4321	Re DEPARIMENT OF PATHOLO AND LABORATORY MEDIC IMMUNO-MOLECULAR PATH Phone: 859-867-5309 Email: nopath@test.com ATTENDING MD: S. Strat FTH Reported: 8/20// DIRECTOR/SUPERVISOR: Collected: 8/5/2017	40503 ollect Date: eceipt Date: age 1 GY INE OLOGY Fax:555-55 m nge, MD Serv 2017 02:02 JJ. Jameson	IM17-6332	^
🕴 🖣 Pag	Interpretation			~

2. The border between the Upper and Lower Panels that split the "Patient Data Panel" and "Pathology Report Data Panel" from the "Pathology Details Grid Panel" and "Selected Pathology Report Text Panel".

Back	k TRAINING DATABASE (90201) DA					
	Patient Data		Reset	IM17-6332 - Selected Pathology Report Data		
	987-65-4321 PATLAST, PATFIRST (0		4/04/1965)	987-65-4321 PATLAST, PATFIRST (04/04/196	5)	
	Middle Name:			Middle Name: M.		
	Maiden Name:			Maiden Name:		
	<u>Sex</u> :		~	Sex: M		
	Race:	01 88 88	88 88	Race: WHITE		
	Ethnicity:		~	Ethnicity: 2186-5Not Hispanic or LatinoCDC		
	Address Address 1:			Address Address 1: 1234 TEST STREET CT		
	Address 2:			Address 1: 1234 FEST STREET CT		
	City, State, Country:			City,State,Country: LEXINGTON, KY		
	Zip Code:	- Val	date Address Zip Code: 40503			
		Create		Copy Pathology Data		
Patholo	gy Details		IM17-6332 - Selec	Rathology Report Text		
SSN	Full Name A	Date of Birth ▲	PATHOLOGY TE TESTING CAN	AL	^	
987-65-4 987-65-4		04/04/1965 04/04/1965	LEXINGTON	03 t Date: 8/10/2017 01:01		
507 05		0 10 11 1505		Date: 8/10/2017 15:59		
			DEPARTMENT AND LABORA	Z IE		
			IMMUNO-MOLE Phone: 859-	LOGY		
			Email: nopa	Fax:555-555-5555 IM17-6332		
				Strange, MD Service: 8/20/2017 02:02		
			DIRECTOR/SUPERV Collected: 8/5/	'ISOR: JJ. Jameson 2017 01:01		
	Page 1 of 1 🕑 🏹	1 - 2 of 2	Interpretation		~	



You can also click the **button**, and it will collapse the bottom sections.

Back	TRAINING DATABASE (90201)			/ID RUST
	Patient Data	Reset	IM17-6332 - Selected Pathology Report Data	
	987-65-4321 PATLAST, PATFIRST (04/04	/1965)	987-65-4321 PATLAST, PATFIRST (04/04/1965)	
	Middle Name:		Middle Name: M.	
	Maiden Name:		Maiden Name:	
	<u>Sex</u> :	v	Sex: M	
	<u>Race</u> : 01 88 88 88 8	38	Race: WHITE	
	Ethnicity:	Y	Ethnicity: 2186-5Not Hispanic or LatinoCDC	
	Address 1:		Address Address 1: 1234 TEST STREET CT	
	Address 2:		Address 2:	
	City, State, Country:	,	City,State,Country: LEXINGTON, KY	
	Zip Code: - Validate A	ddress	Zip Code: 40503	
	Create		Copy Pathology Data	

to snap the panel back into view.

Pathology Details Grid Panel Features:

Click the

The Pathology Details Grid Panel is highly customizable. Each adjustment will be saved automatically. Once a user has set their ideal grid layout, they will not have to worry about changing it again (unless their browser's cookies are cleared).

- 1. Add/Remove new columns:
 - a. By default, the columns displayed are SSN, Full Name (Last, First Middle), and Date of Birth.
 - b. There is a lengthy list of columns available to display in the Details Grid. This list is shown in the image below. Not all available columns are included in the application. If a user needs additional data items, feel free to ask the CPDMS Development team to add them. This is not difficult.
 - c. How to add/remove
 - i. Hover cursor over any column header. You will notice a down arrow appear.
 - ii. Click the down arrow.
 - iii. A menu will drop down. Click the last item, "Columns".
 - iv. Check/uncheck the columns you wish to add/remove.

		ļ		
Pathology De	tails	7		
SSN	Full Name 🔺	▼ Da	ate of Birth	
987-65-4321	PATLAST, PATFIRST M.	04	4/04/1965	
987-65-4321	PATLAST, PATFIRST MIDDLE	04	4/04/1965	
			1 2 -61	
Pathology De			1 - 2 of :	TM12
Pathology De SSN		▼ D	1 - 2 of : ate of Birth <i>4</i>	IM12 PATH
Pathology De	tails		ate of Birth 4	PATH
Pathology De	t ails Full Name ▲	▼ D A Z ↓ X ↓		PATH TEST
Pathology De SSN 987-65-4321	tails Full Name ▲ PATLAST, PATFIRST M.	₽ţ	ate of Birth 4 Sort Ascen	PATH TEST ading I ending
Pathology De SSN 987-65-4321	tails Full Name ▲ PATLAST, PATFIRST M.	Az↑ ZA↓	ate of Birth 4 Sort Ascen Sort Desce	PATH TECT Inding I ending

	City, State, Country:		
	Zip Code: - Validate	V	SSN
			Specimen Date
	Create	✓	Full Name
		V	Date of Birth
Patholo	gy Details IM:		Pathology Id
SSN	Full Name A Date of Birth A PAT		MRN
987-65-4	321 PATLAST, PATFIRST M.		Maiden Name
987-65-4			Race
	A¥ Sol Descending		Ethnicity
	Columns 🕨		Sex
	IM		Report Date
	Ema	a 📃	Address1
	AT		Address 2
	D: Ce	[City
			State
	In		Zip Code
	Page 1 of 1 > > 1 - 2 of 2		Country

- Reorder columns:

 a. It is easy to reorder the columns. Just click and hold the column header you wish to move, and drag and drop it to the desired position in the grid. In this example I click, drag, and drop the Date of Birth field between the SSN and Full Name fields.

	Pathology D	etai)	ils						
	SSN	▼ Fi	ull Nan	ne 🔺			•	Date of Birth	*
	987-65-4321							04/04/1965	
	987-65-4321	F	O 🛇	ate of B	irth	MIDDLE		04/04/1965	
		ige	1	of 1				1 - 2 of	
b.		ige.	1	011	Ĺ				2
b.	Pathology D	-		UT	Ĺ	ا ک			2
b.	<u> </u>)etai	ls			Name 🔺			• 2 •
b.	Pathology D	etai Di	ls ate of	Birth ▲	Full		TFI		• 2
b.	Pathology D	Detai Di 04	ls ate of	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA			~
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	~
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	-
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	₹
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	₹
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	▼
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	• 2 •
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	₹ 2
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	▼
b.	Pathology D SSN 987-65-4321	Detai Di 04	ls ate of 4/04/1	Birth ▲ .965	Full PAT	Name 🔺 LAST, PA		RST M.	▼

3. Adjust column width

a. Users can adjust a column's width by clicking and dragging the divider between column headers. The cursor will look similar to

•||•

	Pathology Det			
	SSN	Full Name 🔶 🛛 🕊	-lijate of Birth	A
	987-65-4321	PATLAST, PATFI	04/04/1965	
	987-65-4321	PATLAST, PATFI	04/04/1965	
b.	A Page	e 1 of 1 🕑		1 - 2 of 2
	Pathology Det	ails		
	Pathology Det SSN	ails Full Name ▲		Date of Birth 🔺
			Г М.	Date of Birth ▲ 04/04/1965
	SSN	Full Name 🔺		
	SSN 987-65-4321 987-65-4321	Full Name A		04/04/1965 04/04/1965
	SSN 987-65-4321	Full Name A PATLAST, PATFIRST PATLAST, PATFIRST	MIDDLE	04/04/1965

4. Sorting fields (2 methods):

- a. Columns display the way the are sorted by a and reaction in the header text. In the example in 4b the headers are sorted Full Name (Last Name) ascending (Z to A) and Date of Birth descending (oldest to youngest)
 b. A user can click the header of the column they wish to sort over:

Pathology Details					
SSN	Full Name 🔺	Date of Birth 👻			
987-65-4321	PATLAST, PATFIRST M.	04/04/1965			
987-65-4321	PATLAST, PATFIRST MIDDLE	04/04/1965			

c. Navigating to the Column header menu by using the cursor to hover over the column header and clicking the selects either "Sort Ascending" or "Sort Descending" from the menu.

Ŧ

	SSN	Full Name 🔺	•	-		
	987-65-4321	PATLAST, PATFIRST M.		0	4/04/1965	LEXIN
i.	987-65-4321	PATLAST, PATFIRST MIDDLE		0	4/04/1965	
	Pathology Det	tails				11
	SSN	Full Name 🔺	Ŧ	D	ate of Birth 🔻	Pl TI
	987-65-4321	PATLAST, PATFIRST M.	Az	1	Sort Ascending	
	987-65-4321	PATLAST, PATFIRST MIDDLE	ZA	ţ	Sort Descendin	g
					Columns	▶ E
						II Pl

Case Data

- Diagnosis
 - Case Sequence Num
 - Case Site Code
 - Case Type
 - ICDO Version
 - ICD-O-3 Conversion Flag Topography Code (ICD-O)

 - Histology Behavior Code
 - Histology (ICD-O-2)
 - Behavior Code (ICD-O-2)
 - Tumor Grade
 - Lymphovascular Invasion
 - Class of Case
 - Place of Diagnosis
 - Date of First Contact
 - Date of Diagnosis
 - Age at Diagnosis
 - Laterality
- Personal
 - Hospital Chart No
 - Family History
 - Marital Status at Diag
 - Menopausal Status

 - Primary Payer
 ACOS Sequence Num
 - SEER Sequence Num
 - Address at Diag 1
 - Address at Diag 2
 - City at Diag
 - State at Diag
 - Zip Code at Diag
 - Country at Diag
 - County at Diag
 - Registry Accession Year
 Diag Confirmation Code

 - Path Report No
- Collab Stg
 - Collaborative Staging
 - Regional Lymph Nodes Examined
 - Regional Lymph Nodes Positive
 - Mets at DX Bone
 - Mets at DX Brain
 - Mets at DX Liver
 - Mets at DX Distant LN
 - Mets at DX Lung
 - Mets at DX Other
 - Summary Stage 1977
 - SummStg1977Disp
 - Summary Stage 2000
 - SummStg2000Disp
 - CS Version Input Current
 - CS Version Derived
 - CS Version Input Original
- EOD
- EOD Primary Tumor
- Prostate Pathological Extension
- EOD Regional Nodes
- Date of Sentinel Lymph Node Biopsy
- Sentinel Lymph Nodes Examined
- Sentinel Lymph Nodes Positive
- Date Regional Lymph Node Dissection
- EOD Metastases
- Derived Summary Stage 2018
- SSDI/Grade
 - Grade Clinical
 - Grade Pathological
 - Grade Post Therapy
 - SSDI
 - SEER SSF 1 (HPV Status)
- AJCC Docs
 - Directly Coded Summ Stg 2000
 - Directly Coded Summary Stage 2018
 - AJCC Staging Of Cancer
 - Tumor Size Pathologic ٠ Tumor Size Clinical

- **Tumor Size Summary**
- AJCC Staging Edition
- **cT** Classification
- cN Classification
- cM Classification
- cTNM Stage Group
- cTNM Descriptor
- Staged By Clinical pT Classification
- pN Classification
- ٠
- pM Classification pTNM Stage Group
- pTNM Descriptor
- Alt (Ped) Stage Sys
- Alt (Ped) Stage
- Managing Physician
- Primary Surgeon
- Medical Oncologist
- Radiation Oncologist
- Staged By Pathologic
- AJCC TNM Clinical T
- AJCC TNM Clinical T Suffix
- AJCC TNM Clinical N
 AJCC TNM Clinical N Suffix
- AJCC TNM Clinical M
- AJCC TNM Clinical Stage Group
 AJCC TNM Pathological T
- AJCC TNM Pathological T Suffix
- AJCC TNM Pathological N
- AJCC TNM Pathological N Suffix
- AJCC TNM Pathological M
- AJCC TNM Pathological Stage Group
- AJCC TNM Post Therapy T
- AJCC TNM Post Therapy T Suffix
- AJCC TNM Post Therapy N
- AJCC TNM Post Therapy N Suffix
- AJCC TNM Post Therapy M
- AJCC TNM Post Therapy Stage Group
- Admin NoTx ٠
 - ACOS Coding Original
 - Type of Reporting Src
 - Abstracted By
 - ACOS Coding Current
 - Reason No Therapy (Non-def Surg)
 - Reason No Therapy (Surg)
 - Reason No Therapy (Chemo)
 Reason No Therapy (Rad)

 - Reason No Therapy (Horm)
 - Reason No Therapy (Immuno)
 - Reason No Therapy (Trans)
 - Reason No Therapy (Other)
 - Tx Follow-back Needed
 - Systemic Therapy/Surg Seq
 - Radiation/Surgery Sequence
 - Treatment Status
 - Date No First Therapy

 - Tx Start Date (ACOS)
 - Tx Composite (First)
 - Tx Composite (All) QA Review Status

 - Central Review Status • Date Case Completed CoC
- ACoS
 - Comorbidity
 - Secondary Diagnosis
 - ICD Revision Secondary Diagnosis
 - Inst Referred From
 - Inst Referred To
 - Palliative Procedure
 - Palliative Procedure This Facility
 - Date Surgical Discharge
 - Date Surgical Discharge Flag
 - Readmit within 30 days
- Overrides
 - Summary Stage Overrides
 - Acsn/Class/Seq Override
 - HospSeq/DxConf Override
 - COC-Site/Type Override
 - HospSeq/Site Override

- Site/TNM-StgGrp Override
- Age/Site/Morph Override (IF15)
- SeqNo/DxConf Override (IF23)
- Site/Lat/SeqNo Override (IR09) Surg/DxConf Override (IF46)
- Site/Type Override (IF25)
 Histology Override (MORPH)
- Report Source Override (IF04)
- III-Define Site Override (IF22)
- Leuk, Lymphoma Override (IF48)
- Site/Behavior Override (IF39)
- Site/Eod/Dx Dt Override (IF40)
- Site/Lat/Eod Override (IF41)
- Site/Lat/Morph Override (IF42)
- CS Override
- Override TNM Tis
- Override TNM Stage
- Override TNM 3
- Historical
 - Grade Path Value
 - Grade Path System
 - Tumor Marker 1
 - Tumor Marker 2
 - Tumor Marker 3
 - Biopsy Procedure
 - Multiplicity Counter
 - Date Multiple Tumors
 - Date Multiple Tumors Flag
 - Type of Multiple Tumors
 - Ambiguous Terminology
 - Date of Conclusive Terminology
 - Date of Conclusive Terminology Flag
 - SEER Extent
 - SEER PEP
 - Tumor Size (largest)
 - SEER Lymph Node
 - Site of Mets
- Text
- Text Local Hospital Id
- Case Text
- Modified By (Case Text)
- Time Modified (Case Text)
- COVID-19 --DX PROC--LAB TESTS
- COVID-19 Impact SURGERY
- COVID-19 Impact RADIATION (BEAM)
- COVID-19 Impact RADIATION OTHER
- COVID-19 Impact CHEMO
- COVID-19 Impact- HORMONE
- COVID-19 Impact BRM
- COVID-19 TEXT
- COVID-19 Impact BMT COVID-19 Impact - RADIATION (ICB)
- Case Misc
 - Case Other Sequence Num
 - Case Other Site Code
 - Year of Diagnosis

 - Case Other Comment
 Modified By (Case Other)
 - Time Modified (Case Other)
 - EOD Coding System
 - Vendor
 - Census Tract 2000
 - Census Tract Certainty 2000
 - Census Tract 2010
 - Census Block Group 2010
 - Census Tract Certainty 2010
 - Latitude
 - Longitude
 - GIS Coordinate Quality
 - Date Case Completed
 - Date Case Last Updated
 - Import Reporting Facility
 - Area Development District
 - Appalachia
 - Beale Code 2003
 - Beale Code 2013
 - Best Stage Group ٠
 - SEER Site
 - ICCC Site

- ICCC Extended Site
 Source Status
 Class Hospital Id
 Original Case Type
 Patient Acc No
 ArchiveFIN
 Modified By (Case)
 Time Modified (Case)
 Date of First Recurrence Flag
 Case User Defined Data a
 2018 Best Stage Group
 sus Tract

- Census Tract
 Census Tract Coding System
 Seer Extent Of Disease
 CPDMS Create Case From Pathology Report Application

Diagnosis

- Case Sequence NumCase Site Code

- Case TypeICDO Version
- ICDO Version
 ICD-0-3 Conversion Flag
 Topography Code (ICD-0)
 Histology
 Behavior Code
 Histology (ICD-0-2)
 Behavior Code (ICD-0-2)
 Tumor Grade
 Lymphovascular Invasion

- Lymphovascular Invasion
 Class of Case

- Class of Case
 Place of Diagnosis
 Date of First Contact
 Date of Diagnosis
 Age at Diagnosis
 Laterality

Case Sequence Num

Organization	Field Name	ID	Required
KCR	Case Sequence Num (SeqNo)	30030	yes

Field Length: 2

The sequence number represents the order of all primary reportable tumors diagnosed during a patient's lifetime. It counts the occurrence of independent, primary diagnoses, regardless of who must report them, but only if diagnosed in years in which they were considered reportable. Thus, it does not include skin malignancies and carcinoma in-situ of the cervix diagnosed in years when they were not considered reportable.

Exception: Benign and borderline CNS tumors are sequenced to include historical tumors, including those diagnosed prior to 2004.

Enter the number which designates the chronological order of this primary tumor in relation to all primary tumors (including in-situ) that the patient has had. (Single digits will be right justified by the computer.)

- 1 1st primary
- 2 2nd primary
- 3 3rd primary
- 4 4th primary
- 5 5th primary
- 6 6th primary
- 7 7th primary
- 8 8th primary
- 9 9th primary
- ... (and so on)

For patients having more than one independent, reportable primary diagnosed at the same time, the selection of the first is assigned to the primary with the worst prognosis. If no difference in prognosis is evident, the selection of the sequence number may be arbitrary.

Only include reportable conditions, as outlined earlier.

Case Site Code

Organization	Field Name	ID	Required
KCR	Case Site Code (SiteCode)	30040	yes

Field Length: 2

A two digit code for the site group into which this primary malignancy is categorized will be calculated by the computer. Appendix C shows the appropriate site groups, based on the anatomic site and histology mentioned for this case.

Starting in 2004, site group 60 is assigned for all benign and borderline intracranial tumors.

Case Type

Organization	Field Name	ID	Required
KCR	Case Type (CaseType)	30050	yes

Field Length: 1

This field indicates whether a case will be entered into the database as a full abstract (case type A) or as an "other" primary (case type O). Use case type O only for primaries that are collected by KCR but which are not reportable by your registry.

ICDO Version

Organization	Field Name	ID	Required
KCR	ICDO Version (ICDOVer)	30060	yes

Field Length: 1

Enter the appropriate code for the version of ICD-O which was used to determine the topography and morphology codes entered in items 32 and 33.

Code	Description
1	ICD-O, 1st edition (1976)
F	ICD-O, Field Trial edition (1988)
2	ICD-O, 2nd Edition (1990)
3	ICD-O, 3rd Edition (2001)

All cases diagnosed before January 1, 2001 should be coded with the ICD-O, 2nd edition used to determine the topography and morphology codes.

All cases diagnosed on or after January 1, 2001 should be coded 3, with the 3rd edition used to determine the topography and morphology codes.

In the computerized record, all cases will have the ICD-O-3 topography, histology and behavior codes stored. Cases diagnosed prior to 2001 will have the ICD-O-2 histology and behavior codes stored as well.

See also "ICD-O-3 Errata and Clarifications" in APPENDIX J, to be used when abstracting cases diagnosed after January 1, 2001.

ICD-O-3 Conversion Flag

Organization	Field Name	ID	Required
KCR	ICD-O-3 Conversion Flag (ICDO3Conversion)	30070	yes
NAACCR	ICD-O-3 Conversion Flag	2116	yes

Field Length: 1

Record the one digit code specifying how the conversion of site and morphology codes from ICD-O-2 to ICD-O-3 was accomplished.

Code	Description
0	Primary site and morphology originally coded in ICD-O-3
1	Primary site and morphology converted without review
3	Primary site computer-converted without review; morphology converted with review

If the diagnosis date is prior to January 1, 2001, the case record must have:

- * an ICD-O-2 histology and behavior codes
- * a conversion flag value of 1 or 3

The computer will automatically convert the ICD-O-2 codes to the ICD-O-3 codes if the conversion flag is 1.

If the diagnosis date is on or after January 1, 2001, the case record must have:

* ICD-O-3 histology and behavior codes

- * a conversion flag of 0
- * blanks in the ICD-O-2 field

ICD-O-3 Conversion Flag Controls Field Editing

0 Originally coded in ICD-O-3

(cursor goes only to ICD-O-3 histology)

1 ICD-O-2 code converted without review

(cursor goes only to ICD-O-2 histology)

3 ICD-O-2 converted with review

(cursor goes only to ICD-O-3 histology)

Topography Code (ICD-O)

Organization	Field Name	ID	Required
KCR	Topography Code (ICD-O) (Topography)		yes
NAACCR	Primary Site	400	yes

Field Length: 5

Enter the ICD-O 3rd edition Topography code which describes the anatomical site of the patient's primary tumor. This is a five character field. After the "C", enter the three digit code; the decimal point is already in the correct position.

The International Classification of Diseases for Oncology (ICD-O) <u>3rd edition</u>, represents an extension of Chapter II of the ICD-10 coding reference. ICD-O permits the coding of all neoplasms by topography, morphology, and cell behavior -- providing greater detail than that permitted with ICD-9 or ICD-10 coding schemes.

The structure of the ICD-O reference book contains three major sections:

Topography - A numerical list of anatomic sites adapted from the malignant neoplasms section of Chapter II of ICD-10. The topographic terms have 3-digit code numbers preceded by a "C" which run from C00.0 to C80.9.

Morphology - A numerical list of histologic terms that is a revised and expanded version of the morphology section of The Manual of Tumor Nomenclature and Coding. The ICD-O, 3rd edition includes new histologic types that have come into the literature since 1990. It has revised the Leukemia and Lymphoma sections and now includes several hematopoietic diseases that were previously considered borderline.

Alphabetic Index - A list of anatomic sites, histologic terms and selected tumor-like lesions and conditions.

Refer to the introductory pages of the International Classification of Diseases for Oncology. 3rd edition, for a more detailed discussion of the differences between ICD-O and ICD-10, as well as for rules governing the appropriate assignment of ICD-O codes. See also APPENDIX J for errata and clarifications to ICD-O-3rd edition.

Coding Instructions for Solid Tumors

Site-Specific Topography Terms

See the Coding Guidelines for Topography and Morphology in the introduction of the ICD-O-3 for additional details.

1. Unless otherwise instructed, use all available information to code the site.

2. Code the site in which the primary tumor originated, even if it extends onto/into an adjacent subsite.

Example 1: Final diagnosis is adenocarcinoma of the upper lobe of the right lung. Code the topography to lung, upper lobe (C341).

Example 2: The patient has a 4 cm tumor in the right breast. The tumor originated in the upper inner quadrant and extends into the lower inner quadrant. Code the primary site to upper inner quadrant of breast (C502).

Example 3: Patient has a right branchial cleft cyst; the pathology report identifies an adenocarcinoma arising in an ectopic focus of thyroid tissue within the branchial cleft cyst. Thyroidectomy pathology is negative. Code the primary site to branchial cleft (C104).

Example 4: The patient had a total hysterectomy with a bilateral salpingo-oophorectomy ten years ago for non-cancer reasons. She now has widespread cystadenocarcinoma in the peritoneum. Code the primary site to peritoneum, NOS (C482). (The chart may or may not state that the patient has extraovarian carcinoma.)

Example 5: Pathology report shows adenocarcinoma arising in a patch of endometriosis on the sigmoid colon. Code the primary site to sigmoid colon (C187), the site in which the cancer originated.

3. Code the last digit of the primary site code to '8' when a single tumor overlaps an adjacent subsite(s) of an organ and the point of origin cannot be determined.

Example: The patient has a 5cm tumor that involves the dorsal surface and anterior 2/3 of tongue. Code the primary site to C028 (overlapping lesion of tongue).

Exception: Skin cancers overlapping sites in the head and neck only: assign the primary site where the bulk of the tumor is; do not use C44.8.

4. Code the site of the invasive tumor when there is an invasive tumor and in situ tumor in different subsites of the same anatomic site.

Example 1: Patient has an invasive breast tumor in the upper-outer quadrant of the left breast and in situ tumor in multiple quadrants of the left breast. Code the primary site to C504 (upper outer quadrant of breast).

Example 2: Patient has in situ Paget disease of the right nipple and invasive duct carcinoma of the lower inner quadrant of the right breast. Code the primary site to C503 (lower inner quadrant).

5. Code the last digit of the primary site code to '9' for single primaries, when multiple tumors arise in different subsites of the same anatomic site and the point of origin cannot be determined.

Example 1: During a TURB, the physician describes multiple papillary tumors in the bladder neck (C675) and the lateral wall of the bladder (C672). Code the primary site as bladder, NOS (C679).

Example 2: Patient has an infiltrating duct tumor in the upper outer quadrant (C504) of the right breast and another infiltrating duct carcinoma in the lower inner (C503) quadrant of the right breast. Code the primary site as breast, NOS (C509).

6. Some histology/behavior terms in ICD-O-3 have a related site code in parentheses; for example: Hepatoma (C220).

a. Code the site as documented in the medical record and ignore the suggested ICD-O-3 code when a primary site is specified in the medical record.

Example: The pathology report says "infiltrating duct carcinoma of the head of the pancreas." The listing in ICD-O-3 is infiltrating duct carcinoma 8500/3 (C50_). Code the primary site to head of pancreas (C250), NOT to breast (C50_) as suggested by the ICD-O-3.

b. Use the site code suggested by ICD-O-3 when the primary site is the same as the site code suggested or the primary site is unknown

Example 1: The biopsy is positive for hepatoma, and no information is available about the primary site. Code the primary site to liver (C220) as suggested by ICD-O-3.

Example 2: An excision of the right axillary nodes reveals metastatic infiltrating duct carcinoma. The right breast is negative. The ICD-O-3 shows infiltrating duct carcinoma (8500) with a suggested site of breast (C50_). Code the primary site as breast, NOS (C509).

7. Code the primary site, not the metastatic site. If a tumor is metastatic and the primary site is unknown, code the primary site as unknown (C809).

8. See the site-specific Coding Guidelines in Appendix C for primary site coding guidelines for the following sites:

Bladder	Kaposi sarcoma
Breast	Lung
Colon	Rectosigmoid, rectum

Esophagus

9. See below for primary site coding guidelines for Sarcoma.

10. Code C422 (Spleen) as the primary site for angiosarcoma of spleen with mets to bone marrow.

11. Gastrointestinal Stromal Tumors (GIST): Code the primary site to the location where the malignant GIST originated.

12. In the absence of any additional information, assign the codes listed for these primary sites

Code	Primary site	
C445	Anal margin	
C162	Angle of the stomach	
C068	Book-leaf lesion (mouth)	
C000	Colored / lipstick portion of upper lip	
C720	Distal conus	
C021	Edge of tongue	
C718	Frontoparietal (brain)	
C163	Gastric angular notch	
C349	Infrahilar area of lung	
C709	Leptomeninges	
C069	Masticatory space	
C446	Nail bed. thumb	
C269	Pancreatobiliary	
C490	Parapharyngeal space	
C240	Perihilar bile duct	

13. When the medical record does not contain enough information to assign a primary site:

a. Consult a physician advisor to assign the site code.

b. Use the NOS category for the organ system or the III-Defined Sites (C760-C768) if the physician advisor cannot identify a primary site.

c. Code Unknown Primary Site (C809) if there is not enough information to assign an NOS or III-Defined Site category.

Note: Assign code C76.0 for occult head and neck primaries with positive cervical lymph nodes. Schema discriminator 1 will identify these cases from others coded to C76.0.

Sarcoma

The majority of sarcomas arise in mesenchymal or connective tissues that are located in the musculoskeletal system, which includes the fat, muscles, blood vessels, deep skin tissues, nerves, bones, and cartilage. The default code for sarcomas of unknown primary site is C499 rather than C809.

Sarcomas may also arise in the walls of hollow organs and in the viscera covering an organ. Code the primary site to the organ of origin.

Example: The pathology identifies a carcinosarcoma of the uterine corpus. Code the primary site to corpus uteri (C549).

Coding Instructions for Hematopoietic and Lymphoid Neoplasms (9590/3-9992/3)

See the Hematopoietic Manual and Database for instructions on coding the primary site for hematopoietic and lymphoid neoplasms.

Histology

Organization	Organization Field Name		Required
KCR	Histology (Histology)	30090	yes
NAACCR	Histologic Type ICD-O-3	522	yes

Field Length: 4

Instructions for Coding

- Record histology using the ICD-O-3 codes in the Numeric Lists/Morphology section (ICD-O-3, pp. 69-104) and in the Alphabetic Index (ICD-O-3, pp. 105-218).
- Follow the coding rules outlined on pages 20 through 40 of ICD-O-3.
- Use the SEER 2007 Multiple Primary and Histology Coding Rules when coding the histology for reportable solid malignant tumors. These rules are effective for cases diagnosed January 1, 2007, or later. Do not use these rules to abstract cases diagnosed prior to this date; for these cases, see the section below entitled "Rules for Coding Histology Prior to 2007."
- Use the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database when coding histology for reportable hematopoietic and lymphoid malignancies diagnosed January 1, 2010 onward. NOTE: The Hematopoietic Database contains additional histologies which are not found in ICD-O-3, but are valid for use from 2010 forward.
- Review all pathology reports.
- Code the final pathologic diagnosis.

EXCEPTION: If the final diagnosis is "Not Otherwise Specified" (carcinoma, NOS; melanoma, NOS; sarcoma, NOS; lymphoma, NOS; or malignant tumor, NOS), then code the histology from the microscopic description or comment if it identifies a more specific histologic type (higher ICD-O-3 code) such as adenocarcinoma, amelanotic melanoma, or spindle cell sarcoma.

- The codes for cancer, NOS (8000) and carcinoma, NOS (8010) are not interchangeable. If the physician says that the patient has carcinoma, then code carcinoma, NOS (8010).
- Note that the determination of multiple primaries for benign and borderline intracranial and CNS tumors is based on histologic groupings. See the table and rules below for histologic groupings for non-malignant brain and CNS tumors.
- See Table of Specific Histologies that should not be coded to ill-defined sites (C76._).

Rules for Coding the Histology of Solid Tumors Diagnosed Prior to 2007

Coding Instructions

Use all of the information for a single primary to code the histology.

1. If there is no tumor specimen, code the histology described by the medical practitioner.

2. Use the histology stated in the final diagnosis from the pathology report. Use the pathology from the procedure that resected the majority of the primary tumor.

If a more specific histologic type is definitively described in the microscopic portion of the pathology report or the comment, code the more specific diagnosis.

3. Cases reported to KCR cannot have a metastatic (/6) behavior code. If the only pathology specimen is from a metastatic site, code the appropriate histology code and the malignant behavior code /3. The primary site and its metastatic site(s) have the same basic histology.

Histology Coding Rules for Single Tumor

- The rules are in hierarchical order. Rule 1 has the highest priority.
- · Use the rules in priority order.
- Use the first rule that applies to the case. (Do not apply any additional rules.)
- 1. Code the histology if only one type is mentioned in the pathology report.
- 2. Code the invasive histology when both invasive and in situ tumor are present.

Example: Pathology report reads infiltrating ductal carcinoma and cribriform ductal carcinoma insitu. Code the invasive histology 8500/3.

Exception: If the histology of the invasive component is an 'NOS' term (e.g., carcinoma, adenocarcinoma, melanoma, sarcoma), then code the histology of the specific term associated with the insitu component and an invasive behavior code.

3. Use a mixed histology code if one exists

Examples of mixed codes: (This is not a complete list, these are examples only)

8490 Mixed tumor, NOS

9085 Mixed germ cell tumor

8855 Mixed liposarcoma

8990 Mixed mesenchymal sarcoma

8951 Mixed mesodermal tumor

8950 Mixed Müllerian tumor

9362 Mixed pineal tumor

8940 Mixed salivary gland tumor, NOS

9081 Teratocarcinoma, mixed embryonal carcinoma and teratoma

4. Use a combination histology code if one exists

Examples of combination codes: (This is not a complete list; these are examples only)

8255 Renal cell carcinoma, mixed clear cell and chromophobe types

8523 Infiltrating duct carcinoma mixed with other types of carcinoma

8524 Infiltrating lobular carcinoma mixed with other types of carcinoma

8560 Adenosquamous carcinoma

8045 Combined small cell carcinoma, combined small cell-large cell

5. Code the more specific term when one of the terms is 'NOS' and the other is a more specific description of the same histology.

Example 1: Pathology report reads poorly differentiated carcinoma, probably

squamous in origin. Code the histology as squamous cell carcinoma rather than the non-specific term "carcinoma."

Example 2: The pathology report from a nephrectomy reads renal cell carcinoma (8312) (renal cell identifies the affected organ system rather than the histologic cell type) in one portion of the report and clear cell carcinoma (8310) (a histologic cell type) in another section of the report. Code clear cell carcinoma (8310); renal cell carcinoma (8312) refers to the renal system rather than the cell type, so renal cell is the less specific code.

6. Code the majority of tumor.

a. Based on the pathology report description of the tumor.

b. Based on the use of majority terms. See definition for majority terms.

Terms that mean the majority of tumor	Terms that DO NOT mean the majority of tumor
Predominantly	With foci of
With features of	Focus of/focal
Major	Areas of
Туре1	Elements of
WithDifferentiation1	Component1
Pattern (Only if written in College of American Pathologists [CAP] Protocol)2	
Architecture (Only if written in College of American Pathologists [CAP] Protocol)2	

Note: Examples of CAP protocols for specific primary sites may be found on the website:

http://www.cap.org/

7. Code the numerically higher ICD-O-3 code. This is the rule with the lowest priority and should be used infrequently.

Histology Coding Rules for Multiple Tumors with Different Behaviors in Same Organ Reported as a Single Primary

1. Code the histology of the invasive tumor when one lesion is in situ (/2) and the other is invasive (/3).

Example: At mastectomy for removal of a 2 cm invasive ductal carcinoma, an additional 5 cm area of intraductal carcinoma was noted. Code histology and behavior as invasive ductal carcinoma (8500/3).

Histology Coding Rules for Multiple Tumors in Same Organ Reported as a Single Primary

1. Code the histology when multiple tumors have the same histology.

2. Code the histology to adenocarcinoma (8140/_; in situ or invasive) when there is an adenocarcinoma and an adenocarcinoma in a polyp (8210/_, 8261 /_, 8263/) in the same segment of the colon or rectum.

3. Code the histology to carcinoma (8010/_; in situ or invasive) when there is a carcinoma and a carcinoma in a polyp (8210/_) in the same segment of the colon or rectum.

4. Use a combination code for the following:

- a. Bladder: Papillary and urothelial (transitional cell) carcinoma (8130)
- b. Breast: Paget Disease and duct carcinoma (8541)
- c. Breast: Duct carcinoma and lobular carcinoma (8522)
- d. Thyroid: Follicular and papillary carcinoma (8340)
- 5. Code the more specific term when one of the terms is 'NOS' and the other is a more specific description of the same histology.
- 6. Code all other multiple tumors with different histologies as multiple primaries.

Histologic groupings to determine same histology for non-malignant brain tumors

When there are multiple tumors, use the following table to determine if the tumors are the same histology or different histologies.

Histologic Group	ICD-O-3
Choroid plexus neoplasm	9390/0, 9390/1
Ependymoma	9383, 9394, 9444
Neuronal and neuronal-glial neoplasm	9384, 9412, 9413, 9442, 9505, 9506
Neurofibroma	9540/0, 9540/1, 9541, 9550, 9560
Neurinomatosis	9560
Neurothekeoma	9562
Neuroma	9570
Perineurioma, NOS	9571

Rules for Using Histologic Group Table for Non-Malignant Brain Tumors

- 1. If both histologies are listed in the table, then
- a. Histologies that are in the same grouping or row in the table are the same histology.

Note: Histologies that are in the same grouping are a progression, differentiation or subtype of a single histologic category.

- b. Histologies listed in different groupings (or rows) in the table are different histologies
- 2. If one or both of the histologies is not listed in the table, then

a. If the ICD-O-3 codes for both histologies have the identical first three digits, the histologies are the same.

b. If the first three digits of the ICD-O-3 histology code are different, the histology types are different.

Specific Histologies with III-Defined Sites

If any of the following histologies appears only with an ill-defined site description (e.g., "abdominal" or "arm"), code it to the tissue in which such tumors arise rather than the ill-defined region (C76._) of the body, which contains multiple tissues.

Description	Code to this Site
Melanoma	C44, Skin
Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma	C49, Connective, Subcutaneous and Other Soft Tissues
Mesenchymoma	C49, Connective, Subcutaneous and Other Soft Tissues
Blood vessel tumors, lymphatic vessel tumors	C49, Connective, Subcutaneous and Other Soft Tissues
Granular cell tumor and alveolar soft part sarcoma	C49, Connective, Subcutaneous and Other Soft Tissues
	Melanoma Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma Mesenchymoma Blood vessel tumors, lymphatic vessel tumors

9240-9252	Mesenchymal chondrosarcoma and giant cell tumors	C40, C41 for Bone and Cartilage
		C49, Connective, Subcutaneous and Other Soft Tissues
8940-8941	Mixed tumor, salivary gland type	C07 for Parotid Gland
		C08 for Other and Unspecified Major Salivary Glands

Refer to the introductory pages of the International Classification of Diseases for Oncology, 3rd edition, for a more detailed discussion of the rules governing the appropriate assignment of ICD-O codes. See also APPENDIX J for errata and clarifications to ICD-O-3rd edition.

Behavior Code

Organization	Field Name	ID	Required
KCR	Behavior Code (BehaviorCode)		yes
NAACCR Behavior Code ICD-O-3		523	yes

Field Length: 1

Record the behavior of the tumor being reported. The fifth digit of the morphology code is the behavior code.

Instructions for Coding

- Code 3 if any invasion is present, no matter how limited.
 If the specimen is from a metastatic site, code the histology of the metastatic site and code 3 for behavior
 Gastro-intestinal stromal tumors (GIST) and thyomas are frquently non-malignant. However, they must be abstracted and assigned a Behavior Code of 3 if they are noted to have multiple foci, metastasis, or positive lymph nodes.

Note: The ICD-O-3 behavior code for juvenile astrocytoma (9421/1) is coded as 3. Refer to the section "Case Reporting Requirements."

Code	Label	Description
0	Benign	Benign
1	Borderline	Uncertain whether benign or malignant
		Borderline malignancy
		Uncertain malignant potential
2	In situ and/or carcinoma in situ	Adenocarcinoma in an adenomatous polyp with no invasion of stalk
		Clark level 1 for melanoma (limited to epithelium)
		Comedocarcinoma, noninfiltrating (C50)
2	Synonymous with in situ	Confined to epithelium
		Hutchinson melanotic freckle, NOS (C44)
		Intracystic, noninfiltrating
		Intraductal
		Intraepidermal, NOS
		Intraepithelial, NOS
		Involvement up to, but not including the basement membrane
		Lentigo maligna (C44)
		Lobular neoplasia (C50)
		Lobular, noninfiltrating (C50)
		Noninfiltrating
		No stromal involvement
		Papillary, noninfiltrating, or intraductal
		Precancerous melanosis (C44)
		Queyrat erythroplasia (C60)
		AIN III (C21.1)
		LIN III (C32.0-C32.9)
		SIN III (squamous intraepithelial neoplasia)
		VAIN III (C52.9)
		VIN III (C51)

		Bowen disease (not reportable for C44)
3	Invasive	Invasive or microinvasive

Histology (ICD-O-2)

Organization	Field Name	ID	Required
KCR	Histology (ICD-O-2) (ICDO2Histology)	30110	yes
NAACCR	Histology (92-00) ICD-O-2	420	yes

Field Length: 4

This field is only completed for cases diagnosed prior to January 1, 2001. For those cases, record the appropriate four digit histology code from the ICD-O, 2nd edition which describes the histologic type of this reportable condition.

Behavior Code (ICD-O-2)

Organization	Field Name	ID	Required
KCR	Behavior Code (ICD-O-2) (ICDO2BehaviorCode)	30120	yes
NAACCR	Behavior (92-00) ICD-O-2	430	yes

Field Length: 1

This field is only completed for cases diagnosed prior to January 1, 2001. The fifth digit of the ICD-O-2 morphology code is the behavior code. Record the behavior of the tumor being reported

Tumor Grade

Organization	Field Name	ID	Required
KCR	Tumor Grade (Grade)	30130	yes
NAACCR	Grade	440	yes

Field Length: 1

CODING INSTRUCTION FOR 2014+

GRADE, DIFFERENTIATION OR CELL INDICATOR

Grade, Differentiation for solid tumors (Codes 1, 2, 3, 4, 9) and Cell Indicator for Lymphoid Neoplasms (Codes 5, 6, 7, 8, 9)

Note: These instructions pertain to the data item Grade, Differentiation or Cell Indicator. These are coding instructions for cases diagnosed 1/1/2014 and forward.

Hematopoietic and Lymphoid Neoplasms

Cell Indicator (Codes 5, 6, 7, 8, 9)

Cell Indicator (Codes 5, 6, 7, 8) describes the lineage or phenotype of the cell. Codes 5, 6, 7, and 8 are used only for hematopoietic and lymphoid neoplasms. Code 9 indicates cell type not determined, not stated, or not applicable.

Coding Grade for Hematopoietic and Lymphoid Neoplasms

1. Determine the histology based on the current Hematopoietic and Lymphoid Neoplasm Manual

https://seer.cancer.gov/tools/heme/Hematopoietic_Instructions_and_Rules.pdf

2. Determine the Cell Indicator by applying the "Grade of Tumor Rules" within the current Hematopoietic and Lymphoid Neoplasm Manual

https://seer.cancer.gov/tools/heme/Hematopoietic_Instructions_and_Rules.pdf to code the grade.

Grade codes for hematopoietic and lymphoid neoplasms

Terminology	Grade Code
T-cell; T-precursor	5
B-Cell; Pre-B; B-precursor	6
Null cell; Non T-non B	7
NK cell (natural killer cell)	8
Grade unknown, not stated, or not applicable	9

Solid Tumors

Grade, Differentiation (Codes 1, 2, 3, 4, 9)

Pathologic examination determines the grade, or degree of differentiation, of the tumor. For these cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). Well-differentiated tumor cells closely resemble the tissue from the organ of origin. Poorly differentiated and undifferentiated tumor cells are disorganized and abnormal looking; they bear little (poorly differentiated) or no (undifferentiated) resemblance to the tissue from the organ of origin. These similarities/differences may be based on pattern (architecture), cytology, nuclear (or nucleolar) features, or a combination of these elements, depending upon the grading system that is used. Some grading systems use only pattern, for example Gleason grading in prostate. Others use only a nuclear grade (usually size, amount of chromatin, degree of irregularity, and mitotic activity). Fuhrman's grade for kidney is based only on nuclear features. Most systems use a combination of pattern and cytologic and nuclear features; for example Nottingham' s for breast combines numbers for pattern, nuclear size and shape, and mitotic activity. The information from this data item is useful for determining prognosis and treatment.

Pathologists describe the tumor grade using three systems or formats:

- 1. Two levels of similarity; also called a two-grade system
- 2. Three levels of similarity; also called a three-grade system (code according to "Coding for solid tumors."

a. Grade I, well

b. Grade II, moderately

c. Grade III, poorly (undifferentiated carcinoma is usually separated from this system, since "poorly" bears some, albeit little, similarity to the host tissue, while "undifferentiated" has none, e.g. Undifferentiated carcinoma).

3. Four levels of similarity; also called a four-grade system. The four-grade system describes the tumor as

a. Grade I; also called well-differentiated

b. Grade II; also called moderately differentiated

c. Grade III; also called poorly differentiated

d. Grade IV; also called undifferentiated or anaplastic

Breast and prostate grades may convert differently than other sites. These exceptions are noted in "Coding for Solid Tumors", #7-8 below.

Coding for Solid Tumors

1. Systemic treatment and radiation can alter a tumor's grade. Therefore, it is important to code grade based on information prior to neoadjuvant therapy even if grade is unknown.

2. Code the grade from the primary tumor only.

a. Do NOT code grade based on metastatic tumor or recurrence. In the rare instance that tumor tissue extends contiguously to an adjacent site and tissue from the primary site is not available, code grade from the contiguous site.

b. If primary site is unknown, code grade to 9.

3. Code the grade shown below (6th digit) for specific histologic terms that imply a grade.

Carcinoma, undifferentiated (8020/34)

Carcinoma, anaplastic (8021/34)

Follicular adenocarcinoma, well differentiated (8331/31)

Thymic carcinoma, well differentiated (8585/31)

Sertoli-Leydig cell tumor, poorly differentiated (8631/33)

Sertoli-Leydig cell tumor, poorly differentiated with heterologous elements (8634/33)

Undifferentiated sarcoma (8805/34)

Liposarcoma, well differentiated (8851/31)

Seminoma, anaplastic (9062/34)

Malignant teratoma, undifferentiated (9082/34)

Malignant teratoma, intermediate type (9083/32)

Intraosseous osteosarcoma, well differentiated (9187/31)

Astrocytoma, anaplastic (9401/34)

Oligodendroglioma, anaplastic (9451/34)

Retinoblastoma, differentiated (9511/31)

Retinoblastoma, undifferentiated (9512/34)

4. In situ and/or combined in situ/invasive components:

a. If a grade is given for an in situ tumor, code it. Do NOT code grade for dysplasia such as high grade dysplasia.

b. If there are both in situ and invasive components, code only the grade for the invasive portion even if its grade is unknown.

5. If there is more than one grade, code the highest grade within the applicable system. Code the highest grade even if it is only a focus. Code grade in the following priority order using the first applicable system:

a. special grade systems for the sites listed in Coding for Solid Tumors #6

b. differentiation: use Coding for Solid Tumors #7: 2-, 3-, or 4- grade system

c. nuclear grade: use Coding for Solid Tumors #7: 2-, 3-, or 4- grade system

d. If it isn't clear whether it is a differentiation or nuclear grade and a 2-, 3-, or 4- grade system was used, code it.

e. Terminology (use Coding for Solid Tumors #8)

6. Use the information from the special grade systems first. If no special grade can be coded, continue with Coding for Solid Tumors #7-9.

Special grade systems for solid tumors

Grade information based on CS Site-specific factors for breast, prostate, heart, mediastinum, peritoneum, retroperitoneum, soft tissue, and kidney parenchyma is used to code grade. See Special Grade System Rules section below for details on how to use this information to code grade.

CS Schema	Special Grade System
Breast	Nottingham or Bloom-Richardson (BR) Score/Grade (SSF7)
Prostate	Gleason's Score on Needle Core Biopsy/Transurethral Resection of Prostate (TURP) (SSF 8)
Prostate	Gleason's Score on Prostatectomy/Autopsy (SSF 10)
Heart, Mediastinum	Grade for Sarcomas (SSF 1)
Peritoneum	Grade for Sarcomas (SSF 1)
Retroperitoneum	Grade for Sarcomas (SSF 1)
Soft Tissue	Grade for Sarcomas (SSF 1)
Kidney Parenchyma	Fuhrman Nuclear Grade (SSF 6)

7. Use the Two-, Three- or Four-grade system information

a. Two-grade system

Term	Description	Grade Code	Exception for Breast and Prostate Grade Code
1/2, I/II	Low grade	2	1
2/2, II/II	High grade	4	3

In transitional cell carcinoma for bladder, the terminology high grade TCC and low grade TCC are coded in the two-grade system.

b. Three-grade system

Term	Description	Grade Code	Exception for Breast and Prostate Grade Code
1/3	Low grade	2	1
2/3	Intermediate grade	3	2
3/3	High grade	4	3

c. Four-grade system: Any four-gradesystem includingEdmondson and Steiner grade for liver.

Term	Description	Grade Code
1/4	Grade I; Well differentiated	1
2/4	Grade II; Moderately differentiated	2
3/4	Grade III; Poorly differentiated	3
4/4	Grade IV; Undifferentiated	4

8. Terminology: use the 'Description' column or the 'Grade' column to code grade. Breast & Prostate use the same grade code with a few noted exceptions.

Description	Grade	Assign Grade Code	Exception for Breast and Prostate Grade Code
Differentiated, NOS	1	1	
Well differentiated	I	1	
Only stated as 'Grade I'	1	1	
Fairly well differentiated	П	2	
Intermediate differentiation	П	2	
Low grade	1-11	2	1

Mid differentiated	П	2	
Moderately differentiated	П	2	
Moderately well differentiated	П	2	
Partially differentiated	П	2	
Partially well differentiated	1-11	2	1
Relatively or generally well	П	2	
differentiated			
Only stated as 'Grade II'	П	2	
Medium grade, intermediate	11-111	3	2
grade			
Moderately poorly	ш	3	
differentiated			
Moderately undifferentiated	ш	3	
Poorly differentiated	Ш	3	
Relatively poorly differentiated	Ш	3	
Relatively undifferentiated	Ш	3	
Slightly differentiated	Ш	3	
Dedifferentiated	Ш	3	
Only stated as 'Grade III'	Ш	3	
High grade	III-IV	4	3
Undifferentiated, anaplastic, not differentiated	IV	4	
Only stated as 'Grade IV'	IV	4	
Non-high grade		9	

9. If no description fits or grade is unknown prior to neoadjuvant therapy, code as a 9 (unknown).

SPECIAL GRADE SYSTEMS RULES

Breast (site: breast excluding lymphomas; CS schema: breast)

Use Bloom Richardson (BR) or Nottingham score/grade to code grade based on CSv2 site-specific factor 7 (SSF) as stated below. If your registry does not collect this SSF, use the description in the table below to determine grade. If you collect this SSF, codes 030-130 could be automatically converted into the grade field.

BR could also be referred to as: Bloom-Richardson, modified Bloom-Richardson, BR, BR grading, Scarff-Bloom-Richardson, SBR grading, Elston-Ellis modification of Bloom-Richardson score, Nottingham modification of Bloom-Richardson score, Nottingham modification of Scarff-Bloom-Richardson, Nottingham-Tenovus grade, or Nottingham grade.

Code the tumor grade using the following priority order

a. BR scores 3-9

b. BR grade (low, intermediate, high)

BR score may be expressed as a range, 3-9. The score is based on three morphologic features: degree of tubule formation/histologic grade, mitotic activity, nuclear pleomorphism/nuclear grade of tumor cells. If a report uses words such as low, intermediate, or high rather than numbers, use the table below to code grade.

If only a grade of 1 through 4 is given with no information on the score and it is unclear if it is a Nottingham or BR Grade, do not use the table below. Continue with the next priority according to "Coding for Solid Tumors" #7 above.

Code the highest score if multiple scores are reported (exclude scores from tests after neoadjuvant therapy began). Examples: different scores may be reported on multiple pathology reports for the same primary cancer; different scores may be reported for multiple tumors assigned to the same primary cancer.

CS Site-Specific Factor 7

Nottingham or Bloom-Richardson (BR) Score/Grade

Description	CS Code	Grade Code

Score of 3	030	1
Score of 4	040	1
Score of 5	050	1
Score of 6	060	2
Score of 7	070	2
Score of 8	080	3
Score of 9	090	3
Low Grade, Bloom-Richardson (BR) grade 1, score not given	110	1
Medium (Intermediate) Grade, BR grade 2, score not given	120	2
High Grade, BR grade 3, score not given	130	3

Kidney Parenchyma (Site: kidney parenchyma excluding lymphomas; CS schema: KidneyParenchyma): Fuhrman Nuclear Grade

The Fuhrman Nuclear Grade should be used to code grade for kidney parenchyma only based on CSv2 SSF 6 as stated below. Do not use for kidney renal pelvis. If your registry does not collect this SSF, use the description in the table to determine grade. If you collect this SSF, the information could be automatically converted into the grade field if it is coded 010-040. Fuhrman nuclear grade is a four-grade system based on nuclear diameter and shape, the prominence of nucleoli, and the presence of chromatin clumping in the highest grade.

Description	CS Code	Grade Code
Grade 1	010	1
Grade 2	020	2
Grade 3	030	3
Grade 4	040	4

SoftTissue (sites excluding lymphomas: soft tissue, heart, mediastinum, peritoneum, and retroperitoneum; for CS users: SoftTissue, HeartMediastinum, Peritoneum, Retroperitoneum schemas): Grade for Sarcomas

The Grade for Sarcomas should be used to code grade based on CSv2 SSF 1 as stated below. If your registry does not collect this SSF, use the description in the table to determine grade. If you collect this SSF, the information could be automatically converted into the grade field if it is coded 010-200. The grading system of the French Federation of Cancer Centers Sarcoma Group (FNCLCC) is the preferred system.

Record the grade from any three-grade sarcoma grading system the pathologist uses. For terms such as "well differentiated" or "poorly differentiated," go to Coding for Solid Tumors #8.

In some cases, especially for needle biopsies, grade may be specified only as "low grade" or "high grade." The numeric grade takes precedence over "low grade" or "high grade."

Description	CS Code	Grade Code
Specified as Grade 1 [of 3]	010	2
Specified as Grade 2 [of 3]	020	3
Specified as Grade 3 [of 3]	030	4
Grade stated as low grade, NOS	100	2
Grade stated as high grade, NOS	200	4

Prostate (site: prostate excluding lymphomas; CS schema: prostate)

Use the highest Gleason score from the biopsy/TURP or prostatectomy/autopsy. Use a known value

over an unknown value. Exclude results from tests performed after neoadjuvant therapy began. This information is collected in CSv2 SSF 8 (Gleason score from biopsy/TURP) and SSF 10 (Gleason score from prostatectomy/autopsy) as stated below. Use the table below to determine grade even if your registry does not collect these SSFs. If you collect these SSFs, the information could be converted into the grade field automatically.

Usually prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10. If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score. If only one number is given on a

particular test and it is less than or equal to 5 and not specified as a score, do not use the information because it could refer to either a score or a grade. If only one number is given and it is greater than 5, assume that it is a score and use it. If the pathology report specifies a specific number out of a total of 10, the first number given is the score. Example: The pathology report says Gleason 3/10. The Gleason score would be 3.

Historic Perspective

Gleason Score	CS Code	Grade Code	AJCC 7th	SEER 2003- 2013	AJCC 6th	SEER prior 2003
2	002	1	G1	G1	G1	G1
3	003	1	G1	G1	G1	G1
4	004	1	G1	G1	G1	G1
5	005	1	G1	G2	G2	G2
6	006	1	G1	G2	G2	G2
7	007	2	G2	G3	G3	G2
8	008	3	G3	G3	G3	G3
9	009	3	G3	G3	G3	G3
10	010	3	G3	G3	G3	G3

Historical perspective on long term trends in prostate grade: The relationship of Gleason score to grade changed for 1/1/2014+ diagnoses in order to have the grade field in sync with AJCC 7th ed. Analysis of prostate grade before 2014 based solely on the grade field is not recommended. In Collaborative Stage (CS), Gleason score was originally coded in CSv1 in one field (SSF 6) and then it was split into two fields in CSv2 based on the tissue used for the test: needle biopsy/TURP (SSF 8) and prostatectomy/autopsy (SSF 10). For trends using data back to 2004, if one collected the various CS Gleason scores, one could design a recode to have the same criteria as the data collected 2014+. The original grade field would NOT be changed, but for analyses this recode could be based on the CS SSFs and the original grade code.

For tumor grade for cases before 2014 go to Appendix N - Pre-2014 Grade Coding Instructions.

Lymphovascular Invasion

Organization	Field Name	ID	Required
KCR	Lymphovascular Invasion (LymphVasInvasion)	30135	yes
NAACCR	Lymphovascular Invasion	1182	yes

Field Length: 1

This field indicates the presence or absence of tumor cells in lymphatic channels (NOT lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist. It is a mandatory field for cases diagnosed January 1, 2010 onward.

Note: This coding convention has been developed and implemented for use in the AJCC Cancer Staging Manual, Seventh Edition, and updated with new codes in the AJCC 8th Edition staging manual for appropriate disease sites.

Note: Revised CAP Protocols and 8th Edition chapters will indicate which chapters will use the new codes (2, 3, and 4) and which will only use the existing codes (0,1,8,9), as there are some disease sites where distinguishing between L and V is not medically appropriate.

Note: Code 8, Not Applicable for benign/borderline brain and CNS tumors.

Note: For cases diagnosed January 1, 2018 and later, new codes indicating lymphatic, small vessel and/or large vessel invasion were added.

Instructions for Coding

- This item may be left blank for cases diagnosed before 2010.
- The primary source of this information is the College of American Pathologists (CAP) synoptic report or checklist. If it is unavailable, code from the pathology report or a physician's statement, in that order of priority.
 - Use code 1 if lymphovascular invasion is identified anywhere in a primary tumor specimen.
 - Use code 8 for histologies 9590-9992.
 - Use code 9 if no pathologic examination of primary site tissue was performed.
 - Use code 9 if primary site tissue was examined pathologically, but the report is not available.
 - Use code 9 if the pathology report indicates that the presence of lymphovascular invasion could not be determined.

Code	Description
0	Lymphovascular invasion is not present (absent) or is not identified
1	Lymphovascular invasion is present or identified
2	Lymphatic and small vessel invasion only (L)
3	Venous (large vessel) invasion only (V)
4	BOTH lymphatic and small vessel AND venous (large vessel) invasion
8	Not applicable
9	Unknown/Indeterminate/not mentioned in path report

Definition

Lymphovascular invasion is defined as the presence of tumor cells found inside small blood vessels or lymphatic channels within the tumor and surrounding tissues in the primary site. The tumor cells have broken free of the primary tumor and now have the capability to float throughout the body. Other names for lymphovascular invasion are LVI, lymphovascular invasion, vascular invasion, blood vessel invasion, and lymphatic invasion. Vascular invasion is not the same as direct tumor extension from the primary tumor into adjacent blood vessels; LVI cells are not attached to or growing into the wall of the blood vessel. Lymphatic invasion is not the same as involvement of regional lymph nodes. Lymphovascular invasion does not include perineural invasion.

Instructions for Coding

- 1. Code from pathology report(s). Code the absence or presence of lymphovascular invasion as described in the medical record.
 - a. The primary sources of information about lymphovascular invasion are the pathology check lists (synoptic reports) developed by the College of American Pathologists. If the case does not have a checklist or synoptic report, code from the pathology report or a physician' s statement, in that order.
 - b. Do not code perineural invasion in this field.
 - c. Information to code this field can be taken from any specimen from the primary tumor (biopsy or resection.)
 - d. If lymphovascular invasion is identified in any specimen, it should be coded as present/identified.
 - e. For cases treated with neoadjuvant therapy, refer to table below in order to code this field. However, if documentation in the medical record indicates information that conflicts with this table, code lymphovascular invasion with the documentation in the medical record.

Code LVI to:

LVI on pathology report PRIOR to neoadjuvant therapy	LVI on pathology report AFTER neoadjuvant therapy	
0 - Not present/Not identified	0 - Not present/Not identified	0 - Not present/Not identified
0 - Not present/Not identified	1 - Present/Identified	1 - Present/Identified
0 - Not present/Not identified	9 - Unknown/Indeterminate	9 - Unknown/Indeterminate
1 - Present/Identified	0 - Not present/Not identified	1 - Present/Identified
1 - Present/Identified	1 - Present/Identified	1 - Present/Identified
1 - Present/Identified	9 - Unknown/Indeterminate	1 - Present/Identified
9 - Unknown/Indeterminate	0 - Not present/Not identified	9 - Unknown/Indeterminate
9 - Unknown/Indeterminate	1 - Present/Identified	1 - Present/Identified
9 - Unknown/Indeterminate	9 - Unknown/Indeterminate	9 - Unknown/Indeterminate

2. Use of codes.

- a. Use code 0 when the pathology report indicates that there is no lymphovascular invasion. This includes cases of purely in situ carcinoma, which biologically have no access to lymphatic or vascular channels below the basement membrane.
 b. Use code 1 when the pathology report or a physician's statement indicates that lymphovascular invasion (or one of its synonyms) is present in the specimen.
 c. Lymphovascular invasion must be coded 0, 1, 2, 3, 4, or 9 for the Schema IDs in the following list:

Schema ID	Description
00071	Lip
00072	Tongue Anterior
00073	Gum
00074	Floor of Mouth
00075	Palate Hard
00076	Buccal Mucosa
00077	Mouth Other
00080	Major Salivary Glands
00100	Oropharynx (p16+)
00111	Oropharynx (p16-)
00112	Hypopharynx
00121	Maxillary Sinus
00122	Nasal Cavity and Ethmoid Sinus
00130	Larynx Other
00131	Larynx Supraglottic
00132	Larynx Glottic
00133	Larynx Subglottic
00161	Esophagus (incl GE Junction) Squamous
00169	Esophagus (incl GE Junction) (excl Squamous)
00170	Stomach
00180	Small Intestine
00190	Appendix
00200	Colon and Rectum
00230	Bile Ducts Intrahepatic

00250	Bile Ducts Perihilar
00260	Bile Ducts Distal
00270	Ampulla Vater
00280	Pancreas
00290	NET Stomach
00301	NET Duodenum
00302	NET Ampulla of Vater
00320	NET Appendix
00330	NET Colon and Rectum
00340	NET Pancreas
00350	Thymus
00360	Lung
00460	Merkel Cell Skin
00470	Melanoma Skin
00500	Vulva
00510	Vagina
00520	Cervix
00530	Corpus Carcinoma
00541	Corpus Sarcoma
00542	Corpus Adenosarcoma
00560	Placenta
00570	Penis
00590	Testis
00620	Bladder
00730	Thyroid
00740	Thyroid Medullary

d. Lymphovascular invasion must be coded 0, 1, 2, 3, 4, 8, or 9 for the Schema IDs in the following list:

Schema ID	Description
00210	Anus
00220	Liver
00241	Gallbladder
00242	Cystic Duct
00381	Bone Appendicular Skeleton
00382	Bone Spine
00383	Bone Pelvis
00400	Soft Tissue Head and Neck
00410	Soft Tissue Trunk and Extremities
00421	Soft Tissue Abdomen and Thorax
00422	Heart, Mediastinum, and Pleura
00440	Retroperitoneum
00450	Soft Tissue Other

00480	Breast (Invasive)
00580	Prostate
00600	Kidney Parenchyma
00610	Kidney Renal Pelvis
00631	Urethra
00632	Urethra-Prostatic
00640	Skin Eyelid
00660	Melanoma Conjunctiva
00671	Melanoma Iris
00672	Melanoma Choroid and Ciliary Body
00700	Orbital Sarcoma
00750	Parathyroid

e. Lymphovascular invasion must be coded 8 (not applicable) for all of Schema IDs:

Schema ID	Description
00060	Cervical Lymph Nodes, Occult Head and Neck
00118	Pharynx Other
00119	Middle Ear
00128	Sinus Other
00140	Melanoma Head and Neck
00150	Cutaneous Carcinoma Head and Neck
00278	Biliary Other
00288	Digestive Other
00358	Trachea
00370	Pleural Mesothelioma
00378	Respiratory Other
00458	Kaposi Sarcoma
00478	Skin Other
00551	Ovary
00552	Primary Peritoneal Carcinoma
00553	Fallopian Tube
00558	Adnexa Uterine Other
00559	Genital Female Other
00598	Genital Male Other
00638	Urinary Other
00650	Conjunctiva
00680	Retinoblastoma
00690	Lacrimal Gland
00698	Lacrimal Sac
00710	Lymphoma Ocular Adnexa
00718	Eye Other

00721	Brain
00722	CNS Other
00723	Intracranial Gland
00770	NET Adrenal Gland
00778	Endocrine Other
00790	Lymphoma
00795	Lymphoma (CLL/SLL)
00811	Mycosis Fungoides
00812	Primary Cutaneous Lymphoma non MF
00821	Plasma Cell Myeloma
00822	Plasma Cell Disorders
00830	Heme/Retic
99999	III-Defined Other

f. Use code 9 when

- there is no microscopic examination of a primary tissue specimen
 the primary site specimen is cytology only or a fine needle aspiration
- the biopsy is only a very small tissue sample
- it is not possible to determine whether lymphovascular invasion is present
 the pathologist indicates the specimen is insufficient to determine lymphovascular invasion
- lymphovascular invasion is not mentioned in the pathology report
- primary site is unknown

g. Clarification between codes 8 and 9:

- Code 8 should only be used in the following situations: 1. Standard-setter does not require this item and you are not collecting it. 2. Those histologies noted above described in code 8 for which LVI is always not applicable.
 For those cases where there is no information/documentation from the pathology report or other sources, use code 9

Class of Case

Organization	Field Name	ID	Required
KCR	Class of Case (CaseClass)	30140	yes
NAACCR	Class of Case	610	yes

Field Length: 2

Class of case reflects the facility's role in managing this cancer, whether the cancer is required to be reported to ACoS by approved facilities, and whether the case was diagnosed after the program's reference date. Enter the two digit code that describes the patient's relationship to the facility.

Instructions for Coding

- Code 00 applies only when it is known that the patient went elsewhere for treatment. If that information is not available, code class of case '10.' It is possible that information for coding class of case will change during the patient's first course of care. If that occurs, edit the code accordingly.
- ACoS approved facilities should document Institution Referred To (item #31660) for patients coded 00 to establish that the patient went elsewhere for treatment.
- A staff physician (codes 10-12, 41) is a physician who is employed by the reporting facility, under contract with it, or who has routine practice privileges there.
- Refer to the "Case Reporting Requirements" section of this manual for a discussion of Classes and KCR requirements.

Codes

Code	Description
	Initial diagnosis at reporting facility
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
10	Initial diagnosis at the reporting facility or in a staff physician's office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS
11	Initial diagnosis in staff physician's office AND part of first course treatment was done at the reporting facility
12	Initial diagnosis in staff physician's office AND all first course treatment or decision not to treat was done at the reporting facility
13	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility
14	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
	Initial diagnosis elsewhere
20	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS
21	Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility
22	Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility
Non-an	alytic Classes of Case (Not required by CoC to be abstracted by accredited programs, but may be required by KCR)
	Patient appears in person at reporting facility
30	Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (i.e., consult only or staging workup)
31	Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care
32	Diagnosis AND all first course treatment provided elsewhere AND patients presents at reporting facility with disease recurrence or persistence
33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only
34	Type of case not required by CoC to be accessioned (i.e., CIS of the cervix) AND initial diagnosis AND part or all of first course treatment by reporting facility
35	Case diagnosed before program's reference date AND initial diagnosis AND all or part of first course treatment by reporting facility
36	Type of case not required by CoC to be accessioned (i.e., CIS of the cervix) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility
37	Case diagnosed before program's reference date AND initial diagnosis elsewhere AND all or part of first course treatment by facility

	Patient does not appear in person at reporting facility
	Do not abstract cases in class 40 - 99- refer them to KCR; these classes are for KCR use only
40	Diagnosis AND all first course treatment given at the same staff physician's office
41	Diagnosis and all first course treatment given in two or more different staff physician offices
42	Nonstaff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and /or treatment by that entity (i.e., hospital abstracts cases from an independent radiation facility)
43	Pathology or other lab specimens only
49	Death certificate only
98	Non-hospital treatment abstracted by KCR
99	Non-hospital cases abstracted by KCR

Place of Diagnosis

Organization	Field Name	ID	Required
KCR	Place of Diagnosis (DiagPlace)	30145	no
NAACCR	TextPlace of Diagnosis	2690	no

Field Length: 60

This item is an optional text field for documentation of the facility, physician office, city, state, or county where the intial diagnosis was made. Text documentation is an essential component of a complete abstract and is heavily utilized for quality control and special studies.

If the patient was diagnosed with this cancer in Kentucky, be as specific as possible. Use this field to indicate the facility, physician's office, or location where the diagnosis was made. If the patient was diagnosed outside Kentucky, be as specific as possible, even though the city, state, or country of residence may be the best available information.

Date of First Contact

Organization	Field Name	ID	Required
KCR	Date of First Contact (DateFirstContact)	30150	yes
NAACCR	Date of 1st Contact	580	yes

Field Length: 8

The date of first contact is the date of the facility's first inpatient or outpatient contact with the patient for diagnosis or treatment of the cancer. In most instances, it is the patient's physical presence at the facility that denotes "contact." When a pathology specimen is collected off-site and submitted to the facility to be read (and the specimen is positive for cancer), but the patient is never seen at the facility, the case is not required to be abstracted (although a copy of the pathology report must be sent to KCR to be abstracted).

Instructions for Coding

- Record the date the patient first had contact with the facility as either an inpatient or outpatient for the diagnosis and/or treatment of a reportable tumor. The date may be the date of an outpatient visit for a biopsy, X-ray, or laboratory test, or the date a pathology specimen was collected at the hospital.
- If this is an autopsy or death certificate only case, then use the date of death.
- When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.

Examples

A patient has an outpatient mammography that is suspicious for malignancy on February 12, 2008, and subsequently und biopsy or radical surgical procedure on February 14, 2008	dergoes an excisional	02 /12 /2008
Patient undergoes a biopsy in a physician's office on September 8, 2009. The pathology specimen is sent to the reporting malignant melanoma. The patient enters the reporting facility on September 14, 2009 for wide re-excision.	g facility and read as	09 /14 /2009
Patient has an MRI of the brain on December 7, 2010, for symptoms including severe headache and disorientation. The suspicious for astrocytoma. Surgery on December 19 removes all gross tumor.	MRI findings are	12 /07 /2010

Date of Diagnosis

Organization	Field Name	ID	Required
KCR	Date of Diagnosis (DiagDate)	30160	yes
NAACCR	Date of Diagnosis	390	yes

Field Length: 8

Enter the month, day, and year of the initial diagnosis.

This field refers to the date of first diagnosis of this cancer by a recognized medical practitioner. This is the date of the first clinical diagnosis, and in some cases, the diagnosis may never be histologically confirmed. Do not change the date of diagnosis when a later biopsy or cytology provides confirmation of a clinical diagnosis. From 2009 forward, for cases which are diagnosed in utero, record the actual date of diagnosis. For pre-2009 cases, the date of diagnosis for in utero cases should be the date of birth.

Code the date using a zero to precede single digit days, or months, i.e., June is entered as 06.

If the exact date is not known, record the best approximation on the basis of available information. As possible guidelines, consider the following:

a. For patients diagnosed without positive tissue while in a hospital, the date of admission may be used as the best estimate of the date of diagnosis.

b. For patients diagnosed before entering the hospital (i.e., clinic or physician's office), the date of first admission may be used if it seems that the patient was hospitalized within three months or less from the true date of diagnosis by the referring physician.

c. If the only information is "Spring of", "Middle of the year", or "Fall", approximate these as April 1st, July 1st, or October 1st, respectively.

The date of death is the date of diagnosis for a class of case 38.

Age at Diagnosis

Organization	Field Name	ID	Required
KCR	Age at Diagnosis (DiagAge)	30170	no
NAACCR	Age at Diagnosis	230	no

Field Length: 3

This field is calculated by the computer for the primary malignancy that is being abstracted. It is the number of years between the date of birth and the date of diagnosis.

Laterality

Organization	Field Name	ID	Required
KCR	Laterality (Laterality)	30410	yes
NAACCR	Laterality	410	yes

Field Length: 1

Enter the one digit code which describes this primary with regard to involvement of one or both sides of paired organs (see list below).

Code	Description
0	Not paired
1	Right origin
2	Left origin
3	Only one side involved, right or left origin unspecified
4	Bilateral, side of origin unknown or single primary (i.e. bilateral Wilms' tumors)
5	Midline origin
9	Paired, but no information concerning laterality

Coding Instructions

- 1. Use code 0 (not a paired organ) for an unknown primary site (C80.9).
- 2. Code laterality using codes 1-9 for all of the sites listed below. Note: Laterality may be coded for sites other than those listed below.
- 3. Code the side where the primary tumor originated.
 - a. Assign code 3 if the laterality is not known but the tumor is confined to a single side of the paired organ.

Example: Pathology report: Patient has a 2cm carcinoma in the upper pole of the kidney. Code laterality as 3 because there is documentation that the disease exists in only one kidney, but it is unknown if the disease originated in the right or left kidney.

- 4. Code 4 is seldom used EXCEPT for the following diseases:
- i. Both ovaries involved simultaneously, single histology
- ii. Bilateral retinoblastomas
- iii. Bilateral Wilms' tumor
- iv. If both lungs have nodules or tumors and the lung of origin is not known
- 5. Assign code 5 when the tumor originates in the midline of a site listed in 5.a.
- a. C700, C710 C714, C722 C725, C443, C445

Example 1:Patient has an excision of a melanoma located just above the umbilicus.

Example 2:Patient has a midline meningioma of the cerebral meninges.

- 6. Assign code 9 when:
- a. The neoplasm originated in a paired site and
- 1. Laterality is unknown

AND

2. There is no statement that only one side of the paired organ is involved.

Example 1: Admitting history says patient was diagnosed with lung cancer based on positive sputum cytology. Patient is treated for painful bony metastases. There is no information about laterality in the diagnosis of this lung cancer.

Example 2: Widely metastatic ovarian carcinoma surgically debulked. Ovaries could not be identified in the specimen.

b. Laterality is unknown for a death certificate only (DCO)case with primary site C079 -C081, C090-C091, C098-C099, C301, C310, C312, C341-C349, C384, C400-C403, C441-C443, C445-C447, C471-C472, C491-C492, C500-C509, C569, C570, C620-C629 C630-C631, C649, C659, C669, C690-C699, C700, C710-C714, C722-C725, C740-C749, or C754.

LIST OF PAIRED ORGANS

ICD-O

Code	Site
C07.9	Parotid gland
C08.0	Submandibular gland
C08.1	Sublingual gland
C09.0	Tonsillar fossa
C09.1	Tonsillar pillar
C09.8	Overlapping lesion of tonsil
C09.9	Tonsil, NOS
C30.0	Nasal cavity (excluding nasal cartilage and nasal septum - use code 0)
C30.1	Middle ear
C31.0	Maxillary sinus
C31.2	Frontal sinus
C34.0	Main bronchus (excluding carina - use code 0)
C34.1	Upper lobe, lung
C34.2	Middle lobe, lung
C34.3	Lower lobe, lung
C34.8	Other parts of lung or bronchus
C34.9	Lung, NOS
C38.4	Pleura
C40.0	Long bones of upper limb and scapula
C40.1	Short bones of upper limb
C40.2	Long bones of lower limb
C40.3	Short bones of lower limb
C41.3	Rib and clavicle (excluding sternum - use code 0)
C41.4	Pelvic bones (excluding sacrum, coccyx, and symphysis pubis - use code 0)
C44.1	Skin of eyelid
C44.2	Skin of external ear
C44.3	Skin of other and unspecified parts of face (if midline, code 5)
C44.5	Skin of trunk (if midline, code 5)
C44.6	Skin of arm and shoulder
C44.7	Skin of leg and hip
C47.1	Peripheral nerves and autonomic nervous system of upper limb and shoulder
C47.2	Peripheral nerves and autonomic nervous system of lower limb and hip
C49.1	Connective, subcutaneous, and other soft tissue of upper limb and shoulder
C49.2	Connective, subcutaneous, and other soft tissue of lower limb and hip
C50.0-C50.9	Breast (male and female)

C56.9	Ovary
C57.0	Fallopian tube
C62.0	Undescended testis
C62.1	Descended testis
C62.9	Testis, NOS
C63.0	Epididymis
C63.1	Spermatic cord
C64.9	Kidney, NOS
C65.9	Renal pelvis
C66.9	Ureter
C69.0-C69.9	Eye and lacrimal gland
C70.0	Cerebral meninges
C71.0	Cerebrum
C71.1	Frontal lobe
C71.2	Temporal lobe
C71.3	Parietal lobe
C71.4	Occipital lobe
C72.2	Olfactory nerve
C72.3	Optic nerve
C72.4	Acoustic nerve
C72.5	Cranial nerve, NOS
C74.0-C74.9	Suprarenal gland
C75.4	Carotid body

Personal

- Hospital Chart No
 Family History
 Marital Status at Diag
 Menopausal Status
 Primary Payer
 ACOS Sequence Num
 SEER Sequence Num
 Address at Diag 1
 Address at Diag 2
 City at Diag
 State at Diag
 Zip Code at Diag
 County at Diag
 County at Diag
 Registry Accession Year
 Diag Confirmation Code
 Path Report No

Hospital Chart No

Organization	Field Name	ID	Required
KCR	Hospital Chart No (ChartNum)	30180	no
NAACCR	Medical Record Number	2300	no

Field Length: 11

Enter the medical record number assigned by the health information management (HIM) department. Dashes or special characters may be entered in this field; however, they should be used consistently.

Family History

Organization	Field Name	ID	Required
KCR	Family History (FamHxCa)	30190	no

Field Length: 1

Record the appropriate code to indicate if any of the patient's primary family members (i.e., parent, grandparent, child, sibling, aunt or uncle) had or has this type of cancer. "This type of cancer" means any diagnosis in the same site group as this patient's.

Code	Description
1	Yes, there is a family history of this cancer
2	No, there is no recorded family history of this cancer
9	Unknown if there is a family history of this cancer

Marital Status at Diag

Organization	Field Name	ID	Required
KCR	Marital Status at Diag (MaritalStatus)	30200	yes
NAACCR	Marital Status at DX	150	yes

Field Length: 1

Record the one digit code specifying the patient's marital status at the time of diagnosis for this tumor, if known.

Code	Description
1	Single (never married)
2	Married (including common law)
3	Separated
4	Divorced
5	Widowed
6	Unmarried or domestic partner (same sex or opposite sex, registered or unregistered) (effective for cases diagnosed 1/1/2011 forward)
9	Unknown

Persons of the opposite sex living together as part of a long term personal relationship would be coded to '2' - Married, including common law.

Menopausal Status

Organization	Field Name	ID	Required
KCR	Menopausal Status (MenopauseStatus)	30210	yes

Field Length: 1

Record the menopausal status if this is a female patient.

Code	Description	
0	Pre menopausal (include perimenopausal patients in code 0)	
1	Post menopausal, (even if surgically or chemically induced)	
9	Unknown/ not applicable	

Assume women over the age of 60 or those undergoing a hysterectomy prior to age 60 as post menopausal, even if it is not specifically stated in the medical chart. For male patients, this field will automatically be coded '9'.

Primary Payer

Organization	Field Name	ID	Required
KCR	Primary Payer (PrimaryPayor)	30220	yes
NAACCR	Primary Payer at DX	630	yes

Field Length: 2

Code the patient's primary payer or insurance carrier at the time of initial admission.

Code	Label	Description		
01	Not insured	Patient has no insurance and is declared a charity write-off		
02	Not insured, self pay	Patient has no insurance and is declared responsible for charges		
10	Insurance, NOS	Type of insurance unknown or other than the types listed in codes 20, 31, 35, 60-68		
20	Managed Care, HMO, PPO	An organized system of prepaid care for a group of enrollees usually within a defined geographic area		
21	Private Insurance: Fee-for-service	An insurance plan that does not have a negotiated fee structure with the participating hospital		
31	Medicaid	State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs		
35	Medicaid administered through a Managed Care Plan	State government administered insurance which is administered through a commercial Managed Care plan		
60	Medicare without supplement, Medicare, NOS	Federal government funded insurance for persons who are retired or disabled, or over 65 years old		
61	Medicare with supplement	Patient has Medicare and another insurance to pay costs not covered by Medicare		
62	Medicare administered through a Managed Care Plan			
63	Medicare with private supplement Patient has Medicare and private insurance to pay costs not covered by Medicare			
64	Medicare with Medicaid eligibility	Federal government Medicare insurance with State Medicaid administered supplement		
65	TRICARE (Formerly CHAMPUS)	Department of Defense program providing supplementary civilian-sector hospital and medical services to military dependents, retirees, and their dependents		
66	Military	Military personnel or their dependents who are treated at a military facility		
67	Veterans Affairs	Veterans who are treated in Veterans Affairs facilities		
68	Indian/Public Health Service	Patient who receives care at an Indian Health Service facility and costs are reimbursed by the Indian Health Service.		
99	Insurance status unknown	It is unknown from the patient's medical record whether or not the patient is insured		

ACOS Sequence Num

Organization	Field Name	ID	Required
KCR	ACOS Sequence Num (ACOSSeqNo)	30230	No
NAACCR	Sequence NumberHospital	560	No

Field Length: 2

The ACoS sequence number represents the order of all primary reportable tumors diagnosed during a patient's lifetime. It counts the occurrence of independent, malignant primaries that are required to be reported to the ACoS for approved cancer programs.

The sequence number 00 indicates that this patient has one primary cancer. The sequence 01 indicates that the case is the first of multiple primaries.

Sequence numbers in the range of 60-88 have a special meaning to ACoS. They are reserved for conditions that are collected by the registry but are not required by ACoS. These include diagnoses required by KCR but not ACoS (such as VIN III, VAIN III, and AIN III, as well as invasive recurrences abstracted after an in-situ cancer.) Pre-invasive carcinomas of the cervix that were diagnosed in 1996 and 1997 will be sequenced in this range also, because they were required by KCR at the time, but not ACoS.

As of January 1, 2004, benign and borderline intracranial tumors became reportable to ACoS as well as KCR. These are sequenced in the 60-88 series.

Codes (conditions reportable to ACoS):

Code	Description
00	One primary only
01	First of two or more primaries
02	Second of two or more primaries
03	Third of three or more primaries
	(Actual number of this primary)
35	Thirty fifth primary
60	First of non-ACoS reportable condition (i.e. VIN III, VAIN III, AIN III, CIN III, CIS of cervix) or benign intracranial tumor
61	Second of non-ACoS reportable condition
87	Twenty seventh non-ACoS reportable condition

This field will automatically be calculated by the computer based on the CPDMS sequence number for this case and the number and types of primaries stored for this patient.

SEER Sequence Num

Organization	Field Name	ID	Required
KCR	SEER Sequence Num (SEERSeqNo)	30240	No
NAACCR	Sequence NumberCentral	380	No

Field Length: 2

The SEER sequence number represents the order of all primary reportable tumors diagnosed during a patient's lifetime. It counts the occurrence of independent, malignant primaries that are required to be reported to the SEER Program.

The sequence number 00 indicates that this patient has one primary cancer. The sequence 01 indicates that the case is the first of multiple primaries.

Sequence numbers in the range of 60-88 have a special meaning to SEER. They are reserved for conditions that are collected by the registry but are not required to be reported to SEER. These include all basal and squamous cell carcinomas of the skin diagnosed and reported before 2003 (C44._ with M8000-M8110) as well as all pre-invasive carcinomas of the cervix diagnosed in 1996 and 1997.

As of January 1, 2004, benign and borderline intracranial tumors became reportable to SEER as well as KCR. These are sequenced in the 60-88 series.

Codes (conditions reportable to SEER):

Code	Description
00	One primary only
01	First of two or more primaries
02	Second of two or more primaries
03	Third of three or more primaries
	(Actual number of this primary)
35	Thirty fifth primary
60	First of non-ACoS reportable condition (i.e. VIN III, VAIN III, AIN III, CIN III, CIS of cervix) or benign intracranial tumor
61	Second of non-ACoS reportable condition
87	Twenty seventh non-ACoS reportable condition

This field will automatically be calculated by the computer based on the CPDMS sequence number for this case and the number and types of primaries stored for this patient.

Address at Diag 1

Organization	Field Name	ID	Required
KCR	Address at Diag 1 (DiagAddress1)	30250	yes
NAACCR	Addr at DXNo & Street	2330	yes

Field Length: 40

This field is automatically filled in with the address entered in Item 10060 (Current Address) when the case is initially entered in CPDMS.net Note that if the patient has multiple tumors, the address may be different for subsequent primaries.

This address is a part of the patient's case data and has multiple uses. It is used in geocoding and allows referral pattern reports and analysis of cancer clusters or environmental studies. These data may be corrected (if erroneous), but never update the address at diagnosis if the patient moves. Changing this field would destroy its usefulness. If it is necessary to edit this field, follow the street address guidelines in Item 10060.

Address at Diag 2

Organization	Field Name	ID	Required
KCR	Address at Diag 2 (DiagAddress2)	30260	no
NAACCR	Addr at DXSupplementl	2335	no

Field Length: 40

This field is automatically filled in with the data in Item 10070 (Current Street Address-Line 2) when the case is initially entered into CPDMS.net. It provides space to record additional address information, such as the name of a nursing home, apartment complex, etc. This line will be used as an alternate address line for geocoding. If Address at Diagnosis-Line 1 cannot be geocoded (i.e. PO Box), then this line will be reviewed for a geocode. Do not update this item if the patient's address changes. Leave this field blank if the additional address space is not needed.

City at Diag

Organization	Field Name	ID	Required
KCR	City at Diag (DiagCity)	30270	yes
NAACCR	Addr at DXCity	70	yes

Field Length: 20

This field is automatically filled in with the data entered in Item 10080 (Current Address - City) when the case is initially entered into CPDMS.net Note that if the patient has multiple tumors, the address may be different for subsequent primaries. A list of Kentucky cities and towns is located in Appendix D.

The address is a part of the patient's case data and has multiple uses. It will provide a referral pattern report and allow analysis of cancer clusters or environmental studies. These data may be corrected, but never update the address at diagnosis if the patient moves. Changing this field would destroy its usefulness.

State at Diag

Organization	Field Name	ID	Required
KCR	State at Diag (DiagState)	30280	yes
NAACCR	Addr at DXState	80	yes

Field Length: 2

This field is automatically filled in with the state entered in Item 10090 (Current Address - State) when the case is initially entered into CPDMS.net. Note that if the patient has multiple tumors, the address may be different for subsequent primaries.

If the address at diagnosis is not the same as the current address, then enter the correct address at diagnosis here. The address at diagnosis is a part of the patient's case data and has multiple uses. This field is critical for cancer incidence reporting. It will allow the state registry to exchange cases with contiguous states. It will also allow analysis of cancer clusters or environmental studies. This data may be corrected, but never update the address at diagnosis if the patient moves.

See APPENDIX B to code this field.

Examples:

Code	Definition
KY	If the state in which the patient resides at the time of diagnosis and treatment is Kentucky, then use the USPS code for the state of Kentucky.
XX	Resident of a country of than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is known.
YY	Resident of a country other than the U.S. (including it territories, commonwealths, or possessions) or Canada and the country is unknown.
US	Resident of the U.S. (including it territories, commonwealths, or possessions) and the state is unknown.
CD	Resident of Canada and the province is unknown.
ZZ	Residence unknown.

Zip Code at Diag

Organization	Field Name	ID	Required
KCR	Zip Code at Diag (DiagZipCode)	30290	yes
NAACCR	Addr at DXPostal Code	100	yes
KCR	Zip Ext at Diag (DiagZipExt)	30300	no
NAACCR	Addr at DXPostal Code	100	no

Field Length: 9

These fields are automatically filled in with the ZIP code entered in Items 10100-10110 (Current ZIP Code). Note that if the patient has multiple tumors, the ZIP code may be different for subsequent primaries.

The address is a part of the patient's demographic data and has multiple uses. It will provide a referral pattern report and allow analysis of cancer clusters or environmental studies. This data may be corrected, but never update the address at diagnosis if the patient moves. Changing this field would destroy its usefulness. If it is necessary to edit this field, follow the ZIP code guidelines in Items 10100-10110.

Country at Diag

Organization	Field Name	ID	Required
KCR	Country at Diag (DiagCountry)	30301	yes
NAACCR	Addr at DXCountry	102	yes

Field Length: 3

Record the three character abbreviation for the country of the patient's residence at the time of diagnosis. This item corresponds to Address at DX items (state, postal code). See APPENDIX B.

Common Country Codes

Code	Description
USA	United States
CAN	Canada
ZZX	Not US or Canada, but no other information
ZZU	Unknown

County at Diag

Organization	Field Name	ID	Required
KCR	County at Diag (County)	30310	yes
NAACCR	County at DX	90	yes

Field Length: 5

This field represents the patient's county of residence at the time of diagnosis. It is a five digit field where the first two digits represent the state of residence and the last three digits represent the county of residence in that state. The codes are taken from FIPS Publication Number 6-4, Counties and Equivalent Entities of the United States, its Possessions, and Associated Areas, as reissued July 7, 2001, and are made available electronically on the National Institute of Standards and Technology Web Site (http://www.itl.nist.gov/fipspubs/co-codes/states.htm). The state code for Kentucky is 21.

The county codes for Kentucky and its contiguous states are listed in Appendix D. CPDMS.net automatically calculates the correct county code from the address at diagnosis if the state is Kentucky and the ZIP code is within a single county. If a Kentucky ZIP code encompasses more than one county, the use must fill in this field. The U.S. Census Bureau web site has a helpful feature which displays the county (along with other information) of a particular address. The URL is http://factfinder.census.gov/servlet/AGSGeoAddressServlet?_lang=en&_programYear=50&_treeld=420.

Use Appendix D to code the state/county code for neighboring states.

Use code '00998' for any county outside Kentucky and its neighboring states.

Use code '00999' for unknown county of residence at diagnosis.

If the patient moves, do not change this code. It should remain the same as it was at the time this primary malignancy was diagnosed.

Note: This field is used to calculate the following geographic variables for Kentucky residents:

Area Development District

Appalachia (or non-Appalachia)

Beale Code (rural-urban continuum)

Registry Accession Year

Organization	Field Name	ID	Required
KCR	Registry Accession Year (AccYear)	30320	yes
KCR	Registry Accession No (AccNo)	30330	yes

Field Length: 9

These fields are used to identify cases by year accessioned in the order in which they were entered into the registry at your institution. The first four digits should be the year the patient was first seen in your institution. The last five digits will be the next number available to be assigned, i.e., the first case accessioned in 1991 will be recorded 19910001.

Exceptions: A patient enters the reporting institution in December 2002 and is diagnosed with cancer in January 2003. The accession number is 2003

The registry's reference date is January 1, 1996. A patient is diagnosed with breast cancer and has a partial mastectomy at the reporting institution in December 1995. The patient starts a course of radiation therapy at the reporting institution in January 1996. Assign the accession number

1996 _ _ _ _ .

Diag Confirmation Code

Organization	Field Name	ID	Required
KCR	Diag Confirmation Code (DiagConfirm)	30470	yes
NAACCR	Diagnostic Confirm	490	yes

Field Length: 1

Instructions for coding solid tumors (all tumors except 9590-9992)

• The codes are in priority order; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods. This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed is only an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases. Record the best mode of diagnostic confirmation recorded at any time in the patient's history of this cancer.

Code	Label	Definition	
1	Positive histology	Histologic confirmation (tissue microscopically examined). Microscopic diagnosis based on tissue specimens from biopsy, frozen section, surgery, autopsy, D&C, or from aspiration or biopsy of bone marrow specimens.	
2	Positive cytology	ytologic confirmation (fluid cells microscopically examined). Microscopic diagnosis based on examination of cells uch as sputum smears, bronchial brushings or washings, prostatic secretions, breast secretions, gastric fluid, spinal uid, peritoneal fluid, pleural fluid, urinary sediment, cervical or vaginal smears, or from paraffin block specimens from oncentrated spinal, pleural, or peritoneal fluid.	
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if tissue or cells were examined.	
5	Positive laboratory test/marker study	clinical diagnosis of cancer based on laboratory tests/marker studies which are clinically diagnostic for ancer. Examples include AFP for liver cancer and abnormal electrophoretic spike for mulitple myeloma. Note: evated PSA is only diagnostic of cancer if the physician uses the PSA as a basis for diagnosing prostate cancer with o further workup.	
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure with no tissue resected for microscopic examination. Use this code when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy, or from gross autopsy findings in the absence of tissue or cytological findings.	
7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from an imaging technique report only.	
8	Clinical diagnosis only	The malignancy was reported by the physician in the medical record. If a physician treats a patient for cancer, in spite of a negative biopsy, this is a reportable clinical diagnosis. Also, if a physician continues to describe a patient as having a reportable tumor, even after reviewing negative pathology results, this too is a reportable clinical diagnosis.	
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed.	

Instructions for coding hematopoietic or lymphoid tumors (9590-9992)

• There is no priority hierarchy for coding diagnostic confirmation for hematopoietic and lymphoid tumors. Code this field according the definitive diagnostic method used to confirm this malignancy. Definitive diagnostic methods are displayed in the hematopoietic database for each reportable hematopoietic and lymphoid neoplasm. Use code 3 whenever it applies-- i.e., whenever a positive histologic diagnosis is supported by a further positive test, such as IHC or genetic testing

Positive histology	Histologic confirmation (tissue microscopically examined). Microscopic diagnosis based on tissue specimens from biopsy, frozen section, surgery, autopsy, or bone marrow aspiration or biopsy. For leukemia only, code 1 when the diagnosis is based only on the complete blood count (CBC), white blood count (WBC), or peripheral blood (PB) smear.
Positive cytology	Cytologic confirmation (fluid cells microscopically examined). Microscopic diagnosis based on examination of cells such as spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical or vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.

3	Positive histology PLUS positive immunophenotyping and /or positive genetic studies	Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results. For example, bone marrow examination is positive for AML (9861/3). Genetic testing shows AML with inv(16)p13. 1q22) (9871/3). Do not use this code for neoplasms diagnosed prior to January 1, 2010.		
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if tissue or cells were examined.		
5	Positive laboratory test /marker study	A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer		
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination. Use this code when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy, or from gross autopsy findings in the absence of tissue or cytological findings.		
7	Radiography and other imaging techniques without microscopic examination	The malignancy was reported by the physician from an imaging technique report only.		
8	Clinical diagnosis only	The malignancy was reported by the physician in the medical record. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.		
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed.		

Path Report No

Organization	Field Name	ID	Required
KCR	Path Report No (PathReportNo)	30480	no

Field Length: 15

Record the pathology report number from which the diagnosis of cancer was made. The field allows for 15 characters - start entering in the left most box and leave any trailing boxes blank.

Collab Stg

- Collaborative Staging
 Regional Lymph Nodes Examined
- Regional Lymph Nodes Examine
 Regional Lymph Nodes Positive
 Mets at DX Bone
 Mets at DX Brain
 Mets at DX Liver

- Mets at DX Distant LN

- Mets at DX Distant LN
 Mets at DX Lung
 Mets at DX Other
 Summary Stage 1977
 SummStg1977Disp
 SummStg2000Disp
 CS Version Input Current
 CS Version Derived
 CS Version Input Original

Collaborative Staging

Collaborative Staging (CS) is to be used for cases diagnosed on or after January 1, 2004 through December 31, 2017. It is not to be used for cases diagnosed prior to that date. Its introduction does not affect CoC requirements for physicians to assign AJCC staging or the requirement that the physicianassigned staging values be recorded in the registry. CS Version 2 was implemented in 2010, and all cases previously entered under CS Version 1 were converted to CSv2.

Collaborative Staging was designed for registrar use. For Collaborative Staging, registrars code discrete pieces of information once and the CS computer algorithm derives the values for AJCC T, N, M and Stage Group, Summary Stage 1977, and Summary Stage 2000. The derived stage codes are ideally suited for data analysis because of the consistency that can be obtained with objectively-recorded, identically-processed data items.

The timing rule for CS coding was designed to make use of the most complete information possible to yield the "best stage" information for the tumor at the time of diagnosis-- "use all information gathered through completion of surgery(ies) in first course of treatment or all information available within four months of the date of diagnosis in the absence of disease progression, whichever is longer." Disease progression is defined as further direct extension or distant metastasis known to have developed after the diagnosis was established. Information about tumor extension, lymph node involvement, or distant metastasis obtained after disease progression is documented should be excluded from the CS coding.

The following CS data items are coded by the registrar.

- 30540. CS Tumor Size
- 30550. CS Extension
- 30560. CS Tumor Size/Ext Eval
- 30570. CS Lymph Nodes
- 30580. CS Reg Lymph Nodes Eval
- 30590. Regional Lymph Nodes Examined
- 30600. Regional Lymph Nodes Positive
- 30610. CS Mets at DX
- 30620. CS Mets Eval
- 30630-30680. CS Site-Specific Factors 1-6
- 32520-32700 CS Site-Specific Factors 7-25

The CS algorithm produces the output items listed below. The derived AJCC items are separate from the physician-coded items; and the derived Summary Stage items are separate from the manually-coded items collected by the CoC in the past. The derived items cannot be manually entered.

- 30780. Derived AJCC 6 T Descriptor
- 30790. Derived AJCC 6 T Code
- 30800. Derived AJCC 6 T Text
- 30810. Derived AJCC 6 N Descriptor
- 30820. Derived AJCC 6 N Code
- 30830. Derived AJCC 6 N Text
- 30840. Derived AJCC 6 M Descriptor
- 30850. Derived AJCC 6 M Code
- 30860. Derived AJCC 6 M Text
- 30870. Derived AJCC 6 Stage Group Code
- 30880. Derived AJCC 6 Stage Group
- 32710. Derived AJCC 7 T Descriptor
- 32720. Derived AJCC 7 T Code
- 32730. Derived AJCC 7 T Text
- 32740. Derived AJCC 7 N Descriptor
- 32750. Derived AJCC 7 N Code
- 32760. Derived AJCC 7 N Text

- 32770. Derived AJCC 7 M Descriptor
- 32780. Derived AJCC 7 M Code
- 32790. Derived AJCC 7 M Text
- 32800. Derived AJCC 7 Stage Group Code
- 32810. Derived AJCC 7 Stage Group
- 30690. Derived SS1977
- 30710. Derived SS2000

Unlike the AJCC and Summary Stage codes that are derived from it, CS is more of a site-specific data collection system. The CS algorithm uses tumor site and histology to determine which CS schema to apply. Depending on the schema, the coding instructions and code definitions will vary. Collaborative Staging codes are defined for every site and histology combination. The AJCC Cancer Staging Manual does not cover all sites, and some histologies are excluded from sites with an AJCC coding scheme. When the CS algorithm processes a site-histology combination that does not have an applicable AJCC code, it assigns the display string "NA" for "Not applicable." A blank display string for a derived item means the CS algorithm was not run for the case.

Coding CS Items

The complete instructions and site-histology defined codes are available in the Collaborative Stage Data Collection System Coding Instructions (CS Manual). Effective 01/01/2014, CS version 02.05 was implemented. Part I, Section 1 provides general instructions and the instructions and codes for generic (non site-specific) items. Part I, Section 2 contains lab tests, tumor markers, and site specific factor notes. Part II contains the site-specific schemas and codes. The CS Manual and related information is available electronically on the AJCC Web site: http://cancerstaging.org/cstage/Pages /default.aspx. For an easily navigable web-based list of site-specific schema and coding instructions, go to http://cancerstaging.org/cstage/schema/Pages /version0205.aspx Use the downloadable manual as well as the website to view the notes and appropriate codes for each schema.

Begin assigning codes for the Collaborative Staging data items. Be sure to read the notes and follow the site/histology-specific instructions at the beginning of each item. Some schemas require additional staging or prognostic information for that particular site. CS Site-Specific Factors 1-25 are designed to collect that information.

- Code the tumor size in the CS Tumor Size item.
- Code how far the tumor has spread directly in the CS Extension item.
- · Code how the farthest tumor spread was determined in the CS Tumor Size/Ext Eval item.
- Code whether regional lymph nodes are involved in the CS Lymph Nodes item.
- · Code how the farthest lymph node spread was determined in the CS Reg Node Eval item.
- Code the number of positive regional lymph nodes from the pathology report in the Regional Nodes Positive item.
- Code the number of regional lymph nodes examined by the pathologist in the Regional Nodes Examined item.
- Code the farthest distant metastasis (including distant lymph nodes) in the CS Mets at Dx item.
- · Code how the distant metastasis was determined in the CS Mets Eval item.
- Code the presence or absence of bone, brain, liver, or lung metastases.
- Code all required CS Site-Specific Factors.

The derived stage information for AJCC 6th edition staging will be calculated when the case is saved, or prior to exiting the case. The derived stage information for AJCC 7th edition will only be calculated for cases diagnosed January 1, 2010, forward. When the computer derives the final stage information, the program will check the histology code and other coded information to determine whether T, N, M and Stage Group will be generated for the case. If the histology code is not in that schema's inclusion list for that site, the T, N, M, and Stage Group will be reported as "Not Applicable." Summary Stage is generated for every case.

Regional Lymph Nodes Examined

Organization	nization Field Name ID Red		Required
KCR	Regional Lymph Nodes Examined	30590	Yes

Field Length: 2

This field applies to cases diagnosed prior to January 1, 2003.

Code	Description
00	No regional lymph nodes removed
01-89	One to 89 regional lymph nodes removed
90	Ninety or more regional lymph nodes removed
95	No regional lymph node(s) removed, but aspiration of regional lymph node(s) was performed
96	Regional lymph node removal documented as sampling and number of lymph nodes unknown/not stated
97	Regional lymph node removal documented as a dissection and number of lymph nodes unknown/not stated
98	Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection
99	Unknown; not stated; death certificate only

Regional Lymph Nodes Positive

Organization	zation Field Name ID Requir		Required
KCR	Regional Lymph Nodes Positive	30600	Yes

Field Length: 2

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable
	Not documented in patient record

Mets at DX - Bone

Organization	Field Name	ID	Required	
KCR	Mets at DX - Bone (CSMetsBone)	30681	yes	
NAACCR	Mets at Dx-Bone	1112	yes	

Field length: 1

This field is required for cases starting 01/01/2010

Instructions for Coding

1. Code information about bone metastases only (discontinuous or distant metastases to bone) identified at the time of diagnosis. This data item should not be coded for bone marrow involvement.

a. Bone involvement may be single or multiple

- b. Information about bone involvement may be clinical or pathologic
- c. Code this data item for bone metastases even if the patient had any preoperative systemic therapy

d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and III-Defined Primary Sites

2. Use of codes. Assign the code that best describes whether the case has bone metastases at diagnosis.

a. Use code 0 when the medical record

i. indicates that there are no distant (discontinuous) metastases at all

ii. includes a clinical or pathologic statement that there are no bone metastases

iii. includes imaging reports that are negative for bone metastases

iv. indicates that the patient has distant (discontinuous) metastases but bone is not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases but not bone

b. Use code 1 when the medical record

i. indicates that the patient has distant (discontinuous) metastases and bone is mentioned as an involved site

ii. indicates that bone is the primary site and there are metastases in a different bone or bones

1.do not assign code 1 for a bone primary with multifocal bone involvement of the same bone

iii. indicates that the patient is diagnosed as an unknown primary (C80.9) and bone is mentioned as a distant metastatic site

c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840- 9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691- C694, C698-C809	9820, 9826, 9831- 9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691- C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS

d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has bone metastases; for example, when there is documentation of carcinomatosis but bone is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include bone.

Code	Description
0	None; no bone metastases
1	Yes; distant bone metastases

8	Not applicable
9	Unknown whether bone is an involved metastatic site
	Not documented in patient record

Mets at DX - Brain

Organization	Field Name	ID	Required
KCR	Mets at DX - Brain (CSMetsBrain)	30682	yes
NAACCR	Mets at Dx-Bone	1113	yes

Field length: 1

This field is required for cases starting 01/01/2010

Instructions for Coding

1. Code information about brain metastases only (discontinuous or distant metastases to brain) identified at the time of diagnosis. This data item should not be coded for involvement of spinal cord or other parts of the central nervous system.

a. Brain involvement may be single or multiple

b. Information about bone involvement may be clinical or pathologic

c. Code this data item for bone metastases even if the patient had any preoperative systemic therapy

d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites

2. Use of codes. Assign the code that best describes whether the case has brain metastases at diagnosis.

a. Use code 0 when the medical record

i. indicates that there are no distant (discontinuous) metastases at all

ii. includes a clinical or pathologic statement that there are no brain metastases

iii. includes imaging reports that are negative for brain metastases

iv. indicates that the patient has distant (discontinuous) metastases but brain is not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases but not brain

b. Use code 1 when the medical record

i. indicates that the patient has distant (discontinuous) metastases and brain is mentioned as an involved site

ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and brain is mentioned as a distant metastatic site

c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840- 9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691- C694, C698-C809	9820, 9826, 9831- 9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691- C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS

d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has brain metastases; for example, when there is documentation of carcinomatosis but brain is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include brain.

Code	Description	
0	None; no brain metastases	
1	Yes; distant brain metastases	
8	Not applicable	
9	Unknown whether brain is an involved metastatic siteNot documented in patient record	

Mets at DX - Liver

Organization	Field Name	ID	Required
KCR	Mets at DX - Liver (CSMetsLiver)	30683	yes
NAACCR	Mets at Dx-Liver	1115	yes

Field length: 1

This field is required for cases starting 01/01/2010

Instructions for Coding

- 1. Code information about liver metastases only (discontinuous or distant metastases to liver) identified at the time of diagnosis.
 - a. Liver involvement may be single or multiple
 - b. Information about liver involvement may be clinical or pathologic
 - c. Code this data item for bone metastases even if the patient had any preoperative systemic therapy
 - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and III-Defined Primary Sites
- 2. Use of codes. Assign the code that best describes whether the case has liver metastases at diagnosis.
 - a. Use code 0 when the medical record
 - i. indicates that there are no distant (discontinuous) metastases at all
 - ii. includes a clinical or pathologic statement that there are no liver metastases
 - iii. includes imaging reports that are negative for liver metastases
 - iv. indicates that the patient has distant (discontinuous) metastases but liver is not mentioned as an involved site. Example: use code 0 when the patient has lung and brain metastases but not liver
 - b. Use code 1 when the medical record
 - i. indicates that the patient has distant (discontinuous) metastases and liver is mentioned as an involved site
 - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and liver is mentioned as a distant metastatic site
 - c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840- 9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691- C694, C698-C809	9820, 9826, 9831- 9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691- C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS

Use code 9 when it cannot be determined from the medical record whether the patient specifically has liver metastases; for example, when there is documentation of carcinomatosis but liver is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include brain.

Code	Description	
0	None; no liver metastases	
1	Yes; distant liver metastases	
8	Not applicable	
9	Unknown whether liver is an involved metastatic site	
	Not documented in patient record	

Mets at DX - Distant LN

	Organization	zation Field Name		Required
KCR Mets at DX - Distant		Mets at DX - Distant LN (MetsDistLymphNodes)	30685	yes
	NAACCR Mets at Dx-Distant LN		1114	yes

Field length: 1

This field is required for cases starting 01/01/2016

Instructions for Coding

1. Code information about distant lymph node(s) metastases only (metastases to distant lymph nodes) identified at the time of diagnosis.

a. Distant lymph node involvement may be single or multiple

b. Information about distant lymph node involvement may be clinical or pathologic

c. Code this data item for distant lymph node metastases even if the patient had any preoperative systemic therapy

d. This data item should not be coded for regional lymph node involvement with the exception of lymph nodes for placenta which are M1

e. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites

2. Use of codes. Assign the code that best describes whether the case has distant lymph node metastases at diagnosis.

a. Use code 0 when the medical record

i. indicates that there are no distant (discontinuous) metastases at all

ii. includes a clinical or pathologic statement that there are no distant lymph node metastases

iii. includes imaging reports that are negative for distant lymph node metastases

iv. indicates that the patient has distant (discontinuous) metastases but distant lymph node(s) is not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases but not distant lymph node(s)

b. Use code 1 when the medical record

i. indicates that the patient has distant (discontinuous) metastases and distant lymph node(s) is mentioned as an involved site

ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and distant lymph node(s) is mentioned as a distant metastatic site

c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840- 9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691- C694, C698-C809	9820, 9826, 9831- 9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691- C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS

d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has distant lymph node(s) metastases; for example, when there is documentation of carcinomatosis but distant lymph node(s) is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include distant lymph node(s).

Code	Description	
0	lone; no distant lymph node metastases	
1	Yes; distant distant lymph nodemetastases	
8	Not applicable	
8	Not applicable	

9	Unknown whether distant lymph node(s) is an involved metastatic site	
	Not documented in patient record	

Mets at DX - Lung

Organization	Field Name	ID	Required
KCR	Mets at DX - Lung (CSMetsLung)	30684	yes
NAACCR	Mets at Dx-Lung	1116	yes

Field length: 1

This field is required for cases starting 01/01/2010

Instructions for Coding

1. Code information about lung metastases only (discontinuous or distant metastases to lung) identified at the time of diagnosis. This data item should not be coded for pleural or pleural fluid involvment.

a. Lung involvement may be single or multiple

- b. Information about lung involvement may be clinical or pathologic
- c. Code this data item for lung metastases even if the patient had any preoperative systemic therapy

d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and III-Defined Primary Sites

2. Use of codes. Assign the code that best describes whether the case has lung metastases at diagnosis.

a. Use code 0 when the medical record

i. indicates that there are no distant (discontinuous) metastases at all

ii. includes a clinical or pathologic statement that there are no lung metastases

iii. includes imaging reports that are negative for lung metastases

iv. indicates that the patient has distant (discontinuous) metastases but lung is not mentioned as an involved site

Example: use code 0 when the patient has liver and brain metastases but not lung

b. Use code 1 when the medical record

i. indicates that the patient has distant (discontinuous) metastases and lung is mentioned as an involved site

ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and lung is mentioned as a distant metastatic site

c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840- 9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691- C694, C698-C809	9820, 9826, 9831- 9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691- C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS

d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has lung metastases; for example, when there is documentation of carcinomatosis but lung is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include lung.

Code	Description
0	None; no lung metastases
1	Yes; distant lung metastases
8	Not applicable
9	Unknown whether lung is an involved metastatic site

Not documented in patient record

Mets at DX - Other

Organization	Field Name	ID	Required
KCR	Mets at DX - Other (MetsOther)	30686	yes
NAACCR	Mets at Dx-Other	1117	yes

Field length: 1

This field is required for cases starting 01/01/2016

Instructions for Coding

1. Code information about other metastases only (discontinuous or distant metastases to other site) identified at the time of diagnosis. This data item should not be coded for bone, brain, liver, lung, or distant lymph node metastases.

a. Other involvement may be single or multiple

b. Information about other involvement may be clinical or pathologic

c. Code this data item for other metastases even if the patient had any preoperative systemic therapy

d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and III-Defined Primary Sites

2. Use of codes. Assign the code that best describes whether the case has other metastases at diagnosis.

a. Use code 0 when the medical record

i. indicates that there are no distant (discontinuous) metastases at all

ii. includes a clinical or pathologic statement that there are no other metastases

iii. includes imaging reports that are negative for other metastases

iv. indicates that the patient has distant (discontinuous) metastases but other sites are not mentioned as an involved site

Example: use code 0 when the patient has lung and liver metastases only

b. Use code 1 when the medical record

i. indicates that the patient has distant (discontinuous) metastases in an site(s) other than bone, brain, liver, lung or distant lymph node(s)

c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840- 9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691- C694, C698-C809	9820, 9826, 9831- 9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691- C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS

d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has metastases other than bone, brain, liver, lung, and distant lymph node(s); for example, when there is documentation of carcinomatosis but the specific site is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known specifically what they are.

Code	Description
0	None; no other metastases
1	Yes; distant metastases in known site(s) other than bone, brain, liver, lung, or distant lymph nodes
2	Generalized metastases such as carcinomatosis
8	Not applicable
9	Unknown whether any other metastatic site

Not documented in patient record

Summary Stage 1977

Organization	Field Name	ID	Required
KCR	Summary Stage 1977 (SummStg1977)	30690	no
NAACCR	Derived SS1977	3010	no

Field Length: 1

For cases diagnosed after 1-1-2004, this field will be calculated from the Collaborative Stage data items.

For cases diagnosed from 1-1-2001 to 12-31-2003, this field will be calculated from the SEER Extent of Disease data items.

For cases diagnosed prior to January 1, 2001, record the one digit code which describes the stage of disease at time of initial diagnosis and/or first treatment. Use all information available in the medical record within four months of the date of diagnosis in the absence of disease progression or through completion of first course surgery(ies), whichever is longer. Note that often surgical procedures will reveal the true anatomic extent of the disease at the time of first treatment and this information may be used in staging this case.

Refer to the Summary Staging Guide of the SEER Program to determine the general stage. Briefly described, they are:

C o de	Description
0	In-situ/non-invasive malignant tumor. The pathology report must state "in-situ". In addition there must be no evidence of invasion mentioned anywhere in the record in order for a tumor to be staged in this category. (The following synonyms may also be used instead of "in-situ": intraepithelial, intraepidermal, non-infiltrating, intraductal, or Bowen's Disease.)
1	Localized - tumor is confined to the organ of origin.
2	Regional by direct extension - tumor has spread by direct extension to immediately adjacent tissues or organs.
3	Regional to lymph nodes - tumor has spread into lymph nodes regional to the primary site of origin.
4	Regional by both direct extension and regional lymph nodes.
5	Regional, NOS - tumor is regionally spread, but the extent of regional spread cannot be determined, or is not specified.
7	Distant metastasis - a tumor that has spread beyond the immediately adjacent tissues and has developed secondary or metastatic tumors, has seeding or implants, or is systemic. Leukemia, multiple myeloma, reticuloendotheliosis, hematopoietic diseases, and Letterer-Siwe's disease are always coded 7.
9	Unknown/Unstageable - Use when there is not enough information available to accurately determine the stage. Every effort should be made to determine the stage by thoroughly reviewing the record or obtaining information from a medical authority before using code 9.

Code '9' should be used for unknown primaries, because staging for these cases is not applicable.

In the case of patients first treated elsewhere and admitted to your hospital for a subsequent course of treatment, enter the stage at the time of initial diagnosis, if it is known. If not, record the stage as "Unknown". Do not record the stage at the time of admission to your hospital for subsequent treatment.

SummStg1977Disp

Organization	Field Name	ID	Required
KCR	SummStg1977Disp (SummStg1977Disp)	30700	No

Field Length: 5

This is the label which appears on screen or in reports and that corresponds to the code stored in Summary Stage 1977 (item #30690).

Code	Display String
0	IS
1	L
2	RE
3	RN
4	RE+RN
5	RNOS
7	D
8	NA
9	U

Summary Stage 2000

Organization	Field Name	ID	Required
KCR	Summary Stage 2000 (SummStg2000)	30710	no
NAACCR	Derived SS200	3020	no

Field Length: 1

This is a one digit code which summarizes the stage of disease at time of initial diagnosis and/or first treatment. It only applies to cancers diagnosed on or after January 1, 2001. It will be calculated based on information coded in the SEER Extent of Disease fields for cases diagnosed from 1-1-2001 to 12-31-2003. For cases diagnosed on or after 1-1-2004, it will be calculated from the Collaborative Stage data items. This will no longer be used for cases beginning January 1, 2018 you will use Summary Stage 2018.

Refer to the Summary Staging Guide of the SEER Program to determine the general stage. Briefly described, they are:

Code	Description	
0	In-situ/non-invasive malignant tumor. The pathology report must state "in-situ". In addition there must be no evidence of invasion mentioned anywhere in the record in order for a tumor to be staged in this category. (The following synonyms may also be used instead of "in-situ": intraepithelial, intraepidermal, non-infiltrating, intraductal, or Bowen's Disease.)	
1	Localized - tumor is confined to the organ of origin.	
2	Regional by direct extension - tumor has spread by direct extension to immediately adjacent tissues or organs.	
3	Regional to lymph nodes - tumor has spread into lymph nodes regional to the primary site of origin.	
4	Regional by both direct extension and regional lymph nodes.	
5	Regional, NOS - tumor is regionally spread, but the extent of regional spread cannot be determined, or is not specified.	
7	Distant metastasis - a tumor that has spread beyond the immediately adjacent tissues and has developed secondary or metastatic tumors, has seeding or implants, or is systemic. Leukemia, multiple myeloma, reticuloendotheliosis, hematopoietic diseases, and Letterer-Siwe's disease are always coded 7.	
8	Not applicable - For non malignant (benign or borderline) tumors of the CNSThis code is never used to stage malignant tumors.	
9	Unknown/Unstageable - Use when there is not enough information available to accurately determine the stage. Every effort should be made to determine the stage by thoroughly reviewing the record or obtaining information from a medical authority before using code 9.	

Code '9' should be used for unknown primaries, because staging for these cases is not applicable.

In the case of patients first treated elsewhere and admitted to your hospital for a subsequent course of treatment, enter the stage at the time of initial diagnosis, if it is known. If not, record the stage as "Unknown". Do not record the stage at the time of admission to your hospital for subsequent treatment.

SummStg2000Disp

Organization	Field Name	ID	Required
KCR	SummStg2000Disp (SummStg2000Disp)	30720	No

Field Length: 5

This is the label which appears on screen or in reports and that corresponds to the code stored in Summary Stage 2000 (item #30710).

Code	Display String
0	IS
1	L
2	RE
3	RN
4	RE+RN
5	RNOS
7	D
8	NA
9	U

CS Version Input Current

Organization	Field Name	ID	Required
KCR	CS Version Input Current (CSVerInputCurrent)	30925	No
NAACCR	CS Version Input Current	2937	No

Field Length: 6

This field does not appear on the patient abstract, but is available for data analysis. This is a calculated item which indicates the version of Collaborative Staging input fields after they have been updated or recoded. This data item is recorded when the CS input fields are initially completed and is updated each time the CS input fields are modified.

The digits are stored as follows:

- The first two digits represent the major version number
 The third and fourth digit represent minor version changes
- The last two digits represent even less significant changes that do not affect coding

CS Version Derived

Organization	Field Name	ID	Required
KCR	CS Version Derived (CSVerDerived)	30920	No
NAACCR	CS Version Derived	2936	No

Field Length: 6

This field does not appear on the patient abstract, but is available for data analysis. It is a computer assigned value which is recorded the first time the Collaborative Stage output fields are derived and is updated each time the CS Derived items are recalculated.

The digits are stored as follows:

- The first two digits represent the major version number
 The third and fourth digit represent minor version changes
 The last two digits represent even less significant changes that do not affect coding

CS Version Input Original

Organization	Field Name	ID	Required
KCR	CS Version Input Original (CSVerInputOrig)	30930	No
NAACCR	CS Version Input Original	2935	No

Field Length: 6

This field does not appear on the patient abstract, but is available for data analysis. It is a computer assigned value which indicates the Collaborative Staging version used to initially code the CS data items. When the CS algorithm is run and the output values stored at the time of initial abstracting, the program automatically stores the value in this field.

The digits are stored as follows:

- The first two digits represent the major version number
- The third and fourth digit represent minor version changes
- The last two digits represent even less significant changes that do not affect coding

Note: This field is not updated if the data item codes are changed.

EOD

- EOD Primary Tumor
 Prostate Pathological Extension
 EOD Regional Nodes
 Date of Sentinel Lymph Node Biopsy
 Sentinel Lymph Nodes Examined
 Sentinel Lymph Nodes Positive
 Date Regional Lymph Node Dissection
 EOD Metastases
 Derived Summary Stage 2018

EOD Primary Tumor

Organization	Field Name	ID	Required
KCR	EOD Primary Tumor (EODPrimaryTumor)	30501	Yes
SEER	EOD–Primary Tumor	772	Yes

Field Length: 3

Effective for cases diagnosed January 1, 2018 and later.

Description

Extent of Disease Primary Tumor is new for 2018. EOD Primary Tumor is part of the EOD 2018 data collection system and is used to classify contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs at the time of diagnosis. See also EOD Regional Nodes and EOD Metastases.

See the most current version of EOD (https://staging.seer.cancer.gov/eod_public/list/1.6/) for rules and site-specific codes and coding structures.

Codes (In addition to schema-specific codes where needed)

Special Codes

Code	Description
000	In situ, intraepithelial, noninvasive
800	No evidence of primary tumor
999	Unknown; primary tumor not stated Primary tumor cannot be assessed Not documented in patient record Death certificate only (DCO)

Prostate Pathological Extension

Organization	Field Name	ID	Required
KCR	Prostate Pathological Extension (EODProstatePathExt)	30607	Yes
NAACCR	Prostate Pathological Extension	3919	Yes

Field Length: 3

Effective for cases diagnosed January 1, 2018 and later.

Description

Pathological extension is used to assign pT category for prostate cancer based on radical prostatectomy specimens.

Rationale Pathological extension is used in EOD. It was previously collected as Prostate, CS SSF# 3.

Codes (See the most current version of EOD (Prostate) (https://staging.seer.cancer.gov/eod_public/schema/1.4/prostate) for rules and site-specific codes and coding structures.)

EOD Regional Nodes

	Organization	Field Name	ID	Required
	KCR	EOD Regional Nodes (EODRegionalNodes)	30502	Yes
	SEER	EOD–Regional Nodes	774	Yes

Field Length: 3

Effective for cases diagnosed January 1, 2018 and later.

Description

Extent of Disease Regional Nodes is new for 2018. EOD Regional Nodes is part of the EOD 2018 data collection system and is used to classify the regional lymph nodes involved with cancer at the time of diagnosis. See also EOD Primary Tumor and EOD Metastases.

See the most current version of EOD (https://staging.seer.cancer.gov/eod_public/list/1.3/) for rules and site-specific codes and coding structures.

Codes (In addition to schema-specific codes where needed)

Special Codes

Code	Description
000	None
800	Regional lymph node(s), NOS
	Lymph node(s), NOS
888	Not applicable – e.g., CNS, hematopoietic
999	Unknown

Date of Sentinel Lymph Node Biopsy

Organization	Field Name	ID	Required
KCR	Date Sentinel Lymph Node Biopsy (DateSenLNBiopsy)	30605	Yes
CoC	Date Sentinel Lymph Node Biopsy	832	Yes

Field Length: 8

Effective for cases diagnosed January 1, 2018 and later.

Description

Records the date of the sentinel lymph node(s) biopsy procedure. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. This data item is required for breast and melanoma cases only.

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of the sentinel lymph node biopsy procedure separate from the date of a subsequent regional node dissection procedure, if performed.

Sentinel Lymph Nodes Examined

Organization	Field Name	ID	Required
KCR	Sentinel Lymph Nodes Examined (SenLNExamined)	30604	Yes
CoC	Sentinel Lymph Nodes Examined	834	Yes

Field Length: 2

Effective for cases diagnosed January 1, 2018 and later.

Description

Records the total number of lymph nodes sampled during the sentinel node biopsy and examined by the pathologist. This data item is required for CoCaccredited facilities as of cases diagnosed 01/01/2018 and later. This data item is required for breast and melanoma cases only.

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the number of lymph nodes biopsied during the sentinel node biopsy procedure separate from the number of lymph nodes dissected during additional subsequent regional node procedures.

Codes	Description
00	No sentinel nodes were examined
01-90	Sentinel nodes were examined (code the exact number of sentinel lymph nodes examined)
95	No sentinel nodes were removed, but aspiration of sentinel node(s) was performed
98	Sentinel lymph nodes were biopsied, but the number is unknown
99	It is unknown whether sentinel nodes were examined; not stated in patient record

Sentinel Lymph Nodes Positive

Organization	Field Name	ID	Required
KCR	Sentinel Lymph Nodes Positive (SenLNPositive)	30603	Yes
CoC	Sentinel Lymph Nodes Positive	835	Yes

Field Length: 2

Effective for cases diagnosed January 1, 2018 and later.

Description

Records the exact number of sentinel lymph nodes biopsied by the pathologist and found to contain metastases. This data item is required for CoCaccredited facilities as of cases diagnosed 01/01/2018 and later. This data item is required for breast and melanoma cases only.

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the number of positive sentinel lymph nodes biopsied separate from the number of positive lymph nodes identified during additional subsequent regional node dissection procedures, if performed.

Codes	Description
00	All sentinel nodes examined are negative
01-90	Sentinel nodes are positive (code exact number of nodes positive)
95	Positive aspiration of sentinel lymph node(s) was performed
97	Positive sentinel nodes are documented, but the number is unspecified; For breast ONLY: SLN and RLND occurred during the same procedure
98	No sentinel nodes were biopsied
99	It is unknown whether sentinel nodes are positive; not applicable; not stated in patient record

Date Regional Lymph Node Dissection

Organization	Field Name	ID	Required
KCR	Date Regional Lymph Node Dissection (DateRegLNDiss)	30601	Yes
NAACCR	Date Regional Lymph Node Dissection	682	Yes

Field Length: 8

Effective for cases diagnosed January 1, 2018 and later.

Description

Records the date non-sentinel regional node dissection was performed. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01 /2018 and later.

Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of regional node dissection separate from the date of sentinel lymph node biopsy if performed.

EOD Metastases

Organization	Field Name	ID	Required
KCR	EOD Mets (EODMets)	30503	Yes
SEER	EOD-Mets	776	Yes

Field Length: 2

Effective for cases diagnosed January 1, 2018 and later.

Description

Extent of Disease Metastases is new for 2018. EOD Metastases is part of the EOD 2018 data collection system and is used to classify the distant site(s) of metastatic involvement at time of diagnosis. See also EOD Primary Tumor and EOD Regional Nodes.

See the most current version of EOD (https://staging.seer.cancer.gov/eod_public/list/1.3/) for rules and site-specific codes and coding structures.

Codes (In addition to schema-specific codes where needed)

Special Codes

Code Description			
00	None No distant metastasis Unknown if distant metastasis		
88	Not applicable: Information not collected for this schema Use for these sites only: HemeRetic; III Defined Other (includes unknown primary site); Kaposi Sarcoma; Lymphoma; Lymphoma- CLL/SLL; Myeloma Plasma Cell Disorder		
99	Death certificate only (DCO)		

Derived Summary Stage 2018

Organization	Field Name	ID	Required
KCR	Summary Stage 2018 (SummStg2018)	30272	YES
SEER	Summary Stage 2018	762	YES

Field length: 1

Description

Derived Summary Stage 2018 is derived using the EOD data collection system (EOD Primary Tumor [772], EOD Regional Nodes [774] and EOD Mets [776]) algorithm. Other data items may be included in the derivation process. Effective for cases diagnosed 1/1/2018+. Please see Summary Stage 2018 Manual for specific schema instructions.

Rationale

The SEER program has collected staging information on cases since its inception in 1973. Summary Stage groups cases into broad categories of in situ, local, regional, and distant. Summary Stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time.

Note: This data item was included in Standards Volume II, Version 16; however, it was not implemented until 2018.

Code	Description
0	In situ
1	Localized
2	Regional, direct extension only
3	Regional, regional lymph nodes only
4	Regional, direct extension and regional lymph nodes
7	Distant
8	Benign, borderline
9	Unknown if extension or metastasis (unstaged, unknown, or unspecified) Death certificate only case

SSDI/Grade

- Grade Clinical
- Grade Pathological
- Grade Post Therapy
 SSDI
 SEER SSF 1 (HPV Status)

Grade Clinical

Organization	Field Name	ID	Required
KCR	Grade Clinical	30136	Yes
AJCC	Grade Clinical	3843	Yes

Field length: 1

For cases diagnosed January 1, 2018, and later, this data item, along with Grade Pathological and Grade Post-Neoadjuvant, replaces NAACCR Data Item Grade [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]). (Refer to the most recent version of the Grade Manual for additional site-specific instructions)

Description

This data item records the grade of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant).

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the clinical stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Chapter. The AJCC Chapter-specific grading systems (codes 1-5) take priority over the generic grade definitions (codes A-E, L, H, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

Grade Pathological

	Organization	Field Name	ID	Required
K	CR	Grade Pathological	30137	Yes
A,	JCC	Grade Pathological	3844	Yes

Field length: 1

For cases diagnosed January 1, 2018, and later, this data item, along with Grade Pathological and Grade Post-Neoadjuvant, replaces NAACCR Data Item Grade [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]). (Refer to the most recent version of the Grade Manual for additional site-specific instructions)

Description

This data item records the grade of a solid primary tumor that has been resected and for which no neoadjuvant therapy was administered. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the AJCC manual. This may include the grade from the clinical workup.

Record the highest grade documented from any microscopic specimen of the primary site whether from the clinical workup or the surgical resection.

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the pathological stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Chapter. The AJCC Chapter-specific grading systems (codes 1-5) take priority over the generic grade definitions (codes A-E, L, H, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

Grade Post Therapy

е

Organization	Field Name	ID	Required
KCR	Grade Post Therapy (GradePostTx)	30138	Yes
AJCC	Grade Post Therapy	3845	Yes

Field list: 1

For cases diagnosed January 1, 2018, and later, this data item, along with Grade Pathological and Grade Post-Neoadjuvant, replaces NAACCR Data Item Grade [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]). (Refer to the most recent version of the Grade Manual for additional site-specific instructions)

Description

This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the AJCC manual.

Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the post-neoadjuvant stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Chapter. The AJCC Chapter-specific grading systems (codes 1-5) take priority over the generic grade definitions (codes A-E, L, H, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

SSDI

Refer to the most recent version of the SSDI Manual for additional site-specific instructions Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.

SEER SSF 1 (HPV Status)

Organization	Field Name	ID	Required
KCR	SEER SSF 1 (HPV Status) (SEERSSF1)	30139	Yes
SEER	SEER SSF 1	3700	Yes

Field length: 1

This item is for cases diagnosed 01/01/2018 and forward. This data item is reserved for human papilloma virus (HPV) status.

Description

A one character field to be used when information for a particular primary site needs to be collected by SEER.

This data item only applies to the schemas:

Schema	Codes
Oropharynx (p16+)	C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C103, C108-C109, C111
Oropharynx (p16-) and Hypopharynx	C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C103, C108-C109, C111, C129, C130-C132, C138-C139
Lip and Oral Cavity	C000-C009, C020-C023, C028-C029, C030-C031, C039, C040-C041, C048-C049, C050, C058-C059, C060-C062, C068-C069

There is evidence that human papilloma virus (HPV) plays a role in the pathogenesis of some cancers. HPV testing may be performed for prognostic purposes; testing may also be performed on metastatic sites to aid in determination of the primary site.

AJCC Docs

- Directly Coded Summ Stg 2000
- Directly Coded Summary Stage 2018
- AJCC Staging Of Cancer
- Tumor Size Pathologic
- Tumor Size Clinical
 Tumor Size Summary
- AJCC Staging Edition
- cT Classification
- cN Classification
- cM Classification
- cTNM Stage Group
- cTNM Descriptor
 cTNM Descriptor
 Staged By Clinical
- pT Classification
- pN Classification
- pM Classification
- pTNM Stage Group
- pTNM Descriptor
- Alt (Ped) Stage Sys
- Alt (Ped) Stage
- Managing Physician
- Primary Surgeon
 Medical Oncologist
- Radiation Oncologist

- Staged By Pathologic
 AJCC TNM Clinical T
 AJCC TNM Clinical T Suffix
- AJCC TNM Clinical N
 AJCC TNM Clinical N Suffix
 AJCC TNM Clinical M
- AJCC TNM Clinical Stage Group
 AJCC TNM Pathological T
- AJCC TNM Pathological T Suffix
- AJCC TNM Pathological N
 AJCC TNM Pathological N Suffix
- AJCC TNM Pathological M
- AJCC TNM Pathological Stage Group
- AJCC TNM Post Therapy T
 AJCC TNM Post Therapy T Suffix
 AJCC TNM Post Therapy N
- AJCC TNM Post Therapy N Suffix
- AJCC TNM Post Therapy M
 AJCC TNM Post Therapy Stage Group

Directly Coded Summ Stg 2000

Organization	Field Name	ID	Required
KCR	Directly Coded Summ Stg 2000 (DirCodedSummStg2000)	30725	no
NAACCR	SEER Summary Stage 2000	759	no

This field will not be used for cases 01/01/2018 forward.

Field length: 1

Codes

Same as 30710 - SUMMARY STAGE 2000

Directly Coded Summary Stage 2018

Organization	Field Name	ID	Requirede
KCR	Directly Coded Summ Stg 2018 (DirCodedSummStg2018)	30726	no
NAACCR	SEER Summary Stage 2018	764	no

Field length: 1

Description

This item stores the directly assigned Summary Stage 2018. Effective for cases diagnosed 01/01/2018 forward. Please see Summary Stage 2018 Manual for specific schema information.

Rationale

The SEER program has collected staging information on cases since its inception in 1973. Summary Stage groups cases into broad categories of in situ, local, regional, and distant. Summary Stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time. *Note*: This data item was included in Standards Volume II, Version 16; however, it was not implemented until 2018.

Code	Description
0	In situ
1	Localized only
2	Regional by direct extension only
3	Regional lymph nodes only
4	Regional by BOTH direct extension AND lymph node involvement
7	Distant site(s)/node(s) involved
8	Benign/borderline*
9	Unknown if extension or metastasis (unstaged, unknown, or unspecified) Death certificate only case

*Applicable for the following SS2018 chapters: Brain, CNS Other, Intracranial Gland.

Note: For SS2018, code 5 for "Regional, NOS" can no longer be coded. Code 5 (Regional, NOS) is still applicable.

AJCC Staging Of Cancer

The extent or stage of cancer at the time of diagnosis is a key factor that defines prognosis and is a critical element in determining appropriate treatment based on the experience and outcomes of groups of previous patients with similar stage. In addition, cancer stage often is a key component of inclusion, exclusion, and stratification criteria for clinical trials. Indeed, accurate staging is necessary to evaluate the results of treatments and clinical trials, to facilitate the exchange and comparison of information across treatment centers and within and between cancer-specific registries, and to serve as a basis for clinical and translational cancer research. At the national and international levels, a cohesive approach to the classification of cancer provides a method of clearly conveying clinical experience to others without ambiguity.

The most clinically useful staging system is the tumor, node, and metastasis (TNM) staging system developed by the American Joint Committee on Cancer (AJCC) in collaboration with the Union for International Cancer Control (UICC), herein referred to as the AJCC TNM staging system. The AJCC TNM system classifies cancers by the size and extent of the primary tumor (T), involvement of regional lymph nodes (N), and the presence or absence of distant metastases (M), supplemented in recent years by evidence-based prognostic and predictive factors.

NOTE: The AJCC Manual for Staging Cancer, Third Edition is used with cases diagnosed from 1989-1992.

The AJCC Manual for Staging Cancer, Fourth Edition, is used with cases diagnosed from 1993 to 1997.

The AJCC Cancer Staging Manual, Fifth Edition, is used with cases diagnosed from 1998 to 2002.

The AJCC Cancer Staging Manual, Sixth Edition, is used with cases diagnosed from 2003 to 2009.

The AJCC Cancer Staging Manual, Seventh Edition, is used with cases diagnosed 2010 to 2017.

The AJCC Cancer Staging Manual, Eighth Edition, is used with cases diagnosed 2018 forward

NOTE: For 2008 diagnoses forward, ACoS requires clinical TNM staging assigned by a physician if available. If not available, these fields must be completed by the registrar. Pathologic TNM is not required. For pre-2008 diagnoses, physician-assigned TNM stage is required for both clinical and pathologic staging in approved programs. Physicians may choose to record both the clinical and the pathologic stage if applicable. Registrars are required to report both if information is available from the physician. KCR requires only one TNM stage-- pathologic if the information is available, otherwise clinical.

The TNM general rules applicable to all sites contained in the Eighth Edition are as follows:

- 1. All cases should be confirmed microscopically for classification by TNM. Cases that do not have any biopsy or cytology of the tumor can be staged, but survival should be analyzed separately. These cases should not be included in overall disease survival analyses.
- 2. Eligible time period for determination of staging:
- 3. Clinical staging, designated cTNM, includes any information obtained about the extent of cancer before initiation of definitive treatment (surgery, systemic or radiation therapy, active surveillance, or palliative care) or within four months after the date of diagnosis, whichever is shorter, as long as the cancer has not clearly progressed during that time frame.
- 4. Pathologic staging, designated pTNM, includes any information obtained about the extent of cancer up through completion of definitive surgery as part of first course treatment or identified within four months after the date of diagnosis, whichever is longer, as long as there is no systemic or radiation therapy initiated or the cancer has not clearly progressed during that time frame.
- 5. Post-therapy staging, designated ypTNM. The time frame should be such that the post neoadjuvant surgery and staging occur within a time frame that accommodates disease-specific circumstances, as outlined in the specific chapters and in relevant guidelines. Note: Clinical stage should be assigned before the start of neoadjuvant therapy.
- 6. In cases where there is documented progression of cancer prior to the initiation of therapy or surgery, only information obtained prior to documented progression is used for staging.
- 7. If uncertainty exists regarding how to assign a category, subcategory, or stage group, the lower of the two possible categories, subcategories, or groups is assigned for T, N, or M prognostic stage group/stage group Stage groups are for patient care and prognosis based on data. Physicians may need to make treatment decisions if staging information is uncertain or unclear. Note: Unknown or missing information for T, N, M or stage group is never assigned the lower category, subcategory, or group.
- 8. If information is not available to the cancer registrar for documentation of a subcategory, the main (umbrella) category should be assigned (e.g., T1 for a breast cancer described as <2 cm in place of T1a, T1b, or T1c). If the specific information to assign the stage group is not available to the cancer registrar (including subcategories or missing prognostic factor categories), the stage group should not be assigned but should be documented as unknown.
- 9. If a required prognostic factor category is unavailable, the category used to assign the stage group is: X, or If the prognostic factor is unavailable, default to assigning the anatomic stage using clinical judgment.
- 10. The recommended histologic grading system for each disease site and/or cancer type, if applicable, is specified in each chapter and should be used by the pathologist to assign grade. The cancer registrar will document grade for a specific site according to the coding structure in the relevant disease site chapter.
- 11. If multiple tumors of the same histology are present in one organ: the tumor with the highest T category is classified and staged, and the (m) suffix is used An example of a preferred designation is: pT3(m) N0 M0. If the number of synchronous tumors is important, an acceptable alternative designation is to specify the number of tumors. For example, pT3(4) N0 M0 indicates four synchronous primary tumors. Note: The (m) suffix applies to multiple invasive cancers. It is not applicable for multiple foci of in situ cancer or for a mixed invasive and in situ cancer.
- 12. If there is no evidence of a primary tumor, or the site of the primary tumor is unknown, staging may be based on the clinical suspicion of the organ site of the primary tumor, with the tumor categorized as T0. The rules for staging cancers categorized as T0 are specified in the relevant disease site chapters. In the case of a primary of unknown origin, staging will be based on reasonable clinical certainty of the primary organ.
- 13. If reasonable clinical certainty is not obvious, the case cannot be staged. For example, if a patient has brain metastases diagnosed by a computed tomographic (CT) imaging scan, and the physician records that the primary is probably lung, code the primary site to lung and use the lung classification system for staging. However, if a patient is noted to have metastatic disease to the liver, and the pathology report cites that the primary may be lung or colon, this case cannot be staged, unless the origin of the primary is documented elsewhere.
- 14. For in-situ classification, if there is an acceptable histologic classification of in-situ carcinoma as determined by your pathologist, but it has not been specified in the AJCC chapter, it can be used to classify pTis. The correct classification for in-situ lesions is pTis cN0 cM0, and should be reported as both clinical stage group 0 and pathologic stage group 0.
- 15. If pathologic assessment of lymph nodes reveals negative nodes but the number of examined lymph nodes is less than the suggested number for lymph node dissection, classify the N category as pN0. Only one lymph node is required to be removed for pathologic staging.

- 16. Isolated tumor cells (ITC's) are single tumor cells or small clusters of cells not more than 0.2 mm in greatest dimension that are usually detected by immunohistochemistry or molecular methods. Cases with ITC's in lymph nodes or at distant sites should be classified as N0 or M0, respectively. The same applies to cases with findings suggestive of tumor cells or their components by non morphologic techniques such as flow cytometry or DNA analysis. These cases should be analyzed separately and have special recording rules in the specific organ site.
- 17. Except where pM is positive, cM should be used along with pT and pN for calculating pathologic stage; "pM0" is not a valid concept. "MX" is not a valid category from 2010 forward. Infer status as cM0 unless known M1.

When physician and registrar disagree on correct TNM stage:

In situations in which the registrar disagrees with the TNM stage assigned by the physician, the registrar should attempt to resolve the discrepancy with the appropriate physician. It is also recommended that hospitals with ACoS approved cancer programs have these discrepancies reviewed by the Cancer Committee liaison to the registry if further resolution is needed. The physician's TNM classification and stage group should be recorded in the cancer registry database and the "staged by" field should indicate physician. Any discussion or disagreement by the registrar and/or registry physician advisors should be recorded in text.

Amin, Mahul B.; Gress, Donna M.; Meyer Vega, Laura R.; Edge, Stephen B. AJCC Cancer Staging Manual, Eighth Edition (Page 22). American College of Surgeons. Kindle Edition.

Tumor Size Pathologic

Organization	Field Name	ID	Required
KCR	Tumor Size Pathologic (TumorSizePath)	30932	yes
NAACCR	Tumor Size Pathologic	754	yes

Field length: 3

Code the size of the primary tumor that has been resected.

Code	Description
000	No mass/tumor found
001	1 mm or described as less than 1 mm
002-988	Exact size in millimeters (2mm-988mm)
989	989 millimeters or larger
990	Microscopic focus or foci only and no size of focus is given
998	SITE-SPECIFIC CODES
	Alternate descriptions of tumor size for specific sites:
	Familial/multiple polyposis:
	Rectosigmoid and rectum (C19.9, C20.9)
	Colon (C18.0, C18.2-C18.9)
	If no size is documented:
	Circumferential:
	Esophagus (C15.0-C15.5, C15.8 C15.9)
	Diffuse; widespread: 3/4s or more; linitis plastica:
	Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)
	Diffuse, entire lung or NOS:
	Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)
	Diffuse:
	Breast (C50.0-C50.6, C50.8-C50.9)
999	Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable

Coding Instructions

Note: Record tumor size only in millimeters (mm). Convert to millimeters from centimeters when size of tumor is measured in centimeters (cm). Often measurements are given in centimeters and must be

converted to millimeters, such as < 1 cm, code as 009; or < 2 cm , code as 019.

Record size:

- 1. Code pathologic tumor size to 999 for unknown when there is no excisional biopsy or tumor resection.
- 2. Record the size of the invasive component, if given

a. Record the size of the invasive component, even if it is smaller, when both an in situ and an invasive component are present and the invasive component is measured.

Example: Tumor is mixed in situ and invasive adenocarcinoma, total 3.7 cm in size, of which 1.4 cm is invasive. Record tumor size as 014 (1.4 cm or 14 mm).

b. Record the size of the entire tumor from the surgical report or pathology report when the size of the invasive component is not given

Example: A breast tumor with infiltrating duct carcinoma with extensive in situ component; total size 2.3 cm. Record tumor size as 023 (2.3 cm or 23 mm).

Example: Duct carcinoma in situ measuring 1.9 cm with an area of invasive ductal carcinoma. Record tumor size as 019 (1.9 cm = 19 mm).

c. Record the size of the primary tumor, including contiguous tumor tissue extension, at thetime of diagnosis

3. Code the largest size of the primary tumor measured on the surgical resection specimen when surgery is administered as part of the first definitive treatment.

Note: This includes pathologic tumor size from surgery when there is neoadjuvant therapy.

a. Code the size from the synoptic report (also known as CAP protocol or pathology report checklist) when there is a discrepancy among tumor size measurements in the various sections of the

pathology report.

b. Use final diagnosis, microscopic, or gross examination, in that order, when no synoptic report is available.

Example 1: Chest x-ray shows 3.5 cm mass. The pathology report from the lobectomy states RUL lung mass: 2.8 cm adenocarcinoma. Record pathologic tumor size as 028 (28 mm).

Example 2: Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record pathologic tumor size as 032 (32 mm).

4. Tumor size is the largest dimension of the tumor, not the depth or thickness of the tumor

5. Include pathologic information obtained through completion of definitive surgery when the surgery is part of the first course of treatment

- 6. Information on size from imaging/radiographic techniques cannot be used to code Tumor Size Pathologic
- 7. Record 'less than' OR 'greater than' tumor size
 - a. Record the tumor size as one mm less than stated when tumor size is reported as "less than x mm" or "less than x cm"

Example: size is < 10 mm code size as 009.

- i. Often measurements are given in centimeters and must be converted to millimeters, such as < 1 cm, code as 009; or < 2 cm, code as 019.
- ii. Code 001 when stated as less than 1 mm.
- b. Record the tumor size as one mm more than stated when tumor size is reported as "more than x mm" or "more than x cm"

i. For example, if size is > 10 mm, code size as 011.

ii. Often measurements are given in centimeters and must be converted to millimeters, such as > 1 cm, code as 011; or > 2 cm, code as 021.

c. Code 989 when tumor size is greater than 989 mm (98.9 cm).

8. Record "between" tumor sizes as the midpoint between the two measurements when tumor size is reported to be between two sizes; i.e., add the two sizes together and divide by two.

Example: "between 2 and 3 cm." Code size as 025 since 2 + 3 =5 divided by 2 = 2.5 (or 025 mm).

9. Round decimals: Round the tumor size only if it is described in fractions of millimeters.

Note 1: Record tumor size as 001 (do not round down to 000) when the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9 mm).

Note 2: Code 001 when tumor size is 1 mm

a. When tumor size is greater than 1 millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter, and round tenths of millimeters in the 5-9 range up to

the nearest whole millimeter.

Examples:

Breast cancer described as 6.5 millimeters in size. Round up to 7 mm and code as 007.

2.3 millimeters cancer in a polyp. Round down to 2 mm and code 002.

Focus of cancer described as 1.4 mm in size. Round down to 1 mm and code as 001.

5.2 cm breast cancer. Convert to millimeters and code 052.

2.5 cm rectal cancer. Do not round, record as 025 millimeters.

b. Do not round tumor size expressed in centimeters to the nearest whole centimeter; rather, convert the measurement to millimeters by moving the decimal point one space to the right

10. Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis. However, when the tumor is described as a "cystic mass" or "polypoid mass" and only the

size of the entire mass is given, code the size of the entire mass, since the cysts or polyps are part of the tumor itself.

11. Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen

or the complete resection of the primary tumor

Example: Tumor is described as 2.4 x 5.1 x 1.8 cm in size. Record tumor size as 051 (51 mm).

12. Record the size as stated for purely in situ lesions

13. Disregard microscopic residual or positive surgical margins when coding tumor size.

Microscopic residual tumor does not affect overall tumor size. The status of primary tumor

margins may be recorded in a separate data field.

14. Record tumor size as 999 when the only measurement describes pieces or chips. Do not add the size of pieces or chips together to create a whole; they may not be from the same location,

or they may represent only a very small portion of a large tumor. However, when the pathologist states an aggregate or composite size (determined by fitting the tumor pieces

together and measuring the total size), record that size.

15. Multifocal/multicentric tumors: Code the size of the largest invasive tumor, or the largest in situ tumor if all tumors are in situ, when the tumor is multifocal or when multiple tumors are

reported as a single primary.

16. Assign tumor size code 999 when size is unknown or not applicable. Sites/morphologies where tumor size is not applicable are listed here

Hematopoietic: Lymphomas, Leukemias, Myeloproliferative neoplasms and other

Hematopoietic neoplasms

(Histology codes 9590-9992)

Kaposi Sarcoma

Melanoma Choroid

Melanoma Ciliary Body

Melanoma Iris

Unknown primary site

17. Document the information to support coded pathologic tumor size in the appropriate text field of the abstract.

Tumor Size Clinical

Organization	Field Name	ID	Required
KCR	Tumor Size Clinical (TumorSizeClin)	30931	yes
NAACCR	Tumor Size Clinical	752	yes

Field length: 3

This data item records the size of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant)

Code	Description	
000	No mass/tumor found	
001	1 mm or described as less than 1 mm	
002-988	Exact size in millimeters (2mm-988mm)	
989	989 millimeters or larger	
990	Microscopic focus or foci only and no size of focus is given	
998	SITE-SPECIFIC CODES	
	Alternate descriptions of tumor size for specific sites:	
	Familial/multiple polyposis:	
	Rectosigmoid and rectum (C19.9, C20.9)	
	Colon (C18.0, C18.2-C18.9)	
	If no size is documented:	
	Circumferential:	
	Esophagus (C15.0-C15.5, C15.8 C15.9)	
	Diffuse; widespread: 3/4s or more; linitis plastica:	
	Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)	
	Diffuse, entire lung or NOS:	
	Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)	
	Diffuse:	
	Breast (C50.0-C50.6, C50.8-C50.9)	
999	Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable	

Coding Instructions

Note: Record tumor size only in millimeters (mm). Convert to millimeters from centimeters when size

of tumor is measured in centimeters. Often measurements are given in centimeters and must be

converted to millimeters, such as 2 cm, which is 20 mm.

1. Record size in specified order using

a. The largest measurement of the primary tumor from physical exam, imaging, or other diagnostic procedures before any form of treatment. See priority order below.

b. The largest size from all information available within four months of the date of diagnosis, in the absence of disease progression when no treatment is administered.

c. Record the size of the primary tumor, including contiguous tumor tissue extension, at the time of diagnosis.

2. Tumor size is the largest dimension of the tumor, not the depth or thickness of the tumor.

3. Code the largest size of the primary tumor before neoadjuvant treatment. Use code 999 if size is unknown.

Example: Patient has a 2.2 cm (22 mm) mass in the oropharynx; fine needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination

chemotherapy. Pathologic size of tumor after total resection is 2.8 cm (28 mm). Record clinical tumor size as 022 (22 mm) since the pathologic resection is after the neoadjuvant therapy.

4. Record 'less than' OR 'greater than' tumor size

a. Record the tumor size as one mm less than stated when tumor size is reported as "less than x mm or less than x cm"

i. For example, if size is < 10 mm, code size as 009

ii. Often measurements are given in centimeters and must be converted to millimeters, such as< 1 cm (<10 mm), which is coded as 009; or < 2 cm (<20 mm), which is coded as 019

iii. Code 001 when stated as less than 1 mm

b. Record the tumor size as one mm more than stated when tumor size is reported as "more than x mm" or "more than x cm"

i. For example, if size is > 10 mm, code size as 011

ii. Often measurements are given in centimeters and must be converted to millimeters such as: > 1 cm (> 10 mm), code as 011; or > 2 cm (> 20 mm), code as 021

iii. Code 989 when described as anything greater than 989 mm (98.9 cm)

5. Record "between" tumor sizes as the midpoint between the two measurements when tumor size is reported to be between two sizes; i.e., add the two sizes together and divide by two.

Examples: Tumor size is "between 2 and 3 cm." Code size as 025 since 2 + 3 = 5 divided by 2 = 2.5 cm (25 mm).

6. Round decimals: Round the tumor size when it is described in fractions (decimals) of millimeters as follows

Note 1: Record tumor size as 001 (do not round down to 000) when the largest dimension of a tumor is less than 1 millimeter (greater than 0 mm and less than 1 mm).

Note 2: Code 001 when tumor size is 1 mm

a. When tumor size is greater than 1 millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter and round tenths of millimeters in the 5-9 range up to

the nearest whole millimeter.

Examples

Breast cancer described as 6.5 millimeters in size. Round up to 7 mm and code as 007. 2.3 millimeters cancer in a polyp. Round down to 2 mm and code as 002. Focus of cancer described as 1.4 mm in size. Round down to 1 mm and code as 001. 5.2 cm breast cancer. Convert to millimeters (52 mm) and do not round; code as 052 millimeters. 2.5 cm rectal cancer. Do not round, record as 025 millimeters.

b. Do not round tumor size expressed in centimeters to the nearest whole centimeter; rather, convert the measurement to millimeters by moving the decimal point one space to the right

7. Priority of imaging/radiographic techniques: Information on size from imaging/radiographic techniques can be used to code clinical size when there is no more specific size information from a

biopsy or operative (surgical exploration) report. It should be taken as a lower priority, but over a physical exam.

8. Tumor size discrepancies among imaging and radiographic reports: Record the largest size in the record regardless of the imaging technique, when there is a difference in reported tumor size among

imaging and radiographic techniques, unless the physician specifies the imaging that is most accurate.

9. Record size from an incisional biopsy. Use the clinical guidelines for TNM to determine if the biopsy was done during the clinical timeframe. Use the source that gives you the best size and take

the largest size.

Note: An incisional biopsy that removed the whole tumor is actually an excisional biopsy. Record tumor size in Tumor Size – Pathologic.

10. Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis. However, when the tumor is described as a "cystic mass or polypoid mass," and only the

size of the entire mass is given, code the size of the entire mass, since the cysts or polyps are part of the tumor itself.

11. Multifocal/multicentric tumors: Code the size of the largest invasive tumor, or the largest in situ tumor if all tumors are in situ, when the tumor is multifocal or when multiple tumors are reported

as a single primary.

12. Assign tumor size code 999 when size is unknown or not applicable. Hematopoietic,

Reticuloendothelial, and Myeloproliferative neoplasms: histology codes 9590-9992

Kaposi Sarcoma

Melanoma Choroid

Melanoma Ciliary Body

Melanoma Iris

Unknown primary site

13. Document the information in the appropriate text field of the abstract to support the clinical tumor size as coded.

Tumor Size Summary

Organization	Field Name	ID	Required
KCR	Tumor Size Summary (TumorSizeSummary)	30933	yes
NAACCR	Tumor Size Summary	756	yes

Field length: 3

Instructions for Coding

Note: All measurements should be in millimeters (mm).

Record size in specified order:

- 1. Size measured on the surgical resection specimen, when surgery is administered as the first definitive treatment, i.e., no pre-surgical treatment administered.
 - a. If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report (also known as CAP protocol or pathology report checklist). If only a text report is available, use: final diagnosis, microscopic, or gross examination, in that order.
 - Example: Chest x-ray shows 3.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 2.8 cm. Record tumor size as 028 (28 mm).
 - Example: Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record tumor size as 032 (32 mm).
- If neoadjuvant therapy followed by surgery, do not record the size of the pathologic specimen. Code the largest size of tumor prior to neoadjuvant treatment; if unknown code size as 999.
 - Example: Patient has a 2.2 cm mass in the oropharynx; find needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination chemotherapy. Pathologic size after total resection is 2.8 cm. Record tumor size as 022 (22mm).
- 3. If no surgical resection, then largest measurement of the tumor from physical exam, imaging, or other diagnostic procedures prior to any other form of treatment.
- 4. If 1, 2, and 3 do not apply, the largest size from all information available within four months of the date of diagnosis, in the absence of disease progression.

Description	
No mass/tumor found	
1 mm or described as less than 1 mm	
Exact size in millimeters (2mm-988mm)	
989 millimeters or larger	
Microscopic focus or foci only and no size of focus is given	
SITE-SPECIFIC CODES	
Alternate descriptions of tumor size for specific sites:	
Familial/multiple polyposis:	
Rectosigmoid and rectum (C19.9, C20.9)	
Colon (C18.0, C18.2-C18.9)	
If no size is documented:	
Circumferential:	
Esophagus (C15.0-C15.5, C15.8 C15.9)	
Diffuse; widespread: 3/4s or more; linitis plastica:	
Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)	
Diffuse, entire lung or NOS:	
Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)	
Diffuse:	
Breast (C50.0-C50.6, C50.8-C50.9)	

Instructions for Coding

Note: All measurements should be in millimeters (mm). Record size in specified order:

1. Size measured on the surgical resection specimen, when surgery is administered as the first definitive treatment, i.e., no pre-surgical treatment administered.

a. If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report (also known as CAP protocol or

pathology report checklist). If only a text report is available, use: final diagnosis, microscopic, or gross examination, in that order.

Example:

Chest x-ray shows 3.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 2.8 cm. Record tumor size as 028 (28 mm).

Example:

Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record tumor size as 032 (32 mm).

2. If neoadjuvant therapy followed by surgery, do not record the size of the pathologic specimen. Code the largest size of tumor prior to neoadjuvant treatment; if unknown code size as 999.

Example: Patient has a 2.2 cm mass in the oropharynx; find needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination

chemotherapy. Pathologic size after total resection is 2.8 cm. Record tumor size as 022 (22mm).

3. If no surgical resection, then largest measurement of the tumor from physical exam, imaging, or other diagnostic procedures prior to any other form of treatment (See Coding Rules below).

4. If 1, 2, and 3 do not apply, the largest size from all information available within four months of the date of diagnosis, in the absence of disease progression.

Coding Rules:

1. Tumor size is the diameter of the tumor, not the depth or thickness of the tumor.

2. Recording less than/greater than Tumor Size:

a. If tumor size is reported as less than x mm or less than x cm, the reported tumor size should be 1 mm less; for example if size is <10 mm, code size as 009. Often these are given in cm

such as < 1 cm which is coded as 009, < 2 cm is coded as 019, < 3 cm is coded as 029, < 4 cm is coded as 039, < 5 cm is coded as 049. If stated as less than 1 mm, use code 001.

b. If tumor size is reported as more than x mm or more than x cm, code size as 1 mm more; for

example if size is >10 mm, size should be coded as 011. Often these are given in cm such as > 1 cm, which is coded as 011, > 2 cm is coded as 021, > 3 cm is coded as 031, > 4 cm is

coded as 041, > 5 cm is coded as 051. If described as anything greater than 989 mm (98.9 cm) code as 989.

c. If tumor size is reported to be between two sizes, record tumor size as the midpoint between the two: i.e., add the two sizes together and then divide by two ("between 2 and 3 cm" is

coded as 025).

3. Rounding: Round the tumor size only if it is described in fractions of millimeters. If the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9 mm), record size as 001 (do not

round down to 000). If tumor size is greater than 1 millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter, and round tenths of millimeters in the 5-9 range up to the nearest whole millimeter. Do not round tumor size expressed in centimeters to the nearest whole centimeter (rather, move the decimal point one space to the right, converting the measurement to millimeters).

Examples: Breast cancer described as 6.5 millimeters in size. Round up Tumor Size as 007. Cancer in polyp described as 2.3 millimeters in size. Round down Tumor Size as 002. Focus of cancer described as 1.4 mm in size. Round down as 001. 5.2 mm breast cancer. Round down to 5 mm and code as 005.

4. Priority of imaging/radiographic techniques: Information on size from imaging/radiographic techniques can be used to code size when there is no more specific size information from a pathology

or operative report, but it should be taken as low priority, over a physical exam.

5. Tumor size discrepancies among imaging and radiographic reports: If there is a difference in reported tumor size among imaging and radiographic techniques, unless the physician specifies which imaging is most accurate, record the largest size in the record, regardless of which imaging technique reports it.

6. Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis. However, if the tumor is described as a "cystic mass," and only the size of the entire mass

is given, code the size of the entire mass, since the cysts are part of the tumor itself.

7. Record the size of the invasive component, if given.

a. If both an in situ and an invasive component are present and the invasive component is measured, record the size of the invasive component even if it is smaller.

Example: Tumor is mixed in situ and invasive adenocarcinoma, total 3.7 cm in size, of which 1.4 cm is invasive. Record tumor size as 014 (14 mm)

b. If the size of the invasive component is not given, record the size of the entire tumor from the surgical report, pathology report, radiology report or clinical examination.

Example: A breast tumor with infiltrating duct carcinoma with extensive in situ component; total size 2.3 cm. Record tumor size as 023 (23 mm).

Example: Duct carcinoma in situ measuring 1.9 cm with an area of invasive ductal carcinoma. Record tumor size as 019 (19 mm).

8. Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor.

Example: Tumor is described as 2.4 x 5.1 x 1.8 cm in size. Record tumor size as 051 (51 mm).

9. Record the size as stated for purely in situ lesions.

10. Disregard microscopic residual or positive surgical margins when coding tumor size. Microscopic residual tumor does not affect overall tumor size. The status of primary tumor margins may be recorded in a separate data item.

11. Do not add the size of pieces or chips together to create a whole; they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if the

pathologist states an aggregate or composite size (determined by fitting the tumor pieces together and measuring the total size), record that size. If the only measurement describes pieces or chips, record tumor size as 999.

12.Multifocal/multicentric tumors: If the tumor is multi-focal or if multiple tumors are reported as a single primary, code the size of the largest invasive tumor or if all of the tumors are in situ, code the size of the largest in situ tumor.

13.Tumor size code 999 is used when size is unknown or not applicable. Sites/morphologies where tumor size is not applicable are listed here.

Hematopoietic, Reticuloendothelial, and Myeloproliferative neoplasms: histology codes 9590-9992 Kaposi Sarcoma Melanoma Choroid Melanoma Ciliary Body Melanoma Iris

14. Document the information to support coded tumor size in the appropriate text data item of the abstract.

AJCC Staging Edition

Organization	Field Name	ID	Required
KCR	AJCC Staging Edition (TNMEdition)	30940	yes
NAACCR	TNM Edition Number	1060	yes

Field Length: 2

This field describes the edition of the AJCC Cancer Staging Manual used to classify the extent of disease at the time of initial diagnosis and/or first treatment.

Code	Description
00	Not staged (cases that have an AJCC staging scheme and staging was not done)
01	First Edition
02	Second Edition
03	Third Edition
04	Fourth Edition
05	Fifth Edition
06	Sixth Edition
07	Seventh Edition
08	Eighth Edition
88	Not Applicable (cases that do not have an AJCC staging scheme)
99	Staged, but the edition is unknown

cT Classification

Organization	Field Name	ID	Required
KCR	cT Classification (CTStage)	30950	no
NAACCR	TNM Clin T	940	no

Field Length: 4

The clinical T evaluates only the primary tumor and reflects tumor size and/or extension prior to the start of any therapy.

Record the clinical T value as documented by the first treating physician or the managing physician in the medical record. If the managed physician has not recorded clinical T, registrars should code this item based on the best available information, without necessarily requiring additional contact with the physician.

If the value is only one digit, record to the left and leave the remaining spaces blank. Choose the lower (less advanced) T category when there is any uncertainty. Refer to the AJCC Cancer Staging Manual for coding rules.

Code	Definition	Code	Definition	Code	Definition
blank	Not recorded	c1B	cT1b	c3	cT3
cX	cTX	c1B1	cT1b1	c3A	cT3a
c0	cT0	c1B2	cT1b2	c3B	cT3b
pА	рТа	c1C	cT1c	c3C	cT3c
pIS	pTis	c1D	cT1d	c3D	cT3d
pISPU	pTispu	c2	cT2	c4	cT4
pISPD	pTispd	c2A	cT2a	c4A	cT4a
c1MI	cT1mi, cT1 mic	c2A1	cT2a1	c4B	cT4b
c1	cT1	c2A2	cT2a2	c4C	cT4c
c1A	cT1a	c2B	cT2b	c4D	cT4d
c1A1	cT1a1	c2C	cT2c	c4E	cT4e
c1A2	cT1a2	c2D	cT2d	88	Not applicable

cN Classification

Organization	Field Name	ID	Required
KCR	cN Classification (CNStage)	30960	no
NAACCR	TNM Clin N	950	no

Field Length: 4

Clinical N identifies the absence or presence of regional lymph node metastasis and describes the extent of regional node metastases prior to the start of any therapy.

Record the clinical N value as documented by the first treating physician or the managing physician in the medical record. If the managing physician has not recorded clinical N, registrars should code this item based on the best available information, without necessarily requiring additional contact with the physician.

If the value is only one digit, record to the left and leave the second space blank. Choose the lower (less advanced) N category when there is any uncertainty. Refer to the AJCC Cancer Staging Manual for coding rules.

When a primary tumor directly extends into lymph nodes, code as lymph node metastasis.

Code	Definition	Code	Definition
blank	cNot recorded	c1B	cN1b
cX	cNX	c1C	cN1c
c0	cN0	c2	cN2
c0I-	cN0i- (Dx year 2015 and prior)	c2A	cN2a
c0l+	cN0i+ (Dx year 2015 and prior)	c2B	cN2b
c0M-	cN0m- (Dx year 2015 and prior)	c2C	cN2c
c0M+	cN0m+ (Dx year 2015 and prior)	c3	cN3
c1MI	cN1mi (Dx year 2015 and prior)	c3A	cN3a
c0A	cN0a	c2B	cN2b
c0B	cN0b	c3C	cN3c
c1	cN1	c4	cN4
c1A	cN1a	88	Not applicable

cM Classification

Organization	Field Name	ID	Required
KCR	cM Classification (CMStage)	30970	no
NAACCR	TNM Clin M	960	no

Field Length: 4

Clinical M records the presence or absence of distant metastases prior to the start of any therapy.

Record the clinical M value as documented by the first treating physician or the managing physician in the medical record. If the managing physician has not recorded clinical M, registrars should code this item based on the best available information, without necessarily requiring additional contact with the physician.

If the value is only one digit, record to the left and leave the remaining spaces blank. Choose the lower (less advanced) M category when there is any uncertainty. Refer to the AJCC Cancer Staging Manual for coding rules.

Code	Definition
blank	Not recorded
cX (AJCC editions 1-6 only)	cMX (AJCC editions 1-6 only)
c0	МО
c0+	M0+
c1	cM1
c1A	cM1a
c1B	cM1b
c1C	cM1c
c1D	cM1d
c1E	cM1e
p1	рМ1
p1A	pM1a
p1B	pM1b
p1C	pM1c
p1D	pM1d
p1E	pM1e
88	Not applicable

cTNM Stage Group

Organization	Field Name	ID	Required
KCR	cTNM Stage Group (CStageGroup)	30980	yes
NAACCR	TNM Clin Stage Group	970	yes

Field Length: 4

This field identifies the anatomic extent of disease based on the T, N, and M elements known prior to the start of any therapy. Code the clinical TNM stage grouping from the cTNM classification in items 30950-30970, using the AJCC Cancer Staging Manual. Record '88' if the TNM staging system is not appropriate for this site/histology of cancer.

Note: For diagnoses prior to 2004, this field was used to calculate Best Stage Group. It becomes the value in Best Stage Group if the pTNM Stage Group is equal to '88' or '99', or if the pathologic descriptor indicates pre-surgical treatment was administered. After 2004, the CS derived AJCC 6th edition stage group is the Best Stage Group.

Code	Definition	Code	Definition
0	Stage 0	2B	Stage IIB
0A	Stage 0A	2C	Stage IIC
0IS	Stage 0is	3	Stage III
1	Stage I	3A	Stage IIIA
1A	Stage IA	3B	Stage IIIB
1A1	Stage IA1	3C	Stage IIIC
1A2	Stage IA2	3C1	Stage IIIC1
1B	Stage IB	3C2	Stage IIIC2
1B1	Stage IB1	4	Stage IV
1B2	Stage IB2	4A	Stage IVA
1C	Stage IC	4A1	Stage IVA1
1S	Stage IS	4A2	Stage IVA2
2	Stage II	4B	Stage IVB
2A	Stage IIA	4C	Stage IVC
2A1	Stage IIA1	OC	Occult
2A2	Stage IIA2	88	Not applicable
		99	Unknown

cTNM Descriptor

Organization	Field Name	ID	Required
KCR	cTNM Descriptor (CTNMDescriptor)	30990	no
NAACCR	TNM Clin Descriptor	980	no

Field Length: 1

Identifies the AJCC clinical stage (prefix/suffix) descriptor of the tumor prior to the start of any therapy. Stage descriptors identify special cases that need separate analysis. The descriptors are adjuncts to and do not change the stage group. This field may not be left blank for cases diagnosed 1/1/2010 forward.

Instructions for Coding

• Record the clinical stage (prefix/suffix) descriptor as documented by the first treating physician or the managing physician in the medical record.

• If the managing physician has not recorded the descriptor, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.

• If the tumor is not staged according to the AJCC manual, leave this data item blank.

• Refer to the current AJCC Cancer Staging Manual for staging rules.

• Previous editions of FORDS included a code 4 for y-classification, and a note that it was not applicable for clinical stage. Code 4 has been removed from the list of valid codes.

Code	Label	Description
0	None	There are no prefix or suffix descriptors that would be used for this case.
1	E – Extranodal, lymphomas only	A lymphoma case involving an extranodal site.
2	S – Spleen, lymphomas only	A lymphoma case involving the spleen.
3	M – Multiple primary tumors in a single site	This is one primary with multiple tumors in the primary site at the time of diagnosis.
5	E&S – Extranodal and spleen, lymphomas only	A lymphoma case with involvement of both an extranodal site and the spleen.
9	Unknown; not stated in patient record	A prefix or suffix would describe this stage, but it is not known which would be correct.

Staged By - Clinical

Organization	Field Name	ID	Required
KCR	Staged By - Clinical (CStagedBy)	31000	yes
NAACCR	TNM Clin Staged By	990	yes

Field Length: 2

This field identifies the person who clinically staged the case using AJCC TNM.

Code	Description
00	Not staged
10	Physician, NOS, or physician type not specified in 11-15
11	Surgeon
12	Radiation Oncologist
13	Medical Oncologist
14	Pathologist
15	Multiple physicians; tumor board, etc
20	Cancer Registrar
30	Cancer registrar and any physician
40	Nurse, physician assistant, or other non-physician medical staff
50	Staging assigned at another facility
60	Staging by Central Registry including consolidation of multiple sources
88	Case is not eligible for staging
99	Staged but unknown who assigned stage

According to ACoS (from the I&R web site) only codes 1 and 3 meet the criteria for 90% physician staging for the CoC standard.

pT Classification

Organization	Field Name	ID	Required
KCR	pT Classification (PTStage)	31010	no
NAACCR	TNM Path T	880	no

Field Length: 4

The pathologic T field evaluates the primary tumor and reflects tumor size and/or extension following the completion of surgical therapy.

Code the pathologic T as documented by the treating physician(s) or the managing physician in the medical record. If the managing physician has not recorded pathologic T, registrars should code this item based on the best available information, without necessarily requiring additional contact the physician.

If the value is only one digit, record to the left and leave the remaining spaces blank. Choose the lower (less advanced) T category when there is any uncertainty. Refer to the AJCC Cancer Staging Manual for coding rules.

Code	Definition	Code	Definition	Code	Definition
blank	Not recorded	p1B	pT1b	р3	pT3
pХ	рТХ	p1B1	pT1b1	рЗА	pT3a
p0	pT0	p1B2	pT1b2	р3В	pT3b
pА	рТа	p1C	pT1c	p3C	pT3c
pIS	pTis	p1D	pT1d	p3D	pT3d
pISPU	pTispu	p2	pT2	p4	pT4
pISPD	pTispd	p2A	pT2a	p4A	pT4a
p1MI	pT1mi, pT1 mic	p2A1	pT2a1	p4B	pT4b
p1	pT1	p2A2	pT2a2	p4C	pT4c
p1A	pT1a	p2B	pT2b	p4D	pT4d
p1A1	pT1a1	p2C	pT2c	p4E	pT4e
p1A2	pT1a2	p2D	pT2d	88	Not applicable

pN Classification

Organization	Field Name	ID	Required
KCR	pN Classification (PNStage)	31020	no
NAACCR	TNM Path N	890	no

Field Length: 4

Pathologic N identifies the absence or presence of regional lymph nodes metastasis and describes the extent of lymph node metastases following the completion of surgical therapy.

Record the pathologic N value as documented by the treating physician or managing physician in the medical record. If the managing physician has not recorded pathologic N, registrars should code this item based on the best available information, without necessarily requiring additional contact with the physician.

If the value is only one digit, record to the left and leave the remaining spaces blank. Choose the lower (less advanced) N category when there is any uncertainty. Refer to the AJCC Cancer Staging Manual for coding rules.

When a primary tumor directly extends into lymph nodes, code as lymph node metastasis.

Code	Definition	Code	Definition
blank	Not recorded	p1B	pN1b
рХ	pNX	p1C	pN1c
c0	cN0	p2	pN2
p0	pN0	p2A	pN2a
p0I-	pN0i-	p2B	pN2b
p0I+	pN0i+	p2C	pN2c
p0M-	pN0m-	р3	pN3
p0M+	pN0m+	рЗА	pN3a
p1MI	pN1mi	p3B	pN2b
p0A	pN0a	p3C	pN3c
p0B	pN0b	p4	pN4
p1	pN1	88	Not applicable
p1A	pN1a		

pM Classification

Organization	Field Name ID Requ		Required
KCR	pM Classification (PMStage)	31030	no
NAACCR	TNM Path M	900	no

Field Length: 4

Pathologic M records the presence or absence of distant metastases following the completion of surgical therapy.

Record the pathologic M value as documented by the treating physician or managing physician in the medical record. If the managing physician has not recorded pathologic M, registrars should code this item based on the best available information, without necessarily requiring additional contact with the physician.

If the value is only one digit, record it in the space to the left and leave the remaining spaces blank. Choose the lower (less advanced) M category when there is any uncertainty. Refer to the AJCC Cancer Staging Manual for coding rules.

Code	Definition
blank	Not recorded
cX (AJCC editions 1-6 only)	cMX (AJCC editions 1-6 only)
c0	МО
c0+	M0+
c1	cM1
c1A	cM1a
c1B	cM1b
c1C	cM1c
c1D	cM1d
c1E	cM1e
p1	рМ1
p1A	pM1a
p1B	pM1b
p1C	pM1c
p1D	pM1d
p1E	pM1e
88	Not applicable

pTNM Stage Group

Organization	Field Name	ID	Required
KCR	pTNM Stage Group (PStageGroup)	31040	yes
NAACCR	TNM Path Stage Group	910	yes

Field Length: 4

This field identifies the anatomic extent of disease based on the T, N, and M elements known following the completion of surgical therapy. Code the pathologic TNM stage grouping from the pTNM classification in items 31010-31030, using the AJCC Cancer Staging Manual. Record '88' if the site /histology does not have a TNM staging scheme. Choose the lower (less advanced) stage grouping when there is any uncertainty.

Note: For diagnoses prior to 2004, this field was used to calculate Best Stage Group. It becomes the Best Stage, unless the value is '88' or '99,' or presurgical treatment was administered. After 2004, the CS derived AJCC 6th edition stage group is the Best Stage Group.

Code	Definition	Code	Definition
0	Stage 0	2B	Stage IIB
0A	Stage 0A	2C	Stage IIC
0IS	Stage 0is	3	Stage III
1	Stage I	ЗA	Stage IIIA
1A	Stage IA	3B	Stage IIIB
1A1	Stage IA1	3C	Stage IIIC
1A2	Stage IA2	3C1	Stage IIIC1
1B	Stage IB	3C2	Stage IIIC2
1B1	Stage IB1	4	Stage IV
1B2	Stage IB2	4A	Stage IVA
1C	Stage IC	4A1	Stage IVA1
1S	Stage IS	4A2	Stage IVA2
2	Stage II	4B	Stage IVB
2A	Stage IIA	4C	Stage IVC
2A1	Stage IIA1	OC	Occult
2A2	Stage IIA2	88	Not applicable
		99	Unknown

pTNM Descriptor

Organization	Field Name	ID	Required
KCR	pTNM Descriptor (PTNMDescriptor)	31050	no
NAACCR	TNM Path Descriptor	920	no

Field Length: 2

Identifies the AJCC pathologic stage (prefix/suffix) descriptor known following the completion surgical therapy. The descriptors do not change the stage grouping. This field may not be left blank for cases diagnosed 1/1/2010 forward.

Instructions for Coding

• Record the pathologic stage (prefix/suffix) descriptor as documented by the treating physician(s) or the managing physician in the medical record.

• If the managing physician has not recorded the descriptor, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician(s).

- If the tumor is not staged using AJCC rules, leave this data item blank.
- Refer to the current AJCC Cancer Staging Manual for staging rules.

Code	Label	Definition
0	None	There are no prefix or suffix descriptors that would be used for this case.
1	E - Extranodal, lymphomas only	A lymphoma case involving an extranodal site.
2	S - Spleen, lymphomas only	A lymphoma case involving the spleen.
3	M - Multiple primary tumors in a single site	This is one primary with multiple tumors in the organ of origin at the time of diagnosis.
4	Y- Classification after initial multimodality therapy	Neoadjuvant treatment given before staging
5	E&S - Extranodal and spleen involvement, lymphomas only	A lymphoma case with involvement of both an extranodal site and the spleen.
6	M&Y - Multi primary tumors and initial multimodality therapy	A case meeting the parameters of both codes 3 (multiple primary tumors in a single site) and 4 (classification after initial multimodality therapy).
9	Unknown; not stated in patient record	A prefix or suffix would describe this stage, but it is not known which would be correct.

Alt (Ped) Stage Sys

Organization	Field Name	ID	Required
KCR	Alt (Ped) Stage Sys (AltStageBasis)	31070	no
NAACCR	Pediatric Staging System	1130	no

Field Length: 2

Some institutions want to record alternate staging schemes for specified sites of malignancies. These are optional, except for pediatric cases (see below). Some alternate staging systems for specific sites are shown below:

Code	Alternate Staging System	Site/Histology
VA	VA staging scheme	lung - small cell
AW	American/Whitmore	prostate
DM	Dukes (Modified)	colon/rectum
С	Clark's levels	melanoma
JM	Jewett-Marshall	bladder
FI	FIGO	cervix
		uterus/endometrium
		ovary
AA	Ann Arbor	lymphoma in adults
RB	Rai Binet	CLL

Pediatric staging is required for pediatric cases. There is no age limit to define pediatric cases -- it is based on the type of tumor. Codes for pediatric staging systems are:

Code	Description
00	None
01	American Joint Committee on Cancer (AJCC)
02	Ann Arbor
03	Children's Cancer Group (CCSG)
04	Evans
05	General Summary
06	Intergroup Ewings
07	Intergroup Hepatoblastoma
08	Intergroup Rhabdomyosarcoma
09	International System
10	Murphy
11	National Cancer Institute (Pediatric oncology)
12	National Wilms' Tumor Study
13	Pediatric Oncology Group (POG)
14	Reese-Ellsworth
15	SEER Extent of Disease
97	Other
98	Not applicable

99

Alt (Ped) Stage

Organization	Field Name ID Req		Required
KCR	Alt (Ped) Stage (AltStage)	31080	no
NAACCR	Pediatric Stage	1120	no

Field Length: 3

When an alternate staging system is designated in Item 31070, enter the alternate stage as defined by that staging system in this element. The field can contain up to three characters and should be left-justified. Always use ARABIC numerals instead of ROMAN numerals.

EXAMPLES:

Stage	Code
FIGO Stage	IIB should be coded 2B
DUKE'S Stage	CI should be coded CI
Pediatric Staging	IIID (for Wilms' Tumors) should be 3D
	IVS (for neuroblastomas) should be 4S
VA Staging	L = limited; E = extended
Leave blank if not applicable	

Managing Physician

Organization	Field Name	ID	Required
KCR	Managing Physician (MngPhys)	31090	yes
NAACCR	PhysicianManaging	2460	yes

Field Length: 7

(effective 1/1/2007)

This field is provided to record the code number of the physician who is managing this patient's care at your institution.

Coding Instructions:

- Enter the code number assigned to the physician managing this patient for treatment at your institution. Use the physician's Kentucky Medical License Number or codes developed by your institution (for non-KY physicians) to record physicians involved with this case. The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License. A lookup for NPI numbers is available at https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do.
- Do not update this item. Once a managing physician has been designated for this patient, this item should not be changed even if a different managing physician is assigned.
- This field may be left blank for cases diagnosed prior to 1/1/2007.

Primary Surgeon

Organization	Field Name	ID	Required
KCR	Primary Surgeon (Surgeon)	31130	yes
NAACCR	PhysicianPrimary Surg	2480	yes

Field Length: 7

The primary surgeon is responsible for the surgical management of the patient's malignancy. Record the code which identifies the surgeon who performed the most definitive surgical procedure. If definitive surgery was not performed, record the code which identifies the surgeon who performed any non-definitive surgical procedure. If no surgery was performed, code '0000000'. If a surgical procedure was performed by someone other than a surgeon (i.e., a radiation oncologist), code '88888'.

Use the Kentucky Medical License number or your own codes developed for identifying physicians. The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License.

A lookup for NPI numbers is available at https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do.

Once the registrar has identified the primary surgeon, this code should not be changed, even if the patient begins receiving care from another physician.

Medical Oncologist

Organization	Field Name	ID	Required
KCR	Medical Oncologist (MedOnc)	31132	no
NAACCR	Physician 4	2500	no

Field Length: 7

This field is provided to record the code number of the physician who performed the most definitive systemic therapy.

Coding Instructions:

- Enter the code number assigned to the primary medical oncologist. Use the physician's Kentucky Medical License Number or codes developed by your institution (for non-KY physicians) to record physicians involved with this case. The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License. A lookup for NPI numbers is available at https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do.
- Physician License. A lookup for NPI numbers is available at https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do.
 Do not update this item. Once a medical oncologist has been designated for this patient, this item should not be changed even if the patient receives care from another medical oncologist.

Radiation Oncologist

Organization	Field Name	ID	Required
KCR	Radiation Oncologist (RadOnc)	31131	no
NAACCR	Physician 3	2495	no

Field Length: 7

This field is provided to record the code number of the physician who performed the most definitive radiation therapy.

Coding Instructions:

- Enter the code number assigned to the primary radiation oncologist. Use the physician's Kentucky Medical License Number or codes developed by your institution (for non-KY physicians) to record physicians involved with this case. The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License. A lookup for NPI numbers is available at https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do.
- Do not update this item. Once a radiation oncologist has been designated for this patient, this item should not be changed even if the patient receives care from another radiation oncologist.

Staged By - Pathologic

Organization	Field Name	ID	Required
KCR	Staged By - Pathologic (PStagedBy)	31060	yes
NAACCR	TNM Path Staged By	930	yes

Field Length: 2

This field identifies the person who recorded the pathologic AJCC staging elements and the stage group in the patient's medical record.

Code	Description
00	Not staged
10	Physician, NOS, or physician type not specified in 11-15
11	Surgeon
12	Radiation Oncologist
13	Medical Oncologist
14	Pathologist
15	Multiple physicians; tumor board, etc
20	Cancer Registrar
30	Cancer registrar and any physician
40	Nurse, physician assistant, or other non-physician medical staff
50	Staging assigned at another facility
60	Staging by Central Registry including consolidation of multiple sources
88	Case is not eligible for staging
99	Staged but unknown who assigned stage

According to ACoS, on the I&R web site, only codes 1 and 3 meet the criteria for 90% physician staging for the CoC standard.

AJCC TNM Clinical T

Organization	Field Name	ID	Required
KCR	AJCC TNM Clin T(AJCC8TNMClinT)	33150	Yes
AJCC	AJCC TNM Clin T	1001	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical tumor (T) as defined by the current AJCC edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC Cancer Staging Manual)

Code	Description
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.
Blank	Information not available to code this item.

Note: See the AJCC Cancer Staging Manual, 8th edition for site-specific categories for the TNM elements and stage groups. See the CURRENT STORE m anual for specifications for codes and data entry rules.

AJCC TNM Clinical T Suffix

Organization	Field Name	ID	Required
KCR	AJCC TNM Clin T Suffix (AJCC8TNMClinTSfx)	33151	Yes
AJCC	TNM Clin T	1031	Yes

Field length: 4

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical T category suffix as defined by AJCC.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (as published in the AJCC 8th Edition Cancer Staging Manual)

Code	Description
(m)	Multiple synchronous tumors OR For thyroid differentiated and anaplastic only, Multifocal tumor
(s)	For thyroid differentiated and anaplastic only, Solitary tumor
Blank	No information available; not recorded

Note: Refer to the current AJCC 8th Edition Cancer Staging Manual for staging rules.

AJCC TNM Clinical N

Organization	Field Name	ID	Required
KCR	AJCC TNM Clin N (AJCC8TNMClinN)	33152	Yes
AJCC	AJCC TNM Clin N	1002	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical nodes (N) as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC *th edition Cancer Staging Manual)

Code	Descirption
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.
Blank	Information not available to code this item.

Note: See the AJCC 8th edition Cancer Staging Manual, 8th edition for site-specific categories for the TNM elements and stage groups. See the CURRENT STORE manual for specifications for codes and data entry rules.

AJCC TNM Clinical N Suffix

Organization	Field Name	ID	Required
KCR	AJCC TNM Clin N Suffix (AJCC8TNMClinNSuffix)	33153	Yes
AJCC	AJCC TNM Clin N Suffix	1034	Yes

Field length: 4

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical N category suffix as defined by AJCC.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Code	Description
(sn)	Sentinel node procedure with or without FNA or core needle biopsy
(f)	FNA or core needle biopsy only
Blank	No suffix needed or appropriate; not recorded

Note: Refer to the current AJCC 8th edition Cancer Staging Manual for staging rules.

AJCC TNM Clinical M

Organization	Field Name	ID	Required
KCR	AJCC TNM Clin M (AJCC8TNMClinM)	33154	Yes
AJCC	AJCC TNM Clin M	1003	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical metastases (M) as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC Cancer Staging Manual)

Code Description	
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.
Blank	Information not available to code this item.

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM elements and stage groups. See the CURRENT STORE m anual for specifications for codes and data entry rules.

AJCC TNM Clinical Stage Group

Organization	Field Name	ID	Required
KCR	AJCC TNM Clin Stage Group (AJCC8TNMCStgGrp)	33155	Yes
AJCC	AJCC TNM Clin Stage Group	1004	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical stage group as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC 8th edition Cancer Staging Manual)

Code	Description	
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.	
99	Unknown, not staged	

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM elements and stage groups. See the CURRENT STORE m anual for specifications for codes and data entry rules.

AJCC TNM Pathological T

Organization	Field Name	ID	Required
KCR	AJCC TNM PathT(AJCC8TNMPathT)	33156	Yes
AJCC	AJCC TNM Path T	1011	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the pathologic tumor (T) as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC Cancer Staging Manual)

Code	Description	
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.	
Blank	Information not available to code this item.	

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM elements and stage groups. See the CURRENT STORE m anual for specifications for codes and data entry rules.

AJCC TNM Pathological T Suffix

Organization	Field Name	ID	Required
KCR	AJCC TNM Path T Suffix (AJCC8TNMPathTSfx)	33157	Yes
AJCC	AJCC TNM Path T	1032	Yes

Field length: 4

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the pathological T category suffix as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (as published in the AJCC 8th edition Cancer Staging Manual)

Code	Description	
(m)	Multiple synchronous tumors OR For thyroid differentiated and anaplastic only, Multifocal tumor	
(s)	For thyroid differentiated and anaplastic only, Solitary tumor	
Blank	No information available; not recorded	

Note: Refer to the current AJCC 8th edition Cancer Staging Manual for staging rules.

AJCC TNM Pathological N

Organization	Field Name	ID	Required
KCR	AJCC TNM Path N (AJCC8TNMCPathN)	33158	Yes
AJCC	AJCC TNM Path N	1012	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the pathologic nodes (N) as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC Cancer Staging Manual)

Code	Description	
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.	
Blank	Information not available to code this item.	

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM elements and stage groups. See the CURRENT S TORE manual for specifications for codes and data entry rules.

AJCC TNM Pathological N Suffix

Organization	Field Name	ID	Required
KCR	AJCC TNM Path N Suffix (AJCC8TNMPathNSuffix)	33159	Yes
AJCC	AJCC TNM Path N Suffix	1035	Yes

Field length: 4

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the pathological N category suffix as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Code	Description
(sn)	Sentinel node procedure without resection of nodal basin
(f)	FNA or core needle biopsy without resection of nodal basin
Blank	No suffix needed or appropriate; not recorded

AJCC TNM Pathological M

Organization	Field Name	ID	Required
KCR	AJCC TNM Path M (AJCC8TNMPathM)	33160	Yes
AJCC	AJCC TNM Path M	1013	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the clinical path (M) as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC 8th edition Cancer Staging Manual)

Code	Code Description 88 Not applicable, no code assigned for this case in the current AJCC 8th edition Staging Man	
88		
Blank Information not available to code this item.		

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM elements and stage groups. See the CURRENT STORE m anual for specifications for codes and data entry rules.

AJCC TNM Pathological Stage Group

Organization	Field Name	ID	Required
KCR	AJCC TNM Path Stage Group (AJCC8TNMPStgGrp)	33161	Yes
AJCC	AJCC TNM Path Stage Group	1014	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the pathologic stage group as defined by the current AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (in addition to those published in the AJCC Cancer Staging Manual)

Code		
88		
99	Unknown, not staged	

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM elements and stage groups. See the CURRENT S TORE manual for specifications for codes and data entry rules.

AJCC TNM Post Therapy T

Organization	Field Name	ID	Required
KCR	AJCC TNM Post Therapy T (AJCC8TNMPostTxT)	33162	Yes
AJCC	AJCC TNM Post Therapy T	1021	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the postneoadjuvant therapy tumor (T) as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection.

Codes (in addition to those published in the AJCC 8th edition Cancer Staging Manual)

Code	Description
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.
Blank	This field is left blank if no information at all is available to code this item.

Note: See the AJCC 8th edition Cancer Staging Manual, current edition for site-specific categories for the TNM categories and stage groups. See the CURRENT *STORE* manual for specifications for codes and data entry rules.

AJCC TNM Post Therapy T Suffix

Organization	Field Name	ID	Required
KCR	AJCC TNM Post Therapy T Suffix (AJCC8TNMPostTxTSfx)	33163	Yes
AJCC	TNM Post Therapy T Suffix	1033	Yes

Field length: 4

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the postneoadjuvant therapy T category suffix as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Codes (as published in the AJCC 8th edition Cancer Staging Manual)

Code	Description
(m)	Multiple synchronous tumors OR For thyroid differentiated and anaplastic only, Multifocal tumor
(s)	For thyroid differentiated and anaplastic only, Solitary tumor
Blank	No information available; not recorded

Note: Refer to the current AJCC 8th edition Cancer Staging Manual for staging rules.

AJCC TNM Post Therapy N

Organization	Field Name	ID	Required
KCR	AJCC TNM Post Therapy N (AJCC8TNMPostTxN)	33164	Yes
AJCC	AJCC TNM Post Therapy N	1022	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the postneoadjuvant therapy nodes (N) as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of lymph node metastasis of the tumor known known following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection.

Codes (in addition to those published in the AJCC Cancer Staging Manual)

Code	Description
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.
Blank	This field is left blank if no information at all is available to code this item.

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM categories and stage groups. See the CURRENT STORE manual for specifications for codes and data entry rules.

AJCC TNM Post Therapy N Suffix

Organization	Field Name	ID	Required
KCR	AJCC TNM Post Therapy N Suffix (AJCC8TNMPostTxNSuffix)	33165	Yes
AJCC	AJCC TNM Post Therapy N Suffix	1036	Yes

Field length: 4

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the postneoadjuvant therapy N category suffix as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Code	Description
(sn)	Sentinel node procedure without resection of nodal basin
(f)	FNA or core needle biopsy without resection of nodal basin
Blank	No suffix needed or appropriate; not recorded

AJCC TNM Post Therapy M

Organization	Field Name	ID	Required
KCR	AJCC TNM Post Therapy M (AJCC8TNMPostTxM)	33166	Yes
AJCC	AJCC TNM Post Therapy M	1023	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the postneoadjuvant therapy category metastases (M) as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

M category for postneoadjuvant therapy staging remains the same as that assigned in the clinical stage before initiation of neoadjuvant therapy, cM or pM.

Codes (in addition to those published in the AJCC 8th edition Cancer Staging Manual)

Code	Description
88	Not applicable, no code assigned for this case in the current AJCC Staging Manual.
Blank	This field is left blank if no information at all is available to code this item.

Note :See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM categories and stage groups. See the CURRENT STORE manual for specifications for codes and data entry rules.

AJCC TNM Post Therapy Stage Group

Organization	Field Name	ID	Required
KCR	AJCC TNM Post Therapy Stage Group (AJCC8TNMPostTxStgGrp)	33167	Yes
AJCC	AJCC TNM Post Therapy Stage Group	1024	Yes

Field length: 15

This field will be used for cases 01/01/2018 and forward.

Description

Detailed site-specific codes for the postneoadjuvant therapy stage group as defined by AJCC 8th edition.

Rationale

CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

Identifies the remaining anatomic extent of disease based on the T and N following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection, and the M status defined during the diagnostic workup.

Codes (in addition to those published in the AJCC 8th edition Cancer Staging Manual)

Code	Description
88	Not applicable, no code assigned for this case in the current AJCC 8th edition Staging Manual.
99	Unknown, not staged

Note: See the AJCC 8th edition Cancer Staging Manual for site-specific categories for the TNM categories and stage groups. See the CURRENT STORE manual for specifications for codes and data entry rules.

Admin NoTx

- ACOS Coding Original
- Type of Reporting Src
 Abstracted By

- Abstracted By
 ACOS Coding Current
 Reason No Therapy (Non-def Surg)
 Reason No Therapy (Surg)
- Reason No Therapy (Chemo)
- Reason No Therapy (Rad)
 Reason No Therapy (Horm)
- Reason No Therapy (Inom)
 Reason No Therapy (Immuno)
 Reason No Therapy (Trans)
 Reason No Therapy (Other)
 Tx Follow-back Needed

- Systemic Therapy/Surg Seq
- Radiation/Surgery Sequence
 Treatment Status
- Date No First Therapy
- Tx Start Date (ACOS)
 Tx Composite (First)
- Tx Composite (All)
- QA Review Status
- Central Review Status
 Date Case Completed CoC

ACOS Coding Original

Organization	Field Name	ID	Required
KCR	ACOS Coding Original (ACOSCoding)	31150	yes
NAACCR	CoC Coding SysOriginal	2150	yes

Field Length: 2

Record the two-digit code which identifies the coding scheme of the American College of Surgeons used when originally abstracting this case.

Code	Description
00	No CoC coding system used
01	Pre-1988 (Cancer Program Manual Supplement)
02	1988 Data Acquisition Manual
03	1989 Data Acquisition Manual Revisions
04	1990 Data Acquisition Manual Revisions
05	1994 Data Acquisition Manual (Interim/Revised)
06	ROADS (effective with cases diagnosed 1996-1997)
07	ROADS and 1998 Supplement (effective with cases diagnosed 1998-2002)
08	FORDS (effective with cases diagnosed 2003-2017)
99	Original CoC coding system is not known
09	STORE (effective with cases diagnosed 2018 and forward)

Type of Reporting Src

Organization	Field Name	ID	Required
KCR	Type of Reporting Src (TypeRptSrc)	31170	yes
NAACCR	Type of Reporting Source	500	yes

Field Length: 1

The Type of Reporting Source identifies the source documents used to abstract the case. This is not necessarily the original document that identified the case; rather, it is the source that provided the best information.

Code	Description	
1	Hospital inpatient; Managed health plans with comprehensive, unified medical records (new code definition effective with diagnosis on or after 1/1/2006)	
2	Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent) (effective with diagnosis on or after 1/1/2006)	
3	Laboratory only (hospital-affiliated or independent)	
4	Physician's Office/Private Medical Practitioner (LMD)	
5	Nursing/Convalescent Home/Hospice	
6	Autopsy only	
7	Death Certificate only	
8	Other hospital outpatient units/surgery centers (effective with diagnosis on or after 1/1/2006)	

Definitions

Managed health plan: HMO or other health plan (e.g. Kaiser, Veterans Administration, military facilities) in which all diagnostic and treatment information is maintained centrally (in a unit record) and is available to the abstractor.

Physician office: Examinations, tests and limited surgical procedures may be performed in a physician office. If called a surgery center, but cannot perform surgical procedures under general anesthesia, code as a physician office.

Serial record: The office or facility stores information separately for each patient encounter.

Surgery center: Surgery centers are equipped and staffed to perform surgical procedures under general anesthesia. Patient does not stay overnight.

Unit record: The office or facility stores information for all of a patient's encounters in one record with one record number.

Priority Order for Assigning Type of Reporting Source

When multiple source documents are used to abstract a case, use the following priority order to assign a code for Type of Reporting Source:

Priority order of codes

1, 2, 8, 4, 3, 5, 6, 7

Note: Beginning with cases diagnosed 1/1/2006, the definitions for this field have been expanded. Codes 2 and 8 were added to identify outpatient sources that were previously grouped under code 1. Laboratory reports now have priority over nursing home reports. The source facilities included in the previous code 1 (hospital inpatient and outpatient) are split between codes 1, 2, and 8. No changes were made to the field for cases already existing in the cancer registry database diagnosed prior to January 1, 2006.

Code Definitions

Code	Label	Source Documents	Priority
1	Hospital inpatient: Managed health plans with comprehensive, unified medical records	-Hospital inpatient -Offices/facilities with unit record -HMO physician office or group -HMO affiliated free-standing laboratory, surgery, radiation or oncology clinic	1

2	Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent)	-Facilities with serial record (not a unit record)	2
		-Radiation treatment centers	
		-Medical oncology centers (hospital affiliated or independent)	
		There were no source documents from code 1.	
3	Laboratory Only (hospital-affiliated or independent)	-Laboratory with serial record (not a unit record)	5
		There were no source documents from codes 1, 2, 8, or 4.	
4	Physician's Office/Private Medical Practitioner (LMD)	-Physician's office that is NOT an HMO or large multi-specialty physician group practice.	4
		There were no source documents from codes 1, 2, or 8.	
5	Nursing/Convalescent Home/ Hospice	-Nursing or convalescent home or a hospice.	6
		There were no source documents from codes 1, 2, 8, 4, or 3.	
6	Autopsy Only	-Autopsy	7
		The cancer was first diagnosed on autopsy.	
		There are no source documents from codes 1, 2, 8, 4, 3, or 5.	
7	Death Certificate Only	-Death Certificate	8
		Death Certificate is the only source of information; follow-back activities did not identify source documents from codes 1, 2, 8, 4, 3, 5, or 6. If another source document is subsequently identified, the Type of Reporting Source code must be changed to the appropriate code in the range of 1, 2, 8, 4, 3, or 6.	
8	Other hospital outpatient units/surgery centers	-Other hospital outpatient units/surgery centers.	3
		Includes, but not limited to, outpatient surgery and nuclear medicine services.	
		There are no source documents from codes 1 or 2.	

Abstracted By

Organization	Field Name	ID	Required
KCR	Abstracted By (AbstractedBy)	31140	yes
NAACCR	Abstracted By	570	yes

Field Length: 2

Record the initials or a two-digit code which identifies the person in your facility who abstracted this case.

ACOS Coding Current

	Organization	Field Name	ID	Required
к	CR	ACOS Coding Current (ACOSCodingCur)	31160	yes
Ν	IAACCR	CoC Coding SysCurrent	2140	yes

Field Length: 2

Record the two-digit code to identify the coding scheme of the American College of Surgeons in which the data are currently stored.

Cases diagnosed from January 1, 2018 and after should be coded 09 for STORE manual.

Reason No Therapy (Non-def Surg)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Non-def Surg) (ReasonNoNonDefSurg)	31175	yes

Field Length: 1

This item records the reason no non-definitive surgical procedure was performed as part of the initial diagnostic work up. If non-definitive surgery was performed and the pathology specimen was diagnostic of malignancy (code 1), a non-definitive surgical therapy record must be created for the earliest positive non-definitive surgical procedure.

NOTE: For this field, record only biopsies which obtain tissue (whether positive or negative for malignancy). Fine needle aspirations (which obtain only cells, not tissue) of the primary tumor or of a metastatic site are not recorded, whether positive or negative. FNA's of regional lymph nodes are recorded as surgical therapies, in the item "Scope of Regional Lymph Node Surgery). Please see item #50090 for further instruction regarding non-definitive surgery.

Code	Description
0	Non-definitive surgery not performed; not applicable; or not recommended for this case. Autopsy only.
1	Non-definitive surgery performed and results diagnostic of malignancy
2	Non-definitive surgery performed but results negative
3	Non-definitive surgery performed and results turned out to be definitive tx (excisional bx)
8	No non-definitive surgery at this hospital, unknown if done elsewhere
9	Unknown if non-definitive surgery performed

Reason No Therapy (Surg)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Surg) (ReasonNoSurg)	31180	yes
NAACCR	Reason For No Surgery	1340	yes

Field Length: 1

Using the codes below, record the reason there was no cancer-directed Surgery of the Primary Site as part of first course treatment.

Code	Description	
0	Surgery performed. Surgery of the Primary Site is coded 10-90.	
1	Surgery not performed because not part of planned 1st course therapy. Assign code 1 when:	
	a. There is no information in the patient's medical record about surgery	
	AND	
	i. It is known that surgery is not usually performed for this type and/or stage of cancer OR	
	ii. There is no reason to suspect that the patient would have had surgery.	
	iii. Reason No Surgery must be coded '1' when the primary site is C42.0, C42.1, C42.3, C42.4, C76.0-C76.8, C80.9 OR when the histology code is one of these: 9750, 9760-9764, 9800-9820, 9826, 9831-9897, 9910-9920, 9931-9964, or 9980-9989.	
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include surgery, or if the option of no treatment was accepted by the patient.	
	c. Patient elects to pursue no treatment following the discussion of surgery treatment. Discussion does not equal a recommendation.	
	d. Only information available is that the patient was referred to a surgeon. Referral does not equal a recommendation.	
	e. Watchful waiting (prostate) is the treatment plan.	
	f. If the patient was diagnosed at autopsy.	
2	Surgery not recommended or performed contraindicated due to patient risk factors (age, comorbid condition, etc).	
5	Surgery planned but patient died prior to treatment.	
6	Reason unknown for no surgery. Surgery would have been the treatment of choice, but no surgery was performed and the reason is not given.	
7	Patient or patient's guardian refused surgery.	
8	Surgery recommended, unknown if done.	
9	Unknown if surgery recommended or performed, diagnosed at autopsy or death certificate only cases.	

Reason No Therapy (Chemo)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Chemo) (ReasonNoChemo)	31190	yes

Field Length: 1

Using the codes below, record the reason there was no chemotherapy administered as part of first course treatment.

Code	Description	
0	Chemotherapy was not administered because it was not part of the planned first course treatment. Use code 0 when:	
	a. There is no information in the patient's medical record about chemotherapy AND	
	i. It is known that chemotherapy is not usually performed for this type and/or stage of cancer OR	
	ii. There is no reason to suspect that the patient would have had chemotherapy.	
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include chemotherapy, or if the option of no treatment was accepted by the patient.	
	c. Patient elects to pursue no treatment following the discussion of chemotherapy treatment. Discussion does not equal a recommendation.	
	d. Only information available is that the patient was referred to an oncologist.	
	Referral does not equal a recommendation.	
	e. Watchful waiting is the planned course of treatment.	
	f. Patient was diagnosed at autopsy.	
1	Chemotherapy was administered.	
2	Chemotherapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, etc.).	
5	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.	
6	Chemotherapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.	
7	Chemotherapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.	
8	Chemotherapy was recommended, but it is unknown whether it was administered.	
9	It is unknown if chemotherapy was recommended or administered, or death certificate only cases.	

Reason No Therapy (Rad)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Rad) (ReasonNoRad)	31200	yes
NAACCR	Reason For No Radiation	1430	yes

Field Length: 1

Using the codes below, record the reason there was no radiotherapy administered as part of first course treatment.

Code	Description
0	Radiation therapy was not administered because it was not part of the planned first course treatment. Use code 0 when:
	a. There is no information in the patient's medical record about radiation AND
	i. It is known that radiation is not usually performed for this type and/or stage of cancer OR
	ii. There is no reason to suspect that the patient would have had radiation.
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include radiation, or if the option of no treatment was accepted by the patient.
	c. Patient elects to pursue no treatment following the discussion of radiation treatment. Discussion does not equal a recommendation.
	d. Only information available is that the patient was referred to a radiation oncologist. Referral does not equal a recommendation.
	e. Watchful waiting (prostate).
	f. If diagnosed at autopsy
1	Radiation therapy was administered.
2	Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, etc.).
5	Radiation therapy was not administered because the patient died prior to planned or recommended therapy.
6	Radiation therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.
7	Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Radiation therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if radiation therapy was recommended or administered. Death certificate and autopsy cases only.

Reason No Therapy (Horm)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Horm) (ReasonNoHorm)	31210	yes

Field Length: 1

Using the codes below, record the reason there was no hormone therapy administered as part of first course treatment.

Code	Description		
0	Hormone therapy was not administered because it was not part of the planned first course treatment. Use code 0 when:		
	a. There is no information in the patient's medical record about hormone therapy AND		
	i. It is known that hormone therapy is not usually performed for this type and/or stage of cancer OR		
	ii. There is no reason to suspect that the patient would have had hormone treatment.		
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include hormone therapy, or if the option of no treatment was accepted by the patient.		
	c. Patient elects to pursue no treatment following the discussion of hormone treatment. Discussion does not equal a recommendation.		
	d. Only information available is that the patient was referred to an oncologist.		
	Referral does not equal a recommendation.		
	e. Watchful waiting is the only planned treatment.		
	f. Patient was diagnosed at autopsy.		
1	Hormone therapy was administered.		
2	Hormone therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, etc.).		
5	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.		
6	Hormone therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.		
7	Hormone therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.		
8	Hormone therapy was recommended, but it is unknown whether it was administered.		
9	It is unknown if hormone therapy was recommended or administered. Death certificate only cases.		

Reason No Therapy (Immuno)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Immuno) (ReasonNoImmuno)	31220	yes

Field Length: 1

Using the codes below, record the reason there was no immunotherapy administered as part of first course treatment.

Code	Description		
0	Immunotherapy was not administered because it was not part of the planned first course treatment. Use code 0 when:		
	a. There is no information in the patient's medical record about immunotherapy AND		
	i. It is known that immunotherapy is not usually performed for this type and/or stage of cancer OR		
	ii. There is no reason to suspect that the patient would have had immunotherapy.		
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include immunotherapy, or if the option of no treatment was accepted by the patient.		
	c. Patient elects to pursue no treatment following the discussion of immunotherapy. Discussion does not equal a recommendation.		
	d. Only information available is that the patient was referred to an oncologist.		
	Referral does not equal a recommendation.		
	e. Watchful waiting is the only planned treatment.		
	f. Patient was diagnosed at autopsy.		
1	Immunotherapy was administered.		
2	Immunotherapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, etc.).		
5	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.		
6	Immunotherapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.		
7	Immunotherapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.		
8	Immunotherapy was recommended, but it is unknown whether it was administered.		
9	It is unknown if immunotherapy was recommended or administered, or death certificate only cases.		

Reason No Therapy (Trans)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Trans) (ReasonNoTrans)	31230	yes

Field Length: 1

Using the codes below, record the reason there was no transplant or endocrine procedures administered as part of first course treatment.

Code	Description		
0	This therapy type was not administered because it was not part of the planned first course treatment. Use code 0 when:		
	a. There is no information in the patient's medical record about transplants or endocrine surgery AND		
	i. It is known that these procedures are not usually performed for this type and/or stage of cancer OR		
	ii. There is no reason to suspect that the patient would have had these procedures.		
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include transplant or endocrine surgery, or if the option of no treatment was accepted by the patient.		
	c. Patient elects to pursue no treatment following the discussion of transplant or endocrine procedures. Discussion does not equal a recommendation.		
	d. Only information available is that the patient was referred to a transplant or endocrine surgeon. Referral does not equal a recommendation.		
	e. Watchful waiting is the only planned treatment.		
	f. Patient was diagnosed at autopsy.		
1	This therapy type was administered.		
2	This therapy type was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, etc.)		
5	This therapy type was not administered because the patient died prior to planned or recommended therapy.		
6	This therapy type was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.		
7	This therapy type was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.		
8	This therapy type was recommended, but it is unknown whether it was administered.		
9	It is unknown if this therapy type was recommended or administered. Death certificate only cases.		

Reason No Therapy (Other)

Organization	Field Name	ID	Required
KCR	Reason No Therapy (Other) (ReasonNoOther)	31240	yes

Field Length: 1

Using the codes below, record the reason there was no other therapy administered as part of first course treatment.

Code	Description
0	Other therapy was not administered because it was not part of the planned first course treatment. Use code 0 when:
	a. There is no information in the patient's medical record about other therapy AND
	i. It is known that other therapy is not usually performed for this type and/or stage of cancer OR
	ii. There is no reason to suspect that the patient would have had other therapy.
	b. If the treatment plan offered multiple treatment options and the patient selected treatment that did not include these other therapies.
	c. Patient elects to pursue no treatment following the discussion of other types of treatment. Discussion does not equal a recommendation.
	d. Only information available is that the patient was referred to an oncologist. Referral does not equal a recommendation.
	e. Watchful waiting is the only planned treatment.
	f. Patient was diagnosed at autopsy.
1	Other therapy was administered.
2	Other therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, etc.).
5	Other therapy was not administered because the patient died prior to planned or recommended therapy.
6	Other therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.
7	Other therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Other therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if other therapy was recommended or administered. Death certificate only cases.

Tx Follow-back Needed

Organization	Field Name	ID	Required
KCR	Tx Follow-back Needed (TxFollowBackNeeded)	31245	no

Field length: 1

Code	Description
0	No
1	Yes

Systemic Therapy/Surg Seq

Organization	Field Name	ID	Required
KCR	Systemic Therapy/Surg Seq (SysSurgSeq)	31250	yes
NAACCR	RX SummSystemic/Sur Seq	1639	yes

Field Length: 1

This field only applies to cases diagnosed on or after January 1, 2006. It records the sequence of systemic therapy and surgical procedures given as part of first course treatment. Systemic therapy includes any chemotherapy, hormone therapy, immunotherapy, transplants or endocrine surgeries. Surgical procedures include any surgery at the primary site, surgery of regional lymph nodes, or surgery at other regional or distant sites. It does not include non-definitive surgeries such as incisional biopsies or bypass surgeries.

Code the administration of systemic therapy in sequence with the first surgery performed. The sequence of systemic therapy and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. If the systemic therapy and surgery were administered on the same day, any code 2-9 could be appropriate. If there was no systemic therapy given or no definitive surgery performed, or if it unknown whether the patient received both surgery and systemic therapy, then code '0'. Code 0 for DCO cases.

Code	Label	Definition
0	No systemic therapy and/or surgical procedures	No systemic therapy was given; and/or no surgical procedure of primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site (s), or distant lymph node(s); or no reconstructive surgery was performed, or it is unknown whether both surgery and systemic treatment were provided; or case diagnosed at autopsy.
2	Systemic therapy before surgery	Systemic therapy was given before surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
3	Systemic therapy after surgery	Systemic therapy was given after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
4	Systemic therapy both before and after surgery	At least two courses of systemic therapy were given before and at least two more after a surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
5	Intraoperative systemic therapy	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative systemic therapy with other therapy administered before or after surgery	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) with other systemic therapy administered before or after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
7	Surgery both before and after systemic therapy	Systemic therapy was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Both surgery and systemic therapy were provided, but the sequence of treatments not stated or unknown; or death certificate only case.

Radiation/Surgery Sequence

Organization	Field Name	ID	Required
KCR	Radiation/Surgery Sequence (RadSurgSeq)	31251	yes
NAACCR	RX SummSurg/Rad Seq	1380	yes

Field Length: 1

For cases diagnosed prior to January 1, 2010, this field is automatically calculated by CPDMS.net.

This field records the sequencing of radiation and surgical procedures given as part of the first course of treatment. Surgical procedures include Surgical Procedure at Primary Site, Scope of Regional Lymph Node Surgery, and Surgical Procedure/Other Site. If no surgical procedures were performed, or if it is not known whether the patient received both surgery and radiation, this item should be coded 0. Code 0 for DCO cases.

Code	Label	Definition
0	No radiation therapy and/or surgical procedures	No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node (s), or it is unknown whether any surgery given.
2	Radiation therapy before surgery	Radiation therapy given before surgery to primary site, regional lymph node surgery, or surgery to other regional site(s), distant site(s), or distant lymph node(s).
3	Radiation therapy after surgery	Radiation therapy given after surgery to primary site, regional lymph node surgery, or surgery to other regional site(s), distant site(s), or distant lymph node(s).
4	Radiation therapy both before and after surgery and after surgery to the site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant node(s).	
5	Intraoperative radiation therapy	Intraoperative radiation therapy was administered during surgery to primary site, regional lymph node surgery, or surgery to other regional site(s), distant site(s), or distant lymph node(s).
therapy with other radiation to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy		Intraoperative radiation therapy given during surgery to primary site, regional lymph node surgery, or surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site, regional lymph node surgery, or surgery to other regional site(s), distant site(s), or distant lymph node surgery, or surgery to other regional site(s), distant site(s), distant site(s), or distant lymph node surgery, or surgery to other regional site(s), distant site(s), distant site(s), or distant lymph node(s).
7	Surgery both before and after radiation	Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
		Administration of radiation therapy and surgery to primary site, regional lymph node surgery, or surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed but the sequence of the treatment is not stated in the patient record.

Treatment Status

Organization	Field Name	ID	Required
KCR	Treatment Status (TreatmentStatus)	31255	yes
NAACCR	RX SummTreatment Status	1285	yes

Field Length: 1

This data item summarizes whether the patient received any treatment or if the tumor was under active surveillance. It is mandatory for cases diagnosed January 1, 2010 onward, but may be left blank for case diagnosed prior to 2010.

Treatment given after a period of active surveillance is considered subsequent treatment and is not coded in this item.

Code	Description	
0 No treatment given 1 Treatment given		
		2Active surveillance (watchful wat9Unknown if treatment was given

Examples

Code	Code Reason	
0 An elderly patient with pancreatic cancer requested no treatment		
 Patient is expected to receive radiation, but it has not occurred Treatment plan for a lymphoma patient is active surveillance. 		

Coding Instructions

- 1. Assign code 1 when the patient receives treatment collected in any of the following fields
- a. Surgery of primary site
- b. Scope of regional lymph node surgery
- c. Surgical procedure of other site
- d. Radiation
- e. Chemotherapy
- f. Hormone therapy
- g. Immunotherapy
- h. Hematologic transplant and endocrine procedures
- i. Other therapy
- 2. Assign code 9 for death certificate only (DCO) cases
- 3. Leave blank for cases diagnosed prior to January 1, 2010

Date No First Therapy

Organization	Field Name	ID	Required
KCR	Date No First Therapy (DateNoFirstTx)	31260	no

Field Length: 8

This field should be filled in when the calculated Treatment Start Date (ACoS) is blank.

If the physician decides not to treat the patient, record the date of this decision as Date No First Therapy. If the patient or guardian refuses treatment, record the date of this decision. For autopsy only cases, record the date of death. If the patient was diagnosed at the reporting facility and no further information is available, record the date the patient was last seen at the reporting facility. Code '99999999' when it is unknown if any treatment was given, or if the date cannot be reasonably estimated.

This means no first course definitive treatment of any type was administered to any site (primary, regional or distant).

Tx Start Date (ACOS)

Organization	Field Name	ID	Required
KCR	Tx Start Date (ACOS) (ACOSTxStartDate)	31270	no
NAACCR	Date 1st Crs RX CoC	1270	no

Field Length: 8

The treatment start date is a case level data item that is calculated by the computer for all records that are entered as a full Abstract Form. It is the date of the initiation of first course definitive therapy for this cancer. The calculation reviews all treatment types except N, including surgeries at regional and distant sites, to determine the earliest start date. If there was no definitive first course therapy recorded, this field will be blank. If the Treatment Start Date =

clank>, then the Date of No First Therapy must be filled in.

Tx Composite (First)

Organization	Field Name	ID	Required
KCR	Tx Composite (First) (TxCompFrst)	31280	no

Field Length: 2

The treatment composite code is a case level data item that will allow you to select and analyze groups of patients based on the therapy they received.

This code will be calculated from the therapy records marked First Course that are stored for the case, and the codes will be defined as they are for the Therapy Report. Surgeries at regional and distant sites will not be considered surgical treatment for this calculation.

Code	Description
00	No Definitive Therapy or Surgery at Regional and/or Distant Sites only
01	Surgery at Primary Site Only
02	Chemotherapy Only
03	Surgery at Primary Site/Chemotherapy
04	Radiation Therapy Only
05	Surgery at Primary Site/Radiation Therapy
06	Chemotherapy/Radiation Therapy
07	Surgery at Primary Site/Chemo/Radiation Therapy
08	Other Therapy Only
09	Surgery at Primary Site/Other Therapy
10	Chemotherapy/Other Therapy
11	Surgery at Primary Site/Chemo/Other Therapy
12	Radiation/Other Therapy
13	Surgery at Primary Site/Radiation/Other Therapy
14	Chemo/Radiation/Other Therapy
15	Surgery at Primary Site/Chemo/Radiation/Other Therapy
64	Unknown if or what therapy received.

Tx Composite (All)

Organization	Field Name	ID	Required
KCR	Tx Composite (All) (TxCompAll)	31290	no

Field Length: 2

The treatment composite code is a case level data item that will allow you to select and analyze groups of patients based on the therapy they received.

This code will be calculated from the all therapy records (First and Subsequent Course) that are stored for the case, and the codes will be defined as they are for the Therapy Report. Surgeries at regional and distant sites will not be considered surgical treatment for this calculation.

Code	Description
00	No Definitive Therapy or Surgery at Regional and/or Distant Sites only
01	Surgery at Primary Site Only
02	Chemotherapy Only
03	Surgery at Primary Site/Chemotherapy
04	Radiation Therapy Only
05	Surgery at Primary Site/Radiation Therapy
06	Chemotherapy/Radiation Therapy
07	Surgery at Primary Site/Chemo/Radiation Therapy
08	Other Therapy Only
09	Surgery at Primary Site/Other Therapy
10	Chemotherapy/Other Therapy
11	Surgery at Primary Site/Chemo/Other Therapy
12	Radiation/Other Therapy
13	Surgery at Primary Site/Radiation/Other Therapy
14	Chemo/Radiation/Other Therapy
15	Surgery at Primary Site/Chemo/Radiation/Other Therapy
64	Unknown if or what therapy received.

QA Review Status

Organization	Field Name	ID	Required
KCR	QA Review Status (QAReview)	31300	no

Field Length: 1

Record the one digit code for the type of coding review performed on this abstract.

Code	Description
1	Physician reviewed abstract
2	Registrar reviewed abstract
3	User defined
4	User defined
5	User defined
6	User defined

Central Review Status

Organization	Field Name	ID	Required
KCR	Central Review Status (CentralReview)	31310	no

Field Length: 1

This field is reserved for KCR use only. It is used to monitor the number and type of reviews performed by KCR staff. Record the one digit code for the type of coding review performed on this abstract.

Code	Description	
1	Complete review of abstract	
2	Selected fields reviewed	
3	Case selected for re-abstracting audit	
4	Both complete review and selected for audit	
5	Both selected fields reviewed and selected for audit	
6	Selected and reviewed for special study	
7	Selected for a special study and any other type of review	

Date Case Completed CoC

Organization	Field Name	ID	Required
KCR	Date Case Completed CoC (DateCompletedCoC)	31405	No
NAACCR	Date Case CompletedCoC	2092	No

Field Length: 8

This is a calculated data item which identifies the date that specified items are completed and pass relevant edits, based on the Class of Case (item #30140). This field is used to evaluate compliance by ACoS-approved facilities with Standard 3.3, which specifies that 90% of cases must be completed within six months of the patient's first contact with the facility. It should not be confused with Date Case Completed (item #31410). This field is blank for cases diagnosed prior to January 1, 2010.

Class of Case	Description	Items That Must Be Completed by Date Case Completed - COC
00-22	All analytic cases	Patient identification, demographic, and diagnostic information
10-22	Patient received part or all first course treatment from facility	Staging, hospital-specific treatment
10, 12, 14, 20, 22	Patient received all first course treatment from facility, or unspecified whether all or part	Summary treatment (treatment at any facility)
00	Patient diagnosed at facility, received all treatment elsewhere	Facility referred to OR a treating physician
20-22	Patient diagnosed elsewhere, received part or all of treatment from facility	Facility referred from OR the managing physician

NOTE: This field will be recalculated if the class of case is updated from 00 to any other analytic class of case.

ACoS

- Comorbidity
 Secondary Diagnosis
 ICD Revision Secondary Diagnosis
 Inst Referred From
 Inst Referred To
 Palliative Procedure
 Palliative Procedure This Facility
 Date Surgical Discharge
 Date Surgical Discharge Flag
 Readmit within 30 days

Comorbidity

Organization	Field Name	ID	Required
KCR	Comorbidity 1 (Comorbid1)	31540	no
NAACCR	Comorbid/Complication 1	3110	no
KCR	Comorbidity 2 (Comorbid2)	31550	no
NAACCR	Comorbid/Complication 2	3120	no
KCR	Comorbidity 3 (Comorbid3)	31560	no
NAACCR	Comorbid/Complication 3	3130	no
KCR	Comorbidity 4 (Comorbid4)	31570	no
NAACCR	Comorbid/Complication 4	3140	no
KCR	Comorbidity 5 (Comorbid5)	31580	no
NAACCR	Comorbid/Complication 5	3150	no
KCR	Comorbidity 6 (Comorbid6)	31590	no
NAACCR	Comorbid/Complication 6	3160	no
KCR	Comorbidity 7 (Comorbid7)	31600	no
NAACCR	Comorbid/Complication 7	3161	no
KCR	Comorbidity 8 (Comorbid8)	31610	no
NAACCR	Comorbid/Complication 8	3162	no
KCR	Comorbidity 9 (Comorbid9)	31620	no
NAACCR	Comorbid/Complication 9	3163	no
KCR	Comorbidity 10 (Comorbid10)	31630	no
NAACCR	Comorbid/Complication 10	3164	no

Record the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. These are considered the same as secondary diagnoses.

Instructions for Coding

- Depending on whether the hospital has implemented use of ICD-10-CM, this information may be identified either in ICD-9-CM or ICD-10-CM form. Do not record ICD-10-CM codes in the comorbidity fields; use the secondary diagnoses fields to record ICD-10-CM codes.
- Some ICD-10-CM codes are more than 5 characters long. Only enter the first five characters.
- Omit the decimal point between the third and fourth characters.
- If there are fewer than five characters, use zeros after the code to fill the spaces.
- · Secondary diagnoses and complications must be reported for patients that have inpatient hospitalizations at your facility.
- Secondary diagnoses and complications should be reported for patients receiving outpatient care or treated in oncology clinics at your facility when available.
- Consult the patient record for the discharge abstract. Secondary diagnoses are found under secondary diagnoses on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- · Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or billing list.
- Report the secondary diagnoses for this cancer using the following priority rules:

- Surgically treated patients:

a) following the most definitive surgery of the primary site

b) following other non-primary site surgeries

- Non-surgically treated patients:

following the first treatment encounter/episode

- In cases of non-treatment:

following the last diagnostic/evaluative encounter

- If the data item Readmission To The Same Hospital Within 30 Days of Surgical Discharge is coded 1, 2, or 3, then use available Comorbidities
 and Complications data items to record codes appearing on the "readmission" discharge abstracts that are coded using ICD-9-CM.
- If no ICD-9-CM comorbid conditions or complications were documented, then code 00000 in the first field, and leave the remaining "Comorbidities and Complications" data items blank.
- If fewer than ten secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining "Comorbidities and Complications" data items blank.

• Allowable ICD-9-CM values are:

00100-13980, 24000-99990,

E8700-E8799, E9300-E9499

V0720-V0739, V1000-V1590,

V2220-V2310, V2540,

V4400-V4589, V5041-V5049

Secondary Diagnosis

Organization	Field Name	ID	Required
KCR	Secondary Diagnosis 1 (SecondaryDx1)	33020	no
NAACCR	Secondary Diagnosis 1	3780	no
KCR	Secondary Diagnosis 2 (SecondaryDx2)	33030	no
NAACCR	Secondary Diagnosis 2	3782	no
KCR	Secondary Diagnosis 3 (SecondaryDx3)	33040	no
NAACCR	Secondary Diagnosis 3	3784	no
KCR	Secondary Diagnosis 4 (SecondaryDx4)	33050	no
NAACCR	Secondary Diagnosis 4	3786	no
KCR	Secondary Diagnosis 5 (SecondaryDx5)	33060	no
NAACCR	Secondary Diagnosis 5	3788	no
KCR	Secondary Diagnosis 6 (SecondaryDx6)	33070	no
NAACCR	Secondary Diagnosis 6	3790	no
KCR	Secondary Diagnosis 7 (SecondaryDx7)	33080	no
NAACCR	Secondary Diagnosis 7	3792	no
KCR	Secondary Diagnosis 8 (SecondaryDx8)	33090	no
NAACCR	Secondary Diagnosis 8	3794	no
KCR	Secondary Diagnosis 9 (SecondaryDx9)	33100	no
NAACCR	Secondary Diagnosis 9	3796	no
KCR	Secondary Diagnosis 10 (SecondaryDx10)	33110	no
NAACCR	Secondary Diagnosis 10	3798	no

Field Length: 5 (x10)

Record the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM codes. The secondary diagnoses are also called comorbidities and complications.

Instructions for Coding

• Use this item to record ICD-10-CMcodes. Use Comorbidities and Complications to record ICD-9-CMcodes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.

• Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CMcode is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.

• Omit the decimal points when coding.

• Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.

- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- · Report the secondary diagnoses for this cancer using the following priority rules:
- Surgically treated patients:
 - a) following the most definitive surgery of the primary site
 - b) following other non-primary site surgeries
- Non-surgically treated patients:
 - following the first treatment encounter/episode
- In cases of non-treatment:
 - following the last diagnostic/evaluative encounter

• If the data item Readmission To The Same Hospital Within 30 Days of Surgical Discharge is coded 1, 2, or 3, report Secondary DiagnosisICD-10-CM codes appearing on the "readmission" discharge abstract.

• If no ICD-10-CM secondary diagnoses were documented, then code 0000000in this data item, and

leave the remaining Secondary Diagnosis data items blank.

• If fewer than ten ICD-10-CMsecondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

• Allowable values are:

0000000; all values beginning with

A-B, E, G-P, R-S; and the following ranges:

T36- T50996XX, Y62-Y849ZZZ, Z1401-Z229ZZZ,

Z681-Z6854ZZ, Z80-Z809ZZZ, Z8500-Z9989ZZ.

ICD Revision Secondary Diagnosis

Organization	Field Name	ID	Required
KCR	ICD Revision Secondary Diagnosis (ComorbidICDRev)	31640	no
NAACCR	ICD Revision Comorbid	3165	no

Field Length: 1

This is a computer generated field based on the Co-morbidities and Complications codes.

Codes	Description	
0	No secondary diagnoses reported (Co-morbidities coded 00000)	
9	ICD-9 codes used in co-morbidities	
	(all cases with co-morbidities >00000 will be coded 9 automatically)	

Inst Referred From

Organization	Field Name	ID	Required
KCR	Inst Referred From (InstRefFrom)	31650	no
NAACCR	Institution Referred From	2410	no

Field Length: 10

Record the code for the referring hospital where the case was diagnosed or the patient received any therapy for this primary.

For facilities with 6-digit ID numbers that were assigned by the ACoS, CoC before January 1, 2001, use the hospital ID number assigned by the Cancer Department, preceded by 0000. For facilities with 8-digit ID numbers, assigned by CoC after January 1, 2001, use the 8-digit code preceded by two zeros.

EXAMPLE: General Hospital, Anytown, Kentucky, has ID number 510999, would be recorded as 0000510999.

Refer to the list of Kentucky healthcare facility ID numbers in Appendix F. A list of hospital code numbers for other states may be obtained from the CoC web site at: http://www.facs.org/.

When there is no referring hospital, this item should be coded with ten zeros. If the patient was referred by an unknown facility, code the field with 0099999999.

If the patient was hospitalized for the malignancy in more than one hospital, record the code for the most recent hospitalization before this admission.

Inst Referred To

Organization	Field Name	ID	Required
KCR	Inst Referred To (InstRefTo)	31660	no
NAACCR	Institution Referred To	2420	no

Field Length: 10

Record the code for the hospital where the patient is referred for definitive treatment following discharge.

For facilities with 6-digit ID numbers that were assigned by the ACoS, CoC before January 1, 2001, use the hospital ID number assigned by the Cancer Department, preceded by 0000. For facilities with 8-digit ID numbers, assigned by CoC after January 1, 2001, use the 8-digit code preceded by two zeros.

EXAMPLE: General Hospital, Anytown, Kentucky, has ID number 510999, would be recorded as 0000510999.

Refer to the list of Kentucky healthcare facility ID numbers in Appendix F. A list of hospital code numbers for other states may be obtained from the CoC web site at: http://www.facs.org/.

If there is no referring hospital, code with 10 zeros. If the patient was referred to an unknown facility, code the field with 00999999999.

If the patient was referred to more than one hospital for definitive treatment, record the first hospital to which the patient was referred.

Palliative Procedure

Organization	Field Name	ID	Required
KCR	Palliative Procedure (PallProc)	31670	no
NAACCR	RX SummPalliative Proc	3270	no

Field Length: 1

- Record the type of palliative care provided. Palliative care is performed to relieve symptoms and may include surgery, radiation, systemic therapy or other pain management therapy.
- Palliative procedures are not used to diagnose or stage the primary tumor.
- Palliative surgical procedures, radiation therapy, and systemic therapy that are part of first course therapy, which also remove or modify primary or secondary malignant tissue, are coded here and in the respective therapy fields as well.

Code	Description
0	No palliative care provided. Diagnosed at autopsy only.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in patient record. Palliative care was provided that does not fit the descriptions in codes 1-6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Palliative Procedure - This Facility

Organization	Field Name	ID	Required
KCR	Palliative Procedure - This Facility (PallProcHere)	31680	no
NAACCR	RX HospPalliative Proc	3280	no

Field Length: 1

- Record the type of palliative procedure performed at this facility.
 This item can be entered or updated at any time following the date of diagnosis.
 Palliative procedures are not used to diagnose or stage the primary tumor.
- Palliative surgical procedures, radiation therapy, and systemic therapy that are part of first course therapy are coded in their respective fields.

Code	Description
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in patient record. Palliative care was provided that does not fit the descriptions in codes 1-6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Date Surgical Discharge

Organization	Field Name	ID	Required
KCR	Date Surgical Discharge (SurgDischDate)	31690	no
NAACCR	RX Date Surg Disch	3180	no

Field Length: 8

Record the date the patient was discharged following primary site surgery. The date corresponds to the event recorded in Surgical Procedure of Primary Site and Date of Most Definitive Surgical Resection.

- If the patient died following the event recorded in Surgical Procedure of Primary Site, but before being discharged from the treating facility, then the Date of Surgical Discharge is the same as the date recorded in the data item Date of Last Contact or Death.
- If the patient received out-patient surgery, then the date of surgical discharge is the same as the date recorded in the data item Date of Most Definitive Surgical Resection of the Primary Site.

Code	Description		
MMDD CCYY	The date of surgical discharge is the month, day, and year that the patient was discharged from the hospital following surgical treatment. The first two digits are the month, the third and fourth digits are the day, and the last four digits are the year.		
999999 99	When it is unknown whether surgical treatment was performed, the date is unknown, or the case was identified by death certificate only.		

Date Surgical Discharge Flag

Organization	Field Name	ID	Required
KCR	Date Surgical Discharge Flag (SurgDischDateFlag)	31691	no
NAACCR	RX Date Surg Disch Flag	3181	no

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Date of Surgical Discharge (item #31690). This item is blank for cases diagnosed prior to January 1, 2003.

Codes

Code	Definition
10	No information whatsoever can be inferred (that is, unknown if any surgery was performed)
11	No proper value is applicable in this context (for example, no surgery performed)
12	A proper value is applicable but not known (that is, surgery was performed but the date is unknown)
(blank)	A valid date value is provided

Readmit within 30 days

Organization	Field Name	ID	Required
KCR	Readmit within 30 days (Readmit)	31700	no
NAACCR	Readm Same Hosp 30 Days	3190	no

Field Length: 1

Record readmission to the same hospital for the same illness within 30 days of discharge following hospitalization for surgical resection of the primary site.

- Consult patient record or information from the billing department to determine if a readmission to the same hospital occurred within 30 days of the date recorded in the item Date of Surgical Discharge.Only record a readmission related to the treatment of this cancer.
- Review the treatment plan to determine whether the readmission was planned.
- If there was an unplanned admission following surgical discharge, check for an ICD-9-CM 'E' code, and record it in the co-morbidity fields if space permits.

Code	Description	
0	No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge.	
1	A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned.	
2	A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned (chemotherapy port insertion, revision of colostomy, etc.)	
3	A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital.	
9	It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge. Death certificate only.	

Overrides

- Summary Stage Overrides
 Acsn/Class/Seq Override
 HospSeq/DxConf Override

- COC-Site/Type Override
 HospSeq/Site Override
 Site/TNM-StgGrp Override
 Age/Site/Morph Override (IF15)
 Control Constraints (IF15)
- SeqNo/DxConf Override (IF23)
 Site/Lat/SeqNo Override (IR09)
 Surg/DxConf Override (IF46)

- Surg/DxConf Override (IF46)
 Site/Type Override (IF25)
 Histology Override (MORPH)
 Report Source Override (IF04)
 Ill-Define Site Override (IF22)
 Leuk, Lymphoma Override (IF48)
 Site/Behavior Override (IF39)
 Site/Eod/Dx Dt Override (IF40)
 Site/Lat/Eod Override (IF41)
 Site/Lat/Morph Override (IF42)
 CS Override
 Override TMM Tis

- Override TNM Tis
- Override TNM This
 Override TNM Stage
 Override TNM 3

Summary Stage Overrides

Organization	Field Name	ID	Required
KCR	SS/NodesPos Override (ORSSNodesPos)	32270	no
NAACCR	Over-ride SS/NodesPos	1981	no
KCR	SS/TNM-N Override (ORTNM_N)	32280	no
NAACCR	Over-ride SS/TNM-N	1982	no
KCR	SS/TNM-M Override (ORTNM_M)	32290	no
NAACCR	Over-ride SS/TNM-M	1983	no
KCR	SS/DisMet1 Override (ORSSDisMet1)	32300	no

Field Length: 1 (x22)

- a. SummStg/Nodes+
- b. SummStg/TNM-N
- c. SummStg/TNM-M
- d. SummStg/Mets1
- e. Accn#/Class/Seq
- f. HospSeq/DxConfirm
- g. COC-Site/Type
- h. HospSeq/Site
- i. Site/TNM Stg Grp
- j. Age/Site (IF 15)
- k. Seq/DiagConfirm (IF 23)
- I. Site/Histo/Lat/Seq (IR 09)
- m. Surg/DxConfirm (IF 46)
- n. Site/Type (IF 25)
- o. Histo/Behave (MORPH)
- p. Reporting Source/Seq (IF 04)
- q. Seq/III-defined site (IF 22)
- r. Leukemias/Lymphomas (IF 48)
- s. Site/Behave (IF 39)
- t. Site/EOD/DxDate (IF 40)
- u. Site/Lat/EOD (IF 41)
- v. Site/Lat/Morph (IF 42)

Override flags are available to indicate that a record with apparently inconsistent or unlikely data has been reviewed and is in fact correct as coded. Enter a '1' in the field that describes the edit check that is to be overridden.

Override flags a-d (fields 32270-32300) are not used by KCR. Override flags e-v are described in greater detail on the following pages.

Acsn/Class/Seq Override

Organization	Field Name	ID	Required
KCR	Acsn/Class/Seq Override (ORAcsnClassSeq)	32310	no
NAACCR	Over-ride Acsn/Class/Seq	1985	no

The edit, Accession Number, Class of Case, Seq Number (CoC), checks the following:

- If the case is the only case or the first of multiple cases diagnosed at the facility (ACoS Sequence Number = 00, 01, 60 or 61, and Class of Case = 0, 1, or 6), then the first 4 characters of the Accession Number must equal the year of the Date of First Contact.
- If the case is first diagnosed at autopsy (Class of Case = 5), and the case is the only case or the first of multiple cases for a patient (ACoS Sequence Number = 00, 01, 60, or 61), then the first 4 characters of the Accession Number must equal the year of the Date of Last Contact or Death AND must equal the year of the Date of First Contact.
- If the case is first diagnosed at autopsy (Class of Case = 5), and the case is the second or more case for a patient (ACoS Sequence Number greater than 01 or greater than 61), then the year of the Date of First Contact must equal the year of Date of Last Contact or Death.

There are some exceptions to the above rules. Override Acsn/Class/Seq may be used to override the edit when the circumstances fit the following situation or one similar to it:

• The case may be the only or the first of multiple malignant cases for a patient (ACoS Sequence Number = 00 or 01), but there is an earlier benign case (with an earlier year of the Date of First Contact) for which the Accession Number applies.

- · Leave blank if the EDITS program does not generate an error message for the edit Accession Number, Class of Case, Sequence Number (CoC).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct.

HospSeq/DxConf Override

Organization	Field Name	ID	Required
KCR	HospSeq/DxConf Override (ORHospSeqDxConf)	32320	no
NAACCR	Over-ride HospSeq/DxConf	1986	no

The edit, Diagnostic Confirm, Seq Num-Hosp (CoC), does the following:

- If any case is one of multiple primaries and is not microscopically confirmed or positive lab test/marker study, i.e., Diagnostic Confirmation > 5 and ACoS Sequence Number > 00 (more than one primary), review is required.
- If Primary Site specifies an ill-defined or unknown primary (C76.0–C76.8, C80.9), no further checking is done. If ACoS Sequence Number is in the range of 60-88, this edit is skipped.

It is important to verify that the non-microscopically-confirmed case is indeed a separate primary from any others that may have been reported. This edit forces review of multiple primary cancers when one of the primaries is coded to a site other than ill-defined or unknown and is not microscopically confirmed or confirmed by a positive lab test/marker study.

- If this edit is failed and the suspect case is confirmed accurate as coded, and the number of primaries is correct, set the Override HospSeq /DxConf to 1. Do not set the override flag on the patient's other primary cancers.
- However, if it turns out that the non-microscopically-confirmed cancer is considered a manifestation of one of the patient's other cancers, delete
 the non-microscopically-confirmed case. Check the sequence numbers of remaining cases, correcting them if necessary. Also check for other
 data items on the remaining cases that may need to be changed as a result of the corrections, such as stage and treatment.

- Leave blank if the EDITS program does not generate an error message for the edit Diagnostic Confirm, Seq Num–Hosp (CoC).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if a review of all items in the error or warning message confirms that all are correct

COC-Site/Type Override

Organization	Field Name	ID	Required
KCR	COC-Site/Type Override (ORCOCSiteType)	32330	no
NAACCR	Over-ride CoC-Site/Type	1987	no

There are multiple versions of edits of the type, Primary Site, Morphology-Type, which check for "usual" combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept Override CoC-Site/Type or Override Site/Type as equivalent.

- The Site/Histology Validation List (available on the SEER Web site) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not be included. These edits require review of all combinations not listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if Primary Site is in the range C44.0-C44.9 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis. Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

- Leave blank if the EDITS program does not generate an error message for edits of the type Primary Site, Morphology-Type Check.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- · Code 1 if a review of all items in the error or warning message confirms they are correct and coded in conformance with coding rules.

HospSeq/Site Override

Organization	Field Name	ID	Required
KCR	HospSeq/Site Override (ORHospSeqSite)	32340	no
NAACCR	Over-ride HospSeq/Site	1988	no

Edits of the type, Seq Num--Hosp, Primary Site, Morph, differ in use of ICD-O-2 or ICD-O-3 morphology. They force review of multiple primary cancers when one of the primaries is coded to a site-morphology combination that could indicate a metastatic site rather than a primary site. If ACoS Sequence Number indicates the person has had more than one primary, then any case with one of the following site-histology combinations requires review:

- C76.0–C76.8 (III-defined sites) or C80.9 (unknown primary) and ICD-O-2 or ICD-O-3 histology < 9590. (Look for evidence that the unknown or illdefined primary is a secondary site from one of the patient's other cancers. For example, a clinical discharge diagnosis of "abdominal carcinomatosis" may be attributable to the patient's primary ovarian cystadenocarcinoma already in the registry, and should not be entered as a second primary.)
- C77.0-C77.9 (lymph nodes) and ICD-O-2 histology not in range 9590-9717 or ICD-O-3 histology not in the range 9590-9729; or C42.0-C42.4 and ICD-O-2 histology not in range 9590-9941 or ICD-O-3 histology not in the range 9590-9989. (That combination is most likely a metastatic lesion. Check whether the lesion could be a manifestation of one of the patient's other cancers.)
- Any site and ICD-O-2 histology in the range 9720-9723, 9740-9741 or ICD-O-3 histology in the range 9740-9758. (Verify that these diagnoses are coded correctly and are indeed separate primaries from the others.)

If it turns out that the suspect tumor is a manifestation of one of the patient's other cancers, delete the metastatic or secondary case, re-sequence remaining cases, and correct the coding on the original case as necessary.

- Leave blank if the EDITS program does not generate an error message for an edit of the type Seq Num--Hosp, Primary Site, Morph
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/TNM-StgGrp Override

Organization	Field Name	ID	Required
KCR	Site/TNM-StgGrp Override (ORSiteTNMStgGrp)	32350	no
NAACCR	Over-ride Site/TNM-StgGrp	1989	no

The edit, Primary Site, AJCC Stage Group - Edition 6 (COC), checks that the pathologic and clinical AJCC stage group codes are valid for the site and histology group according to the AJCC Cancer Staging Manual, Sixth Edition, using the codes described for the items Clinical Stage Group and Pathologic Stage Group. Combinations of site and histology not represented in any AJCC schema must be coded 88. Unknown codes must be coded 99. Blanks are not permitted.

Since pediatric cancers whose sites and histologies have an AJCC scheme may be coded according to a pediatric scheme instead, Override Site/TNM-Stage Group is used to indicate pediatric cases not coded according to the AJCC manual. Pediatric stage groups should not be recorded in the Clinical Stage Group or Pathologic Stage Group items. When neither clinical nor pathologic AJCC staging is used for pediatric cases, code all AJCC items 88. When any components of either is used to stage a pediatric case, follow the instructions for coding AJCC items and leave Override Site/TNM-Stage Group blank.

- Leave blank if the EDITS program does not generate an error message for the edit, Primary Site, AJCC Stage Group Edition 6 (COC).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if the case is confirmed to be a pediatric case that was coded using a pediatric coding system.

Age/Site/Morph Override (IF15)

Organization	Field Name	ID	Required
KCR	Age/Site/Morph Override (IF15) (ORAgeSiteMorph)	32360	no
NAACCR	Over-ride Age/Site/Morph	1990	no

Edits of the type, Age, Primary Site, Morphology differ in using ICD-O-2 or ICD-O-3 morphologies, and require review if a site-ICD-O-3 morphology combination occurs in an age group for which it is extremely rare:

Age	Morphology	Site
< age 15	any histology with behavior = 2	C53
< age 15	9100	C58
< age 20	any histology	C15 , C17 , C19C21 ,
		C23C25, C38.4, C50,
		C54C55
< age 20	any histology other than 8240-8245	C18 , C33C34
< age 20	any histology with behavior = 3	C53
< age 30	9732, 9823, 9863, 9875-9876, 9945, 9946	any site
< age 30	any histology	C60.9
< age 45	8140	C61.9
> age 5	9510-9514	C69
> age 14	8960	any site
> age 45	9100	C58.9

If the edit generates an error or warning message, check that the primary site and histologic type are coded correctly and that the age, date of birth, and date of diagnosis are correct.

Instructions for Coding

- Leave blank if the EDITS program does not generate an error message (and if the case was not diagnosed in utero) for the edit Age, Primary Site, Morphology (CoC) and/or the edit Age, Primary Site, Morphology ICD-O-3 (CoC).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1, 2, or 3 as indicated if review of all items in the error or warning message confirms that all are correct.

Codes

- 1. Reviewed: An unusual occurrence of a particular age/site/histology combination for a given age group has been reviewed.
- 2. Reviewed: Case was diagnosed in utero
- 3. Reviewed: Conditions 1 and 2 above both apply

SeqNo/DxConf Override (IF23)

Organization	Field Name	ID	Required
KCR	SeqNo/DxConf Override (IF23) (ORSeqNoDxConf)	32370	no
NAACCR	Over-ride SeqNo/DxConf	2000	no

This edit forces review of multiple primary cancers when one of the primaries is coded to a site other than ill-defined or unknown and is not microscopically confirmed or confirmed by a positive lab test/marker study. It is important to verify that the non-microscopically-confirmed case is indeed a separate primary from any others that may have been reported. If the suspect case is accurate as coded, and the number of primaries is correct, set the Override SeqNo/DxConf flag to 1 so that the case will not appear in future edits as an error. It is not necessary to set the override flag on the patient's other primary cancers.

If it turns out that the non-microscopically-confirmed cancer is considered a manifestation of one of the patient's other cancers, delete the nonmicroscopically-confirmed case. Check the sequence numbers of remaining cases, correcting them if necessary.

- Leave blank if the EDITS program does not generate an error message for the edit Sequence Number/Diagnostic Confirmation.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/Lat/SeqNo Override (IR09)

Organization	Field Name	ID	Required
KCR	Site/Lat/SeqNo Override (IR09) (ORSiteLatSeqNo)	32380	no
NAACCR	Over-ride Site/Lat/SeqNo	2010	no

Given two records for the same person coded with the same three-digit histology code and - in cases where the sites are paired organs, the same known laterality (see Table 2) - there must be no ambiguity of primary site between specified and NOS. That is, if the site code in one of the records appears in the left column of Table 1 below, then the site in the other records must not occur in the same line on the right side of the table. This edit is performed only for invasive diagnoses (Behavior = 3).

Table 1

NOS	Specified
CAA8	СААх
CBB9	СВВх
C260	C150-C259, C480-C488
C268	C150-C259, C480-C488
C269	C150-C259, C480-C488
C390	C300-C349, C384
C398	C300-C349, C380-C388
C399	C300-C349, C384
C579	C510-C578, C589
C639	C600-C638
C689	C649-C688
C758	C379, C739-C749
C759	C379, C739-C749

(Where AA represents any two-digit number except 16, 53, 71; BB represents any two-digit number and x represents any one-digit number.)

Table 2

Paired Organs

Code	Description
C491	Connective, subcutaneous, and other soft tissues of upper limb and shoulder
C492	Connective, subcutaneous, and other soft tissues of lower limb and hip

- Leave blank if the EDITS program does not generate an error message for this edit.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Surg/DxConf Override (IF46)

Organization	Field Name	ID	Required
KCR	Surg/DxConf Override (IF46) (ORSurgDxConf)	32390	no
NAACCR	Over-ride Surg/DxConf	2020	no

Edits of the type, RX Summ-Surg Prim Site, Diag Conf, check that cases with a primary site surgical procedure coded 20-90 are histologically confirmed.

If the patient had a surgical procedure, most likely there was a microscopic examination of the cancer.

- Verify the surgery and diagnostic confirmation codes, and correct any errors.
- Sometimes there are valid reasons why no microscopic confirmation is achieved with the surgery, for example, the tissue removed may be inadequate for evaluation.

- Leave blank if the EDITS program does not generate an error message for edits of the type, RX Summ-Surg Prim Site, Diag Conf.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/Type Override (IF25)

Organization	Field Name	ID	Required
KCR	Site/Type Override (IF25) (ORSiteType)	32400	no
NAACCR	Over-ride Site/Type	2030	no

There are multiple versions of edits of the type, Primary Site, Morphology-Type, which check for "usual" combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept Override CoC-Site/Type or Override Site/Type as equivalent.

- The Site/Histology Validation List (available on the SEER website) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not be included. These edits require review of all combinations not listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if Primary Site is in the range C440-C449 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis. Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

- Leave blank if the EDITS program does not generate an error message for the edit Primary Site, Morphology-Type Check (SEER IF25) and/or the edit Primary Site, Morphology-Type ICDO3 (SEER IF25).
- · Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Histology Override (MORPH)

Organization	Field Name	ID	Required
KCR	Histology Override (MORPH) (ORHistology)	32410	no
NAACCR	Over-ride Histology	2040	no

I. Edits of the type, Diagnostic Confirmation, Behavior Code, differ in the use of ICD-O-2 or ICD-O-3 and check that, for in situ cases (Behavior = 2), Diagnostic Confirmation specifies microscopic confirmation (1, 2 or 4). The distinction between in situ and invasive is very important to a registry, since prognosis is so different. Since the determination that a neoplasm has not invaded surrounding tissue, i.e. is in situ, is made microscopically, cases coded in situ in behavior should have a microscopic confirmation code. Note: Very rarely, a physician will designate a case noninvasive or in situ without microscopic evidence.

If an edit of the type, Diagnostic Confirmation, Behavior Code, gives an error message or warning, check that Behavior Code and Diagnostic Confirmation have been coded correctly. Check carefully for any cytologic or histologic evidence that may have been missed in coding.

II. Edits of the type, Morphology-Type/Behavior, perform the following overrideable check:

Codes listed in ICD-O-2 or ICD-O-3 with behavior codes of only 0 or 1 are considered valid, since use of the behavior matrix of ICD-O-2 and ICD-O-3 allows for the elevation of the behavior of such histologies when the tumor is in situ or malignant. This edit forces review of these rare cases to verify that they are indeed in situ or malignant.

If a Morphology-Type/Behavior edit produces an error or warning message and the case is one in which the 4-digit morphology code is one that appears in ICD-O-2 or ICD-O-3 only with behavior codes of 0 or 1, verify the coding of morphology and that the behavior should be coded malignant or in situ. The registrar may need to consult a pathologist or medical advisor in problem cases.

Exceptions to the above: If year of Date of Diagnosis > 2000, then a behavior code of 1 is valid for the following ICDO-2 histologies and no override flag is needed: 8931, 9393, 9538, 9950, 9960-9962, 9980-9984, 9989. Similarly, the following ICD-O-3 histologies are valid with a behavior code of 1: 8442, 8451, 8462, 8472, and 8473.

Note: The Morphology-Type/Behavior edits are complex and perform several additional types of checks. No other aspects of their checks are subject to override.

- Leave blank if the EDITS program does not generate an error message for the edits of the types Diagnostic Confirmation, Behavior Code or Morphology-Type/Behavior
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1, 2 or 3 as indicated if review of all items in the error or warning message confirms that all are correct.

Code	Definition
(leave blank)	Not reviewed
1	Reviewed; allow flag for edits of the type Morphology- Type/Behavior (SEER MORPH)
2	Reviewed; allow glad for edits of the type Diagnostic Confirmation, Behavior Code (IF 31)
3	Reviewed; conditions 1 and 2 above both apply

Report Source Override (IF04)

Organization	Field Name	ID	Required
KCR	Report Source Override (IF04) (ORRptSrc)	32420	no
NAACCR	Over-ride Report Source	2050	no

If the Type of Reporting Source specifies a death certificate only case (7) and Histology is not a lymphoma, leukemia, immunoproliferative or myeloproliferative disease (<9590), then ACoS Sequence Number must specify one primary only (00).

- Leave blank if the EDITS program does not generate an error message for this edit.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

III-Define Site Override (IF22)

Organization	Field Name	ID	Required
KCR	III-Define Site Override (IF22) (ORIIIDefSite)	32430	no
NAACCR	Over-ride III-define Site	2060	no

This edit forces review of multiple primary cancers when one of the primaries is coded to a site-morphology combination that could indicate a metastatic site rather than a primary site.

GENERAL

It is important to verify that the suspect case is indeed a separate primary from any others that may have been reported for the patient. Correction of errors may require inspection of the abstracted text, either online or as recorded on a paper abstract. Review of the original medical record may be necessary. If the suspect case is accurate as coded, and the number of primaries is correct, set the Over-ride III-define site flag to 1 so that the case will not be considered in error when the edit is run again. It is not necessary to set the over-ride flag on the patient's other primary cancers.

If it turns out that the suspect cancer is considered a manifestation of one of the patient's other cancers, delete the former case, resequence remaining cases, and correct the coding on the latter case as necessary.

SPECIFIC GUIDELINES

1. Ill-defined sites (C76.0 - C76.8) or unknown primary (C80.9) and histology code less than 9590: Look for evidence that the unknown or ill-defined primary is a secondary site (extension or metastasis) from one of the patient's other cancers. For example, a clinical discharge diagnosis of "r;abdominal carcinomatosis" may be attributable to the patient's primary ovarian cystadenocarcinoma known to the registry, and should not be entered as a second primary.

2. Lymph nodes (C77.0 - C77.9) and histology code not in the range 9590-9714: Primary malignancies of lymph nodes are almost exclusively the lymphomas coded in the range 9590-9714. A carcinoma, sarcoma, leukemia, or other diagnosis outside that range in a lymph node is most likely a metastatic (secondary) lesion. Check whether the lymph node lesion could be a manifestation of one of the patient's other cancers. If the lesion in the lymph node is considered a separate primary, try to ascertain a more appropriate primary site than lymph nodes.

3. Hematopoietic and reticuloendothelial systems (C42.0 - C42.4) and histology not in the range 9590-9941: Primary cancers of the blood, bone marrow, spleen, etc. are almost exclusively lymphomas, leukemias, and related conditions coded in the range 9590-9941. A carcinoma, sarcoma, or other diagnosis outside that range in one of these sites is most likely a metastatic (secondary) lesion. Check whether the lesions could be a manifestation of one of the patient's other cancers. If the lesion is considered a separate primary, try to ascertain a more appropriate primary site other than those in the C42 group.

4. Other lymphoreticular neoplasms and mast cell tumors of any site (histologies 9720-9723 and 9740-9741): Verify that these diagnoses are coded correctly and are indeed separate primaries from the other reported ones.

- Leave blank if the EDITS program does not generate an error message for this edit.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Leuk, Lymphoma Override (IF48)

Organization	Field Name	ID	Required
KCR	Leuk, Lymphoma Override (IF48) (ORLeukLymph)	32440	no
NAACCR	Over-ride Leuk, Lymphoma	2070	no

Edits of the type, Diagnostic Confirmation, Histol Type, differ in use of ICD-O-2 or ICD-O-3 and check the following:

- Since lymphoma and leukemia are almost exclusively microscopic diagnoses, this edit forces review of any cases of lymphoma that have diagnostic confirmation of direct visualization or clinical, and any leukemia with a diagnostic confirmation of direct visualization.
- If histology is 9590-9717 for ICD-O-2 or 9590-9729 for ICD-O-3 (lymphoma), then Diagnostic Confirmation cannot be 6 (direct visualization) or 8 (clinical).
- If histology is 9720-9941 for ICD-O-2 or 9731-9948 for ICD-O-3 (leukemia and other), then Diagnostic Confirmation cannot be 6 (direct visualization).

In an edit of the type, Diagnostic Confirmation, Histol Type, produces an error or warning message, check that the Histology and Diagnostic Confirmation are correctly coded. Remember that positive hematologic findings and bone marrow specimens are included as histologic confirmation (code 1 in Diagnostic Confirmation) for leukemia.

- Leave blank if the EDITS program does not generate an error message for the edits of the type Diagnostic Confirmation, Histol Type.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/Behavior Override (IF39)

Organization	Field Name	ID	Required
KCR	Site/Behavior Override (IF39) (ORSiteBehavior)	32450	no
NAACCR	Over-ride Site/Behavior	2071	no

Edits of the type, Primary Site, Behavior Code, require review of the following primary sites with a behavior of in situ (ICD-O-2 or ICD-O-3 behavior = 2):

Code	Description
C26.9	Gastrointestinal tract, NOS
C39.9	Ill-defined sites within respiratory system
C55.9	Uterus, NOS
C57.9	Female genital tract, NOS
C63.9	Male genital organs, NOS
C68.9	Urinary system, NOS
C72.9	Nervous system, NOS
C75.9	Endocrine gland, NOS
C76.0-C76.8	Ill-defined sites
C80.9	Unknown primary site

Since the designation of in situ is very specific and almost always requires microscopic confirmation, ordinarily specific information should also be available regarding the primary site. Conversely, if inadequate information is available to determine a specific primary site, it is unlikely that information about a cancer being in situ is reliable.

If a specific in situ diagnosis is provided, try to obtain a more specific primary site. A primary site within an organ system can sometimes be
identified based on the diagnostic procedure or treatment given or on the histologic type. If a more specific site cannot be determined, it is usually
preferable to code a behavior code of 3. In the exceedingly rare situation in which it is certain that the behavior is in situ and no more specific-site
code is applicable, set Override Site/Behavior to 1.

- Leave blank if the EDITS program does not generate an error message for the edit Primary Site, Behavior Code (CoC) and/or the edit Primary Site, Behavior Code ICD-O-3 (CoC).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- · Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/Eod/Dx Dt Override (IF40)

Organization	Field Name	ID	Required
KCR	Site/Eod/Dx Dt Override (IF40) (ORSiteEODDxDate)	32460	no
NAACCR	Over-ride Site/EOD/DX Dt	2072	no

The following cancers require review if reported with localized extent of disease:

Code	Description
C069	Mouth, NOS
C189	Colon, NOS not histology 8220 (adenocarcinoma in adenomatous polyposis coli)
C260-C269	Other and ill-defined digestive organs
C390-C399	Other and ill-defined respiratory or intrathoracic sites
C409, C419	Bone, NOS
C479	Peripheral nerves, NOS
C499	Connective tissue, NOS
C559	Uterus, NOS
C579	Female genital system, NOS
C639	Male genital organs, NOS
C760-C768	Other and ill-defined sites
C809	Unknown primary site

The definition of localized disease for each of the extent of disease coding systems is: 10-30.

- Leave blank if the EDITS program does not generate an error message for this edit.
 Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/Lat/Eod Override (IF41)

Organization	Field Name	ID	Required
KCR	Site/Lat/Eod Override (IF41) (ORSiteLatEOD)	32470	no
NAACCR	Over-ride Site/Lat/EOD	2073	no

The IF41 edit for paired organs does not allow EOD to be specified as in situ, localized, or regional by direct extension if laterality is coded as "bilateral, side unknown" or "laterality unknown." Review the source information and use code 3 - One side only, right or left origin unknown - if it applies. Use this override to indicate that the conflict has been reviewed.

- Leave blank if the EDITS program does not generate an error message for this edit.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Site/Lat/Morph Override (IF42)

Organization	Field Name	ID	Required
KCR	Site/Lat/Morph Override (IF42) (ORSiteLatMorph)	32480	no
NAACCR	Over-ride Site/Lat/Morph	2074	no

Edits of the type, Laterality, Primary Site, Morph, differ in whether they produce a warning or an error message and in use of ICD-O-2 or ICD-O-3 morphology. This edit checks the following:

- If the Primary Site is a paired organ and Behavior Code is in situ (2), then Laterality must be 1, 2, or 3.
- If diagnosis year is less than 1988 and Histology is greater than or equal to 9590, then no further editing is performed. If diagnosis year is greater than 1987 and Histology equals 9140, 9700, 9701, 9590-9980, then no further editing is performed.

The intent of this edit is to force a review of in situ cases for which Laterality is coded 4 (bilateral) or 9 (unknown laterality) as to origin.

• In rare instances when the tumor is truly midline (9) or the rare combination is otherwise confirmed correct, enter code 1 for Override Site/Lat /Morph.

Instructions for Coding

• Leave blank if the EDITS program does not generate an error message for the edit Laterality, Primary Site, Morphology (SEER IF42) and/or the edit Laterality, Primary Site, Morph

ICD-O-3 (SEER IF42).

- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- · Code 1 if a review of all items in the error or warning message confirms that all are correct.

CS Override

Organization	Field Name	ID	Required
KCR	CS Override 1 (CSOverride1)	32820	no
NAACCR	Over-ride CS 1	3750	no
KCR	CS Override 2 (CSOverride2)	32830	no
NAACCR	Over-ride CS 2	3751	no
KCR	CS Override 3 (CSOverride3)	32840	no
NAACCR	Over-ride CS 3	3752	no
KCR	CS Override 4 (CSOverride4)	32850	no
NAACCR	Over-ride CS 4	3753	no
KCR	CS Override 5 (CSOverride5)	32860	no
NAACCR	Over-ride CS 5	3754	no
KCR	CS Override 6 (CSOverride6)	32870	no
NAACCR	Over-ride CS 6	3755	no
KCR	CS Override 7 (CSOverride7)	32880	no
NAACCR	Over-ride CS 7	3756	no
KCR	CS Override 8 (CSOverride8)	32890	no
NAACCR	Over-ride CS 8	3757	no
KCR	CS Override 9 (CSOverride9)	32900	no
NAACCR	Over-ride CS 9	3758	no
KCR	CS Override 10 (CSOverride10)	32910	no
NAACCR	Over-ride CS 10	3759	no
KCR	CS Override 11 (CSOverride11)	32920	no
NAACCR	Over-ride CS 11	3760	no
KCR	CS Override 12 (CSOverride12)	32930	no
NAACCR	Over-ride CS 12	3761	no
KCR	CS Override 13 (CSOverride13)	32940	no
NAACCR	Over-ride CS 13	3762	no
KCR	CS Override 14 (CSOverride14)	32950	no
NAACCR	Over-ride CS 14	3763	no
KCR	CS Override 15 (CSOverride15)	32960	no
NAACCR	Over-ride CS 15	3764	no
KCR	CS Override 16 (CSOverride16)	32970	no
NAACCR	Over-ride CS 16	3765	no
KCR	CS Override 17 (CSOverride17)	32980	no
NAACCR	Over-ride CS 17	3766	no
KCR	CS Override 18 (CSOverride18)	32990	no
NAACCR	Over-ride CS 18	3767	no
KCR	CS Override 19 (CSOverride19)	33000	no
NAACCR	Over-ride CS 19	3768	no
KCR	CS Override 20 (CSOverride20)	33010	no
NAACCR	Over-ride CS 20	3769	no

These overrides will be used with collaborative stage edits. They are currently undefined.

Override TNM Tis

KCR	Override TNM Tis (OverrideTNMTis)	33202	no
NAACCR	Over-ride TNM Tis	1993	no

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- TNM Clin T, N, M, In Situ (CoC)
- TNM Path T, N, M, In Situ (CoC)

If the patient has a T value indicating in situ/ noninvasive, this edit verifies that the N, M, and stage group reflect in situ/noninvasive disease. However, there are certain circumstances where AJCC does allow a T value indicating in situ/noninvasive and N, M, and/or stage group that indicates invasive disease. An over-ride is required to accommodate these situations.

Rationale

This over-ride will allow registrars to enter combination of T, N, and M with a stage group that differs from the combinations documented in the AJCC Staging Manual. **Codes**

1	Reviewed and confirmed as reported

Blank Not reviewed or reviewed and corrected

Override TNM Stage

KCR	Override TNM Stage (OverrideTNMStage)	33201	no
NAACCR	Over-ride TNM Tis	1992	no

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Primary Site, TNM Clin Stage Valid A- Ed 7 (CoC)
- Primary Site, TNM Clin Stage Valid B- Ed 7 (CoC)
 Primary Site, TNM Path Stage Valid A- Ed 7 (CoC)
 Clin Stage Valid A- Ed 7 (CoC)
- Primary Site, TNM Path Stage Valid B- Ed 7 (CoC)

These edits check T, N, and M combinations against stage group. Adding this over-ride allows the edit to pass when combinations of T, N, and M are entered that are not included in the stage tables used with the edits.

Rationale

This over-ride will allow registrars to enter combination of T, N, and M with a stage group that differs from the combinations documented in the AJCC Staging Manual. Codes

1	Reviewed and confirmed as reported
Blank	Not reviewed or reviewed and corrected

Override TNM 3

KCR	Override TNM 3 (OverrideTNM3)	33203	no
NAACCR	Over-ride TNM Tis	1994	no

Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct. **Rationale**

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. **Codes**

1	Reviewed and confirmed as reported
Blank	Not reviewed or reviewed and corrected

Historical

- Grade Path ValueGrade Path SystemTumor Marker 1
- Tumor Marker 2

- Tumor Marker 2
 Tumor Marker 3
 Biopsy Procedure
 Multiplicity Counter
 Date Multiple Tumors
 Date Multiple Tumors Flag
 Type of Multiple Tumors
 Ambiguous Terminology
 Date of Conclusive Terminology
 Date of Conclusive Terminology Flag
 SEER Extent
 SEER PEP
 Tumor Size (largest)
 SEER Lymph Node
 Site of Mets

Grade Path Value

Organization	Field Name	ID	Required
KCR	Grade Path Value (GradePathValue)	30131	no
NAACCR	Grade Path Value	441	no

Field Length: 1

*** This data item was discontinued effective 01/01/2014***

This field documents the numerator or first number of a tumor grade reported in a 2, 3, or 4 grade system. It is paired with Grade Path System (item #30132) to describe the original grade of the tumor. It may be left blank for cases diagnosed prior to January 1, 2010.

Instructions for Coding

- Code this item from the same tissue as that used to code Tumor Grade (item #30130)
- Code the histologic grade in priority over a nuclear or architectural grade.
- Do not convert the terms well, moderately, or poorly differentiated, low/high, or anaplastic into codes in this field. Leave blank if those terms are the only available grade information.
- If grade is described in the medical record as a fraction (x/y), this field is the numerator. In other words, this field is the first or upper number of a
 grade expressed in two parts
- Leave this item blank if another grading system is used in the pathology report. For example, do not report grading systems such as Bloom-Richardson for breast primaries, Fuhrman for kidney, Gleason for prostate, or WHO grade. Those grading systems are coded in a site-specific factor for the applicable CS schema.
- Leave this item blank for lymphomas and hematopoietic malignancies (9590-9992)
- This item and Grade Path System (item #30132) should both be coded or both be blank. If both are coded, Tumor Grade (item #30130) must not be 9. Grade Path Value can never be larger than Grade Path System.

Code	Description	
blank	No 2-, 3- or 4-grade system available. Unknown.	
1	Recorded as Grade I or 1	
2	Recorded as Grade II or 2	
3	Recorded as Grade III or 3	
4	Recorded as Grave IV or 4	

Examples

Code	Reason
1	The pathology report indicates the grade is 1/4
2	Synoptic report says grade ii of iii
3	Microscopic description reports high grade III of III
blank	No mention of grade in the pathology report

Grade Path System

Organization	Field Name	ID	Required
KCR	Grade Path System (GradePathSystem)	30132	no
NAACCR	Grade Path System	449	no

Field Length: 1

*** This data item was discontinued effective 01/01/2014***

This field documents the denominator or second number of a tumor grade reported in a 2, 3, or 4 grade system. This item is used in conjunction with Grad e Path Value (item #30131) to describe the original grade of the tumor. It may be left blank for cases diagnosed prior to January 1, 2010

Instructions for Coding

- Code this item from the same tissue as that used to code Tumor Grade (item #30130)
- If grade is described in the medical record as a fraction (x/y), this field is the denominator. In other words, this field is the second or lower number
 of a grade expressed in two parts.
- Leave this item blank if no pathologic grade is available
- Leave this item blank if only a verbal description of grade is reported (i.e., moderately differentiated)
- Leave this item blank if another grading system is used in the pathology report. For example, do not report grading systems such as Bloom-Richardson for breast primaries, Fuhrman for kidney, Gleason for prostate, or WHO grade. Those grading systems are coded in a site-specific factor for the applicable CS schema.
- Leave this item blank for lymphomas and hematopoietic malignancies (9590-9992)
- This item and Grade Path Value (item #30131) should both be coded or both be blank. If both are coded, Tumor Grade (item #30130) must not be 9.

Code	Description	
blank	No 2, 3, or 4 grade system was used. Unknown.	
2	Recorded as Grade II or 2	
3	Recorded as Grade III or 3	
4	Recorded as Grade IV or 4	

Examples

Code	Reason
4	The final pathologic diagnosis indicates that the grade is $1\!/\!4$
3	Synoptic report says grade ii of iii
3	Microscopic description reports high grade III of III
blank	No mention of grade in the pathology report

Tumor Marker 1

Organization	Field Name	ID	Required
KCR	Tumor Marker 1 (TumorMarker1)	30340	no
NAACCR	Tumor Marker 1	1150	no

Field Length: 1

For cases diagnosed on or after January 1, 2004, tumor markers are collected in the Collaborative Stage Site Specific Factors fields and not in this data field. For earlier diagnoses, this table lists the site/histology for which tumor marker 1 is collected.

SITE/HISTOLOGY	MARKER #1	
Breast (C50.0-C50.9)	Estrogen Receptor Assay (ERA)	
Colorectal (C18.0-18.9, C19.9, C20.9)	Carcinoembryonic Antigen (CEA)	
Liver (C22.0, C22.1)	Alpha Fetoprotein (AFP)	
Neuroblastoma (9500/3)	Urine catecholamine	
Ovary (C56.9)	Carbohydrate Antigen 125 (CA-125)	
Prostate (C61.9)	Acid Phosphatase (PAP)	
Testis (C62.0, C62.1, C62.9)	Alpha Fetoprotein (AFP)	
	Range 1 <1,000 ng/ml	
	Range 2 1,000 - 10,000 ng/ml	
	Range 3 > 10,000 ng/ml	

Record the appropriate code as indicated below.

Code	Description
0	None done (test was not ordered and was not performed)
1	Positive/Elevated (breast and prostate only)
2	Negative/Normal
3	Borderline, undetermined whether positive or negative (breast and prostate only)
4	Range 1 (testis only, AFP, See Table)
5	Range 2 (testis only, AFP, See Table)
6	Range 3 (testis only, AFP, See Table)
8	Ordered, but results not in chart; or results not convertible to Range 1, 2, or 3
9	Unknown or no information (all sites other than those specified in the table)

Testicular Cancer

Acceptable codes for testicular cancer are 0, 2, 4, 5, 6, 8, and 9. For testis cases only, record alpha-fetoprotein (AFP) in Tumor Marker 1. If there are serial serum tumor markers, record the lowest (nadir) value of AFP after orchiectomy in the first course of treatment.

Tumor Marker 2

Organization	Field Name	ID	Required
KCR	Tumor Marker 2 (TumorMarker2)	30350	no
NAACCR	Tumor Marker 2	1160	no

Field Length: 1

For cases diagnosed on or after January 1, 2004, tumor markers are collected in the Collaborative Stage Site Specific Factors fields and not in this data field. For earlier diagnoses, this table lists the sites for which tumor marker 2 is collected.

SITE	MARKER
Breast (C50.0-50.9)	Progesterone Receptor Assay (PRA)
Prostate (C61.9)	Prostatic Specific Antigen (PSA)
Testis (C62.0, C62.1, C62.9)	Human chorionic gonadotropin (hCG)
	Range 1 <5,000 mIU/mI
	Range 2 5,000 - 50,000 mIU/mI
	Range 3 >50,000 mIU/mI

Code	Description
0	None done (test was not ordered and was not performed)
1	Positive/Elevated (breast and prostate only)
2	Negative/Normal
3	Borderline, undetermined whether positive or negative (breast and prostate only)
4	Range 1 (testis only, AFP, See Table)
5	Range 2 (testis only, AFP, See Table)
6	Range 3 (testis only, AFP, See Table)
8	Ordered, but results not in chart; or results not convertible to Range 1, 2, or 3
9	Unknown or no information (all sites other than those specified in the table)

Testicular Cancer

Acceptable codes for testicular cancer are 0, 2, 4, 5, 6, 8, 9. For testis cases only, record the Human Chorionic Gonadotropin (hCG) in Tumor Marker 2. If there are serial serum tumor markers, record the lowest (nadir) value of hCG after orchiectomy in the first course of treatment.

Tumor Marker 3

Organization	Field Name	ID	Required
KCR	Tumor Marker 3 (TumorMarker3)	30360	no
NAACCR	Tumor Marker 3	1170	no

Field Length: 1

For cases diagnosed on or after January 1, 2004, tumor markers are collected in the Collaborative Stage Site Specific Factors fields and not in this data field. For earlier diagnoses, "Tumor Marker Three" records prognostic indicators for testicular cancer only.

SITE/HISTOLOGY		MARKER #3	
Testis	(C62.0, C62.1, C62.9)	LDH	
		Range 1	<1.5 x N*
		Range 2	1.5-10 x N*
		Range 3	>10 x N*
		* N equals the	upper limit of normal for the LDH

Record the appropriate code as indicated below.

Code	Description
0	None done (test was not ordered and was not performed)
1	Positive/Elevated (breast and prostate only)
2	Negative/Normal
3	Borderline, undetermined whether positive or negative (breast and prostate only)
4	Range 1 (testis only, AFP, See Table)
5	Range 2 (testis only, AFP, See Table)
6	Range 3 (testis only, AFP, See Table)
8	Ordered, but results not in chart; or results not convertible to Range 1, 2, or 3
9	Unknown or no information (all sites other than those specified in the table)

Biopsy Procedure

Organization	Field Name	ID	Required
KCR	Biopsy Procedure (DiagStgProc1)	30370	no
KCR	Guidance (DiagStgProc2)	30380	no
KCR	Palpability/Approach (DiagStgProc3)	30390	no
KCR	1st Detect/Bx Other Site (DiagStgProc4)	30400	no

Field Length: 1 (x 4)

Specific diagnostic and staging procedures were defined for breast and prostate cancers only for diagnoses dates between 1/1/1998 and 12/31/2002. They are now optional fields and are no longer required to be coded.

If the primary site is other than breast or prostate, code all data items 0 or leave blank. If more than one code applies, use the highest code (excluding 9).

30370 - Biopsy Procedure (Breast Only)

These are biopsies that do not grossly remove the primary tumor and/or surgical margins were macroscopically involved.

If the primary tumor was grossly removed during the biopsy procedure, code Biopsy Procedure and Guidance items 0 (not done, not a separate procedure). The biopsy would be coded as cancer-directed surgery.

Code	Description
0	Not done, not a separate procedure
1	Biopsy, NOS
2	Fine needle aspiration (cytology)
3	Core biopsy (histology)
5	Excision of major duct (if procedure removes all gross primary tumor, code as cancer-directed surgery)
9	Unknown if biopsy performed, death certificate only

30380 - Guidance (Breast Only)

Code	Description
0	Not guided, no biopsy of primary site
1	Guided, NOS
2	Radiographic NOS (no dye or dye unknown)
3	Mammographic; wire/needle localization
4	Stereotactic
5	Dye only
6	Dye plus (1-3)
7	Ultrasound
9	Unknown if guided; biopsy performed; death certificate only

30390 - Palpability of Primary (Breast Only)

Code	Description
0	Not palpable
1	Palpable
9	Palpability not stated; death certificate only

30400 - First Detected By (Breast Only)

Record the method by which the breast mass or abnormality was first recognized.

Code	Description
0	Not a breast or prostate primary
1	Patient first felt lump or noted nipple discharge
2	Physician first felt lump
3	Mammography - routine (screening)
4	Occult; incidental finding during other procedure
9	Unknown how first detected

30370 - Biopsy Procedure (Prostate Only)

Code	Description
0	Not done, not a separate procedure
1	Incisional biopsy, NOS
2	Fine needle aspiration (cytology)
3	Needle core biopsy; biopsy gun (histology)
4	6 cores or more of tissue from both lobes of the prostate
9	Unknown if biopsy of primary was done; death certificate only

30380 - Guidance (Prostate Only)

Code	Description
0	Not guided; no biopsy of primary
1	Guided, NOS
2	Radiographic
3	Ultrasound
9	Unknown if guided, biopsy performed; death certificate only

30390 - Approach for Biopsy of Primary (Prostate Only)

Code	Description
0	No biopsy
1	Transrectal
2	Transperineal
3	Transurethral
4	Laparoscopic
5	Open (laparotomy)
9	Unknown approach, but biopsy performed; death certificate only

30340 - Biopsy of Other than Primary (Prostate Only)

Code	Description
0	No biopsy of other than primary
1	Biopsy of seminal vesicle(s), NOS
2	Unilateral
3	Bilateral

4	Other than seminal vesicle
5	4 + 1
6	4 + 2
7	4 + 3
9	Unknown if biopsy of other than primary; death certificate only

Multiplicity Counter

Organization	Field Name	ID	Required
KCR	Multiplicity Counter (MultiplicityCounter)	30420	no
NAACCR	Multiplicity Counter	446	no

Field Length: 2

This data item is optional effective with 01/01/2013 diagnoses, but remain required for diagnoses in 2007-2012.

This data item is effective with cases diagnosed January 1, 2007, and later. It is used to count the number of tumors (multiplicity) reported as a single primary. Use the multiple primary rules for the specific site to determine whether the tumors are a single primary or multiple primaries.

Coding Instructions

- 1. Code the number of tumors being abstracted as a single primary.
- 2. Do not count metastasis.
- 3. When there is a tumor or tumors with separate single or multiple foci, ignore/do not count the foci.
- 4. Use code 01 when:
- a. There is a single tumor in the primary site being abstracted
- b. There is a single tumor with separate foci of tumor
- 5. Use code 88 for:
- a. Leukemia
- b. Lymphoma
- c. Immunoproliferative diseases
- d. Unknown primary
- 6. Use code 99 when:
- a. The original pathology report is not available and the documentation does not specify whether there was a single or multiple tumors in the primary site
- b. The tumor is described as multifocal or multicentric and the number of tumors is not mentioned
- c. The tumor is described as diffuse
- d. The operative or pathology report describes multiple tumors but does not give an exact number
- e. It is unknown if there is a single tumor or multiple tumors and the multiple primary rules instructed you to default to a single tumor
- 7. Leave this field blank for cases diagnosed prior to 1/1/2007.

Codes

Code	Description
00	No primary tumor identified (effective for cases diagnosed 1/1/2011 forward)
01	One tumor only
02	Two tumors present
03	Three tumors present
88	Information on multiple tumors not collected/not applicable for this site
99	Multiple tumors present, unknown how many

Example 1: The patient has a 2cm infiltrating duct carcinoma in the LIQ and a 1cm infiltrating duct carcinoma in the UIQ of the left breast. Accession as a single primary and enter 02 in the data item Multiplicity Counter.

Example 2: Operative report for TURB mentions multiple bladder tumors. Pathology report: Papillary transitional cell carcinoma present in tissue from bladder neck, dome, and posterior wall. Record 99 (multiple tumors, unknown how many) in Multiplicity Counter.

Example 3: Pathology from colon resection shows a 3cm adenocarcinoma in the ascending colon. Biopsy of liver shows a solitary metastatic lesion compatible with the colon primary. Record 01 in Multiplicity Counter (do not count the metastatic lesion).

Example 4: Patient has an excisional biopsy of the soft palate. The pathology shows clear margins. Record 01 in the Multiplicity Counter. Within six months another lesion is excised from the soft palate. Use the head and neck multiple primary rules to determine this tumor is not accessioned as a second primary. Change the Multiplicity Counter to code 02 to reflect the fact that there were two separate tumors abstracted as a single primary.

Example 5: CT of chest shows two lesions in the left lung and a single lesion in the right lung. Biopsy of the right lung lesions shows adenocarcinoma. No other workup is done. Using the multiple primary rules for lung, the case is abstracted a single primary. Enter the number 03 in the data item Multiplicity Counter.

Date Multiple Tumors

Organization	Field Name	ID	Required
KCR	Date Multiple Tumors (DateMultipleTumors)	30430	no
NAACCR	Date of Mult Tumors	445	no

Field Length: 8

This data item is optional effective with 01/01/2013 diagnoses, but remain required for diagnoses in 2007-2012.

This data item is effective with cases diagnosed January 1, 2007 onward. It is used to identify the month, day, and year the patient is diagnosed with multiple tumors reported as a single primary. Use the multiple primary rules for that specific site to determine whether the tumors are a single primary or multiple primaries.

Date

Record the date in month, day, year format (MMDDCCYY) that the patient was diagnosed with multiple tumors reported as a single primary.

Special Codes

Code	Description
0000000	Single tumor
88888888	Information regarding multiple tumors is not applicable for this cancer (lymphoma, leukemia, immunoproliferative disease, and unknown primary)
99999999	Unknown date

Coding Instructions

1. When multiple tumors are present at diagnosis, record the date of diagnosis.

Example 1: The patient has multiple tumors; a 2cm infiltrating duct carcinoma in the LIQ and a 1cm infiltrating duct carcinoma in the UIQ of the left breast. According to the breast multiple primary rules, these tumors are accessioned as a single primary. Enter the date of diagnosis in Date of Multiple Tumors.

Example 2: Operative report for TURB mentions multiple bladder tumors. Pathology report: Papillary transitional cell carcinoma present in tissue from bladder neck, dome, and posterior wall. According to the Bladder, Renal Pelvis, and Ureter multiple primary rules these tumors are accessioned as a single primary. Enter the date of diagnosis in Date of Multiple Tumors.

2. When subsequent tumor(s) are counted as the same primary, record the date the second/subsequent tumor was diagnosed. Update the multiplicity counter at this time.

Example: Patient has an excisional biopsy of a single tumor in the soft palate on January 2, 2007. The pathology shows clear margins. Record 01 in the Multiplicity Counter field. On July 10, 2007, another tumor is excised from the soft palate. The multiple primary rules for head and neck state that this tumor is the same primary. Change the 01 in Multiplicity Counter to 02 and enter 07102007, the date the second tumor was diagnosed, in Date of Multiple Tumors.

3. Leave this field blank for cases diagnosed prior to 1/1/2007.

Date Multiple Tumors Flag

	Organization	Field Name	ID	Required
	KCR	Date Multiple Tumors Flag (DateMultipleTumorsFlag)	30431	no
	NAACCR	Date of Mult Tumors Flag	439	no

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Date of Multiple Tumors (item #30430). This item is blank for cases diagnosed prior to January 1, 2007.

Codes

Code	Description
11	No proper value is applicable in this context (for example, multiple tumors are not collected for this site and histology)
12	A proper value is applicable but not known (that is, the date of multiple tumors is unknown)
15	A single tumor only
(blank)	A valid date value is provided

Type of Multiple Tumors

Organization	Field Name	ID	Required
KCR	Type of Multiple Tumors (MultTumRptAsOnePrim)	30440	no
NAACCR	Mult Tum Rpt as One Prim	444	no

Item Length: 2

This data item is optional effective with 01/01/2013 diagnoses, but remain required for diagnoses in 2007-2012.

This data item is effective with cases diagnosed January 1, 2007 onward. Code the type of multiple tumors that are abstracted as a single primary. Ignore metastatic tumors for this data item.

Code	Code Text	Description	Example(s)
00	Single tumor	All single tumors. Includes single tumors with both in situ and invasive components	Code 01 in the Multiplicity Counter
10	Multiple benign	At least two benign tumors in same organ/primary site	
		Use this code for reportable tumors in intracranial and CNS sites only	
		May be used for reportable by agreement cases	
11	Multiple borderline	At least two borderline tumors in the same organ/primary site	
	Dordenine	Use this code for reportable tumors in intracranial and CNS sites only	
		May be used for reportable by agreement cases	
12	Benign and borderline	At least one benign AND at least one borderline tumor in the same organ/site group	
		Use this code for reportable tumors in intracranial and CNS sites only	
		May be used for reportable by agreement cases	
20	Multiple in situ	At least two in situ tumors in the same organ/primary site	Cystoscopy reports documents multiple bladder tumors. Pathology: flat transitional cell carcinoma of bladder.
30	In situ and invasive	One or more in situ tumor(s) AND one or more invasive tumors in the same organ/primary site	
31	Polyp and adenocarcinoma	One or more polyps with either	
	adenocarcinoma	In situ carcinoma or	
		Invasive carcinoma	
		AND one or more frank adenocarcinoma(s) in the same segment of colon, rectosigmoid, and/or rectum	
32	FAP with carcinoma	Diagnosis of familial polyposis (FAP) AND carcinoma (in situ or invasive) is present in at least one of the polyps	
40	Multiple invasive	At least two invasive tumors in the same organ	
80	Unknown in situ or invasive	Multiple tumors present in the same organ/primary site, unknown if in situ or invasive	
88	N/A	Information on multiple tumors not collected/not applicable for this site	Leukemia, lymphoma, immunoproliferative diseases, and unknown primaries.
			All codes 88 in Multiplicity Counter
99	Unknown	Unknown	Code 99 in Multiplicity Counter, and DCO cases

Ambiguous Terminology

Organization	Field Name	ID	Required
KCR	Ambiguous Terminology (AmbiguousTerminologyDx)		no
NAACCR	Ambiguous Terminology DX	442	no

Item Length: 1

This data item is optional effective with 01/01/2013 diagnoses, but remain required for diagnoses in 2007-2012.

This data item is collected effective with diagnoses on or after January 1, 2007. It identifies all cases, including DCO and autopsy only, which are accessioned based only on ambiguous terminology. Registrars are required to collect cases based on ambiguous terminology in the diagnosis and it is advantageous to be able to identify those cases in the database.

Definitions

Phrase	Definition	Examples
Ambiguou s terminolo gy	Terms which have been mandated as reportable when used in a diagnosis. See page 3 of the FORDS Manual for detailed instructions on how to use the list.	Clinical: a physician's statement that the patient most likely has lung cancer. Laboratory tests: A CBC suspicious for leukemia. Pathology: A prostate biopsy compatible with adenocarcinoma.
Conclusiv e terminolo gy	A clear and definite statement of cancer. The statement may be from a physician (clinical diagnosis), or may be from a laboratory test, autopsy, cytologic findings, and /or pathology.	Clinical: a physician's statement that the patient has lung cancer. Laboratory tests: A CBC diagnostic of acute leukemia. Cytologic findings: A FNA (fine needle aspiration) with findings of infiltrating duct carcinoma of the breast. Pathology: A colon biopsy showing adenocarcinoma.

List of Ambiguous Terms

Apparent(ly)	Most likely
Appears	Presumed
Comparable with	Probable
Compatible with	Suspect(ed)
Consistent with	Suspicious (for)
Favor(s)	Typical (of)

Malignant appearing

Code	Label	Definition	Time Frame
0	Conclusive term	There was a conclusive diagnosis within 60 days of the original diagnosis. Case was accessioned based on conclusive terminology. Includes all diagnostic methods such as clinical diagnosis, cytology, pathology, etc.	Within 60 days of the date of initial diagnosis
1	Ambiguous term only	The case was accessioned based only on ambiguous terminology. There was not conclusive terminology during the first 60 days following the initial diagnosis. Includes all diagnostic methods except cytology. Note: Cytology is excluded because registrars are not required to collect cases with ambiguous terms describing a cytology diagnosis.	N/A

2	Ambiguous term followed by conclusive term	The case was originally assigned a code 1 (was accessioned based only on ambiguous terminology). More than 60 days after the initial diagnosis, the information is being updated to show that a conclusive diagnosis was made by any diagnostic method including clinical diagnosis, cytology, pathology, autopsy, etc.	60 days or more after the date of diagnosis
9	Unknown term	There is no information about ambiguous terminology.	N/A

Coding Instructions

1. Use code 0 when a case is accessioned based on conclusive terminology. The diagnosis includes clear and definite terminology describing the malignancy within 60 days of the original diagnosis.

Note: Usually the patient undergoes a diagnostic work-up because there is a suspicion of cancer (ambiguous terminology). For example, a mammogram may show calcifications suspicious for intraductal carcinoma; the date of the mammogram is the date of initial diagnosis. When there is a clear and definite diagnosis within 60 days of that mammogram (date of initial diagnosis), such as the pathology from an excisional biopsy showing intraductal carcinoma, assign code 0.

2. Use code 1 when a case is accessioned based on ambiguous terminology and there is no clear and definite terminology used to describe the malignancy within 60 days of the date of initial diagnosis. The diagnosis may be from a pathology report, a radiology report, an imaging report, or in the medical record.

3. Use code 2 when a case is accessioned based on ambiguous terminology followed by clear and definite more than 60 days after the initial diagnosis.

4. Follow back to a physician or subsequent readmission (following the initial 60 day period) may eventually confirm cancer (conclusive cancer term more than 60 days after ambiguous term). Assign code 2.

5. Leave this data item blank for cases diagnosed prior to 1/1/2007.

6. Cases accessioned based on ambiguous terminology (code 1) should be excluded from case selection in research studies. Direct patient contact is not recommended.

Date of Conclusive Terminology

Organization	Field Name	ID	Required
KCR	Date of Conclusive Terminology (DateConclusiveDx)	30460	no
NAACCR	Date Conclusive DX	443	no

Item Length: 8

This data item is optional effective with 01/01/2013 diagnoses, but remain required for diagnoses in 2007-2012.

This data item is effective with cases diagnosed on or after January 1, 2007. For those cases originally accessioned based on ambiguous terminology only, this data item documents the date of a definite statement of malignancy. The abstractor will change the code for the data item Ambiguous Terminology from a 1 to a 2 and enter the date that the malignancy was described clearly and definitely in the Date of Conclusive Terminology.

Date

Record the date in month, day, year format (MMDDCCYY) that the malignancy was described with conclusive terminology at least 60 days after it was initially diagnosed by ambiguous terminology.

Special Codes

Codes	Description		
00000000	Based on ambiguous terminology only (Code 1 in data item "Ambiguous Terminology")		
8888888 8	Not applicable; based on conclusive diagnosis within 60 days (Code 0 in data item "Ambiguous Terminology")		
99999999 Unknown date; unknown if diagnosis was based on ambiguous terminology or conclusive terminology (Code 9 in data it Terminology")			

Leave this field blank for cases diagnosed prior to 1/1/2007.

Date of Conclusive Terminology Flag

Organization	Field Name	ID	Required
KCR	Date of Conclusive Terminology Flag (DateConclusiveDxFlag)	30461	no
NAACCR	Date Conclusive DX Flag	448	no

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Date of Conclusive Terminology (item #30460). This item is blank for cases diagnosed prior to January 1, 2007.

Codes

Code	Definition	
10	No information whatsoever can be inferred (for example, unknown if the diagnosis was initially based on ambiguous terminology)	
11	No proper value is applicable in this context (for example, initial diagnosis made by unambiguous terminology)	
12	A proper value is applicable but not known (that is, the date of conclusive diagnosis is unknown)	
15	Accessioned based on ambiguous terminology only	
(blank)	A valid date value is provided	

SEER Extent

Organization	Field Name	ID	Required
KCR	SEER Extent (ExtOfDz)	30510	yes
NAACCR	EODExtension	790	yes

Field Length: 2

(Required field with all cases diagnosed from January 1, 2000 to December 31, 2003.)

As of 1-1-2004, leave this field blank and code information in the Collaborative Stage item #30540 instead.

Code the farthest documented extension of tumor away from the primary site, either by contiguous extension or distant metastasis.

The description of the primary tumor growth within the organ of origin or its extension to neighboring organs, or its metastasis to distant sites is summarized in a two-digit code. It is a hierarchical code in which the most extensive disease is all that is coded. Thus, information about the extent of the tumor within the primary site is lost if the tumor extends to neighboring organs, and extension to neighboring organs is lost if there is distant metastasis. Code '99' is reserved for unknown extension, except for prostate.

Use the instructions in the SEER Extent of Disease 1998 Codes and Coding Instructions manual, page 7, and the tables that follow, to code this field.

This field must match the behavior code. If behavior is /2, this data element must be coded in-situ\non-invasive (00, 01, 02, 03, 04, 05).

SEER PEP

Organization	Field Name	ID	Required
KCR	SEER PEP (PathExtOfProst)	30520	no
NAACCR	EODExtension Prost Path	800	no

Field Length: 2

DO NOT CODE THIS FIELD IF THE DIAGNOSIS DATE IS ON OR AFTER 1-1-2004. Record the pathologic extent for a prostate cancer in the Collaborativ e Stage, Site Specific Factor 3 field instead.

If the diagnosis date is before 1-1-2004, record the EOD extent code based on information obtained from a prostatectomy, for prostate primaries only. Record '99' if no prostatectomy was done as part of first course therapy. Leave blank for all other types of cancer.

Tumor Size (largest)

Organization	Field Name	ID	Required
KCR	Tumor Size (largest) (TumorSize1)	30490	yes
NAACCR	EODTumor Size	780	yes

Field Length: 3

DO NOT CODE THIS FIELD FOR CANCERS DIAGNOSED ON OR AFTER 1-1-2004. INSTEAD, RECORD TUMOR SIZE IN ITEM 30540 ACCORDING TO INSTRUCTIONS IN THE COLLABORATIVE STAGING MANUAL.

If the diagnosis date is before 1-1-2004, record the size of the tumor here in millimeters as stated in the pathology report. If more than one dimension is recorded, code the greatest one. For example, 6.1 x 9.4 cm should be recorded as 094. To convert centimeters to millimeters, multiply centimeters by 10. If the tumor size is stated in millimeters, such as "breast tumor is 13 mm," code as 013.

Use the instructions in the SEER Extent of Disease 1998 Codes and Coding Instructions manual, pages 3-5 and the tables that follow, to code this field.

If the pathology report does not specify tumor size, a reasonable estimate should be entered from the surgical notes, from scans or radiologic reports, or other clinical findings in that order. If unknown, code '999'.

Use the charts and tables on the following pages for additional guidelines in coding this field.

EXCEPTIONS: For melanomas of the skin, vulva, penis, scrotum, and conjunctiva, use this field to record the DEPTH OF INVASION (thickness of tumor) - and not largest tumor dimension - in HUNDREDTHS OF MILLIMETERS. For example, a melanoma with 1.55 mm depth of invasion should be coded 155. A melanoma of 9.9 mm or greater should be coded 990.

For melanomas of the uvea and other parts of the eye (C69.1-C69.4, C69.8-C69.9), as well as any other anatomic sites, record the tumor size at largest dimension and not depth of invasion.

For mycosis fungoides and Sezary's disease, use this field to record PERIPHERAL BLOOD INVOLVEMENT instead of tumor size.

For Hodgkin's and non-Hodgkin's lymphomas and Kaposi's sarcoma, use this field to record HIV STATUS instead of tumor size.

You may round off if the size is more precise than the coding spaces available.

For example: -ovarian tumor is 16.75 cm - code 168

-skin melanoma is 4.668 mm thick - code 467

Find the type of cancer you are abstracting in the left column. Then follow across the row to see the instructions for coding the field 'Tumor Size' for that type of cancer.

TYPE OF CANCER	ABSTRACTING GUIDELINES
1. Melanoma (8720- 8790)	Code thickness (depth of invasion of tumor)
of skin (C44.0-C44.9)	Code in hundredths of millimeters
of vulva (C51.0-C51.9)	Examples: thickness of .75mm = 075 = T1 if skin
of penis (C60.0-C60.9) of scrotum (C63.2) of conjunctiva (C69.0)	thickness of 2.5mm = 250 = T3 if skin thickness of 4.4mm = 440 = T4 if
	skin thickness of 9.9mm or greater = 990
2. Hodgkins Lymphoma (9650-9667)	Code HIV/AIDS status
Non-Hodgkins Lymphoma (9590-9595, 9670-9717)	001 = Yes, present
Kaposi's Sarcoma (9140)	002 = No
	999 = Unknown
3. Mycosis Fungoides (9700)	Code peripheral blood involvement
Sezary's Disease (9701)	000 No peripheral blood involvement
of skin (C44.0-C44.9)	001 <5% atypical circulating cells

of vulva (C51.0-C51.9)	002 >5% atypical circulating cells
of penis (C60.0-C60.9)	003 % not stated
of scrotum (C63.2)	999 Not applicable
4. Malignant histocytosis (9720)	Code 999 = Not applicable
Letterer-Siwe's disease (9722)	
True histiocytic lymphoma (9723)	
Plasma cell tumors (9731-9732)	
Leukemia (9800-9941)	
Immunoproliferative disease (9760-9768)	
Myeloproliferative disease (9950-9989)	
III defined primary site (C76.0-C76.9)	
C42 and any malignancy not listed above	
Unknown primary site (C80.9)	
5. All tumors other than those listed above on lines 1-4, including melanomas of sites other than skin, vulva, penis, scrotum, and conjunctiva.	Code size of primary tumor at largest dimension. Code in millimeters.
	There are special meanings for certain codes
	001 = microscopic focus or foci
	002 = 2mm or less for all sites except breast & lung
	002 = (for breast) mammography dx only; no size given
	002 = (for lung) malig. cells in secretions
	003 = (for breast & lung) 3 mm or less
	999 = tumor size not given
	Examples: tumor is 5mm x 2mm = 005
	tumor is 5cm x 2cm = 050
	tumor is 10.6cm = 106

WEIGHTS AND MEASURES*

SIZES IN CENTIMETERS, MILLIMETERS, INCHES

10 mm = 1 cm	1 cm = 10 mm		
2.5 cm = 1 inch	1 inch = 025 mm		
	DESCRIPTION	NS OF TUMOR SIZES INTE	RPRETED IN MM'S
Fruits		Miscellaneous Foo	d
Apple	070	Doughnut	090
Apricot	040	Egg	050
Cherry	020	Egg, goose	070
Date	040	Egg, hen	050
Fig, dried	040	Egg, bantam	040
Grape	020	Egg, pigeon	030
Grapefruit	010	Egg, robin	020
Kumquat	050	Lentil	009

Lemon	080	Millet	009
Lime	060		
Olive	020		
Orange	090	Money	
Peach	060		
Pear	090	Dime	010
Plum	030	Dollar, silver	040
Tangerine	060	Dollar, half	030
		Nickel	020
Nuts		Quarter	020
		Penny	010
Almond	030		
Chestnut	040		
Chestnut, horse	040	Other	
Hazel	020		
Hickory	030	Ball, golf	040
Peanut	010	Ball, ping pong	030
Pecan	030	Baseball	070
Walnut	030	Eraser or Pencil	010
Bean	010	Fist	090
Bean, Lima	020	Marble	010
Pea	009	Match Head	009
Pea, split	009	Microscopic focus	001

* From Seer Informational Guidebook Training Aids

SEER Lymph Node

Organization	Field Name	ID	Required
KCR	SEER Lymph Node (NodeInvolve)	30530	yes
NAACCR	EODLymph Node Involv	810	yes

Field Length: 1

(Required field with all cases diagnosed from January 1, 2000 to December 31, 2003.)

As of 1-1-2004, leave this field blank and record this information in the Collaborative Stage Item #30570 instead.

If the diagnosis date is before 1-1-2004, record the highest specific lymph node chain that is involved by tumor.

Use the instructions in the SEER Extent of Disease 1998 Codes and Coding Instructions manual, pages 8-9, and the tables that follow, to code this field.

Nodes which are considered "regional nodes" are defined by primary site in the AJCC Manual for Staging of Cancer.

Site of Mets

Organization	Field Name	ID	Required
KCR	Site of Mets 1 (SiteOfMets1)	30730	no
KCR	Site of Mets 2 (SiteOfMets2)	30740	no
KCR	Site of Mets 3 (SiteOfMets3)	30750	no
KCR	Site of Mets 4 (SiteOfMets4)	30760	no
KCR	Site of Mets 5 (SiteOfMets5)	30770	no

Field Length: 2 (x 5)

Record the appropriate code(s) for up to five sites of distant metastases present at the time of initial diagnosis. Include a distant site here if it is considered metastatic by the AJCC Manual for Staging of Cancer. See Appendix E for General Sites Codes.

The following systemic diseases should not have sites of metastases recorded: leukemia, Letterer-Siwe disease, multiple myeloma, reticuloendotheliosis, Hodgkin's and Non-Hodgkin's lymphomas, and unknown primaries.

When you are abstracting an unknown primary, you may not code site(s) of metastases here, because you cannot be sure they are distant sites.

Precede any single digit codes with a zero.

Text

- Case Text
- COVID-19 --DX PROC--LAB TESTS
 COVID-19 Impact BMT
- COVID-19 Impact BRM

- COVID-19 Impact BRM
 COVID-19 Impact CHEMO
 COVID-19 Impact HORMONE
 COVID-19 Impact RADIATION (BEAM)
 COVID-19 Impact RADIATION (ICB)
 COVID-19 Impact RADIATION OTHER
 COVID-19 Impact SURGERY
 COVID-19 TEXT
 Modified By (Case Text)

- Modified By (Case Text)
 Text Local Hospital Id
 Time Modified (Case Text)

Text Local Hospital Id

Organization	Field Name	ID	Required
KCR	Text Local Hospital Id (TextLocalHospId)	70040	yes

Field Length: 10

This is a calculated field which identifies the facility(ies) which entered case text. A case in a multi-facility database may be associated with more than one facility, and thus may have text for each affiliated facility.

Case Text

Organization	Field Name	ID	Required
KCR	Physical Exams (PhysicalExams)	70050	no
NAACCR	TextDX ProcPE	2520	no
KCR	Xray and Scans (XrayAndScans)	70060	no
NAACCR	TextDX ProcX-ray/Scan	2530	no
KCR	Scopes (Scopes)	70070	no
NAACCR	TextDX ProcScopes	2540	no
KCR	Lab Tests (LabTests)	70080	no
NAACCR	TextDX ProcLab Tests	2550	no
KCR	Operative Report (OperativeReport)	70090	no
NAACCR	TextDX ProcOp	2560	no
KCR	Pathology Report (PathologyReport)	70100	no
NAACCR	TextDX ProcPath	2570	no
KCR	Site Text (SiteText)	70110	no
NAACCR	TextPrimary Site Title	2580	no
KCR	Histology Text (HistologyText)	70120	no
NAACCR	TextHistology Title	2590	no
KCR	Staging (StagingText)	70130	no
NAACCR	TextStaging	2600	no
KCR	Treatment Plan (TreatmentPlan)	70135	no
KCR	General Remarks (GeneralRemarks)	70140	no
NAACCR	TextRemarks	2680	no

Santizing Case Text

When copying and pasting text into any Case Text field, it is possible characters entered lie outside the acceptable NAACCR standard character set.

CPDMS will attempt to sanitize the text by replacing or removing characters that should not be entered in Case Text.

The following special characters will be replaced as follows:

Alpha , , to 'a'. Beta, , to 'B'. Mu, , to 'u'. Greater than or equal to , , to '>=' Less than or equal to , , to '<=' Em Dash, — , to '--' En Dash, – , to '--'

Diacritical marks in text will be removed. Any regular character than cannot be entered on a QWERTY keyboard will be replaced with a '?'

Field Length: 3360 (x 10)

In accordance with new CDC/NPCR requirements, KCR began requiring text documentation on all new cases diagnosed January 1, 2001 and after. The documentation must include explanations regarding the history and physical, diagnostic procedures, surgeries performed surgical findings and place of diagnosis.

Text is needed to justify codes selected for specific data elements and to allow for the recording of information that is not coded at all. It is used by the central registry for quality control of the data and to assure that the data meets the standards of ACoS, NAACCR, NCDB, SEER, and NPCR.

It also is utilized to answer questions which arise during the editing and consolidation process performed at the central registry, thus improving the accuracy and timeliness of that process as well. The best code(s) from all sources can generally be selected when the supporting text is sufficient to help verify the decision.

Through more complete documentation in the text fields, it is expected that fewer cases will need to be returned to the hospital for further review and/or clarification and that error rates in data abstraction will be reduced.

TEXT FIELDS

Field Description

70050	History and Physical
70060	X-rays/Scans/Ultrasounds
70070	Scopes/Endoscopic Exams
70080	Laboratory Tests/Markers
70090	Operative Reports
70100	Pathology Reports
70110	Site Text
70120	Histology Text
70130	Staging: CS/Summary/TNM
70135	Treatment Plan
70140	Miscellaneous/General Remarks

GENERAL INSTRUCTIONS

- 1. Select the category from the previous page which is the most logical to you in recording the required information. Record the information only one time even though multiple categories may apply. As an alternative, all information may be documented in the Miscellaneous/General Text field. The information, however, will need to be labeled with the appropriate text field heading.
- 2. Be brief. Don't record in full sentences.
- Use standard medical abbreviations (see APPENDIX I) when possible to save space, i.e., CXR-chest x-ray; LN-lymph node; LAD-lymphadenopathy.
- 4. Record text information on all analytic cases. For non-analytic cases, record all dates and cancer directed therapies regardless of where received at a minimum.
- Record exact terminology from the source document to justify your codes. Be certain to include ambiguous terminology where pertinent to the information coded, i.e., "most likely" primary lung cancer.
- 6. Document both positive and negative findings, i.e., H & P: peau d'orange skin; CT: neg LAD.
- 7. Enter in chronological order the results of diagnostic examinations and cancer directed surgeries. Record the date first, then name of procedure, the results and pertinent information. (New in NAACCR)
- 8. Enter additional staging information in the Staging Text field that is not documented in the other text fields.
- Record in the Miscellaneous/General Text fields information that is overflow from a more specific text field and other pertinent information for which there is no designated field. For overflow information, indicate the name of the field being extended and then the additional pertinent information.
- 10. Date the open text entries in the Miscellaneous/General Text field at the beginning of the entry, including the month and year only. Record your initials at the end of the entry.

Specific Data Item Instructions

Document the following information as indicated in an appropriate text field category.

- 1. Sequence Number Note any history of a previous cancer with emphasis on the most specific site identified and the laterality when multiple primaries involve paired organs. Record date previous cancer diagnosed. Indicate if estimated.
- 2. Topography
 - a. Document the exact anatomic location of the primary tumor including lobe, quadrant, etc. as well as laterality if a paired organ.
 - b. Include any ambiguous terminology used to describe the primary site.
 - c. Record statements that rule out specific sites when patient has multiple cases of cancer, one of which is an unknown primary.
 - Note unusual topography/histology combinations (i.e., pathologist's diagnosis is endometrioid cancer of uterus ICD-O-3 shows C56.9 ovary).
- 3. Histology and Grade
 - a. Record the exact wording used in the Final Pathologic Diagnosis on the pathology report to support the histology code.b. If the final histologic diagnosis is an NOS term and a more definitive histology is found in the body of the report or in a special NOTE or
 - COMMENT section, indicate from which section the histologic diagnosis was coded.
 - c. When a more definitive diagnosis is obtained from a supplementary document such as an immunohistochemistry report or pathologic consultation, note the source document name which provides the final diagnosis.
 - d. Specify the tumor grade exactly as recorded on the pathology report, i.e., II/III (new in NAACCR).
- 4. Diagnosis Date
 - a. Document the date, place, source document, and exact wording of the first occurrence of a positive cancer diagnosis. Remember to include any ambiguous terms used in making the diagnosis.
 - b. Record the age at diagnosis
- 5. Diagnostic Confirmation
 - a. Explain when codes 6, 7 or 8 are utilized, i.e., patient refused further workup. Remember the confirmation field covers the entire history
 - of the patient's cancer from diagnosis to death and should be updated to a lower code whenever appropriate.
- 6. Tumor Size
 - a. Document source of the most definitive size. See Collaborative Staging Manual and Coding Instructions or EOD (for pre-2004 cases) for priority of documents to use in coding this element.

- b. Record all dimensions of the primary tumor; specify the unit of measure given including comparative descriptions such as "golf ballsized" if applicable.
- c. Note such descriptions as diffuse, widespread, entire circumference.
- d. Document instances where a tumor contains both invasive and in-situ components and only the size of the entire lesion is noted.
- 7. Collaborative Staging items
 - a. SEER Extent of Disease (for pre-2004 cases)
 - b. TNM Classification & Grouping
 - i. Record date, name of exam and any positive or negative findings which support the extent of disease coded for each of the staging systems above. Enter details regarding direct extension to other organs or structures, presence of satellite lesions /nodules and location. Be sure to include any ambiguous terminology used to indicate a positive finding.
 - ii. Note disagreement with TNM staging between registrar and physician.
 - iii. Document abstracting "rules" when pertinent, i.e., TNM chapter does not include sarcomas.
 - iv. Enter notation when staging supplied by another facility's registrar/doctor.
- 8. Regional Nodes Positive and Examined
 - a. List exact name(s) of lymph nodes and corresponding number removed from pathology report. Include information regarding laterality of nodes involved.
- 9. Surgery at Primary Site
 - a. Enter the exact wording of the operative procedure performed. Include names of all organs removed "en bloc" and specify as such.
- 10. Surgical Margins
 - a. Document the exact wording from the path report which supports the code selected. Indicate whether this represents a gross or microscopic description.
- 11. Scope of Regional Lymph Node Surgery
- a. List date, exact name(s) of lymph nodes, corresponding number removed and laterality for each separate surgical procedure performed. 12. Surgery at Regional/Distant Sites
 - a. Record the specific organs/tissues removed (partial or total) during the surgical procedure.
- 13. Chemotherapy Code
- a. Note the exact names of agents administered.
- 14. Other Therapy Codes
 - a. Describe in words the procedures performed and/or drugs utilized.
- 15. Date of Last Contact or Death
 - a. Document source of date of death, i.e., obituaries, expired at your facility, quarterly death list, Social Security Death Index (SSDI), KCR Vital Status Report, other health care facility.
- 16. General Remarks
 - a. Note any and all changes requested by KCR, including the date of the request or the name and date of the document from KCR which requests the change.
 - b. Explain any unusual circumstances which impacted the manner in which the case was coded, i.e., an unusual primary site for a particular histologic type verified by an outside institution, i.e., the Armed Forces Institute of Pathology (AFIP).
 - c. Enter reason why no therapy administered if known.
 - d. Should patient refuse further therapy, document therapy type and refusal.
 - e. Specify any dates which are estimated.
 - f. Record recommended treatment(s), that is, unknown if given.
 - g. Indicate information which has been coded from a source other than the medical record and what the source was, i.e., verbal information from another registrar.

Modified By (Case Text)

Organization	Field Name	ID	Required
KCR	Modified By (Case Text) (XModUser)	70150	no

Field Length: 8

The user name of the person who last edited the case text is recorded by the computer in this field.

Time Modified (Case Text)

Organization	Field Name	ID	Required
KCR	Time Modified (Case Text) (XModTime)	70160	no

Field Length: 19

The computer automatically records the date and time the case text was edited. This field is updated each time the text is edited.

COVID-19 --DX PROC--LAB TESTS

Organization	Field Name	ID	Required
KCR	COVID-19 - Diagnosis (COVID19Diagnosis)	80090	yes
KCR	COVID-19 - Diagnosis Date (COVID19DiagDate)	80091	yes
KCR	COVID-19 - Viral Test (COVID19PcrTest)	80092	yes
KCR	COVID-19 - Viral Test Date (COVID19PcrTestDate)	80093	yes
KCR	COVID-19 - Serology Test (COVID19AbTest)	80094	yes
KCR	COVID-19 - Serology Test Date (COVID19AbTestDate)	80095	yes
NAACCR	COVID TEXTDX PROCLAB TESTS	2550	yes

Chose the appropriate code for COVID-19 viral testing per instructions.

Code	Description
COVID-19 VIRAL: POS	Patient has had a positive COVID-19 test.
COVID-19 VIRAL: NEGATIVE	Patient has had negative COVID-19 test.
<blank></blank>	No COVID-19 testing for the patient.

Code the appropriate date for COVID-19 viral test.

Code	Description
MM/DD/YYYY	Patient had a COVID-19 viral test. (Note: Can have partial date, use 99 for unknown values)
<blank></blank>	Patient did not have a COVID-19 viral test.

Choose the appropriate code for COVID-19 antibody test.

Code	Description
COVID-19 Serology: POS	Patient had a positive COVID-19 serology test.
COVID-19 Serology: Negative	Patient had a negative COVID-19 serology test.
<blank></blank>	Patient did not have a COVID-19 serology test.

Code the appropriate date for COVID-19 serology test.

Code	Description
MM/DD/YYYY	Patient had a COVID-19 serology test. (Note: Can have partial date, use 99 for unknown values)
<blank></blank>	Patient did not have a COVID-19 serology test.

Use the COVID TEXT--DX PROC--LAB TESTS text field to record the interpretation and the date of SARS-CoV-2 viral testing and serology testing. Consist ently use the following abstracting format.

COVID-19 [testing type: viral or serology] [interpretation: POS, NEG] [date: mm/dd/yyyy]

- 1. Record separately viral nucleic acid testing from serology testing.
- 2. Always record the interpretation and date of the latest (most recent) positive serology testing.
- 3. Do not record tests with unknown type (viral nucleic acid vs. serology).
- 4. Do not record tests with no interpretation or interpretation unknown.

Record a partial date when interpretation is available and date is not fully known (month/year or year).
 a. Do not approximate the date if unknown.

- Code presumptive positive COVID-19 test results as confirmed.
 Directions when multiple tests with interpretation are available

 a. Record the date of the first positive test when multiple interpretations are available for multiple viral nucleic acid tests.
 - b. Record the interpretation and date of the last negative test when no positive tests are available, but one or multiple negative SARS-CoV-2 viral nucleic acid are documented.

Examples of abstracting

Example 1: COVID-19 viral POS 05/09/2020

Example 2: COVID-19 viral NEG 03/09/2020 antibody POS 05/09/2020

COVID-19 Impact - SURGERY

Organization	Field Name	ID	Required
KCR	COVID-19 Impact – Surgery (COVID19Surg)	80099	yes
NAACCR	COVID TEXT RX SURGERY	2610	yes

Use the COVID TEXT RX -- SURGERY field to record information about surgery delays or modifications due to COVID-19 The text is intended to identify whether the timing and type of surgical treatment offered the patient given the site/histology/stage of disease present at diagnosis was impacted because of the COVID-19 pandemic. No text is required if the first course of treatment was not delayed, rescheduled or otherwise modified. If COVID-19 impacted the timing or surgical options offered, one of five following situations is to be captured in this field.

Code	Description
SURG DC D/T COVID-19	Surgery was not performed due to COVID-19
SURG CHG D/T COVID-19	Type of surgery offered and performed was changed/modified from what is typically recomme nded due to COVID-19
SURG DELAYED D/T COVID-19	Typical surgery recommended was performed but it was delayed due to COVID-19
SURG CHG & DELAYED D/T COVID-19	Type of surgery offered and performed was changed/modified from what is typically recomme nded due to COVID-19 and it was delayed
SURG DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Surgical treatment was recommended before but administered after disease progression
<blank></blank>	Surgical treatment was not changed or delayed due to COVID-19

- When medical documentation indicates that surgery was not performed due to COVID-19, record

 SURG TX DC D/T COVID-19
- 2. When medical documentation is available to indicate that the type of surgery offered and performed was changed/modified from what is typically r ecommended due to COVID-19, record
 - a. SURG TX CHG D/T COVID-19
- When medical documentation is available to indicate typical surgery recommended was performed but it was delayed due to COVID-19, record

 SURG TX DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate type of surgery offered and performed was changed/modified from what is typically recomme nded and it was delayed due to COVID-19, record
 - a. SURG TX CHG & DELAYED D/T COVID-19
- 5. When medical documentation is available to indicate surgical treatment was recommended before but administered after disease progression, record
 - a. SURG TX DELAYED D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record surgical treatment in Second Course Rx fields

COVID-19 Impact - RADIATION (BEAM)

Organization	Field Name	ID	Required
KCR	COVID-19 - Radiation Beam (COVID19Rad)	80100	yes
NAACCR	COVID TEXT RX Radiation Beam	2620	yes

Use the COVID TEXT RX -- RADIATION (BEAM) field to record information about beam radiation delays, discontinuation, or modifications due to COVID-1 9.

Code	Description
XRT DC D/T COVID-19	Beam radiation was not performed due to COVID-19.
XRT CHG D/T COVID-19	Type of beam radiation offered and performed was changed/modified from what is typically recommended due to COVID-19.
XRT DELAYED D/T COVID-19	Typical beam radiation recommended was performed but it was delayed due to COVID-19.
XRT CHG & DELAYED D/T COVID-19	Type of beam radiation offered and performed changed/modified from what is typically recommended due to COVID-19 and it was delayed.
XRT DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Beam radiation treatment was recommended before but administered after disease progression.
<blank></blank>	No change or delay of beam radiation treatment due to COVID-19.

- 1. When medical documentation is available to indicate that beam radiation was discontinued because of COVID-19 pandemic, record a. XRT DC D/T COVID-19
- When medical documentation is available to indicate that beam radiation was changed/modified because of COVID-19 pandemic, record

 a. XRT CHG D/T COVID-19
- 3. When medical documentation is available to indicate that initiation of beam radiation planning or administration was delayed because of COVID-19 pandemic, record
 - a. XRT DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that beam radiation was changed/modified and delayed because of COVID-19 pandemic, rec ord
 - a. XRT CHG & DELAYED D/T COVID-19
- 5. When radiation (beam) was recommended before but administered after disease progression, record
 - a. XRT DELAYED D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record XRT treatment in Second Course Rx fields

COVID-19 Impact - RADIATION OTHER

Organization Field Name		ID	Required
KCR	COVID-19 Impact - Radiation Other (COVID19RadOther)	80101	yes
NAACCR	COVID TEXT RX Radiation Other	2630	yes

Use the COVID TEXT RX -- RADIATION Other field to record information about radiation delays, discontinuation, or modifications due to COVID-19

Code	Description
RT DC D/T COVID-19	Radiation other than beam was not performed due to COVID-19.
RT CHG D/T COVID-19	Type of radiation other than beam offered and performed was changed/modified from what is typically recommended due to COVID-19.
RT DELAYED D/T COVID-19	Typical radiation other than beam recommended was performed but it was delayed due to COVID-19.
RT CHG & DELAYED D/T COVID-19	Type of radiation other than beam was changed/modified due to COVID-19 and it was delayed.
RT DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Radiation other than beam treatment was recommended before but administered after disease progression.
 	No change or delay of beam radiation treatment due to COVID-19.

- 1. When medical documentation is available to indicate that radiation other than beam was discontinued because of COVID-19 pandemic, record a. RT DC D/T COVID-19
- 2. When medical documentation is available to indicate that radiation other than beam offered and performed was changed/modified because of CO VID-19 pandemic, record
 - a. RT CHG D/T COVID-19
- 3. When medical documentation is available to indicate that initiation of radiation other than beam planning or administration was delayed because of COVID-19 pandemic, record
 - a. RT DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that radiation other than beam offered and performed was changed/modified and delayed be cause of COVID-19 pandemic, record
 - a. RT CHG & DELAYED D/T COVID-19
- 5. When radiation other than beam was recommended before but administered after disease progression, record
 - a. RT DELAYED D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record surgical treatment in Second Course Rx fields

COVID-19 Impact - CHEMO

Organization Field Name		ID	Required
KCR	COVID-19 - Chemo (COVID19Chemo)	80102	yes
NAACCR	COVID TEXT RX Chemo	2640	yes

Use the COVID TEXT RX -- CHEMO field to record information about chemotherapy delays, discontinuation, or modifications due to COVID-19.

Code	Description
CHEMO DC D/T COVID-19	Chemo was not performed due to COVID-19.
CHEMO CHG D/T COVID-19	Type of chemo offered and performed was changed/modified from what is typically reco mmended due to COVID-19.
CHEMO DELAYED D/T COVID-19	Typical chemo recommended was performed but it was delayed due to COVID-19.
CHEMO CHG & DELAYED D/T COVID-19	Type of chemo offered was changed.modified from what is typically recommended due to COVID-19 and it was delayed.
CHEMO DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Chemo treatment was recommended before but administered after disease progression.
<blank></blank>	No change or delay of chemo treatment due to COVID-19.

- 1. When medical documentation is available to indicate that chemotherapy regimen was discontinued or not initiated because of COVID-19 pandemic , record
 - a. CHEMO DC D/T COVID-19
- When medical documentation is available to indicate that chemotherapy regimen was changed (e.g. infusion to oral, reduction in the number of cycles, etc.) because of COVID-19 pandemic, record

 CHEMO CHG D/T COVID-19
- 3. When medical documentation is available to indicate that initiation of chemotherapy administration was delayed because of COVID-19 pandemic, record
 - a. CHEMO DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that chemotherapy regimen was changed (e.g. infusion to oral, reduction in the number of cycles, etc.) and delayed because of COVID-19 pandemic, record
 - a. CHEMO CHG & DELAYED D/T COVID-19
- 5. When chemotherapy was recommended before but administered after disease progression, record
 - a. CHEMO delayed D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record chemo treatment in Second Course Rx fields

COVID-19 Impact- HORMONE

Organization	Organization Field Name		Required
KCR	COVID-19 - Hormone (COVID19Hormone)	80103	yes
NAACCR	COVID TEXT RX Hormone	2650	yes

Use the RX TEXT--HORMONE field to record information about hormone therapy delays, discontinuation, or modifications due to COVID-19.

Code	Description
HORMONE DC D/T COVID-19	Hormone therapy was not performed due to COVID-19.
HORMONE CHG D/T COVID-19	Type of hormone therapy offered and performed was changed/modified from what is typically recommended due to COVID-19.
HORMONE DELAYED D/T COVID-19	Typical hormone therapy recommended was performed but it was delayed due to COVID- 19.
HORMONE CHG & DELAYED D/T COVID-19	Type of hormone therapy offered and performed changed/modified due to COVID-19 and it was delayed.
HORMONE DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Hormone therapy treatment was recommended before but administered after disease pro gression.
 dlank>	No change or delay of hormone therapy treatment due to COVID-19.

- 1. When medical documentation is available to indicate that hormone administration was discontinued or not initiated because of COVID-19 pandemic , record
 - a. HORMONE DC D/T COVID-19
- When medical documentation is available to indicate that hormone prescription was changed/modified because of COVID-19 pandemic, record

 a. HORMONE CHG D/T COVID-19
- 3. When medical documentation is available to indicate that initiation of hormone administration was delayed because of COVID-19 pandemic, record
 - a. HORMONE DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that hormone prescription was changed/modified and delayed because of COVID-19 pandem ic, record
 - a. HORMONE CHG & DELAYED D/T COVID-19
- 5. When hormonal therapy was recommended before but administered after disease progression, record
 - a. HORMONE DELAYED D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record Hormone treatment in Second Course Rx fields

COVID-19 Impact - BRM

Organization	Field Name	ID	Required
KCR	COVID-19 - BRM (COVID19BRM)	80104	yes
NAACCR	COVID TEXT RX BRM	2660	yes

Use the RX TEXT--BRM field to record information about BRM or immunotherapy delays, discontinuation, or modifications due to COVID-19.

Code	Description
BRM DC D/T COVID-19	Immunotherapy was not performed due to COVID-19.
BRM CHG D/T COVID-19	Type of immounotherapy offered and performed was changed/modified from what is typically recommended due to COVID-19.
BRM DELAYED D/T COVID-19	Typical immunotherapy recommended was performed but it was delayed due to COVID-19.
BRM CHG & DELAYED D/T COVID-19	Type of immounotherapy offered and performed was changed/modifieddue to COVID-19 and it was delayed.
BRM DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Immunotherapy treatment was recommended before but administered after disease progres sion.
<black></black>	No change or delay of immunotherapy or bone marrow/stem cell transplant treatment due to COVID-19.

- 1. When medical documentation is available to indicate that immunotherapy administration was discontinued or not initiated because of COVID-19 p andemic, record
 - a. BRM DC D/T COVID-19
- When medical documentation is available to indicate that immunotherapy administration was changed/modified (i.e. reduction in the number of cycles) because of COVID-19 pandemic, record

 a. BRM CHG D/T COVID-19
- 3. When medical documentation is available to indicate that initiation of immunotherapy administration was delayed because of COVID-19 pandemic. record
 - a. BRM DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that immunotherapy administration was changed/modified (i.e. reduction in the number of cycles) and delayed because of COVID-19 pandemic, record
 - a. BRM CHG & DELAYED D/T COVID-19
- 5. When immunotherapy was recommended before but administered after disease progression, record
 - a. BRM delayed D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record BRM treatment in Second Course Rx fields

COVID-19 TEXT

Organization	Field Name	ID	Required
KCR	COVID-19 - Diagnosis (COVID19Diagnosis)	80090	yes
KCR	COVID-19 - Diagnosis Date (COVID19DiagDate)	80091	yes
KCR	COVID-19 - Diagnosis, Staging, or Treatment Delayed (COVID19DxStgTxDelay)	80096	yes
KCR	COVID-19 - Diagnosis, Staging, or Treatment Delayed Date (COVID19DxStgTxDelayDate)	80097	yes
KCR	COVID-19 - First Course Changed (COVID19FirstCrsChgOther)	80098	yes
KCR	COVID-19 - Text (COVID19Text)	80105	yes
NAACCR	COVID TEXT REMARKS	2680	yes

Record the applicable code and associated date in this text field as described below. Also record information related to cancer treatment modifications in this field.

Choose U07.1 when patient meets criteria for coding below.

Code	Description
U07.1	Patient meets criteria for coding per instructions.
<blank></blank>	Patient does not meet criteria.

Code the appropriate date using the instructions when patient is eligible for code U07.1.

Code	Description
MM/DD/YYYY	U07.1 is chosen. (Note: Can have a partial date, use 99 for unknown values)
<blank></blank>	U07.1 is not coded.

Instructions for recording ICD diagnosis codes

- 1. Code only a confirmed diagnosis of the 2019 novel coronavirus disease (COVID-19) as documented by a medical provider.
 - a. Record code U07.1 for a confirmed diagnosis
 - i. In this context, "confirmation" does not require documentation of the type of test performed; the provider's documentation that the individual has COVID-19 is sufficient.
 - b. In addition, record code U07.1 when the code was used for diagnosis within the facility EHR, in the hospital discharge, or as a contributing or underlying cause of death.
- 2. Record code U07.1 for a lab confirmed asymptomatic patient
- 3. Do not record code U07.1 when the provider documents "suspected," "possible," "probable," or "inconclusive" any wording of a suspicion of COVID-19
- 4. Registrars are **not** required to record codes for acute respiratory illness associated with COVID-19 (e.g., pneumonia), exposure to COVID, screening for COVID, signs and symptoms without a definitive diagnosis.
 - a. Two lung injury patterns are noted DAD/ARDS and a thrombotic/vasculitis-like picture
- 5. Record the date of confirmed diagnosis [test date (preferred) or office visit date]. Alternatively, record the hospital admission date, or lastly, the hospital discharge date.

Example of abstracting

Example: U07.1 [date: mm/dd/yyyy]

Diagnosis, staging or Treatment DELAYED due to COVID-19 (Z75.3)

Code	Description
Z75.3	Patient has had a delay due to COVID-19.
<blank></blank>	Patient did not have a delay due to COVID -19.

Date of delay for Diagnosis, staging or Treatment due to COVID-19

Code	Description
MM/DD/YYYY	Z75.3 is chosen. Date of decision to postpone treatment.
	(Note: Can have partial date, use 99 for unknown values)
<blank></blank>	Patient does not have code Z75.3.

First course of treatment changed due to COVID-19

Code	Description		
FCOT CHG D/T COVID-19	First Course Therapy was changed due to COVID-19.		
<blank></blank>	First Course Therapy was not changed due to COVID-19.		

Instructions for recording cancer treatment information.

It is always preferable to abstract information about treatment in the treatment text fields (i.e., RX Text). However, information about specific treatment modalities may not be available and the only available information is about treatment in general with no mention of a specific procedure. For this scenario, use the abstraction rules below.

- 1. When first course of treatment was modified because of COVID-19 and no other specific details are provided in the Rx Text fields, record a. FCOT CHG D/T COVID-19 [first course of treatment changed due to COVID-19]
- When diagnosis, staging, treatment (any modality), or other cancer management events have been delayed because of limited access to facilities or postponement of non-essential procedures due to COVID-19, abstract the date of decision to postpone and the Z75.3 code Z75.3 mm/dd/yyyy [unavailability or inaccessibility of health care facilities]
- 3. The abstracter can use both FCOT and Z75.3 at the same time. This combo is required when multiple steps of cancer management (diagnosis, staging, treatment modalities) were affected by unavailability or inaccessibility of oncology care.
- No recording is necessary when the first course of treatment was not delayed, rescheduled or otherwise modified because of the COVID pandemic.

COVID-19 Impact - BMT

Organization	Field Name	ID	Required
KCR	COVID-19 - BMT (COVID19BMT)	80107	yes
NAACCR	COVID TEXT RX BMT	2660	yes

Use the RX TEXT--BMT field to record information about bone marrow/stem cell delays, discontinuation, or modifications due to COVID-19.

Code	Description
BMT DC D/T COVID-19	Bone marrow/stem cell was not performed due to COVID-19.
BMT CHG D/T COVID-19	Type of bone marrow/stem cell offered and performed was changed/modified from what is typically recommended due to COVID-19.
BMT DELAYED D/T COVID-19	Typical bone marrow/stem cell recommended was performed but it was delayed due to COVID-19.
BMT CHG & DELAYED D/T COVID-19	Type of bone marrow/stem cell offered and performed was changed/modified due to COVID- 19 and it was delayed.
BMT DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	bone marrow/stem cell treatment was recommended before but administered after disease pr ogression.
 	No change or delay of bone marrow/stem cell transplant treatment due to COVID-19.

Note: Record the following information for all cancer patients (when applicable) regardless of whether or not they have a COVID-19 diagnosis or test.

- 1. When medical documentation is available to indicate that bone marrow/stem cell transplant administration was discontinued or not initiated becaus e of COVID-19 pandemic, record
- a. BMT DC D/T COVID-19
 2. When medical documentation is available to indicate that bone marrow/stem cell transplant administration was changed because of COVID-19 pa ndemic, record

a. BMT CHG D/T COVID-19

- 3. When medical documentation is available to indicate that initiation of bone marrow/stem cell transplant administration was delayed because of CO VID-19 pandemic. record
 - a. BMT DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that bone marrow/stem cell transplant administration was changed/modified from what is typically recommended and delayed due to COVID-19, record
- a. BMT CHG & DELAYED D/T COVID-19
- 5. When bone marrow/stem cell transplant was recommended before but administered after disease progression, record
 - a. BMT delayed D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record BMT treatment in Second Course Rx fields

COVID-19 Impact - RADIATION (ICB)

Organization	Field Name	ID	Required
KCR	COVID 19 - Radiation ICB (COVID19RadICB)	80106	yes
NAACCR	COVID TEXT RX Radiation ICB	2630	yes

Code	Description
ICB DC D/T COVID-19	Brachytherapy was not performed due to COVID-19.
ICB CHG D/T COVID-19	Brachytherapy was changed due to COVID-19.
ICB DELAYED D/T COVID-19	Brachytherapy was delayed due to COVID-19.
ICB CHG & DELAYED D/T COVID-19	Brachytherapy was changed and delayed due to COVID-19.
ICB DELAYED D/T COVID-19 & GIVEN AS SUB TX AFTER PROGRESSION	Brachytherapy was recommended before but administered after disease progression.
 	No change or delay of beam radiation treatment due to COVID-19.

- 1. When medical documentation is available to indicate that brachytherapy was discontinued because of COVID-19 pandemic, record a. ICB DC D/T COVID-19
- When medical documentation is available to indicate that brachytherapy was changed/modified because of COVID-19 pandemic, record

 ICB CHG D/T COVID-19
- 3. When medical documentation is available to indicate that initiation of brachytherapy or administration was delayed because of COVID-19 pandemic , record
 - a. ICB DELAYED D/T COVID-19
- 4. When medical documentation is available to indicate that brachytherapy was changed/modified and delayed because of COVID-19 pandemic, record
 - a. ICB CHG & DELAYED D/T COVID-19
- 5. When brachytherapy was recommended before but administered after disease progression, record
 - a. ICB delayed D/T COVID-19 & given as subsequent TX after progression
 - b. Note: Record ICB treatment in Second Course Rx fields

Case Misc

- Case Other Sequence Num
- Case Other Site Code
- Year of Diagnosis
- Case Other Comment
- Modified By (Case Other)
 Time Modified (Case Other)
- EOD Coding System
- Vendor
- Census Tract 2000
- Census Tract Certainty 2000
- Census Tract 2010
- Census Block Group 2010
- Census Tract Certainty 2010
- Latitude
- Longitude
- GIS Coordinate Quality
- Date Case Completed
- Date Case Last Updated
- Import Reporting Facility
- Area Development District
- Appalachia
- Beale Code 2003
 Beale Code 2013
- Best Stage Group
- SEER Site
 ICCC Site
- ICCC Extended Site
- Source Status
- Class Hospital Id
- Original Case Type Patient Acc No
- ArchiveFIN
- Modified By (Case)
- Time Modified (Case) • Date of First Recurrence Flag
- Case User Defined Data a
- 2018 Best Stage Group

Case Other Sequence Num

Organization	Field Name	ID	Required
KCR	Case Other Sequence Num (OSeqNo)	20030	yes

Field Length: 2

This field is for recording a history of cancer that was not diagnosed or treated at your hospital. It may also be used to record a subsequent primary which occurs in one of your cancer patients but is not diagnosed or treated by your hospital.

The sequence number represents the order of all reportable primary tumors diagnosed during a patient's lifetime. It counts the occurrence of independent, primary diagnoses, regardless of who must report them, but only if diagnosed in years for which that condition was considered reportable. Thus, it does not include skin malignancies and carcinoma in-situ of the cervix, diagnosed in years when they were not reportable, BUT it does include benign and borderline intracranial tumors diagnosed before 2004.

Enter the number which designates the chronological order of this primary tumor which is not reportable by your hospital.

- 1 1st primary
- 2 2nd primary
- 3 3rd primary
- ... etc.

Single digits will automatically be right justified in the computer.

This field may be repeated as often as necessary for any given patient.

Case Other Site Code

Organization	Field Name	ID	Required	
KCR	Case Other Site Code (OSiteCode)	20040	yes	

Field Length: 2

Record the two digit code for the site group into which this primary malignancy is categorized. Use Appendix C to determine the appropriate site group, based on the anatomic site and histology mentioned.

Site group code "55" is available only for 'Other Primaries' if you cannot determine to which site group the malignancy is coded. If 'lung cancer' is all that is known, code "23" for non-small cell lung.

Starting in 2004, site group 60 is assigned for all benign and borderline intracranial tumors.

Year of Diagnosis

Organization	Field Name	ID	Required
KCR	Year of Diagnosis (ODiagYear)	20050	yes

Field Length: 4

Record the year of diagnosis for the other primary. If the year of diagnosis is unknown, use 9999.

Case Other Comment

Organization	Field Name	ID	Required	
KCR	Case Other Comment (OComment)	20060	no	

Field Length: 30

Enter a brief description of the primary which is not reportable by your institution. You may wish to include information regarding topography, histology, date of diagnosis, the location where this primary was diagnosed or treated, or the reason the case is not reportable by your registry.

Modified By (Case Other)

Organization	Field Name	ID	Required
KCR	Modified By (Case Other) (OModUser)	20070	no

Field Length: 8

The user name of the person who last edited the case type "O" is recorded by the computer in this field.

Time Modified (Case Other)

Organization	Field Name	ID	Required
KCR	Time Modified (Case Other) (OModTime)	20080	no

Field Length: 19

The computer automatically records the date and time the case type "O" record was edited.

EOD Coding System

Organization	Field Name	ID	Required
KCR	EOD Coding System (EODScheme)	30500	No
NAACCR	Coding System for EOD	870	No

Field Length: 1

This is a calculated field which indicates the type of SEER EOD code (based on the year of diagnosis) applied to the tumor. This field is blank for cases diagnosed after January 1, 2004.

Vendor

Organization	Field Name	ID	Required
KCR	Vendor (Vendor)	31320	No
NAACCR	Vendor Name	2170	No

Field Length: 10

This field records the name of the vendor which programmed the software used by the registry. It may be abbreviated as necessary and may include the software version number where available. The code is self-assigned by the vendor.

This field does not appear in the abstract and is not available for data analysis, but is included in NAACCR format export files. It will be automatically populated in records stored and exported by CPDMS.net.

Census Tract 2000

Organization	Field Name	ID	Required
KCR	Census Tract 2000 (CenTract2000)	31370	No
NAACCR	Census Tract 2000	130	No

Field Length: 6

This field records the census tract of a patient's residence at the time of diagnosis, using codes from the Year 2000 Census conducted by the U.S. Census Bureau. The central registry calculates this code from the patient's address at diagnosis using geocoding software. This field is available only in the KCR central registry database and is considered a confidential field.

Census tract codes allow central registries to calculate incidence rates for geographical areas having population estimates. The Census Bureau provides population data for census tracts. Those rates can be used for general surveillance or special geographical and socioeconomic analysis.

Code	Description
000100-999998	Census tract codes
000000	Area not census tracted
999999	Area census tracted, but census tract not available
blank	Census tract 2000 not coded

Census Tract Certainty 2000

Organization	Field Name	ID	Required
KCR	Census Tract Certainty 2000 (CenTractCert2000)	31380	No
NAACCR	Census Tr Certainty 2000	365	No

Field Length: 1

This code indicates the basis of assignment of census tract for an individual record. It is helpful in identifying cases tracted from incomplete information or P.O. Boxes. This information is provided by the geocoding vendor service used by the central registry. Codes are hierarchical, with lower numbers having priority.

Code	Description
1	Census tract based on complete and valid street address of residence
2	Census tract based on residence ZIP + 4
3	Census tract based on residence ZIP + 2
4	Census tract based on residence ZIP code only
5	Census tract based on ZIP code of P.O. Box
6	Census tract based on residence city where city has only one census tract, or based on residence ZIP code where ZIP code has only one census tract
9	Unable to assign census tract or bloc numbering based on available information
blank	Not applicable (e.g., census coding not attempted)

Census Tract 2010

Organization	Field Name	ID	Required
KCR	Census Tract 2010 (CenTract2010)	31381	No
NAACCR	Census Tract 2010	135	No

Field Length: 6

This field is provided for coding census tract of patient's residence at time of diagnosis. Codes are those used by the U.S. Census Bureau for the Year 2010 Census. Census tract codes have a 4-digit basic number and also may have a 2-digit suffix. Census tract numbers range from 0001.00 to 9999.98.

The Census Bureau provides population data for census tracts. Those rates can be used for general surveillance or special geographical and socioeconomic analysis.

Because census tracts for particular cases can change between censuses, the central registry may wish to assign an alternate census tract code to its cases. For example, a registry may code its 2005 cases using both the 2000 and 2010 census tract boundaries. The central registry can use this information for different comparisons.

Code	Description
000100-999998	Census tract codes
000000	Area not census tracted
999999	Area census tracted, but census tract not available
blank	Census tract 2010 not coded

Census Block Group 2010

Organization	Field Name	ID	Required
KCR	Census Block Group 2010 (CenBlockGroup2010)	31382	No
NAACCR	Census Block Group 2010	363	No

Field Length: 1

Description

This field is provided for coding the block group of patient's residence at time of diagnosis, as defined by the 2010 Census.

Rationale

A block group is a subdivision of a census tract designed to have an average of 1500 people, versus a census tract's average of 4500 people. All land area in the United States is described by a census block group in the 2010 Census. The Census Bureau publishes detailed population and socioeconomic data at this level. Block groups thus offer a high level of specificity for geographical and socioeconomic analyses.

A block group has no meaning in the absence of a census tract. Refer to Census Tract Certainty 2010 to ascertain basis of assignment of Census Block Group 2010.

Comment

Numerous registries find the distinction between "attempted, could not be determined" (zero) and "not coded" (blank) to be useful for geocoding planning purposes.

Note: The values 1 through 9 are nominal, with no hierarchy of values. This number determines the first digit of all the blocks which comprise the block group; for instance, census block group 3 would contain blocks numbered 3000 to 3999.

Code	Description
0	Census block group assignment was attempted, but the value could not be determined
1-9	Census block group values as defined by the Census Bureau
Blank	Census Block Group 2010 not coded

Census Tract Certainty 2010

	Organization	Field Name	ID	Required
к	CR	Census Tract Certainty 2010 (CenTractCert2010)	31383	No
N	IAACCR	Census Tr Certainty 2010	367	No

Field Length: 1

Description

Code indicating basis of assignment of census tract for an individual record. Helpful in identifying cases tracted from incomplete information or P.O. Box. This item is not coded by the hospital. Central registry staff assign the code.

Code	Description
1	Census tract based on complete and valid street address of residence
2	Census tract based on residence ZIP + 4
3	Census tract based on residence ZIP + 2
4	Census tract based on residence ZIP code only
5	Census tract based on ZIP code of P.O. Box
6	Census tract/BNA based on residence city where city has only one census tract, or based on residence ZIP code where ZIP code has only one census tract
9	Not assigned, geocoding attempted
blank	Not assigned, geocoding not attempted

Latitude

Organization	Field Name	ID	Required
KCR	Latitude (Latitude)	31390	No
NAACCR	Latitude	2352	No

Field Length: 10

Cancer registry spatial data for a case record represents the point location of the individual's residence on the Earth's surface, expressed as a coordinate pair of latitude and longitude values. These values, which are provided by a geocoding vendor, may be determined by any one of several methods: geocoding, address matching, GPS readings, and interpolation from paper or electronic maps. This field is available only in the KCR central registry database and is considered a confidential field.

Codes

Latitude and longitude data shall always be stored and exchanged as numeric values. Latitude north of the equator is positive. Longitude west of 0 degrees (the Prime Meridian) and east of 180 (approximately the International Date Line) is negative. This applies to the entirety of North America with the exception of the tip of the Aleutian Islands in Alaska.

Latitude is a 10-byte numeric field, right justified. This coordinate may be carried out to 6 decimal places with an explicit decimal point. It has the following format: x12.345678, where 'x' is reserved for a negative sign of the coordinate represents a location south of the equator.

Spatial data are exchanged in "unprojected" latitude and longitude coordinates. The data units will be in decimal degrees (not in degrees, minutes, seconds).

Correct: Latitude = 41.890833

Incorrect: Latitude = 41 deg 53' 27"

Longitude

Organization	Field Name	ID	Required
KCR	Longitude (Longitude)	31400	No
NAACCR	Longitude	2354	No

Field Length: 11

Cancer registry spatial data for a case record represents the point location of the individual's residence on the Earth's surface, expressed as a coordinate pair of latitude and longitude values. These values, which are provided by a geocoding vendor, may be determined by any one of several methods: geocoding, address matching, GPS readings, and interpolation from paper or electronic maps. This field is available only in the KCR central registry database and is considered a confidential field.

Codes

Latitude and longitude data shall always be stored and exchanged as numeric values. Latitude north of the equator is positive. Longitude west of 0 degrees (the Prime Meridian) and east of 180 (approximately the International Date Line) is negative. This applies to the entirety of North America with the exception of the tip of the Aleutian Islands in Alaska.

Longitude is an 11-byte numeric field, right justified. This coordinate may be carried out to 6 decimal places with an explicit decimal point. It has the following format: x123.456789, where 'x' is reserved for a negative sign of the coordinate represents a location west of 0 degrees and east of 180 degrees.

Spatial data are exchanged in "unprojected" latitude and longitude coordinates. The data units will be in decimal degrees (not in degrees, minutes, seconds).

Correct: Longitude = -123.128943

Incorrect: Longitude = -123 deg 7' 44"

GIS Coordinate Quality

Organization	Field Name	ID	Required
KCR	GIS Coordinate Quality (GISCoordQuality)	31401	No
NAACCR	GIS Coordinate Quality	366	No

Description

Code indicating the basis of assignment of latitude and longitude coordinates for an individual record from an address. This data item is helpful in identifying cases that were assigned coordinates based on incomplete information, post office boxes, or rural routes. This item is coded at the central registry, not by the reporting facility. Most of the time, this information is provided by geocoding software. Alternatively, a central registry staff member manually assigns the code. Codes are hierarchical, with lower numbers having priority.

Rationale

Spatial analysis of cancer data often requires identifying data records with a high degree of geographic precision. Researchers can use this code as a basis for selecting records with a degree of precision that is appropriate to the study.

Instructions for Coding: Where multiple codes are applicable, use the lower code value. Note: This data item is similar in function to Census Tract Certainty 1970/80/90 [364] and Census Tract Certainty 2000 [365]. The codes for this data item and the two census tract data items all describe how location information was assigned based on the patient's resident address at the time of diagnosis.

This data item must be populated if Latitude [31390] and Longitude [31400] are also populated.

Code	Description		
00	Coordinates derived from local government-maintained address points, which are based on property parcel locations, not interpolation over a street segment's address range		
01	Coordinates assigned by Global Positioning System (GPS)		
02	Coordinates are match of house number and street, and based on property parcel location		
03	Coordinates are match of house number and street, interpolated over the matching street segment's address range		
04	Coordinates are street intersections		
05	Coordinates are at mid-point of street segment (missing or invalid building number)		
06	Coordinates are address ZIP code+4 centroid		
07	Coordinates are address ZIP code+2 centroid		
08	Coordinates were obtained manually by looking up a location on a paper or electronic map		
09	Coordinates are address 5-digit ZIP code centroid		
10	Coordinates are point ZIP code of Post Office Box or Rural Route		
11	Coordinates are centroid of address city (when address ZIP code is unknown or invalid, and there are multiple ZIP codes for the city)		
12	Coordinates are centroid of county		
98	Latitude and longitude are assigned, but coordinate quality is unknown		
99	Latitude and longitude are not assigned, but geocoding was attempted; unable to assign coordinates based on available information		
Blank	GIS Coordinate Quality not coded		

Date Case Completed

Organization	Field Name	ID	Required
KCR	Date Case Completed (DateCompleted)	31410	No
NAACCR	Date Case Completed	2090	No

Field Length: 11

This item is a calculated field which indicates the date on which the case was initially saved without errors.

Date Case Last Updated

Organization	Field Name	ID	Required
KCR	Date Case Last Updated (DateLastUpdate)	31420	No
NAACCR	Date Case Last Changed	2100	No

Field Length: 11

This computer generated field records the date the case was most recently updated.

Import Reporting Facility

Organization	Field Name	ID	Required
KCR	Import Reporting Facility (ImportReportFacility)	31445	no

Field length: 10

This is a unique code to KCR which represents the facility reporting the case to an out-of-state central registry, such as the Ohio State Cancer Registry or the Veterans Affairs Central Cancer Registry, and then imported into a CPDMS database. This field is automatically coded when an OSDE or VA Central file is imported, and is filled in with the facility's FIN number as contained in the NAACCR import file.

Area Development District

Organization	Field Name (Database Field Name)	ID	Required
KCR	Area Development District (ADDistrict)	31450	Calculated

Field Length: 2

Area Development Districts are multi-county regions of Kentucky, coded as shown below. These are used to calculate regional incidence rates which are more stable than county level rates. This data item is calculated based on the county code; it is not shown on the data entry screen, but is available for data analysis. See also Appendix O for a map of the Area Development Districts.

Kentucky's Area Development Districts (ADDs):

Code	Description	County Code	County Name
01	Purchase District	007	Ballard
01	Purchase District	145	McCracken
01	Purchase District	039	Carlisle
01	Purchase District	105	Hickman
01	Purchase District	075	Fulton
01	Purchase District	083	Graves
01	Purchase District	035	Calloway
01	Purchase District	157	Marshall
02	Pennyrile District	139	Livingston
02	Pennyrile District	055	Crittenden
02	Pennyrile District	143	Lyon
02	Pennyrile District	033	Caldwell
02	Pennyrile District	107	Hopkins
02	Pennyrile District	177	Muhlenberg
02	Pennyrile District	221	Trigg
02	Pennyrile District	047	Christian
02	Pennyrile District	219	Todd
03	Green River District	225	Union
03	Green River District	233	Webster
03	Green River District	101	Henderson
03	Green River District	149	McLean
03	Green River District	183	Ohio
03	Green River District	059	Daviess
03	Green River District	091	Hancock
04	Barren River District	031	Butler
04	Barren River District	061	Edmonson
04	Barren River District	099	Hart
04	Barren River District	227	Warren
04	Barren River District	141	Logan
04	Barren River District	009	Barren
04	Barren River District	169	Metcalfe
04	Barren River District	213	Simpson
04	Barren River District	003	Allen
04	Barren River District	171	Monroe
05	Lincoln Trail District	027	Breckinridge

05	Lincoln Trail District	163	Meade
05	Lincoln Trail District	085	Grayson
05	Lincoln Trail District	093	Hardin
05	Lincoln Trail District	123	Larue
05	Lincoln Trail District	155	Marion
05	Lincoln Trail District	179	Nelson
05	Lincoln Trail District	229	Washington
06	KIPDA District	029	Bullitt
06	KIPDA District	111	Jefferson
06	KIPDA District	185	Oldham
06	KIPDA District	223	Trimble
06	KIPDA District	103	Henry
06	KIPDA District	211	Shelby
06	KIPDA District	215	Spencer
07	Northern Kentucky District	041	Carroll
07	Northern Kentucky District	187	Owen
07	Northern Kentucky District	081	Grant
07	Northern Kentucky District	191	Pendleton
07	Northern Kentucky District	077	Gallatin
07	Northern Kentucky District	015	Boone
07	Northern Kentucky District	117	Kenton
07	Northern Kentucky District	037	Campbell
08	Buffalo Trace District	023	Bracken
08	Buffalo Trace District	201	Robertson
08	Buffalo Trace District	069	Fleming
08	Buffalo Trace District	161	Mason
08	Buffalo Trace District	135	Lewis
09	Gateway District	173	Montgomery
09	Gateway District	165	Menifee
09	Gateway District	011	Bath
09	Gateway District	205	Rowan
09	Gateway District	175	Morgan
10	FIVCO District	043	Carter
10	FIVCO District	089	Greenup
10	FIVCO District	019	Boyd
10	FIVCO District	063	Elliott
10	FIVCO District	127	Lawrence
11	Big Sandy District	153	Magoffin
11	Big Sandy District	115	Johnson
11	Big Sandy District	071	Floyd
11	Big Sandy District	159	Martin
11	Big Sandy District	195	Pike
12	Kentucky River District	129	Lee
12	Kentucky River District	237	Wolfe
12	Kentucky River District	189	Owsley
	Kentucky River District	025	Breathitt
12			

12	Kentucky River District	119	Knott
12	Kentucky River District	133	Letcher
12	Kentucky River District	131	Leslie
13	Cumberland Valley District	203	Rockcastle
13	Cumberland Valley District	109	Jackson
13	Cumberland Valley District	125	Laurel
13	Cumberland Valley District	235	Whitley
13	Cumberland Valley District	121	Knox
13	Cumberland Valley District	013	Bell
13	Cumberland Valley District	051	Clay
13	Cumberland Valley District	095	Harlan
14	Lake Cumberland District	087	Green
14	Lake Cumberland District	217	Taylor
14	Lake Cumberland District	001	Adair
14	Lake Cumberland District	045	Casey
14	Lake Cumberland District	057	Cumberland
14	Lake Cumberland District	053	Clinton
14	Lake Cumberland District	207	Russell
14	Lake Cumberland District	231	Wayne
14	Lake Cumberland District	199	Pulaski
14	Lake Cumberland District	147	McCreary
15	Bluegrass District	097	Harrison
15	Bluegrass District	209	Scott
15	Bluegrass District	073	Franklin
15	Bluegrass District	239	Woodford
15	Bluegrass District	005	Anderson
15	Bluegrass District	167	Mercer
15	Bluegrass District	021	Boyle
15	Bluegrass District	137	Lincoln
15	Bluegrass District	079	Garrard
15	Bluegrass District	151	Madison
15	Bluegrass District	113	Jessamine
15	Bluegrass District	067	Fayette
15	Bluegrass District	017	Bourbon
15	Bluegrass District	181	Nicholas
15	Bluegrass District	049	Clark
15	Bluegrass District	065	Estill
15	Bluegrass District	197	Powell

Appalachia

Organization	Field Name	ID	Required
KCR	Appalachia (Appalachia)	31460	Calculated

This is a calculated field which is based on the patient's county of residence at the time of diagnosis. It allows for analysis of study groups based on Appalachian designation.

This field is not shown on the data entry screen; however, it is available for data analysis.

Code	Туре
0	non-KY County
1	not Appalachian County
2	Appalachian County

Field Size: 1

There are 52 counties in Kentucky that are designated as part of Appalachia. They are:

There are 52 counties in Kentucky that are designated as part of Appalachia. They are
Adair
Bath
Bell
Boyd
Breathitt
Carter
Casey
Clark
Clay
Clinton
Cumberland
Elliott
Estill
Fleming
Floyd
Garrard
Green
Greenup
Harlan
Jackson
Johnson
Knott
Knox
Laurel
Lawrence
Lee
Leslie

Letcher

Lewis

Lincoln

Madison

Magoffin

Martin

McCreary

Menifee

Metcalfe

Monroe

Montgomery

Morgan

Nicholas

Owsley

Perry

Pike

Powell

Pulaski

Robertson

Rockcastle

Rowan

Russell

Wayne

Whitley

Wolfe

Beale Code 2003

Organization	Field Name	ID	Required
KCR	Beale Code 2003 (BealeCode2003)	31470	Calculated
NAACCR	RuralUrban Continuum 2003	3310	Calculated

Field Length: 2

This rural-urban continuum code classifies all U.S. counties by the degree of urbanization and adjacency to a metropolitan area. This code is used in determining eligibility for several Federal programs, and allows researchers to break county-level data into finer residential groups than the standard metro /non-metro.

These codes are based on the June 2003 definition of metropolitan and non-metropolitan counties as determined by the Office of Management and Budget (OMB).

Note: Adjacent counties must not only be physically adjacent to a metropolitan area, but have at least 2 percent of the employed labor force in the nonmetro county commuting to central metro counties.

For more information about the rural-urban continuum codes contact:

Calvin Beale (202-694-5416).

*BEALE CODE

Code	Description
1	Counties in metro areas of 1 million population or more
2	Counties in metro areas of 250,000 to 1 million population
3	Counties in metro areas of fewer than 250,000 population
4	Urban population of 20,000 or more, adjacent to metro area
5	Urban population of 20,000 or more, not adjacent to a metro area
6	Urban population of 2,500 to 19,999, adjacent to a metro area
7	Urban population of 2,500 to 19,999, not adjacent to a metro area
8	Rural, adjacent to a metro area
9	Rural, not adjacent to a metro area
98	Program run; not in table; outside of state of reporting institution
99	Unknown
-1	Program not run; record not coded

This code is calculated from the patient's county of residence at the time of diagnosis. It is not shown on the data entry screen; however, it is available for data analysis.

Beale Code 2013

Organization	Field Name	ID	Required
KCR	Beale Code 2013 (BealeCode2013)	31471	Calculated
NAACCR	RuralUrban Continuum 2013	3312	Calculated

Field length: 2

The RuralUrban Continuum (2013) codes separate counties into four metropolitan and six non-metropolitan categories, based on the size their populations and form a classification scheme that distinguishes metropolitan counties by size and non-metropolitan counties by degree of urbanization and proximity to metro areas.

These codes can be derived electronically, using patients' state and county at diagnosis, so registrars do not need to provide them. FIPS state and county code mappings to Beale Codes can be obtained in an Excel file athttp://www.ers.usda.gov/Data/RuralUrbanContinuumCodes.

The code is a 9-point continuum, transmitted in standard NAACCR record form with a leading 0, (01-09). Abstractors do not enter these codes.

Areas that are not included in the Rural-Urban Continuum code table, such as Canadian provinces/territories and U.S. territories (other than Puerto Rico) will be coded 98. Records for non-residents of the state of the reporting institution (County at DX = 998) also will be coded 98. If Addr at DX–State is XX, YY or ZZ, or if County at DX = 999, the Rural-Urban Continuum will be coded 99.

Metro	Metropolitan Counties (00-03)				
01	Counties in metro areas of 1 million population or more				
02	Counties in metro areas of 250,000 to 1 million population				
03	Counties in metro areas of fewer than 250,000 population				
Nonm	netropolitan Counties (04-09)				
04	Urban population of 20,000 or more, adjacent to a metro area				
05	Urban population of 20,000 or more, not adjacent to a metro area				
06	Urban population of 2,500 to 19,999, adjacent to a metro area				
07	Urban population of 2,500 to 19,999, not adjacent to a metro area				
08	Completely rural or less than 2,500 urban population, adjacent to a metro area				
09	Completely rural or less than 2,500 urban population, not adjacent to a metro area				
98	Program run, but: (1) area is not included in Rural-Urban Continuum code table, or (2) record is for resident outside of state of reporting institution				
99	Unknown				
Blank	Program not run; record not coded				

Best Stage Group

Organization	Field Name	ID	Required
KCR	Best Stage Group (BestStgGrp)	31510	Calculated

Field Length: 2

This is a field calculated by the computer. It does not appear on the Abstract Form. However, it is available for analysis and reporting purposes. It is calculated from the CS derived stage or the pathologic and clinical TNM Stage Groups recorded for this case. For cases diagnosed from 1/1/2004 through 12/31/2017, the Best Stage Group is the CS derived AJCC 6 stage group. For cases diagnosed prior to 1/1/2004, the value in this field is equal to the pTNM Stage Group, unless that value is '88' or '99' or there was pre-operative treatment (p Descriptor is 'Y'). Then it is equal to the value in the cTNM Stage Group. For case diagnosed 01/01/2018 and forward see 2018 Best Stage Group.

AJCC 6 Storage Code	Description
00	Stage 0
01	Stage 0a
02	Stage 0is
10	Stage I
11	Stage I NOS
12	Stage IA
13	Stage IA1
14	Stage IA2
15	Stage IB
16	Stage IB1
17	Stage IB2
18	Stage IC
19	Stage IS
20	Stage IEA
21	Stage IEB
22	Stage IE
23	Stage ISA
24	Stage ISB
30	Stage II
31	Stage II NOS
32	Stage IIA
33	Stage IIB
34	Stage IIC
35	Stage IIEA
36	Stage IIEB
37	Stage IIE
38	Stage IISA
39	Stage IISB
40	Stage IIS

41	Stage IIESA
42	Stage IIESB
43	Stage IIES
50	Stage III
51	Stage III NOS
52	Stage IIIA
53	Stage IIIB
54	Stage IIIC
55	Stage IIIEA
56	Stage IIIEB
57	Stage IIIE
58	Stage IIISA
59	Stage IIISB
60	Stage IIIS
61	Stage IIIESA
62	Stage IIIESB
63	Stage IIIES
70	Stage IV
71	Stage IV NOS
72	Stage IVA
73	Stage IVB
74	Stage IVC
88	N/A
90	Stage Occult
99	Stage Unknown

SEER Site

Organization	Field Name	ID	Required
KCR	SEER Site (SEERSite)	31520	Calculated

Field Length: 5

This field is calculated by the computer. It is based on ICD-O-3 topography and histology codes and is used by SEER to ensure that site/type definitions in the SEER Cancer Statistics Review are consistent over time. These sites can be found at http://seer.cancer.gov/siterecode.

Code	Description
20010	Lip
20020	Tongue
20030	Salivary Gland
20040	Floor of Mouth
20050	Gum and Other Mouth
20060	Nasopharynx
20070	Tonsil
20080	Oropharynx
20090	Hypopharynx
20100	Other Oral Cavity and Pharynx
21010	Esophagus
21020	Stomach
21030	Small Intestine
21041	Cecum
21042	Appendix
21043	Ascending Colon
21044	Hepatic Flexure
21045	Transverse Colon
21046	Splenic Flexure
21047	Descending Colon
21048	Sigmoid Colon
21049	Large Intestine, NOS
21051	Rectosigmoid Junction
21052	Rectum
21060	Anus, Anal Canal and Anorectum
21071	Liver
21072	Intrahepatic Bile Duct
21080	Gallbladder
21090	Other Biliary
21100	Pancreas
21110	Retroperitoneum
21120	Peritoneum, Omentum and Mesentery

21130	Other Digestive Organs
22010	Nose, Naval Cavity and Middle Ear
22020	Larynx
22030	Lung and Bronchus
22050	Pleura
22060	Trachea, Mediastinum and Other Respiratory Organs
23000	Bones and Joints
24000	Soft Tissue including Heart
25010	Melanoma of the Skin
25020	Other Non-Epithelial Skin
26000	Breast
27010	Cervix Uteri
27020	Corpus Uteri
27030	Uterus, NOS
27040	Ovary
27050	Vagina
27060	Vulva
27070	Other Female Genital Organs
28010	Prostate
28020	Testis
28030	Penis
28040	Other Male Genital Organs
29010	Urinary Bladder
29020	Kidney and Renal Pelvis
29030	Ureter
29040	Other Urinary Organs
30000	Eye and Orbit
31010	Brain
31040	Cranial Nerves Other Nervous System
32010	Thyroid
32020	Other Endocrine including Thymus
33011	Hodgkin - Nodal
33012	Hodgkin - Extranodal
33041	NHL Nodal
33042	NHL Extranodal
34000	Myeloma
35011	Acute Lymphocytic Leukemia
35012	Chronic Lymphocytic Leukemia
35013	Other Lymphocytic Leukemia
	Acute Myeloid Leukemia

35022	Chronic Myeloid Leukemia
35023	Other Myeloid Leukemia
35031	Acute Monocytic Leukemia
35041	Other Acute Leukemia
35043	Aleukemic, Subleukemic and NOS
36010	Mesothelioma
36020	Kaposi Sarcoma
37000	Miscellaneous Malignant Cancer
99999	Invalid

ICCC Site

Organization	Field Name	ID	Required
KCR	ICCC Site (ICCCSite)	31522	No

Field Length: 3

This is a calculated field which does not appear on the abstract form, but is available in data analysis. The International Classification of Childhood Cancer, 3rd Edition (ICCC3) classifies childhood cancer based on tumor morphology and primary site, with an emphasis on morphology, rather than the emphasis on primary site for adults. A guide to the three digit codes may be found on SEER's website: http://seer.cancer.gov/iccc/iccc3.html

ICCC Extended Site

Organization	Field Name	ID	Required
KCR	ICCC Extended Site (ICCCExtendedSite)	31523	No

Field Length: 3

This is a calculated field which does not appear on the abstract form, but is available in data analysis. The International Classification of Childhood Cancer, 3rd Edition (ICCC3) classifies childhood cancer based on tumor morphology and primary site, with an emphasis on morphology, rather than the emphasis on primary site for adults. A guide to the three digit extended site codes may be found on SEER's website: http://seer.cancer.gov/iccc/iccc3_ext.html

Source Status

Organization	Field Name	ID	Required
KCR	Source Status (DataSrc)	31530	No

Field Length: 1

This field identifies the source of all facilities that submitted the case to the central registry. It is automatically calculated at the central registry and does not appear in the patient abstract. It is available for analysis by KCR to identify cases submitted by non-Kentucky facilities.

Source Status is often used to identify cases which cannot be released by KCR to third parties, due to the constraints of data exchange agreements.

Code	Description
1	Kentucky only
2	Out of state only
3	Both Kentucky and out of state

Class Hospital Id

Organization	Field Name	ID	Required
KCR	Class Hospital Id (ClassHospId)	31720	no
NAACCR	Reporting Facility	540	no

Field Length: 11

This calculated field displays the facility ID number of the hospital that owns the case. For a multi-facility database, this is the hospital with the highest class of case.

Original Case Type

Organization	Field Name	ID	Required
KCR	Original Case Type (CaseTypeOrig)	31710	no

Field Length: 1

This field is automatically filled in by the computer. It indicates cases which were originally abstracted as case type 'S' (short forms). The use of short forms was discontinued by KCR in 2000 and all existing short forms were converted to regular abstracts (case type 'A'). These converted cases have certain limitations regarding editing follow-up or adding therapy. Contact KCR technical support staff before attempting to edit cases in which case type original is S.

Patient Acc No

Organization	Field Name	ID	Required
KCR	Patient Acc No (PatAccNo)	31721	yes
NAACCR	Accession NumberHosp	550	yes

Field Length: 10

A unique accession number is assigned to each patient for each reporting institution affiliated with the patient. The accession number identifies the patient even if multiple primaries exist. The first four digits of the accession number specify the year in which the patient was first seen at the reporting institution for the diagnosis and/or treatment of cancer. The last six numbers are the numerical order the reporting institution entered their first reportable case of this patient into the registry's database.

The computer calculates these fields by copying in the accession number of the first abstracted case entered by each reporting institution for this patient.

In a single facility database there is only one reporting institution and therefore only one patient accession number for each patient. In a multi-facility database, the patient accession number displayed in the case will be the one associated with the facility in the Class Hospital Id field.

ArchiveFIN

Organization	Field Name	ID	Required
KCR	ArchiveFIN (ArchiveFIN)	31725	No
NAACCR	Archive FIN	3100	No

Field Length: 10

This field identifies the CoC Facility Identification Number (FIN) of the facility at the time it originally accessioned the case.

When a CoC approved facility merges with another facility or joins a network, its unique FIN may change. Archive FIN preserves the identity of the facility at the time the case was initially accessioned so that records resubmitted subsequent to such a reorganization can be recognized as belonging to the same facility.

Archive FIN is automatically coded by CPDMS.net. This item never changes and must be included as part of the patient record when data are submitted to the NCDB. For facilities that have not merged, Archive FIN and FIN are the same.

Modified By (Case)

Organization	Field Name	ID	Required
KCR	Modified By (Case) (CModUser)	31730	no

Field Length: 8

This is a calculated field which records the user name of the last individual to modify case data. It is updated each time the record is edited.

Time Modified (Case)

Organization	Field Name	ID	Required
KCR	Time Modified (Case) (CModTime)	31740	no

Field Length: 19

This field automatically records the date and time that case data was last modified.

Date of First Recurrence Flag

Organization	Field Name	ID	Required
KCR	Date of First Recurrence Flag (DateFirstRecurFlag)	31811	no
NAACCR	Recurrence Date1st Flag	1861	no

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Date of First Recurrence (item #31810).

Codes

Code	Description	
10 No information whatsoever can be inferred (that is, unknown if the patient was ever disease free or had a first recurrence)		
11	No proper value is applicable in this context (for example, patient became disease free after treatment and never had a recurrence, or pa was never disease free)	
12	A proper value is applicable but not known (that is, there was a recurrence but the date is unknown)	
(blank)	A valid date value is provided	

Case User Defined Data a

Organization	Field Name	ID	Required
KCR	Case User Defined Data a (CUData1)	32070	No
KCR	Case User Defined Data b (CUData2)	32080	No
KCR	Case User Defined Data c (CUData3)	32090	No
KCR	Case User Defined Data d (CUData4)	32100	No
KCR	Case User Defined Data e (CUData5)	32110	No
KCR	Case User Defined Data f (CUData6)	32120	No
KCR	Case User Defined Data g (CUData7)	32130	No
KCR	Case User Defined Data h (CUData8)	32140	No
KCR	Case User Defined Data i (CUData9)	32150	No
KCR	Case User Defined Data j (CUData10)	32160	No
KCR	Case User Defined Data k (CUData11)	32170	No
KCR	Case User Defined Data I (CUData12)	32180	No
KCR	Case User Defined Data m (CUData13)	32190	No
KCR	Case User Defined Data n (CUData14)	32200	No
KCR	Case User Defined Data o (CUData15)	32210	No
KCR	Case User Defined Data p (CUData16)	32220	No
KCR	Case User Defined Data q (CUData17)	32230	No
KCR	Case User Defined Data r (CUData18)	32240	No
KCR	Case User Defined Data s (CUData19)	32250	No
KCR	Case User Defined Data t (CUData20)	32260	No

Field Length: 15 (x20)

This element provides up to 20 fifteen-digit fields for coding additional diagnostic procedures or other relevant information at the case level. These will be user defined fields based on the individual institution's need or desire to track patterns of diagnostic and other procedures with particular types of cancer patients.

For example: The following codes for colon cancers could be established for the first three fields:

- A. Patient Height
- B. Patient Weight
- C. Diagnosed Via Screening Colonoscopy? (Y/N)

2018 Best Stage Group

Organization	Field Name	ID	Required
KCR	2018 Best Stage Group (BestStgGrp2018)	31511	Calculated

For 2018 cases Best Stage Group will be calculated by taking the the Path Stage Group if it is not=99, otherwise we will take the Clinical Stage Group.

Field Length: 2

This is a field calculated by the computer. It does not appear on the Abstract Form. However, it is available for analysis and reporting purposes. It is calculated. For 2018 cases Best Stage Group will be calculated by taking the the Path Stage Group if it is not=99, otherwise we will take the Clinical Stage Group.

Code	Туре
0	Clinical Stage 0
1	Clinical Stage 0a
2	Clinical Stage 0is
5	Pathologic Stage 0
6	Pathologic Stage 0a
7	Pathologic Stage 0is
10	Clinical Stage I
11	Clinical Stage IA
12	Clinical Stage IA1
13	Clinical Stage IA2
14	Clinical Stage IA3
15	Clinical Stage IB
16	Clinical Stage IB1
17	Clinical Stage IB2
18	Clinical Stage IC
19	Clinical Stage IS
20	Clinical Stage IE
21	Pathologic Stage I
22	Pathologic Stage IA
23	Pathologic Stage IA1
24	Pathologic Stage IA2
25	Pathologic Stage IA3
26	Pathologic Stage IB
27	Pathologic Stage IB1
28	Pathologic Stage IB2
29	Pathologic Stage IC
30	Pathologic Stage IS
31	Pathologic Stage IE
40	Clinical Stage II
41	Clinical Stage IIA

42	Clinical Stage IIA1
43	Clinical Stage IIA2
44	Clinical Stage IIB
45	Clinical Stage IIC
46	Clinical Stage IIE
47	Clinical Stage II bulky
50	Pathologic Stage II
51	Pathologic Stage IIA
52	Pathologic Stage IIA1
53	Pathologic Stage IIA2
54	Pathologic Stage IIB
55	Pathologic Stage IIC
56	Pathologic Stage IIE
57	Pathologic Stage II bulky
60	Clinical Stage III
61	Clinical Stage IIIA
62	Clinical Stage IIIA1
63	Clinical Stage IIIA2
64	Clinical Stage IIIB
65	Clinical Stage IIIC
66	Clinical Stage IIIC1
67	Clinical Stage IIIC2
68	Clinical Stage IIID
70	Pathologic Stage III
71	Pathologic Stage IIIA
72	Pathologic Stage IIIA1
73	Pathologic Stage IIIA2
74	Pathologic Stage IIIB
75	Pathologic Stage IIIC
76	Pathologic Stage IIIC1
77	Pathologic Stage IIIC2
78	Pathologic Stage IIID
80	Clinical Stage IV
81	Clinical Stage IVA
82	Clinical Stage IVA1
83	Clinical Stage IVA2
84	Clinical Stage IVB
85	Clinical Stage IVC
90	Pathologic Stage IV
91	Pathologic Stage IVA
92	Pathologic Stage IVA1

93	Pathologic Stage IVA2
94	Pathologic Stage IVB
95	Pathologic Stage IVC
97	Not Applicable
98	Occult Carcinoma
99	Not Recorded

Census Tract

Field Length: 6

For cases diagnosed prior to 1998, the census tract 1970/80/90 code identifies the patient's usual residence when the tumor was diagnosed. The central registry calculates this code from the patient's address at diagnosis. This field is available only in the KCR central registry database and is considered a confidential field.

A census tract is a small statistical subdivision of a county. Census tract codes originate from the U.S. Census Bureau, and are constructed using the patient's address. Codes are available from state health departments or the U.S. Census Bureau. Census tracts change as the population changes.

To interpret census tract, assume that the decimal point is between the fourth and fifth positions of the field. Add zeros to fill all six positions.

EXAMPLE: Census tract 409.6 would be coded 040960, and census tract 516.21 would be coded 051621.

Special codes:

Code	Description	
000000	Area is not census tracted	
999999	Area is census tracted, but census tract is not available	

Census Tract Coding System

Field Length: 1

A census tract is a small statistical subdivision of a county with (generally) between 2,500 and 8,000 residents. The boundaries of census tracts are established cooperatively by local committees and the Census Bureau. An attempt is made to keep the same boundaries from census to census so that historical comparability will be maintained. This goal is not always achieved; old tracts may be subdivided due to population growth, disappear entirely, or have their boundaries changed. The census tract definition used to code the case's census tract field must be recorded so that data are correctly grouped and analyzed.

Codes	Description
0	Not tracted
1	1970 Census Tract Definition
2	1980 Census Tract Defintion
3	1990 Census Tract Definition (1988 + diagnoses)
4	2000 Census Tract Definitions (2000 + diagnoses)

Seer Extent Of Disease

NOTE: This EOD coding scheme is required by KCR for cases diagnosed from January 1, 2000 through December 31, 2003. As of January 1, 2004, data in fields 30490-30530 - Tumor Size, SEER Extent, Pathologic Extent for Prostate, and SEER Lymph Node Involvement - will no longer be collected. Instead, this information will be captured in the Collaborative Stage fields 30540-30680.

The extent of disease scheme used for cases diagnosed after 1988 by SEER is composed of:

Size of Primary Tumor (3 digits)

Extension (2 digits) plus 2 additional digits for prostate pathologic extent

Lymph Nodes (1 digit)

Number of Positive Regional Lymph Nodes (2 digits)

Number of Regional Lymph Nodes Examined (2 digits)

The codes and coding instructions for the SEER Extent of Disease--1988 are detailed in SEER Extent of Disease Codes-- 1988, Codes and Coding Instructions, third edition (revised in 1998). This reference contains the site specific codes for items 30490, 30510, 30520, and 30530: tumor size, SEER extension, prostate pathologic extent, and lymph node involvement.

Extent of Disease should include all information available within four months of diagnosis in the absence of disease progression or through completion of surgery(ies) in first course treatment, whichever is longer. Except for tumor size, Extent of Disease information obtained after treatment with neoadjuvant chemotherapy, radiation therapy, hormonal therapy, or immunotherapy may be included.

All schemes apply to all histologies, unless otherwise noted.

The priority for using information is pathologic, operative and clinical findings.

For "Death Certificate Only" cases, this field is to be coded '999999999' except for death certificate only prostate cases, which are coded '999909999990'.

CPDMS Create Case From Pathology Report Application

This page is to demonstrate the capabilities for populating case data using a pathology report.

You may read through this guide or hop to a specific topic using the following table of contents:

- 1. Pathology Report Search
- 2. Selecting A Pathology Report
- 3. Copying the Discrete Pathology Data to the Case Data
- 4. The Date of Diagnosis Field and Date Types
- 5. Linking the Pathology Report
- 6. The Reset Button
- 7. The Validate Address Button
- 8. Choosing What Case Type to Create
- 9. The Full Abstract Data Panel Fields
- 10. The Case Other Data Panel Fields
- 11. The Create Button
- 12. Create Full Abstract
- 13. Create Case Other Data
- 14. Sample Errors
- 15. Additional Features
 - a. Field Links
 - b. Customizable Interface Options

Pathology Report Search:

On the "Create Case" action, CPDMS will perform a quick search over the Pathology Report Database using the Patient's SSN, Date of Birth, and First and Last Name that is being accessed. In our example we are continuing on from our Create Patient from a Pathology Report example which means our search criteria are:

- SSN = 987-65-4321
- First Name = "PATFIRST"
- Last Name = "PATLAST"
- Date of Birth = "04-04-1965"

One thing different from the search in our example, is we will **always** have the Date of Birth for the search. Users do not have to enter a Date of Birth on patient create. However, DOB is a mandatory patient data item, so we will always have this piece of information when creating a case.

If a report matches on the search criteria, CPDMS is directed to a page similar to the image below:

CPDMS first loads the user info and searches for the matching pathology reports, and it will show the following load screen:

Bad	c -				(*)
ct	Full Abstract			Reset	Pathology Report Data
Full Abstract	Sequence No. : Date of Diagnosis :	mm/dd/YYYY			Date of Diagnosis:
Case Other Data	<u>Topography</u> : <u>Histology</u> : <u>Behavior</u> : <u>CS Factor 25 & Schema</u> :		× ×		
0	Path Report No. : Hosp. Chart No. :				Path Report No.: Hosp. Chart No.:
	Class of Case : Address @ Diagnosis Address 1: Address 2: City,State,Country: Zip Code:	- Valid Create X No pathology report linked	Loading Pat	ient Info	Pathology Address Address 1: Address 2: City,State: Zip Code: Copy & Link Path Data
Patho	ology Details		Pathology Repor	t Text	
	SSN Date of Birth	Full Name	Select a path	ology re	port to auto-populate patient information
	✓ Page 0 of 0 ≥ ≥	No data to display			

In this example we are creating a case with the patient who has the SSN, Last Name, First Name, and Date of Birth of "987-65-4321", "PATLAST", "PATFIRST", "04/04/1965" highlighted in the orange box.

The facility, username, and feedback link are also displayed in the blue boxes.

Once the search has been loaded, all pathology reports that have a **relatable match** are shown in the bottom left grid panel of the application denoted in **p** urple box below:

There are 28 pathology reports found matching the patient criteria. A user will normally see a handful of pathology reports, this patient has so many to demonstrate the sorting and multitude of scores in the **scoring column**.

The green background shows which fields in the pathology report with the ones searched over denoted in the purple box.

Back	c .			Т	RAINING D	ATABASI	E (90201)	DAVID RUST [+]
ť	Full Abstract					Reset	IM17-6330 - Selected Pathology Report Data	
Full Abstract	Г	987-65-432	1 PATLAST, PATFIRST	(04)	/04/1965)		987-65-4321 PATLAST, PATFIRST (04/04/1965)
ull At	Se	equence No. :	1					
	Date	of Diagnosis :	mm/dd/YYYY 🖪				Date of Diagnosis: Do not copy date	¥
ata		Topography :			~			
er D		Histology :			~	7		
oth		Behavior :						
Case Other Data	CS Factor 2	25 & <u>Schema</u> :						
	Pat	h Report No. :					Path Report No.: IM17-6330	
		p. Chart No. :		-			Hosp. Chart No.: 123456789	
		ess @ Diagnosis -					Pathology Address	
		Address 1:					Address 1: 1234 TEST STREET CT	
		Address 2:					Address 2:	
	City,	State, Country:			, ,		City, State: LEXINGTON, KY	
		Zip Code:	-	Valid	ate Address		Zip Code: 40503	
			Create				Copy & Link Path Data	
			X No pathology report link	ed			copy deliner adresa	
			0,,					
Patho	ology Details				IM17-6330 - Se	elected Pat	thology Report Text	
Score	SSN	Date of Birth	Full Name		PATHOLOGY TE			^
100	987-65-4321	04/04/1965	PATLAST, PATFIRST M.	^	TESTING CANC LEXINGTON, K			
90	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.				Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59	
85	987-65-4321	04/04/1965	PATLAST, PATFIRST <mark>A</mark> M.			I	Page 1	
85	987-65-4321	04/04/1965	PATLAST, PATFIRSTA M.		DEPARTMENT O AND LABORAT			
85	987-65-4321	04/04/1965	PATLAST, PATFIRST M.		IMMUNO-MOLEC Phone: 859-8		HOLOGY Fax:555-555-555	
80	123-45-6789	04/04/1965	PATLAST, PATFIRST M.		Email: nopat	h@test.co	DM IM17-6332	
75 14	987-65-4321	04/21/1965	PATLAST, PATFIRSTA M. 1 - 25 o		PTH Report	ed: 8/20/	ange, MD Service: /2017 02:02	
<u> </u>	, la dyc 1	0.2	1-200		DTRECTOR/SU	PERVISOR:	: JJ. Jameson	¥

The first column in this grid panel displays the **match score** of each pathology report. The higher the **match score** the more likely the pathology report matches the patient SSN, First and Last Name, and Date of Birth. These scores range from 100 (all search items match) to 20 (Partial match on first and last name). The pathology report this example uses has a score of 100 meaning all the search criteria matched exactly with the pathology report data. By default, the grid is sorted on the **match score** from the highest to lowest.

NOTE EXAMPLE: Sometimes the patient information doesn't match <u>exactly</u> with what is in the pathology report database. If the patient info is SSN = "123-45-6789", Patient Last Name="PATLAST", Patient First Name = "PATFIRST", and DOB = 19650421 as denoted by the pathology report selected in **blue** b ox. The **mismatched** data will show up in **red** in the grid row denoted in **blue** and the **orange** box. Please notice in our working example all the data is **gre en** which shows that all criteria being searched matches the pathology report selected.

Back				١	FRAINING DA	TABASI	E (90201)	DAVID RUST [+]
Ŀ	Full Ab	stract				Reset	11	M17-6336 - Selected Pathology Report Data	
Full Abstract			987-65-432	1 PATLAST, PATFIRST (04	/04/1965)			123-45-6789 PATLASTA, PATFIRSTA	(04/21/1965)
ull A		Se	quence No. :	1			1		
		<u>Date</u>	of Diagnosis :	mm/dd/YYYY				Date of Diagnosis: Do not copy date	~
Case Other Data			Topography :		×]			
ler D			Histology :		×]			
e otł			Behavior :						
Casi	<u>CS F</u>	actor 2	5 & Schema :						
		Path	Report No. :					Path Report No.: IM17-6336	
		Hos	p. Chart No. :					Hosp. Chart No.: 123456789	
	ſ	Addre	ss @ Diagnosis —			_		Pathology Address	
			Address 1:					Address 1: 1234 TEST STREET CT	
			Address 2:					Address 2:	
		City,	State, Country:			- 1		City, State: LEXINGTON, KY	
			Zip Code:	- Valio	date Address			Zip Code: 40503	
				Create				Copy & Link Path Data	
				X No pathology report linked					
Patho	ology De	tails			IM17-6336 - Sel	ected Pat	hol	logy Report Text	
Score			Date of Birth	Full Name	PATHOLOGY TES	T HOSPIT	TAL		^
45	123-45	-6789	04/04/1965	PATLAST, NOTFIRST M.	TESTING CANCE LEXINGTON, KE			PATLAST, PATFIRST 503 04/04/1965 (Age: 5	52) MW
45	123-45	-6789	04/04/1965	PATLAST, NOTFIRST M.	,	c	Col	lect Date: 8/10/2017 01:01	-,
20	123-45	-6789	04/21/1965	PATLAST, PATFIRSTAM.				eipt Date: 8/10/2017 15:59 me 1	
					DEPARTMENT OF AND LABORATO IMMUNO-MOLECU Phone: 859-86 Email: nopath ATTENDING MD:	RY MEDIC ULAR PATH 7-5309 Qtest.co	CIN HOL	E	
14	🖣 🕴 Page	2	of 2 🕑 🕅	26 - 28 of 28	PTH Reporte DIRECTOR/SUP				~

If a report does not match the search criteria, CPDMS will continue with the original create case workflow (shown below):

		CANCER PATIE	NT DATA MAI	AGEME	NT SYSTEM	net	[+]
DAVID RUST			TRAINING DATA	ABASE		Creat	e Case Data
<u>L</u> ocate	<u>V</u> iew	<u>C</u> reate	<u>K</u> ey-Change	<u>E</u> dit	<u>D</u> elete	L <mark>o</mark> gout	<u>R</u> eturn
Patien	t Reco	rd7					
Soc Sec Nu	umber	987-65-4321					
Last Name		PATLAST	Contact Patier		/es		
First Name		PATFIRST	User Defined D		No		
Total Cases	5	0	Death Certifica	ite l	No		
				_	_		
			Create Case	e Recor	d		
		Sequence Numb					
		Case Type	A Full	Abstract F	orm ~		
			Submit	Cancel			
			Bubinito	ounoci			

Selecting a Pathology Report:

When a report is selected, it populates the pathology's narrative text in the "Selected Pathology Report Text Area" panel denoted in green. The discrete data items available are populated in the CPDMS Data Entry fields denoted in **blue**. The Pathology Report Id is inserted into the header of both **blue** and **g** reen panels. In this example the Pathology Report Id is "IM17-6330".

Back				T	RAINING DATABAS	SE	(90201)	DAVID RUST [+]
ť	Full Abstract	t			Reset	I	IM17-6330 - Selected Pathology Report Data	
Full Abstract		987-65-432	1 PATLAST, PATFIRST	(04	/04/1965)	1	987-65-4321 PATLAST, PATFIRST (0	4/04/1965)
ull Al	9	equence No. :	1			I		
<u> </u>	Dat	e of Diagnosis :	mm/dd/YYYY			I	Date of Diagnosis: Do not copy date	~
ata		Topography :			~	I		
er D		Histology :			~	I		
othe		Behavior :				I		
Case Other Data	CS Eactor	25 & Schema :				I		
0						I	Path Report No.: IM17-6330	
		th Report No. :		-		I	Hosp. Chart No.: 123456789	
		sp. Chart No. :				I	Pathology Address	
	Address @ Diagnosis Address 1: Address 2:					I	Address 1: 1234 TEST STREET CT	
						I	Address 2:	
		Address 2:						
	City	State, Country:					City,State: LEXINGTON, KY	
		Zip Code:		Valid	ate Address	I	Zip Code: 40503	
			Create			I	🗲 🛛 Copy & Link Path Data	
			🗶 No pathology report link	ed		I		_
						I		
						5		
Patho	logy Details				IM17-6330 - Selected Pa	ath	hology Report Text	_
Score	SSN	Date of Birth	Full Name		PATHOLOGY TEST HOSP TESTING CANCER CENTR			^
100	987-65-4321	04/04/1965	PATLAST, PATFIRST M.	^	LEXINGTON, KENTUCKY			2) MW
90	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.				ollect Date: 8/10/2017 01:01 eceipt Date: 8/10/2017 15:59	
85	987-65-4321	04/04/1965	PATLAST, PATFIRST <mark>A</mark> M.			P	age 1	
85	987-65-4321 04/04/1965 PATLAST, PATFIRSTAM.				DEPARTMENT OF PATHO AND LABORATORY MED	_		
85	987-65-4321	04/04/1965	PATLAST, PATFIRST M.		IMMUNO-MOLECULAR PAT	_	OLOGY	
80	123-45-6789	04/04/1965	PATLAST, PATFIRST M.		Phone: 859-867-5309 Email: nopath@test.c	0	Fax:555-555-5555 m IM17-6332	
75	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST <mark>A</mark> M.	4	ATTENDING MD: S. Sti	ra	nge, MD Service:	
H.	Page 1	of 2 📔 🕨 🕅	1 - 25 of	28	PTH Reported: 8/20 DIRECTOR/SUPERVISOR			~

An abstractor can click through the list of reports in order to find the one that matches the case they want to create. (EDIT)

Copying the Discrete Pathology Data to the Case Data:

If we find that the pathology report in our scenario is the right one, we can copy the information over to the "Full Abstract"/"Case Other" panel denoted below in red by clicking the "Copy & Link Path Data" button denoted in blue.

When the pathology data is copied over, a few conversions happen:

- 1. All data values are Upper Cased
- 2. If no Date Type is selected in the Date of Diagnosis, no date is copied over.
 - a. The Date Type for Data of Diagnosis is discussed later in this guide.
- 3. The Country field in the "Full Abstract"/"Case Other" Data Panel denoted in red is calculated based on the pathology report's State value.
- The Zip Extension is not provided in the pathology report, so this will not be populated.
 The Zip Extension can be populated using the "Validate Address" function of this application which is discussed later.
 The pathology report will be "linked" to this case, and is shown beneath the "Create" button denoted in orange

Back				T	RAINING DATABAS	E (90201))	DAVID RUST [+]
ť	Full Abstract				Reset	IM17-6330	- Selected Pathology Report Data	
Full Abstract		987-65-432	1 PATLAST, PATFIRST	(04	/04/1965)	987-6	5-4321 PATLAST, PATFIRST (04	4/04/1965)
ull At	Se	quence No. :	1					
<u> </u>	Date	of Diagnosis :	mm/dd/YYYY 🖪			Date o	of Diagnosis: Do not copy date	v
Case Other Data		Topography :			¥			
er D		Histology :			×			
oth		Behavior :						
Case	CS Factor 2	5 & <u>Schema</u> :						
	Path	Report No. :	IM17-6330			Path	Report No.: IM17-6330	
	Hos	p. Chart No. :	123456789			Hosp	. Chart No.: 123456789	
	Addre	ss @ Diagnosis —				Patholog	gy Address	
		Address 1:	1234 TEST STREET CT			Add	ress 1: 1234 TEST STREET CT	
		Address 2:				Add	ress 2:	
	City,	State, Country:	LEXINGTON		, KY , USA	City,	State: LEXINGTON, KY	
		Zip Code:	40503 -	Valid	ate Address	Zip	Code: 40503	
			Ct.				Copy & Link Path Data	
		6	Create IM17-6330 pathology report	linker				
			intr obse patiology report		-			
Patho	ology Details				IM17-6330 - Selected Pat	hology Repo	rt Text	
Score	SSN	Date of Birth	Full Name		PATHOLOGY TEST HOSPI	TAL	MR #: 111111111	^
100	987-65-4321	04/04/1965	PATLAST, PATFIRST M.	^	TESTING CANCER CENTER LEXINGTON, KENTUCKY		PATLAST, PATFIRST 04/04/1965 (Age: 52	2) MW
90	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.				ce: 8/10/2017 01:01 ce: 8/10/2017 15:59	
85	987-65-4321	04/04/1965	PATLAST, PATFIRST <mark>A</mark> M.			Receipt Dat Page 1	2: 6/10/201/ 15:59	
85	987-65-4321	04/04/1965	PATLAST, PATFIRST <mark>A</mark> M.		DEPARTMENT OF PATHOL			
85	987-65-4321	04/04/1965	PATLAST, PATFIRST M.		IMMUNO-MOLECULAR PAT	HOLOGY		
80	123-45-6789	04/04/1965	PATLAST, PATFIRST M.		Phone: 859-867-5309 Email: nopath@test.co		5-555-5555 IM17-6332	
75	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRSTA M.	~	ATTENDING MD: S. Str PTH Reported: 8/20			
<u>H</u>	Page 1	of 2 🕨 🕅	1 - 25 of	28	DIRECTOR/SUPERVISOR			v

The Date of Diagnosis field and Date Types:

In an effort to obtain the highest quality of data, CPDMS allows the user to copy over 1 of 4 different date type options from a pathology report denoted in o range below

- 1. Do not copy date no date will be copied over to the "Full Abstract"/"Case Other" Data Panel (User must manually fill this in via the Date Field (or calendar drop down)
- 2. Specimen Date Observation date / Date tissue was examined
- 3. Report Date Date report was last changed
- 4. KCR Load Date Date Report was loaded in the KCR Pathology Database

The "Full Abstract"/"Case Other" Date of Diagnosis field denoted in the green box will be populated with the respective value selected in drop down (or no value at all in the case for "Do not copy date") in the "Pathology Report Data Panel" denoted in the blue box below.

By default, the "Date of Diagnosis" field in the "Pathology Report Data Panel" is set for **no date** to be copied over to the case data. In the example below the dates are made up, and they do not reflect what a user will find while creating a case.


Bad	¢ .			TRAINING DA	TABAS	E (90201) DAVID RI	JST [+]
Ŀ	Full Abstract				Reset	IM17-6330 - Selected Pathology Report Data	
Full Abstract		987-65-432	1 PATLAST, PATFIRST (0	4/04/1965)		987-65-4321 PATLAST, PATFIRST (04/04/1965)	
Case Other Data Ful	<u>Date</u> <u>CS Factor 2</u> <u>Patr</u> <u>Hos</u> Addre	of Diagnosis : Topography : Histology : Behavior : 5 & Schema : 1 Report No. : p. Chart No. : p. Chart No. : Sis @ Diagnosis - Address 1: Address 2: State, Country: Zip Code:	mm/dd/YYYY	✓ ✓ , KY , US lidate Address		Date of Diagnosis: Do not copy date Do not copy date Do not copy date 08/02/2017 - Specimen Date 03/30/2018 - Report Date 08/16/2017 - KCR Load Date Path Report No.: IM17-6330 Hosp. Chart No.: 123456789 Pathology Address Address 1: 1234 TEST STREET CT Address 2: City,State: LEXINGTON, KY Zip Code: 40503 Copy & Link Path Data	
Path	ology Details			IM17-6330 - Sel	ected Pat	thology Report Text	
Score 100 90 85 85 85 85 80 75		Date of Birth 04/04/1965 04/21/1965 04/04/1965 04/04/1965 04/04/1965 04/04/1965 04/04/1965 04/21/1965 0f 2 P P	Full Name A PATLAST, PATFIRST M. A	PTH Reporte	R CENTER NTUCKY PATHOLO RY MEDIO LAR PATH 7-5309 @test.co S. Stra d: 8/20/	R PATLAST, PATFIRST 40503 04/04/1965 (Age: 52) MW Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59 Page 1 0GY CINE HOLOGY Fax:555-5555	*

Linking the Pathology Report:

If no pathology report is linked the following will show beneath the "Create" button in the "Full Abstract" Data Panel

💸 No pathology report linked

When a user clicks the "Copy & Link Path Data" button, it "links" the pathology report with the case being created. As described earlier, when the pathology report is link it will be shown in the "Full Abstract" data panel only with a "Chain Link" icon followed by the Path Id of the report underneath the "Create" Button. In our example, the Path Id is IM17-6330 when this is linked by clicking the "Copy & Link Path Data" button, the following is shown below the "Create" Button:



A user can **unlink** the pathology report in 1 of 3 ways:

- 1. Click "Copy & Link Path Data" on another pathology report
- 2. Click the "Reset" button
- 3. Click the "Chain Link" icon next underneath the "Create" button denoted in orange below:



	CANCER		ATA MANAGEN	IENT SY	STEM .net		
DAVID RUST		TRA	AINING DATABASE			Cas	e Data Edit
Diagnosis Personal	Collab Stg	AJCC/Docs	Admin/No Tx	ACoS	Overrides	Historical	Text
-	τ		~				
Hospital Chart No.							
Path Report No.	Deck ID 0					_	
Linked Path Reports		Specimen Date/T: 08/02/2017 15:5	-				
· · · · ·	1417-0550 0	0/02/201/ 13.3	5.00 5554074	^ 🔎 Li	nk Path Reports		
				\vee			
Family History	~						
Marital Status @Diag			~				
Menopausal Status		~					
Primary Payer				~			
Registry Accession No.							
Zip Code	•						
City, State, Country			• •				
Address @ Diagnosis				Sear	ch		
	Click Search			^			
				Acce	nt		
Address 2					p.c.		
County							
	Pro	ev Ne	ext Save	Ca	ancel		Page 2 of

Linking the pathology report at this point allows the user to bypass the section denoted in orange below in the "Personal" Tab of "Case Edit" later on.

The Reset Button:

Every field shown can be reset and the pathology report unlinked at the same time by hitting the "Reset" button denoted in orange.

The SSN, Date of Birth, Last Name, First Name, and Sequence Number will remain unchanged.


Back TRAINING DATABASE (90201)							DAVID RUST [+]
ţ	Full Abstract				Reset	IM17-6330 - Selected Pathology Report Data	а
bstra	987-65-4321 PATLAST, PATFIRST (04/04/19					987-65-4321 PATLAST, PATFIRST	(04/04/1965)
Case Other Data Full Abstract	<u>Date</u> <u>CS Factor 2</u> <u>Pati</u> <u>Hos</u> Addre	Sequence No. : 1 Date of Diagnosis : mm/dd/YYYY Topography : Histology : Behavior : CS Factor 25 & Schema : Path Report No. : Hosp. Chart No. : Address @ Diagnosis Address 1: Address 2: City,State,Country:		v v		Date of Diagnosis: Do not copy date Path Report No.: IM17-6330 Hosp. Chart No.: 123456789 Pathology Address Address 1: 1234 TEST STREET CT Address 2: City,State: LEXINGTON, KY Zip Code: 40503 € Copy & Link Path Data	
Patho	logy Details			IM17-6330 - Se	lected Pat	hology Report Text	
Score	SSN	Date of Birth	Full Name	PATHOLOGY TES TESTING CANCE			· ^
100	987-65-4321			INTUCKY	40503 04/04/1965 (Age: 52) MW		
90	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.			Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59	
85	987-05-4321 04/04/1985 PAILAST, PAILINSTAM. AND LA			DEDADTWENT OF	F	Page 1	
85			AND LABORATO	OF PATHOLOGY ATORY MEDICINE			
85 80	There is the second sec			IMMUNO-MOLECU Phone: 859-86		IOLOGY Fax:555-555-555	
75	987-65-4321	04/04/1965	PATLAST, PATFIRST M.	Email: nopath@test.com IM17-6332 ATTENDING MD: S. Strange, MD Service:			
	Page 1	of 2 🕨 🕅		PTH Reporte	ed: 8/20/		~

The Validate Address Button:

User's can check the address provided against the CPDMS geocoder by hitting the "Validate Address" button denoted below in green.

Back				Т	RAINING DA	TABASI	E (90201)	DAVID RUST [+]
ť	Full Abstract					Reset	IM17-6330 - Selected Pathology Report Data	a
Full Abstract	987-65-4321 PATLAST, PATFIRST (04/				/04/1965)		987-65-4321 PATLAST, PATFIRST	(04/04/1965)
ull At	Sequence No.: 1							
	Date of Diagnosis : mm/dd/YYYY Topography :						Date of Diagnosis: Do not copy date	~
ata					~			
Case Other Data	Histology : Behavior :				¥			
e otł								
Cas	CS Factor 25 & Schema :							
	Path Report No. : IM17-6330						Path Report No.: IM17-6330	
	Hosp. Chart No. : 123456789						Hosp. Chart No.: 123456789	
	Address @ Diagnosis <u>Address 1</u> : 1234 TEST STREET CT <u>Address 2</u> :					_		
						Address 1: 1234 TEST STREET CT		
					Address 2:			
	City,	State, Country:	LEXINGTON		, KY , USA City, State: LEXINGTON, KY			
	Zip Code: 40503 -		40503 -	Validate Address		1	Zip Code: 40503	
			Create				Copy & Link Path Data	
			IM17-6330 pathology report	linked				
		0						
					_			
Patho	logy Details				IM17-6330 - Sel	ected Pat	hology Report Text	
Score	SSN	Date of Birth	Full Name		PATHOLOGY TES			^
100	987-65-4321	04/04/1965	PATLAST, PATFIRST M.	^	TESTING CANCER CENTER PATLAST, PATFIRST LEXINGTON, KENTUCKY 40503 04/04/1965 (Age: 52) MW Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59 Page 1			
90	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.					
85	987-65-4321	04/04/1965	PATLAST, PATFIRSTA M.					
85	987-65-4321	04/04/1965	PATLAST, PATFIRSTA M.	PATLAST, PATFIRSTAM, DEPARTMENT OF PATHOLOGY				
85	987-65-4321	4321 04/04/1965 PATLAST, PATFIRST M. AND LABORATORY MEDICINE IMMUNO-MOLECULAR PATHOLOGY						
80	123-45-6789	04/04/1965	PATLAST, PATFIRST M.	Phone: 859-867-5309 Fax:555-555-5555 Email: nopath@test.com IM17-6332				
75	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRSTA M.	~	ATTENDING MD:	S. Stra	ange, MD Service:	
N.	Image 1 of 2 ▶ ▶ 1 - 25 of 28		28	PTH Reported: 8/20/2017 02:02 DIRECTOR/SUPERVISOR: JJ. Jameson			~	

When this button is click it will pop up the "Validate Address" window denoted below in **blue**. Initially, the user will see a loading message as shown in the image below.



Since this address does not exist, an error will show displaying the cause. The user is allowed to keep the original value by clicking the "Cancel" button denoted below in red

Va	lidate Address		×
	Entered Address		
	Address 1:	1234 TEST STREET CT	
	Address 2:		
	City, State, Country:	LEXINGTON , KY , USA	
	Zip Code:	40503 - Validate	
	Valid Addresses		
	Full Address		
	ERROR: Unknown Street		
	Cancel	Accept	

Or the user could enter another valid address, click "Validate" to search again, click the valid result and hit the "Accept" button denoted in green

Validate Address		×				
Entered Address						
Address 1:	2365 HARRODSBURG ROAD					
Address 2:	SUITE A230					
City,State,Country:	LEXINGTON , KY , USA					
Zip Code:	40504 - Validate					
Valid Addresses						
Full Address						
2365 Harrodsburg Rd, Lex	kington, Kentucky, 40504					
Cancel	Accept					

For the rest of this explanation we will continue to use the original fake address provided.

Choosing what Case Type to Create:

Users can create 1 of 2 different case types

- 1. Full Abstract
- 2. Case Other

A user can select which case type they would like to create by selecting the "Case Type" tabs on the left side of the "Full Abstract"/ "Case Other' Data Panel denoted in red

Users can only create one case type at a time. It is possible to fill out both panels, but the case type that you hit the "Create" button on will be the Case Type that is created.

The data items included in each panel will be discussed later in this guide.

By default, the "Full Abstract" is selected and shown below:

Back					1	RAINING DA	TABASI	E (90201) D/	AVID RUST [+]
ಕ	Ft II.	Abstract					Reset	IM17-6330 - Selected Pathology Report Data	
Full Abstract				L PATLAST, PATFIRST	(04	/04/1965)		987-65-4321 PATLAST, PATFIRST (04/0-	4/1965)
Case Other Data	Sequence No. : 1 Date of Diagnosis : mm/dd/YYYY Topography : Histology : Behavior : CS Factor 25 & Schema : Path Report No. : Hosp. Chart No. : Address 1: Address 1: Address 2: City,State,Country: Zip Code: - Validation Create X No pathology report linked			v v		Date of Diagnosis: Do not copy date Path Report No.: IM17-6330 Hosp. Chart No.: 123456789 Pathology Address Address 1: 1234 TEST STREET CT Address 2: City,State: LEXINGTON, KY Zip Code: 40503 Copy & Link Path Data	ET CT		
Patho	logy	Details				IM17-6330 - Sel	ected Pat	hology Report Text	
Score	SSN		Date of Birth	Full Name		PATHOLOGY TES TESTING CANCE			^
100		-65-4321	04/04/1965	PATLAST, PATFIRST M.	^	LEXINGTON, KE	NTUCKY	40503 04/04/1965 (Age: 52)	MW
90		-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.			F	Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59	
85 85 85 80 75	S5 987-65-4321 04/04/1965 PATLAST, PATFIRST M. AND 85 987-65-4321 04/04/1965 PATLAST, PATFIRST M. IMMUI 80 123-45-6789 04/04/1965 PATLAST, PATFIRST M. Phone Email Email Email Email Email			AND LABORATO IMMUNO-MOLECU Phone: 859-86	Page 1 DEPARIMENT OF PATHOLOGY AND LABORATORY MEDICINE IMMUNO-MOLECULAR PATHOLOGY Phone: 859-867-5309 Fax:555-5555 Email: nopath@test.com IM17-6332				
	1.	age 1	of 2 🕨 🕅		28	PTH Reporte	d: 8/20/		~

When "Case Other Data" Panel is selected it looks similar to this image:

Back			E (90201)	DAVID RUST [+]					
ť	Case Other D	ata				IM17-6330 - Selected Pathology Report Data			
Full Abstract		7-65-4321 PA	ATLAST, PATFIRST (04	/04/	1965)		987-65-4321 PATLAST, PATFIRST (0-	4/04/1965)	
Case Other Data	Year of Diagnosis: Site Code: Comment:					•	Date of Diagnosis: Do not copy date	*	
J			Create				Path Report No.: IM17-6330 Hosp. Chart No.: 123456789 Pathology Address Address 1: 1234 TEST STREET CT Address 2: City,State: LEXINGTON, KY Zip Code: 40503 ← Copy & Link Path Data		
			C. C. C. C. C.		_				
Patho	logy Details				IM17-6330 - Sele	ected Pat	hology Report Text		
Score	SSN	Date of Birth	Full Name		PATHOLOGY TEST TESTING CANCER		•	^	
100	987-65-4321	04/04/1965	PATLAST, PATFIRST M.		LEXINGTON, KEN	ITUCKY	40503 04/04/1965 (Age: 5	2) MW	
90	987-65-4321	04/ <mark>21</mark> /1965	PATLAST, PATFIRST M.				Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59		
85	987-65-4321	04/04/1965	PATLAST, PATFIRST <mark>A</mark> M.			F	Page 1		
85	987-65-4321	04/04/1965	PATLAST, PATFIRST <mark>A</mark> M.		DEPARTMENT OF AND LABORATOR				
85	987-65-4321	04/04/1965	PATLAST, PATFIRST M.		IMMUNO-MOLECUI Phone: 859-867		IOLOGY Fax: 555-555-555		
80	123-45-6789	04/04/1965	PATLAST, PATFIRST M.		Email: nopath@	test.co	Dm IM17-6332		
75	5 987-65-4321 04/21/1965 PATLAST, PATFIRSTA M. ATTEN PTH					ATTENDING MD: S. Strange, MD Service: PTH Reported: 8/20/2017 02:02 DIRECTOR/SUPERVISOR: JJ. Jameson			

Notice how the "Case Other Data" tab is brought to the front when it is selected, and the "Full Abstract" is grayed out and brought to the back.

The Full Abstract Data Panel Items:


An abstractor can change the fields in the "Full Abstract" panel if necessary, but these changes will be overwritten if the "Copy & Link Path Data" button is clicked again.

- 1. Sequence No.
 - a. Sequence No. is a number only field that is automatically populated with the next sequential number based on the patient's amount of cases. (i.e. if a patient has 0 cases so far, the Sequence Number will be 1. If the patient has 2 cases, the Sequence number will be 3)
 - b. Only 1 to 2 digit long numbers are allowed in this field.
- 2. Date of Diagnosis:
 - a. Date of Diagnosis is a date field populated in the format of a "mm/dd/YYYY" (i.e. two digit month, two digit, daty and four digit year separated by forward slashes, "/")

b. A user can click the calendar icon on the right side of the field to select a date from a drop down calendar.

Date of Diagnosis .	11111	uu		-	1			
<u>Topography</u> :			Apr	il 201	8 -			
Histology :	S	М	т	W	т	F	S	
Behavior :	1	2	3	4	5	6	7	
ctor 25 & Schema :	8	9	10	11	12	13	14	
	15	16	17	18	19	20	21	
Path Report No. :	22	23	24	25	26	27	28	
Hosp. Chart No. :	29	30	1	2	3	4	5	
Address @ Diagnosis -	6	7	8	9	10	11	12	
A distance of the								

- 3. Topography
 - a. Topography is drop down field that can be searched over by Code or Description.



4. Histology

- a. Histology is similar to the Topography field where you can search over option by Code or Description
- b. The Histology field also has the user select the value of behavior. In the example below, the user change choose between the behavior codes of "0", "1", and "3"

Histology :	8000	~
Behavior :	8000/0 - BENIGN NEOPLASM/TUMOR	
& Schema :	8000/1 - NEOPLASM, NOS/BORDERLINE	
eport No. :	8000/3 - NEOPLASM, MALIGNANT	

5. Behavior

- a. Behavior is display field that will be populated when a user selects a histology value
- b. The example below shows the value displayed when the histology selected was NEOPLASM, MALIGNANT

Histology :	8000/3 - NEOPLASM, MALIGNANT	~
Behavior :	3 - Malignant	



a. CS Factor 25 is a 3 digit field that will sometimes be autopopulated based on the Date of Diagnosis, Topography, Histology, and Behavior selected prior to it like in the example below:

	987-65-432	1 PATLAST, PATFIRST (04/04/1965)	
	Sequence No. :	1	
	Date of Diagnosis :	03/01/2017	
	Topography :	C00.0 - EXTERNAL UPPER LIP, NOS	~
	Histology :	8000/3 - NEOPLASM, MALIGNANT	~
	Behavior :	3 - Malignant	
	CS Factor 25 & Schema :	988 LipUpper	
b.	Other times, a user must be provid	e the CS Factor 25 code like in the example below	
	987-65-432	1 PATLAST, PATFIRST (04/04/1965)	
	Sequence No. :	1	
	Date of Diagnosis :	03/01/2017	
	Topography :	C24.0 - EXTRAHEPATIC BILE DUCT	~
	Histology :	8160/3 - CHOLANGIOCARCINOMA	*
	Behavior :	3 - Malignant	
	CS Factor 25 & Schema :		
	0	This field is required	

7. CS Schema

a. CS Schema is a displayed field that will be populated based on the Date of Diagnosis, Topography Histology, Behavior, and CS Factor 25 value entered prior. The image below shows an example when all items need to be populated to obtain the CS Schema

987-65-432	1 PAILASI, PAIFIRSI (04/04/1965)	
Sequence No. :	1	
Date of Diagnosis :	03/01/2017	
Topography :	C24.0 - EXTRAHEPATIC BILE DUCT	Y
Histology :	8160/3 - CHOLANGIOCARCINOMA	~
Behavior :	3 - Malignant	
CS Factor 25 & Schema :	040 BileDuctsDistal	

b. There will be times when it takes a little time to look up the CS Schema, and the display field will show the value below

CS Factor 25 & Schema : 040 Calculating CS Schema...

8. Path Report No.

a. Path Report No is a textfield for Pathology Report Id

If a value is populated in the "Path Report No." field, it **does not** mean that path is "linked" to the case. Please use the "Copy & Link Path Data" Button to link the pathology report to the case.

- 9. Hosp. Chart No.
 - a. Hosp Chart No is a text field for the Medical Record Number of the patient.
- 10. Address at Diagnosis Fields Fields can be autopopulated by using the "Validate Address" window
 - a. Address 1 Text Field 40 character limit
 - b. Address 2 Text Field 40 character limit
 - c. City Text Field 20 character limit
 - d. State Text Field/Drop down 2 character field user can type in field and select from a drop down field.
 - e. Country Text Field/Drop down 3 character field Country can be auto-populated if provided with a US state. Country is similar to the State field where you can type in the field and a drop down field will show the options you can select from.
 - f. Zip Code 5 digit field
 - g. Zip Code Ext 4 digit field
 - h. Path Linked Icon and Display field showing if a pathology report has been linked to this case.

The Case Other Data Panel Fields:

1. Sequence No.

- a. Sequence No. is a number only field that is automatically populated with the next sequential number based on the patient's amount of cases. (i.e. if a patient has 0 cases so far, the Sequence Number will be 1. If the patient has 2 cases, the Sequence number will be 3)
 b. Only 1 to 2 digit long numbers are allowed in this field.
- 2. Year of Diagnosis:
- a. Year of Diagnosis is a 4 digit field for a Year
- 3. Site Code:
 - a. Site code is a drop down field that can be searched over Code or Description

22 - Trachea,bronchus,lung-small	
23 - Trachea,bronchus,lung-NSC	

4. Comment

a. Comment is a 255 character long text area.

The Create Button:

Once the user reviews the data in either "Full Abstract" or "Case Other" Data Panel, they can hit the "Create" button denoted in green in both images below to create the Full Abstract or Case Other respectively.

Back	TRAINING DATABASE (90201) DAVID RU							
ť	Full Abstract			Reset	IM17-6330 - Selected Pathology Report Data			
Full Abstract	987-65-432 Sequence No. :	1 PATLAST, PATFIRST	(04/04/1965)		987-65-4321 PATLAST, PATFIRST (04/04/1965)			
Case Other Data	Date of Diagnosis : <u>Topography</u> : <u>Histology</u> : <u>Behavior</u> : 3 <u>CS Factor 25 & Schema</u> : <u>Path Report No.</u> : <u>Hosp. Chart No.</u> : <u>Address @ Diagnosis</u> <u>Address 1:</u> <u>Address 2:</u> <u>City,State,Country:</u> <u>Zip Code</u> :	08/02/2017 C00.0 - EXTERNAL UPPE 8000/3 - NEOPLASM, MA 3 - Malignant 988 LipUpper IM17-6330 123456789 1234 TEST STREET CT LEXINGTON	ALIGNANT 🗸		Date of Diagnosis: 08/02/2017 - Specimen Date Path Report No.: IM17-6330 Hosp. Chart No.: 123456789 Pathology Address Address 1: 1234 TEST STREET CT Address 2: City,State: LEXINGTON, KY Zip Code: 40503 ← Copy & Link Path Data	×		
Patho	logy Details		IM17-6330 - Se	lected Pat	hology Report Text			
Score	SSN Date of Birth	Full Name	PATHOLOGY TES			^		
100	987-65-4321 04/04/1965	PATLAST, PATFIRST M.	TESTING CANCE	ER CENTER	R PATLAST, PATFIRST			
90	987-65-4321 04/21/1965	PATLAST, PATFIRST M.	LEAINGION, KI	0	Collect Date: 8/10/2017 01:01			
85	987-65-4321 04/04/1965	PATLAST, PATFIRSTA M.			Receipt Date: 8/10/2017 15:59 Page 1			
85	987-65-4321 04/04/1965	PATLAST, PATFIRSTA M.	DEPARTMENT OF	F PATHOLO	DGY			
85	987-65-4321 04/04/1965	PATLAST, PATFIRST M.	AND LABORATO	JLAR PATH	HOLOGY			
80	123-45-6789 04/04/1965	PATLAST, PATFIRST M.	Phone: 859-86 Email: nopath		Fax: 555-555-5555 m IM17-6332			
75	987-65-4321 04/ <mark>21</mark> /1965	PATLAST, PATFIRSTA M.	ATTENDING MD:	S. Stra	ange, MD Service:			
	Page 1 of 2 🕨 🕅	1 - 25 of			/2017 02:02 : JJ. Jameson	~		

Back	TRAINING DATABASE (90201) DAVID RUST [*]								
Ŀ	Case Other Data				Reset	IM17-6330 - Selected Pathology Report Data			
Full Abstract		5-4321 PATLAST, P e No.: 1	ATFIRST (04/	04/1965)		987-65-4321 PATLAST, PATFIRST (04/04/1965)		
	Year of Dia	2017 Code: 01 - Lip			~	Date of Diagnosis: 08/02/2017 - Specim	en Date 💌		
Case Other Data	Comment: Some test	comments							
			Create			Path Report No.: IM17-6330 Hosp. Chart No.: 123456789 Pathology Address Address 1: 1234 TEST STREET CT Address 2: City,State: LEXINGTON, KY Zip Code: 40503 ← Copy & Link Path Data			
Patho	logy Details			IM17-6330 - 5e	lected Pat	hology Report Text	_		
Score		te of Birth Full Name		PATHOLOGY TE			^		
100 90 85	00 987-65-4321 04/04/1965 PATLAST, PATFIRST M. 4 10 987-65-4321 04/21/1965 PATLAST, PATFIRST M. 4		TESTING CANC LEXINGTON, K	ENTUCKY C F	R PATLAST, PATFIRST 40503 04/04/1965 (Age: 52) MW Collect Date: 8/10/2017 01:01 Receipt Date: 8/10/2017 15:59				
85 85 80	85 987-65-4321 04/04/1965 PATLAST, PATFIRSTA M. 85 987-65-4321 04/04/1965 PATLAST, PATFIRST M.			AND LABORAT IMMUNO-MOLEC	Page 1 DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE IMMUNO-MOLECULAR PATHOLOGY Phone: 859-867-5309 Fax:555-5555 Email: nooath@test.com IM17-6332				
75 [4]		21/1965 PATLAST, 2 ▶ ▶	PATFIRST <mark>A</mark> M. 1 - 25 of 2	ATTENDING MD PTH Report	: S. Stra ed: 8/20/	nge, MD Service: 2017 02:02 JJ. Jameson	~		

Create Full Abstract:

Hitting the create button on the "Full Abstract" panel will direct the user to the "Case Data Edit" screen below. The data that had been entered in the "Full Abstract" Panel will be populated in the "Case Data Edit" tab panel. The abstractor can continue entering other necessary information for the case.

		CANCER	PATIENT DA		IENT SY	STEM .net			[+]
DAVID RUST			TRAI	NING DATABASE			Ca	se Data B	Edit
Diagnosis	Personal	Collab Stg	AJCC/Docs	Admin/No Tx	ACoS	Overrides	Historical	Te x t	
987-65-4321, PATFIRST PATLAST									
	SEE ICD-O-3 Co Topography (le (ICD-O) & B & Behavior Co Lymph-vasc Plac		1 01 20010 3 08/02/2017 52 C00.0 EXTERNA	321, PATFIRST PAT	LAST	✓			
		Laterality			~				
		2		t					
ESC - Cance	el, ALT+(Highligh	Pre		LT+Down - Activate (ancel	ext, F9 - Affiliation	-	e 1 of 9 ave

The "Personal" and "Collab Stg" tabs have multple fields populated from the Pathology Report as well.

	CANCER PATIENT DATA MANAGEMENT SYSTEM .net										
DAVID RUST			TRA	Ca	se Data Ed	lit					
Diagnosis	Personal	Collab Stg	AJCC/Docs	Historical	Text						
			987-65-4	321, PATFIRST PA	LAST						
Diag. Confirma	ation Code 📑			~							
Hospita	l Chart No.	123456789									
Path	Report No.	IM17-6330									
		Path ID	Specimen Date/Ti	me KCR Msg ID							
Linked Pa	th Reports	IM17-6330	08/02/2017 15:59	:00 9954874	^ 🔎 Li	ink Path Reports					
					V						
For	nily History	9 Unknown 🗸			· ·						
Marital Sta		9 UNKNOWN V									
	isal Status	9 Unkn./NA	~	~							
	nary Payer	9 UNKN./NA	~								
Registry Acc					~						
Registry Acc	Zip Code	40503 -									
City, Stat	e, Country	LEXINGTON		• KY •	USA 🔎						
Address @		1234 TEST STREET CT Search									
		Click Search									
		GIICK BEALCI.									
					 Acce 	ept					
	Address 2										
	County	21067 🔎									
		P	ev Ne	xt Save	C	ancel		Page 2	2 of 9		
ESC - Cance	el, ALT+(Highliah	hted Key) - Page	Tab, F2 - Search. A	LT+Down - Activate	Dropdown, F	F7 - Prev, F8 - Ne	xt, F9 - Affiliation	s, F10 - Sav	e		

AVID RUST			TRAI	INING DA	ATABASE			Ca	se Data Edit
Diagnosis Personal	Collab 9	Stg AJC	C/Docs	Admi	n/No Tx	ACoS	Overrides	Historical	Text
		9	987-65-43	21, PATE	FIRST PAT	LAST			
CS Schema	LipUpper								
CS Tumor Size	T								
CS Extension									
CS Size/Extent Eval									
CS Lymph Nodes									
CS Reg Nodes Eval									
Nodes Positive	99 🔎								
Nodes Examined	99 🔎								
CS Mets at Dx									
CS Mets Eval									
Mets at DX - Bone			~						
Mets at DX - Brain			~						
Mets at DX - Liver			~						
Mets at DX - Lung			~						
ets at DX - Distant LN			~						
Mets at DX - Other			~						
CS Site Spec Factors	1	2 988							
<u>do one opeer detoro</u>	<u>6</u>			988	4	5	988		
	11			988	9	88 15			
	<u>16</u> 988	<u>12</u> 988 <u>17</u> 988		988		88 <u>15</u> 88 <u>20</u>			
	<u>21</u> 988	<u>17</u> 988 <u>22</u> 988		988		88 <u>25</u>			
CS Version Derived	020550	<u>22</u> 500	23		27 5	23			
Version Input Current	020550								
		Prev	Ne	v.t.	Save		Cancel		Page 3 of

Create Case Other Data:

Hitting the create button on the "Case Other Data" panel will direct the user to the "Data Entry Status" screen below. There is no other information necessary to populate a Case Other, so there are no other fields for the abstractor to fill.

AVID RUST	CANCERTAI	TRAINING DATABAS		SYSTEM .ne		[⁺)ata Entry
ocate <u>V</u> iew	<u>C</u> reate	<u>K</u> ey-Change	<u>E</u> dit	<u>D</u> elete	L <u>o</u> gout	<u>R</u> etur
Patient Red	cord					
Soc Sec Number	987-65-4321					
Last Name	PATLAST	Contact Patient	Yes			
First Name	PATFIRST	User Defined Data	No			
Total Cases	1	Death Certificate	No			
Case Re Year of Diagr Sequence Nu Site Group Type	nosis 2017					

ALT+(Highlighted Key) - Menu

Sample Errors:


As with all software, errors can occur; some intended, some not. This new feature does its best to display the necessary information to the abstractor when an error occurs.

Here are some examples a user may encoutner:

Invalid value in field:

1. If a field has an error related to it, it will display an error description in red text underneath.								
	Full Abstract		Reset					
	987-65-4321 PATLAST, PATFIRST (04/04/196	i5)						
	Sequence No. : 1							
	Date of Diagnosis: 123							
	123 is not a valid date - it must be in th m/d/Y	ne format	:					
	Topography : C00.0 - EXTERNAL UPPER LIP, NOS	×						
	Histology: 8000/3 - NEOPLASM, MALIGNANT	×						
	Behavior : 3 - Malignant							
	CS Factor 25 & Schema : 988							
	Path Report No. : IM17-6330							
	Hosp. Chart No. : 123456789							
	Address @ Diagnosis		_					
	Address 1: 1234 TEST STREET CT							
	Address 2:							
	City, State, Country: LEXINGTON , K	(Y , USA						
Zip Code: - Validate Address								
	Create							
	IM17-6330 pathology report linked							

2. A window will pop up displaying all missing or incorrect field information when you hit the create button.



Pop up window error:

In the example below the user's session has expired. This would only occur if the user sat at this screen for over a half hour without progressing.

Back					
Ŀ	Full Abstract			Pathology Report Data	
a Full Abstra					
Case Other Data					
				Path Report No.:	
		Session Expired		Σ	3
	Class of Case : Address @ Diagnosis - Address 1: Address 2: City,State,Country: Zip_Code:	Phone: (8		e contact support. 5PM Eastern	Path Data
Datha	ology Details	Dat	hology Report Text		
	SSN Date of Birth	Full Name Sea			

Additional Features:

Field Links:

Each field has a link beside it which will direct the user via a new browser window to the Kentucky Cancer Registry's Registrar Manual to the respective field's page.

Full Abstract		Reset
987-65-432	1 PATLAST, PATFIRST (04/04/1965)	
Sequence No. :	1	
Date of Diagnosis :	mm/dd/YYYY 🖪	
Topography :	*	
Histology :	·	
Behavior :		
CS Factor 25 & Schema :		
Path Report No. :		
Hosp. Chart No. :		
Address @ Diagnosis -		
Address 1:		
Address 2:		
City, State, Country:	, ,	
Zip Code:	- Validate Address	
	Create	
	& No pathology report linked	

O A https://confluence.kcr.uky.edu/display/KAM/Case+Sequence+Num					🖾 🤉 🖓 Search	☆自♣
≡ ≍ Confluence Spaces ▼						٩
KCR Abstractors Manual		g nosis g uence Num t, last modified by Isaac Hands on Apr 10), 2017			
PAGE TREE	Organization	Field Name	ID	Required		
Introduction	KCR	Case Sequence Num (SegNo)	30030	ves		
Patient Data						
Y Case Data						
✤ Diagnosis	Field Length: 2					
Case Sequence Num					; diagnosed during a patient's lifetime. It counts the occurrence of independent, primary diagnoses, regardless of who must report th ; and carcinoma in-situ of the cervix diagnosed in years when they were not considered reportable.	em, but only if diagnosed in year
Case Site Code		Exception: Benign and borderline CNS tumors are sequenced to include his Enter the number which designates the chronological order of this priman				
Case Type	Enter the number				tumor in relation to all primary tumors (including in-situ) that the patient has had. (Single digits will be right justified by the compute	er.)
ICDO Version	1 - 1st primary					
 ICD-O-3 Conversion Flag 	2 - 2nd primary					
 Topography Code (ICD-O) 	3 - 3rd primary					
 Histology 	4 - 4th primary					
Behavior Code	. 5 - 5th primary					
 Histology (ICD-O-2) 	6 - 6th primary					
Behavior Code (ICD-O-2)	7 - 7th primary					
Tumor Grade	8 - 8th primary					
Lymph-vascular Invasion	9 - 9th primary					
Class of Case	(and so on)					
Place of Diagnosis		ng more than one independent, r	eportable r	primary diag	sed at the same time, the selection of the first is assigned to the primary with the worst prognosis. If no difference in prognosis is evi	ident, the selection of the sequen
Date of First Contact	may be arbitrary.	J	, ,	,		
Date of Diagnosis	Only include repo	rtable conditions, as outlined ear	lier.			

Customizable Interface Options:

Create Case from Pathology Report has the same customizable options as Create Patient. Please visit Create Patient Customizable Options for more details.

Follow Up

- Primary Follow-Up Physician
- Follow-Up Physician 2
 Follow-Up Physician 3

- Follow-Up Physician 3
 Follow-Up Physician 4
 Follow-Up Physician 5
 Date of Last Contact or Death
- Survival Status
- Cancer Status
- Date of First Recurrence
- Survival Interval
- Type of First Recurrence
- First Disease Free Start Date
 Site of First Recurrence 1
- Dz Free Interval
- Following Registry
 Follow-Up Last Name
 Follow-Up First Name
- Follow-Up Source Central
 Follow-Up Source COC
 Next Follow-Up Method

- Alternate Follow-Up Method
- Follow-Up Address 1
 Follow-Up City

- Follow-Up State
 Follow-Up Zip Code
 Follow-Up Phone
 Follow-Up Relationship
- Follow-Up Text
 Last Follow-up Hosp Id
 Modified By (FU)

- Time Follow-up Modified
 Date of Last Cancer (Tumor) Status

Primary Follow-Up Physician

Organization	Field Name	ID	Required
KCR	Primary Follow-Up Physician (FupPhys)	31100	yes
NAACCR	PhysicianFollow-Up	2470	yes

Field Length: 7

This field is provided for entry of a code number assigned to the physician following this patient for treatment at this institution. Use the physician's Kentucky License Number and develop your own codes for identifying out-of-state physicians who may be following your patients.

The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License.

A lookup for NPI numbers is available at https://npiregistry.cms.hhs.gov/.

This field will be used to generate mailing labels to physicians to use with your follow up letters.

Hospitals may code '9999999' for "Unknown", but this field may not be left blank.

Organization	Field Name	ID	Required	
KCR	Follow-Up Physician 2 (FupPhys2)	31110	no	

Field Length: 7

This field is provided for entry of a code number assigned to an additional follow up physician for this patient. Use the Kentucky License Number, or your own code numbers developed for identifying out-of-state physicians.

The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License.

A lookup for NPI numbers is available at https://npiregistry.cms.hhs.gov/.

This field may also be used to generate mailing labels for follow up letters to these physicians.

Hospitals may use a special code for "Unknown" and/or leave this field blank if there is no alternate follow up physician.

Organization	Field Name	ID	Required
KCR	Follow-Up Physician 3 (FupPhys3)	31120	no

Field Length: 7

This field is provided for entry of a code number assigned to any physician involved with this patient and who may potentially be a source of follow up information. Use the Kentucky License Number, or your own code developed for identifying out-of-state physicians. The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile /Verification of Physician License.

A lookup for NPI numbers is available at https://npiregistry.cms.hhs.gov/

This field may be used to generate mailing labels for follow up letters to these physicians.

Hospitals may use a special code for "Unknown" and/or leave this field blank if there was no other physician.

Organization	Field Name	ID	Required
KCR	Follow-Up Physician 4 (FupPhys4)	31121	no

Field Length: 7

This field is provided for entry of a code number assigned to the physician following this patient for treatment at this institution. Use the physician's Kentucky License Number and develop your own codes for identifying out-of-state physicians who may be following your patients.

The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License.

A lookup for NPI numbers is available at https://npiregistry.cms.hhs.gov/

This field may also be used to generate mailing labels for follow up letters to these physicians.

Hospitals may use a special code for "Unknown" and/or leave this field blank if there is no alternate follow up physician.

Organization	Field Name	ID	Required
KCR	Follow-Up Physician 5 (FupPhys5)	31122	no

Field Length: 7

This field is provided for entry of a code number assigned to the physician following this patient for treatment at this institution. Use the physician's Kentucky License Number and develop your own codes for identifying out-of-state physicians who may be following your patients.

The web site for the Kentucky Board of Medical Licensure is located at: http://kbml.ky.gov/. The link for the online directory is found under Online Searches, called Physician Profile/Verification of Physician License.

A lookup for NPI numbers is available at https://npiregistry.cms.hhs.gov/

This field may also be used to generate mailing labels for follow up letters to these physicians.

Hospitals may use a special code for "Unknown" and/or leave this field blank if there is no alternate follow up physician.

Date of Last Contact or Death

Organization	Field Name	ID	Required
KCR	Date of Last Contact or Death (FUDateLastContact)	31750	yes
NAACCR	Date of Last Contact	1750	yes

Field Length: 8

Enter the month, day, and year of the last patient contact recorded at the time of abstraction. If the patient has died, the date of death should be recorded here and must be the last date of last contact recorded for this patient.

Survival Status

Organization	Field Name	ID	Required
KCR	Survival Status (SurvStatus)	31760	yes

Field Length: 1

Enter the one digit code which describes the patient and tumor status at last contact.

Code	Description	
1	Alive, no evidence of this tumor present	
2	Alive, this tumor present	
3	Alive, presence of this tumor unknown	
4	Dead, cause unrelated to this tumor - including those dead due to another cancer	
5	Dead, due to this tumor	
6	Dead from complications related to this tumor	
9	Dead, cause unknown	

If a patient is recorded as dead (codes 4-9), then none of the seven "Reason No Therapy" fields can be coded 8. Review and update this code, if applicable.

Cancer Status

Organization	Field Name	ID	Required
KCR	Cancer Status (CancerStatus)	31770	yes
NAACCR	Cancer Status	1770	yes

Field Length: 1

Code	Description	
1	No evidence of tumor	
2	Tumor present	
9	Unknown if cancer present or not	

Code this field as of the last time the patient's vital status and disease status is known. If the patient dies due to an unknown cause, code this field as of the last known status for this disease.

Date of First Recurrence

Organization	Field Name	ID	Required
KCR	Date of First Recurrence (DateFirstRecur)	31810	no
NAACCR	Recurrence Date1st	1860	no

Field Length: 8

Enter the month, day, and year of first recurrence since the patient was reported to be disease-free in Item 31800. If a recurrence is evident from the medical chart, but the date of recurrence is not known you must estimate the recurrence date.

If the patient has never been disease-free, or is still in a disease-free state, leave blank.

Survival Interval

Organization	Field Name	ID	Required
KCR	Survival Interval (SurvInterval)	31780	No

Field Size: 4

This is a field calculated by the computer. It does not appear on the Abstract Form. However, it is available for analysis and reporting purposes. It is calculated as the interval of time (in months) from the date of diagnosis to the date of last contact. This calculation is used in survival analyses.

Type of First Recurrence

Organization	Field Name	ID	Required
KCR	Type of First Recurrence (RecurStatus)	31790	yes
NAACCR	Recurrence Type1st	1880	yes

Field Length: 2

This item identifies the type of first recurrence after a period of documented disease-free intermission or remission.

Instructions for Coding

- · Code the type of first recurrence. First recurrence may occur well after completion of the first course of treatment or after subsequent treatment.
- If the patient has never been disease-free (code 70), continue to track for disease-free status. This may occur after subsequent treatment has been completed.
- If the patient is disease-free (code 00), continue to track until a recurrence occurs. First recurrence may occur well after completion of the first course of treatment.
- Once a recurrence has been recorded (code 04-62 or 88), subsequent recurrences are NOT to be recorded.
- Codes 00 through 70 are hierarchical. Record the highest numbered applicable response.
- If the tumor was originally diagnosed as in situ, code recurrence to 06, 16, 17, 26, 27, 36, or 46 only. Do not use those codes for any other tumors. Codes 00, 88, or 99 may apply to any tumor.
- Codes 51-59 (organ or organ system of distant recurrence) apply only if all first occurrences were in a single category. There may be multiple metastases (or "seeding") within the distant location.
- Code lymphomas or leukemias that are in remission 00. If the patient relapses, then code recurrence status as 59. If one of these is controlled by
 drugs (for example Gleevec for CML), the patient is in remission.
- If there is more than one primary tumor and the physician is unable to decide which has recurred, code the recurrent disease for each tumor. If, at a later date, the recurrent primary is identified, revise the codes as appropriate.

Code	Description
00	Patient became disease-free after treatment and has not had a recurrence
04	In situ recurrence of an invasive tumor
06	In situ recurrence of an in-situ tumor
10	Local recurrence, NOS
13	Local recurrence of an invasive tumor
14	Trocar recurrence of an invasive tumor
15	Combination of 13 and 14
16	Local recurrence of an in situ tumor
17	Both local and trocar recurrence of an in situ tumor
20	Regional, NOS
21	Recurrence of an invasive tumor in adjacent tissue or organ(s) only
22	Recurrence of an invasive tumor in regional lymph nodes only
25	Combination of 21 and 22
26	Regional recurrence of an in situ tumor
27	Combination of 26 with 21, 22 and/or 25
30	Any combination of 10-15 and 20-25
36	Any combination of 16-17 and 26-27
40	Distant recurrence, NOS
46	Distant recurrence of an in situ tumor
51	Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid
52	Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura
53	

	Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid
54	Distant recurrence of an invasive tumor in the liver only
55	Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site
56	Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye
57	Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site
58	Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site
59	Distant systemic recurrence of an invasive tumor only. This includes lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease
60	Distant recurrence of an invasive tumor in a single distant site (51-58) and local, trocar and/or regional recurrence (10-15, 20-25, or 30)
62	Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51-59)
70	Since diagnosis, patient has never been disease-free
88	Recurred, site unknown
99	It is unknown whether the disease has recurred or if the patient was ever disease-free

First Disease Free Start Date

Organization	Field Name	ID	Required
KCR	First Disease Free Start Date (DFStartDate)	31800	no

Field Length: 8

Enter the month, day, and year on which the patient was first considered disease-free. Use all information available in the chart when making an evaluation. If it appears that the patient is disease-free, but no exact date is known, make an estimate.

The definition of disease-free status is related to the site of the cancer being studied. With solid tumors, the patient is considered disease-free when there is no reported clinical evidence of any residual tumor (i.e., the pathology report states that the margins are clear) and there is no evidence of cancer in any lymph nodes or metastatic sites. With leukemias, lymphomas, hematopoietic diseases, etc., complete remission is considered a disease-free status. When recording this information for the latter kinds of cases, enter a date only if the record indicates "remission" or "complete remission", leave blank if the record says only "partial remission" or "stable".

Site of First Recurrence 1

Organization	Field Name	ID	Required
KCR	Site of First Recurrence 1 (RecurSite1)	31820	no
KCR	Site of First Recurrence 2 (RecurSite2)	31830	no
KCR	Site of First Recurrence 3 (RecurSite3)	31840	no
KCR	Site of First Recurrence 4 (RecurSite4)	31850	no
KCR	Site of First Recurrence 5 (RecurSite5)	31860	no

Field Length: 2 (x5)

Use the General Sites Dictionary in Appendix E and code up to five sites of first recurrence. If not applicable, leave blank.

Precede any single digit codes with a zero.

This field cannot be blank if you put in a recurrence date; code 99 if unknown site.

Dz Free Interval

Organization	Field Name	ID	Required
KCR	Dz Free Interval (DFInterval)	31870	No

Field Length: 4

This is a field calculated by the computer. It does not appear on the Abstract Form. However, it is available for analysis and reporting purposes. It is calculated as the interval of time (in months) from the date disease free to the date of first recurrence. This field pertains to the first disease free interval only.

Following Registry

Organization	Field Name	ID	Required
KCR	Following Registry (FURegistry)	31880	yes
NAACCR	Following Registry	2440	yes

Field Length: 10

Record the facility identification number of the registry responsible for following the patient.

This data item is useful when the same patient is recorded in multiple registries.

Instructions for Coding

• For facilities with six-digit FINs that were assigned by the CoC before January 1, 2001, the coded FIN will consist of four leading zeros followed by the full six-digit number.

• For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.

Code	Description
(fill spaces)	Ten-digit facility identification number
0099999999	If the following registry's identification number is unknown

Note: Use Appendix F to find facility ID numbers for Kentucky.

Note: A written agreement may be drawn up between two registries noting which hospital will be responsible for follow-up.

Follow-Up Last Name

Organization	Field Name	ID	Required
KCR	Follow-Up Last Name (FULName)	31930	no
NAACCR	Follow-Up ContactName	2394	no

Field Length: 20

Enter the last name of the patient's closest living relative, or friend, who may be contacted for follow-up information.

Otherwise, leave blank; this field is merely an aid for follow-up.

Follow-Up First Name

Organization	Field Name	ID	Required
KCR	Follow-Up First Name (FUFName)	31940	no
NAACCR	Follow-Up ContactName	2394	no

Field Length: 15

Enter the first name of the patient's closest living relative or friend, who may be contacted for follow up information.

This field is an aid for follow-up, and may be left blank.

Follow-Up Source Central

Organization	Field Name	ID	Required
KCR	Follow-Up Source Central (FUSourceCentral)	31890	yes
NAACCR	Follow-up Source Central	1791	yes

Field Length: 2

Record the source from which the latest follow-up information was obtained.

This data item is used by hospital and central registries to identify the most recent source of follow-up information. This item will be used to calculate the Fol low-Up Source data item for CoC requirements. It is also used at the Central Registry to reflect the source of information contained in the fields for vital status and date of last contact, particularly when these data come from external file linkages (see codes 01-29).

Source of Information:

Code	Description
(01-29)	File Linkages (primarily for Central Registry use)
01	Medicare/Medicaid File
02	Center for Medicare and Medicaid Services (CMS, formerly HCFA)
03	Department of Motor Vehicle Registration
04	National Death Index (NDI)
05	State Death Tape/Death Certificate File
06	County/Municipality Death Tape/Death Certificate File
07	Social Security Administration Death Master File
08	Hospital Discharge Data
09	Health Maintenance Organization (HMO) file
10	Social Security Epidemiological Vital Status Data
11	Voter Registration File
12	Research/Study Related Linkage
29	Linkages, NOS
(30-39)	Hospitals and Treatment Facilities
30	Hospital inpatient/outpatient
31	Casefinding
32	Hospital cancer registry
33	Radiation treatment center
34	Oncology clinic
35	Ambulatory surgical center
39	Clinic/facility, NOS
(40-49)	Physicians
40	Attending physician
41	Medical oncologist
42	Radiation oncologist
43	Surgeon
48	Other specialist
49	Physician, NOS

	ļ
(50-59)	Patient
50	Patient contact
51	Relative contact
59	Patient, NOS
(60-98)	Other
60	Central or Regional cancer registry
61	Internet sources
62	Hospice
63	Nursing homes
64	Obituary
65	Other research/study related sources
98	Other, NOS
99	Unknown source

Follow-Up Source COC

Organization	Field Name	ID	Required
KCR	Follow-Up Source COC (FUSource)	31900	no
NAACCR	Follow-Up Source	1790	no

Field Length: 1

Records the source from which the latest follow-up information was obtained.

This data item is used by hospital and central registries to identify the most recent source of follow-up information.

Instructions for Coding

Code	List	Description
0	Reported hospitalization	Hospitalization at another institution/hospital or first admission to the reporting facility
1	Readmission	Hospitalization or outpatient visit at the reporting facility
2	Physician	Information from a physician
3	Patient	Direct contact with the patient
4	Dept of Motor Vehicles	The Department of Motor Vehicles confirmed the patient has a current license
5	Medicare/Medicaid file	The Medicare or Medicaid office confirmed the patient is alive
7	Death certificate	Information from the death certificate only
8	Other	Friends, relatives, employers, other registries, or any sources not covered by other codes
9	Unknown; not stated in patient record	The follow-up source is unknown or not stated in patient record

Starting with 2006 cases, this field is calculated from Follow-Up Source - Central.

Next Follow-Up Method

Organization	Field Name	ID	Required
KCR	Next Follow-Up Method (FUMethod1)	31910	yes
NAACCR	Next Follow-Up Source	1800	yes

Field Length: 2

Record the code that describes the primary source of follow-up information to be contacted on the next follow-up attempt.

Code	Description
00	Lost to follow up
01	Primary following physician (coded in item 31100)
02	Follow-up Physician 2 (coded in item 31110)
03	Follow-up Physician 3 (coded in item 31120)
04	Patient by letter
05	Patient by phone call
06	Other contact person (coded in items 31930-32020)
07	Public records, agencies, newspapers, etc
08	Hospital chart/records
09	No follow up required
10	Follow-up Physician 4 (coded in item 31121)
11	Follow-up Physician 5 (coded in item 31122)

There is an edit check between this field and the patient level field "Contact Patient" (item 10301). When Contact Patient is coded '0', this field cannot be coded '04' ("Patient by letter") or '05' ("Patient by phone call").

Alternate Follow-Up Method

Organization	Field Name	ID	Required
KCR	Alternate Follow-Up Method (FUMethod2)	31920	no
NAACCR	Next Follow-Up Source	1800	no

Field Length: 2

Record the code which describes the alternate source to be contacted for follow-up information.

Code	Description
00	Lost to follow up
01	Primary following physician (coded in item 31100)
02	Follow-up Physician 2 (coded in item 31110)
03	Follow-up Physician 3 (coded in item 31120)
04	Patient by letter
05	Patient by phone call
06	Other contact person (coded in items 31930-32020)
07	Public records, agencies, newspapers, etc
08	Hospital chart/records
09	No follow up required
10	Follow-up Physician 4 (coded in item 31121)
11	Follow-up Physician 5 (coded in item 31122)

There is an edit check between this field and the patient level field "Contact Patient" (item 10301). When Contact Patient is coded '0', this field cannot be coded '04' ("Patient by letter") or '05' ("Patient by phone call").

Follow-Up Address 1

Organization	Field Name	ID	Required
KCR	Follow-Up Address 1 (FUAddress1)	31950	no
NAACCR	Follow-Up ContactNo&St	2392	no
KCR	Follow-Up Address 2 (FUAddress2)	31960	no
NAACCR	Follow-Up ContactSuppl	2393	no

Field Length: 20 (x2)

Enter the address of the patient's closest living relative, or friend.

This field is an aid for follow-up, and may be left blank.

Follow-Up City

Organization	Field Name	ID	Required
KCR	Follow-Up City (FUCity)	31970	no
NAACCR	Follow-Up ContactCity	1842	no

Field Length: 20

Enter the city of the address of the patient's closest living relative, or friend.

This field is an aid for follow-up, and may be left blank.

Follow-Up State

Organization	Field Name	ID	Required
KCR	Follow-Up State (FUState)	31980	no
NAACCR	Follow-Up ContactState	1844	no

Field Length: 2

Enter the state abbreviation for the address of the patient's closest living relative, or friend. This field is an aid for follow-up, and may be left blank.

Follow-Up Zip Code

Organization	Field Name	ID	Required
KCR	Follow-Up Zip Code (FUZipCode)	31990	no
NAACCR	Follow-Up ContactPostal	1846	no
KCR	Follow-Up Zip Ext (FUZipExt)	32000	no
NAACCR	Follow-Up ContactPostal	1846	no

Field Length: 9

Enter the ZIP code of the address of the patient's closest living relative, or friend.

This field is an aid for follow-up, and may be left blank.

Follow-Up Phone

Organization	Field Name	ID	Required
KCR	Follow-Up Phone (FUPhone)	32010	no

Field Length: 10

Enter the telephone number of the patient's closest living relative, or friend.

This field is an aid for follow-up, and may be left blank.

Follow-Up Relationship

Organization	Field Name	ID	Required
KCR	Follow-Up Relationship (FURelation)	32020	no

Field Length: 15

Enter the relationship of the other contact person to the patient. For example,

Spouse

Father

Mother

Sister

Brother

Son

Daughter

Grandparent

Neighbor, etc.

Follow-Up Text

Organization	Field Name	ID	Required
KCR	Follow-Up Text (FUText)	32030	no

Field Length: 30

This field may be used to type in any pertinent information about follow-up. It is an optional field and may be left blank.

Last Follow-up Hosp Id

Organization	Field Name	ID	Required
KCR	Last Follow-up Hosp Id (LastFUHospId)	32040	no

Field Length: 11

This field does not appear on the abstract but is available for data analysis. It is auto filled with the facility ID number of the hospital which most recently updated the patient's record. This field is mainly utilized in multi-facility registries and at the central registry.

Modified By (FU)

Organization	Field Name	ID	Required
KCR	Modified By (FU) (FModUser)	32050	no

Field Length: 8

This is a calculated field which records the user name of the last individual to modify follow-up data. It is updated each time the record is edited.

Time Follow-up Modified

Organization	Field Name	ID	Required
KCR	Time Follow-up Modified (FModTime)	32060	no

Field Length: 19

This field automatically records the date and time that follow-up data was last modified.

Date of Last Cancer (Tumor) Status

Organization	Field Name	ID	Required
KCR	Date of Last Cancer (Tumor) Status (DateLastCancerStatus)	31741	no
CoC	Date of Last Cancer (Tumor) Status	1772	no

Field length: 8

Description

This data item documents the date of last cancer (tumor status) of the patient's malignant or non-malignant tumor. This data item is required for CoCaccredited facilities as of cases diagnosed 01/01/2018 and later.

Rationale

This information is used for patient follow-up and outcomes studies.

Therapy Data

- Common
 - Tx Type
 - Tx Course
 - Date Tx Started
 - Therapy Facility Therapy Local Hospital Id
 - Treatment Notes

 - Therapy Clinical Trial Number Modified By (Therapy)
 - Time Modified (Therapy)
 - Therapy Information
- Surgery
 - Surgery Primary Site (STORE)
 - Scope Regional LN (STORE)
 - Surgery Other Site (STORE)
 - Surgical Margins (STORE)
 - Surgical Approach 2010
 - Surgical Approach (ROADS)
 - Surg Prim Site (ROADS)
 Scope Reg LN (ROADS)

 - Num LN Removed (ROADS)
 - Surg Other Site (ROADS)
 - Reconstruction (ROADS)
- Non-Definitive Surgery
 - Non-Definitive Surgery Code
- Chemotherapy Chemotherapy Code
- Radiation
 - Radiation Therapy Code
 - Radiation Site 1
 - Total Rads
 - Location of Radiation
 - Rad Treatment Volume
 - Regional Tx Modality
 - Regional Dose
 - Boost Tx Modality
 - Boost Dose
 - Num Treatments This Volume
 - Date Radiation Ended
 - Date Radiation Ended Flag
 - Phase I Radiation Primary Treatment Volume
 - Phase I Radiation to Draining Lymph Nodes
 - Phase I Radiation Treatment Modality
 - Phase I Radiation External Beam Planning Technique
 - Phase I Dose per Fraction
 - Phase I Number of Fractions
 - Phase I Total Dose
 - Phase I Therapy Local Hospital ID
 - Phase II Radiation Primary Treatment Volume
 - Phase II Radiation to Draining Lymph Nodes
 - Phase II Radiation Treatment Modality
 - Phase II Radiation External Beam Planning Technique
 - Phase II Dose per Fraction
 - Phase II Number of Fractions
 - Phase II Total Dose

 - Phase II Therapy Local Hospital ID
 Phase III Radiation Primary Treatment Volume
 - Phase III Radiation to Draining Lymph Nodes
 - Phase III Radiation Treatment Modality
 - Phase III Radiation External Beam Planning Technique
 - Phase III Dose per Fraction
 - Phase III Number of Fractions
 - Phase III Total Dose
 - Phase III Therapy Local Hospital ID
 - Radiation Treatment Discontinued Early
 - Number of Phases of Radiation Treatment to this Volume
 - Total Dose
- Hormone Hormone Therapy Code
- Immunotherapy
- Immunotherapy Code
- Trans Endo
- Transplant/Endocrine Code • Other
 - Other Therapy Code

Common

- Tx Type
 Tx Course
 Date Tx Started
 Therapy Facility
 Therapy Local Hospital Id
 Treatment Notes
 Therapy Clinical Trial Number
 Modified By (Therapy)
 Time Modified (Therapy)
 Therapy Information

Тх Туре

Organization	Field Name	ID	Required
KCR	Tx Type (TxType)	50040	yes

Field Length: 1

Using the codes below, record the type of therapy the patient received, regardless of where it was given.

THERAPY TYPES

Code	Description
Ν	Non-definitive surgery
S	Surgery
R	Radiotherapy
С	Chemotherapy
Н	Hormone therapy
I	Immunotherapy
Т	Transplant or Endocrine procedures
0	Other therapy

Other therapy includes: experimental, alternative, complementary, and any other types of therapy not elsewhere listed.

If no definitive therapy was administered to this patient, or you may leave items 50040-50400 blank and record an appropriate code in Reason No Therapy and Date No First Therapy.

Tx Course

Organization	Field Name	ID	Required
KCR	Tx Course (Course)	50050	yes

Field Length: 1

Enter the letter which indicates whether this therapy type was administered as part of the first course of therapy or was part of a subsequent course of therapy.

Code	Description
F	First course
S	Subsequent

Refer to the General Coding Principals section of this manual for a discussion of the definition of first course of therapy.

Date Tx Started

Organization	Field Name	ID	Required
KCR	Date Tx Started (TxStartDate)	50060	yes

Field Length: 8

Enter the month, day, and year this treatment type was initiated for this case of cancer.

Therapy Facility

Organization	Field Name	ID	Required
KCR	Therapy Facility (Facility)	50070	no

Field Length: 10

Enter the name or code of the facility where treatment was given. These codes are optional and defined by each institution, for its own use. The codes for many health care facilities in Kentucky listed in Appendix F may be used.

Therapy Local Hospital Id

Organization	Field Name	ID	Required
KCR	Therapy Local Hospital Id (TxLocalHospId)	50075	yes

Field Length: 10

Select the appropriate code to indicate if this therapy was administered at your facility. Otherwise, enter '0' for No.

Code	Description
0	Not administered by this facility
<hosp id=""></hosp>	<hospital name=""></hospital>
9	Valid only for diagnoses before 1/1/2003

Treatment Notes

Organization	Field Name	ID	Required
KCR	Treatment Notes (TxAgents)	50380	no

Field Length: 1000

This field is available with each of the therapy types: surgery, radiation, chemotherapy, etc. It is an optional text field in which you may wish to record notes about a specific therapeutic occurrence or regimen. For chemotherapy, hormone and immunotherapy, enter the names or abbreviations (separated by a comma) of the treatment agents used. A list of names and accepted abbreviations is available in SEER Rx and Appendix H. A list of common abbreviations for combination regimens of therapy is also included in SEER Rx and Appendix H.

Use this field to code 'PALL' for palliative surgery, radiation, or chemotherapy.

Therapy Clinical Trial Number

Organization	Field Name	ID	Required
KCR	Therapy Clinical Trial Number (TxClinTrialNum)	50385	no

Choose the Clinical Trial number coded in the patient segment of the abstract where this treatment is part of the protocol or treatment regimen.

Code	Description
0	None or unknow
1	Clinical Trial 1
2	Clinical Trial 2
3	Clinical Trial 3
4	Clinical Trial 4

Modified By (Therapy)

Organization	Field Name	ID	Required	
KCR	Modified By (Therapy) (TModUser)	50390	no	

Field Length: 8

The user name of the last individual to modify therapy data is automatically recorded in this field and is updated each time the record is edited.

Time Modified (Therapy)

Organization	Field Name	ID	Required
KCR	Time Modified (Therapy) (TModTime)	50400	no

Field Length: 19

The date and time that therapy data was last modified is automatically recorded in this field and is updated each time the record is edited.

Therapy Information

Data items 50040-50400

Each type of definitive therapy (surgery, radiation, chemotherapy, etc.) that the patient received should be recorded in detail in data items 50040-50400. These items may be repeated as often as necessary in order to record every type of treatment administered to the patient. If the same type of treatment is given more than once during a course, it only needs to be recorded one time -- UNLESS the procedure code or treatment agents change. Then, items 50040-50400 would have to be repeated in order to record the differences in those item(s). For example, if a patient has both a lumpectomy and a mastectomy, you would have to complete items 50040-50400 for each instance of surgery because the procedure code is different. See special note for radiation treatment below.

Coding Surgery: The CPDMS software uses the same data fields (items 50040-50400) to record both definitive and non-definitive therapies. Non-definitive surgical procedures include incisional biopsies, bypass surgeries, etc., and the codes for these procedures are the same for all types of cancer. Coding non-definitive surgical procedures became required by the ACoS for approved facilities in 1996. Beginning with 2010 diagnoses, KCR requires the first non-definitive surgical procedure which is positive for malignancy to be recorded.

The definitive surgical procedure codes are site specific and they are contained in Appendix G. These surgery codes changed significantly in 1998 with the ACoS ROADS Manual, and again in 2003 with the FORDS Manual. Surgery codes collected prior to 1998 were converted to the 1998 ROADS definitions and are stored in data items 50240-50290. Surgeries coded for cancers diagnosed from 1998 to 2002 are also collected in items 50240-50290 and are defined by the ACoS ROADS Manual. Starting with cancers diagnosed in 2003, the site specific surgery codes are stored in data items 50100-50120 and are defined by the ACoS FORDS Manual. Both sets of codes are included in Appendix G. Be sure to use the correct table based on the diagnosis year of the cancer being abstracted.

Note on Coding Radiation Treatment: (This is for ACoS approved hospitals and pertains to treatment given to patients diagnosed after January 1, 2003.) You should summarize the entire first course of radiation treatment on one radiation therapy segment. Code all eight new radiation fields implemented with FORDS. If you learn of more radiation given after you have abstracted and entered this patient record, then EDIT the EXISTING radiation treatment segment instead of creating a new radiation therapy record segment. This is important for NCDB submissions. They require one summary record of first course radiation treatment. If there are more in your database, only the one with the earliest start date will be sent to NCDB. If palliative radiation is also given, it must also be recorded in the rapy fields. Each data element and the appropriate codes are further explained on the following pages. Follow-up information about subsequent therapies may be recorded in the same manner as the first course of therapy.

Surgery

- Surgery Primary Site (STORE)
 Scope Regional LN (STORE)
 Surgery Other Site (STORE)
 Surgical Margins (STORE)
 Surgical Approach 2010
 Surgical Approach (ROADS)
 Surg Prim Site (ROADS)
 Scope Reg LN (ROADS)
 Num LN Removed (ROADS)
 Surg Other Site (ROADS)
 Reconstruction (ROADS)

Surgery Primary Site (STORE)

Organization	Field Name	ID	Required
KCR	Surgery Primary Site (STORE) (StoreSurgCode)	50100	yes
NAACCR	RX SummSurg Prim Site	1290	yes

Field Length: 2

Record the surgical procedure(s) performed to the primary site.

- Site-specific codes for this data item are found in Appendix G- Surgery Codes-FORDS.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is unavailable.
- Biopsies that remove all of the tumor and/or leave only microscopic margins are to be coded in this item, even if documented as "incisional biopsy."
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery no tumor remains, DO NOT consider the needle biopsy to be an excisional biopsy.
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in Appendix G- Surgery Codes-FORDS.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results.
 - Example:
 - Enter 2 surgeries, but on the second surgery therapy, use the surgical procedure code that means the complete removal of the
 organ (or the more extensive surgery). For example, if you have a right thyroid lobectomy code 21) and then later a subtotal
 thyroidectomy (code 40) which removes all of the remaining thyroid, then use code 50 for Total thyroidectomy in the second
 surgical treatment code.
- For all hematopoietic, reticuloendothelial, immunoproliferative, and myeloproliferative diseases, this code is 98. Any surgical procedures performed for these diagnoses are recorded in the data item Surgical Procedure Other Site-FORDS.

Scope Regional LN (STORE)

Organization	Field Name	ID	Required
KCR	Scope Regional LN (STORE) (StoreRegLNSurg)	50110	yes
NAACCR	RX SummScope Reg LN Sur	1292	yes

Field Length: 1

Record the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.
- Record surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose or stage disease in this data item.
- Codes 0-7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- For primaries of the meninges, brain, spinal cord, cranial nerves, and other parts of the central nervous system (C70.0-C70.9, C71.0-C71.9, C72. 0-C72.9), code 9.
- For lymphomas (M-9590-9596, 9650-9719, 9727-9729) with a lymph node primary site (C77.0-C77.9), code 9.
- For an unknown or ill-defined primary (C76.0-C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989), code 9.
- Do not code distant lymph nodes removed during surgery to the primary site for this data item. Distant nodes are coded in the data field Surgical Procedure/Other Site.
- Refer to the current AJCC Cancer Staging Manual for site-specific identification of regional lymph nodes.
- If the operative report lists a lymph node dissection, but no nodes were found by the pathologist, code this field 0 (no lymph nodes removed).
- If the patient has two primaries with common regional lymph nodes, code the removal of regional nodes for both primaries.
- If a sentinel lymph node biopsy is attempted and fails to map this should be coded as 2 in the absence of an axillary lymph node dissection.
- If sentinel lymph node biopsy is attempted and fails to map and the patient does have an axillary lymph node dissection, then the correct code would be 6.

Code	Label	Description
0	None	No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy
1	Biopsy or aspiration of regional lymph node, NOS	Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.
2	Sentinel lymph node biospy	Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor.
3	Number of regional nodes removed unknown or not stated; regional lymph nodes removed, NOS	Sampling or dissection of regional lymph node(s) and the number of nodes removed is unknown or not states. The procedure is not specified as sentinel nodes node biopsy.
4	1-3 regional lymph nodes removed	Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.
5	4 or more regional lymph nodes removed	Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.
6	Sentinel node biopsy and code 3, 4, or 5, at same time, or timing not stated	Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 were performed, but timing was not stated in patient record.
7	Sentinel node biopsy and code 3, 4, or 5 at different times	Code 2 was followed in a subsequent surgical event by procedures coded 3, 4, or 5.
9	Unknown or not applicable	It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

Surgery Other Site (STORE)

Organization	Field Name	ID	Required
KCR	Surgery Other Site (STORE) (StoreSurgOtherSite)	50120	yes
NAACCR	RX SummSurg Oth Reg/Dis	1294	yes

Field Length: 1

Record the surgical removal of distant lymph nodes or other tissue(s)/organ(s) beyond the primary site.

- Assign the highest numbered code that describes the surgical resection of distant lymph node(s) and/or regional/distant tissue or organs.
- Incidental removal of tissue or organs is not a "Surgical Procedure/Other Site."
 Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0-C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9750, 9760-9764, 9800-9820, 9826,

9831-9920, 9931-9964, 9980-9989).		
Code	Description	
0	No surgical procedure of nonprimary site was performed.	
1	Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.	
2	Nonprimary surgical procedure to other regional sites	
3	Nonprimary surgical procedure to distant lymph node(s)	
4	Nonprimary surgical procedure to distant site	
5	Any combination of surgical procedures 2, 3, or 4.	
9	Unknown; death certificate only	

Surgical Margins (STORE)

Organization	Field Name	ID	Required
KCR	Surgical Margins (STORE) (SurgMargins)	50130	yes
NAACCR	RX SummSurgical Margins	1320	yes

Field Length: 1

This field describes the status of the surgical margins after resection of the primary tumor. The codes for surgical margins are not site specific and were converted for cancers diagnosed before 2003.

Microscopic involvement cannot be seen by the naked eye. The pathology report usually documents microscopic involvement in the final diagnosis or the microscopic portion of the report.

Macroscopic involvement is gross tumor which is visible to the naked eye. However, it must be documented in the pathology report.

Code	Label	Description
0	No residual tumor	All margins are grossly and microscopically negative
1	Residual tumor, NOS	Involvement is indicated, but not otherwise specified.
2	Microscopic residual tumor	Cannot be seen by the naked eye.
3	Macroscopic residual tumor	Gross tumor of the primary site which is visible to the naked eye.
7	Margins not evaluable	Cannot be assessed (indeterminate).
8	No primary site surgery	No surgical procedure of the primary site. Diagnosed at autopsy.
9	Unknown or not applicable	Unknown whether a surgical procedure to the primary site was performed; DCO; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic diseases.

Coding Instructions

- Record the margin status as it appears in the pathology report.
- Codes 0–3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- Code 7 if the pathology report indicates the margins could not be determined.
- If no surgery of the primary site was performed, code 8.
- Code 9 if the pathology report makes no mention of margins or no tissue was sent to pathology.

• For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0–C77. 9), code 9.

• For an unknown or ill-defined primary site (C76.0–C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4, or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.

Surgical Approach 2010

Organization	Field Name	ID	Required
KCR	Surgical Approach 2010 (SurgApproach2010)	50135	no
NAACCR	RX HospSurg App 2010	668	no

Field Length: 1

This item is used to describe the surgical method used to approach the primary site for patients undergoing surgery of the primary site. It should not be confused with the obsolete field "Surgical Approach (ROADS)" (item #50240).

Instructions for Coding

- This item may be left blank for cases diagnosed prior to January 1, 2010.
- Assign code 2 or 4 if the surgery began as robotic assisted or endoscopic and was converted to open.
- If both robotic and endoscopic surgery were used, code to robotic (codes 1 or 2).
 For ablation procedures, assign code 3.

Code	Description
0	No surgical procedure of primary site at this facility; Diagnosed at autopsy
1	Robotic assisted
2	Robotic converted to open
3	Endoscopic or laparoscopic
4	Endoscopic converted to open
5	Open or approach unspecified
9	Unknown whether surgery was performed at this facility

Surgical Approach (ROADS)

Organization	Field Name	ID	Required
KCR	Surgical Approach (ROADS) (SurgApproach)	50240	yes
NAACCR	RX SummSurgical Approch	1310	yes

Field Length: 1

This data field applies only to cancers diagnosed before 2003. Collection of this data item was discontinued as of 1/1/2003 with FORDS implementation.

"Surgical Approach" describes the method used to approach the organ of origin and/or primary tumor. Code the approach for surgical treatments of the primary site only. If no definitive surgical procedure at the primary site was done ("Surgery of Primary Site" is coded 00), "Surgical Approach" must be coded 0.

"Endoscopy, image guided" is a generic term for guidance provided by any imaging technique include, but not limited to, CT scans, MRI scans, ultrasound, or radiographic imaging.

"Open" is a generic term describing all non-scope approaches. Procedures for which "Surgical Approach" would be coded open include, but are not limited to, mastectomy; excision of a melanoma of the skin; glossectomy.

"Open, assisted by endoscopy" means that the scope is being used (present in the body) at the same time the primary tumor is resected. DO NOT CODE a procedure as assisted by endoscopy when the scope is used and removed prior to the resection or when it is inserted and used after the resection of the primary tumor.

Example: Patient with lung cancer is taken to the surgical suite. A bronchoscopy and mediastinoscopy are done to evaluate whether the lesion is resectable. The scopes are removed before the surgeon performs a wedge resection. Code "Surgical Approach" open, NOT assisted by endoscopy.

The codes for surgical approach when Therapy type = S are site specific and they are contained in Appendix G Surgical Codes-ROADS.

Surg Prim Site (ROADS)

Organization	Field Name	ID	Required
KCR	Surg Prim Site (ROADS) (RoadsSurgCode)	50250	yes
NAACCR	RX SummSurg Site 98-02	1646	yes

Field Length: 2

When therapy type = S, the Surgery at Primary Site code indicates a definitive surgical treatment for this cancer. Enter the two digit code to indicate the specific surgical procedure performed at the primary cancer site. These codes are listed in Appendix G - Surgery Codes - ROADS. They are site specific codes, as taken from the ACoS Registry Operations and Data Standards Manual, revised for 1998. This data item applies only to cancers diagnosed before 2003. (Surgeries performed on patients diagnosed after 1/1/2003 are recorded in data item 50100.)

Use the following guidelines to complete this field:

Only record surgeries of the primary site. Surgery to remove regional tissue or organs is coded in this field only if the tissue/organs are removed with the primary site as part of a specified code definition or in an en bloc resection. An en bloc resection is the removal of organs in one piece at one time.

Example: When a patient has a modified radical mastectomy, since the breast and axillary contents are removed in one piece (en bloc), surgery of primary site is coded as a modified radical mastectomy (50) even if the pathology finds no nodes in the specimen.

The range of codes from 10-79 are hierarchical and supersede codes '80', '90', and '99'. If more than one code describes the procedure, use the numerically higher code. If surgery was previously done, code the total result of that surgery with the current surgery. Biopsies that remove all gross tumor or leave only microscopic margins should be coded as surgery to the primary site.

If there was no surgical procedure at the primary site, code 00.

Scope Reg LN (ROADS)

Organization	Field Name	ID	Required
KCR	Scope Reg LN (ROADS) (RoadsRegLNSurg)	50260	yes
NAACCR	RX SummScope Reg 98-02	1647	yes

Field Length: 1

This data field applies only to cancers diagnosed before 2003. Collection of this data item was discontinued as of 1/1/2003 with FORDS implementation.

For the majority of sites, "Scope of Regional Lymph Node Surgery" defines the removal of regional lymph node(s). This refers to the farthest regional node removed regardless of involvement with disease. There is no minimum number of nodes that must be removed. If at least one regional lymph node was removed, the code for this field must be in the range of 1-5. If a regional lymph node was aspirated or biopsied, enter code '1'.

For head and neck sites, this field describes neck dissections. Codes 2-5 indicate only that a neck dissection procedure was done; they do not imply that nodes were found during the pathologic examination of the surgical specimen. Code the neck dissection even if no nodes were found in the specimen.

These codes are site specific and they are contained in Appendix G - Surgery Codes - ROADS. The codes are hierarchical; if more than one applies, record the highest code (except 9). A list identifies the regional lymph nodes for each site. Any other nodes are distant; code their removal in the data field " Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s)". For unknown primaries, leukemias, lymphomas (except lymphomas of the spleen), hematopoietic diseases, and brain primaries code '9' in this field.

If no regional lymph nodes were removed, code 0.

Nodes which are considered regional are those defined in the AJCC Manual for Staging of Cancer in each site specific chapter.

Num LN Removed (ROADS)

Organization	Field Name	ID	Required
KCR	Num LN Removed (ROADS) (NumRegLNRemoved)	50270	yes
NAACCR	RX SummReg LN Examined	1296	yes

Field Length: 2

This data field applies only to cancers diagnosed before 2003. Collection of this data item was discontinued as of 1/1/2003 with FORDS implementation.

Record the number of regional lymph nodes microscopically examined in the pathology report DURING THIS SURGICAL PROCEDURE ONLY. DO NOT add numbers of nodes removed at different surgical events.

If no regional lymph nodes are identified in the pathology report, code 00 even if the surgical procedure includes a lymph node dissection (i.e., modified radical mastectomy) or even if the operative report documents removal of nodes.

Because this field is not cumulative and not affected by timing, it does not necessarily replace or duplicate the field "Regional Lymph Node Examined." Use the Surgical Codes in Appendix G to identify the regional lymph nodes for each site.

Code	Description
00	No regional lymph nodes removed
01	One regional lymph node removed
02	Two regional lymph nodes removed
90	Ninety or more regional lymph nodes removed
95	No regional lymph node(s) removed but aspiration of regional lymph node(s) was performed.
96	Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated.
97	Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated.
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection.
99	Unknown; not stated; death certificate ONLY

Use code 95 for a lymph node aspiration when the cytology or histology is positive for malignant cells.

Use code 99 if information about regional lymph nodes is unknown, or if the field is not applicable for that site or histology, i.e., unknown primaries (C80.9).

Surg Other Site (ROADS)

Organization	Field Name	ID	Required
KCR	Surg Other Site (ROADS) (RoadsSurgOtherSite)	50280	yes
NAACCR	RX SummSurg Oth 98-02	1648	yes

Field Length: 1

This data field applies only to cancers diagnosed before 2003. Collection of this data item was discontinued as of 1/1/2003 with FORDS implementation.

"Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s)" describes the removal of tissues(s) or organ(s) other than the primary tumor or organ of origin. This field is for all procedures that do not meet the definitions of Surgery of Primary Site or Scope of Regional Lymph Node Surgery.

Example: A patient has an excisional biopsy of a hard palate lesion is removed from the floor of the mouth and a resection of a metastatic lung nodule during the same surgical event. Code the resection of the lung nodule as 6 (distant site).

Code the removal of non-primary tissue which was removed because the surgeon suspected it was involved with malignancy even if the pathology is negative.

DO NOT CODE the incidental removal of tissue. Incidental is defined as tissue removed for reasons other than the malignancy. For example: During a colon resection, the surgeon noted that the patient had cholelithiasis and removed the gall bladder. Do not code removal of the gall bladder.

These codes are site specific and are contained in Appendix G, Surgical Codes-ROADS.

Reconstruction (ROADS)

Organization	Field Name	ID	Required
KCR	Reconstruction (ROADS) (Reconstruction)	50290	yes
NAACCR	RX SummReconstruct 1st	1330	yes

Field Length: 1

This data field applies only to cancers diagnosed for 2003. Collection of this data item was discontinued as of 1/1/2003 with FORDS implementation. Only breast reconstruction continues to be recorded and this is captured in the Surgery at Primary Site-FORDS code.

"Reconstruction/Restoration" is a surgical procedure that improves the shape and appearance or function of body structures that are missing, defective, damaged, or misshapen by cancer or cancer-directed therapies. It must be a restoration of primary site or organ.

"Reconstruction/Restoration - First Course" is limited to procedures started during the first course of therapy. Some reconstructive/restorative procedures involve several surgical events. Code as "Reconstructive/Restoration - First Course" if the first event occurred during the first course of treatment.

Each site-specific surgery code scheme in Appendix G - Surgery Codes-ROADS has either a list of reconstructive/restorative procedures or codes that define specific procedures. Code only those procedures listed under each site.

Reconstructive/restorative procedures may be performed after first course of therapy is complete. Code these procedures in this field with therapy course is "S" for subsequent therapy.

Non-Definitive Surgery

Non-Definitive Surgery Code

Non-Definitive Surgery Code

Organization	Field Name	ID	Required
KCR	Non-Definitive Surgery Code (NonDefSurgCode)	50090	yes
NAACCR	RX SummDX/Stg Proc	1350	yes

Field Length: 2

When therapy type = N, you may record surgical procedures that are NOT considered treatment in this field. The codes are the same for all sites:

Code	Description	
01	ncisional biopsy of other than primary site leaving gross residual disease. Needle biopsy of other than primary site	
02	Incisional biopsy of primary site leaving gross residual disease. Needle biopsy of primary site	
03	Exploratory ONLY (no biopsy)	
04	Bypass surgery (no biopsy); - ostomy ONLY (no biopsy)	
05	Exploratory ONLY and incisional or needle biopsy of primary site or other sites	
06	Bypass surgery and incisional or needle biopsy of primary site or other sites - ostomy ONLY and incisional or needle biopsy of primary site or other sites	
07	Non-definitive surgery, NOS	

• Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility.

 If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).

• For lymphomas of lymph node primary site (C77._), you may code the excision of a lymph node in this item (code 02) if it is for diagnostic and/or staging purposes. The surgical removal of lymph nodes for eradication of the lymphoma would be coded in Surgical Procedure of Primary Site.

Do not code surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in this
data item. Use the data item Scope of Regional Lymph Node Surgery to code these procedures.

Do not code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears). These are not considered surgical
procedures.

Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item Surgical Procedure of Primary Site.
If a needle biopsy precedes an excisional biopsy, even if no tumor is found at the time of surgery, both the needle biopsy and surgery must be recorded. Code the needle biopsy in the Non-definitive surgery field and code the excision in the Surgery at Primary Site. Surgical margins must be evaluated in order to determine if a biopsy is incisional or excisional; and margins cannot be evaluated for a needle biopsy.

- Do not code palliative surgical procedures in this data item. Use the data item Palliative Procedure.
- Do not record biopsies that are negative for cancer.

Chemotherapy

Chemotherapy Code

Chemotherapy Code

Organization	Field Name	ID	Required
KCR	Chemotherapy Code (ChemoCode)	50190	yes
NAACCR	RX SummChemo	1390	yes

Field Length: 1

Code the type of chemotherapy that the patient received. Refer to the SEER*Rx Interactive Drug Database for a list of chemotherapeutic agents.

For all sites, the codes are:

Code	Description	
1	nemotherapy, NOS	
2	Chemotherapy, single agent	
3	Chemotherapy, multiple agents (combination regimens)	

Record any chemical that is administered to treat cancer tissue that is not considered to achieve its effect through a change in the hormonal balance. Only the agent is coded, not the method of drug administration (i.e., chemoembolization). One planned course of chemotherapy may be given in multiple segments or cycles (i.e., CHOP x 6). Record as a single course of therapy.

If the patient has an adverse reaction to a particular chemotherapeutic drug, the physician may substitute another If the replacement drug belongs to the same group as the original drug, it is considered to be the same regimen for coding purposes. If the replacement drug is in a different group than the original drug, code as a new subsequent course of therapy.

Two or more single agents given at separate times during the first course of cancer-directed therapy are considered a combination regimen and coded 3 (chemotherapy, multiple agents). If an agent in a combination regimen is a hormone (such as Prednisone in CHOP), code '3' here and record the hormonal agent again, under Hormone therapy.

When chemotherapeutic agents are used as radiosensitizers or radioprotectants, they are given at a much lower dosage and do not affect the cancer. Radiosensitizers and radioprotectants are classified as ancillary drugs. Do not code as chemotherapy.

Effective with diagnoses in 2005 and later, use the SEER Rx program for a list of all cancer therapeutic agents (available from SEER's web site: http://seer. cancer.gov/tools/seerrx/.) For pre-2005 cases, refer to Appendix H and/or the SEER Program Self-Instructional Manual for Tumor Registrars, Book 8, Antineoplastic Drugs Second Edition.

Radiation

- Radiation Therapy Code
- Radiation Site 1
- ٠ **Total Rads**
- Location of Radiation
- Rad Treatment Volume
 Regional Tx Modality
- Regional Dose Boost Tx Modality
- Boost Dose
- Num Treatments This Volume
- Date Radiation Ended
- Date Radiation Ended Flag
- Phase I Radiation Primary Treatment Volume
- Phase I Radiation to Draining Lymph Nodes
- Phase I Radiation Treatment Modality
- Phase I Radiation External Beam Planning Technique
- Phase I Dose per Fraction
- Phase I Number of Fractions
- Phase I Total Dose
- Phase I Therapy Local Hospital ID
- Phase II Radiation Primary Treatment Volume
- Phase II Radiation to Draining Lymph Nodes
 Phase II Radiation Treatment Modality
- Phase II Radiation External Beam Planning Technique
- Phase II Dose per Fraction
 Phase II Number of Fractions
 Phase II Total Dose

- Phase II Therapy Local Hospital ID
 Phase III Radiation Primary Treatment Volume
 Phase III Radiation to Draining Lymph Nodes
- •
- Phase III Radiation Treatment Modality
- Phase III Radiation External Beam Planning Technique
- Phase III Dose per Fraction • Phase III Number of Fractions
- Phase III Total Dose
- Phase III Therapy Local Hospital ID Radiation Treatment Discontinued Early
- Number of Phases of Radiation Treatment to this Volume
- Total Dose

Radiation Therapy Code

Organization	Field Name	ID	Required
KCR	Radiation Therapy Code (RadCode)	50140	yes
NAACCR	RX SummRadiation	1360	yes

Field Length: 1

Code the type of radiation therapy that the patient received. This field will be calculated for ACoS approved facilities from items 50320 and 50340. Non-approved facilities MUST enter the radiation therapy code manually.

For all sites, the codes are:

Code	Description	
1	Beam radiation	
2	Radioactive Implants	
3	Radioisotopes	
4	Combinations of beam radiation with radioactive implants or radioisotopes	
5	Radiation therapy, NOS	

Code 1 (beam radiation) includes treatment given with X ray, cobalt, linear accelerator, neutron beam, intensity modulated radiation therapy (IMRT), and betatron, as well as spray radiation and stereotactic radiosurgery, such as gamma knife and proton beam, regardless of the source of the radiation.

Code 2 (radioactive implants) includes brachytherapy, radioembolization, interstitial implants, molds, seeds, needles, or intracavity applicators of radioactive materials, such as cesium, radium, radon, and radioactive gold.

Code 3 (radioisotopes) includes internal use of radioactive isotopes, such as iodine-131 or phosphorus-32, given orally or intracavitarily, or by intravenous injection.

If the method or source is not given, code 5 (radiation therapy, NOS).

Radiation Site 1

Organization	Field Name	ID	Required
KCR	Radiation Site 1 (RadSite1)	50150	no
KCR	Radiation Site 2 (RadSite2)	50160	no
KCR	Radiation Site 3 (RadSite3)	50170	no

Field Length: 2 (x3)

When the treatment type is R, record a two digit code for up to three sites to which radiotherapy was directed. Use the General Sites Dictionary in Appendix E. When more than three sites are indicated, enter the code for the three most definitive sites, coding the primary site of the cancer in the first set of boxes.

Precede any single digit codes with a zero.

Total Rads

Organization	Field Name	ID	Required
KCR	Total Rads (RadTotal)	50180	no

Field Length: 5

Enter the total dosage of radiation, directed to the site specified in items 50150-50170, that was received by the patient for this particular type and course of radiation therapy.

Location of Radiation

Organization	Field Name	ID	Required
KCR	Location of Radiation (RadLocation)	50300	no
NAACCR	RadLocation of RX	1550	no

Field Length: 1

Description

Identifies the location of the facility where radiation therapy was administered during the first course of treatment It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

This data item provides information useful to understanding the referral patterns for radiation therapy services and for assessing the quality and outcome of radiation therapy by delivery site.

Instructions for Coding

Code	Description	
1	All radiation therapy was administered at the reporting facility. Diagnosed at autopsy.	
2	Regional treatment was administered at the reporting facility; a boost dose was administered elsewhere.	
3	Regional treatment was administered elsewhere; a boost dose was administered at the reporting facility.	
4 All radiation therapy was administered elsewhere.		
8	Radiation therapy was administered, but the pattern does not fit the above categories.	
9	Radiation therapy was administered, but the location of the treatment facility is unknown or not stated in patient record; it is unknown whether radiation therapy was administered.	

Examples:

- 2 A patient received radiation therapy to the entire head and neck region at the reporting facility and is then referred to another facility for a highdose-rate (HDR) intracavitary boost.
- 3 A patient was diagnosed with breast cancer at another facility and received surgery and regional radiation therapy at that facility before being referred to the reporting facility for boost dose therapy.
- 8 Regional treatment was initiated at another facility and midway through treatment the patient was transferred to the reporting facility to complete the treatment regime.
- 9 Patient is known to have received radiation therapy, but records do not define the facility or facility(s) where the treatment was administered.

Rad Treatment Volume

Organization	Field Name	ID	Required
KCR	Rad Treatment Volume (RadVolume)	50310	no
NAACCR	RadTreatment Volume	1540	no

Field Length: 2

Description

Identifies the volume or anatomic target of the most clinically significant regional radiation therapy delivered to the patient during the first course of treatment. It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

This data item provides information describing the anatomical structures targeted by the regional radiation therapy and can be used to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility (local analysis of physician practices) and on a regional or national basis.

Instructions for Coding

Radiation treatment volume will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the exact treatment volume may require assistance from the radiation oncologist for consistent coding.

Code	Label	Description	
01	Eye/orbit	The radiation therapy target volume is limited to the eye and/or orbit.	
02	Pituitary	The target volume is restricted to the pituitary gland and all adjacent volumes are irradiated incidentally.	
03	Brain (NOS)	reatment is directed at tumors lying within the substance of the brain, or its meninges.	
04	Brain (limited)	The treatment volume encompasses less than the total brain, or less than all of meninges.	
05	Head and Neck (NOS)	The treatment volume is directed at a primary tumor o the oropharyngeal complex, usually encompassing regional lymph nodes.	
06	Head and Neck (limited)	Limited volume treatment of a head and neck primary with the exception of glottis (code 8), sinuses (code 9), or parotid (code 10).	
07	Glottis	reatment is limited to a volume in the immediate neighborhood of the vocal cords.	
08	Sinuses	The primary target is one or both of the maxillary sinuses or the ethmoidal frontal sinuses. In some cases, the adjacent lymph node regions may be irradiated.	
09	Parotid	The primary target is one of the parotid glands. There may be secondary regional lymph node irradiation as well.	
10	Chest /lung (NOS)	Radiation therapy is directed to some combination of hilar, mediastinal, and/or supraclavicular lymph nodes, and/or peripheral lung structures.	
11	Lung (limited)	Radiation therapy is directed at one region of the lung without nodal irradiation.	

12	Esophagu s	The primary target is some portion of the esophagus. Regional lymph nodes may or may not be included in the treatment. Include tumors of the gastroesophageal junction.		
13	Stomach	The primary malignancy is in the stomach. Radiation is directed to the stomach and possibly adjacent lymph nodes.		
14	Liver	The primary target is all or a portion of the liver, for either primary or metastatic disease.		
15	Pancreas	The primary tumor is in the pancreas. The treatment field encompasses the pancreas and possibly adjacent lymph node regions.		
16	Kidney	The target is primary or metastatic disease in the kidney or the kidney bed after resection of a primary kidney tumor. Adjacent lymph node regions may be included in the field.		
17	Abdomen (NOS)	Include all treatment of abdominal contents that do not fit codes 12-16.		
18	Breast	The primary target is the intact breast and no attempt has been made to irradiate the regional lymph nodes.		
19	Breast /lymph nodes	A deliberate attempt has been made to include regional lymph nodes in the treatment of an intact breast.		
20	Chest wall	Treatment encompasses the chest wall (following mastectomy).		
21	Chest wall /lymph nodes	Treatment encompasses the chest wall (following mastectomy) plus fields directed at regional lymph nodes.		
22	Mantle, mini- mantle	Treatment consists of a large radiation field designed to encompass all of the regional lymph nodes above the diaphragm, including cervical, supraclavicular axillary, mediastinal, and hilar nodes (mantel), or most of them (mini-mantle). This code is used exclusively for patients with Hodgkin's or non-Hodgkin's lymphoma.		
23	Lower extended field	The target zone includes lymph nodes below the diaphragm along th paraaortic chain. It may include extension to one side of the pelvis. This code includes the 'hockey stick' field utilized to treat seminomas.		
24	Spine	The primary target relates to the bones of the spine, including the sacrum. Spinal cord malignancies should be coded 40 (Spina cord).		
25	Skull	Treatment is directed at the bones of the skull. Any brain irradiation is a secondary consequence.		
26	Ribs	Treatment is directed toward metastatic disease in one or more ribs. Fields may be tangential or direct.		
27	Hip	The target includes the proximal femur for metastatic disease. In many cases there may be acetabular disease as well.		
28	Pelvic Bones	The target includes structures of the bones of the pelvis other than the hip or sacrum.		
29	Pelvis (NOS)	Irradiation is directed at soft tissues within the pelvic region and codes 34-36 do not apply.		
30	Skin	The primary malignancy originates in the skin and the skin is the primary target. So-called skin metastasis are usually subcutaneous and should be coded 31 (soft tissue).		
31	Soft tissue	All treatment of primary or metastatic soft tissue malignancies not fitting other categories.		
32	Hemibody	A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. This is almost always administered for palliation of widespread bone metastasis in patients with prostate or breast cancer.		
33	Whole body	Entire body included in a single treatment.		
34	Bladder and pelvis	The primary malignancy originated in the bladder, all or most of the pelvis is treated as prat of the plan, typically with a boost to the bladder.		

35	Prostate and pelvis	The primary malignancy originated in the prostate, all or most of the pelvis is treated as part of the plan, typically with a boost to the prostate.
36	Uterus and cervix	Treatment is confined to the uterus and cervix or vaginal cuff, usually by intracavitary or interstitial technique. If entire pelvis is included in a portion of the treatment, then code 29 (Pelvis, NOS).
37	Shoulder	Treatment is directed to the proximal humerus, scapula, clavicle, or other components of the shoulder complex. This is usually administered for control of symptoms for metastasis.
38	Extremity bone, NOS	Bones of the arms or legs. This excludes the proximal femur, code 27 (Hip). This excludes the proximal humerus, code 37 (Shoulder).
39	Inverted Y	Treatment has been given to a field that encompasses the paraaortic and bilateral inguinal or inguinofemoral lymph nodes in a single port.
40	Spinal Cord	Treatment is directed at the spinal cord or its meninges.
41	Prostate	Treatment is directed at the prostate with or without the seminal vesicles, without regional lymph node treatment.
50	Thyroid	Treatment is directed at the thyroid gland.
60	Lymph node region, NOS	The target is a group of lymph nodes not listed above. Examples include isolated treatment of a cervical, supraclavicular, or inguinofemoral region.
98	Other	Radiation therapy administered, treatment volume other than those previously categorized.
99	Unknown	Radiation therapy administered, treatment volume unknown or not stated in patient record; it is unknown if radiation therapy was administered.

Regional Tx Modality

Organization	Field Name	ID	Required
KCR	Regional Tx Modality (RadRegMod)	50320	no
NAACCR	RadRegional RX Modality	1570	no

Field Length: 2

Description

Records the dominant modality of radiation therapy used to deliver the most clinically significant regional dose to the primary volume of interest during the first course of treatment. It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

Radiation treatment is frequently delivered in two or more phases which can be summarized as "regional" and "boost" treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding

• Radiation treatment modality will typically be found in the radiation oncologist's summary letter for the first course of treatment. Segregation of treatment components into regional and boost and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.

- In the event multiple radiation therapy modalities were employed in the treatment of the patient, record only the dominant modality.
- Note that in some circumstances the boost treatment may precede the regional treatment.
- For purposes of this data item, photons and x-rays are equivalent.

Code	Label	Description
20	External beam, NOS	The treatment is known to be by external beam, but there is insufficient information to determine the specific modality.
21	Orthovoltage External beam therapy administered using equipment with a maximum energy of less than o (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV).	
22	Cobalt-60, Cesium-137	External beam therapy using a machine containing either a Cobalt-60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51.
23	Photons (2-5 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 2-5 MV.
24	Photons (6-10 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 6-10 MV.
25	Photons (11-19 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 11-19 MV.
26	Photons (>19 External beam therapy using a photon producing machine with a beam energy of more than 19 MV. MV)	
27	Photons (mixed energies)	External beam therapy using more than one energy over the course of treatment.
28	Electrons	Treatment delivered by electron beam.
29	Photons and electrons mixed	Treatment delivered using a combination of photon and electron beams.
30	Neutrons, with or without photons/electrons	Treatment delivered using neutron beam.
31	IMRT	Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record.
32	Conformal or 3-D therapy	An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.
40	Protons	Treatment delivered using proton therapy.

41	Stereotactic radiosurgery, NOS	Treatment delivered using stereotactic radiosurgery, type not specified in patient record.	
42	Linac radiosurgery	Treatment categorized as using stereotactic technique delivered with a linear accelerator.	
43	Gamma Knife	Treatment categorized as using stereotactic technique delivered using a Gamma Knife machine.	
50	Brachytherapy, NOS	Brachytherapy, interstitial implants, molds, seeds, needles, or intracavitary applicators of radioactive materials not otherwise specified. Includes radioembolization.	
51	Brachytherapy, Intracavity, LDR	Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator).	
52	Brachytherapy, Intracavity, HDR	Intracavitary (no direct insertion into tissues) radio-isotope treatment using high dose rate after-loading applicators and isotopes.	
53	Brachytherapy, Interstitial, LDR	Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources.	
54	Brachytherapy, Interstitial, HDR	Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources.	
55	Radium	Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy.	
60	Radioisotopes, NOD	lodine-131, Phosphorus-32, etc.	
61	Strontium-89	Treatment primarily by intravenous routes for bone metastases.	
62	Strontium-90		
98	Other, NOS	Radiation therapy administered, but the treatment modality is not specified or is unknown.	
99	Unknown	It is unknown whether radiation therapy was administered.	

Regional Dose

Organization	Field Name	ID	Required
KCR	Regional Dose (RadRegDose)	50330	no
NAACCR	RadRegional Dose: cGy	1510	no

Field Length: 5

Description

Records the dominant or most clinically significant total dose of regional radiation therapy delivered to the patient during the first course of treatment. The unit of measure is centigray (cGy). It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

To evaluate patterns of radiation oncology care, it is necessary to capture information describing the prescribed regional radiation dose. Outcomes are strongly related to the dose delivered.

Instructions for Coding

- The International Council for Radiation Protection (ICRP) recommends recording doses at the axis point where applicable (opposed fields, four field box, wedged pair, and so on). For maximum consistency in this data item, the ICRP recommendations should be followed whenever possible. Where there is no clear axis point, record the dose as indicated in the summary chart. Determining the exact dose may be highly subjective and require assistance from the radiation oncologist for consistent coding.
- Regional dose will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the total dose of
 regional therapy may require assistance from the radiation oncologist for consistent coding.
- For photon treatment, dosage is reported in cGe units (Cobalt Grey Equivalent) rather than cGy. You must multiply cGe by 100 to get cGy.
- Do not include the boost dose, if one was administered.
- Code 88888 when brachytherapy or radioisotopes codes 50-62 for Regional Treatment Modality were administered to the patient.
- Note that dose is still occasionally specified in "rads." One rad is equivalent to one centigray (cGy).

Code	Description
(fill spaces)	Record the actual regional dose delivered.
88888	Not applicable, brachytherapy or radioisotopes administered to the patient.
99999	Regional radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered.

Boost Tx Modality

Organization	Field Name	ID	Required
KCR	Boost Tx Modality (RadBoostMod)	50340	no
NAACCR	RadBoost RX Modality	3200	no

Field Length: 2

Description

Records the dominant modality of radiation therapy used to deliver he most clinically significant boost dose to the primary volume of interest during the first course of treatment. This is accomplished with external beam fields of reduced size (relative to the regional treatment fields), implants, stereotactic radiosurgery, conformal therapy, or IMRT. External beam boosts may consist of two or more successive phases with progressively smaller fields generally coded as a single entity. It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

Radiation treatment is frequently delivered in two or more phases which can be summarized as "regional" and "boost" treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding

- Radiation boost treatment modalities will typically be found in the radiation oncologist's summary letter for the first course of treatment. Segregation of treatment components into regional and boost and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- In the event that multiple radiation therapy boost modalities were employed during the treatment of the patient, record only the dominant modality.
- Note that in some circumstances, the boost treatment may precede the regional treatment.
- For purposes of this field, photons and x-rays are equivalent.

Code	Label	Description	
00	No boost treatment	A boost dose was no administered to the patient.	
20	External beam, NOS	The treatment is known to be by external beam, but there is insufficient information to determine the specific modality.	
21	Orthovoltage	External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV).	
22	Cobalt-60, Cesium-137	External beam therapy using a machine containing either a Cobalt-60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51.	
23	Photons (2-5 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 2-5 MV.	
24	Photons (6-10 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 6-10 MV.	
25	Photons (11-19 MV)	External beam therapy using a photon producing machine with a beam energy in the range of 11-19 MV.	
26	Photons (>19 MV)	External beam therapy using a photon producing machine with a beam energy of more than 19 MV.	
27	Photons (mixed energies)	External beam therapy using more than one energy over the course of treatment.	
28	Electrons	Treatment delivered by electron beam.	
29	Photons and electrons mixed	Treatment delivered using a combination of photon and electron beams.	
30	Neutrons, with or without photons/electrons	Treatment delivered using neutron beam.	
31	IMRT	Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record.	

32	Conformal or 3-D therapy	An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.	
40	Protons	Treatment delivered using proton therapy.	
41	Stereotactic radiosurgery, NOS	Treatment delivered using stereotactic radiosurgery, type not specified in patient record.	
42	Linac radiosurgery	Treatment categorized as using stereotactic technique delivered with a linear accelerator.	
43	Gamma Knife	Treatment categorized as using stereotactic technique delivered using a Gamma Knife machine.	
50	Brachytherapy, NOS	Brachytherapy, interstitial implants, molds, seeds, needles, or intracavitary applicators of radioactive materials not otherwise specified. Includes radioembolization.	
51	Brachytherapy, Intracavity, LDR	Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator).	
52	Brachytherapy, Intracavity, HDR	Intracavitary (no direct insertion into tissues) radio-isotope treatment using high dose rate after-loading applicators and isotopes.	
53	Brachytherapy, Interstitial, LDR	Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources.	
54	Brachytherapy, Interstitial, HDR	Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources.	
55	Radium	Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy.	
60	Radioisotopes, NOD	lodine-131, Phosphorus-32, etc.	
61	Strontium-89	Treatment primarily by intravenous routes for bone metastases.	
62	Strontium-90		
98	Other, NOS	Radiation therapy administered, but the treatment modality is not specified or is unknown.	
99	Unknown	It is unknown whether boost treatment was administered.	

Boost Dose

Organization	Field Name	ID	Required
KCR	Boost Dose (RadBoostDose)	50350	no
NAACCR	RadBoost Dose cGy	3210	no

Field Length: 5

Description

Records the additional dose delivered to that part of the treatment volume encompassed by the boost fields or devices. The unit of measure is centiGray (cGy). It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

To evaluate patterns of radiation oncology care, it is necessary to capture information describing the prescribed boost radiation dose. Outcomes are strongly related to the dose delivered.

Instructions for Coding

- The International Council for Radiation (ICRP) recommends recording doses at the axis point where applicable (opposed fields, four field box, wedged pair, and so on). For maximum consistency in this data item, the ICRP recommendations should be followed whenever possible. Where there is no clear axis point, record the dose as indicated in the summary chart. Consult the radiation oncologist for the exact dose, if necessary.
- Radiation boost treatment will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- Determination of the additional boost dose of radiation therapy may require assistance from the radiation oncologist for consistent coding.
 Do not include the regional dose. In general, the boost dose will be calculated as the difference between the maximum prescribed dose and the regional dose. Many patients will not have a boost.
- Code 88888 when brachytherapy or radioisotopes codes 50-62 for Boost Treatment Modality were administered to the patient.
- Note that dose is still occasionally specified in "rads" One rad is equivalent to one centiGray (cGy).

Code	Description
(fill spaces)	Record the actual regional dose delivered.
88888	Not applicable, brachytherapy or radioisotopes administered to the patient.
99999	Regional radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered.

Num Treatments This Volume

Organization	Field Name	ID	Required
KCR	Num Treatments This Volume (RadNumTreat)	50360	no
NAACCR	RadNo of Treatment Vol	1520	no

Field Length: 3

Description

Records the total number of treatment sessions (fractions) administered during the first course of treatment. It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

This data item is used to evaluate patterns of radiation therapy and the treatment schedules.

Instructions for Coding

- The number of treatments or fractions will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the exact number of treatments or fractions delivered to the patient may require assistance from the radiation oncologist for consistent coding.
- Although a treatment session may include several treatment portals delivered within relatively confined period of time usually a few minutes it is still considered one session.
- The total number of treatment sessions (fractions) is the sum of the number of fractions of regional treatment and the number of fractions of boost treatment.

Code	Label	Description	
000	None	Radiation therapy was not administered to the patient. Diagnosed at autopsy.	
001- 998	Number of Treatments	Total number of treatment sessions administered to the patient.	
999	Unknown	Radiation therapy was administered, but the number of treatments is unknown. Or, it is unknown whether radiation therapy was administered. Death certificate only.	

Examples:

- 025 A patient with breast carcinoma had treatment sessions in which treatment was delivered to the chest wall and separately to the ipsilateral supraclavicular region for a total of three treatment portals. Twenty-five treatment sessions were given. Record 25 treatments.
- 035 A patient with Stage IIIB bronchogenic carcinoma received 25 treatments to the left hilum and mediastinum, given in 25 daily treatments over five weeks. A left hilar boost was then given in 10 additional treatments. Record 35 treatments.
- 050 A patient with advanced head and neck cancer was treated using "hyperfractionation." Three fields were delivered in each session, two sessions were given each day, six hours apart, with each session delivering a total dose of 150 cGy. Treatment was given for a total of 25 days. Record 50 treatments.

Date Radiation Ended

Organization	Field Name	ID	Required
KCR	Date Radiation Ended (RadLastDate)	50370	no
NAACCR	RX Date Rad Ended	3220	no

Field Length: 8

Description

The date on which the patient completes or received the last radiation treatment at any facility. It is an optional field and it is only required for data entry to ACoS flagged hospitals.

Rationale

The length of time over which radiation therapy is administered to a patient is a factor in tumor control and treatment morbidity. It is useful to evaluate the quality of care and the success of patient support programs designed to maintain continuity of treatment.

Instructions for Coding

The date when treatment ended will typically be found in the radiation oncologist's summary letter for the first course of treatment.

Code	Description	
MMDDC CYY	The month, day, and year (MMDDCCYY) radiation therapy ended at any facility. The first two digits are the month, the third and fourth digits are the day, and the last four digits are the year.	
8888888 8	When radiation was administered and was still ongoing at the time of most recent follow-up. The date should be revised at the next follow-up.	
99999999 When it is unknown whether any radiation therapy was administered, the date is unknown, or the case was identified by conly.		

Date Radiation Ended Flag

Organization	Field Name	ID	Required
KCR	Date Radiation Ended Flag (RadLastDateFlag)	50371	no
NAACCR	RX Date Rad Ended Flag	3221	no

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Date Radiation Ended (item #50370).

Codes

Code	Description	
10	No information whatsoever can be inferred (for example, unknown if radiation was given)	
11	No proper value is applicable in this context (that is, no radiation given)	
12 A proper value is applicable but not known (that is, radiation was given, but the date is unknown) 15 Information is not available at this time, but it is expected that it will be available later (that is, radiation therapy had begins most recent follow-up, but was not yet completed)		
		(blank)

Phase I Radiation Primary Treatment Volume

Organization	Field Name	ID	Required
KCR	Phase I Radiation Primary Treatment Volume (RadP1Volume)	50432	yes
CoC	Phase I Radiation Primary Treatment Volume	1504	yes

Field Length: 2

Description

Identifies the primary treatment volume or primary anatomic target treated during the first phase of radiation therapy during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation treatment is commonly delivered in one or more phases. Typically, in each phase, the primary tumor or tumor bed is treated. This data item should be used to indicate the primary target volume, which might include the primary tumor or tumor bed. If the primary tumor was not targeted, record the other regional or distant site that was targeted. Draining lymph nodes may also be targeted during the first phase. These will be identified in a separate data item Phase I Radiation to Draining Lymph Nodes [1505].

This data item provides information describing the anatomical structure targeted by radiation therapy during the first phase of radiation treatment and can be used to determine whether the site of the primary diseases was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility and on a regional or national basis. The breakdown and reorganization of the sites will allow for concise reporting.

Code	Description
00	No radiation treatment
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/ Chestwall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
09	Lymph node region, NOS
10	Eye/orbit/optic nerve
11	Pituitary
12	Brain
13	Brain (Limited)
14	Spinal cord
20	Nasopharynx
21	Oral Cavity
22	Oropharynx
23	Larynx (glottis) or hypopharynx
24	Sinuses/Nasal tract
25	Parotid or other salivary glands
26	Thyroid
29	Head and neck (NOS)
30	Lung or bronchus
31	Mesothelium

32	Thymus
39	Chest/lung (NOS)
40	Breast - whole
41	Breast - partial
42	Chest wall
50	Esophagus
51	Stomach
52	Small bowel
53	Colon
54	Rectum
55	Anus
56	Liver
57	Biliary tree or gallbladder
58	Pancreas or hepatopancreatic ampulla
59	Abdomen (NOS)
60	Bladder - whole
61	Bladder - partial
62	Kidney
63	Ureter
64	Prostate - whole
65	Prostate - partial
66	Urethra
67	Penis
68	Testicle or scrotum
70	Ovaries or fallopian tubes
71	Uterus or Cervix
72	Vagina
73	Vulva
80	Skull
81	Spine/vertebral bodies
82	Shoulder
83	Ribs
84	Нір
85	Pelvic bones
86	Pelvis (NOS, non-visceral)
88	Extremity bone, NOS
90	Skin
91	Soft tissue
92	Hemibody
93	Whole body
94	Mantle, mini-mantle (obsolete after 2017)

95	Lower extended field (obsolete after 2017)
96	Inverted Y (obsolete after 2017)
97	Invalid historical FORDS value
98	Other
99	Unknown

Phase I Radiation to Draining Lymph Nodes

Organization	Field Name	ID	Required
KCR	Phase I Radiation to Draining Lymph Nodes (RadP1LN)	50433	yes
CoC	Phase I Radiation to Draining Lymph Nodes	1505	yes

Field length: 2

Description

Identifies the draining lymph nodes treated (if any) during the first phase of radiation therapy delivered to the patient during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

The first phase of radiation treatment commonly targets both the primary tumor (or tumor bed) and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the first phase of radiation.

Code	Description	
00	No radiation treatment	
01	Neck lymph node regions	
02	Thoracic lymph node regions	
03	Neck and thoracic lymph node regions	
04	Breast/Chest wall lymph node regions	
05	Abdominal lymph nodes	
06	Pelvic lymph nodes	
07	Abdominal and pelvic lymph nodes	
08	Lymph node region, NOS	
88	Not applicable; Phase I Radiation Primary Treatment Volume is lymph nodes	
99	Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered	

Phase I Radiation Treatment Modality

Organization	Field Name	ID	Required
KCR	Phase I Radiation Treatment Modality (RadP1TxMod)	50430	yes
CoC	Phase I Radiation Treatment Modality	1506	yes

Field length: 2

Description

Identifies the radiation modality administered during the first phase of radiation treatment delivered during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation modality reflects whether a treatment was external beam, brachytherapy, a radioisotope as well as their major subtypes, or a combination of modalities. This data item should be used to indicate the radiation modality administered during the first phase of radiation.

Historically, the previously-named Regional Treatment Modality data item [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of radiation modality and radiation treatment planning techniques is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	External beam, photons
03	External beam, protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, Interstitial, LDR
11	Brachytherapy, Interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, Radium-232
15	Radioisotopes, Strontium-89
16	Radioisotopes, Strontium-90
99	Treatment radiation modality unknown; Unknown if radiation treatment administered

Phase I Radiation External Beam Planning Technique

Organization	Field Name	ID	Required
KCR	Phase I Radiation External Beam Planning Tech (RadP1ExtBeamPlan)	50431	yes
CoC	Phase I Radiation External Beam Planning Tech	1502	yes

Field length: 2

Description

Identifies the external beam radiation planning technique used to administer the first phase of radiation treatment during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

External beam radiation is the most commonly-used radiation modality in North America. In this data item we specified the planning technique for external beam treatment. Identifying the radiation technique is of interest for patterns of care and comparative effectiveness studies.

Historically, the previously-named Regional Treatment Modality data item [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of Phase I Radiation Treatment Modality [1506] and Phase I Radiation External Beam Planning Tech [1502] is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	Low energy x-ray/photon therapy
03	2-D therapy
04	Conformal or 3-D conformal therapy
05	Intensity modulated therapy
06	Stereotactic radiotherapy or radiosurgery, NOS
07	Stereotactic radiotherapy or radiosurgery, robotic.
08	Stereotactic radiotherapy or radiosurgery, Gamma Knife®
09	CT-guided online adaptive therapy
10	MR-guided online adaptive therapy
88	Not Applicable
98	Other, NOS
99	Unknown

Phase I Dose per Fraction

Organization	Field Name	ID	Required
KCR	Phase I Dose per Fraction (RadP1FractionDose)	50434	yes
CoC	Phase I Dose per Fraction	1501	yes

Field length: 5

Description

Records the dose per fraction (treatment session) delivered to the patient in the first phase of radiation during the first course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation therapy is delivered in one or more phases with identified dose per fraction. It is necessary to capture information describing the dose per fraction to evaluate patterns of radiation oncology care. Outcomes are strongly related to the dose delivered.

Code	Description	
00000 Radiation therapy was not administered		
00001- 99997	Record the actual Phase I dose delivered in cGy	
99998	Not applicable, brachytherapy or radioisotopes administered to the patient	
99999 Regional radiation therapy was administered but dose is unknown, it is unknown whether radiation therapy was administered but dose is unknown, it is unknown whether radiation therapy was administered but dose is unknown.		

Phase I Number of Fractions

Organization	Field Name	ID	Required
KCR	Phase I Number of Fractions (RadP1FractionNum)	50435	yes
CoC	Phase I Number of Fractions	1503	yes

Field length: 3

Description

Records the total number of fractions (treatment sessions) delivered to the patient in the first phase of radiation during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

Radiation therapy is delivered in one or more phases with each phase spread out over a number of fractions (treatment sessions). It is necessary to capture information describing the number of fraction(s) to evaluate patterns of radiation oncology care.

Code	Description	
000	Radiation therapy was not administered to the patient.	
001- 998	Number of fractions administered to the patient during the first phase of radiation therapy.	
999	Phase I Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered.	

Phase I Total Dose

Organization	Field Name	ID	Required
KCR	Phase I Total Dose (RadP1TotalDose)	50436	yes
CoC	Phase I Total Dose	1507	yes

Field length: 6

Description

Identifies the total radiation dose delivered to the patient in the first phase of radiation treatment during the first course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities as of 01/01/2018.

Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the prescribed dose of Phase I radiation to the patient during the first course of treatment. Outcomes are strongly related to the total dose delivered.

Code	Description	
000000	No therapy administered	
000001-999997	Record the actual total dose delivered in cGy	
999998	Not applicable, radioisotopes administered to the patient	
9999999 Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered		

Phase I Therapy Local Hospital ID

Organization	Field Name	ID	Required
KCR	Phase I Therapy Local Hospital ID	50451	yes

Field length: 10

Select the appropriate code to indicate if this therapy was administered at your facility. Otherwise, enter '0' for No.

Code	Description
0	Not administered by this facility
<hosp id=""></hosp>	<hospital name=""></hospital>
9	Valid only for diagnoses before 1/1/2003

Phase II Radiation Primary Treatment Volume

Organization	Field Name	ID	Required
KCR	Phase II Radiation Primary Treatment Volume (RadP2Volume)	50439	yes
CoC	Phase II Radiation Primary Treatment Volume	1514	yes

Field length: 2

Description

Identifies the primary treatment volume or primary anatomic target treated during the second phase of radiation therapy during the first course of treatment. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

Radiation treatment is commonly delivered in one or more phases. Typically, in each phase, the primary tumor or tumor bed is treated. This data item should be used to indicate the primary target volume, which might include the primary tumor or tumor bed. If the primary tumor was not targeted, record the other regional or distant site that was targeted. Draining lymph nodes may also be targeted during the second phase. These will be identified in a separate data item Phase II Radiation to Draining Lymph Nodes [1515].

This data item provides information describing the anatomical structure targeted by radiation therapy during the second phase of radiation treatment and can be used to determine whether the site of the primary diseases was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility and on a regional or national basis. The breakdown and reorganization of the sites will allow for concise reporting.

Code	Description
00	No radiation treatment
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/ Chestwall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
09	Lymph node region, NOS
10	Eye/orbit/optic nerve
11	Pituitary
12	Brain
13	Brain (Limited)
14	Spinal cord
20	Nasopharynx
21	Oral Cavity
22	Oropharynx
23	Larynx (glottis) or hypopharynx
24	Sinuses/Nasal tract
25	Parotid or other salivary glands
26	Thyroid
29	Head and neck (NOS)
30	Lung or bronchus
31	Mesothelium
32	Thymus

39	Chest/lung (NOS)
40	Breast - whole
41	Breast - partial
42	Chest wall
50	Esophagus
51	Stomach
52	Small bowel
53	Colon
54	Rectum
55	Anus
56	Liver
57	Biliary tree or gallbladder
58	Pancreas or hepatopancreatic ampulla
59	Abdomen (NOS)
60	Bladder - whole
61	Bladder - partial
62	Kidney
63	Ureter
64	Prostate - whole
65	Prostate - partial
66	Urethra
67	Penis
68	Testicle or scrotum
70	Ovaries or fallopian tubes
71	Uterus or Cervix
72	Vagina
73	Vulva
80	Skull
81	Spine/vertebral bodies
82	Shoulder
83	Ribs
84	Нір
85	Pelvic bones
86	Pelvis (NOS, non-visceral)
88	Extremity bone, NOS
90	Skin
91	Soft tissue
92	Hemibody
93	Whole body
94	Mantle, mini-mantle (obsolete after 2017)
95	Lower extended field (obsolete after 2017)

96	Inverted Y (obsolete after 2017)
97	Invalid historical FORDS value
98	Other
99	Unknown

Phase II Radiation to Draining Lymph Nodes

Organization	Field Name	ID	Required
KCR	Phase II Radiation to Draining Lymph Nodes (RadP2LN)	50440	yes
CoC	Phase II Radiation to Draining Lymph Nodes	1515	yes

Field length: 2

Description

Identifies the draining lymph nodes treated (if any) during the second phase of radiation therapy delivered to the patient during the first course of treatment. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

The second phase of radiation treatment commonly targets both the primary tumor (or tumor bed) and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the second phase of radiation.

Code	Description
00	No radiation treatment
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/Chest wall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
08	Lymph node region, NOS
88	Not applicable; Phase I Radiation Primary Treatment Volume is lymph nodes
99	Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered

Phase II Radiation Treatment Modality

Organization	Field Name	ID	Required
KCR	Phase II Radiation Treatment Modality (RadP2TxMod)	50437	yes
CoC	Phase II Radiation Treatment Modality	1516	yes

Field length: 2

Description

Identifies the radiation modality administered during the second phase of radiation treatment delivered during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

Radiation modality reflects whether a treatment was external beam, brachytherapy, a radioisotope as well as their major subtypes, or a combination of modalities. This data item should be used to indicate the radiation modality administered during the second phase of radiation.

Historically, the previously-named Regional Treatment Modality data item [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of radiation modality and radiation treatment planning techniques is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	External beam, photons
03	External beam, protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, Interstitial, LDR
11	Brachytherapy, Interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, Radium-232
15	Radioisotopes, Strontium-89
16	Radioisotopes, Strontium-90
99	Treatment radiation modality unknown; Unknown if radiation treatment administered

Phase II Radiation External Beam Planning Technique

Organization	Field Name	ID	Required
KCR	Phase II Radiation External Beam Planning Tech (RadP2ExtBeamPlan)	50438	yes
CoC	Phase II Radiation External Beam Planning Tech	1522	yes

Field length: 2

Description

Identifies the external beam radiation planning technique used to administer the second phase of radiation treatment during the first course of treatment. This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

External beam radiation is the most commonly-used radiation modality in North America. In this data item we specified the planning technique for external beam treatment. Identifying the radiation technique is of interest for patterns of care and comparative effectiveness studies.

Historically, the previously-name Regional Treatment Modality data item [3200] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of Phase II Radiation Treatment Modality [1516] and Phase II Radiation External Beam Planning Tech [1512] is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	Low energy x-ray/photon therapy
03	2-D therapy
04	Conformal or 3-D conformal therapy
05	Intensity modulated therapy
06	Stereotactic radiotherapy or radiosurgery, NOS
07	Stereotactic radiotherapy or radiosurgery, robotic.
08	Stereotactic radiotherapy or radiosurgery, Gamma Knife®
09	CT-guided online adaptive therapy
10	MR-guided online adaptive therapy
88	Not Applicable
98	Other, NOS
99	Unknown

Phase II Dose per Fraction

Organization	Field Name	ID	Required
KCR	Phase II Dose per Fraction (RadP2FractionDose)	50441	yes
CoC	Phase II Dose per Fraction	1511	yes

Field length: 5

Description

Records the dose per fraction (treatment session) delivered to the patient in the second phase of radiation during the first course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

Radiation therapy is delivered in one or more phases with identified dose per fraction. It is necessary to capture information describing the dose per fraction to evaluate patterns of radiation oncology care. Outcomes are strongly related to the dose delivered.

Code	Description
00000	Radiation therapy was not administered
00001- 99997	Record the actual Phase I dose delivered in cGy
99998	Not applicable, brachytherapy or radioisotopes administered to the patient
99999	Regional radiation therapy was administered but dose is unknown, it is unknown whether radiation therapy was administered. Death Certificate only.

Phase II Number of Fractions

Organization	Field Name	ID	Required
KCR	Phase II Number of Fractions (RadP2FractionNum)	50442	yes
CoC	Phase II Number of Fractions	1513	yes

Field length: 3

Description

Records the total number of fractions (treatment sessions) administered to the patient in the second phase of radiation during the first course of treatment. This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

Radiation therapy is delivered in one or more phases with each phase spread out over a number of fractions (treatment sessions). It is necessary to capture information describing the number of fraction(s) to evaluate patterns of radiation oncology care.

Code	Description
000	Radiation therapy was not administered to the patient.
001- 998 Number of fractions administered to the patient during the first phase of radiation therapy.	
999	Phase I Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered.

Phase II Total Dose

Organization	Field Name	ID	Required
KCR	Phase II Total Dose (RadP2TotalDose)	50443	yes
CoC	Phase II Total Dose	1517	yes

Field length: 6

Description

Identifies the total radiation dose administered in the second phase of radiation treatment delivered to the patient during the second course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the prescribed dose of Phase II radiation to the patient during the first course of treatment. Outcomes are strongly related to the total dose delivered.

Code	Description
000000	No therapy administered
000001-999997	Record the actual total dose delivered in cGy
999998	Not applicable, radioisotopes administered to the patient
999999	Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered

Phase II Therapy Local Hospital ID

Organization	Field Name	ID	Required
KCR	Phase II Therapy Local Hospital ID	50452	yes

Field length: 10

Select the appropriate code to indicate if this therapy was administered at your facility. Otherwise, enter '0' for No.

Code	Description
0	Not administered by this facility
<hosp id=""></hosp>	<hospital name=""></hospital>
9	Valid only for diagnoses before 1/1/2003

Phase III Radiation Primary Treatment Volume

Organization	Field Name	ID	Required
KCR	Phase III Radiation Primary Treatment Volume (RadP3Volume)	50446	yes
CoC	Phase III Radiation Primary Treatment Volume	1524	yes

Field length: 2

Description

Identifies the primary treatment volume or primary anatomic target treated during the third phase of radiation therapy during the first course of treatment. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018. Blanks allowed if no Phase III radiation treatment administered.

Rationale

Radiation treatment is commonly delivered in one or more phases. Typically, in each phase, the primary tumor or tumor bed is treated. This data item should be used to indicate the primary target volume, which might include the primary tumor or tumor bed. If the primary tumor was not targeted, record the other regional or distant site that was targeted. Draining lymph nodes may also be targeted during the second phase. These will be identified in a separate data item Phase II Radiation to Draining Lymph Nodes [1515].

This data item provides information describing the anatomical structure targeted by radiation therapy during the third phase of radiation treatment and can be used to determine whether the site of the primary diseases was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility and on a regional or national basis. The breakdown and reorganization of the sites will allow for concise reporting.

Code	Description
00	No radiation treatment
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/ Chestwall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
09	Lymph node region, NOS
10	Eye/orbit/optic nerve
11	Pituitary
12	Brain
13	Brain (Limited)
14	Spinal cord
20	Nasopharynx
21	Oral Cavity
22	Oropharynx
23	Larynx (glottis) or hypopharynx
24	Sinuses/Nasal tract
25	Parotid or other salivary glands
26	Thyroid
29	Head and neck (NOS)
30	Lung or bronchus
31	Mesothelium
32	Thymus

39	Chest/lung (NOS)
40	Breast - whole
41	Breast - partial
42	Chest wall
50	Esophagus
51	Stomach
52	Small bowel
53	Colon
54	Rectum
55	Anus
56	Liver
57	Biliary tree or gallbladder
58	Pancreas or hepatopancreatic ampulla
59	Abdomen (NOS)
60	Bladder - whole
61	Bladder - partial
62	Kidney
63	Ureter
64	Prostate - whole
65	Prostate - partial
66	Urethra
67	Penis
68	Testicle or scrotum
70	Ovaries or fallopian tubes
71	Uterus or Cervix
72	Vagina
73	Vulva
80	Skull
81	Spine/vertebral bodies
82	Shoulder
83	Ribs
84	Нір
85	Pelvic bones
86	Pelvis (NOS, non-visceral)
88	Extremity bone, NOS
90	Skin
91	Soft tissue
92	Hemibody
93	Whole body
94	Mantle, mini-mantle (obsolete after 2017)
95	Lower extended field (obsolete after 2017)

96	Inverted Y (obsolete after 2017)
97	Invalid historical FORDS value
98	Other
99	Unknown

Phase III Radiation to Draining Lymph Nodes

Organization	Field Name	ID	Required
KCR	Phase III Radiation to Draining Lymph Nodes (RadP3LN)	50447	yes
CoC	Phase III Radiation to Draining Lymph Nodes	1525	yes

Field length: 2

Description

Identifies the draining lymph nodes treated (if any) during the third phase of radiation therapy delivered to the patient during the first course of treatment. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018. Blanks allowed if no Phase III radiation treatment administered.

Rationale

The second phase of radiation treatment commonly targets both the primary tumor (or tumor bed) and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the third phase of radiation.

Code	Description
00	No radiation treatment
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/Chest wall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
08	Lymph node region, NOS
88	Not applicable; Phase I Radiation Primary Treatment Volume is lymph nodes
99	Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered

Phase III Radiation Treatment Modality

Organization	Field Name	ID	Required
KCR	Phase III Radiation Treatment Modality (RadP3TxMod)	50444	yes
CoC	Phase III Radiation Treatment Modality	1526	yes

Field length: 2

Description

Identifies the radiation modality administered during the third phase of radiation treatment delivered during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018. Blanks allowed if no Phase III radiation treatment administered.

Rationale

Radiation modality reflects whether a treatment was external beam, brachytherapy, a radioisotope as well as their major subtypes, or a combination of modalities. This data item should be used to indicate the radiation modality administered during the third phase of radiation.

Historically, the previously-named Regional Treatment Modality data item [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of radiation modality and radiation treatment planning techniques is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	External beam, photons
03	External beam, protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, Interstitial, LDR
11	Brachytherapy, Interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, Radium-232
15	Radioisotopes, Strontium-89
16	Radioisotopes, Strontium-90
99	Treatment radiation modality unknown; Unknown if radiation treatment administered

Phase III Radiation External Beam Planning Technique

Organization	Field Name	ID	Required
KCR	Phase III Radiation External Beam Planning Tech (RadP3ExtBeamPlan)	50445	yes
CoC	Phase III Radiation External Beam Planning Tech	1522	yes

Field length: 2

Description

Identifies the external beam radiation planning technique used to administer the third phase of radiation treatment during the first course of treatment. This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase III radiation treatment administered.

Rationale

External beam radiation is the most commonly-used radiation modality in North America. In this data item we specified the planning technique for external beam treatment. Identifying the radiation technique is of interest for patterns of care and comparative effectiveness studies.

Historically, the previously-name Regional Treatment Modality data item [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of Phase III Radiation Treatment Modality [1526] and Phase III Radiation External Beam Planning Tech [1522] is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

Code	Description
00	No radiation treatment
01	External beam, NOS
02	Low energy x-ray/photon therapy
03	2-D therapy
04	Conformal or 3-D conformal therapy
05	Intensity modulated therapy
06	Stereotactic radiotherapy or radiosurgery, NOS
07	Stereotactic radiotherapy or radiosurgery, robotic.
08	Stereotactic radiotherapy or radiosurgery, Gamma Knife $\ensuremath{\mathbb{R}}$
09	CT-guided online adaptive therapy
10	MR-guided online adaptive therapy
88	Not Applicable
98	Other, NOS
99	Unknown

Phase III Dose per Fraction

Organization	Field Name	ID	Required
KCR	Phase III Dose per Fraction (RadP3FractionDose)	50448	yes
CoC	Phase III Dose per Fraction	1521	yes

Description

Records the dose per fraction (treatment session) delivered to the patient in the third phase of radiation during the first course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase III radiation treatment administered.

Rationale

Radiation therapy is delivered in one or more phases with identified dose per fraction. It is necessary to capture information describing the dose per fraction to evaluate patterns of radiation oncology care. Outcomes are strongly related to the dose delivered.

Code	Description
00000	No radiation treatment
00001- 99997	Record the actual Phase III dose delivered in cGy
99998	Not applicable, radioisotopes administered to the patient
99999	Phase III radiation therapy was administered but dose is unknown, it is unknown whether Phase III radiation therapy was administered. Death Certificate only.

Phase III Number of Fractions

Organization	Field Name	ID	Required
KCR	Phase III Number of Fractions (RadP3FractionNum)	50449	yes
CoC	Phase III Number of Fractions	1523	yes

Description

Records the total number of fractions (treatment sessions) delivered to the patient in the third phase of radiation during the first course of treatment. This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase III radiation treatment administered.

Rationale

Radiation therapy is delivered in one or more phases with each phase spread out over a number of fractions (treatment sessions). It is necessary to capture information describing the number of fraction(s) to evaluate patterns of radiation oncology care.

Code	Description
000	No radiation treatment
001- 998	Number of fractions administered to the patient during the third phase of radiation therapy.
999	Phase III Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered.

Phase III Total Dose

Organization	Field Name	ID	Required
KCR	Phase III Total Dose (RadP3TotalDose)	50450	yes
CoC	Phase III Total Dose	1527	yes

Field length: 6

Description

Identifies the total radiation dose administered in the second phase of radiation treatment delivered to the patient during the third course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018. Blanks allowed if no Phase II radiation treatment administered.

Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the prescribed dose of Phase III radiation to the patient during the first course of treatment. Outcomes are strongly related to the total dose delivered.

Code	Description	
000000	No therapy administered	
000001-999997	Record the actual total dose delivered in cGy	
999998	Not applicable, radioisotopes administered to the patient	
999999	Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered	

Phase III Therapy Local Hospital ID

Organization	Field Name	ID	Required	
KCR	Phase II Therapy Local Hospital ID	50453	yes	

Field length: 10

Select the appropriate code to indicate if this therapy was administered at your facility. Otherwise, enter '0' for No.

Code	Description	
0	Not administered by this facility	
<hosp id=""></hosp>	<hospital name=""></hospital>	
9	Valid only for diagnoses before 1/1/2003	

Radiation Treatment Discontinued Early

Organization	Field Name	ID	Required
KCR	Radiation Treatment Discontinued Early (RadTXDiscontinued)	50553	no
CoC	Radiation Treatment Discontinued Early	1531	no

Field length: 2

Description

This field is used to identify patients/tumors whose radiation treatment course was discontinued earlier than initially planned. That is the patients/tumors received fewer treatment fractions (sessions) than originally intended by the treating physician. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

Rationale

Currently, the total dose of radiation reflects what was actually delivered rather than what was intended. When a patient doesn't complete a radiation course as initially intended this is typically commented on within the radiation end of treatment summary. By flagging these patients within the cancer registry database, these patients can be excluded from analyses attempting to describe adherence to radiation treatment guidelines or patterns of care analyses.

Code	Description
00	No radiation treatment
01	Radiation treatment completed as prescribed
02	Radiation treatment discontinued early - toxicity
03	Radiation treatment discontinued early - contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.)
04	Radiation treatment discontinued early – patient decision
05	Radiation discontinued early – family decision
06	Radiation discontinued early - patient expired
07	Radiation discontinued early - reason not documented
99	Unknown if radiation treatment discontinued; Unknown whether radiation therapy administered

Number of Phases of Radiation Treatment to this Volume

Organization	Field Name	ID	Required
KCR	Number of Phases of Radiation Treatment to this Volume (RadNumPhases)	50551	no
CoC	Number of Phases of Radiation Treatment to this Volume	1532	no

Field length: 2

Description

Identifies the total number of phases administered to the patient during the first course of treatment. A "phase" consists of one or more consecutive treatments delivered to the same anatomic volume with no change in the treatment technique. Although the majority of courses of radiation therapy are completed in one or two phases (historically, the "regional" and "boost" treatments) there are occasions in which three or more phases are used, most typically with head and neck malignancies. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

Rationale

The number of phases of radiation treatment is used to evaluate patterns of radiation therapy and the treatment schedule.

Code	Description
00	No radiation treatment
01	1 phase
02	2 phases
03	3 phases
04	4 or more phases
99	Unknown number of phases; Unknown if radiation therapy administered

Total Dose

Organization	Field Name	ID	Required
KCR	Total Does (RadTotalDose)	50552	no
NAACCR	RX Date Rad Ended	1533	no

Field length: 6

Description

Identifies the total radiation dose administered to the patient across all phases during the first course of treatment. The unit of measure is centiGray (cGy). This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

To evaluate the patterns of radiation care, it is necessary to capture information describing the prescribed total dose of radiation during the first course of treatment. Outcomes are strongly related to the dose delivered.

Code	Description	
000000	No radiation treatment	
000001-999997	Record the actual dose delivered in cGy	
999998	Not applicable, radioisotopes administered to the patient	
999999	Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered	

Hormone

• Hormone Therapy Code

Hormone Therapy Code

Organization	Field Name	ID	Required
KCR	Hormone Therapy Code (HormoneCode)	50200	yes
NAACCR	RX SummHormone	1400	yes

Field Length: 1

Record '1' if hormone treatment agents were administered as first course treatment at this or any other facilities.

- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment. For example, a patient
 has advanced lung cancer with multiple metastases to the brain. The physician orders Decadron to reduce the edema in the brain and relieve the
 neurological symptons. Decadron is not coded as hormone therapy. Or, a patient with advanced disease is given Prednisone to stimulate the
 appetite and improve nutritional status. Do not code the Prednisone as hormone therapy.
- Some types of cancers are slowed or suppressed by hormones. These cancers are treated by administering hormones.

Example 1: Endometrial cancer may be treated with progesterone. Code all administration of progesterone to patients with endometrial cancer in this field. Even if the progesterone is given for menopausal symptoms, it has an effect on the growth or recurrence of endometrial cancer.

Example 2: Follicular and papillary cell cancers of the thyroid are often treated with thyroid hormone to suppress serum thyroid-stimulating hormone (TSH). If a patient with follicular cell-derived cancer of the thyroid (8260, 8330, 8331, 8332, 8335, 8340, or 8346) is given a thyroid hormone, code the treatment in this field.

- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary
 to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy, except for thyroid
 replacement therapy, as described above.
- Use the SEER Rx program (available from web site: http://seer.cancer.gov/tools/seerrx/) to identify hormonal agents. For pre-2005 diagnoses, refer to Appendix H and to the Self-Instructional Manual for Tumor Registrars: Book 8 Antineoplastic Drugs, Third Edition.
- Code surgery or radiation given for hormonal effect under Transplant/Endocrine Procedures (Item # 50220).

Immunotherapy

• Immunotherapy Code

Immunotherapy Code

Organization	Field Name	ID	Required
KCR	Immunotherapy Code (ImmunoCode)	50210	yes
NAACCR	RX SummBRM	1410	yes

Field Length: 1

Record '1' if immunotherapy was administered as first course treatment at this or any other facilities. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

Types of immunotherapy

Cancer Vaccines: Cancer vaccines are still in the experimental phase and are not coded in this data item. They may be coded in the field Other Therapy. Currently clinical trials use cancer vaccines for brain, breast, colon, kidney, lung, melanoma and ovary.

Interferons: Interferons belong to a group of proteins called cytokines. They are produced naturally by the white blood cells in the body. Interferon-alpha is able to slow tumor growth directly as well as activate the immune system. It is used for a number of cancers including multiple myeloma, chronic myelogenous leukemia (CML), hairy cell leukemia, and malignant melanoma.

Interleukins (IL-2) are often used to treat kidney cancer and melanoma.

Monoclonal Antibodies: Prior to 2005, monoclonal antibodies were coded as immunotherapy. Monoclonal antibodies are produced in a laboratory. The artificial antibodies are injected into the patient to seek out and disrupt cancer cell activities and to enhance the immune response against the cancer. For example, Rituximab (Rituxan) may be used for non-Hodgkin lymphoma, and trastuzumab (Herceptin) may be used for certain breast cancers.

With the introduction of SEER Rx in 2005 for coding systemic therapy, monoclonal antibodies are coded as chemotherapy if they act as cytostatic agents (such as Rituxan and Herceptin) or as radioisotopes if they deliver cytotoxic radioisotopes to the cells (such as Bexxar and Zevalin).

Effective with diagnoses in 2005 and later, use the SEER Rx program (available from web site: http://seer.cancer.gov/tools/seerrx/) to identify immunotherapeutic agents. For pre-2005 cases, refer to Appendix H and to the Self-Instructional Manual for Tumor Registrars: Book 8 - Antineoplastic Drugs, Third Edition.

Trans Endo

• Transplant/Endocrine Code

Transplant/Endocrine Code

Organization	Field Name	ID	Required
KCR	Transplant/Endocrine Code (TransplantCode)	50220	yes
NAACCR	RX SummTranspInt/Endocr	3250	yes

Field Length: 2

Record any systemic therapeutic procedures administered as part of the first course of treatment at this and all other facilities. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

Instructions for Coding

- Bone marrow transplants should be coded as either autologous (bone marrow originally taken from the patient) or allogeneic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.
- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- Endocrine irradiation and/or endocrine surgery are procedures which suppress the naturally occurring hormonal activity of the patient and thus
 alter or effect the long-term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine
 radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or
 endocrine radiation.

Code	Description
10	A bone marrow transplant procedure was administered, but the type was not specified.
11 Bone marrow transplant - autologous.	
12	Bone marrow transplant - allogeneic.
20	Stem cell harvest (and infusion).
30	Endocrine surgery and/or endocrine radiation therapy.
40	Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 and 10, 11, 12, or 20.)

Other

• Other Therapy Code

Other Therapy Code

Organization	Field Name	ID	Required
KCR	Other Therapy Code (OtherTxCode)	50230	yes
NAACCR	RX SummOther	1420	yes

Field Length: 1

These codes are available for any 'other' treatment received by the patient-- other than surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy, transplants or endocrine procedures.

Code 0 indicates nonsurgical types of non-definitive treatment. These are optional and do not have to be recorded. Ancillary drugs such as allopurinol, growth stimulating factors (i.e., Neupogen and Epogen) and antibiotics for MALT lymphoma are examples of non-definitive therapy.

Code	Label	Description
0	Non- cancer directed treatme nt	OPTIONAL CODE - may be used to record ancillary drugs, supportive care, stent placement, etc.
1	Other treatme nt	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic). Examples include treatment unique to hematopoietic diseases (see Notes below), tumor embolization which does not involve a chemotherapy or radiotherapy agent (i.e., when alcohol is used as the embolizing agent in head and neck cancers), photophoresis for thin melanomas or for mycosis fungoides, and PUVA (psoralen and long-wave ultraviolet radiation).
2	Other - Experi mental	This code is not defined. It may be used to record participation in institution-based clinical trials. Gene therapy is coded 2.
3	Other - Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other - Unprov en	Unconventional therapies; alternative and complementary therapies (see below).

Treatment for certain reportable hematopoietic diseases can be supportive care that does not meet the usual definition of treatment which "modifies, controls, removes, or destroys proliferating cancer tissue." Such treatments include phlebotomy, transfusions, and aspirin (see Notes below), and should be coded 1.

Notes for Hematopoietic diseases:

- The hematopoietic diseases for which transfusions may be coded as other therapy are comprised of the following histologies ONLY: 9945, 9980, 9982-9986, and 9989. Do not code transfusions as therapy for leukemias, lymphomas, or other hematopoietic histologies not on the previous list. Transfusions may include whole blood, RBCs, platelets, plateletpheresis, fresh frozen plasma (FFP), plasmapheresis, and cryoprecipitate.
- Phlebotomy may be coded as other therapy only for 9950/3, polycythemia vera. Phlebotomy may be called blood removal, blood letting, or venisection.
- Aspirin (also known as acetylsalicylic acid (ASA), or by a brand name) is coded as other therapy for 9962/3, essential thrombocythemia. Record
 aspirin therapy ONLY if given to thin the blood for symptomatic control of thrombocythemia. To determine whether aspirin is administered for pain,
 cardiovascular protection, or thinning of platelets in the blood, use the following general guideline:

-Pain control is approximately 325-1000 mg every 3-4 hours.

-Cardiovascular protection starts at about 160 mg/day.

-Aspirin treatment for essential thrombocythemia is low dose, approximately 70-100 mg/day.

Use code 3 - Double blind for clinical trial before the code is broken. After the code is broken, review and re-code therapy as needed, according to the treatment actually administered.

Use code 6 - Unproven therapy - for unconventional methods whether they are given alone or in combination with other cancer directed treatments.

Unconventional treatment agents are:

Cancell, Carnivora, Glyoxylide, Iscador, Koch synthetic antitoxins, Krebiozen, Laetrile, Malonide, Parabenzoquinone

Use code 6 - Unproven therapy - for alternative and complementary therapies ONLY if they are NOT given in combination with other cancer directed treatments.

Alternative & Complementary Therapies are:

- Alternative Systems
- ٠ Acupuncture
- AyurvedaEnvironmental medicine
- Homeopathic medicine
- Natural Products
- Native American, Latin American, or traditonal Oriental medicine
 Bioelectromagnetic Applications
- Blue light treatment
- Electroacupuncture
 Magnetoresonance spectroscopy
- Diet, Nutrition, Lifestyle
- ٠ Changes in lifestyle
- Diet
- Gerson Therapy
- ٠ Macrobiotics
- Megavitamins
 Nutritional Supplements
- Herbal Medicine
- GingerGinkgo Biloba extract
- Ginseng rootManual Healing

- AcupressureBiofield Therapeutics
- Massage therapy
 Reflexology
 Zone therapy

- Mind/Body Control
- Biofeedback
- Humor therapy
- Meditation
- Relaxation techniques
- Yoga
- Pharmacological and Biological Treatments
- Anti-oxidizing agents
 Cell treatment
 Metabolic therapy

- Oxidizing agents

Naaccr Tx

- RX Date Systemic [3230]
- RX Date Systemic Flag [3231]
- RX Hosp--Palliative Proc [3280] ٠ •
- Date Initial RX SEER [1260] •
- Date Initial RX SEER Flag [1261] Date 1st Crs RX CoC [1270] •
- Date 1st Crs RX CoC Flag [1271]
- RX Summ--Treatment Status [1285]
- RX Summ--Reg LN Examined [1296]
- ٠ Reason for No Surgery [1340]
- RX Summ--Palliative Proc [3270]
- RX Summ--Surg/Rad Seq [1380] •
- Reason for No Radiation [1430] ٠
- . RX Summ--Systemic/Sur Seg [1639]
- Readm Same Hosp 30 Days [3190]
- Naaccr Chemotherapy
 - RX Hosp--Chemo [700]
 - RX Date Chemo [1220]
 - RX Date Chemo Flag [1221]
 - RX Summ--Chemo [1390]
- Naaccr Hormone
 - RX Hosp--Hormone [710]
 - RX Date Hormone [1230]
 - RX Date Hormone Flag [1231]
 - RX Summ--Hormone [1400]
- Naaccr Immunotherapy
 - RX Hosp--BRM [720]
 - RX Date BRM [1240]
 - RX Date BRM Flag [1241]
 - RX Summ--BRM [1410]
- Naaccr Non-Definitive Surgery
 - RX Hosp--DX/Stg Proc [740]
 - RX Date DX/Stg Proc [1280]
 - RX Date DX/Stg Proc Flag [1281]
 - RX Summ--DX/Stg Proc [1350]
- Naaccr Other
 - RX Hosp--Other [730]
 - RX Date Other [1250]
 - RX Date Other Flag [1251]
 - RX Summ--Other [1420]
- Naaccr Radiation
 - RX Date Radiation [1210]
 - RX Hosp--Radiation [690]
 - RX Date Radiation Flag [1211]
 - RX Date Rad Ended [3220]
 - RX Date Rad Ended Flag [3221]
 - RX Summ--Radiation [1360]
 - RX Summ--Rad to CNS [1370]
 - Rad--Regional Dose: cGy [1510]
 - Rad--No of Treatment Vol [1520]
 - Rad--Treatment Volume [1540]
 - Rad--Location of RX [1550]
 - Rad--Regional RX Modality [1570]
 - Rad--Boost RX Modality [3200]
 - Rad--Boost Dose cGy [3210]
- Naaccr Surgery
 - RX Date Surgery [1200]
 - RX Date Surgery Flag [1201]

 - RX Hosp--Surg App 2010 [668]
 RX Hosp--Surg Prim Site [670]
 - RX Date Mst Defn Srg [3170]
 - RX Hosp--Scope Reg LN Sur [672]
 - RX Date Mst Defn Srg Flag [3171]
 - RX Hosp--Surg Oth Reg/Dis [674]
 - RX Date Surg Disch [3180]
 - RX Hosp--Reg LN Removed [676]
 - RX Date Surg Disch Flag [3181]
 - RX Hosp--Surg Site 98-02 [746]
 - RX Hosp--Scope Reg 98-02 [747]
 - RX Hosp--Surg Oth 98-02 [748]
 - RX Summ--Surg Prim Site [1290]
 - RX Summ--Scope Reg LN Sur [1292]
 - RX Summ--Surg Oth Reg/Dis [1294]
 - RX Summ--Surgical Approch [1310]
 - RX Summ--Surgical Margins [1320]
 - RX Summ--Reconstruct 1st [1330]

- RX Summ--Surgery Type [1640]
 RX Summ--Surg Site 98-02 [1646]
 RX Summ--Scope Reg 98-02 [1647]
 RX Summ--Surg Oth 98-02 [1648]
 Naaccr Trans Endo
 RX Summ--Transplnt/Endocr [3250]

RX Date Systemic [3230]

Organization	Field Name	ID	Required
KCR	RX Date Systemic [3230] (NADateSystemic)	60220	No
NAACCR	RX Date Systemic	3230	No

Field Length: 8

This is a calculated field which records the date of initiation of systemic therapy as part of the first course of treatment. Systemic therapy includes the administration of chemotherapy agents, hormone agents, biologic response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

Special Codes

Code	Description
0000000	No systemic therapy administered; autopsy only cases.
88888888	Systemic therapy was planned as part of the first course of therapy, but has not yet been administered.
999999999	Unknown if systemic therapy was administered; date of systemic therapy unknown; death certificate only cases.

RX Date Systemic Flag [3231]

Organization	Field Name	ID	Required
KCR	RX Date Systemic Flag [3231] (NADateSystemicFlag)	60221	No
NAACCR	RX Date Systemic Flag	3231	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Systemic (item #60220).

Code	Description
10 No information whatsoever can be inferred (i.e., unknown if any systemic therapy was given)	
11 No proper value is applicable in this context (i.e., no systemic therapy given)	
12	A proper value is applicable but not known (i.e., systemic therapy was given, but the date is unknown)
15	Information not available at this time, but it is expected that it will be available later (i.e., systemic therapy is planned as part of first course therapy, but has not been started at the time of the most recent follow-up)
(blank)	A valid date value is provided

RX Hosp--Palliative Proc [3280]

Organization	Field Name	ID	Required
KCR	RX HospPalliative Proc [3280] (NHPalliativeProc)	60130	No
NAACCR	RX HospPalliative Proc	3280	No

Field Length: 1

This is a calculated field which identifies care provided at the reporting facility in an effort to palliate or alleviate symptoms. Palliative procedures are performed to relieve symptoms and may included surgery, radiation therapy, systemic therapy, and/or pain management therapy.

Code	Description
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in patient record. Palliative care was provided that does not fit the descriptions in codes 1-6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

Date Initial RX SEER [1260]

Organization	Field Name	ID	Required
KCR	Date Initial RX SEER [1260] (NADateInitialRxSEER)	60270	No
NAACCR	Date Initial RX SEER	1260	No

Field Length: 8

This is a calculated field which records the initiation of the first course of therapy. This is the start date of any type of treatment for cancer. Treatment may be given in a hospital or non-hospital setting. The third and fourth digits (day) are re-coded to 99 when the data are transmitted to SEER.

Special Codes

Code	Description	
00000000	No cancer-directed therapy	
999999999 Unknown if therapy administered, or unknown date of thera		

Date Initial RX SEER Flag [1261]

Organization	Field Name	ID	Required
KCR	Date Initial RX SEER Flag [1261] (NADateInitialRxSEERFlag)	60271	No
NAACCR	Date Initial RX SEER Flag	1261	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Date of Initial Rx SEER (item #60270).

Code	Description	
10	No information whatsoever can be inferred (e.g, unknown if therapy was administered)	
11	No proper value is applicable in this context (e.g., therapy was not administered)	
12	A proper value is applicable but not known (e.g., therapy was given, but the date is unknown)	
(blank)	A valid date is provided	

Date 1st Crs RX CoC [1270]

Organization	Field Name	ID	Required
KCR	Date 1st Crs RX CoC [1270] (NADateFirstCrsRxCOC)	60280	No
NAACCR	Date 1st Crs RX CoC	1270	No

Field Length: 8

This is a calculated field which records the date on which treatment began at any facility, using the CoC definition of first course. The date of first treatment includes the date a decision was made not to treat the patient.

Special Codes

Code	Description
0000000	Diagnosed at autopsy
99999999	Unknown if any treatment was administered, treatment date unknown, or death certificate only

Date 1st Crs RX CoC Flag [1271]

Organization	Field Name	ID	Required
KCR	Date 1st Crs RX CoC Flag [1271] (NADateFirstCrsRxCOCFlag)	60281	No
NAACCR	Date 1st Crs RX CoC Flag	1271	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Date of 1st Course Rx COC (item # 60280).

Code	Description	
10	No information whatsoever can be inferred (e.g, unknown if therapy was administered)	
11	No proper value is applicable in this context (e.g., therapy was not administered)	
12	A proper value is applicable but not known (e.g., therapy was given, but the date is unknown)	
(blank)	A valid date is provided	

RX Summ--Treatment Status [1285]

Organization	Field Name	ID	Required
KCR	RX SummTreatment Status [1285] (NATreatmentStatus)	60295	No
NAACCR	RX SummTreatment Status	1285	No

Field Length: 1

This is a calculated field which summarizes whether the patient received any treatment or if the tumor was under active surveillance. It is blank for case diagnosed prior to 2010.

Treatment given after a period of active surveillance is considered subsequent treatment and is not coded in this item.

Code	Definition
0	No treatment given
1	Treatment given
2	Active surveillance (watchful waiting)
9	Unknown if treatment was given

RX Summ--Reg LN Examined [1296]

Organization	Field Name	ID	Required
KCR	RX SummReg LN Examined [1296] (NARegLNExamined)	60330	No
NAACCR	RX SummReg LN Examined	1296	No

Field Length: 2

This field applies to cases diagnosed prior to January 1, 2003. This is a calculated code which indicates the number of lymph nodes surgically examined.

Code	Description
00	No regional lymph nodes removed
01-89	One to 89 regional lymph nodes removed
90	Ninety or more regional lymph nodes removed
95	No regional lymph node(s) removed, but aspiration of regional lymph node(s) was performed
96	Regional lymph node removal documented as sampling and number of lymph nodes unknown/not stated
97	Regional lymph node removal documented as a dissection and number of lymph nodes unknown/not stated
98	Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection
99	Unknown; not stated; death certificate only

Reason for No Surgery [1340]

Organization	Field Name	ID	Required
KCR	Reason for No Surgery [1340] (NAReasonNoSurg)	60370	No
NAACCR	Reason for No Surgery	1340	No

Field Length: 1

This is a calculated field which records the reason that no surgery was performed on the primary site.

Code	Description
0	Surgery of the primary site was performed.
1	Surgery of the primary site was not performed because it was not part of the planned first course treatment
2	Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors
5	Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.
6	Surgery was recommended by the patient's physician, but was not performed. No reason was noted in the patient's record.
7	Surgery was recommended by the patient's physician, but was refused by the patient, patient's family member, or guardian. Refusal was noted in the patient record.
8	Surgery was recommended, but it is unknown if it was performed.
9	It is unknown if surgery was recommended or performed. Death certificate only cases.

RX Summ--Palliative Proc [3270]

Organization	Field Name	ID	Required
KCR	RX SummPalliative Proc [3270] (NAPalliativeProc)	60390	No
NAACCR	RX SummPalliative Proc	3270	No

Field Length: 1

This is a calculated field which identifies care provided at any facility in an effort to palliate or alleviate symptoms.

Code	Description
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in patient record. Palliative care was provided that does not fit the descriptions in codes 1-6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

RX Summ--Surg/Rad Seq [1380]

Organization	Field Name	ID	Required
KCR	RX SummSurg/Rad Seq [1380] (NASurgRadSeq)	60420	No
NAACCR	RX SummSurg/Rad Seq	1380	No

Field Length: 1

This is a calculated field which records the sequencing of radiation and surgery performed as part of first course of treatment. Surgery may be to the primary site, regional lymph nodes, or other site(s).

Code	Description
0	No radiation and/or no cancer-directed surgery
2	Radiation before surgery
3	Radiation after surgery
4	Radiation both before and after surgery
5	Intraoperative radiation
6	Intraoperative radiation with other radiation given before or after surgery
9	Both surgery and radiation given, but sequence unknown

Reason for No Radiation [1430]

Organization	Field Name	ID	Required
KCR	Reason for No Radiation [1430] (NAReasonNoRad)	60480	No
NAACCR	Reason for No Radiation	1430	No

Field Length: 1

This is a calculated field which records the reason the patient did not receive radiation therapy as part of the first course of treatment.

Code	Description
0	Radiation therapy was administered.
1	Radiation therapy not administered because it was not part of the planned first course treatment.
2	Radiation therapy was not recommended/administered because it was contraindicated due to patient risk factors.
5	Radiation therapy was not administered because the patient died prior to planned or recommended treatment.
6	Radiation therapy was recommended by the patient's physician, but was not administered. No reason was noted in the patient's record.
7	Radiation therapy was recommended by the patient's physician, but was refused by the patient, patient's family member, or guardian. Refusal was noted in the patient record.
8	Radiation therapy was recommended, but it is unknown if it was administered.
9	It is unknown if radiation therapy was recommended or performed. Death certificate only cases.

RX Summ--Systemic/Sur Seq [1639]

Organization	Field Name	ID	Required
KCR	RX SummSystemic/Sur Seq [1639] (NASystemicSurgSeq)	60560	No
NAACCR	RX SummSystemic/Sur Seq	1639	No

Field Length: 1

This is a calculated field which records the sequencing of systemic therapy and surgical procedures given as part of the first course of treatment. Surgery may be to the primary site, regional lymph nodes, or other site(s).

Code	Description
0	No systemic therapy and/or no surgical procedure
2 Systemic therapy before surgery 3 Systemic therapy after surgery	
5	Intraoperative systemic therapy
6	Intraoperative systemic therapy with other therapy given before or after surgery
9	Both surgery and systemic therapy given, but sequence unknown

Readm Same Hosp 30 Days [3190]

Organization	Field Name	ID	Required
KCR	Readm Same Hosp 30 Days [3190] (NAReadmSameHosp30Days)	60580	No
NAACCR	Readm Same Hosp 30 Days	3190	No

Field Length: 1

This is a calculated field which records a readmission to the same hospital within 30 days of discharge following hospitalization for surgical resection of the primary site.

Code	Description	
0	No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge.	
1	A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned.	
2	A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned (chemotherapy port insertion, revision of colostomy, etc.)	
3	A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital.	
9	It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge. Death certificate only.	

Naaccr Chemotherapy

- RX Hosp--Chemo [700]
 RX Date Chemo [1220]
 RX Date Chemo Flag [1221]
 RX Summ--Chemo [1390]

RX Hosp--Chemo [700]

Organization	Field Name	ID	Required
KCR	RX HospChemo [700] (NHChemo)	60080	No
NAACCR	RX HospChemo	700	No

Field Length: 2

This is a calculated field which specifies the type of chemotherapy the patient received as part of their initial treatment at the reporting facility. If chemotherapy was not administered, this item records the reason.

Code	Description	
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.	
01	Chemotherapy administered as part of first course therapy, but the type and number of agents is not documented.	
02	Single-agent chemotherapy administered as first course therapy.	
03	Multi-agent chemotherapy administered as first course therapy.	
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors.	
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.	
86	Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in the patient record.	
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.	
88	Chemotherapy was recommended, but it is unknown if it was administered.	
99	It is unknown whether chemotherapy was recommended or administered because it is not stated in the patient record. Death certificate only.	

RX Date Chemo [1220]

Organization	Field Name	ID	Required
KCR	RX Date Chemo [1220] (NADateChemo)	60230	No
NAACCR	RX Date Chemo	1220	No

Field Length: 8

This is a calculated field which records the date of initiation of chemotherapy at any facility as part of the first course of treatment.

Special Codes

Code	Description
00000000No chemotherapy administered; autopsy only cases.88888888Chemotherapy was planned as part of the first course of therapy, but has not yet been administered.99999999Unknown if chemotherapy was administered; date of chemotherapy unknown; death certificate only case	

RX Date Chemo Flag [1221]

Organization	Field Name	ID	Required
KCR	RX Date Chemo Flag [1221] (NADateChemoFlag)	60231	No
NAACCR	RX Date Chemo Flag	1221	No

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Chemo (item #60230).

Code	Description	
10	No information whatsoever can be inferred (i.e., unknown if any chemotherapy was given)	
11	o proper value is applicable in this context (i.e., no chemotherapy given)	
12	A proper value is applicable but not known (i.e., chemotherapy was given, but the date is unknown)	
15	Information not available at this time, but it is expected that it will be available later (i.e., chemotherapy is planned as part of first course therapy, but has not been started at the time of the most recent follow-up)	
(blank)	A valid date value is provided	

RX Summ--Chemo [1390]

Organization	Field Name	ID	Required
KCR	RX SummChemo [1390] (NAChemo)	60440	No
NAACCR	RX SummChemo	1390	No

Field Length: 2

This is a calculated field which records chemotherapy given at any facility as part of the first course of treatment, or the reason chemotherapy was not given.

Code	Description	
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.	
01	Chemotherapy administered as part of first course therapy, but the type and number of agents is not documented.	
02	Single-agent chemotherapy administered as first course therapy.	
03	Multi-agent chemotherapy administered as first course therapy.	
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors.	
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.	
86	Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in the patient record.	
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.	
88	Chemotherapy was recommended, but it is unknown if it was administered.	
99	It is unknown whether chemotherapy was recommended or administered because it is not stated in the patient record. Death certificate only.	

Naaccr Hormone

- RX Hosp--Hormone [710]
 RX Date Hormone [1230]
 RX Date Hormone Flag [1231]
 RX Summ--Hormone [1400]

RX Hosp--Hormone [710]

Organization	Field Name	ID	Required
KCR	RX HospHormone [710] (NHHormone)	60090	No
NAACCR	RX HospHormone	710	No

Field Length: 2

This is a calculated field which records whether systemic hormonal agents were administered as first course treatment at the reporting facility, or records the reason they were not given.

Codes

Code	Description
00	None, hormone therapy was not administered as part of first course treatment. Diagnosed at autopsy.
01	Hormone therapy was given as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors.
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of first course therapy. No reason was stated in the patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether hormone therapy was recommended or administered because it is not stated in the patient record. Death certificate only.

RX Date Hormone [1230]

Organization	Field Name	ID	Required
KCR	RX Date Hormone [1230] (NADateHormone)	60240	No
NAACCR	RX Date Hormone	1230	No

Field Length: 8

This is a calculated field which records the date of initiation of hormone therapy at any facility as part of the first course of treatment.

Special Codes

Code	Description
0000000	No hormone therapy administered; autopsy only cases.
88888888	Hormone therapy was planned as part of the first course of therapy, but has not yet been administered.
999999999	Unknown if hormone therapy was administered; date of hormone therapy unknown; death certificate only cases.

RX Date Hormone Flag [1231]

Organization	Field Name	ID	Required
KCR	RX Date Hormone Flag [1231] (NADateHormoneFlag)	60241	No
NAACCR	RX Date Hormone Flag	1231	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Hormone (item #60240).

Code	Description	
10	No information whatsoever can be inferred (i.e., unknown if any hormone therapy was given)	
11	No proper value is applicable in this context (i.e., no hormone therapy given)	
12	A proper value is applicable but not known (i.e., hormone therapy was given, but the date is unknown)	
15	Information not available at this time, but it is expected that it will be available later (i.e., hormone therapy is planned as part of first course therapy, but has not been started at the time of the most recent follow-up)	
(blank)	A valid date value is provided	

RX Summ--Hormone [1400]

Organization	Field Name	ID	Required
KCR	RX SummHormone [1400] (NAHormone)	60450	No
NAACCR	RX SummHormone	1400	No

Field Length: 2

This is a calculated field which records whether systemic hormonal agents were administered at any facility as first course treatment, or the reason they were not given.

Code	Description	
00	None, hormone therapy was not administered as part of first course treatment. Diagnosed at autopsy.	
01	Hormone therapy was given as first course therapy.	
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors.	
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.	
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of first course therapy. No reason was stated in the patient record.	
87	Hormone therapy was not administered. It was recommended by the patient's physician, but treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.	
88	Hormone therapy was recommended, but it is unknown if it was administered.	
99	It is unknown whether hormone therapy was recommended or administered because it is not stated in the patient record. Death certificate only.	

Naaccr Immunotherapy

RX Hosp--BRM [720]

Organization	Field Name	ID	Required
KCR	RX HospBRM [720] (NHBRM)	60100	No
NAACCR	RX HospBRM	720	No

Field Length: 2

This is a calculated field which records whether immunotherapeutic agents (biologic response modifiers) were administered as first course treatment at the reporting facility, or records the reason they were not given.

Codes

Code	Description
00	None, immunotherapy was not administered as part of first course treatment. Diagnosed at autopsy.
01	Immunotherapy was given as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors.
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of first course therapy. No reason was stated in the patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether immunotherapy was recommended or administered because it is not stated in the patient record. Death certificate only.

RX Date BRM [1240]

Organization	Field Name	ID	Required
KCR	RX Date BRM [1240] (NADateBRM)	60250	No
NAACCR	RX Date BRM	1240	No

Field Length: 8

This is a calculated field which records the date of initiation of immunotherapy at any facility as part of the first course of treatment.

Special Codes

Code	Description
0000000	No immunotherapy administered; autopsy only cases.
88888888	Immunotherapy was planned as part of the first course of therapy, but has not yet been administered.
99999999	Unknown if immunotherapy was administered; date of immunotherapy unknown; death certificate only cases.

RX Date BRM Flag [1241]

Organization	Field Name	ID	Required
KCR	RX Date BRM Flag [1241] (NADateBRMFlag)	60251	No
NAACCR	RX Date BRM Flag	1241	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--BRM (item #60250).

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any immunotherapy was given)
11 No proper value is applicable in this context (i.e., no immunotherapy given)	
12	A proper value is applicable but not known (i.e., immunotherapy was given, but the date is unknown)
15	Information not available at this time, but it is expected that it will be available later (i.e., immunotherapy is planned as part of first course therapy, but has not been started at the time of the most recent follow-up)
(blank)	A valid date value is provided

RX Summ--BRM [1410]

Organization	Field Name	ID	Required
KCR	RX SummBRM [1410] (NABRM)	60460	No
NAACCR	RX SummBRM	1410	No

Field Length: 2

This is a calculated field which records whether immunotherapeutic (biologic response modifiers) were administered at any facility as part of first course treatment, or the reason they were not given.

Code	Description
00	None, immunotherapy was not administered as part of first course treatment. Diagnosed at autopsy.
01	Immunotherapy was given as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors.
85 Immunotherapy was not administered because the patient died prior to planned or recommended therapy.	
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of first course therapy. No reason was stated in the patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether immunotherapy was recommended or administered because it is not stated in the patient record. Death certificate only.

Naaccr Non-Definitive Surgery

- RX Hosp--DX/Stg Proc [740]
 RX Date DX/Stg Proc [1280]
 RX Date DX/Stg Proc Flag [1281]
 RX Summ--DX/Stg Proc [1350]

RX Hosp--DX/Stg Proc [740]

Organization	Field Name	ID	Required
KCR	RX HospDX/Stg Proc [740] (NHDxStgProc)	60120	No
NAACCR	RX HospDX/Stg Proc	740	No

Field Length: 2

This is a calculated field which identifies surgical procedure(s) performed at the reporting facility in order to diagnose and/or stage disease.

Codes

Code	Description
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information regarding whether a diagnostic or staging procedure was performed.

RX Date DX/Stg Proc [1280]

Organization	Field Name	ID	Required
KCR	RX Date DX/Stg Proc [1280] (NADateDxStgProc)	60290	No
NAACCR	RX Date DX/Stg Proc	1280	No

Field Length: 8

This is a calculated field which records the date on which the first surgical diagnostic and/or staging procedure was performed at any facility.

Special codes

Code Description	
00000000No diagnostic or staging procedure performed; autopsy only cases99999999Unknown if diagnostic or staging procedure performed, or date of procedure unknown; death ce	

RX Date DX/Stg Proc Flag [1281]

Organization	Field Name	ID	Required
KCR	RX Date DX/Stg Proc Flag [1281] (NADateDxStgProcFlag)	60291	No
NAACCR	RX Date DX/Stg Proc Flag	1281	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Dx/Stg Proc (item #60290). This field is blank for cases diagnosed prior to January 1, 2007.

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any diagnostic or staging procedure performed)
11	No proper value is applicable in this context (i.e., no no diagnostic or staging procedure performed)
12	A proper value is applicable but not known (i.e., diagnostic or staging procedure was performed, but the date is unknown)
(blank)	A valid date value is provided

RX Summ--DX/Stg Proc [1350]

Organization	Field Name	ID	Required
KCR	RX SummDX/Stg Proc [1350] (NADxStgProc)	60380	No
NAACCR	RX SummDX/Stg Proc	1350	No

Field length: 2

This is a calculated field which identifies the surgical procedure(s) performed at any facility in an effort to diagnose and/or stage disease.

Code	Description	
00	No surgical diagnostic or staging procedure was performed.	
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.	
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.	
03	A surgical exploration only. The patient was not biopsied or treated.	
04	A surgical procedure with a bypass was performed, but no biopsy was done.	
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.	
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.	
07	A procedure was done, but the type of procedure is unknown.	
09	No information regarding whether a diagnostic or staging procedure was performed.	

Naaccr Other

- RX Hosp--Other [730]
 RX Date Other [1250]
 RX Date Other Flag [1251]
 RX Summ--Other [1420]

RX Hosp--Other [730]

Organization	Field Name	ID	Required
KCR	RX HospOther [730] (NHOther)	60110	No
NAACCR	RX HospOther	730	No

Field Length: 1

This is a calculated field which identifies other treatment given at the reporting facility that cannot be defined as surgery, radiation, or systemic therapy, or records the reason it was not given.

Code	Description	
0	None. All cancer treatment was coded in other treatment fields. Diagnosed at autopsy.	
1	Cancer treatment that cannot be assigned to other fields was given. Use this code for treatment unique to hematopoietic diseases.	
2	Patient received treatment as part of an institution based clinical trial.	
3	Patient received treatment as part of a double-blind clinical trial. Code the treatment actually administered when the double-blind code is broken.	
6	Cancer treatments administered by nonmedical personnel.	
7	Other treatment was not administered. It was recommended by the patient's physician, but was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.	
8	Other treatment was recommended, but it is unknown whether it was administered.	
9	It is unknown whether other treatment was recommended or administered because it is not stated in the patient record. Death certificate only.	

RX Date Other [1250]

Organization	Field Name	ID	Required
KCR	RX Date Other [1250] (NADateOther)	60260	No
NAACCR	RX Date Other	1250	No

Field Length: 8

This is a calculated field which records the date of initiation of other treatment at any facility as part of the first course of treatment.

Special Codes

Code	Description
0000000	No other treatment administered; autopsy only cases.
88888888	Other treatment was planned as part of the first course of therapy, but has not yet been administered.
999999999	Unknown if other treatment was administered; date of other treatment unknown; death certificate only cases.

RX Date Other Flag [1251]

Organization	Field Name	ID	Required
KCR	RX Date Other Flag [1251] (NADateOtherFlag)	60261	No
NAACCR	RX Date Other Flag	1251	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Other (item #60260).

Code	Description	
10	No information whatsoever can be inferred (i.e., unknown if any other therapy was given)	
11	o proper value is applicable in this context (i.e., no other therapy given)	
12	A proper value is applicable but not known (i.e., other therapy was given, but the date is unknown)	
15	Information not available at this time, but it is expected that it will be available later (i.e., other therapy is planned as part of first course therapy, but had not been started at the time of the most recent follow-up)	
(blank)	A valid date value is provided	

RX Summ--Other [1420]

Organization	Field Name	ID	Required
KCR	RX SummOther [1420] (NAOther)	60470	No
NAACCR	RX SummOther	1420	No

Field Length: 1

This is a calculated field which identifies other treatment given at any facility that cannot be defined as surgery, radiation, or systemic therapy, or the reason such treatment was not administered.

Code	Description	
0	None. All cancer treatment was coded in other treatment fields. Diagnosed at autopsy.	
1	Cancer treatment that cannot be assigned to other fields was given. Use this code for treatment unique to hematopoietic diseases.	
2	Patient received treatment as part of an institution based clinical trial.	
3	Patient received treatment as part of a double-blind clinical trial. Code the treatment actually administered when the double-blind code is broken.	
6	Cancer treatments administered by nonmedical personnel.	
7	Other treatment was not administered. It was recommended by the patient's physician, but was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record.	
8	Other treatment was recommended, but it is unknown whether it was administered.	
9	It is unknown whether other treatment was recommended or administered because it is not stated in the patient record. Death certificate only.	

Naaccr Radiation

- RX Date Radiation [1210]

- RX Date Radiation [1210]
 RX Hosp--Radiation [690]
 RX Date Radiation Flag [1211]
 RX Date Rad Ended [3220]
 RX Date Rad Ended Flag [3221]
 RX Summ--Radiation [1360]
 RX Summ--Rad to CNS [1370]
 RA Date Descine Descenter (1556)

- RX Summ--Rad to CNS [1370]
 Rad--Regional Dose: cGy [1510]
 Rad--No of Treatment Vol [1520]
 Rad--Treatment Volume [1540]
 Rad--Location of RX [1550]
 Rad--Regional RX Modality [1570]
 Rad--Boost RX Modality [3200]
 Rad--Boost Dose cGy [3210]

RX Date Radiation [1210]

Organization	Field Name	ID	Required
KCR	RX Date Radiation [1210] (NADateRadiation)	60200	No
NAACCR	RX Date Radiation	1210	No

Field Length: 8

This is a calculated field which records the date on which radiation therapy began at any facility as part of the first course of treatment.

Special Codes

Code	Description
0000000	No radiation therapy administered; autopsy only cases.
88888888	Radiation therapy was planned as part of the first course of therapy, but has not yet been administered.
999999999	Unknown if radiation therapy was administered; date of radiation unknown; death certificate only cases.

RX Hosp--Radiation [690]

Organization	Field Name	ID	Required
KCR	RX HospRadiation [690] (NHRadiation)	60070	No
NAACCR	RX HospRadiation	690	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which specifies the type of radiation therapy the patient received as part of the initial treatment at the reporting facility.

Code	Description
0	None
1	Beam Radiation
2	Radioactive implants
3	Radioisotopes
4	Combination of 1 with 2 or 3
5	Radiation, NOS
9	Unknown if radiation therapy administered

RX Date Radiation Flag [1211]

Organization	Field Name	ID	Required
KCR	RX Date Radiation Flag [1211] (NADateRadiationFlag)	60201	No
NAACCR	RX Date Radiation Flag	1211	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Radiation (item #60200).

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any radiation was given)
11	No proper value is applicable in this context (i.e., no radiation given)
12	A proper value is applicable but not known (i.e., radiation was given, but the date is unknown)
15	Information not available at this time, but it is expected that it will be available later (i.e., radiation is planned as part of first course therapy, but has not been started at the time of the most recent follow-up)
(blank)	A valid date value is provided

RX Date Rad Ended [3220]

Organization	Field Name	ID	Required
KCR	RX Date Rad Ended [3220] (NADateRadiationEnded)	60210	No
NAACCR	RX Date Rad Ended	3220	No

Field Length: 8

This is a calculated field which records the date on which the patient completes or receives the last radiation treatment at any facility.

Special Codes

Code	Description
00000000	No radiation therapy administered; autopsy only cases.
88888888	Radiation therapy was planned as part of the first course of therapy, but has not yet been administered.
99999999	Unknown if radiation therapy was administered; date of radiation unknown; death certificate only cases.

RX Date Rad Ended Flag [3221]

Organization	Field Name	ID	Required
KCR	RX Date Rad Ended Flag [3221] (NADateRadiationEndedFlag)	60211	No
NAACCR	RX Date Rad Ended Flag	3221	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Radiation Ended (item #60210).

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any radiation was given)
11	No proper value is applicable in this context (i.e., no radiation given)
12	A proper value is applicable but not known (i.e., radiation was given, but the date is unknown)
15	Information not available at this time, but it is expected that it will be available later (i.e., radiation had begun at the time of the most recent follow-up, but was not yet completed)
(blank)	A valid date value is provided

RX Summ--Radiation [1360]

Organization	Field Name	ID	Required
KCR	RX SummRadiation [1360] (NARadiation)	60400	No
NAACCR	RX SummRadiation	1360	No

Field Length: 1

This is a calculated field which records the type of radiation therapy given at any facility as part of the first course of treatment.

Code	Description
0	None
1	Beam radiation
2	Radioactive implants
3	Radioisotopes
4	Combination of 1 with 2 or 3
5	Radiation, NOS- method or source not specified
6	Historic cases (pre-1996)
7	Patient or patient's guardian refused
8	Radiation recommended, unknown if administered
9	Unknown if radiation therapy administered

RX Summ--Rad to CNS [1370]

Organization	Field Name	ID	Required
KCR	RX SummRad to CNS [1370] (NARadToCNS)	60410	No
NAACCR	RX SummRad to CNS	1370	No

Field Length: 1

This field only applies to lung and leukemia cases diagnosed prior to 1996. It is a calculated field which records radiation given to the brain or central nervous system.

Code	Description
0	No radiation to the brain and/or CNS
1	Radiation
7	Patient or patient's guardian refused
8	Radiation recommended, unknown if administered
9	Unknown or not applicable

Rad--Regional Dose: cGy [1510]

Organization	Field Name	ID	Required
KCR	RadRegional Dose: cGy [1510] (NARadRegDose)	60490	No
NAACCR	RadRegional Dose: cGy	1510	No

Field Length: 5

This is a calculated field which records the dominant or most clinically significant total dose of regional radiation therapy delivered to the patient during the first course of treatment. The unit of measure is centiGray (cGy).

Special codes

Code	Description	
00000	Radiation therapy was not administered	
88888	Brachytherapy or radioisotopes	
99999	Radiation therapy administered, but dose unknown	

Rad--No of Treatment Vol [1520]

Organization	Field Name	ID	Required
KCR	RadNo of Treatment Vol [1520] (NARadNoTreatmentVol)	60500	No
NAACCR	RadNo of Treatment Vol	1520	No

Field Length: 3

This is a calculated field which records the actual number of treatment sessions (fractions) administered during the first course of therapy.

Code	Description
000	None
001-998	Number of treatments
999	Unknown

Rad--Treatment Volume [1540]

Organization	Field Name	ID	Required
KCR	RadTreatment Volume [1540] (NARadTreatmentVolume)	60510	No
NAACCR	RadTreatment Volume	1540	No

Field Length: 2

This is a calculated field which identifies the volume or anatomic target of the most clinically significant regional radiation therapy delivered to the patient during the first course of therapy.

	Description
00	Radiation therapy not given
01	Eye/orbit
02	Pituitary
03	Brain (NOS)
04	Brain (limited)
05	Head and neck (NOS)
06	Head and neck (limited)
07	Glottis
08	Sinuses
09	Parotid
10	Chest/lung (NOS)
11	Lung (limited)
12	Esophagus
13	Stomach
14	Liver
15	Pancreas
16	Kidney
17	Abdomen (NOS)
18	Breast
19	Breast/lymph nodes
20	Chest wall
21	Chest wall/lymph nodes
22	Mantle, mini-mantle
23	Lower extended field
24	Spine
25	Skull
26	Ribs
27	Нір
28	Pelvic bones
29	Pelvis (NOS)
30	Skin

31	Soft tissue
32	Hemibody
33	Whole body
34	Bladder and pelvis
35	Prostate and pelvis
36	Uterus and cervix
37	Shoulder
38	Extremities bone, NOS
39	Inverted Y
40	Spinal cord
41	Prostate
50	Thyroid
60	Lymph node region, NOS
98	Other volume
99	Unknown volume; unknown if radiation therapy given

Rad--Location of RX [1550]

Organization	Field Name	ID	Required
KCR	RadLocation of RX [1550] (NARadLocation)	60520	No
NAACCR	RadLocation of RX	1550	No

Field Length: 1

This is a calculated field which identifies the location of the facility where radiation treatment was administered during first course of treatment.

Code	Description
0	No radiation therapy; autopsy only
1	All radiation therapy at this facility
2	Regional treatment at this facility, boost elsewhere
3	Boost at this facility, regional elsewhere
4	All radiation therapy elsewhere
8	Other, NOS
9	Unknown

Rad--Regional RX Modality [1570]

Organization	Field Name	ID	Required
KCR	RadRegional RX Modality [1570] (NARadRegRxModality)	60530	No
NAACCR	RadRegional RX Modality	1570	No

Field Length: 2

This is a calculated field which records the dominant modality of radiation therapy used to deliver the clinically most significant regional dose to the primary volume of interest during the first course of treatment.

Code	Description
00	No radiation therapy given
20	External beam, NOS
21	Orthovoltage
22	Cobalt-60, Cesium-137
23	Photons (2-5 MV)
24	Photons (6-10 MV)
25	Photons (11-19 MV)
26	Photons (>19 MV)
27	Photons (mixed energies)
28	Electrons
29	Photons and electrons mixed
30	Neutrons, with or w/o photons/electrons
31	IMRT
32	Conformational or 3-D therapy
40	Protons
41	Stereotactic radiosurgery, NOS
42	Linac radiosurgery
43	Gamma knife
50	Brachytherapy, NOS
51	Brachytherapy, intracavitary, low dose rate (LDR)
52	Brachytherapy, intracavitary, high dose rate (HDR)
53	Brachytherapy, interstitial, low dose rate (LDR)
54	Brachytherapy, interstitial, high does rate (HDR)
55	Radium
60	Radioisotopes, NOS
61	Strontium-89
62	Strontium-90
80	Combination modality, specified
85	Combination modality, NOS
98	Other, NOS
99	Unknown

Rad--Boost RX Modality [3200]

Organization	Field Name	ID	Required
KCR	RadBoost RX Modality [3200] (NARadBoostRxModality)	60540	No
NAACCR	RadBoost RX Modality	3200	No

Field Length: 2

This is a calculated field which records the dominant modality of radiation therapy used to deliver the most clinically significant boost dose to the primary volume of interest during the first course of treatment.

Code	Description
00	No boost treatment given
20	External beam, NOS
21	Orthovoltage
22	Cobalt-60, Cesium-137
23	Photons (2-5 MV)
24	Photons (6-10 MV)
25	Photons (11-19 MV)
26	Photons (>19 MV)
27	Photons (mixed energies)
28	Electrons
29	Photons and electrons mixed
30	Neutrons, with or w/o photons/electrons
31	IMRT
32	Conformational or 3-D therapy
40	Protons
41	Stereotactic radiosurgery, NOS
42	Linac radiosurgery
43	Gamma knife
50	Brachytherapy, NOS
51	Brachytherapy, intracavitary, low dose rate (LDR)
52	Brachytherapy, intracavitary, high dose rate (HDR)
53	Brachytherapy, interstitial, low dose rate (LDR)
54	Brachytherapy, interstitial, high does rate (HDR)
55	Radium
60	Radioisotopes, NOS
61	Strontium-89
62	Strontium-90
98	Other, NOS
99	Unknown

Rad--Boost Dose cGy [3210]

Organization	Field Name	ID	Required
KCR	RadBoost Dose cGy [3210] (NARadBoostDose)	60550	No
NAACCR	RadBoost Dose cGy	3210	No

Field Length: 5

This is a calculated field which records the additional dose delivered to that part of the treatment volume encompassed by the boost fields or devices. The unit of measure is centiGray (cGy).

Code	Description
00000	Boost radiation was not administered
88888	Brachytherapy or radioisotopes administered
99999	Boost radiation administered, dose unknown

Naaccr Surgery

- RX Date Surgery [1200]
 RX Date Surgery Flag [1201]
 RX Hosp--Surg App 2010 [668]

- RX Hosp--Surg App 2010 [000]
 RX Hosp--Surg Prim Site [670]
 RX Date Mst Defn Srg [3170]
 RX Hosp--Scope Reg LN Sur [672]
 RX Date Mst Defn Srg Flag [3171]
 RX Date Mst Defn Srg Flag [3171]
- RX bate Mist Dein Stg Flag [3171]
 RX Hosp--Surg Oth Reg/Dis [674]
 RX Date Surg Disch [3180]
 RX Hosp--Reg LN Removed [676]
 RX Date Surg Disch Flag [3181]
 RX Hosp--Scope Reg 98-02 [746]
 RX Hosp--Scope Oth 20 20 [747]

- RX Hosp--Surg Oth 98-02 [748]
- RX Summ--Surg Prim Site [1290]
 RX Summ--Scope Reg LN Sur [1292]
- RX Summ--Surg Oth Reg/Dis [1294]
 RX Summ--Surgical Approch [1310]
 RX Summ--Surgical Margins [1320]

- RX Summ--Reconstruct 1st [1330]
- RX Summ--Surgery Type [1640]
- RX Summ--Surg Site 98-02 [1646]
 RX Summ--Scope Reg 98-02 [1647]
- RX Summ--Surg Oth 98-02 [1648]

RX Date Surgery [1200]

Organization	Field Name	ID	Required
KCR	RX Date Surgery [1200] (NADateSurgery)	60170	No
NAACCR	RX Date Surgery	1200	No

Field Length: 8

This is a calculated field which records the date the first surgery described in Surgery of Primary Site, Scope of Regional Lymph Node Surgery, or Surgery of Other Regional/Distant Sites was performed.

Special Codes

Code	Description
0000000	No surgical procedures performed; autopsy only
99999999	Unknown if any surgical procedures were performed, date of surgical procedure is unknown, or death certificate only

RX Date Surgery Flag [1201]

Organization	Field Name	ID	Required
KCR	RX Date Surgery Flag [1201] (NADateSurgeryFlag)	60171	No
NAACCR	RX Date Surgery Flag	1201	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Surgery (item #60170).

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any surgery was performed)
11	No proper value is applicable in this context (i.e., no surgery performed)
12	A proper value is applicable but not known (i.e., surgery was performed, but the date is unknown)
(blank)	A valid date value is provided

RX Hosp--Surg App 2010 [668]

Organization	Field Name	ID	Required
KCR	RX HospSurg App 2010 [668] (NHSurgApp2010)	60025	No
NAACCR	RX HospSurg App 2010	668	No

Field Length: 1

This is a calculated field which describes the surgical method used to approach the primary site for the most invasive surgery of the primary site at this facility. This field is blank for cases diagnosed prior to January 1, 2010.

Code	Description
0	No surgical procedure of primary site at this facility; Diagnosed at autopsy
1	Robotic assisted
2	Robotic converted to open
3	Endoscopic
4	Endoscopic converted to open
5	Open or approach unspecified
9	Unknown whether surgery was performed at this facility

RX Hosp--Surg Prim Site [670]

	Organization	Field Name	ID	Required
	KCR	RX HospSurg Prim Site [670] (NHSurgPrimSite)	60030	No
	NAACCR	RX HospSurg Prim Site	670	No

Field Length: 2

This is a calculated field which records the most invasive surgical procedure at the primary site which was performed at the reporting facility.

Code	Description
00	No surgical procedure of primary site. Autopsy only.
10-19 Site-specific codes. Tumor destruction; no pathologic specimen	
20-80	Site-specific codes. Resection. Path specimen produced.
90	Surgery, NOS.
98	Site-specific codes. Special
99	Unknown. Death certificate only.

RX Date Mst Defn Srg [3170]

Organization	Field Name	ID	Required
KCR	RX Date Mst Defn Srg [3170] (NADateMostDefinSurg)	60180	No
NAACCR	RX Date Mst Defn Srg	3170	No

Field Length: 8

This is a calculated field which records the date of the most definitive surgical resection of the primary site as part of the first course of treatment.

Special codes

Code	Description
00000000	No surgical resection of the primary site. Diagnosed at autopsy.
99999999	Unknown if any surgical procedure of primary site was performed, or date of surgery at primary site is unknown. Death certificate only.

RX Hosp--Scope Reg LN Sur [672]

Organization	Field Name	ID	Required
KCR	RX HospScope Reg LN Sur [672] (NHScopeRegLNSur)	60040	No
NAACCR	RX HospScope Reg LN Sur	672	No

Field Length: 1

Calculated field which records the removal, biopsy, or aspiration of regional lymph node(s) at the reporting facility. If multiple lymph node procedures were performed, the highest code predominates.

Codes

Code	Description
0	No regional lymph nodes removed
1	Biopsy or aspiration of regional lymph node, NOS
2	Sentinel lymph node biopsy
3	Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS
4	1 to 3 regional lymph nodes removed
5	4 or more regional lymph nodes removed
6	Sentinel node biopsy and code 3, 4, or 5 at the same time or time not stated
7	Sentinel node biopsy and code 3, 4, or 5 at different times
9	Unknown or not applicable

RX Date Mst Defn Srg Flag [3171]

Organization	Field Name	ID	Required
KCR	RX Date Mst Defn Srg Flag [3171] (NADateMostDefinSurgFlag)	60181	No
NAACCR	RX Date Mst Defn Srg Flag	3171	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Most Defin Surg (item #60180). This field is blank for cases diagnosed prior to January 1, 2003.

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any surgery was performed)
11	No proper value is applicable in this context (i.e., no surgery performed)
12	A proper value is applicable but not known (i.e., surgery was performed, but the date is unknown)
(blank)	A valid date value is provided

RX Hosp--Surg Oth Reg/Dis [674]

Organization	Field Name	ID	Required
KCR	RX HospSurg Oth Reg/Dis [674] (NHSurgOthRegDis)	60050	No
NAACCR	RX HospSurg Oth Reg/Dis	674	No

Field Length: 1

This calculated field records the surgical removal of distant lymph nodes or other tissue(s)/organ(s) at the reporting facility. If multiple procedures to other sites were performed, the highest code (excluding 9) is recorded.

Code	Description
0	None. Diagnosed at autopsy.
1	Non-primary surgical resection to other site(s), unknown if regional or distant.
2	Resection of regional site.
3	Resection of distant lymph node(s).
4	Resection of distant site.
5	Any combination of codes 2, 3, or 4
9	Unknown or death certificate only.

RX Date Surg Disch [3180]

Organization	Field Name	ID	Required
KCR	RX Date Surg Disch [3180] (NADateSurgicalDisch)	60190	No
NAACCR	RX Date Surg Disch	3180	No

Field Length: 8

This is a calculated field which records the date the patient was discharged following the most definitive primary site surgery.

Special codes

Code	Description
0000000	No surgical procedures performed; autopsy only
999999999	Unknown if any surgical procedures were performed, date of surgical procedure is unknown, or death certificate only

RX Hosp--Reg LN Removed [676]

Organization	Field Name	ID	Required
KCR	RX HospReg LN Removed [676] (NHRegLNRemoved)	60060	No
NAACCR	RX HospReg LN Removed	676	No

Field Length: 2

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which describes the number of regional lymph nodes removed as part of first course treatment at the reporting facility.

Codes

Code	Description
00	No regional lymph nodes removed
01-89	One to 89 regional lymph nodes removed
90	Ninety or more regional lymph nodes removed
95	No regional lymph node(s) removed, but aspiration of regional lymph node(s) was performed
96	Regional lymph node removal documented as sampling and number of lymph nodes unknown/not stated
97	Regional lymph node removal documented as a dissection and number of lymph nodes unknown/not stated
98	Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection
99	Unknown; not stated; death certificate only

RX Date Surg Disch Flag [3181]

Organization	Field Name	ID	Required
KCR	RX Date Surg Disch Flag [3181] (NADateSurgicalDischFlag)	60191	No
NAACCR	RX Date Surg Disch Flag	3181	No

Field Length: 2

This is a calculated field which explains why there is no appropriate value in the field Rx Date--Surgical Disch (item #60190). This field is blank for cases diagnosed prior to January 1, 2003.

Code	Description
10	No information whatsoever can be inferred (i.e., unknown if any surgery was performed)
11	No proper value is applicable in this context (i.e., no surgery performed)
12	A proper value is applicable but not known (i.e., surgery was performed, but the date is unknown)
(blank)	A valid date value is provided

RX Hosp--Surg Site 98-02 [746]

Organization	Field Name	ID	Required
KCR	RX HospSurg Site 98-02 [746] (NHSurgSite98To02)	60140	No
NAACCR	RX HospSurg Site 98-02	746	No

Field Length: 2

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which describes the most invasive surgical procedure to the primary site performed at the reporting facility. Site specific surgery codes are taken from the ROADS Manual.

Special codes

Code	code Description	
00 No cancer directed surgery performed		
99 Unknown if cancer directed surgery performed		

RX Hosp--Scope Reg 98-02 [747]

Organization	Field Name	ID	Required
KCR	RX HospScope Reg 98-02 [747] (NHScopeReg98To02)	60150	No
NAACCR	RX HospScope Reg 98-02	747	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which describes the removal, biospy, or aspiration of regional lymph nodes(s) at the reporting facility. Site specific surgery codes are taken from the ROADS Manual.

RX Hosp--Surg Oth 98-02 [748]

Organization	Field Name	ID	Required
KCR	RX HospSurg Oth 98-02 [748] (NHSurgOth98To02)	60160	No
NAACCR	RX HospSurg Oth 98-02	748	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which records the surgical removal of distant lymph nodes or other tissue(s)/organ(s) beyond the primary site at the reporting facility. Site specific surgery codes are taken from the ROADS Manual.

RX Summ--Surg Prim Site [1290]

Organization	Field Name	ID	Required
KCR	RX SummSurg Prim Site [1290] (NASurgPrimSite)	60300	No
NAACCR	RX SummSurg Prim Site	1290	No

Field Length: 2

This is a calculated field which records the code for the most definitive site specific surgery performed as first course of treatment at any facility.

Code	Description
00	No surgical procedure of primary site. Diagnosed at autopsy.
10-19	Tumor destruction, no pathologic specimen produced.
20-80	Tumor resection.
90	Surgery, NOS
98	Special code.
99	Unknown if surgery at primary site. Death certificate only.

RX Summ--Scope Reg LN Sur [1292]

Organization	Field Name	ID	Required
KCR	RX SummScope Reg LN Sur [1292] (NAScopeRegLNSur)	60310	No
NAACCR	RX SummScope Reg LN Sur	1292	No

Field Length: 1

This is a calculated field which describes the removal, biopsy, or aspiration of regional lymph nodes(s) at any facility. These codes are hierarchical and the numerically highest code (excluding 9) is recorded.

Code	Description
0	No regional lymph nodes removed
1	Biopsy or aspiration of regional lymph node, NOS
2	Sentinel lymph node biopsy
3	Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS
4	1 to 3 regional lymph nodes removed
5	4 or more regional lymph nodes removed
6	Sentinel node biopsy and code 3, 4, or 5 at the same time or time not stated
7 Sentinel node biopsy and code 3, 4, or 5 at different times	
9	Unknown or not applicable

RX Summ--Surg Oth Reg/Dis [1294]

Organization	Field Name	ID	Required
KCR	RX SummSurg Oth Reg/Dis [1294] (NASurgOthRegDis)	60320	No
NAACCR	RX SummSurg Oth Reg/Dis	1294	No

Field Length: 1

This is a calculated field which records the surgical removal of distant lymph nodes or other tissue(s)/organ(s) beyond the primary site performed at any facility. These codes are hierarchical; if multiple procedures to distant lymph nodes or sites were performed, the highest code (excluding 9) predominates.

Code	Description
0	None. Diagnosed at autopsy.
1	Non-primary surgical resection to other site(s), unknown if regional or distant.
2	Resection of regional site.
3	Resection of distant lymph node(s).
4	Resection of distant site.
5	Any combination of codes 2, 3, or 4
9	Unknown or death certificate only.

RX Summ--Surgical Approch [1310]

Organization	Field Name	ID	Required
KCR	RX SummSurgical Approch [1310] (NASurgApproch)	60340	No
NAACCR	RX SummSurgical Approch	1310	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. This is a calculated field which records the method used to approach the surgical field for the primary site. These codes are site-specific and may be found in the ROADS Manual.

RX Summ--Surgical Margins [1320]

Organization	Field Name	ID	Required
KCR	RX SummSurgical Margins [1320] (NASurgMargins)	60350	No
NAACCR	RX SummSurgical Margins	1320	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. This is a calculated field which records the final status of the surgical margins after resection of the primary tumor.

Code	Descriptions	
0	All margins are grossly and microscopically negative.	
1	Involvement is indicated, but not otherwise specified.	
2	Microscopic residual tumor.	
3	Macroscopic residual tumor.	
7	Cannot be assessed.	
8	No surgical procedure of the primary site; diagnosed at autopsy.	
9	Unknown or not applicable.	

RX Summ--Reconstruct 1st [1330]

Organization	Field Name	ID	Required
KCR	RX SummReconstruct 1st [1330] (NAReconstruct)	60360	No
NAACCR	RX SummReconstruct 1st	1330	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which records surgical procedures done to reconstruct, restore, or improve the shape and appearance or function of body structures that are missing, defective, damaged, or misshapen by cancer or cancer-directed therapies. These codes are site-specific and may be found in the ROADS Manual.

RX Summ--Surgery Type [1640]

Organization	Field Name	ID	Required
KCR	RX SummSurgery Type [1640] (NASurgType)	60570	No
NAACCR	RX SummSurgery Type	1640	No

Field Length: 2

This is a calculated field which records site specific surgery codes for cases diagnosed prior to 1996.

RX Summ--Surg Site 98-02 [1646]

Organization	Field Name	ID	Required
KCR	RX SummSurg Site 98-02 [1646] (NASurgSite98To02)	60590	No
NAACCR	RX SummSurg Site 98-02	1646	No

Field Length: 2

This field only applies to cases diagnosed prior to January 1, 2003. This is a calculated field which records the site-specific surgery code for the type of surgery to the primary site performed as part of the first course of treatment.

Special codes

Code	Description		
00	No surgery to the primary site		
99	Unknown if surgery performed		

RX Summ--Scope Reg 98-02 [1647]

Organization	Field Name	ID	Required
KCR	RX SummScope Reg 98-02 [1647] (NAScopeReg98To02)	60600	No
NAACCR	RX SummScope Reg 98-02	1647	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which records the removal, biopsy, or aspiration of regional lymph node(s). See the ROADS Manual for site-specific codes.

RX Summ--Surg Oth 98-02 [1648]

Organization	Field Name	ID	Required
KCR	RX SummSurg Oth 98-02 [1648] (NASurgOth98To02)	60610	No
NAACCR	RX SummSurg Oth 98-02	1648	No

Field Length: 1

This field only applies to cases diagnosed prior to January 1, 2003. It is a calculated field which records the surgical removal of distant lymph node(s) or other tissue(s)/organ(s) beyond the primary site as part of the first course of treatment. See the ROADS Manual for site-specific codes.

Naaccr Trans Endo

• RX Summ--Transplnt/Endocr [3250]

RX Summ---TranspInt/Endocr [3250]

Organization	Field Name	ID	Required
KCR	RX SummTranspint/Endocr [3250] (NATranspintEndocr)	60430	No
NAACCR	RX SummTranspint/Endocr	3250	No

Field Length: 2

This is a calculated field which identifies transplant and endocrine surgeries/radiation administered at any facility as part of the first course of treatment.

Code	Description
00	None; diagnosed at autopsy
10	Bone marrow transplant, type not specified
11	Bone marrow transplant, autologous
12	Bone marrow transplant, allogeneic
20	Stem cell harvest and infusion
30	Endocrine surgery and/or endocrine radiation therapy
40	Combination of endocrine surgery and/or radiation with a transplant procedure (code 30 plus 10, 11, 12, or 20)
82	Transplant and/or endocrine surgery/radiation not recommended/administered because it was contraindicated due to patient risk factors
85	Transplant and/or endocrine surgery/radiation not administered because the patient died prior to planned or recommended therapy
86	Transplant and/or endocrine surgery/radiation recommended by the patient's physician, but was not administered; no reason was stated in the patient record
87	Transplant and/or endocrine surgery/radiation recommended by the patient's physician, but refused by the patient, patient's family, or guardian; refusal noted in patient record
88	Transplant and/or endocrine surgery/radiation recommended, but it is unknown if it was administered
99	It is unknown whether transplant and/or endocrine surgery/radiation was recommended or administered; death certificate only cases

Class Data

- Hospital Chart No (Class)
- Class Local Hosp Id
- Class Edda Hosp Id
 Registry Accession Year (Class)
 Class of Case (Class)
 Date of First Contact (Class)
 Inst Referred From (Class)
 Inst Referred From (Class)

- Inst Referred To (Class)
- Date Class Hx Completed CoC
 Date Class Hx Completed
- Palliative Procedure This Facility (Class)
- Abstracted By (Class)
 Patient Acc No (Class)
 ArchiveFIN (Class)
- Date Class Hx Last Updated
- Import Reporting Facility (Class)
 CS Override 1 (Class)
 Modified By (Class)

- Time Modified (Class)

Hospital Chart No (Class)

Organization	Field Name	ID	Required
KCR	Hospital Chart No (Class) (LChartNum)	40040	no
NAACCR	Medical Record Number	2300	no

Field Length: 15

This field records the patient's medical record number at the reporting facility. It is stored with the patient's class history. A patient record which is associated with multiple facilities may thus have a unique medical record number corresponding to each facility.

Class Local Hosp Id

Organization	Field Name	ID	Required
KCR	Class Local Hosp Id (LHospId)	40050	yes
NAACCR	Reporting Facility	540	yes

Field Length: 10

This is a unique code which represents the facility reporting the case. A case in a multi-facility database may be associated with more than one registry, and this field exists in the class history record for each affiliated facility. This field is automatically coded when a facility creates or associates itself with a case, and is filled in with the facility's FIN number.

Registry Accession Year (Class)

Organization	Field Name	ID	Required
KCR	Registry Accession Year (Class) (LAccYear)	40060	yes

Field Length: 9

This field provides a unique identifier for the patient and consists of the year in which the patient was first seen at the reporting facility and the consecutive order in which the case was abstracted.

The first four numbers specify the year and the last five numbers are the numeric order in which the patient was entered into the registry database. A patient's accession number is never reassigned.

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the facility's Registry Accession Year and Number (items 30320 - 30330).

Class of Case (Class)

Organization	Field Name	ID	Required
KCR	Class of Case (Class) (LCaseClass)	40080	yes
NAACCR	Class of Case	610	yes

Field Length: 2

Class of case reflects the facility's role in managing this cancer, whether the cancer is required to be reported to ACoS by approved facilities, and whether the case was diagnosed after the program's reference date. Enter the two digit code that describes the patient's relationship to the facility.

Instructions for Coding

- Code 00 applies only when it is known that the patient went elsewhere for treatment. If that information is not available, code class of case '10.' It is possible that information for coding class of case will change during the patient's first course of care. If that occurs, edit the code accordingly.
- ACoS approved facilities should document Institution Referred To (item #31660) for patients coded 00 to establish that the patient went elsewhere for treatment.
- A staff physician (codes 10-12, 41) is a physician who is employed by the reporting facility, under contract with it, or who has routine practice privileges there.
- Refer to the "Case Reporting Requirements" section of this manual for a discussion of Classes and KCR requirements.

Codes

	Initial diagnosis at reporting facility			
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere			
10	Initial diagnosis at the reporting facility or in a staff physician's office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS			
11	Initial diagnosis in staff physician's office AND part of first course treatment was done at the reporting facility			
12	Initial diagnosis in staff physician's office AND all first course treatment or decision not to treat was done at the reporting facility			
13	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility			
14	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility			
	Initial diagnosis elsewhere			
20	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS			
21	Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility			
22	Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility			
No	on-analytic Classes of Case (Not required by CoC to be abstracted by accredited programs, but may be required by KCR)			
	Patient appears in person at reporting facility			
30	Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (i.e., consult only or staging workup			
31	Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care			
32	Diagnosis AND all first course treatment provided elsewhere AND patients presents at reporting facility with disease recurrence or persistence			
33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only			
34	Type of case not required by CoC to be accessioned (i.e., CIS of cervix) AND initial diagnosis AND part or all of first course treatment by reporting facility			
35	Case diagnosed before program's reference date AND initial diagnosis AND all or part of first course treatment by reporting facility			
36	Type of case not required by CoC to be accessioned (i.e., a basal cell skin cancer) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility			
37	Case diagnosed before program's reference date AND initial diagnosis elsewhere AND all or part of first course treatment by facility			
38	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death			
	Patient does not appear in person at reporting facility Do not abstract cases in class 40 - 99- refer them to KCR; these classes are for KCR use onl			

40 Diagnosis AND all first course treatment given at the same staff physician's office
41 Diagnosis and all first course treatment given in two or more different staff physician offices
42 Nonstaff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (i.e., hospital abstracts cases from an independent radiation facility)
43 Pathology or other lab specimens only
49 Death certificate only
98 Non-hospital treatment abstracted by KCR
99 Non-hospital cases abstracted by KCR

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the facility's Class of Case (item 30140).

Date of First Contact (Class)

Organization	Field Name	ID	Required
KCR	Date of First Contact (Class) (LDateFirstContact)	40081	yes
NAACCR	Date of 1st Contact	580	yes

Field Length: 8

This is the date the patient had initial contact with the facility as either an inpatient or outpatient for diagnosis and/or treatment of a reportable tumor. For autopsy-only or DCO cases, use the date of death. When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the facility's Date of First Contact (item 30150).

Inst Referred From (Class)

Organization	Field Name	ID	Required
KCR	Inst Referred From (Class) (LInstRefFrom)	40082	no
NAACCR	Institution Referred From	2410	no

Field Length: 10

This field identifies the facility that referred the patient to the reporting facility. Enter the FIN of the facility that referred the patient to your institution, or use one of the special codes below.

000000000 The patient was not referred to the reporting facility from another facility

9999999999 The patient was referred, but the referring facility's ID number is unknown

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the value from Institution Referred From (item 31650).

Inst Referred To (Class)

Organization	Field Name	ID	Required
KCR	Inst Referred To (Class) (LInstRefTo)	40083	no
NAACCR	Institution Referred To	2420	no

Field Length: 10

This field identifies the facility to which the patient was referred for further care after discharge from the reporting facility. Enter the FIN of the facility to which the patient was referred, or use one of the special codes below.

000000000 The patient was not referred to another facility

9999999999 The patient was referred to another facility, but the facility's ID number is unknown

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the value from Institution Referred To (item 31660).

Date Class Hx Completed CoC

Organization	Field Name	ID	Required
KCR	Date Class Hx Completed CoC (LDateCompletedCoC)	40089	No
NAACCR	Date Case CompletedCoC	2092	No

Field Length: 8

This is a calculated data item which identifies the date that specified items are completed and pass relevant edits, based on the Class of Case (item #30140). This field is used to evaluate compliance by ACoS-approved facilities with Standard 3.3, which specifies that 90% of cases must be completed within six months of the patient's first contact with the facility. It should not be confused with Date Case Completed (item #31410). This field will be blank for cases diagnosed prior to January 1, 2010.

Class of Case	Description	Items That Must Be Completed by Date Case Completed - COC
00-22	All analytic cases	Identification, demographics, diagnostic
10-22	Patient received part or all first course treatment from facility	Staging, hospital-specific treatment
10, 12, 14, 20, 22	Patient received all first course treatment from facility, or unspecified whether all or part	Summary treatment (treatment at any facility)
00	Patient diagnosed at facility, received all treatment elsewhere	Facility referred to OR a treating physician
20-22	Patient diagnosed elsewhere, received part or all of treatment from facility	Facility referred from OR the managing physician

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the value from Date Case Completed - COC (item #31405).

Date Class Hx Completed

Organization	Field Name	ID	Required
KCR	Date Class Hx Completed (LDateCompleted)	40090	No
NAACCR	Date Case Completed	2090	No

Field Length: 8

This field records the date that the case was initially saved without errors by each facility affiliated with a case. It is automatically calculated.

Palliative Procedure - This Facility (Class)

Organization	Field Name	ID	Required
KCR	Palliative Procedure - This Facility (Class) (LPallProcHere)	40084	no
NAACCR	RX HospPalliative Proc	3280	no

Field Length: 1

This field allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent. Palliative procedures are performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy, and/or pain management therapy.

Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable should be coded as palliative care and as first course therapy if that procedure removes or modifies malignant tissue.

Code	Description	
0	No palliative care provided. Diagnosed at autopsy.	
1 Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt is made to diagnose, stage, or treat t		
2	Radiation therapy to alleviate symptoms, but no attempt is made to diagnose, stage, or treat the primary tumor.	
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt is made to diagnose, stage, or treat the primary tumor.	
4	Patient received or was referred for pain management therapy with no other palliative care.	
5	Any combination of codes 1, 2, and/or 3 without code 4.	
6	Any combination of codes 1, 2, and/or 3 with code 4.	
7	Palliative care was performed or referred, but no information on the type of procedure is available. Palliative care was provided that does not fit the descriptions for codes 1-6.	
9	It is unknown if palliative care was performed or referred; not stated in patient record.	

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the value from Palliative Procedure At This Facility (item 31680).

Abstracted By (Class)

Organization	Field Name	ID	Required
KCR	Abstracted By (Class) (LAbstractedBy)	40085	yes
NAACCR	Abstracted By	570	yes

Field Length: 3

The field records the initials or assigned code of the registrar who abstracted the case. A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the value from Abstracted By (item 31140).

Patient Acc No (Class)

Organization	Field Name	ID	Required
KCR	Patient Acc No (Class) (LPatAccNo)	40088	yes
NAACCR	Accession NumberHosp	550	yes

Field Length: 10

A unique accession number is assigned to each patient for each reporting institution affiliated with the patient. The accession number identifies the patient even if multiple primaries exist. The first four digits of the accession number specify the year in which the patient was first seen at the reporting institution for the diagnosis and/or treatment of cancer. The last six numbers are the numerical order the reporting institution entered their first reportable case of this patient into the registry's database.

The computer calculates these fields by copying in the accession number of the first abstracted case entered by each reporting institution for this patient.

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility owns the case, this field is automatically filled in with the value from Patient Accession Number (item 31721).

ArchiveFIN (Class)

Organization	Field Name	ID	Required
KCR	ArchiveFIN (Class) (LArchiveFIN)	40086	No
NAACCR	Archive FIN	3100	No

Field Length: 10

This field identifies the CoC Facility Identification Number (FIN) of the facility at the time it originally accessioned the case.

When a CoC approved facility merges with another facility or joins a network, its unique FIN may change. Archive FIN preserves the identity of the facility at the time the case was initially accessioned so that records resubmitted subsequent to such a reorganization can be recognized as belonging to the same facility.

Archive FIN is automatically coded by CPDMS.net. This item never changes and must be included as part of the patient record when data are submitted to the NCDB. For facilities that have not merged, Archive FIN and FIN are the same.

A case in a multi-facility database may be associated with more than one facility, and this field exists in the class history record for each affiliated facility. When a facility creates or associates itself with a case, this field is automatically filled in with the value from Archive FIN (item 31725).

Date Class Hx Last Updated

Organization	Field Name	ID	Required
KCR	Date Class Hx Last Updated (LDateLastUpdate)	40100	No
NAACCR	Date Case Last Changed	2100	No

Field Length: 8

The field records the date the class history was last changed or updated. It is automatically calculated any time the class history is edited.

Import Reporting Facility (Class)

Organization	Field Name	ID	Required
KCR	Import Reporting Facility (Class) (LImportReportFacility)	40115	no

Field length: 10

This is a unique code to KCR which represents the facility reporting the case to an out-of-state central registry, such as the Ohio State Cancer Registry or the Veterans Affairs Central Cancer Registry, and then imported into a CPDMS database. A case in a multi-facility database may be associated with more than one registry, and this field exists in the class history record for each affiliated facility. This field is automatically coded when an OSDE or VA Central file is imported, and is filled in with the facility's FIN number as contained in the NAACCR import file.

CS Override 1 (Class)

Organization	Field Name	ID	Required
KCR	CS Override 1 (Class) (LCSOverride1)	40400	no
NAACCR	Over-ride CS 1	3750	no
KCR	CS Override 2 (Class) (LCSOverride2)	40410	no
NAACCR	Over-ride CS 2	3751	no
KCR	CS Override 3 (Class) (LCSOverride3)	40420	no
NAACCR	Over-ride CS 3	3752	no
KCR	CS Override 4 (Class) (LCSOverride4)	40430	no
NAACCR	Over-ride CS 4	3753	no
KCR	CS Override 5 (Class) (LCSOverride5)	40440	no
NAACCR	Over-ride CS 5	3754	no
KCR	CS Override 6 (Class) (LCSOverride6)	40450	no
NAACCR	Over-ride CS 6	3755	no
KCR	CS Override 7 (Class) (LCSOverride7)	40460	no
NAACCR	Over-ride CS 7	3756	no
KCR	CS Override 8 (Class) (LCSOverride8)	40470	no
NAACCR	Over-ride CS 8	3757	no
KCR	CS Override 9 (Class) (LCSOverride9)	40480	no
NAACCR	Over-ride CS 9	3758	no
KCR	CS Override 10 (Class) (LCSOverride10)	40490	no
NAACCR	Over-ride CS 10	3759	no
KCR	CS Override 11 (Class) (LCSOverride11)	40500	no
NAACCR	Over-ride CS 11	3760	no
KCR	CS Override 12 (Class) (LCSOverride12)	40510	no
NAACCR	Over-ride CS 12	3761	no
KCR	CS Override 13 (Class) (LCSOverride13)	40520	no
NAACCR	Over-ride CS 13	3762	no
KCR	CS Override 14 (Class) (LCSOverride14)	40530	no
NAACCR	Over-ride CS 14	3763	no
KCR	CS Override 15 (Class) (LCSOverride15)	40540	no
NAACCR	Over-ride CS 15	3764	no
KCR	CS Override 16 (Class) (LCSOverride16)	40550	no
NAACCR	Over-ride CS 16	3765	no
KCR	CS Override 17 (Class) (LCSOverride17)	40560	no
NAACCR	Over-ride CS 17	3766	no
KCR	CS Override 18 (Class) (LCSOverride18)	40570	no
NAACCR	Over-ride CS 18	3767	no
KCR	CS Override 19 (Class) (LCSOverride19)	40580	no
NAACCR	Over-ride CS 19	3768	no
KCR	CS Override 20 (Class) (LCSOverride20)	40590	no
NAACCR	Over-ride CS 20	3769	no

These fields will be defined in the future for use in overriding Collaborative Stage edits.

Modified By (Class)

Organization	Field Name	ID	Required
KCR	Modified By (Class) (LModUser)	40360	no

Field Length: 8

This is a calculated field which records the user name of the last individual to modify class history data. It is updated each time the record is edited.

Time Modified (Class)

Organization	tion Field Name		Required
KCR	Time Modified (Class) (LModTime)	40370	no

Field Length: 19

This field automatically records the date and time that class history data was last modified.

Appendices

- Appendix A Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases
 Appendix B SEER Geocodes
 Appendix C Site Groups

- Appendix D County Codes for Kentucky and its Contiguous States

- Appendix D County Codes for reindoxy c
 Appendix E General Site Codes
 Appendix F Facility ID Numbers
 Appendix G Site Specific Surgery Codes

- Appendix H Therapy Agents
 Appendix I Common Abbreviations
 Appendix J ICD-O-3 Errata and Clarifications

- Appendix K Race Coding Rules and Tables
 Appendix L Frequent Surnames
 Appendix M Supplemental ICD-10-CM Codes
 Appendix N Pre-2014 Grade Coding Instructions
- Appendix O Area Development District Map

Appendix A - Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases

For the Multiple Primary Determination tables for hematologic malignancies diagnosed after January 1, 2001, click on the link below to go to the SEER web site:

http://seer.cancer.gov/seertools/hemelymph/

For the Multiple Primary Determination tables for hematologic malignancies diagnosed before January 1, 2001, go to:

http://www.seer.cancer.gov/manuals/codeman.pdf and go to page 22.

Appendix B - SEER Geocodes

The SEER Geocodes can be found at: https://seer.cancer.gov/manuals/2018/SPCSM_2018_AppendixB.pdf

Appendix C - Site Groups

#	Site Group Name	Valid ICD-O Topography Codes	Valid ICD-O-3 Morphology Codes	Valid ICD-O-3 Behavior Codes
01	Lip	C00.0 - C00.9	any valid code EXCEPT lymphomas and melanomas & plasma cell tumors	2, 3
02	Tongue	C01.9 - C02.9	n	2, 3
03	Salivary Glands	C07.9, C08.0 - C08.9	n	2, 3
04	Gum & Hard Palate	C03.0 - C03.9, C05.0	•	2, 3
05	Floor of Mouth	C05.8, C05.9, C06.2 C04.0 - C04.9	и и	2, 3
06	Buccal Mucosa	C06.0, C06.1, C06.8 C06.9	n	2, 3
07	Oropharynx	C05.1, C05.2, C09.0 - C09.9 C10.0 - C10.9	n	2, 3
08	Nasopharynx	C11.0 - C11.9	n	2, 3
09	Hypopharynx	C12.9, C13.0 - C13.9	n	2, 3
10	Other Oral Cavity	C14.0 - C14.8	п	2, 3
11	Esophagus	C15.0 - C15.9	n	2, 3
12	Stomach	C16.0 - C16.9	n	2, 3
13	Small Intestine	C17.0 - C17.9	п	2, 3
14	Colon	C18.0 - C18.9	п	2, 3
15	Rectum/Anus	C19.9, C20.9, C21.0 - C21.8	u	2, 3
16	Liver	C22.0 - C22.1	п	2, 3
17	Gallbladder	C23.9 - C24.9	п	2, 3
18	Pancreas	C25.0 - C25.9	n	2, 3
19	Other Digestive Tract	C48.0 - C48.8 C26.0 - C26.9	Any valid code except lymphoma, melanoma, and plasma cell tumors	2, 3
20	Nasal Cavities, Sinuses & Ear	C30.0 - C30.1 C31.0 - C31.9	any valid code EXCEPT lymphomas and melanomas and plasma cell tumors	2, 3
21	Larynx	C32.0 - C32.9	n	2, 3
22	Trachea, Bronchus and Lung - Small Cell	C33.9, C34.0 - C34.9	8041/3, 8042/3, 8043/3, 8044/3, 8045/3, 8073/3	2, 3
23	Trachea, Bronchus and Lung - Non-Small Cell	C33.9, C34.0 - C34.9,	any valid code EXCEPT small cell carcinoma lymphomas, melanomas, and plasma cell tumors	2, 3
24	Other Respiratory Sites	C38.0 - C38.8 C37.9, C39.0 - C39.9	any valid code EXCEPT melanomas, lymphomas, and plasma cell tumors	2, 3
25	Bone	C40.0 - C40.9 C41.0 - C41.9	any valid code except lymphomas, plasma cell tumors	2, 3
26	Connective & Soft Tissue	C47.0 - C47.9 C49.0 - C49.9 C42.2	Any valid code except lymphomas, melanomas, plasma cell tumors	2, 3
27	Malignant Melanoma	C44.0 - C44.9 or any other valid site, i.e.,	8720 - 8790	2, 3

		C51.0 - C51.2,		1
		C60.0, C60.9,		
28	Other Skin	C69.0 - C69.9, etc. C44.0 - C44.9	any valid code except lymphomas, melanomas, and	2, 3
20		044.0 - 044.9	plasma cell tumors	2, 3
29	Breast (Male & Female)	C50.0 - C50.9	any valid code EXCEPT lymphomas and melanomas and plasma cell tumors	2, 3
30	Cervix	C53.0 - C53.9	"	3
31	Endometrium (Corpus Uteri)	C54.0 - C54.9	"	2, 3
32	Ovary	C56.9	n	2, 3
33	Other Female Genital Organs	C52.9, C55.9, C58.9,	"	2, 3
		C57.0 - C57.9,		
		C51.0 - C51.9		
34	Prostate	C61.9	n	2, 3
35	Testis	C62.0 - C62.9	n	2, 3
36	Other Male Genital Organs	C60.0 - C60.9	"	2, 3
		C63.0 - C63.9		
37	Bladder	C67.0 - C67.9	n	2, 3
38	Kidney	C64.9	n	2, 3
39	Other Urinary Organs	C65.9, C66.9,	n	2, 3
		C68.0 - C68.9		
40	Еуе	C69.0 - C69.9	n	2, 3
41	Brain	C71.0 - C71.9	n	2, 3
42	Other CNS	C70.0 - C70.9	n	2, 3
		C72.0 - C72.9		
43	Thyroid	C73.9	n	2, 3
44	Other Endocrine	C74.0 - C74.9	n	2, 3
		C75.0 - C75.9		
45	Hodgkin's	C77.0 - C77.9 or any valid extranodal site	9650/3-9667/3	3
46	Non-Hodgkin's Lymphomas	C77.0 - C77.9 or any valid code	9590/3-9597/3, 9670/3-9699/3, 9702/3-9729/3, 9735/3- 9738/3	3
		Any valid code NOT C42.	9811/3-9818/3, 9823/3, 9827/3, 9837/3	
		-	9811/3-9818/3, 9828/3, 9827/3, 9837/3	
		C42.2		
47	Plasma Cell Tumors	C42.0 - C42.4 or any valid code	9731/3-9734/3	3
48	Lymphoid Leukemias	C42.0 - C42.4	9820/3-9826/3,	3
			9832/3-9837/3, 9827/3, if w/C42	
49	Myeloid Leukemias	C42.0 - C42.4	9840/3-9931/3	3
50	Other Leukemias	C42.0 - C42.4	9742/3,	3
			9800/3-9809/3,	
			9940/3-9948/3	
51	Myleoproliferative, Myelodysplastic Diseases	C42.0 - C42.4	9950/3-9992/3	3
52	Other Hematopoietic Diseases	C42.0 - C42.4,	9700/3, 9701/3, 9740/3, 9741/3, 9750/3-9758/3, 9760	3
		C44.0 - C44.9 for mycosis fungoides,	/3- 9769/3, 9971/3	
		C17.0 - C17.9 for Mediterranean lymphoma		
53	Other and III-Defined Sites	C76.0 - C76.8	any valid code EXCEPT lymphomas and melanomas and plasma cell tumors	2, 3

54	Unknown Primary	C80.9	"	3
55	Cannot determine site group from information available. (Use only when recording other primaries.)			
60	Benign & borderline intracranial tumors	C70.0 - C72.9,	any valid code	0, 1
		C75.1 - C75.3		

CPDMS SITE GROUP CODE ASSIGNMENT

By Topography and Histology

(revised Feb 2019)

Melanomas (Group 27)	L Plasma cell tumors (Group 47)
8720-8790	e u 9731-9734
Hodgkin's Lymphomas (Group 45)	k e Other Hematopoietic Dz (Grp 52)
9650-9667	m ias 9700-9701
NonHodgkin's Lymphomas (Group 46)	9 9750-9758
9590-9596 9727-9729	8 0 9740-9741
9670-9699 9827 unless with C42	0 - 9760-9769
9702-9719	9 8 27
	9 8 3 1 -
	9 9 20
	9 9 3 1
	9 9 48
IF TOPOGRAPHY=	A THEN SITE GROUP CODE=
	S T O L O
	G Y=
C00.0 - C00.9	8 Group 27 7 2 0 -
	8 7 90
	9 Group 47 7 3 1
	- 9

	4	
	Group 45	5, 46, or 52
	Not valid	
	Group 49)
	Group 01	
C01.9 - C02.9	Group 27	,
	Group 47	,
	Group 45	5, 46, or 52
	Not valid	
	Group 49)
	Group 02	2
C07.9 - C08.9	Group 27	
	Group 47	

	3 1 - 9 7 34 L y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 03 se
C03.0 - C03.9 C05.0, C05.8, C05.9, C06.2	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 04 se
C04.0 - C04.9	8 Group 27 7 2 0 - 8 7 90

	7 3 1 - 9 7 34 L Group 45, 46, or 52
	y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 05 se
C06.0 - C06.1 C06.8 - C06.9	8 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 06 se
C05.1 - C05.2, C09.0 - C09.9, C10.0 - C10.9	8 Group 27 7 2 0 - 8

	7 90	
		Group 47
		Group 45, 46, or 52
	L N e u k e m ia	Not valid
	9 (9 30	Group 49
	el (se	Group 07
C11.0 - C11.9	8 (7 2 0 - 8 7 90	Group 27
	9 (7 3 1 - 9 7 34	Group 47
	L (y p h o ma	Group 45, 46, or 52
	L N e u k e m ia	Not valid
	9 (9 30	Group 49
	el (se	Group 08
C12.9 - C13.9	8 (7 2 0	Group 27

	- 8 7 90 9 7 3 1 - 9 7 34 L y m P h o ma	Group 47 Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 09
C14.0 - C14.8	8 7 2 0 - 8 7 90	Group 27
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 10
C15.0 - C15.9	8 7	Group 27

	2 0 - 8 7 90	
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L u k m ia	Not valid
	9 9 30	Group 49
	el se	Group 11
C16.0 - C16.9	8 7 2 0 - 8 7 90	Group 27
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 12

C17.0 - C17.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 13 se
C18.0 - C18.9	8 Not valid 9 0 - 8 0 9 98
	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k

	e
	e m ia
	9 Group 49 9 30
	el Group 14 se
C19.9 - C21.8	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 15 se
C22.0 - C22.1	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e

	u k e m ia
	9 Group 49 9 30
	el Group 16 se
C23.9 - C24.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 17 se
C25.0 - C25.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma

	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 18 se
C26.0 - C26.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 19 se
C30.0 - C31.9	9 Not valid 2 5 0 - 9 3 42
	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9

	Group 45, 46, c	or 52
	Not valid	
	Group 49	
	Group 20	
C32.0 - C32.9	Not valid	
	Group 27	
	Group 47	
	Group 45, 46, c	or 52
	Not valid	
	Group 49	
	Group 21	
C33.9 - C34.9	Group 27	

	- 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	8 Group 22 0 4 1 - 8 0 4 5 , 8 0 73
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 23 se
C37.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u

	k e m ia	
	9 (9 30	Group 49
	el (se	Group 24
C38.0 - C38.8	8 I 0 1 0 - 8 6 71	Not valid
	8 1 9 4 0 - 8 9 41	Not valid
	8 1 7 2 0 - 8 7 90	Not valid
	9 0 7 3 1 - 9 7 34	Group 47
	L (y m p h o ma	Group 45, 46, or 52
	L I e u k e m ia	Not valid
	9 (9 30	Group 49
	el (se	Group 24
C39.0 - C39.9	8 0 7 2 0 - 8 7 90	Group 27

	9 7 3 1 - 9 7 34 L	Group 47 Group 45, 46, or 52
	y m p h o ma	
	L u k m ia	Not valid
	9 9 30	Group 49
	el se	Group 24
C40.0 - C41.9	8 0 1 0 - 8 0 50	Not valid
	8 0 5 2 - 8 0 60	Not valid
	8 0 7 5 - 8 6 71	Not valid
	8 7 2 0 - 8 7 90	Not valid
	8 9 4 0 - 8 9 41	Not valid
	9 7 3	Group 47

	197197111<
	9 Group 49 9 30 el Group 25
C42.0 - C42.4	8 Group 26 8 0 1 , 9 1 2 0 , 9 1 3 3
	9 Group 47 7 3 1 - 9 9 7 34
	9 Group 48 8 2 0 - 9 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	9 Group 48 8 3 1 - 9 8 3 3 3 7
	9 8 4 0 9 9 31 Group 49 8 8 4 0 9 9 31

	9 7 4 2 , 9 8 0 0 - 9 8 05
	9 Group 50 9 4 0 - 9 9 9 48
	9 Group 51 9 5 0 - 9 89
	L Group 45, 46, or 52 y m p h o ma
	el Not valid se
C44.0 - C44.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9
	7 34
	7 34 L Group 45, 46, or 52 y m p h o ma
	34 L Group 45, 46, or 52 y m p h o

	el se	Group 28
C47.0 - C47.9	8 0 1 0 - 8 6 71	Not valid
	8 9 4 0 - 8 9 41	Not valid
	9 7 3 1 - 9 7 34	Group 47
	8 7 2 0 - 8 7 90	Not valid
	L y m h o ma	Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 26
C49.0 - C49.9	9 7 3 1 - 9 7 34	Group 47
	8 7 2 0 - 8 7 90	Not valid

	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 26 se
C48.0 - C48.8	L Group 45, 46, or 52 y m p h o ma
	8 Not valid 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 19 se
C50.0 - C50.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9

	7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 29 se
C53.0 - C53.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 30 se
C54.0 - C54.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1

	- 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 31 se
C56.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 32 se
C51.0 - C51.9 C52.9, C55.9, C58.9 C57.0 - C57.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7

	3 1 9 7 734 Group 45, 46, or 52 y m p h o ma L Not valid
	u k e m ia
	9 Group 49 9 30
	el Group 33 se
C61.9	8 Group 27 7 2 0 - 8 7 90
	9 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 34 se
C62.0 - C62.9	8 Group 27 7 2 0 - 8 7 90
	90

	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 35 se
C60.0 - C60.9 C63.0 - C63.9	8 Group 27 7 2 0 - 8 7 90
	9 Group 47 7 3 1 - 9 7 34
	L Group 45, 46, or 52 y m p h o ma
	L Not valid e u k e m ia
	9 Group 49 9 30
	el Group 36 se
C67.0 - C67.9	8 Group 27 7 2 0 - 8

	-	1
	7 90	
	9 7 3 1 - 9	Group 47
	7 34	
	L y p h o ma	Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 37
C64.9	8 7 2 0 - 8 7 90	Group 27
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L e u k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 38
C65.9, C66.9 C68.0 - C68.9	8 7 2	Group 27
	0	

	- 8	
	8 7 90	
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L u k m ia	Not valid
	9 9 30	Group 49
	el se	Group 39
C69.0 - C69.9	8 7 2 0 - 8 7 90	Group 27
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Group 40
C71.0 - C71.9	8 9	Not valid

	4 0	
	- 8	
	9 41	
	8 0	Not valid
	1 0	
	- 8	
	6 71	
	8 7	Group 27
	2 0	
	- 8	
	7 90	
	9	Group 47
	7 3 1	
	- 9	
	7 34	
	L	Group 45, 46, or 52
	y m	
	p h o	
	ma	
	L e	Not valid
	u k	
	e m ia	
		Group 49
	9 30	
	w it	Group 60
	h b	
	e h	
	a vi	
	o r	
	= 0	
	, 1	
	el se	Group 41
C70.0 - C70.9	8 9	Not valid
C72.0 - C72.9	4 0	
	- 8	
	9 41	

8 0 1 0 - 8 6 71	Not valid
8 7 2 0 - 8 7 90	Group 27
9 7 3 1 - 9 7 34	Group 47
L y p h o ma	Group 45, 46, or 52
L e k e m ia	Not valid
9 9 30	Group 49
Withbehavior=0,1	Group 60
el se	Group 42
8 7 2 0 - 8 7 90	Group 27
9 7 3 1 -	Group 47
	010-8671 8720-8790 9731-9734 Lymphoma Leukemia 9930 withbehavior=0,1 else 8720-8790 9731

C73.9

	9	
	7 34	
	L y p h o ma	Group 45, 46, or 52
	L u k m ia	Not valid
	9 9 30	Group 49
	el se	Group 43
C74.0 - C74.9 C75.0 - C75.9	8 7 2 0 - 8 7 90	Group 27
	9 7 3 1 - 9 7 34	Group 47
	L y p h o ma	Group 45, 46, or 52
	L e k e m ia	Not valid
	9 9 30	Group 49
	if b e h a vi o r = 0 , 1	Group 60
	el se	Group 44

C77.0 - C77.9	L y p h o ma	Group 45, 46, or 52
	9 7 3 1 - 9 7 34	Group 47
	L e k e m ia	Not valid
	9 9 30	Group 49
	el se	Not valid
C76.0 - C76.8	8 0 0 - 8 8 33	Not valid
	8 8 4 0 - 8 9 21	Not valid
	9 0 4 0 - 9 0 44	Not valid
	8 9 0 - 8 9 91	Not valid
	8 9 4 0 - 8 9 41	Not valid
	9 1 2	Not valid

	0	
1	- 9 1 75	
	9 2 4 0 - 9 2 52	Not valid
	9 5 4 0 - 9 5 60	Not valid
	9 5 0 - 9 5 82	Not valid
	8 7 2 0 - 8 7 90	Not valid
	L m p h o ma	Group 45, 46, or 52
	9 7 3 1 - 9 7 34	Group 47
	L u k m ia	Not valid
!	9 9 30	Group 49
	el se	Group 53
	8 7 2 0 - 8	Not valid

C80.9

7 90	
9 7 3 1 - 9 7 34	Group 47
L y p h o ma	Group 45, 46, or 52
L e k e m ia	Not valid
9 9 30	Not valid
el se	Group 54

Appendix D - County Codes for Kentucky and its Contiguous States

The U.S. Postal Service web site has a search feature which allows users to search for ZIP codes by address or by city, and to list all cities within a particular ZIP code. The URL is http://zip4.usps.com/zip4/welcome.jsp. To determine which county a particular address is in, use the "Search By Address" tool. Enter the street address, city, and state, and then click "Submit." Once the results are displayed, click on the link to the right labeled "Mailing Industry Information" to see the county.

County FIPS	County Name	ADD	Urban/Rural	Beale Code	App/non-App
21001	Adair	Lake Cumberland	Rural	7	Appalachia
21003	Allen	Barren River	Rural	6	Non-Appalachia
21005	Anderson	Bluegrass	Rural	6	Non-Appalachia
21007	Ballard	Purchase	Rural	9	Non-Appalachia
21009	Barren	Barren River	Rural	6	Non-Appalachia
21011	Bath	Gateway	Rural	8	Appalachia
21013	Bell	Cumberland Valley	Rural	7	Appalachia
21015	Boone	Northern Kentucky	Urban	1	Non-Appalachia
21017	Bourbon	Bluegrass	Urban	2	Non-Appalachia
21019	Boyd	Fivco	Urban	2	Appalachia
21021	Boyle	Bluegrass	Rural	7	Non-Appalachia
21023	Bracken	Buffalo Trace	Urban	1	Non-Appalachia
21025	Breathitt	Kentucky River	Rural	7	Appalachia
21027	Breckinridge	Lincoln Trail	Rural	8	Non-Appalachia
21029	Bullitt	Kipda	Urban	1	Non-Appalachia
21031	Butler	Barren River	Rural	8	Non-Appalachia
21033	Caldwell	Pennyrile	Rural	6	Non-Appalachia
21035	Calloway	Purchase	Rural	7	Non-Appalachia
21037	Campbell	Northern Kentucky	Urban	1	Non-Appalachia
21039	Carlisle	Purchase	Rural	9	Non-Appalachia
21041	Carroll	Northern Kentucky	Rural	6	Non-Appalachia
21043	Carter	Fivco	Rural	6	Appalachia
21045	Casey	Lake Cumberland	Rural	9	Appalachia
21047	Christian	Pennyrile	Urban	3	Non-Appalachia
21049	Clark	Bluegrass	Urban	2	Appalachia
21051	Clay	Cumberland Valley	Rural	7	Appalachia
21053	Clinton	Lake Cumberland	Rural	9	Appalachia
21055	Crittenden	Pennyrile	Rural	6	Non-Appalachia
21057	Cumberland	Lake Cumberland	Rural	9	Appalachia
21059	Daviess	Green River	Urban	3	Non-Appalachia
21061	Edmonson	Barren River	Urban	3	Appalachia
21063	Elliott	Fivco	Rural	9	Appalachia
21065	Estill	Bluegrass	Rural	6	Appalachia
21067	Fayette	Bluegrass	Urban	2	Non-Appalachia
21069	Fleming	Buffalo Trace	Rural	7	Appalachia
21071	Floyd	Big Sandy	Rural	7	Appalachia
21073	Franklin	Bluegrass	Rural	4	Non-Appalachia
21075	Fulton	Purchase	Rural	7	Non-Appalachia
21077	Gallatin	Northern Kentucky	Urban	1	Non-Appalachia

21079	Garrard	Bluegrass	Rural	6	Appalachia
21081	Grant	Northern Kentucky	Urban	1	Non-Appalachia
21083	Graves	Purchase	Rural	7	Non-Appalachia
21085	Grayson	Lincoln Trail	Rural	6	Non-Appalachia
21087	Green	Lake Cumberland	Rural	8	Appalachia
21089	Greenup	Fivco	Urban	2	Appalachia
21091	Hancock	Green River	Urban	3	Non-Appalachia
21093	Hardin	Lincoln Trail	Urban	3	Non-Appalachia
21095	Harlan	Cumberland Valley	Rural	7	Appalachia
21097	Harrison	Bluegrass	Rural	6	Non-Appalachia
21099	Hart	Barren River	Rural	8	Appalachia
21101	Henderson	Green River	Urban	2	Non-Appalachia
21103	Henry	Kipda	Urban	1	Non-Appalachia
21105	Hickman	Purchase	Rural	9	Non-Appalachia
21107	Hopkins	Pennyrile	Rural	4	Non-Appalachia
21109	Jackson	Cumberland Valley	Rural	9	Appalachia
21111	Jefferson	Kipda	Urban	1	Non-Appalachia
21113	Jessamine	Bluegrass	Urban	2	Non-Appalachia
21115	Johnson	Big Sandy	Rural	7	Appalachia
21117	Kenton	Northern Kentucky	Urban	1	Non-Appalachia
21119	Knott	Kentucky River	Rural	9	Appalachia
21121	Knox	Cumberland Valley	Rural	7	Appalachia
21123	Larue	Lincoln Trail	Urban	3	Non-Appalachia
21125	Laurel	Cumberland Valley	Rural	7	Appalachia
21127	Lawrence	Fivco	Rural	6	Appalachia
21129	Lee	Kentucky River	Rural	9	Appalachia
21131	Leslie	Kentucky River	Rural	9	Appalachia
21133	Letcher	Kentucky River	Rural	9	Appalachia
21135	Lewis	Buffalo Trace	Rural	8	Appalachia
	Lincoln	Bluegrass	Rural	7	Appalachia
21137	Livingston	Pennyrile	Rural	9	Non-Appalachia
21141	Logan	Barren River	Rural	6	Non-Appalachia
21143	Lyon	Pennyrile	Rural	8	Non-Appalachia
21145	McCracken	Purchase	Rural	5	Non-Appalachia
21147	McCreary	Lake Cumberland	Rural	9	Appalachia
21149	McLean	Green River	Urban	3	Non-Appalachia
21151	Madison	Bluegrass	Rural	4	Appalachia
21153	Magoffin	Big Sandy	Rural	9	Appalachia
21155	Marion	Lincoln Trail	Rural	6	Non-Appalachia
21157	Marshall	Purchase	Rural	7	Non-Appalachia
21159	Martin	Big Sandy	Rural	8	Appalachia
21161	Mason	Buffalo Trace	Rural	6	Non-Appalachia
21163	Meade	Lincoln Trail	Urban	1	Non-Appalachia
21165	Menifee	Gateway	Rural	9	Appalachia
21167	Mercer	Bluegrass	Rural	6	Non-Appalachia
21169	Metcalfe	Barren River	Rural	9	Appalachia

21171	Monroe	Barren River	Rural	9	Appalachia
21173	Montgomery	Gateway	Rural	6	Appalachia
21175	Morgan	Gateway	Rural	7	Appalachia
21177	Muhlenberg	Pennyrile	Rural	6	Non-Appalachia
21179	Nelson	Lincoln Trail	Urban	1	Non-Appalachia
21181	Nicholas	Bluegrass	Rural	8	Appalachia
21183	Ohio	Green River	Rural	6	Non-Appalachia
21185	Oldham	Kipda	Urban	1	Non-Appalachia
21187	Owen	Northern Kentucky	Rural	8	Non-Appalachia
21189	Owsley	Kentucky River	Rural	9	Appalachia
21191	Pendleton	Northern Kentucky	Urban	1	Non-Appalachia
21193	Perry	Kentucky River	Rural	7	Appalachia
21195	Pike	Big Sandy	Rural	7	Appalachia
21197	Powell	Bluegrass	Rural	6	Appalachia
21199	Pulaski	Lake Cumberland	Rural	5	Appalachia
21201	Robertson	Buffalo Trace	Rural	8	Appalachia
21203	Rockcastle	Cumberland Valley	Rural	7	Appalachia
21205	Rowan	Gateway	Rural	7	Appalachia
21207	Russell	Lake Cumberland	Rural	9	Appalachia
21209	Scott	Bluegrass	Urban	2	Non-Appalachia
21211	Shelby	Kipda	Urban	1	Non-Appalachia
21213	Simpson	Barren River	Rural	6	Non-Appalachia
21215	Spencer	Kipda	Urban	1	Non-Appalachia
21217	Taylor	Lake Cumberland	Rural	7	Non-Appalachia
21219	Todd	Pennyrile	Rural	8	Non-Appalachia
21221	Trigg	Pennyrile	Urban	3	Non-Appalachia
21223	Trimble	Kipda	Urban	1	Non-Appalachia
21225	Union	Green River	Rural	6	Non-Appalachia
21227	Warren	Barren River	Urban	3	Non-Appalachia
21229	Washington	Lincoln Trail	Rural	8	Non-Appalachia
21231	Wayne	Lake Cumberland	Rural	7	Appalachia
21233	Webster	Green River	Urban	2	Non-Appalachia
21235	Whitley	Cumberland Valley	Rural	7	Appalachia
21237	Wolfe	Kentucky River	Rural	9	Appalachia
21239	Woodford	Bluegrass	Urban	2	Non-Appalachia

CODES FOR COUNTIES IN THE STATES BORDERING KENTUCKY

ILLINOIS 17

CODE COUNTY NAME

001 Adams

003 Alexander

005 Bond

007 Boone

009 Brown

011 Bureau

- 013 Calhoun
- 015 Carroll
- 017 Cass
- 019 Champaign
- 021 Christian
- 023 Clark
- 025 Clay
- 027 Clinton
- 029 Coles
- 031 Cook
- 033 Crawford
- 035 Cumberland
- 037 DeKalb
- 039 De Witt
- 041 Douglas
- 043 DuPage
- 045 Edgar
- 047 Edwards
- 049 Effingham
- 051 Fayette
- 053 Ford
- 055 Franklin
- 057 Fulton
- 059 Gallatin
- 061 Greene
- 063 Grundy
- 065 Hamilton
- 067 Hancock
- 069 Hardin
- 071 Henderson
- 073 Henry
- 075 Iroquois
- 077 Jackson
- 079 Jasper
- 081 Jefferson
- 083 Jersey
- 085 Jo Daviess
- 087 Johnson
- 089 Kane
- 091 Kankakee
- 093 Kendall

- 095 Knox
- 097 Lake
- 099 La Salle
- 101 Lawrence
- 103 Lee
- 105 Livingston
- 107 Logan
- 109 McDonough
- 111 McHenry
- 113 McLean
- 115 Macon
- 117 Macoupin
- 119 Madison
- 121 Marion
- 123 Marshall
- 125 Mason
- 127 Massac
- 129 Menard
- 131 Mercer
- 133 Monroe
- 135 Montgomery
- 137 Morgan
- 139 Moultrie
- 141 Ogle
- 143 Peoria
- 145 Perry
- 147 Piatt
- 149 Pike
- 151 Pope
- 153 Pulaski
- 155 Putnam
- 157 Randolph
- 159 Richland
- 161 Rock Island
- 163 St. Clair
- 165 Saline
- 167 Sangamon
- 169 Schuyler
- 171 Scott
- 173 Shelby

- 175 Stark
- 177 Stephenson
- 179 Tazewell
- 181 Union
- 183 Vermilion
- 185 Wabash
- 187 Warren
- 189 Washington
- 191 Wayne
- 193 White
- 195 Whiteside
- 197 Will
- 199 Williamson
- 201 Winnebago
- 203 Woodford

INDIANA 18

- CODE COUNTY NAME
- 001 Adams
- 003 Allen
- 005 Bartholomew
- 007 Benton
- 009 Blackford
- 011 Boone
- 013 Brown
- 015 Carroll
- 017 Cass
- 019 Clark
- 021 Clay
- 023 Clinton
- 025 Crawford
- 027 Daviess
- 029 Dearborn
- 031 Decatur
- 033 DeKalb
- 035 Delaware
- 037 Dubois
- 039 Elkhart
- 041 Fayette
- 043 Floyd
- 045 Fountain
- 047 Franklin

- Fulton 049 051 Gibson 053 Grant 055 Greene 057 Hamilton 059 Hancock 061 Harrison 063 Hendricks 065 Henry 067 Howard 069 Huntington 071 Jackson 073 Jasper 075 Jay 077 Jefferson 079 Jennings 081 Johnson 083 Knox 085 Kosciusko 087 Lagrange 089 Lake LaPorte 091 093 Lawrence 095 Madison 097 Marion 099 Marshall 101 Martin 103 Miami 105 Monroe 107 Montgomery 109 Morgan 111 Newton Noble 113 115 Ohio 117 Orange 119 Owen 121 Parke
- 123 Perry
- 125 Pike
- 127 Porter

- 129 Posey
- 131 Pulaski
- 133 Putnam
- 135 Randolph
- 137 Ripley
- 139 Rush
- 141 St. Joseph
- 143 Scott
- 145 Shelby
- 147 Spencer
- 149 Starke
- 151 Steuben
- 153 Sullivan
- 155 Switzerland
- 157 Tippecanoe
- 159 Tipton
- 161 Union
- 163 Vanderburgh
- 165 Vermillion
- 167 Vigo
- 169 Wabash
- 171 Warren
- 173 Warrick
- 175 Washington
- 177 Wayne
- 179 Wells
- 181 White
- 183 Whitley

MISSOURI 29

CODE	COUNTY NAME
001	Adair
003	Andrew
005	Atchison
007	Audrain
009	Barry
011	Barton
013	Bates
015	Benton
017	Bollinger
019	Boone

021 Buchanan 023 Butler 025 Caldwell 027 Callaway 029 Camden 031 Cape Girardeau 033 Carroll 035 Carter 037 Cass 039 Cedar 041 Chariton Christian 043 045 Clark 047 Clay 049 Clinton 051 Cole 053 Cooper 055 Crawford 057 Dade 059 Dallas 061 Daviess DeKalb 063 065 Dent 067 Douglas 069 Dunklin 071 Franklin 073 Gasconade 075 Gentry 077 Greene 079 Grundy 081 Harrison 083 Henry 085 Hickory 087 Holt 089 Howard 091 Howell 093 Iron 095 Jackson 097 Jasper 099 Jefferson

- 101 Johnson
- 103 Knox
- 105 Laclede
- 107 Lafayette
- 109 Lawrence
- 111 Lewis
- 113 Lincoln
- 115 Linn
- 117 Livingston
- 119 McDonald
- 121 Macon
- 123 Madison
- 125 Maries
- 127 Marion
- 129 Mercer
- 131 Miller
- 133 Mississippi
- 135 Moniteau
- 137 Monroe
- 139 Montgomery
- 141 Morgan
- 143 New Madrid
- 145 Newton
- 147 Nodaway
- 149 Oregon
- 151 Osage
- 153 Ozark
- 155 Pemiscot
- 157 Perry
- 159 Pettis
- 161 Phelps
- 163 Pike
- 165 Platte
- 167 Polk
- 169 Pulaski
- 171 Putnam
- 173 Ralls
- 175 Randolph
- 177 Ray
- 179 Reynolds
- 181 Ripley

- 183 St. Charles
- 185 St. Clair
- 186 St. Genevieve
- 187 St. Francois
- 189 St. Louis County
- 195 Saline
- 197 Schuyler
- 199 Scotland
- 201 Scott
- 203 Shannon
- 205 Shebly
- 207 Stoddard
- 209 Stone
- 211 Sullivan
- 213 Taney
- 215 Texas
- 217 Vernon
- 219 Warren
- 221 Washington
- 223 Wayne
- 225 Webster
- 227 Worth
- 229 Wright
- OHIO 39
- CODE COUNTY NAME
- 001 Adams
- 003 Allen
- 005 Ashland
- 007 Ashtabula
- 009 Athens
- 011 Auglaize
- 013 Belmont
- 015 Brown
- 017 Butler
- 019 Carroll
- 021 Champaign
- 023 Clark
- 025 Clermont
- 027 Clinton
- 029 Columbiana

- 031 Coshocton 033 Crawford 035 Cuyahoga 037 Darke 039 Defiance 041 Delaware 043 Erie Fairfield 045 047 Fayette 049 Franklin 051 Fulton Gallia 053 055 Geauga 057 Greene 059 Guernsey Hamilton 061 063 Hancock 065 Hardin 067 Harrison 069 Henry 071 Highland 073 Hocking 075 Holmes 077 Huron 079 Jackson 081 Jefferson 083 Knox 085 Lake 087 Lawrence 089 Licking 091 Logan
 - 093 Lorain
 - 095 Lucas
 - 097 Madison
 - 099 Mahoning
 - 101 Marion
 - 103 Medina
 - 105 Meigs
 - 107 Mercer
 - 109 Miami
 - 111 Monroe

- 113 Montgomery
- 115 Morgan
- 117 Morrow
- 119 Muskingum
- 121 Noble
- 123 Ottawa
- 125 Paulding
- 127 Perry
- 129 Pickaway
- 131 Pike
- 133 Portage
- 135 Preble
- 137 Putnam
- 139 Richland
- 141 Ross
- 143 Sandusky
- 145 Scioto
- 147 Seneca
- 149 Shelby
- 151 Stark
- 153 Summit
- 155 Trumbull
- 157 Tuscarawas
- 159 Union
- 161 VanWert
- 163 Vinton
- 165 Warren
- 167 Washington
- 169 Wayne
- 171 Williams
- 173 Wood
- 175 Wyandot

TENNESSEE 47

- CODE COUNTY NAME
- 001 Anderson
- 003 Bedford
- 005 Benton
- 007 Bledsoe
- 009 Blount
- 011 Bradley

- 013 Campbell
- 015 Cannon
- 017 Carroll
- 019 Carter
- 021 Cheatham
- 023 Chester
- 025 Claiborne
- 027 Clay
- 029 Cocke
- 031 Coffee
- 033 Crockett
- 035 Cumberland
- 037 Davidson
- 039 Decatur
- 041 DeKalb
- 043 Dickson
- 045 Dyer
- 047 Fayette
- 049 Fentress
- 051 Franklin
- 053 Gibson
- 055 Giles
- 057 Grainger
- 059 Greene
- 061 Grundy
- 063 Hamblen
- 065 Hamilton
- 067 Hancock
- 069 Hardeman
- 071 Hardin
- 073 Hawkins
- 075 Haywood
- 077 Henderson
- 079 Henry
- 081 Hickman
- 083 Houston
- 085 Humphreys
- 087 Jackson
- 089 Jefferson
- 091 Johnson
- 093 Knox

- 095 Lake 097 Lauderdale 099 Lawrence 101 Lewis 103 Lincoln 105 Loudon 107 McMinn 109 McNairy 111 Macon Madison 113 Marion 115 Marshall 117 119 Maury 121 Meigs 123 Monroe 125 Montgomery 127 Moore 129 Morgan 131 Obion 133 Overton 135 Perry Pickett 137 Polk 139 141 Putnam 143 Rhea 145 Roane 147 Robertson 149 Rutherford 151 Scott
- 153 Sequatchie
- 155 Sevier
- 157 Shelby
- 159 Smith
- 161 Stewart
- 163 Sullivan
- 165 Sumner
- 167 Tipton
- 169 Trousdale
- 171 Unicoi
- 173 Union

- 175 Van Buren
- 177 Warren
- 179 Washington
- 181 Wayne
- 183 Weakley
- 185 White
- 187 Williamson
- 189 Wilson

VIRGINIA 51

- CODE COUNTY NAME
- 001 Accomack
- 003 Albermarle
- 005 Alleghany
- 007 Amelia
- 009 Amherst
- 011 Appomattox
- 013 Arlington
- 015 Augusta
- 017 Bath
- 019 Bedford
- 021 Bland
- 023 Botetourt
- 025 Brunswick
- 027 Buchanan
- 029 Buckingham
- 031 Campbell
- 033 Caroline
- 035 Carroll
- 036 Charles City
- 037 Charlotte
- 041 Chesterfield
- 043 Clarke
- 045 Craig
- 047 Culpeper
- 049 Cumberland
- 051 Dickenson
- 053 Dinwiddie
- 057 Essex
- 059 Fairfax
- 061 Fauquier
- 063 Floyd

- 065 Fluvanna 067 Franklin Frederick 069 071 Giles 073 Gloucester 075 Goochland 077 Grayson 079 Greene 081 Greensville Halifax 083 085 Hanover Henrico 087 089 Henry 091 Highland 093 Isle of Wight 095 James City 097 King And Queen
- 099 King George
- 101 King William
- 103 Lancaster
- 105 Lee
- 107 Loudoun
- 109 Louisa
- 111 Lunenburg
- 113 Madison
- 115 Mathews
- 117 Mecklenburg
- 119 Middlesex
- 121 Montgomery
- 125 Nelson
- 127 New Kent
- 131 Northampton
- 133 Northumberland
- 135 Nottoway
- 137 Orange
- 139 Page
- 141 Patrick
- 143 Pittsylvania
- 145 Powhatan
- 147 Prince Edward

- 149 Prince George
- 153 Prince William
- 155 Pulaski
- 157 Rappahannock
- 159 Richmond
- 161 Roanoke
- 163 Rockbridge
- 165 Rockingham
- 167 Russell
- 169 Scott
- 171 Shenandoah
- 173 Smyth
- 175 Southampton
- 177 Spotsylvania
- 179 Stafford
- 181 Surry
- 183 Sussex
- 185 Tazewell
- 187 Warren
- 191 Washington
- 193 Westmoreland
- 195 Wise
- 197 Wythe
- 199 York
- WEST VIRGINIA 54
- CODE COUNTY NAME
- 001 Barbour
- 003 Berkeley
- 005 Boone
- 007 Braxton
- 009 Brooke
- 011 Cabell
- 013 Calhoun
- 015 Clay
- 017 Doddridge
- 019 Fayette
- 021 Gilmer
- 023 Grant
- 025 Greenbrier
- 027 Hampshire
- 029 Hancock

031	Hardy
033	Harrison
035	Jackson
037	Jefferson
039	Kanawha
041	Lewis
043	Lincoln
045	Logan
047	McDowell
049	Marion
051	Marshall
053	Mason
055	Mercer
057	Mineral
059	Mingo
061	Monongalia
063	Monroe
065	Morgan
067	Nicholas
069	Ohio
071	Pendleton
073	Pleasants
075	Pocahontas
077	Preston
079	Putnam
081	Raleigh
083	Randolph
085	Ritchie
087	Roane
089	Summers
091	Taylor
093	Tucker
095	Tyler
097	Upshur
099	Wayne
101	Webster
103	Wetzel
105	Wirt
107	Wood
109	Wyoming

OTHER STATES 00

998 - Known County

999 - Unknown County

Appendix E - General Site Codes

The General Site Codes are used for coding several data items: sites of metastases, sites of radiation therapy, and sites of recurrence. The first 44 codes are essentially the same as the first 44 site group codes found in Appendix C, which are based on the ICD-O topography and morphology classifications. General Site Codes from 67 to 99 are additional names of parts of the body that may be useful in coding metastatic or radiation sites.

Code	Description
01	Lip
02	Tongue
03	Salivary Glands
04	Gum/Hard Palate
05	Floor of Mouth
06	Buccal Mucosa
07	Oropharynx
08	Nasopharynx
09	Hypopharynx
10	Other Oral Cavity
11	Esophagus
12	Stomach
13	Small Intestine
14	Colon
15	Rectum/Anus
16	Liver
17	Gallbladder
18	Pancreas
19	Other Digestive Tract
20	Nasal Cavities/Ear
21	Larynx
22	Lung
24	Other Respiratory
25	Bone
26	Connective/Soft Tissue
29	Breast
30	Cervix Uteri
31	Corpus Uteri
32	Ovary
33	Other Female Genital
34	Prostate
35	Testis
36	Other Male Genital
37	Bladder
38	Kidney - Renal Parenchyma
39	Other Urinary Organs

40	Eye
41	Brain
42	Other CNS
43	Thyroid
44	Other Endocrine
66	Skin, NOS
67	Head
68	Neck/Face
69	Mediastinum
71	Arm
72	Axilla
73	Peritoneum
74	Flank
75	Abdomen
76	Pelvis
77	Perineum
78	Bone Marrow
79	Hand
80	Leg
81	Foot
82	Back
83	Mantle - includes cervical, supraclavicular, axillary, hilar, medistinal LN radiation
84	Yoke - Bilateral supraclavicular
85	Lymph nodes
86	Blood
87	Spleen
88	Omentum
89	Retroperitoneum
90	Chest Wall
91	Shoulder
92	Spine
97	Total Body
98	Other III-Defined
99	Unknown

Appendix F - Facility ID Numbers

HOSPITALS

Code	Name	City
510088	BAPTIST HEALTH - CORBIN	CORBIN
510373	BAPTIST HEALTH - LA GRANGE	LAGRANGE
510407	BAPTIST HEALTH - LEXINGTON	LEXINGTON
510375	BAPTIST HEALTH - LOUISVILLE	LOUISVILLE
510670	BAPTIST HEALTH - MADISONVILLE	MADISONVILLE
510815	BAPTIST HEALTH - PADUCAH	PADUCAH
510900	BAPTIST HEALTH - RICHMOND	RICHMOND
510175	BLANCHFIELD ARMY COMM HOSP	FORT CAMPBELL
510956	BLUEGRASS COMMUNITY HOSPITAL	VERSAILLES
510834	BOURBON COMMUNITY HOSPITAL	PARIS
510266	BRECKINRIDGE MEMORIAL HOSPITAL	HARDINSBURG
510874	CALDWELL MEDICAL CENTER	PRINCETON
510081	CARROLL CNTY MEMORIAL HOSPITAL	CARROLLTON
510473	CASEY COUNTY WAR MEMORIAL HOSP	LIBERTY
510970	CLARK COUNTY REG MEDICAL CNTR	WINCHESTER
519001	CLINTON CNTY WAR MEMORIAL HOSP	ALBANY
510680	CRITTENDEN HEALTH SYSTEMS	MARION
519020	CUMBERLAND COUNTY HOSPITAL	BURKESVILLE
510140	EPHRAIM MCDOWELL REGIONAL MC	DANVILLE
510048	FLAGET MEMORIAL HOSPITAL	BARDSTOWN
510172	FLEMING COUNTY HOSPITAL	FLEMINGSBURG
510938	FORT LOGAN HOSPITAL	STANFORD
510195	FRANKFORT REGIONAL MED CENTER	FRANKFORT
510395	GARRARD COUNTY MEMORIAL HOSP	LANCASTER
510230	GEORGETOWN COMMUNITY HOSPITAL	GEORGETOWN
510065	GREENVIEW REGIONAL HOSP, HCA	BOWLING GREEN
510165	HARDIN MEMORIAL HOSPITAL	ELIZABETHTOWN
510275	HARLAN APPALACHIAN REG HOSP	HARLAN
510130	HARRISON MEMORIAL HOSPITAL	CYNTHIANA
510287	HAZARD APPALACHIAN REG MED CTR	HAZARD
510873	HIGHLANDS REGIONAL MED CTR	PRESTONSBURG
510695	JACKSON PURCHASE MEDICAL CTR	MAYFIELD
510280	JAMES B HAGGIN MEMORIAL HOSP	HARRODSBURG
510255	JANE TODD CRAWFORD MEM HOSP	GREENSBURG
510358	JENKINS COMMUNITY HOSPITAL	JENKINS
510330	JENNIE STUART MEDICAL CENTER	HOPKINSVILLE
510510	U OF L HEALTH JEWSIH CAMPUS	LOUISVILLE

510920	U OF L HEALTH SHELBYVILLE	SHELBYVILLE
510082	JOHNSON MATHERS HEALTHCARE	CARLISLE
510359	KENTUCKY RIVER MEDICAL CENTER	JACKSON
510040	KING'S DAUGHTERS' MEDICAL CNTR	ASHLAND
510044	BARBOURVILLE ARH	BARBOURVILLE
510940	LAKE CUMBERLAND REGIONAL HOSP	SOMERSET
519070	LIVINGSTON COUNTY HOSPITAL	SALEM
510915	LOGAN MEMORIAL HOSP	RUSSELLVILLE
510810	LOURDES HOSPITAL	PADUCAH
510355	MARCUM & WALLACE MEMORIAL HOSP	IRVINE
510049	MARSHALL COUNTY HOSPITAL	BENTON
510350	MARY BRECKINRIDGE HOSPITAL	HYDEN
510712	MCDOWELL APPALACHIAN REGIONAL	MCDOWELL
510710	MEADOWVIEW HOSPITAL	MAYSVILLE
510070	MED CENTER AT BOWLING GREEN	BOWLING GREEN
519055	MEDICAL CENTER AT CAVERNA	HORSE CAVE
510203	MEDICAL CENTER AT FRANKLIN	FRANKLIN
510916	MEDICAL CENTER AT SCOTTSVILLE	SCOTTSVILLE
519065	ADVENT HEALTH MANCHESTER	MANCHESTER
510785	MERCY HOSPITAL	OWENSBORO
510560	METHODIST EVANGELICAL HOSPITAL	LOUISVILLE
510320	METHODIST HOSPITAL	HENDERSON
510715	MIDDLESBORO APPALACHIAN REG	MIDDLESBORO
510947	MONROE COUNTY MEDICAL CENTER	TOMPKINSVILLE
510960	MORGAN COUNTY APP REG HOSP	WEST LIBERTY
510260	MUHLENBERG COMMUNITY HOSPITAL	GREENVILLE
510750	MURRAY-CALLOWAY COUNTY HOSP	MURRAY
510795	NEW HORIZON MEDICAL CENTER	OWENTON
510610	NORTON AUDUBON HOSPITAL	LOUISVILLE
10001050	NORTON BROWNSBORO HOSPITAL	LOUISVILLE
510485	NORTON CHILDREN'S HOSPITAL	LOUISVILLE
510488	NORTON HOSPITAL	LOUISVILLE
510575	NORTON SOUTHWEST HOSPITAL	LOUISVILLE
510615	NORTON WOMEN'S AND CHILDREN'S	LOUISVILLE
510283	OHIO COUNTY HOSPITAL	HARTFORD
510042	OUR LADY OF BELLEFONTE HOSP	ASHLAND
510790	OWENSBORO MEDICAL HEALTH SYS	OWENSBORO
510220	PARKWAY REGIONAL HOSPITAL	FULTON
510830	PAUL B HALL REGIONAL MED CTR	PAINTSVILLE
510860	PIKEVILLE MEDICAL CENTER	PIKEVILLE
510870	PINEVILLE COMMUNITY HOSPITAL	PINEVILLE

510745	ROCKCASTLE COUNTY HOSPITAL	MOUNT VERNON
511000	RUSSELL COUNTY HOSPITAL	RUSSELL SPRINGS
510420	SAMARITAN HOSPITAL	LEXINGTON
510400	SPRINGVIEW HOSPITAL	LEBANON
510600	ST ANTHONY MEDICAL CENTER	LOUISVILLE
510717	ST CLAIRE MEDICAL CENTER	MOREHEAD
510969	ST ELIZABETH GRANT COUNTY	WILLIAMSTOWN
510110	ST ELIZABETH EDGEWOOD - COVINGTON	COVINGTON
510685	ST JOSEPH MARTIN HOSPITAL	MARTIN
510184	ST ELIZABETH FT THOMAS	FORT THOMAS
510120	ST ELIZABETH FLORENCE	FLORENCE
510050	ST. JOSEPH BEREA HOSPITAL	BEREA
510440	ST. JOSEPH HOSPITAL	LEXINGTON
510435	ST. JOSEPH HOSPITAL EAST	LEXINGTON
510475	ST. JOSEPH LONDON	LONDON
510740	ST. JOSEPH MOUNT STERLING	MOUNT STERLING
510620	U OF L MARY'S & ELIZABETH	LOUISVILLE
510240	T J SAMSON COMMUNITY HOSPITAL	GLASGOW
510076	TAYLOR REGIONAL HOSPITAL	CAMPBELLSVILLE
510477	THREE RIVERS MEDICAL CENTER	LOUISA
510073	TRIGG COUNTY HOSPITAL	CADIZ
510935	TUG VALLEY REGIONAL MEDICAL CENTER	S WILLIAMSON
510403	TWIN LAKES REGIONAL MED CENTER	LEITCHFIELD
510732	UNION COUNTY METHODIST	MORGANFIELD
510455	UNIVERSITY OF KENTUCKY HOSP	LEXINGTON
510550	UNIVERSITY OF LOUISVILLE HOSP	LOUISVILLE
510180	US IRELAND ARMY COMMUNITY HOSP	FORT KNOX
510470	VA MEDICAL CENTER - LEXINGTON	LEXINGTON
510570	VA MEDICAL CENTER - LOUISVILLE	LOUISVILLE
510708	WAYNE COUNTY HOSPITAL	MONTICELLO
510086	WESTLAKE CUMBERLAND HOSPITAL	COLUMBIA
510967	WHITESBURG APP REG HOSP	WHITESBURG
510935	WILLIAMSON APP REG HOSP	S WILLIAMSON
510950	WOODFORD COUNTY MEMORIAL	VERSAILLES

COMBINED IDS

Code	Name	City
513012	BOWLING GREEN COMBINED	BOWLING GREEN
513014	U OF L HEALTH JEWISH COMBINED	LOUISVILLE
513001	NORTON HEALTHCARE	LOUISVILLE

513009	OWENSBORO MEDICAL HEALTH SYSTEMS	OWENSBORO
513015	ST ELIZABETH HEALTHCARE	COVINGTON
513016	KENTUCKY ONE HEALTH	LEXINGTON
513017	BAPTIST HEALTH CANCER CARE - KY	LOUISVILLE

NON-HOSPITAL FACILITIES

Code	Name	City
518120	ARH CUMBERLAND VALLEY PCC	LYNCH
518096	ASHLAND BELLEFONTE CANCER CTR	ASHLAND
518108	BAPTIST HEALTH CANCER CARE	PADUCAH
518128	BEREA CANCER TREATMENT CENTER	BEREA
518110	BLUE GRASS HEMATOLOGY ONCOLOGY	LEXINGTON
518098	BLUEGRASS CANCER CENTER	FRANKFORT
518026	BLUEGRASS RADIATION ONCOLOGY	CAMPBELLSVILLE
518097	BOWLING GREEN RX ONC ASSOC	BOWLING GREEN
518067	BRANDENBURG PC	BRANDENBURG
518029	CANCER & BLOOD SPECIALISTS	LOUISVILLE
518044	CENTER FOR SURGICAL CARE	FORT THOMAS
518031	CINCINNATI HEM/ONC	CRESTVIEW HILLS
518052	COLORECTAL SURGICAL & GI ASSOC	LEXINGTON
518109	COMMONWEALTH HEMATOLOGY/ONCOL	FRANKFORT
518127	CONSULTANTS IN BLOOD DISORDERS	LOUISVILLE
518114	CRONIN'S CANCER CTR AT LEX CL	LEXINGTON
518053	CUMBERLAND VALLEY SURGERY CTR	CORBIN
518099	DANVILLE RADIATION TX CENTER	DANVILLE
518043	DIAGNOSTIC IMAGING	SHELBYVILLE
518119	DR CATHERINE HELTSLEY	BOWLING GREEN
518129	DR VISA	LONDON
518028	DUPONT MEDICAL IMAGING-NORTON	LOUISVILLE
518021	E. C. GREEN CANCER CENTER	HOPKINSVILLE
518121	EAST TN ONCOLOGY HEMATOLOGY	MIDDLESBORO
518122	E-TOWN ONCOLOGY HEMATOLOGY	ELIZABETHTOWN
518042	FAMILY HLTH CARE CENTER	SCOTTSVILLE
518043	GARDENVIEW WOMENS HLTH SERV	MANCHESTER
518018	GEORGETOWN CANCER TREATMENT CT	GEORGETOWN
518100	GLASGOW RX TX CENTER	GLASGOW
518101	GRAVES GILBERT CLINIC	BOWLING GREEN
518025	HEMATOLOGY & ONCOLOGY CENTER	SOMERSET
518047	HENDERSON CANCER CENTER	HENDERSON

518019	HIGHLANDS CANCER CENTER	PRESTONBURG
518126	JAMES GOULD, MD	PADUCAH
518001	JAMES GRAHAM BROWN CANCER CNTR	LOUISVILLE
518102	JAMES GRAHAM BROWN CLIN/DENTAL	LOUISVILLE
518040	JEWISH CANCER CARE	LOUISVILLE
518023	KENTUCKIANA CANCER INSTITUTE	LOUISVILLE
518104	KENTUCKY CANCER CLINIC	HAZARD
518030	KENTUCKY RAD THERAPY ASSOC	BOWLING GREEN
518103	KINDRED RADIATION CENTER	LOUISVILLE
518056	KNOX FAMILY MEDICINE	BARBOURVILLE
518039	KOSAIR CHILDREN'S MED CENTER	LOUISVILLE
518055	KY DIAGNOSTIC CENTER	EDGEWOOD
518017	LAKE CUMBERLAND AMB SG CENTER	SOMERSET
518057	LEATHERWOOD/BLACKEY MED CTR	CORNETTSVILLE
518058	LEWIS COUNTY PCC	VANCEBURG
518061	LEXINGTON CLINIC	LEXINGTON
518059	LEXINGTON DIAGNOSTIC CENTER	LEXINGTON
518111	LEXINGTON ONCOLOGY ASSOCIATES	LEXINGTON
518060	LEXINGTON SURGERY CENTER	LEXINGTON
518062	LEXINGTON/FAYETTE HEALTH DEPT	LEXINGTON
518130	LOUISVILLE ONCOLOGY(HISTORIC)	LOUISVILLE
518107	LOUISVILLE RADIATION ONCOLOGY	LOUISVILLE
518063	LOUISVILLE SURGERY CENTER	LOUISVILLE
518123	M AZEEM NIAZI, MD	MANCHESTER
518064	MAGNETIC RESONANCE IMAGING	LOUISVILLE
518065	MARTIN COUNTY RADIOLOGY	INEZ
518112	MAYSVILLE CANCER TREATMENT CTR	MAYSVILLE
518066	MCROBERTS MED CLINIC RHC	MCROBERTS
518068	MEDICAL ASSESSMENT CLINIC	LOUISVILLE
518069	MEDICAL HEIGHTS SURG CENTER	LEXINGTON
518070	MENIFEE MEDICAL CENTER	FRENCHBURG
518020	MONTGOMERY CANCER CENTER	MOUNT STERLING
518016	MOREHEAD CANCER TREATMENT CTR	MOREHEAD
518071	MOREHEAD CLINIC	MOREHEAD
518072	MRI ASSOCIATES	LEXINGTON
518022	MT STERLING CANCER TRTMENT CTR	MOUNT STERLING
518073	MUD CREEK CLINIC	GRETHEL
518037	NCI AUDUBON	LOUISVILLE
518046	NCI BARDSTOWN	BARDSTON
518049	NCI CLARKSVILLE	CLARKSVILLE
	1	

518033	NCI JEFFERSONVILLE	JEFFERSONVILLE
518045	NCI LAGRANGE	LAGRANGE
518050	NCI NEW ALBANY	NEW ALBANY
518036	NCI OBC	LOUISVILLE
518032	NCI PAVILLION	LOUISVILLE
518048	NCI RADIATION CENTER NORTHEAST	LOUISVILLE
518035	NCI SHELBYVILLE	SHELBYVILLE
518038	NCI WOMEN AND CHILDREN'S	LOUISVILLE
518074	NEWBURG PRIMARY CARE CENTER	LOUISVILLE
518024	NORTON BROWNSBORO HOSPITAL	LOUISVILLE
518106	ONCOLOGY HEMATOLOGY CARE	CRESTVIEW HILLS
518075	OWENSBORO AMBULATORY SURG	OWENSBORO
518041	OWSLEY BROWN FRAZIER RADIATION	LOUISVILLE
518076	OWSLEY CO MEDICAL CLINIC	BOONEVILLE
518078	PADUCAH AREA PHYSICIANS	PADUCAH
518077	PADUCAH MRI	PADUCAH
518079	PARK DUVALLE COMM HLTH CTR	LOUISVILLE
518080	PARKWAY MEDICAL CLINIC	MANCHESTER
518081	PINE MOUNTAIN CLINIC	BLEDSOE
518027	PREMIER DIAGNOSTICS-NORTON	LOUISVILLE
518137	RADIATION CENTERS OF KY	LOUISVILLE
518082	RED BIRD MOUNTAIN MED CTR	BEVERLY
518113	RICHMOND REGIONAL ONCOLOGY CTR	RICHMOND
518083	SALYERSVILLE HEALTH CARE CTR	SALYERSVILLE
518084	SOMERSET SURGERY CENTER	SOMERSET
518086	SOUTHEASTERN KY. DIAGNOSTIC	CORBIN
518085	SOUTHEASTERN KY RX ONCOLOGY	CORBIN
518015	SOUTHERN KY HEMATOLOGY & ONC	SOMERSET
518087	SPENCER COUNTY RHC	TAYLORSVILLE
518054	ST ELIZABETH IMAGING CENTERS	EDGEWOOD
518088	ST JOHNS HEALTH CLINIC	LOUISVILLE
518089	SURGECENTER OF LOUISVILLE	LOUISVILLE
518090	SURGICAL CTR OF ELIZABETHTOWN	ELIZABETHTOWN
518115	SURGICARE CENTER	PADUCAH
518092	THE EYE SURG CTR OF PADUCAH	PADUCAH
518092 518091	THE EYE SURG CTR OF PADUCAH THE MCPEAK SURGERY CENTER	PADUCAH GLASGOW
518091	THE MCPEAK SURGERY CENTER	GLASGOW
518091 518094	THE MCPEAK SURGERY CENTER TRI STATE REGIONAL CANCER CTR	GLASGOW ASHLAND
518091 518094 518105	THE MCPEAK SURGERY CENTER TRI STATE REGIONAL CANCER CTR U OF L PC CLINICS	GLASGOW ASHLAND LOUISVILLE

518004	UK CLINICS-GYNECOLOGY\ONCOLOGY	LEXINGTON
518009	UK CLINICS-INTERNAL MEDICINE	LEXINGTON
518012	UK CLINICS-KY CLINICS	LEXINGTON
518010	UK CLINICS-KY CLINIC SOUTH	LEXINGTON
518014	UK CLINICS-OPHTHALMOLOGY	LEXINGTON
518008	UK CLINICS-PEDIATRICS	LEXINGTON
518011	UK CLINICS-PLASTICS	LEXINGTON
518007	UK CLINICS-SURGERY	LEXINGTON
518006	UK CLINICS-UROLOGY	LEXINGTON
518002	UNITED RADIATION ONCOLOGY	LEXINGTON
518118	UNIVERSITY OB-GYN	LOUISVILLE
518124	VINAY VERMANI, MD	ASHLAND
518125	WESTERN KY HEMATOLOGY/ONC GRP	PADUCAH
518095	WOOTON RURAL HEALTH CLINIC	WOOTON

FREESTANDING PATHOLOGY LABORATORIES

Code	Name	City
517022	AMERIPATH KENTUCKY	LEXINGTON
517003	ASSOCIATED PATHOLOGY LABS	LEXINGTON
517005	CLINICAL PATH ASSOC	LOUISVILLE
517006	CORBIN PATHOLOGY	CORBIN
517007	CUMBERLAND MEDICAL LABS	SOMERSET
517008	DERMATOLOGISTS	STATEWIDE
517012	FIRST UROLOGY	JEFFERSONVILLE
517013	KY CABINET FOR HUM RES LABS	FRANKFORT
517018	LABCORP, INC.	LOUISVILLE
517032	LABORATORY PHYSICIANS	LOUISVILLE
517014	LABORATORY PHYSICIANS, PSC	LOUISVILLE
517033	LEXINGTON CLINIC PATH LAB	LEXINGTON
517015	LOUISVILLE JEFF CO PUBLIC HLTH	LOUISVILLE
517016	MEDICAL LAB OF HOPKINSVILLE	HOPKINSVILLE
517017	MEDICAL LAB SERVICES	OWENSBORO
517009	MEDICAL LABORATORY CONSULTANTS	LOUISVILLE
517010	NORTON CLINICAL PATH ASSOC	LOUISVILLE
517019	OFFICE PARK DX SERVICES	LEXINGTON
517031	OUT OF STATE LABS	OUTSIDE KY
517020	OWENSBORO MED CTR LAB	OWENSBORO
517021	P&C LABS	LEXINGTON
517023	PATHOLOGY LAB	ERLANGER
517001	QUEST DIAGNOSTICS	LEXINGTON

517024	ROCHE BIOMEDICAL LAB	PADUCAH
517025	ROCHE BIOMEDICAL LAB	LEXINGTON
517026	ROCHE BIOMEDICAL LAB	GLASGOW
517027	SOUTHERN MEDICAL LAB	GLASGOW
517028	TOTAL CARE	PINEVILLE
517029	TROVER CLINIC	MADISONVILLE
517004	U OF L ORAL PATH LAB	LOUISVILLE
517002	UK ORAL PATHOLOGY	LEXINGTON
517030	WL MILL PSC CLINICAL LAB	GREENVILLE

Appendix G - Site Specific Surgery Codes

The site-specific surgery codes are taken from Appendix C of the 2018 SEER Program Coding and Staging Manual, which is based on Appendix B of the ACoS STORE Manual - revised 2018. The surgery codes are identical to STORE but the SEER appendix also contains supplementary annotations, including the 2018 Solid Tumor Rules and EOD coding instructions. It can be found at:

SEER Appendix C

To download the 2018 STORE Manual, go to: https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals

For diagnoses prior to January 1, 2003, use the ROADS surgery codes, which can be found at:

http://seer.cancer.gov/manuals/AppendC.pdf

Appendix H - Therapy Agents

For cases diagnosed from 2005 onward, the SEER Rx software should be used to identify and categorize treatment agents as chemotherapy, hormone agents, immunotherapy or ancillary agents. (Ancillary agents are not considered treatment.) The software is available from the SEER web page: https://see r.cancer.gov/seertools/seerrx/

It looks like this:

) 🛾 🔒 🛛	https://seer.cancer.gov/seertools/seern/			C ^e Q Search	☆ 自 🕹 🏠
Most Visite	ed 😻 Getting Started 🛞				
	NIH Surveillance, I	<mark>ER INSTITUTE</mark> Epidemiology, and	End Results Progr	am	Search SEER
	Cancer Statistics Statistical Summaries Interact	ive Tools Publications	For Researchers Datasets and Software	For Cancer Registrars Coding Rules, Training and Support	About SEER Our Registries and Research
	▲ ► Registrars ► SEER*Rx Interactive	Antineoplastic Drugs Databa	se		
	SEER*Rx Interactive Ant	ineoplastic Drugs	Database		
				earch Dow	vnload Drugs Download Regimens
		_	5	sarch	United Drugs Download Regimens
	Drugs (1860) Regimen (510)			Showing results 1–25	<< < Prev Next > >>
	▲ Name	Category		Primary Site	Code?
	1,25-Dihydroxyvitamin D3	Differentiation inducing a	igent		No
	1-Methyl-D-tryptophan	Chemotherapy		Melanoma, Other types, NOS	Yes
	1018-ISS	Chemotherapy		Lymphoma	Yes
	109881	Chemotherapy		Brain cancer	Yes
	1311-MIBG	Radiation		Neuroblastoma	Yes
	131I-TM-601	Radiation		Glioma	Yes
	17-DMAG	Chemotherapy		Solid tumors	Yes
	2,4-Dinitrochlorobenzene	Biologic therapy (BRM, im	munotherapy)	AIDS, being studied in Melanoma (EORTC Opportunistic infection	C-18851), Yes
	2-Alizapride Hydrochloride	Ancillary Agent			No
	2B1 bispecific murine MAb	Biologic therapy (BRM, im	munotherapy)	Breast cancer, Ovarian cancer	Yes
	4'-Hydroperoxycyclophosphamide	Biologic therapy (BRM, im	munotherapy)	AML, Breast	Yes
	4-Hydroxyphenyl retinamide	Differentiation inducing a	igent	Kaposi's sarcoma, breast	Yes
		Hormones and hormonal	mechanisms	Breast	Yes
	4–Nitroestrone				
	4-Nitroestrone 5'-Inosinic acid polymers	Biologic therapy (BRM, im	munotherapy)		Yes
		Biologic therapy (BRM, im Chemotherapy	munotherapy)	CML	Yes Yes

The rest of Appendix H is to be used for diagnoses made prior to 2005.

THERAPY AGENTS (PRE-2005)
(Alphabetical Listing)
Helpful Information
*Different names for the same agent are separated by commas (,) within a line.
*Individual agents in combo regimens are separated by forward slashes (/).
*Some combo regimens consist of chemotherapy and hormone therapy agents (C, H); both categories should be
entered as therapies.
*When looking up a combo regimen by the individual agents, begin searching for the agent that comes
alphabetically first.
If it is not listed under that agent begin searching for the agent that comes alphabetically next, etc.
Remember that agents listed as a part of a combo regimen may be known by different names (synonyms).
Тhегару Туре
biological response modifiers, otherwise known as immunotherapy

chemotherapy agents
hormone therapy agents
AGENT CROSS-REFERENCE
2-FAS, 2-Fluroadenosine
2-Fluroadenosine, 2-FAS
5-Azacytidine, Azacytidine, AZA
5-azacytidine/Ara-C/Daunomycin/Prednisone/Vincristine, D-AZPO
5-Fluorouracil/Adriamycin/Cytoxan, CAF
5-fluorouracil/Andriamycin/Cytoxan/Methotrexate, CAMF
5-Fluorouridine, F3TDR
5-Fluoruracil, Adrucil, 5-FU
5-FU, Adrucil, 5-Fluoruracil
5-FU/Adriamycin/Cytoxan, FAC
5-FU/Adriamycin/Mitomycin C, FAM
5-FU/Adriamycin/Platinol, FAP
5-FU/BCNU/Dacarbazine/Vincristine, FIVB
5-FU/Cytoxan/Hexamethylmelamine/Methotrexate, HEXA-CAF
5-FU/Cytoxan/Methotrexate, CMF
5-FU/Cytoxan/Methotrexate/Prednisone, FACP
5-FU/Cytoxan/Methotrexate/Prednisone/Vincristine, COMFP
5-FU/Mitomycin C, MF
5-FU/Mitomycin C/Streptozotocin, SMF
5-FU/Mitomycin C/Vincristine, FOMi
5-FU/Mitomycin C/Vindesine, FEMi
5-FU/Mitomycin/Oncovin, MOF
5-FU/Mitomycin/Oncovin/Streptozotocin, MOF-S
6-Mercaptopurine riboside, 6MP
6-Mercaptopurine/Amethopterin/Prednisone/Vincristine, VAMP
6-mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine, POMPA
6-Mercaptopurine/Methotrexate/Prednisone/Vincristine, POMP
6-Methylmercaptopurine riboside, 6-MMPR
6-MMPR, 6-Methylmercaptopurine riboside
6MP, 6-Mercaptopurine riboside
6TG, Thioguanine
6-Thioguanine/Ara-C/Daunomycin, TAD
13-CIS retinoic acid
A3, Chromomycin
AB-121, Meturedepa, TURLOC
ABVD, Adriamycin/Bleomycin/DTIC/Velban
AC, Adriamycin/Cytoxan, cyclophosphamide

ACDA, Anthracenedicarboxaldehyde, Orange crush, Bisantrene
ACE, Adriamycin/Cytoxan/VP-16, etoposide
Acivicin, AT-125
Acla A, adarubicin, Aclacinomycin A
Aclacinomycin A, adarubicin, Acla A
Acridinyl Anisidide, amsacrine, AMSA
ACTD, Cosmegan, Actinomycin D, Dactinomycin
ACTH, Adrenocorticotropin, Corticotropin
Actinomycin D, Dactinomycin, Cosmegan, ACTD
Actinomycin D/Chlorambucil/Methotrexate, MAC
Actinomycin D/DTIC/Vindesine, VAD
AD-32, Adriamycin derivative
Adarubicin, Aclacinomycin A, Acla A
ADCA, Orange Crush, Bisantrene
ADOAP, Adriamycin/Ara-C/Prednisone/Vincristine
ADR, Adriamycin, Doxorubicin
Adrenocorticotropin, Corticotropin, ACTH
Adriamycin derivative, AD-32
Adriamycin, Doxorubicin, ADR
Adriamycin/Ara-C/Prednisone/Vincristine, ADOAP
Adriamycin/BCNU/Prednisone/Vincristine, VBAP
Adriamycin/BCNU/Prednisone/Vindesine, EBAP
Adriamycin/Bleomycin/CCNU/Velban, BCAV
Adriamycin/Bleomycin/DTIC/Velban, ABVD
Adriamycin/Bleomycin/Platinol/Velban, PVBA
Adriamycin/CCNU/Cytoxan/Vincristine, CCV-AV
Adriamycin/CCNU/CytoxanMethotrexate, MACC
Adriamycin/CCNU/Methotrexate/Mitomycin C, MACM
Adriamycin/CIS-platinum/Cytoxan, CAP
Adriamycin/CIS-platinum/Cytoxan, PLAC
Adriamycin/CIS-platinum/Cytoxan/Hexamethylmelamine, CHAP
Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine, CAMP
Adriamycin/Cytoxan, AC, cyclophosphamide
Adriamycin/Cytoxan, CA
Adriamycin/Cytoxan/BCNU/Prednisone, BCAP
Adriamycin/Cytoxan/Bleomycin/Oncovin/Prednisone, BACOP
Adriamycin/Cytoxan/DTIC/Vincristine, CYVADIC
Adriamycin/Cytoxan/Epipodophyllotoxin/Methotrexate/Prednisone, PRO-MACE
Adriamycin/Cytoxan/Hexamethylmelamine, CAH
Adriamycin/Cytoxan/Methotrexate, CAM
Adriamycin/Cytoxan/Platinol, PAC-5

Adriamycin/Cytoxan/Prednisone/Procarbazine/Vincristine, CHOPP
Adriamycin/Cytoxan/Prednisone/Vincristine, CHOP
Adriamycin/Cytoxan/Prednisone/Vincristine, VCAP
Adriamycin/Cytoxan/Tamoxifen, TAC
Adriamycin/Cytoxan/Tamoxifen/Vincristine, TACO
Adriamycin/Cytoxan/Vincristine, CAV
Adriamycin/Cytoxan/Vincristine, VAC
Adriamycin/Cytoxan/Vincristine/VP-16, CAVV
Adriamycin/Cytoxan/Vincristine/VP-16, EVAC
Adriamycin/Cytoxan/VP-16, ACE, etoposide
Adriamycin/Mitomycin C, MA
Adriamycin/Platinol, PA
Adriamycin/Procarbazine/Vindesine, VAP
Adriamycin/Vincristine, AV
Adrucil, 5-Fluoruracil, 5-FU
Alanosine
Aldara, Imiquinod
Aldesleukin, Proleukin
Alemtuzumab, Campath
Alimta
Alkeran, Melphalan, L-PAM, L-Phenylalanine Mustard, Phenylalamine Mustard
Alkeran/Prednisone, AP
Altretamine, Hexalen
Amethopterin, Methotrexate, MTX
Aminoglutethimide, Cytodren, Elipten
Aminopterin, APGA
Aminothiadiazole, ATDA
Amnestrogen
Amonofide, nafidimide, Ara A
AMSA, Acridinyl anisidide, Amsacrine
AMSA/CIS-platinum/Vindesine, APPLE
Amsacrine, Acridinyl anisidide, AMSA
Anastrozole, Arimidex
Anguidine
Aniline Mustard
Anthracenedicarboxaldehyde, ACDA, Orange crush, Bisantrene
AP, Alkeran/Prednisone
APGA, Aminopterin
APPLE, AMSA/CIS-platinum/Vindesine
Ara A, nafidimide, Amonofide
Ara-C, Cytarabine, Cytosar, Cytosine Arabinoside, Cytoclne Arabinoside

Ara-C/Daunorubicin, DA
Ara-C/DNR, Cytosar/Daunorubicin
Ara-C/PrednisoneRubidazone/Vincristine, ROAP
Ara-C/TG, Cytosar/Thioguanine
Arimidex, Anastrozole
Aromasin, Exemestane
Arsenic trioxide, Trisenox
Asparaginase
AT-125, Acivicin
Atabrine, Quinacrine, QUIN
ATDA, Aminothiadiazole
AV, Adriamycin/Vincristine
AZA, 5-Azacytidine, Azacytidine
Azacytidine, 5-Azacytidine, AZA
AZAG, Azaguanine
Azaguanine, AZAG
AZAS, Azaserine
Azaserine, AZAS
AZAT, Azathioprine
Azathioprine, AZAT
Azauracil, AZU
Azauridine, AZUR
Aziridinylbenzoquinone, AZQ
AZOT, Azotomycin
Azotomycin, AZOT
AZQ, Aziridinylbenzoquinone
AZU, Azauracil
AZUR, Azauridine
Bacillus of Calmette-Connaught, BCG-Connaught
Bacillus of Calmette-Guerin, BCG
Bacillus of Calmette-Pasteur, BCG-Pasteur
Bacillus of Calmette-Tice, BCG-Tice
BACOP, Adriamycin/Cytoxan/Bleomycin/Oncovin/Prednisone
BAF, Triazinate, Baker's Antifol
Baker's Antifol, Triazinate, BAF
Bayer 305, Moryanly, Sodium Suramin
BCAP, Adriamycin/Cytoxan/BCNU/Prednisone
BCAV, Adriamycin/Bleomycin/CCNU/Velban
BCG, Bacillus of Calmette-Guerin
BCG-Connaught, Bacillus of Calmette-Connaught
BCG-Pasteur, Bacillus of Calmette-Pasteur

DOW	l, Mannomustine
всм	IF, Bleomycin/Cytoxan/Fluorouracil/Methotrexate
BCN	U, Carmustine
BCN	U/Bleomycin/Hexamethylmelamine/Velban, HEXA-BVB
BCN	U/Cytoxan/Methotrexate/MGBG/Vincristine, BCOMM
BCN	U/Cytoxan/Oncovin/Prednisone, BCOP
BCN	U/Cytoxan/Prednisone/Procarbazine/Vincristine, BVCPP
BCN	U/DTIC/Hydroxyurea, BHD
BCN	U/DTIC/Vincristine, BVD
BCN	U/Prednisone/Procarbazine/Vincristine, BOPP
всо	MM, BCNU/Cytoxan/Methotrexate/MGBG/Vincristine
всо	P, BCNU/Cytoxan/Oncovin/Prednisone
BCP	, Cytoxan/BCNU/Prednisone
BDC	A, Diammine platinum, Carboplatin, CBDCA
Beta	methasone, Celestone
Beta	-TGdR, BTGR
Bexa	arotene, Targretin, LGD 1069
BHD	, BCNU/DTIC/Hydroxyurea
Bical	utamide, Casodex
Bisar	ntrene, Orange crush, Anthracenedicarboxaldehyde, ACDA
Blen	oxane, Bleomycin. BLEO
BLE	O, Blenoxane, Bleomycin
Bleo	mycin, Blenoxane, BLEO
Bleo	mycin/CIS-platinum/Velban, CVB
Bleo	mycin/Cytoxan/Fluorouracil/Methotrexate, BCMF
Bleo	mycin/Metomycin C, BM
Bleo	mycin/Mitomycin C/Vincristine, MOB
Bleo	mycin/Platinol/Velban, PVB
BM,	Bleomycin/Metomycin C
Bone	Marrow Transplant
BOP	P, BCNU/Prednisone/Procarbazine/Vincristine
Brom	nocriptine
Brom	nodeoxyuridine, BUDR
Bruc	eantin
BTG	R, Beta-TGdR
BUD	R, Bromodeoxyuridine
BUS	, Busulfan, Myleran
Busu	Ilfan, Myleran, BUS
Buta	noic Acid, Indicine-N-oxide

AVD, BCNU/DTIC/Vincristine SA, Adriamycin/Cytoxan SAF, 5-Fluorouracil/Adriamycin/Cytoxan SAH, Adriamycin/Cytoxan/Hexamethylmelamine SAL, Calusterone, Methosarb Salusterone, Methosarb Salusterone, Methosarb, CAL SAM, Adriamycin/Cytoxan/Methotrexate SAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate SAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate SAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate SAMP, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Sampath, Alemtuzumab Samptosar, Irinotecan Samptothecin Sapetitabine, Xeloda Saracemide Sarbostrol Saracemide Sarbostrol Sarmustine, BCNU Sarodex, Bicalutamide SAVV, Adriamycin/Cytoxan/Vincristine SAVV, Adriamycin/Cytoxan/Vincristine/P-16 SBDCA, Carboplatin, Diammine platinum, BDCA
AF, 5-Fluorouracil/Adriamycin/Cytoxan AH, Adriamycin/Cytoxan/Hexamethylmelamine AL, Calusterone, Methosarb Calusterone, Methosarb Calusterone, Methosarb, CAL AM, Adriamycin/Cytoxan/Methotrexate CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate/Procarbazine Campath, Alemtuzumab Camptosar, Irinotecan Camptosar, Irinotecan CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
AH, Adriamycin/Cytoxan/Hexamethylmelamine AL, Calusterone, Methosarb Calusterone, Methosarb, CAL CAM, Adriamycin/Cytoxan/Methotrexate CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate CAMP, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Campath, Alemtuzumab Campatosar, Irinotecan Campatosar, Irinotecan Campatohecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Caracemide Caracemide Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
SAL, Calusterone, Methosarb Salusterone, Methosarb, CAL SAM, Adriamycin/Cytoxan/Methotrexate SAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate SAMF, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Sampath, Alemtuzumab Samptosar, Irinotecan Samptothecin SAP, Adriamycin/CIS-platinum/Cytoxan Sapecitabine, Xeloda Saracemide Saracemide Sarmustine with Prolifeprosan 20 Implant, Gliadel Wafer Sarmustine, BCNU Sasodex, Bicalutamide SAV, Adriamycin/Cytoxan/Vincristine SAV, Adriamycin/Cytoxan/Vincristine/VP-16
Calusterone, Methosarb, CAL CAM, Adriamycin/Cytoxan/Methotrexate CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate CAMP, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Campath, Alemtuzumab Camptosar, Irinotecan Camptosar, Irinotecan Camptothecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
CAM, Adriamycin/Cytoxan/Methotrexate CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate CAMP, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Campath, Alemtuzumab Camptosar, Irinotecan Camptosar, Irinotecan CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
CAMF, 5-fluorouracil/Andriamycin/Cytoxan/Methotrexate CAMP, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Campath, Alemtuzumab Camptosar, Irinotecan Camptothecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
CAMP, Adriamycin/Cyclophosphamide/Methotrexate/Procarbazine Campath, Alemtuzumab Camptosar, Irinotecan Camptothecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
Campath, Alemtuzumab Camptosar, Irinotecan Camptothecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carbostrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
Camptosar, Irinotecan Camptothecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine
Camptothecin CAP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
AP, Adriamycin/CIS-platinum/Cytoxan Capecitabine, Xeloda Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
Caracemide Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine/VP-16
Carbestrol Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine CAVV, Adriamycin/Cytoxan/Vincristine/VP-16
Carboplatin, Diammine platinum, BDCA, CBDCA Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine CAVV, Adriamycin/Cytoxan/Vincristine/VP-16
Carmustine with Prolifeprosan 20 Implant, Gliadel Wafer Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine CAVV, Adriamycin/Cytoxan/Vincristine/VP-16
Carmustine, BCNU Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine CAVV, Adriamycin/Cytoxan/Vincristine/VP-16
Casodex, Bicalutamide CAV, Adriamycin/Cytoxan/Vincristine CAVV, Adriamycin/Cytoxan/Vincristine/VP-16
CAV, Adriamycin/Cytoxan/Vincristine
CAVV, Adriamycin/Cytoxan/Vincristine/VP-16
BDCA, Carboplatin, Diammine platinum, BDCA
CNU, Lomustine
CNU/Cytoxan/Procarbazine/Vincristine, POCC
CNU/Cytoxan/Vincristine, CCV
CNU/Procarbazine/Vincristine, PCV
CSG, L-asparaginase/Prednisone/Vincristine
CCV, CCNU/Cytoxan/Vincristine
CCV-AV, Adriamycin/CCNU/Cytoxan/Vincristine
C-DDP, Platinol, CIS-platinum, cisplatin
Celestone, Betamethasone
CHAP, Adriamycin/CIS-platinum/Cytoxan/Hexamethylmelamine
HIP
CHL, Chlorambucil, Leukeran
Chlorambucil, Leukeran, CHL
Chlormadinone acitate
Chlorotrinanisene, TACE
Chlorozotocin, DCNU
CHOP, Adriamycin/Cytoxan/Prednisone/Vincristine

С	nromomycin, A3
С	splatin, Platinol, C-DDP, CIS-Platinum
С	S-platinum, Platinol, C-DDP, cisplatin
С	adrabine, Leustatin
С	MC, Cytoxan/Lomustine/Methotrexate
С	MF, 5-FU/Cytoxan/Methotrexate
С	MFVP, Cytoxan/Fluorouracil/Methotrexate/Prednisone/Vincristine
С	MOPP, Cytoxan/Methotrexate/Oncovin/Prednisone/Procanbazine
С	OAP, Cytosine arabinoside/Cytoxan/Prednisone/Vincristine
С	blchicine
С	DM, Cytoxan/Methotrexate/Vincristine
С	OMFP, 5-FU/Cytoxan/Methotrexate/Prednisone/Vincristine
С	OMP, Cytoxan/Methotrexate/Prednisone/Vincristine
С	ompound E, Cortisone acetate
С	onjugated Estrogens
С	OP, Cytoxan/Prednisone/Vincristine
С	oparvax, C-Parvum, Corynebacterium Parvum, CPAR
С	orticotropin, ACTH, Adrenocorticotropin
С	ortisone acetate, Compound E
С	orynebacterium Parvum, C-Parvum, Coparvax, CPAR
С	osmegan, Actinomycin D, Dactinomycin, ACTD
С	bumarin
С	PAR, C-Parvum, Corynebacterium Parvum, Coparvax
C	Parvum, Corynebacterium Parvum, Coparvax CPAR
С	PT-11
C	TB, Cytembena
C	TX, Neosar, Cyclophosphamide, Cytoxine, Cytoxan
C	/B, Bleomycin/CIS-platinum/Velban
C	vclo-C, Cyclocytidine
C	vclocytidine, Cyclo-C
C	vclo-L, Cycloleucine
C	vcloleucine, Cyclo-L
C	vclophosphamide, AC, Adriamycin/Cytoxan
C	vclophosphamide, Cytoxine, Neosar, CTX, Cytoxan
C	vproterone acetate
C	/tarabine liposomal, Depocyt
C	vtarabine, Cytosar, Cytosine Arabinoside, Ara-C
C	/tembena, CTB
C	vtoclne Arabinoside, Cytosine Arabinoside, Ara-C, Cytosar, Cytarabine

Cytosar, Cytosine Arabinoside, Cytoclne Arabinoside, Cytarabine, Ara-C
Cytosar/Daunorubicin, Ara-C/DNR
Cytosar/Thioguanine, Ara-C/TG
Cytosine Arabinoside, Cytoclne Arabinoside, Cytosar, Cytarabine, Ara-C
Cytosine arabinoside/Cytoxan/Prednisone/Vincristine, COAP
Cytoxan, Cyclophosphamide, CTX, Neosar, Cytoxine
Cytoxan/BCNU/Prednisone, BCP
Cytoxan/Fluorouracil/Methotrexate/Prednisone/Vincristine, CMFVP
Cytoxan/Lomustine/Methotrexate, CMC
Cytoxan/Methotrexate/Oncovin/Prednisone/Procanbazine, C-MOPP
Cytoxan/Methotrexate/Prednisone/Vincristine, COMP
Cytoxan/Methotrexate/Vincristine, COM
Cytoxan/Prednisone/Vincristine, COP
Cytoxine, Cyclophosphamide, Neosar, CTX, Cytoxan
CYVADIC, Adriamycin/Cytoxan/DTIC/Vincristine
DA, Ara-C/Daunorubicin
Dacarbazine, DTIC
Dactinomycin, Actinomycin D, Cosmegan, ACTD
DAG, Dianhydrogaloctitol
Danazol
Daraprim/Dexamethasone/Oncovin/Thioquanine, TODD
Daunomycin, Daunorubicin, DNR
Daunorubicin liposomal, Daunoxome
Daunorubicin, Daunomycin, DNR
Daunoxome, Daunorubicin liposomal
D-AZPO, 5-azacytidine/Ara-C/Daunomycin/Prednisone/Vincristine
DBD, Dibromodulcitol
DBM, Dibromolannitol
DCM, Dichloromethotrexate
DCNU, Chlorozotocin
DDMP, Meteprine
Deazauridine
DECA*, Dexamethasone*, Decadron*
Decadron*, DECA*, Dexamethasone*
Denileukin diftitox, Ontak
Deoxycoformycin, Nipent, Pentostatin
Deoxydoxorubincin
Deoxyspergualin
Depo Provera, Medroxyprogesterone Acetate
Depocyt, Cytarabine liposomal
DES, Diethylstilbestrol, Stilbesterol

Dexamethasone*, Decadron*, DECA*	
DHAD, Mitoxantrone, Dihydroxyanthracenedione	
DHEA Mustard, DHEA	
DHEA, DHEA Mustard	
Diammine platinum, Carboplatin, BDCA, CBDCA	
Dianhydrogaloctitol, DAG	
Dibromodulcitol, DBD	
Dibromolannitol, DBM	
Dichloromethotrexate, DCM	
Diethylstilbestrol, Stilbesterol, DES	
Diglycoaldehyde, STGdR	
Dihydro-5Azacytidine	
Dihydropenperone	
Dihydroxyanthracenedione, Mitoxantrone, DHAD	
Dimethisterone	
Dimethyl Sulfoxide, DMSO	
DMSO, Dimethyl Sulfoxide	
DNCB	
DNR, Daunomycin, Daunorubicin	
Docetaxel, Taxotere	
DON, Duazomycin	
Doxil, Doxorubicin liposomal	
Doxorubicin liposomal, Doxil	
Doxorubicin liposomal, Doxil	
Doxorubicin, Adriamycin, ADR	
Drolban, Dromostanolone propionate	
Dromostanolone propionate, Drolban	
DTIC, Dacarbazine	
Duazomycin, DON	
DVA, Vindesine	
EBAP, Adriamycin/BCNU/Prednisone/Vindesine	
Echinomycin, Quinomycin A	
Eligard, Leuprolide acetate	
Elipten, Aminoglutethimide, Cytodren	
Ellence, Epirubicin, Epi-Doxorubicin, Epi	
Eloxatine, Oxaliplatin	
Elspar, L-Asparaginase, L-ASP	
Emcyt, Estramustine	
EMET, Emetine HCI	
Emetine HCI, EMET	

Epi-Doxorubicin, Epirubicin, Ellence, Epl Epirubicin, Epi-Doxorubicin, Ellence, Epl Epratuzumab Equilin Ergamisol, Levamisole Estradiol Estradiol Estranustine, Emcyt Estriol Estrone Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethisterone, Hydroxprogesterone Ethopohos, Etoposide phosphate Etopophos, Etoposide phosphate Etopophos, Etoposide phosphate Etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etuexin, Flutamide EtVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Flu/Adriamycin/Cytoxan
Epratuzumab Equilin Ergamisol, Levamisole Estradiol Estradiol Estranustine, Emcyt Estriol Estrone Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethiynediol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Etulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Equilin Equilin Ergamisol, Levamisole Estradiol Estradiol Estramustine, Emcyt Estriol Estriol Estrone Ethidium Chloride Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Etaposide, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Ergamisol, Levamisole Estradiol Estradiol Estradiol Estramustine, Emcyt Estriol Estrone Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etopophase Etopophos, Etopophos etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etuexin, Flutamide EVAC, Adriamycin/Cytoxan/VI-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan/Prednisone
Estradiol Estramustine, Emcyt Estriol Estrone Ethidium Chloride Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EtVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Estemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Estramustine, Emcyt Estriol Estrone Ethidium Chloride Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Estriol Estrone Ethidium Chloride Ethidium Chloride Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Estrone Ethidium Chloride Ethidium Chloride Ethinyl estradiol Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Ethidium Chloride Ethinyl estradiol Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
Ethinyl estradiol Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Ethisterone, Hydroxprogesterone Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Ethynodiol Diacetate Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan
Etopophos, Etoposide phosphate Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
Etoposide phosphate, Etopophos etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
etoposide, ACE, Adriamycin/Cytoxan/VP-16 Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
Etoposide, VP-16-213, VP-16 Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
Eulexin, Flutamide EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
EVAC, Adriamycin/Cytoxan/Vincristine/VP-16 Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
Exemestane, Aromasin F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
F3TDR, 5-Fluorouridine FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
FAC, 5-FU/Adriamycin/Cytoxan FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
FACP, 5-FU/Cytoxan/Methotrexate/Prednisone
FAM 5-FU/Adriamycin/Mitomycin C
, in, or on an any one monitority on o
FAP, 5-FU/Adriamycin/Platinol
Fareston, Toremifene
Faslodex, Fulvestrant
Femara, Letrozole
FEMi, 5-FU/Mitomycin C/Vindesine
FIVB, 5-FU/BCNU/Dacarbazine/Vincristine
Flavone Acetic Acid
Floxuridine, FUDR
Fludarabine Phosphate
Fluorouracil
Fluoxymesterone, Halotestin, HAL
Fluprednisolone
Flutamide, Eulexin
FOMi, 5-FU/Mitomycin C/Vincristine
FUDR, Floxuridine
Fulvestrant, Faslodex

Gallum Nitrate, GA(N03)3 Gefrinib, ZD 1839, Iressa Gemcitabine, Gemzar Gemtuzumab-acogamicin, Mylotarg Gemzar, Gemcitabine Gemzar, Gemcitabine Gelevec, Imatinib mesylate Giladel Wafer, Carmustine with Prolifeprosan 20 Implant Guanazole HAL, Fluoxymesterone, Halotestin Halotestin, HAL, Fluoxymesterone Herx-PVB, BCNU/Bieornycin/Hexamethylmelamine/Velban HEXA-EVAF, S-FU/Cytoxan/Hexamethylmelamine/Velban Hexamethylmelamine, HXM Hexamethylmelamine, Mtornycin C/Velban, HVM Hexamethylmelamine/Mtotrexate/VP-16, MVH Hexamethylmelamine/Mtotrexate/VP-16, MVH Hexamethylmelamine/Mtotreycate/VP-16, MVH Hexamethylmelamine/Mtornycin C/Velban, HVM Hexamethylmelamine/Mtornycin C/Velban, HVM HVMA HVM, Hexamethylmelamine/Mtornycin C/Velban HVM, Hexamethylmelamine/Mto	GA(N03)3, Gallium Nitrate
Gemcitabine, Gemzar Gemcitabine Gemzar, Gemcitabine Gemzar, Gemcitabine Giadel Water, Carmustine with Prolifeprosan 20 Implant Guanazole HAL, Fluxymesterone, Halotestin Halotestin, HAL, Fluxymesterone Harceptin, Trastuzumab Herceptin, Trastuzumab HEXA-EVB, BCNU/Bleomycin/Nexamethylmelamine/Velban HEXA-FS, 5-FU/Cytoxan/Nexamethylmelamine/Velban Hexaten, SFU/Cytoxan/Nexamethylmelamine/Velban Hexaten, SFU/Cytoxan/Nexamethylmelamine/Velban Hexaten, SFU/Cytoxan/Nexamethylmelamine/Velban Hexatentylmelamine/Methotrexate Hexatentylmelamine/Methotrexate Hexatentylmelamine/Velban Hexatentylmelamine/Velban Hexatentylmelamine/Nethotrexate Hexatentylmelamine/Nethotrexate/P-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Mitomycin C/Velban, HVM Hexarentylmelamine/Methotrexate/VP-16, MVH Hexarentylmelamine/Mitomycin C/Velban, HVM Hexarentylmelamine/Mitomycin C/Velban HNZ, Nustargen, Nitrogen Mustard, Mechlorethamine HVD, Oxymetholone HVZ, Hexarentylmelamine/Mitomycin C/Velban HVM, Hexarentylmelamine/Mitomycin	Gallium Nitrate, GA(N03)3
Gemtuzumab-ozogamicin, Mylotarg Gemzar, Gemcitabine Gileovec, Imatinib mesylate Giladel Wafer, Carmustine with Prolifeprosan 20 Implant Guanazole HAL, Fluoxymesterone, Halotestin Halotestin, HAL, Fluoxymesterone Herceptin, Trastuzumab HEX-A-BVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEX-A-FS, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexamethylmelamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexamethylmelamine/Mitomycin C/Velban, HVM Hexamethylmelamine/Mitomycin C/Velban HVX, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, Hydroxyurea, HU Hydroxyurea, Hydroxyurea, HU Hydroxyurea, Hydrea, Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idarwicin, Idarubicin Idarwicin, Idarubicin Idoxurdine, IDU IDU, Idoxurdine IF, Interferon, Interfeukan 2 IFOS, Isophosphamide, IFOS	Gefitinib, ZD1839, Iressa
Gemzar, Gemcitabine Gleevec, Imatinib mesylate Gliadel Wafer, Carmustine with Prolifeprosan 20 Implant Guanazole HAL, Fluoxymesterone, Halotestin Halotestin, HAL, Fluoxymesterone Harceptin, Trastuzumab HEXA-EVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxar/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxar/Hexamethylmelamine/Methotrexate Hexamethylmelamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mtiomycin/Velban, HVM Hexamethylmelamine/Mtiomycin/C/Velban, HVM Hexamethylmelamine/Mtiomycin/C/Velban, HVM Hexamethylmelamine/Mtiomycin/C/Velban, HVM Hexamethylmelamine/Mtiomycin/C/Velban, HVM Hexamethylmelamine/Mtiomycin/C/Velban, HVM Hexamethylmelamine/Mtiomycin C/Velban, HVM Hexamethylmelamine/Mtiomycin C/Velban, HVM Hexamethylmelamine/Mtiomycin C/Velban HVJ, Aystargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mtiomycin C/Velban HVZ, Mustargen, Nitrogen Kustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mtiomycin C/Velban HVZ, Mustargen, Nitrogen Kustard, Mechlorethamine HU, Hydrea, Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idarubicin, Idaruycin Idarubicin, Idaruycin Idoxuridine, IDU IDU, Idoxuridine, IDU IDU, Idoxuridine, IDU IDU, Idoxuridine, ICOS Inatinib mesylate, Gleevec Iniquinod, Aldara	Gemcitabine, Gemzar
Glevec, Inatinib mesylate Gliadel Wafer, Carmustine with Prolifeprosan 20 Implant Guanazole HAL, Fluoxymesterone, Halotestin Halotestin, HAL, Fluoxymesterone Herceptin, Trastuzumab HEXA-ESVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexalen, altretamine Hexalen, altretamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HNZ, Mustargen, Nitrogen Mustard, Mechlorethamine HV, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban Hydrocortisone* Hydrocortisone* Hydrocortisone* Hydrocortisone* Hydroxyurea, HU Idarubicin, Idaruycin Idoxuridine, IDU IDU, Idoxuridine, IDU IDU, Idoxuridine, ISophosphamide, IFOS Imatinib mesylate, Gleevec </td <td>Gemtuzumab-ozogamicin, Mylotarg</td>	Gemtuzumab-ozogamicin, Mylotarg
Glevec, Inatinib mesylate Gliadel Wafer, Carmustine with Prolifeprosan 20 Implant Guanazole HAL, Fluoxymesterone, Halotestin Halotestin, HAL, Fluoxymesterone Herceptin, Trastuzumab HEXA-ESVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexalen, altretamine Hexalen, altretamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HNZ, Mustargen, Nitrogen Mustard, Mechlorethamine HV, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban Hydrocortisone* Hydrocortisone* Hydrocortisone* Hydrocortisone* Hydroxyurea, HU Idarubicin, Idaruycin Idoxuridine, IDU IDU, Idoxuridine, IDU IDU, Idoxuridine, ISophosphamide, IFOS Imatinib mesylate, Gleevec </td <td>Gemzar, Gemcitabine</td>	Gemzar, Gemcitabine
Guanazole HAL, Fluxxymesterone, Halotestin Halotestin, HAL, Fluxxymesterone Herceptin, Trastuzumab HEXA-BVB, BCNU/Bloomycin/Hexamethylmelamine/Netbotrexate HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Netbotrexate Hexalen, altretamine Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexastrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HV, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban Hydroxyurea, HU <	
HAL, Fluoxymesterone, Halotestin Halotestin, HAL, Fluoxymesterone Herceptin, Trastuzumab HEXA-BVB, BCNU/Bleomycin/Hexamethylmelamine/Nethotrexate HEXA-BVB, BCNU/Bleomycin/Hexamethylmelamine/Nethotrexate Hexalen, altretamine Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexestrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban HVM, Hexamethylmelamine/Mitomycin C/Velban Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idarubicin Idarubicin, idarubicin Idarubicin, idarubicin <td>Gliadel Wafer, Carmustine with Prolifeprosan 20 Implant</td>	Gliadel Wafer, Carmustine with Prolifeprosan 20 Implant
Halotestin, HAL, Fluoxymesterone Herceptin, Trastuzumab HEXA-BVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexalen, altretamine Hexanethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexarethylmelamine/Mitomycin C/Velban, HVM Hexestrol HMD, Oxymetholone HND, Oxymetholone HV, Mydrea, Hydroxyurea HVK, Hexamethylmelamine/Mitomycin C/Velban HVK, Hexamethylmelamine/Mitomycin C/Velban HVK, Hexamethylmelamine/Mitomycin C/Velban HVM, Hexamethylmelamine/Mitomycin C/Velban HVM, Hexamethylmelamine/Mitomycin C/Velban HVM, Hexamethylmelamine/Mitomycin C/Velban HVM, Hexamethylmelamine/Mitomycin C/Velban Hydrea, Hydroxyurea, HU Hydroxortisone* Hydroxortisone* Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idarubicin Idarubicin, Idarubicin Idarubicin, Idarubicin Idarubicin, Idarubicin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 <	Guanazole
Herceptin, Trastuzumab HEXA-BVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexalen, altretamine Hexanethylmelamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexarethylmelamine/Mitomycin C/Velban, HVM Hexastrol HMBA HMD, Oxymetholone HVD, Nymetholone HVM, Hexamethylmelamine/Mitomycin C/Velban Hydrea, Hydroxyurea HVM, Hexamethylmelamine Hycamtin, Topotecan Hydroxprogesterone, Ethisterone Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idarubicin Idarubicin, idarubicin Idurycin, Interleukan 2 IFOS, Isophosphamide, IfOS Imalinib mesylate, Gleevec Imalinib mesylate, Gleevec Imalinib mesylate, Gleevec	HAL, Fluoxymesterone, Halotestin
HEXA-BVB, BCNU/Bleomycin/Hexamethylmelamine/Velban HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexalen, altretamine Hexamethylmelamine, MXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HV2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hydroxyurea, Hydroxyurea Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, Idarubicin Idarubicin, Idarubicin Idarubicin, Idarubicin Iduxuridine, IDU IDU, Idoxuridine IF, Interferon, Interlexan 2 IFOS Imatinib mesylate, Gleevec Imatinib mesylate, Gleevec	Halotestin, HAL, Fluoxymesterone
HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate Hexalen, altretamine Hexamethylmelamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycanthone mesylate Hydrea, Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Herceptin, Trastuzumab
Hexalen, altretamine Hexamethylmelamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitorycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycantin, Topotecan Hydrea , Hydroxyurea, HU Hydrea , Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine IPO, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, IFoS Imatinib mesylate, Gleevec Imiquinod, Aldara	HEXA-BVB, BCNU/Bleomycin/Hexamethylmelamine/Velban
Hexamethylmelamine, HXM Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban Hydrea, Hydroxyurea Hycamtin, Topotecan Hycamtin, Topotecan Hydrea, Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idarubicin Idarubicin Idarubicin Idarubicin, Idarubicin Idoxuridine, IDU IDU, Idoxuridine IFOS, Isophosphamide, Ifosfamide IFoS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imquinod, Aldara	HEXA-CAF, 5-FU/Cytoxan/Hexamethylmelamine/Methotrexate
Hexamethylmelamine/Methotrexate/VP-16, MVH Hexamethylmelamine/Mitomycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban Hycantin, Topotecan Hydrea, Hydroxyurea, HU Hydrea, Hydroxyurea, HU Hydrea, Hydroxyurea, HU Idarubicin Idarubicin Idarubicin, Idarubicin Idarubicin, Idarubicin Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imquinod, Aldara	Hexalen, altretamine
Hexamethylmelamine//Mitomycin C/Velban, HVM Hexestrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine//Mitomycin C/Velban HXM, Hexamethylmelamine Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxprogesterone, Ethisterone Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imatinib mesylate, Gleevec	Hexamethylmelamine, HXM
Hexestrol HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycamtin, Topotecan Hydrea, Hydroxyurea, HU Hydrocortisone* Hydroxyurea, HU Hydroxyurea, Hydroxyurea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IFOS, Isophosphamide, IfoSfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Hexamethylmelamine/Methotrexate/VP-16, MVH
HMBA HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycamtin, Topotecan Hydrea , Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Hydroxyurea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IFOS, Isophosphamide, IfoSfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imatinib mesylate, Gleevec	Hexamethylmelamine/Mitomycin C/Velban, HVM
HMD, Oxymetholone HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine/Mitomycin C/Velban Hycantin, Topotecan Hycanthone mesylate Hydroxyurea, HU Hydroxprogesterone, Ethisterone Hydroxyurea, HU Idamycin, Idarubicin Idavubicin, idamycin IbU, Idoxuridine IFOS, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imatinib mesylate, Gleevec	Hexestrol
HN2, Mustargen, Nitrogen Mustard, Mechlorethamine HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycanthin, Topotecan Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxyurea, HU Hydroxyurea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	НМВА
HU, Hydrea, Hydroxyurea HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycantin, Topotecan Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxprogesterone, Ethisterone Hydroxyurea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, IfoS Imatinib mesylate, Gleevec Imiquinod, Aldara	HMD, Oxymetholone
HVM, Hexamethylmelamine/Mitomycin C/Velban HXM, Hexamethylmelamine Hycamtin, Topotecan Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxyurea, Hydrea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFoS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	HN2, Mustargen, Nitrogen Mustard, Mechlorethamine
HXM, Hexamethylmelamine Hycamtin, Topotecan Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxyurea, Hydrea, HU Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	HU, Hydrea, Hydroxyurea
Hycamtin, Topotecan Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxprogesterone, Ethisterone Hydroxyurea, Hydrea, HU Idarnycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IPU, Idoxuridine IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	HVM, Hexamethylmelamine/Mitomycin C/Velban
Hycanthone mesylate Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxprogesterone, Ethisterone Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, IfoSfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	HXM, Hexamethylmelamine
Hydrea , Hydroxyurea, HU Hydrocortisone* Hydroxprogesterone, Ethisterone Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idaxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, IfoSfamide Ifosfamide, Isophosphamide, IFOS	Hycamtin, Topotecan
Hydrocortisone* Hydroxprogesterone, Ethisterone Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idarnycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Hycanthone mesylate
Hydroxprogesterone, Ethisterone Hydroxyurea, Hydrea, HU Idarubicin Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Hydrea , Hydroxyurea, HU
Hydroxyurea, Hydrea, HU Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec	Hydrocortisone*
Idamycin, Idarubicin Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec	Hydroxprogesterone, Ethisterone
Idarubicin, idamycin Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Hydroxyurea, Hydrea, HU
Idoxuridine, IDU IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Idamycin, Idarubicin
IDU, Idoxuridine IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Idarubicin, idamycin
IF, Interferon, Interleukan 2 IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	Idoxuridine, IDU
IFOS, Isophosphamide, Ifosfamide Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	IDU, Idoxuridine
Ifosfamide, Isophosphamide, IFOS Imatinib mesylate, Gleevec Imiquinod, Aldara	IF, Interferon, Interleukan 2
Imatinib mesylate, Gleevec Imiquinod, Aldara	IFOS, Isophosphamide, Ifosfamide
Imiquinod, Aldara	Ifosfamide, Isophosphamide, IFOS
	Imatinib mesylate, Gleevec
Indicine-N-Oxide, Butanoic Acid	Imiquinod, Aldara
	Indicine-N-Oxide, Butanoic Acid

Interferon, IF, Interleukan 2 Interleukan 2, IF, Interferon Iressa, Gefitinib, ZD1839 Irinotecan, camptosar
Iressa, Gefitinib, ZD1839
Irinotecan, camptosar
Isophosphamide, Ifosfamide, IFOS
LAK cells
L-ASP, Elspar, L-Asparaginase
L-Asparaginase, Elspar, L-ASP
L-asparaginase/Prednisone/Vincristine, CCSG
L-asparaginase/Prednisone/Vincristine, VPL-ASP
LCR, Vincristine Sulfate, Leurocristine, Leurocristine Oncovin, Vincristine, Oncovin, VCR
Letrozole, Femara
Leukeran, Chlorambucil, CHL
Leuprolide acetate implant, Viadur
Leuprolide acetate, Eligard
Leuprolide, Lupron
Leurocristine Oncovin, Vincristine Sulfate, Vincristine, Oncovin, Leurocristine, VCR, LCR
Leurocristine, Vincristine Sulfate, Vincristine, Leurocristine Oncovin, Oncovin, VCR, LCR
Leustatin, Cladrabine
Levamisole, Ergamisol
Levothyroxine
LGD 1069, Bexarotene, Targretin
Liothyronine
Liotrix
Lomustine, CCNU
L-PAM, Melphalan, Alkeran, L-Phenylalanine Mustard, Phenylalamine Mustard
L-Phenylalanine Mustard, L-PAM, Melphalan, Alkeran, Phenylalamine Mustard
Lupron, Leuprolide
MA, Adriamycin/Mitomycin C
MAC, Actinomycin D/Chlorambucil/Methotrexate
MACC, Adriamycin/CCNU/CytoxanMethotrexate
MACE, Methotrexate/Adriamycin/CCNU/Cytoxan
MACM, Adriamycin/CCNU/Methotrexate/Mitomycin C
Mannomustine, BCM
Maytansine
MCCNU, Methyl-CCNU, Semustine
Mechlorethamine, Nitrogen Mustard, Mustargen, HN2
Medroxyprogesterone Acetate, Depo Provera
Megace, Megestrol Acetate
Megestrol Acetate, Megace

Adaphalan/Prednisone, MP Adaphalan/Prednisone, MP Adelphalan/Prednisone, MP Ader, Mer-BCG Ader, Mer-BCG Aderbarone Adersan, Methyltetrahydrohomofolate Adersane Aderborsane Aderborgesterone Aderborges	Melengestrol Acetate
Metphalan/Procarbazine/Velban, PAVe MER, Mer-BCG Mer-BCG, MER Merson Merson, Methyltetrahydrohomololate Mesna, Methyltetrahydrohomololate Mestanol Methyltetrahydrohomololate Methyltetrahydrohomololate Methyltetrahydrohomololate Methyltetrahydrohomololate Methyltetrahydrohomololate Methyltetrahydrohomololate Methyltetrahydrohomololate Methotexate, Amethopterin, MTX Methotexate, Amethopterin, MTX Methotexate, Amethopterin, MTX Methotexate, Amethopterin, MTX Methotexate, Mitoguazone, MGBG Methyltexate/Prednisolone acetate Methyltexate/Nednisolone acetate Methylprednisolone acetate Methylprednisolone acetate Methylprednisolone folder Methylprednisolone folder Methyltetrahydrohomololate, Mesna Methyltetrahydrohomololate, Mesna Methyltetrahydrohomololate, Mesna Methyltetrahydrohomololate, Mesna Methyltetrahydrohomololate, Mesna Methyltetrahydrohomololate, Mesna Methyltetrahydrohomololate, Mesna	Melphalan, Alkeran, L-PAM, L-Phenylalanine Mustard, Phenylalamine Mustard
MER, Mer-BCG Merbacone MerbCG, MER Mesna, Methyltetrahydrohomofolate Mestranol Methyltetrahydrohomofolate Mestranol Methyltetrahydrohomofolate Mestranol Methyltetrahydrohomofolate Methyltetrahydrohomofolate Methoriexate, DPMP Methoriexate, Amethopterin, MTX Methorexate/Prednisone/Vincristine, VMP Methorexate/Prednisoner/Vincristine, VMP MethyltecNU, Semustine, MCCNU MethyltecNU, Semustine, MCCNU Methylterdhisolone acetate* Methylterdhisolone acetate* Methylterdhisolone acetate* Methylterdhisolone, Mesna Methylterdhisolone, TURLOC Methylterdhisolone, TURLOC Methylterdhydrohofolate, Mesna Methylterdina, DC, AB-121 MET, SFU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Mithramycin Mithramycin, MITH Mitor, Vindesine, MIVE Mitorycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitorwycin, Mitomycin	Melphalan/Prednisone, MP
Methanone MersBCG, MER Mesna, Methyltetrahydrohomololate Mesna, Methyltetrahydrohomololate Mesna, Methyltetrahydrohomololate Mestranol Methyltetrahydrohomololate Methyltetrahydrohomololate Methonicostenolone Methonicostenolone Methortexate, Amethopterin, MTX Methortexate/Prednisone/Vincristine, VMP Methortexate/Prednisone/Vincristine, VMP MethoylcoRU, Semustine, MCCNU Methylterdhisolone acetate* Methylterdhisolone acetate Methylterdhisolone acetate* Methylterdhisolone acetate Methylterdhisolone, TURLOC Methylterdhydrohmololate, Mesna Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 Methylterydnic Platinum/Vindesine Milsonidazole MITH, Mithramycin Mithramycin, MITH Mito C/Vindesine, MIVe Mitorycin, C/Platinum/Vindesine, MIPE Mitorycin C/Platinum/Vindesine, MIPE	Melphalan/Procarbazine/Velban, PAVe
de-BCG, MER de-BCG, MER de-BCG, MER de-BCG, MER det-BCG, MER det-BCG, MER det-BCG, MER detsranol detsranol dettandrostenolone dethorsarb, CAL, Calusterone dethortexate, Amethopterin, MTX dethortexate, Amethopterin, MTX dethortexate/Prednisone/Vincristine, VMP dethortexate/Prednisone/Vincristine, VMP dethoxsalen dethyl-CCNU, Semustine, MCCNU dethyl-CRNU, Semustine, MCCNU dethyl-prednisolone acetate* dethyl-prednisolone sodium succinate* dethylprednisolone sodium succinate* dethylprednisolone of dethylprednisolone dethylprednisolone dethylprednisolone folate, Mesna deturedepa, AB-121, TURLOC deturedepa, TURLOC, AB-121 detryletertahydrohomofolate, Mesna disonidazole differ, Mitomycin C/Platinum/Vindesine disonidazole dithramycin, MITH dito C/Vindesine, MIVE ditoxycin C/Platinum/Vindesine, MIPE <	MER, Mer-BCG
Mesna, Methyltetrahydrohomofolate Mesna, Methyltetrahydrohomofolate Mestranol Methyn, DDMP Methyn, DDMP Methonarostenolone Methyleradhisolone acetate* Methylprednisolone acetate* Methylprednisolone Methyltetrahydrohomofolate, Mesna Methyltetrahydro	Merbarone
Mestranol Meterprine, DDMP Aethoardrostenolone Aethosarb, CAL, Calusterone Aethotrexate, Amethopterin, MTX Aethotrexate, Amethopterin, MTX Aethotrexate/Adriamycin/CCNU/Cytoxan, MACE Aethotrexate/Prednisonov/incristine, VMP Aethotrexate/Prednisolone acetate* Aethyl-CCNU, Semustine, MCCNU Aethyl-GAG, Mitoguazone, MGBG Aethylorgesterone Aethylorgesterone Aethylogesterone Aethylogen, Mitonycin C Aethordea, TURLOC, AB-121 After Geg, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine	Mer-BCG, MER
Weteprine, DDMP Wethandrostenolone Wethosarb, CAL, Calusterone Wethotraxate, Amethopterin, MTX Wethotraxate/Adriamycin/CCNU/Cytoxan, MACE Wethotraxate/Prednisone/Vincristine, VMP Wethotraxate/Prednisone, MCCNU Wethotraxate/Prednisone, MCCNU Wethyl-GAG, Mitoguazone, MGBG Wethylprednisolone acetate* Aethylprednisolone acetate* Aethylprednisolone* Aethylprednisolone* Aethylprednisolone* Aethylprednisolone Methylterahydrohomofolate, Mesna Aethylterahydrohomofolate, Mesna Aethylterahydrohomofolate, Mesna Meturedepa, TURLOC, AB-121 MCBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Mithramycin Mithramycin, MITH Mito C/Vindesine, MIVE MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Mesna, Methyltetrahydrohomofolate
Aethandrostenolone Methosarb, CAL, Calusterone Methotrexate, Amethopterin, MTX Alethotrexate/Adriamycin/CCNU/Cytoxan, MACE Alethotrexate/Prednisone/Vincristine, VMP Methotxate/Prednisone/Vincristine, VMP Methotxate/Prednisone, MCCNU Methotxate/Prednisolone acetate* Methylprednisolone acetate* Methylprednisolone sodium succinate* Methylprednisolone* Methylprednisolone Methylpredn	Mestranol
Wethosarb, CAL, Calusterone Wethotareate, Amethopterin, MTX Alethotrexate/Adriamycin/CCNU/Cytoxan, MACE Alethotrexate/Prednisone/Vincristine, VMP Wethoxsalen Methyl-CCNU, Semustine, MCCNU Methyl-CQNU, Semustine, MCCNU Methyl-CQNU, Semustine, MCCNU Methyl-CGNG, Mitoguazone, MGBG Methylprednisolone acetate* Methylprednisolone sodium succinate* Methylprednisolone* Methyltestosterone Methyltestosteron	Meteprine, DDMP
Wethotrexate, Amethopterin, MTX Wethotrexate/Adriamycin/CCNU/Cytoxan, MACE Alethotrexate/Prednisone/Vincristine, VMP Wethotxsalen Wethyl-CCNU, Semustine, MCCNU Wethyl-CCNU, Semustine, MCCNU Wethyl-CCNU, Semustine, MCCNU Wethyl-CGNU, Semustine, MCCNU Wethyl-CGNU, Semustine, MCCNU Wethyl-CCNU, Semustine, MCCNU Wethyl-CCNU, Semustine, MCCNU Wethyl-CSGN, Mitoguazone, MGBG Wethylprednisolone acetate* Methylprednisolone acetate Methylprednisolone ace	Methandrostenolone
Wethotrexate/Adriamycin/CCNU/Cytoxan, MACE Wethotrexate/Prednisone/Vincristine, VMP Methoxsalen Methotxsalen Methyl-CCNU, Semustine, MCCNU Methyl-CGNG, Mitoguazone, MGBG Methyl-GAG, Mitoguazone, MGBG Methylprednisolone acetate* Methylprednisolone acetate* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methylprednisolone Methylprogesterone Methylterahydrohomofolate, Mesna Methylterahydrohomofolate, Mesna Meturedepa, AB-121, TURLOC Aleturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Mitoracin, Plicamycin Mithramycin Mithracin, Plicamycin Mithramycin, MITH Mitor C/Vindesine, MIVE Mitorycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Methosarb, CAL, Calusterone
Wethotrexate/Prednisone/Vincristine, VMP Methoxsalen Methoxsalen Methyl-CCNU, Semustine, MCCNU Methyl-CAG, Mitoguazone, MGBG Methylprednisolone acetate* Methylprednisolone acetate* Methylprednisolone acetate* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methyltestosterone MEOC, AB-121	Methotrexate, Amethopterin, MTX
Wethoxsalen Wethyl-CCNU, Semustine, MCCNU Wethyl-GAG, Mitoguazone, MGBG Wethylprednisolone acetate* Methylprednisolone acetate* Methylprednisolone acetate* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methylprednisolone* Methyltestosterone Methyltestosterone Methyltetrahydrohomofolate, Mesna Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mitor, Vindesine, MIVE MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Platinum/Vindesine, MIPE	Methotrexate/Adriamycin/CCNU/Cytoxan, MACE
Alethyl-CCNU, Semustine, MCCNU Alethyl-GAG, Mitoguazone, MGBG Alethylprednisolone acetate* Alethylprednisolone sodium succinate* Alethylprednisolone sodium succinate* Alethylprednisolone* Alethylprednisolone* Alethylprednisolone Alethylprednisolone* Alethylprednisolone* Alethylprednisolone* Alethyltetrahydrohomofolate, Mesna Alethyltetrahydrohomofolate, Mesna Aleturedepa, AB-121, TURLOC Aleturedepa, TURLOC, AB-121 MF, S-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Mithramycin Mithramycin Mithramycin Mithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Platinum/Vindesine, MIPE	Methotrexate/Prednisone/Vincristine, VMP
Wethyl-GAG, Mitoguazone, MGBG Wethylprednisolone acetate* Wethylprednisolone sodium succinate* Wethylprednisolone* Wethylprednisolone* Wethylprednisolone* Wethyltestosterone Wethylterahydrohomofolate, Mesna Weturedepa, AB-121, TURLOC Weturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Withracin, Plicamycin Withracycin, MITH Mitoguazone, Methyl-GAG, MGBG WITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Witomycin C/Platinum/Vindesine, MIPE Witomycin C/Platinum/Vindesine, MIPE	Methoxsalen
Wethylprednisolone acetate* Wethylprednisolone sodium succinate* Wethylprednisolone* Wethylprogesterone Wethyltestosterone Methyltestosterone Methyltetrahydrohomofolate, Mesna Methyltetrahydrohomofolate, Mesna Methyltetrahydrohomofolate, Mesna Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Mithracin, Plicamycin Mithracin, Plicamycin Mithracin, MITH Mitoguazone, Methyl-GAG, MGBG Mitoguazone, Methyl-GAG, MGBG Mitoguazone, Methyl-GAG, MIPE Mitomycin C/Platinum/Vindesine, MIPE Mitoguazone, Methyl-GAG, MGBG	Methyl-CCNU, Semustine, MCCNU
Methylprednisolone sodium succinate* Methylprednisolone* Methylprogesterone Methyltestosterone Methyltetrahydrohomofolate, Mesna Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Mithramycin Mithramycin Mithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIVE	Methyl-GAG, Mitoguazone, MGBG
Methylprednisolone* Methylprogesterone Methyltestosterone Methyltestosterone Methyltestosterone Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracin, Plicamycin Mithracin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE	Methylprednisolone acetate*
Methylprogesterone Methyltestosterone Methyltetrahydrohomofolate, Mesna Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole Mithracin, Plicamycin Mithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE	Methylprednisolone sodium succinate*
Methyltestosterone Methyltestosterone Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracin, Plicamycin Mithracin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Methylprednisolone*
Methyltetrahydrohomofolate, Mesna Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracin, Plicamycin Mithracin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Methylprogesterone
Meturedepa, AB-121, TURLOC Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracin, Plicamycin Mithranycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Methyltestosterone
Meturedepa, TURLOC, AB-121 MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracin, Plicamycin Mithracin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Methyltetrahydrohomofolate, Mesna
MF, 5-FU/Mitomycin C MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracin, Plicamycin Mithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Meturedepa, AB-121, TURLOC
MGBG, Mitoguazone, Methyl-GAG MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithracycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Meturedepa, TURLOC, AB-121
MIPE, Mitomycin C/Platinum/Vindesine Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithrarycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE	MF, 5-FU/Mitomycin C
Misonidazole MITH, Mithramycin Mithracin, Plicamycin Mithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	MGBG, Mitoguazone, Methyl-GAG
MITH, Mithramycin Mithracin, Plicamycin Mithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	MIPE, Mitomycin C/Platinum/Vindesine
Aithracin, Plicamycin Aithramycin, MITH Mito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Aitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Misonidazole
Aithramycin, MITH Aito C/Vindesine, MIVe AITO-C, Mutomycin, Mitomycin-C Aitoguazone, Methyl-GAG, MGBG Aitomycin C/Platinum/Vindesine, MIPE Aitomycin C/Velban, VM	MITH, Mithramycin
Vito C/Vindesine, MIVe MITO-C, Mutomycin, Mitomycin-C Vitoguazone, Methyl-GAG, MGBG Vitomycin C/Platinum/Vindesine, MIPE Vitomycin C/Velban, VM	Mithracin, Plicamycin
MITO-C, Mutomycin, Mitomycin-C Mitoguazone, Methyl-GAG, MGBG Mitomycin C/Platinum/Vindesine, MIPE Mitomycin C/Velban, VM	Mithramycin, MITH
Vitoguazone, Methyl-GAG, MGBG Vitomycin C/Platinum/Vindesine, MIPE Vitomycin C/Velban, VM	Mito C/Vindesine, MIVe
Aitomycin C/Platinum/Vindesine, MIPE Aitomycin C/Velban, VM	MITO-C, Mutomycin, Mitomycin-C
Aitomycin C/Velban, VM	Mitoguazone, Methyl-GAG, MGBG
	Mitomycin C/Platinum/Vindesine, MIPE
Attomycin-C. Mutomycin MITO-C	Mitomycin C/Velban, VM
	Mitomycin-C, Mutomycin, MITO-C
Aitotane, O'p'-DDD	Mitotane, O'p'-DDD
Aitoxantrone, Dihydroxyanthracenedione, DHAD	Mitoxantrone, Dihydroxyanthracenedione, DHAD

MIVe, Mito C/Vindesine
MOB, Bleomycin/Mitomycin C/Vincristine
MOF, 5-FU/Mitomycin/Oncovin
MOF-S, 5-FU/Mitomycin/Oncovin/Streptozotocin
Monoclonal antibody
MOPP, Nitrogen mustard/Prednisone/Procarbazine/Vincristine
Moryanly, Sodium Suramin, Bayer 305
MP, Melphalan/Prednisone
MTX, Methotrexate, Amethopterin
Mustargen, Nitrogen Mustard, Mechlorethamine, HN2
Mutomycin, Mitomycin-C, MITO-C
MVE 2, Pyran copolymer
MVH, Hexamethylmelamine/Methotrexate/VP-16
Myleran, Busulfan, BUS
Mylotarg, Gemtuzumab-ozogamicin
Nafidimide, Amonofide, Ara A
Nalfoxidine HCL, NFX
Nandrolone Decanoate
Navalbine, Vinorelbine tartrate
Neosar, Cyclophosphamide, Cytoxine, CTX, Cytoxan
NFX, Nalfoxidine HCL
Nilandron, Nilutamide
Nilutamide, Nilandron
Nipent, Pentostatin, Deoxycoformycin
Nitrogen Mustard, Mechlorethamine, Mustargen, HN2
Nitrogen mustard/Prednisone/Procarbazine/Vincristine, MOPP
N-Methylformamide
Norethindrone Acetate
Novaldex, TMX, Tamoxifen Citrate
Oncaspar, Pegasparagase
Oncovin, Vincristine, Leurocristine, Vincristine Sulfate, Leurocristine Oncovin, LCR, VCR
Ontak, Denileukin diftitox
O'p'-DDD, Mitotane
Orange crush, ACDA, Anthracenedicarboxaldehyde, Bisantrene
Oxaliplatin, Eloxatine
Oxandrolone
Oxiplatin
Oxymetholone, HMD
PA, Adriamycin/Platinol
PAC-5, Adriamycin/Cytoxan/Platinol
Paclitaxel, Paxene, Taxol
ר מטוומאסו, ד מאסווס, דמאטו

Paramethasone* PAVe, Melphalan/Procarbazine/Velban Pavene, Paciltaxel, Taxol Pavene, Paciltaxel, Taxol PCN, Procarbazine HCI PCNU PCV, CCNU/Procarbazine/Vincristine PDA, Phosphorodiamidic Acid PDN, Prednisone* Pagasparagase, Oncaspar Paramethylmelamine, PMM Partmethylmelamine, PMM Partostatin, Deoxycoformycin, Nipent Phosphorodiamidic Acid, PDA Phosphorodiamidic Acid, PDA Phosphorodiamidic Acid, PDA Phosphorodiamidic Acid, PDA Phosphoronan PIBR, Pipobroman PIP, Piperazenedione Pipobroman, PIBR Pipobroman, PIBR Piposulfan, PISU PLA, Chdiamycin/ClS-platinum/Cytoxan Planch, ClS-platinum, C-DDP, ClSplatin Proc, CCNU/Cytoxan/Procarbazine/Vincristine Poolphyllin, SPG Poly-S-Iodocytidilic Poly-S-Iodocytidilic Poly-S-Iodocytidilic Poly-S-Iodocytidilic Poly-S-Iodocytidilic Poly-S-Iodocytidilic Poly-S-Iodocytidilic
Pakene, Paclitaxel, Taxol PCH, Procarbazine HCI PCNU PCV, CCNU/Procarbazine/Vincristine PDA, Phosphorodiamidic Acid PDN, Prednisone* Pagasparagase, Oncaspar Partamethylmelamine, PMM Partamethylmelamine, PMM Partostatin, Deoxycoformycin, Nipent Phosphorodiamidic Acid, PDA Phosphorodiamidic Acid, PDA Phosphorodiamidic Acid, PDA Phosphoroman PIP, Piperazenedione Pipobroman PIP, Piperazenedione, PIP Pipobroman, PIBR Piposulfan, PISU PLA, Adriamycin/CIS-platinum/Cytoxan PIA, Piperamethylmelamine POC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin, SPG Polosytidic, Poly-1C Polysetradiol Phosphate Poly-1C, Poly-5-lodocytidilic POM-2-lodocytidilic POM-2-lodocytidilic POM-2-lodocytidilic
CH, Procarbazine HCI CRU VCV, CCNU/Procarbazine/Vincristine PDA, Phosphorodiamidic Acid PDA, Phosphorodiamidic Acid PDN, Prednisone* Pagasparagase, Oncaspar Partamethylmelamine, PMM Partamethylmelamine, PMM Partostatin, Deoxycoformycin, Nipent Phenylalamine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalamine Mustard Phosphorodiamidic Acid, PDA Photofrin PilP, Piperazenedione Piperazenedione, PIP Pipobroman PISU, Piposulfan, PISU PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Picoc, CCNU/Cytoxan/Procarbazine/Vincristine Podocytidliic, Poly-IC Polypstradiol Phosphate Poly-S-Iodocytidliic Poly-S-Iodocytidliic POM, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
CV, CCNU/Procarbazine/Vincristine CV, CCNU/Procarbazine/Vincristine CPDA, Phosphorodiamidic Acid PDA, Phosphorodiamidic Acid PDA, Prednisone* Peqasparagase, Oncaspar Pentamethylmelarnine, PMM Pentostatin, Deoxycoformycin, Nipent Phenylalarnine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalarnine Mustard Phosphorodiamidic Acid, PDA Photofrin PlBR, Pipobroman PlP, Piperazenedione PlP Pipobroman, PIBR Piposulfan, PISU PlSU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, CIS-platinum, C-DDP, Cisp
PCV, CCNU/Procarbazine/Vincristine PCV, CCNU/Procarbazine/Vincristine PDA, Phosphorodiamidic Acid PDN, Prednisone* Peqasparagase, Oncaspar Pentamethylmelamine, PMM Pentamethylmelamine, PMM Pentostatin, Deoxycoformycin, Nipent Phosphorodiamidic Acid, PDA Phosphorodiamidic Acid, PDA Photofrin PIR, Pipobroman PIP, Piperazenedione, PIP Piopobroman, PIBR Pioposulfan, PISU PISU, Piposulfan PLCC, CCNU/CIS-platinum/Cytoxan Pationol, CIS-platinum/Cytoxan Padophyllin. SPG Polys-5-lodocytidilic, Poly-IC Polysetradiol Phosphate Poly-5-lodocytidilic Poly-5-lodocytidilic Poly-6-mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
PDA, Phosphorodiamidic Acid PDA, Phosphorodiamidic Acid PDN, Prednisone* Peqasparagase, Oncaspar Pentamethylmelamine, PMM Pentostatin, Deoxycoformycin, Nipent Phosphorodiamidic Acid, PDA Photofrin Phosphorodiamidic Acid, PDA Photofrin PIBR, Pipobroman PIP, Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Pipobroman, PIBR Piposulfan, PISU PISU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, SPG Poly-5-fodocytidlic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidlic POMPA, 6-mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
PDN, Prednisone* Pegasparagase, Oncaspar Pentamethylmelamine, PMM Pentamethylmelamine, PMM Pentostatin, Deoxycoformycin, Nipent Phenylalamine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalamine Mustard Phosphorodiamidic Acid, PDA Photofrin PlaBR, Pipobroman PIP, Piperazenedione Piposuffan, PISU Piposuffan PLAC, Adriamycin/CIS-platinum/Cytoxan Plationl, CIS-platinum, C-DDP, Cisplatin Platond, Platonethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Pody-S-I-odocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-S-I-odocytidilic Poly-R, 6-mercaptopurine/L-Asparag
Pegasparagase, Oncaspar Pegasparagase, Oncaspar Pentamethylmelamine, PMM Pentostatin, Deoxycoformycin, Nipent Phenylalamine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalamine Mustard Phosphorodiamidic Acid, PDA Photofrin PlBR, Pipotroman PlP, Piperazenedione Piperazenedione, PIP Pipotroman, PIBR Pipotroman, PIBR Piposulfan, PISU P
Pertamethylmelamine, PMM Pertamethylmelamine, PMM Pertamethylmelamine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalamine Mustard Phosphorodiamidic Acid, PDA Photofrin PIBR, Pipobroman PIP, Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Pipobroman, PIBR Piposulfan, PISU PISU PISU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Picamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMPA, 6-Mercaptopurine/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/Lasparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/Lasparaginase/Methotrexate/Predniso
Pentostatin, Deoxycoformycin, Nipent Phenylalamine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalamine Mustard Phosphorodiamidic Acid, PDA Photofrin PlBR, Pipobroman PlP, Piperazenedione Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Pipobroman, PIBR Piposulfan, PISU PlSU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-C, Poly-5-lodocytidilic POMPA, 6-Mercaptopurine/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
Phenylalamine Mustard, L-PAM, Melphalen, Alkeran, L-Phenylalamine Mustard Phosphorodiamidic Acid, PDA Photofrin PIBR, Pipobroman PIP, Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Piposulfan, PISU PISOL, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Picorc, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin, SPG Poly-5-lodocytidilic, Poly-IC Poly-5-lodocytidilic Poly-6, emercaptopurine/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
Phosphorodiamidic Acid, PDA Photofrin Photofrin PIER, Pipobroman PIP, Piperazenedione Piperazenedione, PIP Piposuffan, PISU Piposulfan, PISU Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, CIS-platinum, C-DDP, Cisplatin Platinol, SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine POMPA
Photofrin PIBR, Pipobroman PIP, Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Pipobroman, PIBR Piposulfan, PISU PISU, Piposulfan PICAC, Adriamycin/CIS-platinum/Cytoxan PLAC, Adriamycin/CIS-platinum/Cytoxan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMPA, 6-mercaptopurine/Methotrexate/Prednisolone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
PIBR, Pipobroman PIP, Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Pipobroman, PIBR Pipobroman, PIBR Pipobroman, PISU Pipobroman, CIS-platinum/Cytoxan PILAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Picamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Poly-5-lodocytidilic, Poly-IC Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
Piperazenedione Piperazenedione, PIP Pipobroman, PIBR Piposulfan, PISU PISU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin PlocC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Poly-5-lodocytidilic Poly-6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
Piperazenedione, PIP Pipobroman, PIBR Piposulfan, PISU PISU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
² ipobroman, PIBR ² ipobroman, PIBR ² iposulfan, PISU ² ISU, Piposulfan ² ISU, Piposulfan ² IAC, Adriamycin/CIS-platinum/Cytoxan ² Platinol, CIS-platinum, C-DDP, Cisplatin ² Platinol, CIS-platinum, C-DDP, Cisplatin ² NM, Pentamethylmelamine ² OCC, CCNU/Cytoxan/Procarbazine/Vincristine ² Podophyllin. SPG ² Poly-5-lodocytidilic, Poly-IC ² Poly-5-lodocytidilic ² Poly-5-lodocytidilic ² POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine ² POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
² iposulfan, PISU ² Igosulfan, PISU ² ISU, Piposulfan ² ILAC, Adriamycin/CIS-platinum/Cytoxan ² Platinol, CIS-platinum, C-DDP, Cisplatin ² Platinol, CIS-platinum, C-DDP, Cisplatin ² Platiamycin, mithracin ² PloCC, CCNU/Cytoxan/Procarbazine/Vincristine ² POCC, CCNU/Cytoxan/Procarbazine/Vincristine ² Podophyllin. SPG ² Poly-5-lodocytidilic, Poly-IC ² Polyestradiol Phosphate ² Poly-6-mercaptopurine/Methotrexate/Prednisone/Vincristine ² POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine ² PORF, Porfiromycin
PISU, Piposulfan PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
PLAC, Adriamycin/CIS-platinum/Cytoxan Platinol, CIS-platinum, C-DDP, Cisplatin Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
Platinol, CIS-platinum, C-DDP, Cisplatin Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
Plicamycin, mithracin PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-Iodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-Iodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
PMM, Pentamethylmelamine POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-Iodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-Iodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
POCC, CCNU/Cytoxan/Procarbazine/Vincristine Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
Podophyllin. SPG Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
Poly-5-lodocytidilic, Poly-IC Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
Polyestradiol Phosphate Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
Poly-IC, Poly-5-lodocytidilic POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
POMP, 6-mercaptopurine/Methotrexate/Prednisone/Vincristine POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine PORF, Porfiromycin
POMPA, 6-Mercaptopurine/L-Asparaginase/Methotrexate/Prednisolone/Vincristine
PORF, Porfiromycin
Porfiromycin, PORF
Prednisone*, PDN
Prednisone/Vincristine, VP
Procarbazine HCL, PCH
Progesterone
Proleukin, Aldesleukin
RO-MACE, Adriamycin/Cytoxan/Epipodophyllotoxin/Methotrexate/Prednisone
VB, Bleomycin/Platinol/Velban

PVBA, Adriamycin/Bleomycin/Platinol/Velban
Pyran copolymer, MVE 2
Pyrazofurin
Pyrazole
QUIN, Atabrine, Quinacrine
Quinacrine, Atabrine, QUIN
Quinomycin A, Echinomycin
Raltitrexed, Tomudex
Riboxamide, Tiazofurin, TCAR
Rituxan, Rituximab
Rituximab, Rituxan
ROAP, Ara-C/PrednisoneRubidazone/Vincristine
RUB, Rubidazone
Rubidazone, RUB
Sandostatin, Octreotide (deleted in 2005 - considered ancillary drug)
Semustine, Methyl-CCNU, MCCNU
SMF, 5-FU/Mitomycin C/Streptozotocin
Sodium Suramin, Moryanly, Bayer 305
SPG, Podophyllin
Spiro-32, Spirogermanium
Spirogermanium, Spiro-32
Spiromustin
Spironolactone
SR-2508
Stanolone
Stanozolol
Stem cell transplant
STGdR, Diglycoaldehyde
Stilbesterol, DES, Diethylstilbestrol
Streptozotocin, STZ
STZ, Streptozotocin
Synthroid (for papillary and/or follicular cancers of the thyroid only)
TAC, Adriamycin/Cytoxan/Taxotere
TACE, Chlorotrinanisene
TACO, Adriamycin/Cytoxan/Tamoxifen/Vincristine
TAD, 6-Thioguanine/Ara-C/Daunomycin
Tamoxifen Citrate, Novaldex, TMX
Targretin, Bexarotene, LGD 1069
TATBA, Triamcinolone hexacetonide
Taxol, Paxene, Paclitaxel
Taxotere, Docetaxel

TCAR, Riboxamide, Tiazofurin
Temodar, Temozolamide, Temodol
Temodol, Temodar, Temozolamide
Temozolamide, Temodar, Temodol
Teniposide, VM-26
TEPA, Triethylene Phosphoramide
Teslac, TL, Testaolactone
Testaolactone, Teslac, TL
Testosterone Enanthate
Testosterone Propionate, TP
Tetrahydrouridine, THU
Thioguanine, 6TG
Thio-TEPA, Thiotepa, TSPA
Thiotepa, Thio-TEPA, TSPA
THU, Tetrahydrouridine
Thymidine
Thymosin
Thyroglobulin
Thyrotropin, TSH
Tiazofurin, Riboxamide, TCAR
TL, Testaolactone, Teslac
TMCA, Trimethylcolchilcinic acid
TMX, Tamoxifen Citrate, Novaldex
TODD, Daraprim/Dexamethasone/Oncovin/Thioquanine
Tomudex, Raltitrexed
Topotecan, Hycamtin
Toremifene, Fareston
TP, Testosterone Propionate
Trastuzumab, Herceptin
Trelstar Depot, Triptorelin pamoate
Triamcinolone
Triamcinolone hexacetonide, TATBA
Triapine
Triazinate, Baker's Antifol, BAF
Tricirloinephosphate
Triethylene Phosphoramide, TEPA
Triiodothyronine, TRIT
Trilostane
Trimethylcolchilcinic acid, TMCA
Trimetrexate
Triptorelin pamoate, Trelstar Depot

Trisenox, Arsenic trioxide
TRIT, Triiodothyronine
TSH, Thyrotropin
TSPA, Thio-TEPA, Thiotepa
Tubercidin
TURLOC, Meturedepa, AB-121
UR, Uracil
Uracil, UR
VAC, Adriamycin/Cytoxan/Vincristine
Vaccine therapy
VAD, Actinomycin D/DTIC/Vindesine
Valrubicin, Valstar
Valstar, Valrubicin
VAMP, 6-Mercaptopurine/Amethopterin/Prednisone/Vincristine
VAP, Adriamycin/Procarbazine/Vindesine
VBAP, Adriamycin/BCNU/Prednisone/Vincristine
VCAP, Adriamycin/Cytoxan/Prednisone/Vincristine
VCR, Leurocristine Oncovin, Vincristine Sulfate, Vincristine, Leurocristine, LCR, Oncovin
Velban, Vinblastine Sulfate, VLB
Viadur, Leuprolide acetate implant
Vinblastine Sulfate, Velban, VLB
Vincristine Sulfate, Leurocristine, Oncovin, Leurocristine Oncovin, Vincristine, LCR, VCR
Vincristine, Oncovin, Leurocristine Oncovin, Vincristine Sulfate, Leurocristine, VCR, LCR
Vindesine, DVA
Vinorelbine tartrate, navalbine
Virus therapy
VIT-A, Vitamin A
Vitamin A, VIT-A
VLB, Velban, Vinblastine Sulfate
VM, Mitomycin C/Velban
VM-26, Teniposide
VMP, Methotrexate/Prednisone/Vincristine
VP, Prednisone/Vincristine
VP-16, Etoposide, VP-16-213
VP-16-213, Etoposide, VP-16
VPL-ASP, L-asparaginase/Prednisone/Vincristine
WR-2721
Xeloda, Capecitabine
Yoshi-864
ZD1839, Iressa, Gefitinib
Zoladex

Appendix I - Common Abbreviations

Word	Abbreviation
Abdomen	ABD
Abdominal Perineal	AP
Acid Phosphatase	ACID PHOS
Acquired Immunodeficiency Syndrome	AIDS
Acute Lymphocytic Leukemia	ALL
Acute Myelogenous Leukemia	AML
Adenocarcinoma	ADENOCA
Additional	ADDTL
Adjacent	ADJ
Adrenal	ADR
Armed Forces Institute of Pathology	AFIP
Alcohol	ETOH
Alkaline Phosphatase	ALK PHOS
Alpha-fetoprotein	AFP
Ambulatory	АМВ
Anaplastic	ANAP
Angiography	ANGIO
Anterior	ANT
Anteroposterior	AP
Appendix	APP
Approximatley	APPROX
Aspiration	ASP
Axilla(ry)	AX
Bacillus Calmette-Guerin	BCG
Barium	ВА
Barium Enema	BE
Benign Prostatic Hypertrophy/Hyperplasia	ВРН
Bilateral	BIL
Bilateral Salpingo-oophorectomy	BSO
Biological Response Modifier	BRM
Biopsy	BX
Blood Urea Nitrogen	BUN
Bone Marrow	BM
Bone Scan	BSC
Carcinoembryonic Antigen	CEA
Carcinoma	CA
Carcinoma In Situ	CIS

Centimeter	СМ
Central Nervous System	CNS
Cerebrospinal Fluid	CSF
Cervical Intraepithelial neoplasia	CIN
Cervical Intraepinelial neoplasia	CIN C1-C7
Cervix	CX
Cesium	CSF
Chemotherapy	СНЕМО
Chest Xray	CXR
Chronic Lymphocytic Leukemia	CLL
Chronic Myeloid Leukemia	CML
Cigarettes	CIG
Clear	CLR
Colon:	
Ascending	A-COLON
Decending	D-COLON
Sigmoid	S-CLON
Transverse	T-COLON
Common Bile Duct	CBD
Computerized Axial Tomography Scan	CT,CAT SCAN
Consist with	C/W
Continue	CONT
Cystoscopy	CYSTO
Cytology	СҮТО
Cytomegalovirus	CMV
Date of Birth	DOB
Dermatology	DERM
Diagnosis	DX
Diameter	DIAM
Differentiated	DIFF
Dilatation and Curettage	D&c
Discharge	DIS,DISCH,DS
Discontinued	DC
Disease	DZ, DIS
Doctor	DR, MD
Ears, Nose, and Throat	ENT
Endoscopic Retrograde Cholangiopancreatography	ERCP
Enlarged	ENL
Esophagogastroduodenoscopy	EGD
Estrogen Receptor (Assay)	ER(A)

Examination	EXAM
Examination Under Anesthesia	EUA
Excision	EXC
Exploratory Laparotomy	EXP LAP
Extend	EXT
Extension	EXT
External	EXT
Eyes, Ears, Nose, and Throat	EENT
Floor of Mouth	FOM
Follow-up	FU
Fracture	FX
Frozen Section	FS
Gallbladder	GB
Gastroenterostomy	GE
Gastroesophageal	GE
Gastrointestinal	GI
Genitourinary	GU
Grade	GR
Gynecology	GYN
Head, Eyes, Ears, Nose, Throat	HEENT
Hepatosplenomegaly	HSM
Histology	HISTO
History	НХ
History and Physical	H&P
History of	но
history of Present Illness	HPI
Hormone	HORM
Hospital	HOSP
Human Chorionic Gonadotropin	HCG
Human Immunodeficiency Virus	HIV
Human Papilloma Virus	HPV
Human T-Lymphotrophic Virus Type III	HTLV-III
Hysterctomy	HYST
Immunoglobulin	IG
Impression	IMP
Includes, Including	INCL
Inferior Vena Cava	IVC
Infiltrating	INFILT
Information	INFO
Inpatient	IP

Intrathecal	п
Intravaneous	IVC
Intraveneous Pyelogram	IVP
Kidneys, Ureters, Bladder	КИВ
Laparotomy	LAP
Large	LG
Lateral	LAT
Left	L, LT
Left Lower Extremity	LLE
Left Lower Lobe	LLL
Left Lower Quadrant	LLQ
Left Salpingo-oophorectomy	LSO
Left Upper Extremity	LUE
Left Upper Lobe	LUL
Left Upper Quadrant	LUQ
Local M.D.	LMD
Lower Extremity	LE
Lower Inner Quadrant	LIQ
Lower Outer Quadrant	LOQ
Lumbar Puncture	LP
Lumbar Vertebra	L1-L5
Lumbosacral	LS
Lymphadenopathy	LAD/LAN
Lymphadenopathy-Associated Virus	LAV
Lymph Node(s)	LN, LN'S, LNS
Magnetic Resonance Imaging	MRI
Malignant	MALIG, MAL
mandible	MAND
Mastectomy	MAST
Maxilla(ry)	MAX
Mediastinum	MEDIAS
Medical Doctor	DR, MD
Medicine	MED
Metastatic, Metastases	MET, METS
Microscopic	MICRO
Middle Lobe	ML
Millimeter	ММ
Million Electron Volts	MEV
Minimum	MIN
Moderate	MOD
Moderately Differentiated	MD, MOD DIFF

Negative	NEG (OR -)
Neurolgoy	NEURO
No Evidence of Disease	NED
Normal	NL
No Significant Findings	NSF
Not Applicable	ΝΑ
Not Otherwise Specified	NOS
Not Recorded	NR
Obstructed (-ing, -ion)	OBST
Operation	OP
Operative Report	OP REPORT
Outpatient	OP
Packs per Day	PPD
Palpated (-able)	PALP
Papanicolaou Smear	РАР
Papillary	РАР
Past Medical History	РМН
Pathology	PATH
Patient	PT
Pelvic Inflammatory Disease	PID
Percutaneous	PERC
Physical Examination	PE
Platelets	PLT
Pleural effusion	PL E
Poorly Differentiated	PD, POOR DIFF
Positive	POS (or +)
Positron Emission Tomography	PET
Possible	POSS
Posterior	POST
Posteroanterior	PA
Postoperative (-ly)	PO, POSTOP
Preoperative (-ly)	PREOP
Primary	PRIM
Probable (-ly)	PROB
Progesterone Receptor (Assay)	PR(A)
Pulmonary	PULM
Pulmonary Artery	РА
Radiation	RAD
Radiation Absorbed Dose	RAD
Radiation Therapy	RT/XRT

Radioimmunoassay	RIA
Radium	RA
Red Blood Cells	RBC
Resection	RESEC
Respiratory	RESPIR
Right	R, RT
Right Lower Extremity	RLE
Right Lower Lobe	RLL
Right Lower Quadrant	RLQ
Right Middle Lobe	RML
Right Salpingo-oophorectomy	RSO
Right Upper Extremity	RUE
Right Upper Lobe	RUL
Right Upper Quadrant	RUQ
Rule Out	RO, R/O
Sacral Vertebra	S1-S5
Salpingo-oophorectomy	SO
Skilled Nursing Facility	SNF
Specimen	SPEC
Split Thickness Skin Graft	STSG
Small	SM, SML
Small Bowel	SB, SML BWL
Social Security Death Index	SSDI
Spine:	
Cervical	C-SPINE
Lumbar	L-SPINE
Sacral	S-SPINE
Thoracic	T-SPINE
Squamous	SQ, SQUAM
Squamous Cell Carcinoma	SCC
Stage	STG
Status Post	S/P
Subcutaneous	SUB-Q, SUBQ, SQ
Superior Vena Cava	SVC
Surgery, Surgical	SURG
Suspect, Suspicious	SUSP
Symptoms	SX
Thoracic	T-SPINE
Thoracic Vertebra	T1-T12
Topography	TOPOG

Total Abdominal Hysterectomy-	
Bilateral Salpingo-oophorectomy	TAH-BSO
Total Vaginal Hysterectomy	түн
Transitional Cell Carcinoma	тсс
Transurethral Resection	TUR
Transurethral Resection Bladder (tumor)	TURB(T)
Transurethral Resection Prostate	TURP
Treatment	RX, TX
Tumor Size	TS
Undifferentiated	UNDIFF
Unknown	UNK
Upper Extremity	UE
Upper Gastrointestinal	UGI
Upper Inner Quadrant	UIQ
Upper Outer Quadrant	UOQ
Vagina, Vaginal	VAG
Vaginal Hysterectomy	VAG HYST
Vaginal Intraepithelial Neoplasia	VAIN
Vascular	VASC
Vulvar Intraepithelial Neoplasia	VIN
Well Differentiated	WD, WELL DIFF
White Blood Cells	WBC
With	W/ or C
Within Normal Limits	WNL
Without	W/O
Work-up	W/U
Xray	XR
Year	YR

At	@
Comparison	1
Decrease, less than	<
Equals	=
Increase, more than	>
Negative	-
Number*	#
Positive	+
Pounds**	#
Times	x

**if it appears after a numeral.	

Appendix J - ICD-O-3 Errata and Clarifications

These can be found at: http://www.seer.cancer.gov/icd-o-3/.

Appendix K - Race Coding Rules and Tables

(Effective with 2004 diagnoses)

Race (and ethnicity) is defined by specific physical, hereditary and cultural traditions or origins, not necessarily by birthplace, place of residence, or citizenship. 'Origin' is defined by the US Census Bureau as the heritage, nationality group, lineage, or in some cases, the country of birth of the person or the person's parents or ancestors before their arrival in the United States.

All resources in the facility, including the medical record, face sheet, physician and nursing notes, photographs, and any other sources, must be used to determine race. If a facility does not print race in the medical record but does maintain it in electronic form, the electronic data must also be reviewed. Recommendation: document how the race code was determined in a text field.

Coding Instructions

- 1. Code the primary race(s) of the patient in fields Race 1, Race 2, Race 3, Race 4, and Race 5. The five race fields allow for the coding of multiple races consistent with the Census 2000. Rules 2 8 further specify how to code Race 1, Race 2, Race 3, Race 4 and Race 5.
- 2. If a person's race is a combination of white and any other race(s), code the appropriate other

race(s) first and code white in the next race field.

3. If a person's race is a combination of Hawaiian and any other race(s), code Race 1 as 07

Hawaiian and code the other races in Race 2, Race 3, Race 4, and Race 5 as appropriate.

Example: Patient is described as Japanese and Hawaiian. Code Race 1 as 07 Hawaiian, Race 2

as 05 Japanese, and Race 3 through Race 5 as 88.

4. If the person is not Hawaiian, code Race 1 to the first stated non-white race (02-98).

Example: Patient is stated to be Vietnamese and Black. Code Race 1 as 10 Vietnamese, Race 2

as 02 Black, and Race 3 through Race 5 as 88.

Note: in the following scenarios, only the race code referred to in the example is coded. For

cases diagnosed after January 1, 2000, all race fields must be coded.

5. The fields Place of Birth, Race, Marital Status, Name, Maiden Name, and Hispanic Origin are

inter-related. Use the following guidelines in priority order:

a. Code the patient's stated race, if possible. Refer to Appendix "Race and Nationality

Descriptions from the 2000 Census and Bureau of Vital Statistics" for guidance.

Example 1: Patient is stated to be Japanese. Code as 05 Japanese.

Example 2: Patient is stated to be German-Irish. Code as 01 White.

Example 3: Patient is described as Arabian. Code as 01 White.

Exception: When the race is recorded as Oriental, Mongolian, or Asian (coded to 96

Other Asian) and the place of birth is recorded as China, Japan, the Philippines, or

another Asian nation, code the race based on birthplace information.

Example 4: The person's race is recorded as Asian and the place of birth is recorded as

Japan. Code race as 05 Japanese because it is more specific than 96 Asian, NOS.

Example 5: The person describes himself as an Asian-American born in Laos. Code race as 11 Laotian because it is more specific than 96 Asian, NOS.

6. If the patient's race is determined on the basis of the races of relatives, there is no priority to

coding race, other than to list the non-white race(s) first.

Example: The patient is described as Asian-American with Korean parents. Code race as 08

Korean because it is more specific than 96 Asian [-American].

7. If no race is stated in the medical record, or if the stated race cannot be coded, review the

documentation for a statement of a race category.

Example 1: Patient described as a black female. Code as 02 Black.

Example 2: Patient describes herself as multi-racial (nothing more specific) and nursing notes say "African-American." Code as 02 Black.

Example 3: Patient states she has a Polynesian mother and Tahitian father. Code Race 1 as 25

Polynesian, Race 2 as 26 Tahitian and Race 3 through Race 5 as 88.

8. If race is unknown or not stated in the medical record and birth place is recorded, in some cases

race may be inferred from the nationality. Refer to the Appendix entitled "Race and Nationality

Descriptions from the 2000 Census and Bureau of Vital Statistics" to identify nationalities from

which race codes may be inferred.

Example 1: Record states: "this native of Portugal..." Code race as 01 White per the Appendix.

Example 2: Record states: "this patient was Nigerian..." Code race as 02 Black per the

Appendix.

Exception: If the patient's name is incongruous with the race inferred on the basis of

nationality, code Race 1 through Race 5 as 99, Unknown.

Example 1: Patient's name is Siddhartha Rao and birthplace is listed as England. Code Race

1 through Race 5 as 99 Unknown.

Example 2: Patient's name is Ping Chen and birthplace is Ethiopia. Code Race 1 through

Race 5 as 99 Unknown.

9. Use of patient name in determining race:

a. Do not code race from name alone, especially for females with no maiden name given.

b. In general, a name may be an indicator of a racial group, but should not be taken as the only indicator of race.

c. A patient name may be used to identify a more specific race code.

Example 1: Race reported as Asian, name is Hatsu Mashimoto. Code race as 05 Japanese.

Example 2: Birthplace is reported as Guatemala and name is Jose Chuicol [name is identified as Mayan]. Code race as 03 Native American

d. A patient name may be used to infer Spanish ethnicity or place of birth, but a Spanish name alone (without a statement about race or place of birth) cannot be used to determine the race code. Refer to ethnicity guidelines for further information.

Example: Alice Gomez is a native of Indiana (implied birthplace: United States). Code Race 1 through Race 5 as 99 Unknown, because nothing is known about her race.

10. Persons of Spanish or Hispanic origin may be of any race, although persons of Mexican, Central American, South American, Puerto Rican, or Cuban origin are usually white. Do NOT code a patient stated to be Hispanic or Latino as 98 Other Race in Race 1 and 88 in Race 2 through Race 5

Example: Sabrina Fitzsimmons is a native of Brazil. Code race as 01 White per Appendix.

11. When the race is recorded as Negro or African-American, code race as 02 Black.

12. Code 03 should be used for any person stated to be Native American or [western hemisphere]

Indian, whether from North, Central, South, or Latin America. For Central, South, or Latin

American Indians, see additional ethnicity coding guidelines under Spanish Surname or Origin.

13. Death certificate information may be used to supplement antemortem race information only when race is coded unknown in the patient record or when the death certificate information is more specific.

Example 1: In the cancer record Race 1 through Race 5 are coded as 99 Unknown. The death

certificate states race as black. Change cancer record for Race 1 to 02 Black and Race 2 through

Race 5 to 88.

Example 2: Race 1 is coded in the cancer record as 96 Asian. Death certificate gives birthplace

as China. Change Race 1 in the cancer record to 04 Chinese and code Race 2 through Race 5 as

88.

Race and nationality descriptions from the 2000 Census and Bureau of Vital Statistics can be found at:

https://seer.cancer.gov/manuals/2016/SPCSM_2016_AppendixD.pdf

Appendix L - Frequent Surnames

A list of frequently occurring heavily Hispanic surnames compiled by the U.S. Census Bureau may be found at:

http://www.census.gov/population/documentation/twpno13.pdf on page 20.

Appendix M - Supplemental ICD-10-CM Codes

These ICD-10-CM and ICD-9-CM codes may also be used for casefinding. The detailed casefinding list contains each individual reportable code. ICD-9-CM and ICD-10-CM Supplemental casefinding lists follow. Many of these codes are for diseases associated with cancer or represent neoplasm-related secondary conditions. Experience among the SEER registries has proven that using the supplementary list significantly improves casefinding outcomes for benign brain and CNS tumors, hematopoietic and lymphoid neoplasms, and other reportable diseases. It is recommended that each registry screen cases using the supplementary list as time permits.

SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/2017-9/30/2018)

ICD- 10- CM CODE	EXPLANATION OF CODE
B20	Human immunodeficiency virus [HIV] disease with other diseases
B97.33, B97.34, B97.35	Human T-cell lymphotrophic virus,(type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere
B97.7	Papillomarvirus as the cause of diseases classified elsewhere
C44.01, C44.02	Basal/squamous cell carcinoma of skin of lip
C44. 11_, C44.12_	Basal/squamous cell carcinoma of skin of eyelid
C44.21- , C44. 22-	Basal/squamous cell carcinoma of skin of ear and external auricular canal
C44.31- , C44. 32-	Basal/squamous cell carcinoma of skin of other and unspecified parts of face
C44.41, C44.42	Basal/squamous cell carcinoma of skin of scalp and neck
C44.51- , C44. 52-	Basal/squamous cell carcinoma of skin of trunk
C44.61- , C44. 62-	Basal/squamous cell carcinoma of skin of upper limb, including shoulder
C44.71- , C44. 72-	Basal/squamous cell carcinoma of skin of lower limb, including hip
C44.81, C44.82	Basal/squamous cell carcinoma of skin of overlapping sites of skin
C44.91, C44.92	Basal/squamous cell carcinoma of skin of unspecified sites of skin
D10 D31, D34, D35.0, D35.1, D35.5- D35.9, D36	Benign neoplasms (see "must collect" list for reportable benign neoplasms) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.
D3A	Benign carcinoid tumors
D37 D41	Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors
D44.0 - D44.2, D44.6- D44.9	Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors

D47.01	Cutaneous mastocytosis (9740/1) Note: Effective 10/1/2017
D47.09	Other mast cell neoplasms of uncertain behavior Note: Effective 10/1/2017
D47.2	Monoclonal gammopathy Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia
D47.Z2	Castleman disease
D48	Neoplasm of uncertain behavior of other and unspecified sites
D49.0 - D49.9	Neoplasm of unspecified behavior (except for D49.6 and D49.7)
D61.1	Drug-induced aplastic anemia (also known as "aplastic anemia due to antineoplastic chemotherapy") ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug
D61.810	Antineoplastic chemotherapy induced pancytopenia
D61.82	Myelophthisis ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50)
D63.0	Anemia in neoplastic disease ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)
D64.81	Anemia due to antineoplastic chemotherapy
D69.49, D69.59, D69.6	Other thrombocytopenia Note: Screen for incorrectly coded thrombocythemia
D70.1	Agranulocytosis secondary to cancer chemotherapy ICD-10-CM Coding instruction: code also underlying neoplasm
D72.1	Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is a malignancy. Reportable Diagnosis is "Hypereosonophilic syndrome.")
D75.81	Myelofibrosis (note: this is not primary myelofibrosis [9961/3] ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of breast (C50)
D76	Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
D89.0, D89.1	Other disorders involving the immune mechanism, not elsewhere classified <i>Note: Review for miscodes</i>
D89.4-	Mast cell activation syndrome and related disorders Note: Effective 10/1/2016
E08	Diabetes mellitus due to underlying condition ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96)
E31.2-	Multiple endocrine neoplasia [MEN] syndromes ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes
E34.0	Carcinoid syndrome ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor
E83.52	Hypercalcemia
E88.09	Other disorders of plasma-protein metabolism, not elsewhere classified
E88.3	Tumor lysis syndrome (following antineoplastic chemotherapy)
G13.0	Paraneoplastic neuromyopathy and neuropathy ICD-10-CM Coding instruction note:: Code first underlying neoplasm (C00-D49)
G13.1	Other systemic atrophy primarily affecting central nervous system in neoplastic disease ICD-10-CM Coding instruction note:: Code first underlying neoplasm (C00-D49)
C32.8-	Other specified degenerative disorders of nervous system in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49)
G53	Cranial nerve disorders in diseases classified elsewhere Note: Code first underlying neoplasm (C00-D49)
G55	Nerve root and plexus compressions in diseases classified elsewhere ICD-10-CM Coding instruction note: code also underlying disease, such as neoplasm (C00-D49)

G63	Polyneuropathy in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49)
G73.1	Lambert-Eaton syndrome in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)
G89.3	Neoplasm related pain (acute)(chronic)
G99.2	Myelopathy in diseases classified elsewhere ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49)
H47.42	Disorders of optic chiasm in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition
H47.52-	Disorders of visual pathways in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition
H47.63-	Disorders of visual cortex in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition
J34.81	Nasal mucositis (ulcerative)
J91.0	Malignant pleural effusion ICD-10-CM Coding instruction: Code first underlying neoplasm
J93.12	Secondary spontaneous pneumothorax ICD-10-CM Coding instruction: Code first underlying condition, such as: Malignant neoplasm of bronchus and lung (C34) Secondary malignant neoplasm of lung (C78.0_)
K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy
K12.33	Oral mucositis (ulcerative) due to radiation
K22.711	Barrett's esophagus with high grade dysplasia
K62.7	Radiation proctitis
K62.82	Dysplasia of anus (AIN I and AIN II)
K92.81	Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)
M36.0	Dermato(poly)myositis in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)
M36.1	Arthropathy in neoplastic disease <i>ICD-10-CM Coding instruction: Code first underlying neoplasm, such as:</i> Leukemia (C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0)
M84.5-	Pathologic fracture in neoplastic disease ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49)
M90.6-	Osteitis deformans in neoplastic disease ICD-10-CM Coding instruction: Code first the neoplasm (C40, C41)
N42.3	Dysplasia of prostate (PIN I and PIN II)
N76.81	Mucositis (ulcerative) of vagina and vulva
N87	Dysplasia of cervix uteri (CIN I and CIN II)
N89.0, N89.1, N89.3	Vaginal dysplasia (VIN I and VIN II)
N90.0, N90.1, N90.3	Vulvar dysplasia (VAIN I and VAIN II)
O01	Hydatidiform mole Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3,) malignancy code in the C00- C97 range
O9A.1-	Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96) ICD-10-CM Coding instruction: Use additional code to identify neoplasm
Q85.0-	Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable
R18.0	Malignant ascites ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)

R53.0	Neoplastic (malignant) related fatigue ICD-10-CM Coding instruction: Code first associated neoplasm
R59	Enlarged lymph nodes
R85.6-	Abnormal findings on cytological and histological examination of digestive organs Note: see "must collect" list for R85.614
R87.61- , R87. 62-	Abnormal findings on cytological/histological examination of female genital organs Note: see "must collect" list for R87.614 and R87.624
R92	Abnormal findings on diagnostic imaging of breast
R97	Abnormal tumor markers
T38.6-	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
T38.8-, T38.9-	Poisoning by hormones and their synthetic substitutes
T45.1-	Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs
T45.8-, T45.9-	Poisoning by primary systemic and hematological agent, unspecified
T66	Unspecified effects of radiation
T80.1	Vascular complications following infusion, transfusion and therapeutic injection
T80.2-	Infections following infusion, transfusion and therapeutic injection
T80.810	Extravasation of vesicant antineoplastic chemotherapy
T80.818	Extravasation of other vesicant agent
T86.0	Complications of bone marrow transplant ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)
Y63.2	Overdose of radiation given during therapy
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Z03.89	Encounter for observation for other suspected diseases and conditions ruled out
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85)
Z12	Encounter for screening for malignant neoplasms
Z13.0	Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Z15.0	Genetic susceptibility to malignant neoplasm ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85)
Z17.0, Z17.1	Estrogen receptor positive and negative status ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50)
Z40.0-	Encounter for prophylactic surgery for risk factors related to malignant neoplasms
Z42.1	Encounter for breast reconstruction following mastectomy
Z48.3	Aftercare following surgery for neoplasm ICD-10-CM Coding instruction: Use additional code to identify the neoplasm
Z48.290	Encounter for aftercare following bone marrow transplant
Z51.0	Encounter for antineoplastic radiation therapy
Z51.1-	Encounter for antineoplastic chemotherapy and immunotherapy
Z51.5, Z51.89	Encounter for palliative care and other specified aftercare
Z79.81-	Long term (current) use of agents affecting estrogen receptors and estrogen levels ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50), malignant neoplasm of prostate (C61)
Z80	Family history of primary malignant neoplasm

Z85	Personal history of malignant neoplasm ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08)
Z86.0-, Z86.01- , Z86.03	Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior
Z92.21, Z92.23, Z92.25. Z92.3	Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)
Z94.81, Z94.84	Bone marrow and stem cell transplant status

ICD-10-CM Detailed Casefinding List

ICD-10-CM Code	Explanation of Code
C00	Malignant neoplasm of lip
C000	Malignant neoplasm of external upper lip
C001	Malignant neoplasm of external lower lip
C002	Malignant neoplasm of external lip, unspecified
C003	Malignant neoplasm of upper lip, inner aspect
C004	Malignant neoplasm of lower lip, inner aspect
C005	Malignant neoplasm of lip, unspecified, inner aspect
C006	Malignant neoplasm of commissure of lip, unspecified
C008	Malignant neoplasm of overlapping sites of lip
C009	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue
C02	Malignant neoplasm of other and unspecified parts of tongue
C020	Malignant neoplasm of dorsal surface of tongue
C021	Malignant neoplasm of border of tongue
C022	Malignant neoplasm of ventral surface of tongue
C023	Malig neoplasm of anterior two-thirds of tongue, part unsp
C024	Malignant neoplasm of lingual tonsil
C028	Malignant neoplasm of overlapping sites of tongue
C029	Malignant neoplasm of tongue, unspecified
C03	Malignant neoplasm of gum
C030	Malignant neoplasm of upper gum
C031	Malignant neoplasm of lower gum
C039	Malignant neoplasm of gum, unspecified
C04	Malignant neoplasm of floor of mouth
C040	Malignant neoplasm of anterior floor of mouth
C041	Malignant neoplasm of lateral floor of mouth
C048	Malignant neoplasm of overlapping sites of floor of mouth
C049	Malignant neoplasm of floor of mouth, unspecified
C05	Malignant neoplasm of palate

C050	Malignant neoplasm of hard palate
C051	Malignant neoplasm of soft palate
C052	Malignant neoplasm of uvula
C058	Malignant neoplasm of overlapping sites of palate
C059	Malignant neoplasm of palate, unspecified
C06	Malignant neoplasm of other and unspecified parts of mouth
C060	Malignant neoplasm of cheek mucosa
C061	Malignant neoplasm of vestibule of mouth
C062	Malignant neoplasm of retromolar area
C068	Malignant neoplasm of ovrlp sites of and unsp parts of mouth
C0680	Malignant neoplasm of ovrlp sites of unsp parts of mouth
C0689	Malignant neoplasm of overlapping sites of oth prt mouth
C069	Malignant neoplasm of mouth, unspecified
C07	Malignant neoplasm of parotid gland
C08	Malignant neoplasm of other and unsp major salivary glands
C080	Malignant neoplasm of submandibular gland
C081	Malignant neoplasm of sublingual gland
C089	Malignant neoplasm of major salivary gland, unspecified
C09	Malignant neoplasm of tonsil
C090	Malignant neoplasm of tonsillar fossa
C091	Malig neoplasm of tonsillar pillar (anterior) (posterior)
C098	Malignant neoplasm of overlapping sites of tonsil
C099	Malignant neoplasm of tonsil, unspecified
C10	Malignant neoplasm of oropharynx
C100	Malignant neoplasm of vallecula
C101	Malignant neoplasm of anterior surface of epiglottis
C102	Malignant neoplasm of lateral wall of oropharynx
C103	Malignant neoplasm of posterior wall of oropharynx
C104	Malignant neoplasm of branchial cleft
C108	Malignant neoplasm of overlapping sites of oropharynx
C109	Malignant neoplasm of oropharynx, unspecified
C11	Malignant neoplasm of nasopharynx
C110	Malignant neoplasm of superior wall of nasopharynx
C111	Malignant neoplasm of posterior wall of nasopharynx
C112	Malignant neoplasm of lateral wall of nasopharynx
C113	Malignant neoplasm of anterior wall of nasopharynx
C118	Malignant neoplasm of overlapping sites of nasopharynx
C119	Malignant neoplasm of nasopharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13	Malignant neoplasm of hypopharynx
C130	Malignant neoplasm of postcricoid region

C131	Malig neoplasm of aryepiglottic fold, hypopharyngeal aspect
C132	Malignant neoplasm of posterior wall of hypopharynx
C138	Malignant neoplasm of overlapping sites of hypopharynx
C139	Malignant neoplasm of hypopharynx, unspecified
C14	Malig neoplasm of sites in the lip, oral cavity and pharynx
C140	Malignant neoplasm of pharynx, unspecified
C142	Malignant neoplasm of Waldeyer's ring
C148	Malig neoplm of ovrlp sites of lip, oral cavity and pharynx
C15	Malignant neoplasm of esophagus
C153	Malignant neoplasm of upper third of esophagus
C154	Malignant neoplasm of middle third of esophagus
C155	Malignant neoplasm of lower third of esophagus
C158	Malignant neoplasm of overlapping sites of esophagus
C159	Malignant neoplasm of esophagus, unspecified
C16	Malignant neoplasm of stomach
C160	Malignant neoplasm of cardia
C161	Malignant neoplasm of fundus of stomach
C162	Malignant neoplasm of body of stomach
C163	Malignant neoplasm of pyloric antrum
C164	Malignant neoplasm of pylorus
C165	Malignant neoplasm of lesser curvature of stomach, unsp
C166	Malignant neoplasm of greater curvature of stomach, unsp
C168	Malignant neoplasm of overlapping sites of stomach
C169	Malignant neoplasm of stomach, unspecified
C17	Malignant neoplasm of small intestine
C170	Malignant neoplasm of duodenum
C171	Malignant neoplasm of jejunum
C172	Malignant neoplasm of ileum
C173	Meckel's diverticulum, malignant
C178	Malignant neoplasm of overlapping sites of small intestine
C179	Malignant neoplasm of small intestine, unspecified
C18	Malignant neoplasm of colon
C180	Malignant neoplasm of cecum
C181	Malignant neoplasm of appendix
C182	Malignant neoplasm of ascending colon
C183	Malignant neoplasm of hepatic flexure
C184	Malignant neoplasm of transverse colon
C185	Malignant neoplasm of splenic flexure
C186	Malignant neoplasm of descending colon
C187	Malignant neoplasm of sigmoid colon
C188	Malignant neoplasm of overlapping sites of colon

C189	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21	Malignant neoplasm of anus and anal canal
C210	Malignant neoplasm of anus, unspecified
C211	Malignant neoplasm of anal canal
C212	Malignant neoplasm of cloacogenic zone
C218	Malig neoplasm of ovrlp sites of rectum, anus and anal canal
C22	Malignant neoplasm of liver and intrahepatic bile ducts
C220	Liver cell carcinoma
C221	Intrahepatic bile duct carcinoma
C222	Hepatoblastoma
C223	Angiosarcoma of liver
C224	Other sarcomas of liver
C227	Other specified carcinomas of liver
C228	Malignant neoplasm of liver, primary, unspecified as to type
C229	Malig neoplasm of liver, not specified as primary or sec
C23	Malignant neoplasm of gallbladder
C24	Malignant neoplasm of other and unsp parts of biliary tract
C240	Malignant neoplasm of extrahepatic bile duct
C241	Malignant neoplasm of ampulla of Vater
C248	Malignant neoplasm of overlapping sites of biliary tract
C249	Malignant neoplasm of biliary tract, unspecified
C25	Malignant neoplasm of pancreas
C250	Malignant neoplasm of head of pancreas
C251	Malignant neoplasm of body of pancreas
C252	Malignant neoplasm of tail of pancreas
C253	Malignant neoplasm of pancreatic duct
C254	Malignant neoplasm of endocrine pancreas
C257	Malignant neoplasm of other parts of pancreas
C258	Malignant neoplasm of overlapping sites of pancreas
C259	Malignant neoplasm of pancreas, unspecified
C26	Malignant neoplasm of other and ill-defined digestive organs
C260	Malignant neoplasm of intestinal tract, part unspecified
C261	Malignant neoplasm of spleen
C269	Malignant neoplasm of ill-defined sites within the dgstv sys
C30	Malignant neoplasm of nasal cavity and middle ear
C300	Malignant neoplasm of nasal cavity
C301	Malignant neoplasm of middle ear
C31	Malignant neoplasm of accessory sinuses
C310	Malignant neoplasm of maxillary sinus

C311	Malignant neoplasm of ethmoidal sinus
C312	Malignant neoplasm of frontal sinus
C313	Malignant neoplasm of sphenoid sinus
C318	Malignant neoplasm of overlapping sites of accessory sinuses
C319	Malignant neoplasm of accessory sinus, unspecified
C32	Malignant neoplasm of larynx
C320	Malignant neoplasm of glottis
C321	Malignant neoplasm of supraglottis
C322	Malignant neoplasm of subglottis
C323	Malignant neoplasm of laryngeal cartilage
C328	Malignant neoplasm of overlapping sites of larynx
C329	Malignant neoplasm of larynx, unspecified
C33	Malignant neoplasm of trachea
C34	Malignant neoplasm of bronchus and lung
C340	Malignant neoplasm of main bronchus
C3400	Malignant neoplasm of unspecified main bronchus
C3401	Malignant neoplasm of right main bronchus
C3402	Malignant neoplasm of left main bronchus
C341	Malignant neoplasm of upper lobe, bronchus or lung
C3410	Malignant neoplasm of upper lobe, unsp bronchus or lung
C3411	Malignant neoplasm of upper lobe, right bronchus or lung
C3412	Malignant neoplasm of upper lobe, left bronchus or lung
C342	Malignant neoplasm of middle lobe, bronchus or lung
C343	Malignant neoplasm of lower lobe, bronchus or lung
C3430	Malignant neoplasm of lower lobe, unsp bronchus or lung
C3431	Malignant neoplasm of lower lobe, right bronchus or lung
C3432	Malignant neoplasm of lower lobe, left bronchus or lung
C348	Malignant neoplasm of overlapping sites of bronchus and lung
C3480	Malignant neoplasm of ovrlp sites of unsp bronchus and lung
C3481	Malignant neoplasm of ovrlp sites of right bronchus and lung
C3482	Malignant neoplasm of ovrlp sites of left bronchus and lung
C349	Malignant neoplasm of unspecified part of bronchus or lung
C3490	Malignant neoplasm of unsp part of unsp bronchus or lung
C3491	Malignant neoplasm of unsp part of right bronchus or lung
C3492	Malignant neoplasm of unsp part of left bronchus or lung
C37	Malignant neoplasm of thymus
C38	Malignant neoplasm of heart, mediastinum and pleura
C380	Malignant neoplasm of heart
C381	Malignant neoplasm of anterior mediastinum
C382	Malignant neoplasm of posterior mediastinum
C383	Malignant neoplasm of mediastinum, part unspecified

C384	Malignant neoplasm of pleura
C388	Malig neoplm of ovrlp sites of heart, mediastinum and pleura
C39	Malig neoplm of sites in the resp sys and intrathorac organs
C390	Malignant neoplasm of upper respiratory tract, part unsp
C399	Malignant neoplasm of lower respiratory tract, part unsp
C40	Malignant neoplasm of bone and articular cartilage of limbs
C400	Malignant neoplasm of scapula and long bones of upper limb
C4000	Malig neoplasm of scapula and long bones of unsp upper limb
C4001	Malig neoplasm of scapula and long bones of right upper limb
C4002	Malig neoplasm of scapula and long bones of left upper limb
C401	Malignant neoplasm of short bones of upper limb
C4010	Malignant neoplasm of short bones of unspecified upper limb
C4011	Malignant neoplasm of short bones of right upper limb
C4012	Malignant neoplasm of short bones of left upper limb
C402	Malignant neoplasm of long bones of lower limb
C4020	Malignant neoplasm of long bones of unspecified lower limb
C4021	Malignant neoplasm of long bones of right lower limb
C4022	Malignant neoplasm of long bones of left lower limb
C403	Malignant neoplasm of short bones of lower limb
C4030	Malignant neoplasm of short bones of unspecified lower limb
C4031	Malignant neoplasm of short bones of right lower limb
C4032	Malignant neoplasm of short bones of left lower limb
C408	Malig neoplasm of ovrlp sites of bone/artic cartl of limb
C4080	Malig neoplm of ovrlp sites of bone/artic cartl of unsp limb
C4081	Malig neoplm of ovrlp sites of bone/artic cartl of r limb
C4082	Malig neoplm of ovrlp sites of bone/artic cartl of left limb
C409	Malignant neoplasm of unsp bones and artic cartilage of limb
C4090	Malig neoplasm of unsp bones and artic cartlg of unsp limb
C4091	Malig neoplasm of unsp bones and artic cartlg of right limb
C4092	Malig neoplasm of unsp bones and artic cartlg of left limb
C41	Malignant neoplasm of bone/artic cartl of and unsp sites
C410	Malignant neoplasm of bones of skull and face
C411	Malignant neoplasm of mandible
C412	Malignant neoplasm of vertebral column
C413	Malignant neoplasm of ribs, sternum and clavicle
C414	Malignant neoplasm of pelvic bones, sacrum and coccyx
C419	Malignant neoplasm of bone and articular cartilage, unsp
C43	Malignant melanoma of skin
C430	Malignant melanoma of lip
C430	Malignant melanoma of eyelid, including canthus
C4310	Malignant melanoma of unspecified eyelid, including canthus

C4311	Malignant melanoma of right eyelid, including canthus
C4312	Malignant melanoma of left eyelid, including canthus
C432	Malignant melanoma of ear and external auricular canal
C4320	Malignant melanoma of unsp ear and external auricular canal
C4321	Malignant melanoma of right ear and external auricular canal
C4322	Malignant melanoma of left ear and external auricular canal
C433	Malignant melanoma of other and unspecified parts of face
C4330	Malignant melanoma of unspecified part of face
C4331	Malignant melanoma of nose
C4339	Malignant melanoma of other parts of face
C434	Malignant melanoma of scalp and neck
C435	Malignant melanoma of trunk
C4351	Malignant melanoma of anal skin
C4352	Malignant melanoma of skin of breast
C4359	Malignant melanoma of other part of trunk
C436	Malignant melanoma of upper limb, including shoulder
C4360	Malignant melanoma of unsp upper limb, including shoulder
C4361	Malignant melanoma of right upper limb, including shoulder
C4362	Malignant melanoma of left upper limb, including shoulder
C437	Malignant melanoma of lower limb, including hip
C4370	Malignant melanoma of unspecified lower limb, including hip
C4371	Malignant melanoma of right lower limb, including hip
C4372	Malignant melanoma of left lower limb, including hip
C438	Malignant melanoma of overlapping sites of skin
C439	Malignant melanoma of skin, unspecified
C4A	Merkel cell carcinoma
C4A0	Merkel cell carcinoma of lip
C4A1	Merkel cell carcinoma of eyelid, including canthus
C4A10	Merkel cell carcinoma of unsp eyelid, including canthus
C4A11	Merkel cell carcinoma of right eyelid, including canthus
C4A12	Merkel cell carcinoma of left eyelid, including canthus
C4A12	Merkel cell carcinoma of ear and external auricular canal
C4A2	Merkel cell carcinoma of unsp ear and external auric canal
C4A21	Merkel cell carcinoma of right ear and external auric canal
C4A21	Merkel cell carcinoma of left ear and external auric canal
C4A3	Merkel cell carcinoma of other and unspecified parts of face
C4A30	Merkel cell carcinoma of unspecified part of face
C4A31	Merkel cell carcinoma of nose
C4A39	Merkel cell carcinoma of other parts of face
C4A4	Merkel cell carcinoma of scalp and neck
C4A5	Merkel cell carcinoma of trunk

C4A51	Merkel cell carcinoma of anal skin
C4A52	Merkel cell carcinoma of skin of breast
C4A59	Merkel cell carcinoma of other part of trunk
C4A6	Merkel cell carcinoma of upper limb, including shoulder
C4A60	Merkel cell carcinoma of unsp upper limb, including shoulder
C4A61	Merkel cell carcinoma of right upper limb, inc shoulder
C4A62	Merkel cell carcinoma of left upper limb, including shoulder
C4A7	Merkel cell carcinoma of lower limb, including hip
C4A70	Merkel cell carcinoma of unsp lower limb, including hip
C4A71	Merkel cell carcinoma of right lower limb, including hip
C4A72	Merkel cell carcinoma of left lower limb, including hip
C4A8	Merkel cell carcinoma of overlapping sites
C4A9	Merkel cell carcinoma, unspecified
C4400	Unspecified malignant neoplasm of skin of lip
C4409	Other specified malignant neoplasm of skin of lip
C4410	Unsp malignant neoplasm of skin of eyelid, including canthus
C44101	Unsp malignant neoplasm skin/ unsp eyelid, including canthus
C44102	Unsp malignant neoplasm skin/ right eyelid, inc canthus
C44109	Unsp malignant neoplasm skin/ left eyelid, including canthus
C4419	Oth malignant neoplasm of skin of eyelid, including canthus
C44191	Oth malignant neoplasm skin/ unsp eyelid, including canthus
C44192	Oth malignant neoplasm skin/ right eyelid, including canthus
C44199	Oth malignant neoplasm skin/ left eyelid, including canthus
C4420	Unsp malignant neoplasm skin/ ear and external auric canal
C44201	Unsp malig neoplasm skin/ unsp ear and external auric canal
C44202	Unsp malig neoplasm skin/ right ear and external auric canal
C44209	Unsp malig neoplasm skin/ left ear and external auric canal
C4429	Oth malignant neoplasm skin/ ear and external auric canal
C44291	Oth malig neoplasm skin/ unsp ear and external auric canal
C44292	Oth malig neoplasm skin/ right ear and external auric canal
C44299	Oth malig neoplasm skin/ left ear and external auric canal
C4430	Unsp malignant neoplasm of skin of and unsp parts of face
C44300	Unsp malignant neoplasm of skin of unspecified part of face
C44301	Unspecified malignant neoplasm of skin of nose
C44309	Unsp malignant neoplasm of skin of other parts of face
C4439	Oth malignant neoplasm of skin of oth and unsp parts of face
C44390	Oth malignant neoplasm of skin of unspecified parts of face
C44391	Other specified malignant neoplasm of skin of nose
C44399	Oth malignant neoplasm of skin of other parts of face
C4440	Unspecified malignant neoplasm of skin of scalp and neck
C4449	Other specified malignant neoplasm of skin of scalp and neck

C4450	Unspecified malignant neoplasm of skin of trunk
C44500	Unspecified malignant neoplasm of anal skin
C44501	Unspecified malignant neoplasm of skin of breast
C44509	Unsp malignant neoplasm of skin of other part of trunk
C4459	Other specified malignant neoplasm of skin of trunk
C44590	Other specified malignant neoplasm of anal skin
C44591	Other specified malignant neoplasm of skin of breast
C44599	Oth malignant neoplasm of skin of other part of trunk
C4460	Unsp malignant neoplasm skin/ upper limb, including shoulder
C44601	Unsp malignant neoplasm skin/ unsp upper limb, inc shoulder
C44602	Unsp malignant neoplasm skin/ right upper limb, inc shoulder
C44609	Unsp malignant neoplasm skin/ left upper limb, inc shoulder
C4469	Oth malignant neoplasm skin/ upper limb, including shoulder
C44691	Oth malignant neoplasm skin/ unsp upper limb, inc shoulder
C44692	Oth malignant neoplasm skin/ right upper limb, inc shoulder
C44699	Oth malignant neoplasm skin/ left upper limb, inc shoulder
C4470	Unsp malignant neoplasm of skin of lower limb, including hip
C44701	Unsp malignant neoplasm skin/ unsp lower limb, including hip
C44702	Unsp malignant neoplasm skin/ right lower limb, inc hip
C44709	Unsp malignant neoplasm skin/ left lower limb, including hip
C4479	Oth malignant neoplasm of skin of lower limb, including hip
C44791	Oth malignant neoplasm skin/ unsp lower limb, including hip
C44792	Oth malignant neoplasm skin/ right lower limb, including hip
C44799	Oth malignant neoplasm skin/ left lower limb, including hip
C4480	Unspecified malignant neoplasm of overlapping sites of skin
C4489	Oth malignant neoplasm of overlapping sites of skin
C4490	Unspecified malignant neoplasm of skin, unspecified
C4499	Other specified malignant neoplasm of skin, unspecified
C45	Mesothelioma
C450	Mesothelioma of pleura
C451	Mesothelioma of peritoneum
C452	Mesothelioma of pericardium
C457	Mesothelioma of other sites
C459	Mesothelioma, unspecified
C46	Kaposi's sarcoma
C460	Kaposi's sarcoma of skin
C461	Kaposi's sarcoma of soft tissue
C462	Kaposi's sarcoma of palate
C463	Kaposi's sarcoma of lymph nodes
C464	Kaposi's sarcoma of gastrointestinal sites
C465	Kaposi's sarcoma of lung

C4651	Kaposi's sarcoma of right lung
C4652	Kaposi's sarcoma of left lung
C467	Kaposi's sarcoma of other sites
C469	Kaposi's sarcoma, unspecified
C47	Malignant neoplasm of prph nerves and autonomic nervous sys
C470	Malignant neoplasm of prph nerves of head, face and neck
C471	Malig neoplasm of prph nerves of upper limb, inc shoulder
C4710	Malig neopIm of prph nerves of unsp upper limb, inc shoulder
C4711	Malig neoplm of prph nerves of right upper limb, inc shldr
C4712	Malig neoplm of prph nerves of left upper limb, inc shoulder
C472	Malignant neoplasm of prph nerves of lower limb, inc hip
C4720	Malig neoplasm of prph nerves of unsp lower limb, inc hip
C4721	Malig neoplasm of prph nerves of right lower limb, inc hip
C4722	Malig neoplasm of prph nerves of left lower limb, inc hip
C473	Malignant neoplasm of peripheral nerves of thorax
C474	Malignant neoplasm of peripheral nerves of abdomen
C475	Malignant neoplasm of peripheral nerves of pelvis
C476	Malignant neoplasm of peripheral nerves of trunk, unsp
C478	Malig neoplm of ovrlp sites of prph nrv and autonm nrv sys
C479	Malig neoplasm of prph nerves and autonm nervous sys, unsp
C48	Malignant neoplasm of retroperitoneum and peritoneum
C480	Malignant neoplasm of retroperitoneum
C481	Malignant neoplasm of specified parts of peritoneum
C482	Malignant neoplasm of peritoneum, unspecified
C488	Malig neoplasm of ovrlp sites of retroperiton and peritoneum
C49	Malignant neoplasm of other connective and soft tissue
C490	Malig neoplm of conn and soft tissue of head, face and neck
C491	Malig neoplm of conn and soft tiss of upper limb, inc shldr
C4910	Malig neoplm of conn & soft tiss of unsp upr lmb, inc shldr
C4911	Malig neoplm of conn and soft tiss of r upr limb, inc shldr
C4912	Malig neoplm of conn and soft tiss of I upr limb, inc shldr
C492	Malig neoplm of conn and soft tissue of lower limb, inc hip
C4920	Malig neoplm of conn and soft tiss of unsp low limb, inc hip
C4921	Malig neopIm of conn and soft tiss of r low limb, inc hip
C4922	Malig neoplm of conn and soft tiss of left low limb, inc hip
C493	Malignant neoplasm of connective and soft tissue of thorax
C494	Malignant neoplasm of connective and soft tissue of abdomen
C495	Malignant neoplasm of connective and soft tissue of pelvis
C496	Malignant neoplasm of conn and soft tissue of trunk, unsp
C498	Malignant neoplasm of ovrlp sites of conn and soft tissue

C499	Malignant neoplasm of connective and soft tissue, unsp
C50	Malignant neoplasm of breast
C500	Malignant neoplasm of nipple and areola
C5001	Malignant neoplasm of nipple and areola, female
C50011	Malignant neoplasm of nipple and areola, right female breast
C50012	Malignant neoplasm of nipple and areola, left female breast
C50019	Malignant neoplasm of nipple and areola, unsp female breast
C5002	Malignant neoplasm of nipple and areola, male
C50021	Malignant neoplasm of nipple and areola, right male breast
C50022	Malignant neoplasm of nipple and areola, left male breast
C50029	Malignant neoplasm of nipple and areola, unsp male breast
C501	Malignant neoplasm of central portion of breast
C5011	Malignant neoplasm of central portion of breast, female
C50111	Malignant neoplasm of central portion of right female breast
C50112	Malignant neoplasm of central portion of left female breast
C50119	Malignant neoplasm of central portion of unsp female breast
C5012	Malignant neoplasm of central portion of breast, male
C50121	Malignant neoplasm of central portion of right male breast
C50122	Malignant neoplasm of central portion of left male breast
C50129	Malignant neoplasm of central portion of unsp male breast
C502	Malignant neoplasm of upper-inner quadrant of breast
C5021	Malignant neoplasm of upper-inner quadrant of breast, female
C50211	Malig neoplm of upper-inner quadrant of right female breast
C50212	Malig neoplasm of upper-inner quadrant of left female breast
C50219	Malig neoplasm of upper-inner quadrant of unsp female breast
C5022	Malignant neoplasm of upper-inner quadrant of breast, male
C50221	Malig neoplasm of upper-inner quadrant of right male breast
C50222	Malig neoplasm of upper-inner quadrant of left male breast
C50229	Malig neoplasm of upper-inner quadrant of unsp male breast
C503	Malignant neoplasm of lower-inner quadrant of breast
C5031	Malignant neoplasm of lower-inner quadrant of breast, female
C50311	Malig neoplm of lower-inner quadrant of right female breast
C50312	Malig neoplasm of lower-inner quadrant of left female breast
C50319	Malig neoplasm of lower-inner quadrant of unsp female breast
C5032	Malignant neoplasm of lower-inner quadrant of breast, male
C50321	Malig neoplasm of lower-inner quadrant of right male breast
C50322	Malig neoplasm of lower-inner quadrant of left male breast
C50329	Malig neoplasm of lower-inner quadrant of unsp male breast
C504	Malignant neoplasm of upper-outer quadrant of breast
C5041	Malignant neoplasm of upper-outer quadrant of breast, female
C50411	Malig neoplm of upper-outer quadrant of right female breast

C50419	Malig neoplasm of upper-outer quadrant of unsp female breast
C5042	Malignant neoplasm of upper-outer quadrant of breast, male
C50421	Malig neoplasm of upper-outer quadrant of right male breast
C50421	Malig neoplasm of upper-outer quadrant of left male breast
C50422	Malig neoplasm of upper-outer quadrant of unsp male breast
C505	Malignant neoplasm of lower-outer quadrant of breast
C5051	Malignant neoplasm of lower-outer quadrant of breast, female
C50511	Malig neoplm of lower-outer quadrant of right female breast
C50512	Malig neoplasm of lower-outer quadrant of left female breast
C50519	Malig neoplasm of lower-outer quadrant of unsp female breast
C5052	Malignant neoplasm of lower-outer quadrant of breast, male
C50521	Malig neoplasm of lower-outer quadrant of right male breast
C50522	Malig neoplasm of lower-outer quadrant of left male breast
C50529	Malig neoplasm of lower-outer quadrant of unsp male breast
C506	Malignant neoplasm of axillary tail of breast
C5061	Malignant neoplasm of axillary tail of breast, female
C50611	Malignant neoplasm of axillary tail of right female breast
C50612	Malignant neoplasm of axillary tail of left female breast
C50619	Malignant neoplasm of axillary tail of unsp female breast
C5062	Malignant neoplasm of axillary tail of breast, male
C50621	Malignant neoplasm of axillary tail of right male breast
C50622	Malignant neoplasm of axillary tail of left male breast
C50629	Malignant neoplasm of axillary tail of unsp male breast
C508	Malignant neoplasm of overlapping sites of breast
C5081	Malignant neoplasm of overlapping sites of breast, female
C50811	Malignant neoplasm of ovrlp sites of right female breast
C50812	Malignant neoplasm of ovrlp sites of left female breast
C50819	Malignant neoplasm of ovrlp sites of unsp female breast
C5082	Malignant neoplasm of overlapping sites of breast, male
C50821	Malignant neoplasm of overlapping sites of right male breast
C50822	Malignant neoplasm of overlapping sites of left male breast
C50829	Malignant neoplasm of overlapping sites of unsp male breast
C509	Malignant neoplasm of breast of unspecified site
C5091	Malignant neoplasm of breast of unspecified site, female
C50911	Malignant neoplasm of unsp site of right female breast
C50912	Malignant neoplasm of unspecified site of left female breast
C50919	Malignant neoplasm of unsp site of unspecified female breast
C5092	Malignant neoplasm of breast of unspecified site, male
C50921	Malignant neoplasm of unspecified site of right male breast
C50922	Malignant neoplasm of unspecified site of left male breast

051	Malignant neoplasm of unsp site of unspecified male breast
C51	Malignant neoplasm of vulva
C510	Malignant neoplasm of labium majus
C511	Malignant neoplasm of labium minus
C512	Malignant neoplasm of clitoris
C518	Malignant neoplasm of overlapping sites of vulva
C519	Malignant neoplasm of vulva, unspecified
C52	Malignant neoplasm of vagina
C53	Malignant neoplasm of cervix uteri
C530	Malignant neoplasm of endocervix
C531	Malignant neoplasm of exocervix
C538	Malignant neoplasm of overlapping sites of cervix uteri
C539	Malignant neoplasm of cervix uteri, unspecified
C54	Malignant neoplasm of corpus uteri
C540	Malignant neoplasm of isthmus uteri
C541	Malignant neoplasm of endometrium
C542	Malignant neoplasm of myometrium
C543	Malignant neoplasm of fundus uteri
C548	Malignant neoplasm of overlapping sites of corpus uteri
C549	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C56	Malignant neoplasm of ovary
C561	Malignant neoplasm of right ovary
C562	Malignant neoplasm of left ovary
C569	Malignant neoplasm of unspecified ovary
C57	Malignant neoplasm of other and unsp female genital organs
C570	Malignant neoplasm of fallopian tube
C5700	Malignant neoplasm of unspecified fallopian tube
C5701	Malignant neoplasm of right fallopian tube
C5702	Malignant neoplasm of left fallopian tube
C571	Malignant neoplasm of broad ligament
C5710	Malignant neoplasm of unspecified broad ligament
C5711	Malignant neoplasm of right broad ligament
C5712	Malignant neoplasm of left broad ligament
C572	Malignant neoplasm of round ligament
C5720	Malignant neoplasm of unspecified round ligament
C5721	Malignant neoplasm of right round ligament
C5722	Malignant neoplasm of left round ligament
C573	Malignant neoplasm of parametrium
C574	Malignant neoplasm of uterine adnexa, unspecified
C577	Malignant neoplasm of other specified female genital organs

C578	Malignant neoplasm of ovrlp sites of female genital organs
C579	Malignant neoplasm of female genital organ, unspecified
C58	Malignant neoplasm of placenta
C60	Malignant neoplasm of penis
C600	Malignant neoplasm of prepuce
C601	Malignant neoplasm of glans penis
C602	Malignant neoplasm of body of penis
C608	Malignant neoplasm of overlapping sites of penis
C609	Malignant neoplasm of penis, unspecified
C61	Malignant neoplasm of prostate
C62	Malignant neoplasm of testis
C620	Malignant neoplasm of undescended testis
C6200	Malignant neoplasm of unspecified undescended testis
C6201	Malignant neoplasm of undescended right testis
C6202	Malignant neoplasm of undescended left testis
C621	Malignant neoplasm of descended testis
C6210	Malignant neoplasm of unspecified descended testis
C6211	Malignant neoplasm of descended right testis
C6212	Malignant neoplasm of descended left testis
C629	Malignant neoplasm of testis, unsp descended or undescended
C6290	Malig neoplasm of unsp testis, unsp descended or undescended
C6291	Malig neoplm of right testis, unsp descended or undescended
C6292	Malig neoplasm of left testis, unsp descended or undescended
C63	Malignant neoplasm of other and unsp male genital organs
C630	Malignant neoplasm of epididymis
C6300	Malignant neoplasm of unspecified epididymis
C6301	Malignant neoplasm of right epididymis
C6302	Malignant neoplasm of left epididymis
C631	Malignant neoplasm of spermatic cord
C6310	Malignant neoplasm of unspecified spermatic cord
C6311	Malignant neoplasm of right spermatic cord
C6312	Malignant neoplasm of left spermatic cord
C632	Malignant neoplasm of scrotum
C637	Malignant neoplasm of other specified male genital organs
C638	Malignant neoplasm of ovrlp sites of male genital organs
C639	Malignant neoplasm of male genital organ, unspecified
C64	Malignant neoplasm of kidney, except renal pelvis
C641	Malignant neoplasm of right kidney, except renal pelvis
C642	Malignant neoplasm of left kidney, except renal pelvis
C649	Malignant neoplasm of unsp kidney, except renal pelvis
C65	Malignant neoplasm of renal pelvis

C651	Malignant neoplasm of right renal pelvis
C652	Malignant neoplasm of left renal pelvis
C659	Malignant neoplasm of unspecified renal pelvis
C66	Malignant neoplasm of ureter
C661	Malignant neoplasm of right ureter
C662	Malignant neoplasm of left ureter
C669	Malignant neoplasm of unspecified ureter
C67	Malignant neoplasm of bladder
C670	Malignant neoplasm of trigone of bladder
C671	Malignant neoplasm of dome of bladder
C672	Malignant neoplasm of lateral wall of bladder
C673	Malignant neoplasm of anterior wall of bladder
C674	Malignant neoplasm of posterior wall of bladder
C675	Malignant neoplasm of bladder neck
C676	Malignant neoplasm of ureteric orifice
C677	Malignant neoplasm of urachus
C678	Malignant neoplasm of overlapping sites of bladder
C679	Malignant neoplasm of bladder, unspecified
C68	Malignant neoplasm of other and unspecified urinary organs
C680	Malignant neoplasm of urethra
C681	Malignant neoplasm of paraurethral glands
C688	Malignant neoplasm of overlapping sites of urinary organs
C689	Malignant neoplasm of urinary organ, unspecified
C69	Malignant neoplasm of eye and adnexa
C690	Malignant neoplasm of conjunctiva
C6900	Malignant neoplasm of unspecified conjunctiva
C6901	Malignant neoplasm of right conjunctiva
C6902	Malignant neoplasm of left conjunctiva
C691	Malignant neoplasm of cornea
C6910	Malignant neoplasm of unspecified cornea
C6911	Malignant neoplasm of right cornea
C6912	Malignant neoplasm of left cornea
C692	Malignant neoplasm of retina
C6920	Malignant neoplasm of unspecified retina
C6921	Malignant neoplasm of right retina
C6922	Malignant neoplasm of left retina
C693	Malignant neoplasm of choroid
C6930	Malignant neoplasm of unspecified choroid
C6931	Malignant neoplasm of right choroid
C6932	Malignant neoplasm of left choroid
C694	Malignant neoplasm of ciliary body

C6940	Malignant neoplasm of unspecified ciliary body
C6941	Malignant neoplasm of right ciliary body
C6942	Malignant neoplasm of left ciliary body
C695	Malignant neoplasm of lacrimal gland and duct
C6950	Malignant neoplasm of unspecified lacrimal gland and duct
C6951	Malignant neoplasm of right lacrimal gland and duct
C6952	Malignant neoplasm of left lacrimal gland and duct
C696	Malignant neoplasm of orbit
C6960	Malignant neoplasm of unspecified orbit
C6961	Malignant neoplasm of right orbit
C6962	Malignant neoplasm of left orbit
C698	Malignant neoplasm of overlapping sites of eye and adnexa
C6980	Malignant neoplasm of ovrlp sites of unsp eye and adnexa
C6981	Malignant neoplasm of ovrlp sites of right eye and adnexa
C6982	Malignant neoplasm of ovrlp sites of left eye and adnexa
C699	Malignant neoplasm of unspecified site of eye
C6990	Malignant neoplasm of unspecified site of unspecified eye
C6991	Malignant neoplasm of unspecified site of right eye
C6992	Malignant neoplasm of unspecified site of left eye
C70	Malignant neoplasm of meninges
C700	Malignant neoplasm of cerebral meninges
C701	Malignant neoplasm of spinal meninges
C709	Malignant neoplasm of meninges, unspecified
C71	Malignant neoplasm of brain
C710	Malignant neoplasm of cerebrum, except lobes and ventricles
C711	Malignant neoplasm of frontal lobe
C712	Malignant neoplasm of temporal lobe
C713	Malignant neoplasm of parietal lobe
C714	Malignant neoplasm of occipital lobe
C715	Malignant neoplasm of cerebral ventricle
C716	Malignant neoplasm of cerebellum
C717	Malignant neoplasm of brain stem
C718	Malignant neoplasm of overlapping sites of brain
C719	Malignant neoplasm of brain, unspecified
C72	Malig neoplm of spinal cord, cranial nerves and oth prt cnsl
C720	Malignant neoplasm of spinal cord
C721	Malignant neoplasm of cauda equina
C722	Malignant neoplasm of olfactory nerve
C7220	Malignant neoplasm of unspecified olfactory nerve
C7221	Malignant neoplasm of right olfactory nerve
C7222	Malignant neoplasm of left olfactory nerve

C723	Malignant neoplasm of optic nerve
C7230	Malignant neoplasm of unspecified optic nerve
C7231	Malignant neoplasm of right optic nerve
C7232	Malignant neoplasm of left optic nerve
C724	Malignant neoplasm of acoustic nerve
C7240	Malignant neoplasm of unspecified acoustic nerve
C7241	Malignant neoplasm of right acoustic nerve
C7242	Malignant neoplasm of left acoustic nerve
C725	Malignant neoplasm of other and unspecified cranial nerves
C7250	Malignant neoplasm of unspecified cranial nerve
C7259	Malignant neoplasm of other cranial nerves
C729	Malignant neoplasm of central nervous system, unspecified
C73	Malignant neoplasm of thyroid gland
C74	Malignant neoplasm of adrenal gland
C740	Malignant neoplasm of cortex of adrenal gland
C7400	Malignant neoplasm of cortex of unspecified adrenal gland
C7401	Malignant neoplasm of cortex of right adrenal gland
C7402	Malignant neoplasm of cortex of left adrenal gland
C741	Malignant neoplasm of medulla of adrenal gland
C7410	Malignant neoplasm of medulla of unspecified adrenal gland
C7411	Malignant neoplasm of medulla of right adrenal gland
C7412	Malignant neoplasm of medulla of left adrenal gland
C749	Malignant neoplasm of unspecified part of adrenal gland
C7490	Malignant neoplasm of unsp part of unspecified adrenal gland
C7491	Malignant neoplasm of unsp part of right adrenal gland
C7492	Malignant neoplasm of unspecified part of left adrenal gland
C75	Malignant neoplasm of endo glands and related structures
C750	Malignant neoplasm of parathyroid gland
C751	Malignant neoplasm of pituitary gland
C752	Malignant neoplasm of craniopharyngeal duct
C753	Malignant neoplasm of pineal gland
C754	Malignant neoplasm of carotid body
C755	Malignant neoplasm of aortic body and other paraganglia
C758	Malignant neoplasm with pluriglandular involvement, unsp
C759	Malignant neoplasm of endocrine gland, unspecified
C7A	Malignant neuroendocrine tumors
C7A0	Malignant carcinoid tumors
C7A00	Malignant carcinoid tumor of unspecified site
C7A01	Malignant carcinoid tumors of the small intestine
C7A010	Malignant carcinoid tumor of the duodenum
C7A011	Malignant carcinoid tumor of the jejunum

C7A012	Malignant carcinoid tumor of the ileum
C7A019	Malignant carcinoid tumor of the sm int, unsp portion
C7A02	Malig carcinoid tumors of the appendix, Ig int, and rectum
C7A020	Malignant carcinoid tumor of the appendix
C7A021	Malignant carcinoid tumor of the cecum
C7A022	Malignant carcinoid tumor of the ascending colon
C7A023	Malignant carcinoid tumor of the transverse colon
C7A024	Malignant carcinoid tumor of the descending colon
C7A025	Malignant carcinoid tumor of the sigmoid colon
C7A026	Malignant carcinoid tumor of the rectum
C7A029	Malignant carcinoid tumor of the lg int, unsp portion
C7A09	Malignant carcinoid tumors of other sites
C7A090	Malignant carcinoid tumor of the bronchus and lung
C7A091	Malignant carcinoid tumor of the thymus
C7A092	Malignant carcinoid tumor of the stomach
C7A093	Malignant carcinoid tumor of the kidney
C7A094	Malignant carcinoid tumor of the foregut NOS
C7A095	Malignant carcinoid tumor of the midgut NOS
C7A096	Malignant carcinoid tumor of the hindgut NOS
C7A098	Malignant carcinoid tumors of other sites
C7A1	Malignant poorly differentiated neuroendocrine tumors
C7A8	Other malignant neuroendocrine tumors
C7B	Secondary neuroendocrine tumors
C7B0	Secondary carcinoid tumors
C7B00	Secondary carcinoid tumors, unspecified site
C7B01	Secondary carcinoid tumors of distant lymph nodes
C7B02	Secondary carcinoid tumors of liver
C7B03	Secondary carcinoid tumors of bone
C7B04	Secondary carcinoid tumors of peritoneum
C7B09	Secondary carcinoid tumors of other sites
C7B1	Secondary Merkel cell carcinoma
C7B8	Other secondary neuroendocrine tumors
C76	Malignant neoplasm of other and ill-defined sites
C760	Malignant neoplasm of head, face and neck
C761	Malignant neoplasm of thorax
C762	Malignant neoplasm of abdomen
C763	Malignant neoplasm of pelvis
C764	Malignant neoplasm of upper limb
C7640	Malignant neoplasm of unspecified upper limb
C7641	Malignant neoplasm of right upper limb
C7642	Malignant neoplasm of left upper limb

C765	Malignant neoplasm of lower limb
C7650	Malignant neoplasm of unspecified lower limb
C7651	Malignant neoplasm of right lower limb
C7652	Malignant neoplasm of left lower limb
C768	Malignant neoplasm of other specified ill-defined sites
C77	Secondary and unspecified malignant neoplasm of lymph nodes
C770	Sec and unsp malig neoplasm of nodes of head, face and neck
C771	Secondary and unsp malignant neoplasm of intrathorac nodes
C772	Secondary and unsp malignant neoplasm of intra-abd nodes
C773	Sec and unsp malig neoplasm of axilla and upper limb nodes
C774	Sec and unsp malig neoplasm of inguinal and lower limb nodes
C775	Secondary and unsp malignant neoplasm of intrapelv nodes
C778	Sec and unsp malig neoplasm of nodes of multiple regions
C779	Secondary and unsp malignant neoplasm of lymph node, unsp
C78	Secondary malignant neoplasm of resp and digestive organs
C780	Secondary malignant neoplasm of lung
C7800	Secondary malignant neoplasm of unspecified lung
C7801	Secondary malignant neoplasm of right lung
C7802	Secondary malignant neoplasm of left lung
C781	Secondary malignant neoplasm of mediastinum
C782	Secondary malignant neoplasm of pleura
C783	Secondary malignant neoplasm of and unsp respiratory organs
C7830	Secondary malignant neoplasm of unsp respiratory organ
C7839	Secondary malignant neoplasm of other respiratory organs
C784	Secondary malignant neoplasm of small intestine
C785	Secondary malignant neoplasm of large intestine and rectum
C786	Secondary malignant neoplasm of retroperiton and peritoneum
C787	Secondary malig neoplasm of liver and intrahepatic bile duct
C788	Secondary malignant neoplasm of and unsp digestive organs
C7880	Secondary malignant neoplasm of unspecified digestive organ
C7889	Secondary malignant neoplasm of other digestive organs
C79	Secondary malignant neoplasm of other and unspecified sites
C790	Secondary malignant neoplasm of kidney and renal pelvis
C7900	Secondary malignant neoplasm of unsp kidney and renal pelvis
C7901	Secondary malignant neoplasm of r kidney and renal pelvis
C7902	Secondary malignant neoplasm of left kidney and renal pelvis
C791	Sec malig neoplm of bladder and oth and unsp urinary organs
C7910	Secondary malignant neoplasm of unspecified urinary organs
C7911	Secondary malignant neoplasm of bladder
C7919	Secondary malignant neoplasm of other urinary organs
C792	Secondary malignant neoplasm of skin

C793	Secondary malignant neoplasm of brain and cerebral meninges
C7931	Secondary malignant neoplasm of brain
C7932	Secondary malignant neoplasm of cerebral meninges
C794	Secondary malig neoplasm of and unsp parts of nervous sys
C7940	Secondary malignant neoplasm of unsp part of nervous system
C7949	Secondary malignant neoplasm of oth parts of nervous system
C795	Secondary malignant neoplasm of bone and bone marrow
C7951	Secondary malignant neoplasm of bone
C7952	Secondary malignant neoplasm of bone marrow
C796	Secondary malignant neoplasm of ovary
C7960	Secondary malignant neoplasm of unspecified ovary
C7961	Secondary malignant neoplasm of right ovary
C7962	Secondary malignant neoplasm of left ovary
C797	Secondary malignant neoplasm of adrenal gland
C7970	Secondary malignant neoplasm of unspecified adrenal gland
C7971	Secondary malignant neoplasm of right adrenal gland
C7972	Secondary malignant neoplasm of left adrenal gland
C798	Secondary malignant neoplasm of other specified sites
C7981	Secondary malignant neoplasm of breast
C7982	Secondary malignant neoplasm of genital organs
C7989	Secondary malignant neoplasm of other specified sites
C799	Secondary malignant neoplasm of unspecified site
C80	Malignant neoplasm without specification of site
C800	Disseminated malignant neoplasm, unspecified
C801	Malignant (primary) neoplasm, unspecified
C802	Malignant neoplasm associated with transplanted organ
C81	Hodgkin lymphoma
C810	Nodular lymphocyte predominant Hodgkin lymphoma
C8100	Nodular lymphocyte predominant Hodgkin lymphoma, unsp site
C8101	Nodlr lymphocy predom Hdgkn lymph, nodes of head, face, & nk
C8102	Nodular lymphocy predom Hodgkin lymphoma, intrathorac nodes
C8103	Nodular lymphocyte predom Hodgkin lymphoma, intra-abd nodes
C8104	Nodir lymphocy predom Hdgkn lymph, nodes of axla and upr lmb
C8105	Nodlr lymphocy predom Hdgkn lymph, nodes of ing rgn & low lmb
C8106	Nodular lymphocyte predom Hodgkin lymphoma, intrapelv nodes
C8107	Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C8108	Nodular lymphocyte predom Hodgkin lymphoma, nodes mult site
C8109	Nodlr lymphocy predom Hdgkn lymph, extrnod & solid org site
C811	Nodular sclerosis classical Hodgkin lymphoma
C8110	Nodular sclerosis classical Hodgkin lymphoma, unsp site
C8111	Nodlr scler class Hdgkn lymph, nodes of head, face, and neck

C8112	Nodular sclerosis class Hodgkin lymphoma, intrathorac nodes
C8113	Nodular sclerosis class Hodgkin lymphoma, intra-abd nodes
C8114	Nodlr scler class Hdgkn lymph, nodes of axla and upper limb
C8115	Nodlr scler class Hdgkn lymph, nodes of ing rgn and low limb
C8116	Nodular sclerosis class Hodgkin lymphoma, intrapelv nodes
C8117	Nodular sclerosis classical Hodgkin lymphoma, spleen
C8118	Nodular sclerosis class Hodgkin lymphoma, nodes mult site
C8119	Nodlr scler class Hdgkn lymph, extrnod and solid organ sites
C812	Mixed cellularity classical Hodgkin lymphoma
C8120	Mixed cellularity classical Hodgkin lymphoma, unsp site
C8121	Mix cellular class Hdgkn lymph, nodes of head, face, and nk
C8122	Mixed cellular classical Hodgkin lymphoma, intrathorac nodes
C8123	Mixed cellular classical Hodgkin lymphoma, intra-abd nodes
C8124	Mix cellular class Hdgkn lymph, nodes of axla and upper limb
C8125	Mix cellular class Hdgkn lymph, nodes of ing rgn and low lmb
C8126	Mixed cellular classical Hodgkin lymphoma, intrapelv nodes
C8127	Mixed cellularity classical Hodgkin lymphoma, spleen
C8128	Mixed cellular classical Hodgkin lymphoma, nodes mult site
C8129	Mix cellular class Hdgkn lymph, extrnod and solid org sites
C813	Lymphocyte depleted classical Hodgkin lymphoma
C8130	Lymphocyte depleted classical Hodgkin lymphoma, unsp site
C8131	Lymphocy deplet class Hdgkn lymph, nodes of head, face, & nk
C8132	Lymphocy depleted class Hodgkin lymphoma, intrathorac nodes
C8133	Lymphocy depleted class Hodgkin lymphoma, intra-abd nodes
C8134	Lymphocy deplet class Hdgkn lymph, nodes of axla and upr Imb
C8135	Lymphocy deplet class Hdgkn lymph,nodes of ing rgn & low Imb
C8136	Lymphocy depleted class Hodgkin lymphoma, intrapelv nodes
C8137	Lymphocyte depleted classical Hodgkin lymphoma, spleen
C8138	Lymphocy depleted class Hodgkin lymphoma, nodes mult site
C8139	Lymphocy deplet class Hdgkn lymph, extrnod & solid org site
C814	Lymphocyte-rich classical Hodgkin lymphoma
C8140	Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
C8141	Lymp-rich class Hodgkin lymph, nodes of head, face, and neck
C8142	Lymp-rich classical Hodgkin lymphoma, intrathorac nodes
C8143	Lymp-rich classical Hodgkin lymphoma, intra-abd lymph nodes
C8144	Lymp-rich class Hdgkn lymph, nodes of axilla and upper limb
C8145	Lymp-rich class Hdgkn lymph, nodes of ing rgn and lower limb
C8146	Lymp-rich classical Hodgkin lymphoma, intrapelv lymph nodes
C8147	Lymphocyte-rich classical Hodgkin lymphoma, spleen
C8148	Lymp-rich classical Hodgkin lymphoma, lymph nodes mult site
C8149	Lymp-rich class Hodgkin lymph, extrnod and solid organ sites

C817	Other classical Hodgkin lymphoma
C8170	Other classical Hodgkin lymphoma, unspecified site
C8171	Oth class Hodgkin lymphoma, nodes of head, face, and neck
C8172	Other classical Hodgkin lymphoma, intrathoracic lymph nodes
C8173	Oth classical Hodgkin lymphoma, intra-abdominal lymph nodes
C8174	Oth class Hodgkin lymphoma, nodes of axilla and upper limb
C8175	Oth class Hodgkin lymph, nodes of ing region and lower limb
C8176	Other classical Hodgkin lymphoma, intrapelvic lymph nodes
C8177	Other classical Hodgkin lymphoma, spleen
C8178	Oth classical Hodgkin lymphoma, lymph nodes mult site
C8179	Oth class Hodgkin lymphoma, extrnod and solid organ sites
C819	Hodgkin lymphoma, unspecified
C8190	Hodgkin lymphoma, unspecified, unspecified site
C8191	Hodgkin lymphoma, unsp, lymph nodes of head, face, and neck
C8192	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C8193	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C8194	Hodgkin lymphoma, unsp, lymph nodes of axilla and upper limb
C8195	Hodgkin lymphoma, unsp, nodes of ing region and lower limb
C8196	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C8197	Hodgkin lymphoma, unspecified, spleen
C8198	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C8199	Hodgkin lymphoma, unsp, extranodal and solid organ sites
C82	Follicular lymphoma
C820	Follicular lymphoma grade I
C8200	Follicular lymphoma grade I, unspecified site
C8201	Follicular lymphoma grade I, nodes of head, face, and neck
C8202	Follicular lymphoma grade I, intrathoracic lymph nodes
C8203	Follicular lymphoma grade I, intra-abdominal lymph nodes
C8204	Follicular lymphoma grade I, nodes of axilla and upper limb
C8205	Foliclar lymph grade I, nodes of ing region and lower limb
C8206	Follicular lymphoma grade I, intrapelvic lymph nodes
C8207	Follicular lymphoma grade I, spleen
C8208	Follicular lymphoma grade I, lymph nodes of multiple sites
C8209	Follicular lymphoma grade I, extrnod and solid organ sites
C821	Follicular lymphoma grade II
C8210	Follicular lymphoma grade II, unspecified site
C8211	Follicular lymphoma grade II, nodes of head, face, and neck
C8212	Follicular lymphoma grade II, intrathoracic lymph nodes
C8213	Follicular lymphoma grade II, intra-abdominal lymph nodes
C8214	Follicular lymphoma grade II, nodes of axilla and upper limb
C8215	Foliclar lymph grade II, nodes of ing region and lower limb

C8217	Follicular lymphoma grade II, spleen
C8218	
	Follicular lymphoma grade II, lymph nodes of multiple sites
C8219	Follicular lymphoma grade II, extrnod and solid organ sites
C822	Follicular lymphoma grade III, unspecified
C8220	Follicular lymphoma grade III, unspecified, unspecified site
C8221	Foliclar lymph grade III, unsp, nodes of head, face, and nk
C8222	Follicular lymphoma grade III, unsp, intrathorac lymph nodes
C8223	Follicular lymphoma grade III, unsp, intra-abd lymph nodes
C8224	Foliclar lymph grade III, unsp, nodes of axla and upper limb
C8225	Foliclar lymph grade III, unsp, nodes of ing rgn and low Imb
C8226	Follicular lymphoma grade III, unsp, intrapelvic lymph nodes
C8227	Follicular lymphoma grade III, unspecified, spleen
C8228	Follicular lymphoma grade III, unsp, lymph nodes mult site
C8229	Foliclar lymph grade III, unsp, extrnod and solid org sites
C823	Follicular lymphoma grade Illa
C8230	Follicular lymphoma grade IIIa, unspecified site
C8231	Foliclar lymphoma grade IIIa, nodes of head, face, and neck
C8232	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C8233	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C8234	Foliclar lymphoma grade IIIa, nodes of axilla and upper limb
C8235	Foliclar lymph grade IIIa, nodes of ing rgn and lower limb
C8236	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C8237	Follicular lymphoma grade IIIa, spleen
C8238	Follicular lymphoma grade IIIa, lymph nodes mult site
C8239	Foliclar lymphoma grade IIIa, extrnod and solid organ sites
C824	Follicular lymphoma grade IIIb
C8240	Follicular lymphoma grade IIIb, unspecified site
C8241	Foliclar lymphoma grade IIIb, nodes of head, face, and neck
C8242	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C8243	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C8244	Foliclar lymphoma grade IIIb, nodes of axilla and upper limb
C8245	Foliclar lymph grade IIIb, nodes of ing rgn and lower limb
C8246	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C8247	Follicular lymphoma grade IIIb, spleen
C8248	Follicular lymphoma grade IIIb, lymph nodes mult site
C8249	Foliclar lymphoma grade IIIb, extrnod and solid organ sites
C825	Diffuse follicle center lymphoma
C8250	Diffuse follicle center lymphoma, unspecified site
C8251	Diffuse folicic center lymph, nodes of head, face, and neck
C8252	Diffuse follicle center lymphoma, intrathoracic lymph nodes

C8253	Diffuse follicle center lymphoma, intra-abd lymph nodes
C8254	Diffuse folicl center lymph, nodes of axilla and upper limb
C8255	Diffus folicl cntr lymph, nodes of ing region and lower limb
C8256	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C8257	Diffuse follicle center lymphoma, spleen
C8258	Diffuse follicle center lymphoma, lymph nodes mult site
C8259	Diffuse folicl center lymph, extrnod and solid organ sites
C826	Cutaneous follicle center lymphoma
C8260	Cutaneous follicle center lymphoma, unspecified site
C8261	Cutan folicl center lymphoma, nodes of head, face, and neck
C8262	Cutaneous follicle center lymphoma, intrathorac lymph nodes
C8263	Cutaneous follicle center lymphoma, intra-abd lymph nodes
C8264	Cutan folicl center lymphoma, nodes of axilla and upper limb
C8265	Cutan folicl cntr lymph, nodes of ing region and lower limb
C8266	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C8267	Cutaneous follicle center lymphoma, spleen
C8268	Cutaneous follicle center lymphoma, lymph nodes mult site
C8269	Cutan folicl center lymphoma, extrnod and solid organ sites
C828	Other types of follicular lymphoma
C8280	Other types of follicular lymphoma, unspecified site
C8281	Oth types of foliclar lymph, nodes of head, face, and neck
C8282	Oth types of follicular lymphoma, intrathoracic lymph nodes
C8283	Oth types of follicular lymphoma, intra-abd lymph nodes
C8284	Oth types of foliclar lymph, nodes of axilla and upper limb
C8285	Oth types of foliclar lymph, nodes of ing rgn and lower limb
C8286	Other types of follicular lymphoma, intrapelvic lymph nodes
C8287	Other types of follicular lymphoma, spleen
C8288	Oth types of follicular lymphoma, lymph nodes mult site
C8289	Oth types of foliclar lymph, extrnod and solid organ sites
C829	Follicular lymphoma, unspecified
C8290	Follicular lymphoma, unspecified, unspecified site
C8291	Follicular lymphoma, unsp, nodes of head, face, and neck
C8292	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C8293	Follicular lymphoma, unsp, intra-abdominal lymph nodes
C8294	Follicular lymphoma, unsp, nodes of axilla and upper limb
C8295	Foliclar lymphoma, unsp, nodes of ing region and lower limb
C8296	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C8297	Follicular lymphoma, unspecified, spleen
C8298	Follicular lymphoma, unsp, lymph nodes of multiple sites
C8299	Follicular lymphoma, unsp, extranodal and solid organ sites
C83	Non-follicular lymphoma

C830	Small cell B-cell lymphoma
C8300	Small cell B-cell lymphoma, unspecified site
C8301	Small cell B-cell lymphoma, nodes of head, face, and neck
C8302	Small cell B-cell lymphoma, intrathoracic lymph nodes
C8303	Small cell B-cell lymphoma, intra-abdominal lymph nodes
C8304	Small cell B-cell lymphoma, nodes of axilla and upper limb
C8305	Small cell B-cell lymph, nodes of ing region and lower limb
C8306	Small cell B-cell lymphoma, intrapelvic lymph nodes
C8307	Small cell B-cell lymphoma, spleen
C8308	Small cell B-cell lymphoma, lymph nodes of multiple sites
C8309	Small cell B-cell lymphoma, extranodal and solid organ sites
C831	Mantle cell lymphoma
C8310	Mantle cell lymphoma, unspecified site
C8311	Mantle cell lymphoma, lymph nodes of head, face, and neck
C8312	Mantle cell lymphoma, intrathoracic lymph nodes
C8313	Mantle cell lymphoma, intra-abdominal lymph nodes
C8314	Mantle cell lymphoma, lymph nodes of axilla and upper limb
C8315	Mantle cell lymphoma, nodes of ing region and lower limb
C8316	Mantle cell lymphoma, intrapelvic lymph nodes
C8317	Mantle cell lymphoma, spleen
C8318	Mantle cell lymphoma, lymph nodes of multiple sites
C8319	Mantle cell lymphoma, extranodal and solid organ sites
C833	Diffuse large B-cell lymphoma
C8330	Diffuse large B-cell lymphoma, unspecified site
C8331	Diffuse large B-cell lymphoma, nodes of head, face, and neck
C8332	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
C8333	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
C8334	Diffuse large B-cell lymph, nodes of axilla and upper limb
C8335	Diffus large B-cell lymph, nodes of ing rgn and lower limb
C8336	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
C8337	Diffuse large B-cell lymphoma, spleen
C8338	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
C8339	Diffuse large B-cell lymphoma, extrnod and solid organ sites
C835	Lymphoblastic (diffuse) lymphoma
C8350	Lymphoblastic (diffuse) lymphoma, unspecified site
C8351	Lymphoblastic lymphoma, nodes of head, face, and neck
C8352	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C8353	Lymphoblastic (diffuse) lymphoma, intra-abd lymph nodes
C8354	Lymphoblastic lymphoma, nodes of axilla and upper limb
C8355	Lymphoblastic lymphoma, nodes of ing region and lower limb
C8356	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes

C8357	Lymphoblastic (diffuse) lymphoma, spleen
C8358	Lymphoblastic (diffuse) lymphoma, lymph nodes mult site
C8359	Lymphoblastic lymphoma, extrnod and solid organ sites
C837	Burkitt lymphoma
C8370	Burkitt lymphoma, unspecified site
C8371	Burkitt lymphoma, lymph nodes of head, face, and neck
C8372	Burkitt lymphoma, intrathoracic lymph nodes
C8373	Burkitt lymphoma, intra-abdominal lymph nodes
C8374	Burkitt lymphoma, lymph nodes of axilla and upper limb
C8375	Burkitt lymphoma, nodes of inguinal region and lower limb
C8376	Burkitt lymphoma, intrapelvic lymph nodes
C8377	Burkitt lymphoma, spleen
C8378	Burkitt lymphoma, lymph nodes of multiple sites
C8379	Burkitt lymphoma, extranodal and solid organ sites
C838	Other non-follicular lymphoma
C8380	Other non-follicular lymphoma, unspecified site
C8381	Oth non-follic lymphoma, lymph nodes of head, face, and neck
C8382	Other non-follicular lymphoma, intrathoracic lymph nodes
C8383	Other non-follicular lymphoma, intra-abdominal lymph nodes
C8384	Oth non-follic lymphoma, nodes of axilla and upper limb
C8385	Oth non-follic lymphoma, nodes of ing region and lower limb
C8386	Other non-follicular lymphoma, intrapelvic lymph nodes
C8387	Other non-follicular lymphoma, spleen
C8388	Other non-follicular lymphoma, lymph nodes of multiple sites
C8389	Oth non-follic lymphoma, extranodal and solid organ sites
C839	Non-follicular (diffuse) lymphoma, unspecified
C8390	Non-follicular (diffuse) lymphoma, unsp, unspecified site
C8391	Non-follic lymphoma, unsp, nodes of head, face, and neck
C8392	Non-follic (diffuse) lymphoma, unsp, intrathorac lymph nodes
C8393	Non-follic (diffuse) lymphoma, unsp, intra-abd lymph nodes
C8394	Non-follic lymphoma, unsp, nodes of axilla and upper limb
C8395	Non-follic lymph, unsp, nodes of ing region and lower limb
C8396	Non-follic (diffuse) lymphoma, unsp, intrapelvic lymph nodes
C8397	Non-follicular (diffuse) lymphoma, unspecified, spleen
C8398	Non-follic (diffuse) lymphoma, unsp, lymph nodes mult site
C8399	Non-follic lymphoma, unsp, extrnod and solid organ sites
C84	Mature T/NK-cell lymphomas
C840	Mycosis fungoides
C8400	Mycosis fungoides, unspecified site
C8401	Mycosis fungoides, lymph nodes of head, face, and neck
C8402	Mycosis fungoides, intrathoracic lymph nodes

C8403	Mycosis fungoides, intra-abdominal lymph nodes
C8404	Mycosis fungoides, lymph nodes of axilla and upper limb
C8405	Mycosis fungoides, nodes of inguinal region and lower limb
C8406	Mycosis fungoides, intrapelvic lymph nodes
C8407	Mycosis fungoides, spleen
C8408	Mycosis fungoides, lymph nodes of multiple sites
C8409	Mycosis fungoides, extranodal and solid organ sites
C841	Sezary disease
C8410	Sezary disease, unspecified site
C8411	Sezary disease, lymph nodes of head, face, and neck
C8412	Sezary disease, intrathoracic lymph nodes
C8413	Sezary disease, intra-abdominal lymph nodes
C8414	Sezary disease, lymph nodes of axilla and upper limb
C8415	Sezary disease, nodes of inguinal region and lower limb
C8416	Sezary disease, intrapelvic lymph nodes
C8417	Sezary disease, spleen
C8418	Sezary disease, lymph nodes of multiple sites
C8419	Sezary disease, extranodal and solid organ sites
C844	Peripheral T-cell lymphoma, not classified
C8440	Peripheral T-cell lymphoma, not classified, unspecified site
C8441	Prph T-cell lymph, not class, nodes of head, face, and neck
C8442	Peripheral T-cell lymphoma, not class, intrathorac nodes
C8443	Peripheral T-cell lymphoma, not classified, intra-abd nodes
C8444	Prph T-cell lymph, not class, nodes of axilla and upper limb
C8445	Prph T-cell lymph, not class, nodes of ing rgn and low limb
C8446	Peripheral T-cell lymphoma, not classified, intrapelv nodes
C8447	Peripheral T-cell lymphoma, not classified, spleen
C8448	Peripheral T-cell lymphoma, not classified, nodes mult site
C8449	Prph T-cell lymph, not class, extrnod and solid organ sites
C846	Anaplastic large cell lymphoma, ALK-positive
C8460	Anaplastic large cell lymphoma, ALK-positive, unsp site
C8461	Anaplstc Ig cell lymph, ALK-pos, nodes of head, face, and nk
C8462	Anaplastic large cell lymphoma, ALK-pos, intrathorac nodes
C8463	Anaplastic large cell lymphoma, ALK-pos, intra-abd nodes
C8464	Anaplstc Ig cell lymph, ALK-pos, nodes of axla and upr limb
C8465	Anaplstc Ig cell lymph, ALK-pos, nodes of ing rgn & low Imb
C8466	Anaplastic large cell lymphoma, ALK-pos, intrapelv nodes
C8467	Anaplastic large cell lymphoma, ALK-positive, spleen
C8468	Anaplastic large cell lymphoma, ALK-pos, nodes mult site
C8469	Anaplstc Ig cell lymph, ALK-pos, extrnod and solid org sites
C847	Anaplastic large cell lymphoma, ALK-negative

C8470	Anaplastic large cell lymphoma, ALK-negative, unsp site
C8471	Anaplstc Ig cell lymph, ALK-neg, nodes of head, face, and nk
C8472	Anaplastic large cell lymphoma, ALK-neg, intrathorac nodes
C8473	Anaplastic large cell lymphoma, ALK-neg, intra-abd nodes
C8474	Anaplstc Ig cell lymph, ALK-neg, nodes of axla and upr limb
C8475	Anaplstc Ig cell lymph, ALK-neg, nodes of ing rgn & low Imb
C8476	Anaplastic large cell lymphoma, ALK-neg, intrapelv nodes
C8477	Anaplastic large cell lymphoma, ALK-negative, spleen
C8478	Anaplastic large cell lymphoma, ALK-neg, nodes mult site
C8479	Anaplstc Ig cell lymph, ALK-neg, extrnod and solid org sites
C84A	Cutaneous T-cell lymphoma, unspecified
C84A0	Cutaneous T-cell lymphoma, unspecified, unspecified site
C84A1	Cutan T-cell lymphoma, unsp nodes of head, face, and neck
C84A2	Cutaneous T-cell lymphoma, unsp, intrathoracic lymph nodes
C84A3	Cutaneous T-cell lymphoma, unsp, intra-abdominal lymph nodes
C84A4	Cutan T-cell lymphoma, unsp, nodes of axilla and upper limb
C84A5	Cutan T-cell lymph, unsp, nodes of ing region and lower limb
C84A6	Cutaneous T-cell lymphoma, unsp, intrapelvic lymph nodes
C84A7	Cutaneous T-cell lymphoma, unspecified, spleen
C84A8	Cutaneous T-cell lymphoma, unsp, lymph nodes mult site
C84A9	Cutan T-cell lymphoma, unsp, extrnod and solid organ sites
C84Z	Other mature T/NK-cell lymphomas
C84Z0	Other mature T/NK-cell lymphomas, unspecified site
C84Z1	Oth mature T/NK-cell lymph, nodes of head, face, and neck
C84Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84Z3	Oth mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84Z4	Oth mature T/NK-cell lymph, nodes of axilla and upper limb
C84Z5	Oth mature T/NK-cell lymph, nodes of ing rgn and lower limb
C84Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84Z7	Other mature T/NK-cell lymphomas, spleen
C84Z8	Oth mature T/NK-cell lymphomas, lymph nodes mult site
C84Z9	Oth mature T/NK-cell lymph, extrnod and solid organ sites
C849	Mature T/NK-cell lymphomas, unspecified
C8490	Mature T/NK-cell lymphomas, unspecified, unspecified site
C8491	Mature T/NK-cell lymph, unsp, nodes of head, face, and neck
C8492	Mature T/NK-cell lymphomas, unsp, intrathoracic lymph nodes
C8493	Mature T/NK-cell lymphomas, unsp, intra-abd lymph nodes
C8494	Mature T/NK-cell lymph, unsp, nodes of axilla and upper limb
C8495	Mature T/NK-cell lymph, unsp, nodes of ing rgn and low limb
C8496	Mature T/NK-cell lymphomas, unsp, intrapelvic lymph nodes
C8497	Mature T/NK-cell lymphomas, unspecified, spleen

C8499	Mature T/NK-cell lymph, unsp, extrnod and solid organ sites
C85	Oth and unspecified types of non-Hodgkin lymphoma
C851	Unspecified B-cell lymphoma
C8510	Unspecified B-cell lymphoma, unspecified site
C8511	Unsp B-cell lymphoma, lymph nodes of head, face, and neck
C8512	Unspecified B-cell lymphoma, intrathoracic lymph nodes
C8513	Unspecified B-cell lymphoma, intra-abdominal lymph nodes
C8514	Unsp B-cell lymphoma, lymph nodes of axilla and upper limb
C8515	Unsp B-cell lymphoma, nodes of ing region and lower limb
C8516	Unspecified B-cell lymphoma, intrapelvic lymph nodes
C8517	Unspecified B-cell lymphoma, spleen
C8518	Unspecified B-cell lymphoma, lymph nodes of multiple sites
C8519	Unsp B-cell lymphoma, extranodal and solid organ sites
C852	Mediastinal (thymic) large B-cell lymphoma
C8520	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C8521	Mediastnl large B-cell lymph, nodes of head, face, and neck
C8522	Mediastnl (thymic) large B-cell lymphoma, intrathorac nodes
C8523	Mediastinal (thymic) large B-cell lymphoma, intra-abd nodes
C8524	Mediastnl large B-cell lymph, nodes of axilla and upper limb
C8525	Mediastnl Ig B-cell lymph, nodes of ing rgn and lower limb
C8526	Mediastinal (thymic) large B-cell lymphoma, intrapelv nodes
C8527	Mediastinal (thymic) large B-cell lymphoma, spleen
C8528	Mediastinal (thymic) large B-cell lymphoma, nodes mult site
C8529	Mediastnl large B-cell lymph, extrnod and solid organ sites
C858	Other specified types of non-Hodgkin lymphoma
C8580	Oth types of non-Hodgkin lymphoma, unspecified site
C8581	Oth types of non-hodg lymph, nodes of head, face, and neck
C8582	Oth types of non-Hodgkin lymphoma, intrathoracic lymph nodes
C8583	Oth types of non-Hodgkin lymphoma, intra-abd lymph nodes
C8584	Oth types of non-hodg lymph, nodes of axilla and upper limb
C8585	Oth types of non-hodg lymph, nodes of ing rgn and lower limb
C8586	Oth types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C8587	Other specified types of non-Hodgkin lymphoma, spleen
C8588	Oth types of non-Hodgkin lymphoma, lymph nodes mult site
C8589	Oth types of non-hodg lymph, extrnod and solid organ sites
C859	Non-Hodgkin lymphoma, unspecified
C8590	Non-Hodgkin lymphoma, unspecified, unspecified site
C8591	Non-Hodgkin lymphoma, unsp, nodes of head, face, and neck
C8592	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C8593	Non-Hodgkin lymphoma, unsp, intra-abdominal lymph nodes

C8594	Non-Hodgkin lymphoma, unsp, nodes of axilla and upper limb
C8595	Non-hodg lymphoma, unsp, nodes of ing region and lower limb
C8596	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C8597	Non-Hodgkin lymphoma, unspecified, spleen
C8598	Non-Hodgkin lymphoma, unsp, lymph nodes of multiple sites
C8599	Non-Hodgkin lymphoma, unsp, extranodal and solid organ sites
C86	Other specified types of T/NK-cell lymphoma
C860	Extranodal NK/T-cell lymphoma, nasal type
C861	Hepatosplenic T-cell lymphoma
C862	Enteropathy-type (intestinal) T-cell lymphoma
C863	Subcutaneous panniculitis-like T-cell lymphoma
C864	Blastic NK-cell lymphoma
C865	Angioimmunoblastic T-cell lymphoma
C866	Primary cutaneous CD30-positive T-cell proliferations
C88	Malig immunoproliferative dis and certain oth B-cell lymph
C880	Waldenstrom macroglobulinemia
C882	Heavy chain disease
C883	Immunoproliferative small intestinal disease
C884	Extrnod mrgnl zn B-cell lymph of mucosa-assoc lymphoid tiss
C888	Other malignant immunoproliferative diseases
C889	Malignant immunoproliferative disease, unspecified
C90	Multiple myeloma and malignant plasma cell neoplasms
C900	Multiple myeloma
C9000	Multiple myeloma not having achieved remission
C9001	Multiple myeloma in remission
C9002	Multiple myeloma in relapse
C901	Plasma cell leukemia
C9010	Plasma cell leukemia not having achieved remission
C9011	Plasma cell leukemia in remission
C9012	Plasma cell leukemia in relapse
C902	Extramedullary plasmacytoma
C9020	Extramedullary plasmacytoma not having achieved remission
C9021	Extramedullary plasmacytoma in remission
C9022	Extramedullary plasmacytoma in relapse
C903	Solitary plasmacytoma
C9030	Solitary plasmacytoma not having achieved remission
C9031	Solitary plasmacytoma in remission
C9032	Solitary plasmacytoma in relapse
C91	Lymphoid leukemia
C910	Acute lymphoblastic leukemia [ALL]
C9100	Acute lymphoblastic leukemia not having achieved remission

C9101	Acute lymphoblastic leukemia, in remission
C9102	Acute lymphoblastic leukemia, in relapse
C911	Chronic lymphocytic leukemia of B-cell type
C9110	Chronic lymphocytic leuk of B-cell type not achieve remis
C9111	Chronic lymphocytic leukemia of B-cell type in remission
C9112	Chronic lymphocytic leukemia of B-cell type in relapse
C913	Prolymphocytic leukemia of B-cell type
C9130	Prolymphocytic leukemia of B-cell type not achieve remission
C9131	Prolymphocytic leukemia of B-cell type, in remission
C9132	Prolymphocytic leukemia of B-cell type, in relapse
C914	Hairy cell leukemia
C9140	Hairy cell leukemia not having achieved remission
C9141	Hairy cell leukemia, in remission
C9142	Hairy cell leukemia, in relapse
C915	Adult T-cell lymphoma/leukemia (HTLV-1-associated)
C9150	Adult T-cell lymph/leuk (HTLV-1-assoc) not achieve remission
C9151	Adult T-cell lymphoma/leukemia (HTLV-1-assoc), in remission
C9152	Adult T-cell lymphoma/leukemia (HTLV-1-assoc), in relapse
C916	Prolymphocytic leukemia of T-cell type
C9160	Prolymphocytic leukemia of T-cell type not achieve remission
C9161	Prolymphocytic leukemia of T-cell type, in remission
C9162	Prolymphocytic leukemia of T-cell type, in relapse
C91A	Mature B-cell leukemia Burkitt-type
C91A0	Mature B-cell leukemia Burkitt-type not achieve remission
C91A1	Mature B-cell leukemia Burkitt-type, in remission
C91A2	Mature B-cell leukemia Burkitt-type, in relapse
C91Z	Other lymphoid leukemia
C91Z0	Other lymphoid leukemia not having achieved remission
C91Z1	Other lymphoid leukemia, in remission
C91Z2	Other lymphoid leukemia, in relapse
C919	Lymphoid leukemia, unspecified
C9190	Lymphoid leukemia, unspecified not having achieved remission
C9191	Lymphoid leukemia, unspecified, in remission
C9192	Lymphoid leukemia, unspecified, in relapse
C92	Myeloid leukemia
C920	Acute myeloblastic leukemia
C9200	Acute myeloblastic leukemia, not having achieved remission
C9201	Acute myeloblastic leukemia, in remission
C9202	Acute myeloblastic leukemia, in relapse
C921	Chronic myeloid leukemia, BCR/ABL-positive
C9210	Chronic myeloid leuk, BCR/ABL-positive, not achieve remis

C9211	Chronic myeloid leukemia, BCR/ABL-positive, in remission
C9212	Chronic myeloid leukemia, BCR/ABL-positive, in relapse
C922	Atypical chronic myeloid leukemia, BCR/ABL-negative
C9220	Atyp chronic myeloid leuk, BCR/ABL-neg, not achieve remis
C9221	Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
C9222	Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
C923	Myeloid sarcoma
C9230	Myeloid sarcoma, not having achieved remission
C9231	Myeloid sarcoma, in remission
C9232	Myeloid sarcoma, in relapse
C924	Acute promyelocytic leukemia
C9240	Acute promyelocytic leukemia, not having achieved remission
C9241	Acute promyelocytic leukemia, in remission
C9242	Acute promyelocytic leukemia, in relapse
C925	Acute myelomonocytic leukemia
C9250	Acute myelomonocytic leukemia, not having achieved remission
C9251	Acute myelomonocytic leukemia, in remission
C9252	Acute myelomonocytic leukemia, in relapse
C926	Acute myeloid leukemia with 11q23-abnormality
C9260	Acute myeloid leukemia w 11q23-abnormality not achieve remis
C9261	Acute myeloid leukemia with 11q23-abnormality in remission
C9262	Acute myeloid leukemia with 11q23-abnormality in relapse
C92A	Acute myeloid leukemia with multilineage dysplasia
C92A0	Acute myeloid leuk w multilin dysplasia, not achieve remis
C92A1	Acute myeloid leukemia w multilin dysplasia, in remission
C92A2	Acute myeloid leukemia w multilineage dysplasia, in relapse
C92Z	Other myeloid leukemia
C92Z0	Other myeloid leukemia not having achieved remission
C92Z1	Other myeloid leukemia, in remission
C92Z2	Other myeloid leukemia, in relapse
C929	Myeloid leukemia, unspecified
C9290	Myeloid leukemia, unspecified, not having achieved remission
C9291	Myeloid leukemia, unspecified in remission
C9292	Myeloid leukemia, unspecified in relapse
C93	Monocytic leukemia
C930	Acute monoblastic/monocytic leukemia
C9300	Acute monoblastic/monocytic leukemia, not achieve remission
C9301	Acute monoblastic/monocytic leukemia, in remission
C9302	Acute monoblastic/monocytic leukemia, in relapse
C931	Chronic myelomonocytic leukemia
C9310	Chronic myelomonocytic leukemia not achieve remission

C9312	Chronic myelomonocytic leukemia, in remission Chronic myelomonocytic leukemia, in relapse
C933	Juvenile myelomonocytic leukemia
C9330	Juvenile myelomonocytic leukemia, not achieve remission
C9331	Juvenile myelomonocytic leukemia, in remission
C9332	Juvenile myelomonocytic leukemia, in relapse
C93Z	Other monocytic leukemia
C93Z0	Other monocytic leukemia, not having achieved remission
C93Z1	Other monocytic leukemia, in remission
C93Z2	Other monocytic leukemia, in relapse
C939	Monocytic leukemia, unspecified
C9390	Monocytic leukemia, unsp, not having achieved remission
C9391	Monocytic leukemia, unspecified in remission
C9392	Monocytic leukemia, unspecified in relapse
C94	Other leukemias of specified cell type
C940	Acute erythroid leukemia
C9400	Acute erythroid leukemia, not having achieved remission
C9401	Acute erythroid leukemia, in remission
C9402	Acute erythroid leukemia, in relapse
C942	Acute megakaryoblastic leukemia
C9420	Acute megakaryoblastic leukemia not achieve remission
C9421	Acute megakaryoblastic leukemia, in remission
C9422	Acute megakaryoblastic leukemia, in relapse
C943	Mast cell leukemia
C9430	Mast cell leukemia not having achieved remission
C9431	Mast cell leukemia, in remission
C9432	Mast cell leukemia, in relapse
C944	Acute panmyelosis with myelofibrosis
C9440	Acute panmyelosis w myelofibrosis not achieve remission
C9441	Acute panmyelosis with myelofibrosis, in remission
C9442	Acute panmyelosis with myelofibrosis, in relapse
C946	Myelodysplastic disease, not classified
C948	Other specified leukemias
C9480	Other specified leukemias not having achieved remission
C9481	Other specified leukemias, in remission
C9482	Other specified leukemias, in relapse
C95	Leukemia of unspecified cell type
C950	Acute leukemia of unspecified cell type
C9500	Acute leukemia of unspecified cell type Acute leukemia of unsp cell type not achieve remission
C9501 C9502	Acute leukemia of unspecified cell type, in remission Acute leukemia of unspecified cell type, in relapse

C951	Chronic leukemia of unspecified cell type
C9510	Chronic leukemia of unsp cell type not achieve remission
C9511	Chronic leukemia of unspecified cell type, in remission
C9512	Chronic leukemia of unspecified cell type, in relapse
C959	Leukemia, unspecified
C9590	Leukemia, unspecified not having achieved remission
C9591	Leukemia, unspecified, in remission
C9592	Leukemia, unspecified, in relapse
C96	Oth & unsp malig neoplm of lymphoid, hematpoetc and rel tiss
C960	Multifocal and multisystemic Langerhans-cell histiocytosis
C962	Malignant mast cell tumor
C964	Sarcoma of dendritic cells (accessory cells)
C965	Multifocal and unisystemic Langerhans-cell histiocytosis
C966	Unifocal Langerhans-cell histiocytosis
C96A	Histiocytic sarcoma
C96Z	Oth malig neoplm of lymphoid, hematpoetc and related tissue
C969	Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
D00	Carcinoma in situ of oral cavity, esophagus and stomach
D000	Carcinoma in situ of lip, oral cavity and pharynx
D0000	Carcinoma in situ of oral cavity, unspecified site
D0001	Carcinoma in situ of labial mucosa and vermilion border
D0002	Carcinoma in situ of buccal mucosa
D0003	Carcinoma in situ of gingiva and edentulous alveolar ridge
D0004	Carcinoma in situ of soft palate
D0005	Carcinoma in situ of hard palate
D0006	Carcinoma in situ of floor of mouth
D0007	Carcinoma in situ of tongue
D0008	Carcinoma in situ of pharynx
D001	Carcinoma in situ of esophagus
D002	Carcinoma in situ of stomach
D01	Carcinoma in situ of other and unspecified digestive organs
D010	Carcinoma in situ of colon
D011	Carcinoma in situ of rectosigmoid junction
D012	Carcinoma in situ of rectum
D013	Carcinoma in situ of anus and anal canal
D014	Carcinoma in situ of other and unsp parts of intestine
D0140	Carcinoma in situ of unspecified part of intestine
D0149	Carcinoma in situ of other parts of intestine
D015	Carcinoma in situ of liver, gallbladder and bile ducts
D017	Carcinoma in situ of other specified digestive organs
D019	Carcinoma in situ of digestive organ, unspecified

D02	Carcinoma in situ of middle ear and respiratory system
D020	Carcinoma in situ of larynx
D021	Carcinoma in situ of trachea
D022	Carcinoma in situ of bronchus and lung
D0220	Carcinoma in situ of unspecified bronchus and lung
D0221	Carcinoma in situ of right bronchus and lung
D0222	Carcinoma in situ of left bronchus and lung
D023	Carcinoma in situ of other parts of respiratory system
D024	Carcinoma in situ of respiratory system, unspecified
D03	Melanoma in situ
D030	Melanoma in situ of lip
D031	Melanoma in situ of eyelid, including canthus
D0310	Melanoma in situ of unspecified eyelid, including canthus
D0311	Melanoma in situ of right eyelid, including canthus
D0312	Melanoma in situ of left eyelid, including canthus
D032	Melanoma in situ of ear and external auricular canal
D0320	Melanoma in situ of unsp ear and external auricular canal
D0321	Melanoma in situ of right ear and external auricular canal
D0322	Melanoma in situ of left ear and external auricular canal
D033	Melanoma in situ of other and unspecified parts of face
D0330	Melanoma in situ of unspecified part of face
D0339	Melanoma in situ of other parts of face
D034	Melanoma in situ of scalp and neck
D035	Melanoma in situ of trunk
D0351	Melanoma in situ of anal skin
D0352	Melanoma in situ of breast (skin) (soft tissue)
D0359	Melanoma in situ of other part of trunk
D036	Melanoma in situ of upper limb, including shoulder
D0360	Melanoma in situ of unsp upper limb, including shoulder
D0361	Melanoma in situ of right upper limb, including shoulder
D0362	Melanoma in situ of left upper limb, including shoulder
D037	Melanoma in situ of lower limb, including hip
D0370	Melanoma in situ of unspecified lower limb, including hip
D0371	Melanoma in situ of right lower limb, including hip
D0372	Melanoma in situ of left lower limb, including hip
D038	Melanoma in situ of other sites
D039	Melanoma in situ, unspecified
D04	Carcinoma in situ of skin
D040	Carcinoma in situ of skin of lip
D041	Carcinoma in situ of skin of eyelid, including canthus
D0410	Carcinoma in situ of skin of unsp eyelid, including canthus

D0411	Carcinoma in situ of skin of right eyelid, including canthus
D0412	Carcinoma in situ of skin of left eyelid, including canthus
D042	Ca in situ skin of ear and external auricular canal
D0420	Ca in situ skin of unsp ear and external auricular canal
D0421	Ca in situ skin of right ear and external auricular canal
D0422	Ca in situ skin of left ear and external auricular canal
D043	Carcinoma in situ of skin of other and unsp parts of face
D0430	Carcinoma in situ of skin of unspecified part of face
D0439	Carcinoma in situ of skin of other parts of face
D044	Carcinoma in situ of skin of scalp and neck
D045	Carcinoma in situ of skin of trunk
D046	Carcinoma in situ of skin of upper limb, including shoulder
D0460	Ca in situ skin of unsp upper limb, including shoulder
D0461	Ca in situ skin of right upper limb, including shoulder
D0462	Ca in situ skin of left upper limb, including shoulder
D047	Carcinoma in situ of skin of lower limb, including hip
D0470	Carcinoma in situ of skin of unsp lower limb, including hip
D0471	Carcinoma in situ of skin of right lower limb, including hip
D0472	Carcinoma in situ of skin of left lower limb, including hip
D048	Carcinoma in situ of skin of other sites
D049	Carcinoma in situ of skin, unspecified
D05	Carcinoma in situ of breast
D050	Lobular carcinoma in situ of breast
D0500	Lobular carcinoma in situ of unspecified breast
D0501	Lobular carcinoma in situ of right breast
D0502	Lobular carcinoma in situ of left breast
D051	Intraductal carcinoma in situ of breast
D0510	Intraductal carcinoma in situ of unspecified breast
D0511	Intraductal carcinoma in situ of right breast
D0512	Intraductal carcinoma in situ of left breast
D058	Other specified type of carcinoma in situ of breast
D0580	Oth type of carcinoma in situ of unspecified breast
D0581	Other specified type of carcinoma in situ of right breast
D0582	Other specified type of carcinoma in situ of left breast
D059	Unspecified type of carcinoma in situ of breast
D0590	Unspecified type of carcinoma in situ of unspecified breast
D0591	Unspecified type of carcinoma in situ of right breast
D0592	Unspecified type of carcinoma in situ of left breast
D06	Carcinoma in situ of cervix uteri
D060	Carcinoma in situ of endocervix
D061	Carcinoma in situ of exocervix

D067	Carcinoma in situ of other parts of cervix
D069	Carcinoma in situ of cervix, unspecified
D07	Carcinoma in situ of other and unspecified genital organs
D070	Carcinoma in situ of endometrium
D071	Carcinoma in situ of vulva
D072	Carcinoma in situ of vagina
D073	Carcinoma in situ of other and unsp female genital organs
D0730	Carcinoma in situ of unspecified female genital organs
D0739	Carcinoma in situ of other female genital organs
D074	Carcinoma in situ of penis
D075	Carcinoma in situ of prostate
D076	Carcinoma in situ of other and unsp male genital organs
D0760	Carcinoma in situ of unspecified male genital organs
D0761	Carcinoma in situ of scrotum
D0769	Carcinoma in situ of other male genital organs
D09	Carcinoma in situ of other and unspecified sites
D090	Carcinoma in situ of bladder
D091	Carcinoma in situ of other and unspecified urinary organs
D0910	Carcinoma in situ of unspecified urinary organ
D0919	Carcinoma in situ of other urinary organs
D092	Carcinoma in situ of eye
D0920	Carcinoma in situ of unspecified eye
D0921	Carcinoma in situ of right eye
D0922	Carcinoma in situ of left eye
D093	Carcinoma in situ of thyroid and other endocrine glands
D098	Carcinoma in situ of other specified sites
D099	Carcinoma in situ, unspecified
D1802	Hemangioma of intracranial structures
D181	Lymphangioma, any site
D32	Benign neoplasm of meninges
D320	Benign neoplasm of cerebral meninges
D321	Benign neoplasm of spinal meninges
D329	Benign neoplasm of meninges, unspecified
D33	Benign neoplasm of brain and oth prt central nervous system
D330	Benign neoplasm of brain, supratentorial
D331	Benign neoplasm of brain, infratentorial
D332	Benign neoplasm of brain, unspecified
D333	Benign neoplasm of cranial nerves
D334	Benign neoplasm of spinal cord
D337	Benign neoplasm of oth parts of central nervous system
D339	Benign neoplasm of central nervous system, unspecified

D352	Benign neoplasm of pituitary gland
D353	Benign neoplasm of craniopharyngeal duct
D354	Benign neoplasm of pineal gland
D42	Neoplasm of uncertain behavior of meninges
D420	Neoplasm of uncertain behavior of cerebral meninges
D421	Neoplasm of uncertain behavior of spinal meninges
D429	Neoplasm of uncertain behavior of meninges, unspecified
D43	Neoplasm of uncertain behavior of brain and cnsl
D430	Neoplasm of uncertain behavior of brain, supratentorial
D431	Neoplasm of uncertain behavior of brain, infratentorial
D432	Neoplasm of uncertain behavior of brain, unspecified
D433	Neoplasm of uncertain behavior of cranial nerves
D434	Neoplasm of uncertain behavior of spinal cord
D438	Neoplasm of uncertain behavior of prt central nervous system
D439	Neoplasm of uncertain behavior of cnsl, unsp
D443	Neoplasm of uncertain behavior of pituitary gland
D444	Neoplasm of uncertain behavior of craniopharyngeal duct
D445	Neoplasm of uncertain behavior of pineal gland
D45	Polycythemia vera
D46	Myelodysplastic syndromes
D460	Refractory anemia without ring sideroblasts, so stated
D461	Refractory anemia with ring sideroblasts
D462	Refractory anemia with excess of blasts
D4620	Refractory anemia with excess of blasts, unspecified
D4621	Refractory anemia with excess of blasts 1
D4622	Refractory anemia with excess of blasts 2
D46A	Refractory cytopenia with multilineage dysplasia
D46B	Refract cytopenia w multilin dysplasia and ring sideroblasts
D46C	Myelodysplastic syndrome w isolated del(5q) chromsoml abnlt
D464	Refractory anemia, unspecified
D46Z	Other myelodysplastic syndromes
D469	Myelodysplastic syndrome, unspecified
D471	Chronic myeloproliferative disease
D473	Essential (hemorrhagic) thrombocythemia
D474	Osteomyelofibrosis
D47Z	Oth neoplm of uncrt behav of lymphoid, hematpoetc & rel tiss
D47Z1	Post-transplant lymphoproliferative disorder (PTLD)
D47Z9	Oth neoplm of uncrt behav of lymphoid, hematpoetc & rel tiss
D479	Neoplm of uncrt behav of lymphoid, hematpoetc & rel tiss, unsp
D496	Neoplasm of unspecified behavior of brain
D497	Neoplm of unsp behav of endo glands and oth prt nervous sys

R85614	Cytologic evidence of malignancy on smear of anus
R87614	Cytologic evidence of malignancy on smear of cervixe
R87624	Cytologic evidence of malignancy on smear of vagina

ICD-10-CM Supplemental Casefinding List (Effective Date: 10/01/2016 - 09/30/2017)

ICD- 10- CM CODE	EXPLANATION OF ICD-10-CM CODE
320	Human immunodeficiency virus [HIV] disease with other diseases
397.33, 397.34, 397.35	Human T-cell lymphotrophic virus,(type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere
397.7	Papillomarvirus as the cause of diseases classified elsewhere
C44.01, C44.02	Basal/squamous cell carcinoma of skin of lip
C44. 11_, C44.12_	Basal/squamous cell carcinoma of skin of eyelid
C44.21- C44. 22-	Basal/squamous cell carcinoma of skin of ear and external auricular canal
C44.31- C44. 32-	Basal/squamous cell carcinoma of skin of other and unspecified parts of face
C44.41, C44.42	Basal/squamous cell carcinoma of skin of scalp and neck
C44.51- , C44. 52-	Basal/squamous cell carcinoma of skin of trunk
C44.61- , C44. 62-	Basal/squamous cell carcinoma of skin of upper limb, including shoulder
C44.71- , C44. 72-	Basal/squamous cell carcinoma of skin of lower limb, including hip
C44.81, C44.82	Basal/squamous cell carcinoma of skin of overlapping sites of skin
C44.91, C44.92	Basal/squamous cell carcinoma of skin of unspecified sites of skin
D10 D31, D34, D35.0, D35.1, D35.5- D35.9, D36	Benign neoplasms (see "must collect" list for reportable benign neoplasms) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.
D3A	Benign carcinoid tumors
037 041	Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors
044.0 - 044.2, 044.6- 044.9	Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors
047.0	Histiocytic and mast cell tumors of uncertain behavior ICD-10-CM Coding instruction note: Excludes: malignant mast cell tumor (C96.2), mastocytosis (congenital)(cutaneous) (Q852.2)

D47.2	Monoclonal gammopathy Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia
D48	Neoplasm of uncertain behavior of other and unspecified sites
D49.0 - D49.9	Neoplasm of unspecified behavior (except for D49.6 and D49.7)
D61.1	Drug-induced aplastic anemia (also known as "aplastic anemia due to antineoplastic chemotherapy") ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug
D61.810	Antineoplastic chemotherapy induced pancytopenia
D61.82	Myelophthisis ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50)
D63.0	Anemia in neoplastic disease ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)
D64.81	Anemia due to antineoplastic chemotherapy
D69.49, D69.59, D69.6	Other thrombocytopenia Note: Screen for incorrectly coded thrombocythemia
D70.1	Agranulocytosis secondary to cancer chemotherapy ICD-10-CM Coding instruction: code also underlying neoplasm
D72.1	Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is a malignancy. Reportable Diagnosis is "Hypereosonophilic syndrome.")
D75.81	Myelofibrosis (note: this is not primary myelofibrosis [9961/3] ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of breast (C50)
D76	Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
D89.0, D89.1	Other disorders involving the immune mechanism, not elsewhere classified Note: Review for miscodes
E08	Diabetes mellitus due to underlying condition ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96)
E31.2-	Multiple endocrine neoplasia [MEN] syndromes ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes
E34.0	Carcinoid syndrome ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor
E83.52	Hypercalcemia
E88.09	Other disorders of plasma-protein metabolism, not elsewhere classified
E88.3	Tumor lysis syndrome (following antineoplastic chemotherapy)
G13.0	Paraneoplastic neuromyopathy and neuropathy ICD-10-CM Coding instruction note:: Code first underlying neoplasm (C00-D49)
G13.1	Other systemic atrophy primarily affecting central nervous system in neoplastic disease ICD-10-CM Coding instruction note:: Code first underlying neoplasm (C00-D49)
C32.8-	Other specified degenerative disorders of nervous system in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49)
G53	Cranial nerve disorders in diseases classified elsewhere Note: Code first underlying neoplasm (C00-D49)
G55	Nerve root and plexus compressions in diseases classified elsewhere ICD-10-CM Coding instruction note: code also underlying disease, such as neoplasm (C00-D49)
G63	Polyneuropathy in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49)
G73.1	Lambert-Eaton syndrome in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)
G89.3	Neoplasm related pain (acute)(chronic)
G99.2	Myelopathy in diseases classified elsewhere ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49)

H47.42	Disorders of optic chiasm in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition			
H47.52-	Disorders of visual pathways in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition			
H47.63-	Disorders of visual cortex in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition			
J34.81	Nasal mucositis (ulcerative)			
J91.0	Malignant pleural effusion ICD-10-CM Coding instruction: Code first underlying neoplasm			
J93.12	Secondary spontaneous pneumothorax ICD-10-CM Coding instruction: Code first underlying condition, such as: Malignant neoplasm of bronchus and lung (C34) Secondary malignant neoplasm of lung (C78.0_)			
K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy			
K12.33	Oral mucositis (ulcerative) due to radiation			
K22.711	Barrett's esophagus with high grade dysplasia			
K62.7	Radiation proctitis			
K62.82	Dysplasia of anus (AIN I and AIN II)			
K92.81	Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)			
M36.0	Dermato(poly)myositis in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)			
M36.1	Arthropathy in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm, such as: Leukemia (C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0)			
M84.5-	Pathologic fracture in neoplastic disease ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49)			
M90.6-	Osteitis deformans in neoplastic disease ICD-10-CM Coding instruction: Code first the neoplasm (C40, C41)			
N42.3	Dysplasia of prostate (PIN I and PIN II)			
N76.81	Mucositis (ulcerative) of vagina and vulva			
N87	Dysplasia of cervix uteri (CIN I and CIN II)			
N89.0, N89.1, N89.3	Vaginal dysplasia (VIN I and VIN II)			
N90.0, N90.1, N90.3	Vulvar dysplasia (VAIN I and VAIN II)			
O01	Hydatidiform mole Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3,) malignancy code in the C00- C97 range			
O9A.1-	Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96) ICD-10-CM Coding instruction: Use additional code to identify neoplasm			
Q85.0-	Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable			
R18.0	Malignant ascites ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)			
R53.0	Neoplastic (malignant) related fatigue ICD-10-CM Coding instruction: Code first associated neoplasm			
R59	Enlarged lymph nodes			
R85.6-	Abnormal findings on cytological and histological examination of digestive organs Note: see "must collect" list for R85.614			
	Abnormal findings on cytological/histological examination of female genital organs Note: see "must collect" list for R87.614 and R87.624			

R87.61- , R87. 62-			
R92	Abnormal findings on diagnostic imaging of breast		
R97	Abnormal tumor markers		
T38.6-	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified		
T38.8-, T38.9-	Poisoning by hormones and their synthetic substitutes		
T45.1-	Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs		
T45.8-, T45.9-	Poisoning by primary systemic and hematological agent, unspecified		
T66	Unspecified effects of radiation		
T80.1	Vascular complications following infusion, transfusion and therapeutic injection		
T80.2-	Infections following infusion, transfusion and therapeutic injection		
T80.810	Extravasation of vesicant antineoplastic chemotherapy		
T80.818	Extravasation of other vesicant agent		
T86.0	Complications of bone marrow transplant ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)		
Y63.2	Overdose of radiation given during therapy		
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure		
Z03.89	Encounter for observation for other suspected diseases and conditions ruled out		
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85)		
Z12	Encounter for screening for malignant neoplasms		
Z13.0	Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism		
Z15.0	Genetic susceptibility to malignant neoplasm ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85)		
Z17.0, Z17.1	Estrogen receptor positive and negative status ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50)		
Z40.0-	Encounter for prophylactic surgery for risk factors related to malignant neoplasms		
Z42.1	Encounter for breast reconstruction following mastectomy		
Z48.3	Aftercare following surgery for neoplasm ICD-10-CM Coding instruction: Use additional code to identify the neoplasm		
Z48.290	Encounter for aftercare following bone marrow transplant		
Z51.0	Encounter for antineoplastic radiation therapy		
Z51.1-	Encounter for antineoplastic chemotherapy and immunotherapy		
Z51.5, Z51.89	Encounter for palliative care and other specified aftercare		
Z79.81-	Long term (current) use of agents affecting estrogen receptors and estrogen levels ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50), malignant neoplasm of prostate (C61)		
Z80	Family history of primary malignant neoplasm		
Z85	Personal history of malignant neoplasm ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08)		
Z86.0-, Z86.01- , Z86.03	Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior		

Z92.21, Z92.23, Z92.25. Z92.3	Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)
Z94.81, Z94.84	Bone marrow and stem cell transplant status

ICD-9-CM Supplemental Casefinding List

ICD-9-CM CODE*	EXPLANATION OF ICD-9-CM CODE		
042	Acquired Immunodeficiency Syndrome (AIDS) Note: Screen 042 for history of cancers with HIV/AIDS		
079.51-079.53	Retrovirus (HTLV, types I, II and 2)		
173.01, 173.02	Basal and squamous cell carcinoma of skin of lip		
173.11, 173.12	Basal and squamous cell carcinoma of eyelid, including canthus		
173.21, 173.22	Basal and squamous cell carcinoma of ear and external auricular canal		
173.31, 173.32	Basal and squamous cell carcinoma of skin of other and unspecified parts of face		
173.41, 173.42	Basal and squamous cell carcinoma of scalp and skin of neck		
173.51, 173.52	Basal and squamous cell carcinoma of skin of trunk, except scrotum		
173.61, 173.62	Basal and squamous cell carcinoma of skin of upper limb, including shoulder		
173.71, 173.72	Basal and squamous cell carcinoma of skin of lower limb, including hip		
173.81, 173.82	Basal and squamous cell carcinoma of other specified sites of skin		
173.91, 173.92	Basal and squamous cell carcinoma of skin, site unspecified		
209.40 - 209.69	Benign carcinoid tumors		
210.0 - 229.9	Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 228.02, 228.1, which are listed in the Reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors		
235.0-236.99	Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands Note: screen for incorrectly coded malignancies or reportable by agreement tumors		
237.2-237.4	Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands Note: screen for incorrectly coded malignancies or reportable by agreement tumors		
237.7_	Neurofibromatosis and Schwannomatosis		
238.0-239.9	Neoplasms of uncertain behavior (except for 238.4, 238.71-238.79, 239.6, 239.7, which are listed in the reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors		
259.2	Carcinoid syndrome		
273.0	Polyclonal hypergammaglobulinemia (Note: screen for blood disorders due to neoplasm)		
273.1	Monoclonal gammopathy of undetermined significance (9765/1) Note: Screen for incorrectly coded Waldenstrom macroglobulinemia or progression		
273.2	Other paraproteinemias		
273.8, 273.9	Other and unspecified disorders of plasma protein metabolism Note: includes plasma disorders due to neoplastic disease		
275.42	Hypercalcemia (Note: Includes hypercalcium due to neoplastic disease)		
277.88	Tumor lysis syndrome (following neoplastic chemotherapy)		
284.1_	Pancytopenia (Note: screen for anemia disorder related to neoplasm)		
285.22	Anemia in neoplastic disease		
285.3	Anemia due to antineoplastic chemotherapy		
287.39, 287.49, 287.5	Secondary, other primary and unspecified thrombocytopenia Note: Screen for incorrectly coded thrombocythemia		
288.03	Drug induced neutropenia (note: screen for anemia disorder related to neoplasm)		

288.3	Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is with a malignancy. Diagnosis must be "Hypereosonophilic syndrome" to be reportable.)		
288.4	Hemophagocytic syndrome		
338.3	Neoplasm related pain (acute)(chronic)		
528.01	Mucositis due to antineoplastic therapy		
530.85	Barrett's esophagus (High grade dysplasia of esophagus)		
569.44	Dysplasia of anus (Anal intraepithelial neoplasia [AIN I and II])		
602.3	Dysplasia of prostate (Prostatic intraepithelial neoplasia [PIN I and II])		
622.10-622.12	Dysplasia of cervix, unspecified and CIN I, CIN II		
623.0	Dysplasia of vagina (Vaginal intraepithelial neoplasia [VAIN I and II]		
624.01, 624.02	Vulvar intraepithelial neoplasia: unspecified, VIN I and VIN II		
630	Hydatidiform mole (Note: benign tumor that can become malignant. If malignant, it should be reported as Choriocarcinoma (9100/3) with malignancy code in 140-209 range)		
780.79	Neoplastic (malignant) related fatigue		
785.6	Enlargement of lymph nodes		
789.51	Malignant ascites		
790.93	Elevated prostate specific antigen (PSA)		
793.8_	Nonspecific (abnormal) findings on radiological & examination of body structure (breast)		
795.0 795.1_	Papanicolaou smear of cervix and vagina with cytologic evidence of malignancy		
796.7_	Abnormal cytologic smear of anus and anal HPV		
795.8_	Abnormal tumor markers; Elevated tumor associated antigens [TAA]		
963.1	Poisoning by primarily systemic agents: antineoplastic and immunosuppressive drugs		
990	Effects of radiation, unspecified (radiation sickness)		
999.3_	Complications due to central venous catheter		
E858.0	Accidental poisoning by other drugs: Hormones and synthetic substitutes		
E858.1	Accidental poisoning by other drugs: Primary systemic agents		
E858.2	Agents primarily affecting blood constituents		
E873.2	Failure in dosage, overdose of radiation in therapy (radiation sickness)		
E879.2	Overdose of radiation given during therapy (radiation sickness)		
E930.7	Adverse reaction of antineoplastic therapy-Antineoplastic antibiotics		
E932.1	Adverse reaction to antineoplastic therapy-Androgens and anabolic congeners		
E933.1	Adverse effect (poisoning) of immunosuppressive drugs		
V10.0 V10.9_	Personal history of malignancy Note: Screen for recurrences, subsequent primaries, and/or subsequent treatment		
V12.41	Personal history of benign neoplasm of the brain		
V13.89	Personal history of unspecified. malignant neoplasm, history of in-situ neoplasm of other site		
V15.3	Other personal history presenting hazards to health or (therapeutic) radiation		
V42.81, V42.82	Organ or tissue replaced by transplant: Bone marrow, peripheral stem cells		
V51.0	Encounter for breast reconstruction following mastectomy		
V58.0, V58.1_	Encounter for radiotherapy, chemotherapy, immunotherapy		
V66.1, V66.2	Convalescence and palliative care following radiotherapy, chemotherapy		
V66.7	Encounter for palliative care		
V67.1, V67.2	Follow up examination: following radiotherapy or chemotherapy		

V71.1	Observation for suspected malignant neoplasm	
V76	Special screening for malignant neoplasms	
V86	Estrogen receptor positive status [ER+], negative status [ER-]	
V87.41	Personal history of antineoplastic chemotherapy	
V87.43	Personal history of estrogen therapy	
V87.46	Personal history of immunosuppression therapy	

*International Classification of Diseases, 9th Revision, Clinical Modification, Sixth Edition, 2014

Appendix N - Pre-2014 Grade Coding Instructions

CODING INSTRUCTIONS PRIOR TO 2014

Grade, Differentiation (Codes 1, 2, 3, 4, 9) - for solid tumors

Pathologic testing determines the grade, or degree of differentiation, of the tumor. For cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). Well differentiated tumor cells closely resemble the tissue from the organ of origin. Poorly differentiated and undifferentiated tumor cells are disorganized and abnormal looking; they bear little or no resemblance to the tissue from the organ of origin.

Pathologists describe the tumor grade by levels of similarity. Pathologists may define the tumor by describing two levels of similarity (two-grade system which may be used for colon); by describing three levels of similarity (three-grade system); or by describing four levels of similarity (four-grade system). The four-grade system describes the tumor as grade I, grade II, grade III, and grade IV (also called well differentiated, moderately differentiated, poorly differentiated, and undifferentiated/anaplastic). These similarities/differences may be based on pattern (architecture), cytology, or nuclear features or a combination of these elements depending upon the grading system that is used. The information from this data item is useful for determining prognosis.

Cell Indicator (Codes 5, 6, 7, 8, 9) - for hematopoietic and lymphoid malignancies

Cell indicator codes describe the lineage or phenotype of the cell that became malignant. If marker studies are not documented in the record, then code information on cell type from any source (i.e., history & physical). These codes apply to lymphomas and leukemias. Cell indicator codes take precedence over grade/differentiation codes for lymphoma and leukemia cases. Do not use "high grade," "low grade," or "intermediate grade" descriptions of lymphomas as a basis for differentiation. These terms are categories in the Working Formulation of Lymphoma Diagnoses and do not relate to grade /differentiation. For all hematopoietic and lymphoma cases diagnosed January 1, 2010 forward, use the guidelines in Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual to code grade. For cases diagnosed prior to that date, see the ICD-O-3 chapter Morphology for further instructions on coding grade.

Codes

Code	Grade/Cell	Label
1	Grade I, 1, i	Well differentiated; differentiated, NOS
2	Grade II, 2, ii I/III or 1/3	Moderately differentiated; moderately well differentiated; intermediate differentiation
3	Grade III, 3, iii II/III or 2/3	Poorly differentiated; dedifferentiated
4	Grade IV, 4, iv III/III or 3/3	Undifferentiated; anaplastic
For Lyr	nphomas and Le	eukemias
5		T cell; T-precursor
6		B cell; pre-B; B-percursor
7		Null cell; non T- non B
8		NK (natural killer) cell (effective with diagnosis 1/1/95 and after)
For Use	e in All Histologi	es
9		Cell type not determined, not stated or not applicable; unknown primary; high grade dysplasia

General Coding Instructions

- The site specific coding guidelines in Appendix C of the SEER Program Coding and Staging Manual include instructions for coding grade for the following primary sites/histologies: colon, breast, prostate, kidney, renal pelvis, ureter, bladder, urethra, astrocytoma, and sarcoma. Site-specific instructions take priority over general instructions.
- Code the grade or differentiation as stated in the final pathologic diagnosis. If grade is not stated in the final pathologic diagnosis, use the
 information from the microscopic description or comments.
- Record the tumor grade from the pathology report prior to neoadjuvant treatment. If there is no pathology report prior to neoadjuvant treatment, assign code 9.
- Code the grade from the primary tumor only, never from a metastatic site or a recurrence. Code to 9 when the primary site is unknown.
- If more than one grade is recorded for a single tumor, code the highest grade, even if it is a focus.
- Differentiation has priority over nuclear grade when both are specified. (Example: Liver biopsy histology described as "well differentiated hepatocellular carcinoma, nuclear grade 2/4." Code the tumor grade as grade 1.)
- Code the grade for in situ lesions if it is available. Code the grade of the invasive component when the tumor has both in situ and invasive portions. If the grade of the invasive component is unknown, code tumor grade as 9.
- Do not code the grade assigned to dysplasia (Example: High grade dysplasia (adenocarcinoma in situ). Code to 9 (unknown).)
- Code the grade of tumor given on a CT scan, MRI, or PET report only if there is no tissue diagnosis
- Do not use WHO grade to code this data item

- Some terms in ICD-O-3 carry an implied statement of grade. These histologies must be reported with the correct grade as stated below even if another grade is given or the primary site is unknown (C80.9):
- 8020/34 Carcinoma, undifferentiated
- 8021/34 Carcinoma, anaplastic
- 8331/31 Follicular adenocarcinoma, well differentiated
- 8851/31 Liposarcoma, well differentiated
- 9062/34 Seminoma, anaplastic
- 9082/34 Malignant teratoma, undifferentiated
- 9083/32 Malignant teratoma, intermediate type
- 9401/34 Astrocytoma, anaplastic
- 9451/34 Oligodendroglioma, anaplastic
- 9511/31 Retinoblastoma, differentiated
- 9512/34 Retinoblastoma, undifferentiated

Terminology Conversion Table

Description	Grade	SEER Code
Differentiated, NOS	I	1
Well differentiated	I	1
Fairly well differentiated	11	2
Intermediate differentiation	II	2
Low grade	1-11	2
Mid differentiated	II	2
Moderately differentiated	II	2
Moderately well differentiated	11	2
Partially differentiated	11	2
Partially well differentiated	1-11	2
Relatively or generally well differentiated	11	2
Medium grade, intermediate grade	11-111	3
Moderately poorly differentiated	Ш	3
Moderately undifferentiated	ш	3
Poorly differentiated	Ш	3
Relatively poorly differentiated	Ш	3
Relatively undifferentiated	Ш	3
Slightly differentiated	ш	3
Dedifferentiated	ш	3
High grade	III-IV	4
Undifferentiated, anaplastic, not differentiated	IV	4
Non-high grade		9

- Two-Grade System

Two grade systems apply to colon, rectosigmoid junction, rectum (C18.0-C20.9), and heart (C38.0). Code these sites using a two-grade system- Low Grade (2) or High Grade (4). If the grade is listed as 1/2 or as Low Grade, use code 2. If the grade is listed as 2/2 or as High Grade, use code 4.

Code	Terminology	Histologic Grade	
2	Low grade	1/2	
4	High grade	2/2	

-Three-Grade System

There are several sites for which a three-grade system is used: peritoneum, endometrium, fallopian tubes, bladder, brain and spinal cord, and soft tissue sarcoma. For these sites, code the tumor grade using the following priority order: (1) terminology, (2) histologic grade, and (3) nuclear grade as show in the table below. The patterns of cell growth are measured on a scale of 1, 2, and 3 (also referred to as low, medium, and high grade). This system measures the proportion of cancer cells that are growing and making new cells and how closely they resemble the cells of the host tissue. Thus, it is similar to a four-grade system, but simply divides the spectrum into three rather than four categories (see comparison table below). The expected outcome is more favorable for lower grades. If the grade is written as 2/3, that means this is a grade 2 of a 3 grade system; do not simply code the numerator. Use the following table to convert the grade to the correct code.

Code	Terminology
2	Low grade, well to moderately differentiated; I/III or 1/3
3	Medium grade, intermediate grade, moderately undifferentiated, relatively undifferentiated; II/III or 2/3
4	High grade; poorly differentiated to undifferentiated; III/III or 3/3

Refer to the following instructions for breast, kidney, prostate, and CNS tumors.

-Breast (C50.0-C50.9)

For breast cancers, code the tumor grade using the following priority order: 1) Bloom-Richardson (Nottingham) Scores 3-9; 2) Bloom-Richardson Grade (low, intermediate, high); 3) Nuclear Grade only; 4) Terminology; and 5) Differentiation (well differentiated, moderately differentiated, etc.); 6) Histologic Grade.

BLOOM-RICHARDSON GRADING FOR BREAST CANCER

Synonyms for this grading system include modified Bloom-Richardson, Scarff-Bloom-Richardson, SBR grading, BR grading, Elston-Ellis and Nottingham modification of Bloom-Richardson grading. The Bloom-Richardson grading scheme is based on numeric scores assigned to three different morphologic features of invasive, no-special-type breast cancers (degree of tubule formation/histologic grade, mitotic activity, and nuclear pleomorphism of tumor cells). Use the table below to convert BR score, grade, or terminology:

BR Scores	BR Grade	Nuclear Grade	Terminology	Histologic Grade	Code
3-5	Low	1/3; 1/2	Well differentiated	I, I/III, 1/3	1
6, 7	Intermediate	2/3	Moderately differentiated	II, II/III, 2/3	2
8, 9	High	2/2; 3/3	Poorly differentiated	III, III/III, 3/3	3
		4/4	Undifferentiated/anaplastic	IV, IV/IV, 4/4	4

Ductal carcinoma in situ (DCIS) is not always graded. When DCIS is graded, it is genearly divided into three grades: low grade, intermediate grade, and high grade. Use the following table to convert DCIS grade in the SEER code.

DCIS Grade	Terminology	SEER Code
Grade I	Low	1
Grade II	Intermediate	2
Grade III	High	3

-Kidney (C64.9)

For kidney cancers, code the tumor grade using the following priority rules: 1) Fuhrman Grade; 2) Nuclear Grade; 3) Terminology (well diff, mod. diff); 4) Histologic Grade. These prioritization rules do not apply to Wilms tumor (M-8960).

-Prostate (C61.9)

For prostate cancers, code the tumor grade using the following priority order: 1) Gleason Score (this is the sum of the patterns, e.g., if the pattern is 2-4, the score is 6); 2) Terminology; 3) Histologic Grade; and 4) Nuclear Grade.

Gleason's Pattern

Prostate cancers are commonly graded using Gleason's score or pattern. Gleason's grading is based on a 5-component system, meaning it is based on 5 histologic patterns. The pathologist will evaluate the primary (majority) and secondary patterns for the tumor. The pattern is written as a range, with the majority pattern appearing first and the secondary pattern as the last number.

Gleason's Score

The patterns are added together to create a score. If the pathology report contains only one number, and that number is less than or equal to 5, it is a pattern. If the pathology report contains only one number, and that number is greater than 5, it is a score. If the pathology report specifies a specific number out of a total of 10, the first number given is the score. If there are two numbers other than 10, assume they refer to two patterns. The first number is the primary pattern and the second is the secondary pattern. Use the following table to convert Gleason's pattern or score into SEER codes:

Gleason Conversion Table

Code	Gleason's Score (sum of primary and secondary patterns)	Terminology	Histologic Grade
1	2, 3, 4	Well differentiated	1
2	5, 6	Moderately differentiated	11
3	7, 8, 9, 10	Poorly differentiated	111

- CNS Tumors


- Grade astrocytomas (M-9383, 9400, 9401, 9410-9412, 9420, 9421) according to ICD-O-3 rules: I (well differentiated), Code 1; II (intermediate differentiation), Code 2; III (poorly differentiated), Code 3; IV (anaplastic), Code 4.

Do not automatically code glioblastoma multiforme as Grade IV. If no grade is given, code 9 (unknown).

• For primary tumors of the brain and spinal cord (C71.0-C72.9) do not record the WHO grade in the field Grade/Differentiation; record the WHO grade in the data item CS Site-Specific Factor 1.

• All benign and borderline intracranial tumors should be coded grade 9.

Appendix O - Area Development District Map



Instructional Videos

CPDMS Videos

Locate Patient

• Searching With Date Of Birth

Create Patient from Existing Pathology Report

- Navigating to ApplicationIn-Depth Walkthrough
- Customizing the Application

Create Case From Existing Pathology Report

- Create Case From Pathology Zoom Demo
 - You will want to start at the 12 minute mark